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The initiation, modulation and resolution of thrombus associated with eroded or
unstable coronary plaques are critical determinants of acute coronary events. This
itself is dependent on the cellular function of the surrounding endothelium and
vascular wall. In particular, the regulation of vascular tone and the acute release of
tissue plasminogen activator by the endothelium make important contributions to the
defence against intravascular thrombosis. These aspects of endothelial function will
provide major new insights into the pathophysiology of cardiovascular disease, and
to shape future therapeutic interventions.
The experimental medicine models presented here originate from an early interest in
exploring these novel aspects of endothelial function, and in particular, the acute
release of the endothelium-derived fibrinolytic factor, tissue plasminogen activator.
This model was initiated, developed and applied to a diverse range of physiological
and pathophysiological circumstances that have informed health and disease.
Publications are grouped into 5 main sections.
Section 1 describes the early validation and exploration of the model to stimulate
acute tissue plasminogen activator release using a variety of physiological and
pathophysiological mediators. This describes the early identification of potent
stimulators of acute tissue plasminogen activator release including substance P,
bradykinin, desmopressin and thrombin receptor agonists. This work was extended to
demonstrate the important role of nitric oxide and vascular inflammation in this
process. Subsequent sections cover the application of these techniques in patient
populations with a predisposition to cardiovascular disease (Section 2) as well as
with established (Section 3) and end-stage disease (Section 4). These sections also
explore the potentially important modulation of the renin-angiotensin system with
particular reference to angiotensin-converting enzyme inhibition and the role of
bradykinin. Section 5 contains some miscellaneous work and reviews of the subject
area bring together the key aspects of the field as well as an important study to
address the vascular endothelial function in patients with a rare haematological
deficiency, type 3 von Willebrand disease.
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Summary
The effects on blood flow and plasma fibrinolytic and coagulation
parameters of intraarterial substance P, an endothelium dependent
vasodilator, and sodium nitroprusside, a control endothelium indepen¬
dent vasodilator, were studied in the human forearm circulation. At
subsystemic locally active doses, both substance P (2-8 pmol/min) and
sodium nitroprusside (2 8 pg/min) caused dose dependent vasodilata
tion (p <0.001 for both) without affecting plasma concentrations of
PAI-1, von Willebrand factor antigen or factor V1II:C activity. Sub¬
stance P caused local increases in t PA antigen and activity (p <0.001)
in the infused arm while sodium nitroprussidc did not. At higher doses,
substance P increased blood flow and t PA concentrations in the
noninfused arm. We conclude that brief, locally active and subsystemic
infusions of intraarterial substance P cause a rapid and substantial
local release of t-PA which appear to act via a flow and nitric oxide
independent mechanism. This model should provide a useful and
selective method of assessing the in vivo capacity of the forearm
endothelium to release t PA acutely.
Introduction
Endothelial cells of the precapillary arterioles and postcapillary
venules (1) synthesisc and constitutively secrete tissue type plasmino
gen activator (t-PA) and its inhibitor, plasminogen activator inhibitor
type 1 (PAI 1). The release of t PA may be rapidly increased through
the translocation of a dynamic intracellular storage pool (2) in response
to stimulation by blood coagulation and humoral factors (3). Acute
t-PA release plays a pivotal role in endogenous fibrinolysis and this is
exemplified by a plasminogen activator deficient gene knockout mouse
model that exhibits an increased incidence of endotoxin-induced
thrombosis (1). The time course of t PA release is important, with
thrombus dissolution being much more effective if t-PA is incorporated
during, rather than after, thrombus formation (5, 6). Thus, the speed
with which, and extent to which, t-PA can be released from endothelial
cells may have a substantial impact on the efficacy of endogenous
fibrinolysis.
When studying in vivo vascular responses in man, systemic drug
administration can cause concomitant effects on other organ systems,
such as the liver, brain, kidney and heart, as well as influence neuro¬
humoral reflexes through changes in systemic haemodynamics. There-
Corrc3pondcncc to: Dr. D. E. Ncwby, Clinical Pharmacology Unit and
Research Centre, University of Edinburgh, Western General Hospital, Crewe
Road, Edinburgh EIM 2XU, Scotland, UK - Tel. -M1 131 332 1205;
FAX Number I 41 131 343 6017; E mail D.E.Newby@cd.ac.uk
fore, because of these confounding influences, vascular and humoral
responses cannot bo wholly attributed to a direct effect of the drug on
the blood vessels. Endogenous fibrinolysis in man has been assessed
using systemic infusion of agents such as desmopressin (7, 8) and
angiotensin 11 (9). These agents are vasoactive, producing changes in
blood pressure and regional blood flow, as well as having widespread
effects on many tissues. Thus, changes in systemic fibrinolytic para¬
meters might be attributable to a number of factors including changes in
hepatic release and clearance of t PA and PAI 1, and the concomitant
release of other stimulatory, vasoactive and humoral mediators. In
contrast, the use of bilateral forearm blood flow measurements coupled
with unilateral brachial artery infusion of vasoactive drugs at subsyste
mic, locally active doses, provides a powerful and reproducible method
of directly assessing vascular responses in vivo (10, 11). Combined
with bilateral forearm venous sampling, this technique permits the
assessment of local release of tissue and endothelium derived factors
(12).
Substance Pisa member of the tachykinin family of peptides, acting
through stimulation of neurokinin receptors, and having a particularly
high affinity for the type 1 (NK,) receptor (13). It is widely distributed
in the body and has actions as a central, peripheral and enteric neuro
transmitter (14-17), inflammatory mediator (18-20) and neurohumoral
regulator (15, 21, 22). When given intra-arterial 1y in man, substance P
enhances local fibrinolytic activity through an unknown mechanism
(23) and has actions as a potent vasodilator (24-26) through an
endothelium dependent (27) and predominantly nitric oxide mediated
mechanism (28, 29). The determination of vascular responses to the
intraarterial infusion of endothelial cell stimulants such as substance P
has been widely used to assess the integrity of endothelium dependent
vasodilatation in health and disease (30-33).
The initial aim of the present study was to assess the acute release of
coagulation and fibrinolytic factors within the forearm vascular bed in
response to intraarterial substance P using an ascending dose design to
define the dose at which systemic effects intervene. Thereafter, endo
thelial cell release of these factors was assessed in response to locally
active doses of substance P and a control endothelium-independent
nitric oxide donor, sodium nitroprusside (32, 33).
Materials and Methods
Subjects
Sixteen healthy non smoking men aged between 20 and 34 years partici
putcd in two studies which were undertaken with the approval of the local
research ethics committee and in accordance with the Declaration of Helsinki.
The written informed concent of each subject was obtained before entry into the
study. None of the subjects received vasoactive or nonsteroidal antiinflamma
tory drugs in the week before each phase of the study, and all abstained from
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alcohol for 24 h, and from food and caffeine-containing drinks for at least 5 h,
before each study. All studies were performed in a quiet, temperature control¬
led room maintained at 23.5-24.5° C.
Blood pressure was monitored in the noninfused arm at intervals through¬
out each study using a semiautomated noninvasive oscillometry sphygmo¬
manometer (34) (Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).
Intraarterial Administration
The brachial artery of the nondominant arm was cannulated with a 27-
standard wire gauge steel needle (Cooper's Needle Works Ltd, Birmingham,
UK) under 1% lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings
Langley, UK) local anaesthesia and attached to a 16-gauge epidural catheter
(Portex Ltd, Hythe, UK). Patency was maintained by infusion of saline via an
IVAC P1000 syringe pump (1VAC Ltd, Basingstoke, UK). The total rate of
intra-arterial infusions was maintained constant throughout all studies at
1 ml/min.
Drugs
Pharmaceutical-grade substance P (Clinalfa AG, Laufelfingen, Switzerland)
and sodium nitroprusside (Nipride; Roche, Welwyn Garden City, UK) were
administered following dissolution in saline (0.9%: Baxter Healthcare Ltd,
Thetford, UK).
Forearm Blood Flow and Blood Pressure
Blood flow was measured in both forearms by venous occlusion plethysmo¬
graphy using mercury-in-silastic strain gauges applied to the widest part of the
forearm (10, 11). During measurement periods the hands were excluded from
the circulation by rapid inflation of the wrist cuffs to a pressure of 220 mmHg
using E20 Rapid Cuff Inflators (D.E. Hokanson Inc, Washington, USA). Upper
arm cuffs were inflated intermittently to 40 mmHg for 10 s in every 15 s to
achieve venous occlusion and obtain plethysmography recordings. Analogue
voltage output from an EC-4 Strain Gauge Plethysmograph (D.E. Hokanson)
was processed by a MacLab® analogue-to-digital converter and Chart v3.3.8
software (AD Instruments Ltd, Castle Hill, Australia) and recorded onto a
Macintosh Classic II computer (Apple Computers Inc, Cupertino, USA).
Calibration was achieved using the internal standard of the plethysmograph.
Venous Sampling and Assays
Venous cannulae (19G) were inserted into large subcutaneous veins of the
antecubital fossa in both arms as described previously (12). Ten ml of blood
was withdrawn simultaneously from each arm and collected into acidified
buffered citrate (Biopool® Stabilyte™, Umea, Sweden) and citrate (Monovette®,
Sarstedt, Niimbrecht, Germany) tubes, and kept on ice before being centrifuged
at 2,000 g for 30 min at 4° C. Platelet free plasma was decanted and stored at
-80° C before assay.
Plasma PAl-I and t-PA antigen concentrations were determined using an
enzyme-linked immunosorbent assay; Coaliza® PAI-1 (35) and Coaliza® t-PA
(36) (Chromogenix AB, Molndal, Sweden) respectively. Plasma PAI-1 and
t-PA activities were determined by a photometric method, Coatest® PAI-1 (37)
and Coaset® t-PA (38) (Chromogenix AB). Intraassay coefficients of variation
were 7.0% and 5.5% for t-PA and PAI-1 antigen, and 4.0% and 2.4% for
activity, respectively. Interassay coefficients of variability were 4.0%, 7.3%,
4.0% and 7.6% respectively. The sensitivities of the assays were 2.5 ng/ml,
0.5 ng/ml, 5 AU/ml and 0.10 IU/ml respectively. Von Willebrand factor (vWf)
antigen was determined (39) using an enzyme-linked immunosorbent assay
(Dako A/S, Glostrup, Denmark) with a sensitivity of 0.05 lU/ml. The intra¬
assay and interassay coefficients of variability were 5.2% and 7.3% respec¬
tively. Factor VIILC procoagulant activity was determined using a standard one
stage assay on an ACL-3000+ coagulometer (Instrumentation Laboratory,
Warrington, UK).
Study Design
Subjects rested recumbent throughout each study. Strain gauges and cuffs
were applied and the brachial artery of the nondominant arm cannulated.
Measurements of forearm blood flow were made between 3 and 6 min of each
infusion period unless otherwise stated. Before participating in one of the
following protocols, saline was infused for the first 30 min to allow time for
Table 1 Dose ranging study: syste¬
mic haemodynamics, forearm blood
flow, estimated net t-PA antigen and
activity release, and vWf concentra¬
tions and factor VIILC activity in the
infused and non-infused forearms
at baseline and during substance P
infusion (n = 7). * p = 0.05 (t-test);
t p <0.001 (ANOVA); § p = 0.06
(ANOVA)
Substance P Infusion (pmol/min)













Heart Rate (/min) 57 ±4 56 ±4 61 ±3 63 ± 3
Percentage Change in
Forearm Blood Flow
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equilibration, with forearm blood flow measured every 10 min and the final
measurement taken as basal blood flow.
Dose Ranging Study
In seven men, intrabrachial substance P was administered in incremental
doubling doses from 0.5 to a maximum of 128 pmol/min for 6 min at each
dose and was followed by 30 min saline infusion. Venous samples were taken
at baseline, following 2 pmol/min, 16 pmol/min and the maximal dose of
substance P, and after the final 30 min saline infusion.
Estimated net release of t-PA activity and antigen was defined as the product of
the infused forearm plasma flow (based on the hematocrit, HCt and the infused
forearm blood flow, FBF) and the concentration difference between the infused
(|t-PA]i„f) and non-infused arms ([t-PA]Nonjnf).
Estimated net t-PA release = FBF X (1-HCt) X {[t-PA]Inf — [t-PA]Nonjnf)
Data were examined, where appropriate, by two way analysis of variance
(ANOVA) with repeated measures and two tailed paired Student's (-test using
Excel v4.0 (Microsoft). All results are expressed as means ± standard errors of
the mean. Statistical significance was taken at the 5% level.
Local Forearm Study
Twelve men were given intraarterial doubling doses of substance P at
2, 4 and 8 pmol/min for 10 min at each dose, and sodium nitroprusside at 2,4
and 8 pg/min for 10 min at each dose, separated by a 30 min saline infusion.
Substance P and sodium nitroprusside were given single blind, in randomised
order. Venous samples were obtained at the end of each period of saline infu¬
sion and with each dose of substance P and sodium nitroprusside.
Results
All subjects were normotensive (Tables 1 and 2) and had a normal
fasting lipid profile with a mean total cholesterol concentration of
3.90 ±0.16 mM (150 ± 6 mg/dl), high density lipoprotein cholesterol
concentration of 1.02 ± 0.05 mM (39 ± 2 mg/dl) and triglyceride
concentration of 0.87 ± 0.08 mM (77 ± 7 mg/dl).
Data Analysis and Statistics
Plethysmography data were extracted from the Chart data files and forearm
blood flows were calculated for individual venous occlusion cuff inflations by
use of a template spreadsheet (Excel v4.0; Microsoft Corporation, Cambridge,
USA). Recordings from the first 60 s after wrist cuff inflation were not used
because of the reflex vasoconstriction this causes (10, 11). Usually, the last
five flow recordings in each 3 min measurement period were calculated and
averaged for each arm. To reduce the variability of blood flow data, the ratio of
flows in the two arms was calculated for each time point; in effect using the
non-infused arm as a contemporaneous control for the infused arm (10, 11).
Dose Ranging Study
There were no significant changes in arterial pressure or heart rate
throughout the study. Substance P caused an increase in blood flow
of the infused forearm (p <0.001) from a baseline of 3.7 ±
0.7 ml/lOOml/min to a maximum of 22 ± 2.4 ml/lOOml/min at
64 pmol/min in a dose-dependent manner (Fig. 1). Five subjects
received 64 pmol/min and 2 received 128 pmol/min as the maximum
dose, further infusion of substance P being discontinued because of
forearm skin oedema and facial flushing. There was a significant
Table 2 Local forearm study: systemic haemodynamics, forearm blood flow, estimated net t-PA antigen and activity release, and vWf concentrations and factor





0 2 4 8
132 ± 4 133 ± 4
70 + 2 70 ± 2
63 ±2 61 ±2
Substance P (pmol/min)
0 2 4
135 + 4 133 ± 4
69 ± 2 68 ± 1
61+2 61+2
131 ± 3 138 + 4
70 + 2 71 ± 3
64 ±2 61 ±2
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135 ± 3 136 ± 3




Absolute Forearm Non-infused Arm
Blood Flow
(ml/100 ml/min) Infused Arm
247 ± 53 370 ±73 541 ±111 *
4.1 ±0.5 4.1 ±0.6 3.8 ± 0.6 3.8±0.6
4.6 ± 0.7 11.6 ± 0.8 14.8 ± 1.1 18.1 ±1.4 *
193 ±41 286 ±77 383 ± 79
3.8 ±0.6 4.0 ±0.6 4.0 ±0.6 3.9 ±0.7







-0.5 ±0.3 -1.6 + 0.8 -0.5 ±1.4 0.5 ±2.7
-0.2 ±0.1 -0.8 ±1.0 -0.7 ±1.7 -1.1 ±3.5
0.0 ± 0.2 2.9 ± 1.3 7.3 ±2.1 15.6 ± 3.7
0.3 ±0.2 5.0 ±1.7 8.8 ±2.5 17.8 ±3.9
von Willebrand Non-infused Arm 0.66 ± 0.08 0.60 ± 0.07 0.64±0.10 0.68 ± 0.08 0.65 ±0.10 0.59 ± 0.08 0.61+0.10 0.60±0.13
Factor
(lU/ml) Infused Arm 0.64 ± 0.08 0.62 ± 0.09 0.65 ±0.09 0.67 ± 0.09 0.62 ±0.07 0.58 ±0.09 0.58+0.10 0.63 ± 0.08
Factor VII1:C
(IU/ml)
Non-infused Arm 0.61 ±0.08 0.57 ± 0.08 0.59 ±0.08 0.62 ± 0.08 0.57 ± 0.09 0.60 ± 0.08 0.59 ± 0.09 0.60 ±0.09
Infused Arm 0.64 ± 0.07 0.64 ± 0.09 0.65 ± 0.09 0.67 ± 0.09 0.53 ± 0.08 0.57 ±0.10 0.57 ±0.10 0.63 ± 0.09
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increase in the blood flow of the contralateral, noninfused arm
(p = 0.001, ANOVA) which was apparent from 16 pmol/min (p = 0.05).
The relative percentage increase in blood flow of the infused compared
with the noninfused arm was dose-dependent, peaking at 32 pmol/min
before declining at 64 pmol/min (Fig. 1).
Substance P caused increases in plasma t-PA antigen and activity
concentrations in the infused (p <0.001 for both) and noninfused arm
(p <0.003 for both) which were dose-dependent (Fig. 2). Plasma from
the infused arm demonstrated significantly greater increases in both
t-PA activity and antigen concentrations than the noninfused arm
(p <0.001). At the maximal dose, mean t-PA activity increased by
630% in the infused arm and 210% in the noninfused arm, whilst
mean t-PA antigen increased by 240% and 62% respectively.
There were no significant or consistent changes in plasma PAI-1
antigen or activity concentrations in the infused arm. There was a
significant decrease in the plasma PAI-1 activity in the noninfused
arm (p = 0.03) although PAI-1 antigen concentrations did not change
significantly (p = 0.64). There were no significant changes in plasma
vWf concentration or factor VIITC activity in either arm (Table 1).
Local Forearm Study
There were no significant changes in blood pressure, heart rate or
forearm blood flow in the contralateral arm throughout the study
(Table 2).
Both substance P and sodium nitroprusside caused selective in¬
creases in forearm blood flow in the infused arm (p <0.001 for both) in
a dose dependent manner (Table 2). Substance P caused a selective and
dose dependent increase in the estimated net release (p <0.001 for both)
and venous plasma concentrations (p <0.001 for both) of both t-PA
activity and antigen (Table 2; Fig. 3). In contrast, there were no signifi¬
cant changes in plasma t-PA activity or antigen concentrations in the
noninfused arm, or in PA1-1 antigen and activity, vWf or factor VIITC
concentrations in either arm (Table 2; Fig. 3). There were no significant
changes in t-PA, PAI-1, vWf or factor VIITC in either arm during
sodium nitroprusside infusion (Table 2; Fig. 3).
Discussion
We have shown, for the first time, that intraarterial substance P
administration causes acute, selective and substantial t-PA ielease in
vivo in man. At both systemic and locally active doses, substance P
causes t-PA release from the forearm vascular bed without significant
effects on the release of PAI-1, vWf and factor VIITC. This model
provides a selective in vivo method of assessing acute t-PA release from
the endothelium in man.
Intrabrachial substance P has been shown previously to induce
local fibrinolysis in the forearm (23) although the mechanism of this
effect had not been determined. However, taken together with our
findings, it is apparent that this enhancement of fibrinolytic activity is,
at least in part, mediated through t-PA release. Previously, bradykinin
was thought to be one of the most potent agents causing t-PA release
in animals (3, 40) and man (3, 41). However, a recent study in man
(41) using systemic intravenous bradykinin administration at doses of
up to 380 pmol/kg/min, did not show a significant release of t-PA
antigen except in the presence of angiotensin converting enzyme
inhibition and alterations in systemic hacmodynamic parameters. Jem
and colleagues (42) have shown a significant net local release of t-PA
antigen and activity in response to intra-brachial methacholine.
However, a significant increase in venous concentrations of t-PA
antigen was not detected and, although measurement of arteriovenous
differences should enhance the accuracy of assessing local tissue
release, there were no significant increases in the arteriovenous
gradients of t-PA antigen or activity. Indeed, the clearest changes were
observed in the arterial t-PA activity which should have remained
constant, suggesting that there was systemic stimulation of t-PA
release in this study.
Venous plasma t-PA concentrations obtained from a given tissue
bed are composed of three components; circulating arterial t-PA, basal
or constitutive endothelial cell release of t-PA and facultative or
stimulated endothelial cell release of t-PA. The net tissue release of
t-PA is equivalent to the product of the plasma flow through the tissue
and the arteriovenous difference in plasma t-PA concentrations across
it. In the absence of endothelial cell stimulation, but with an increase in
blood flow across the tissue bed, venous plasma t-PA concentrations
would be expected to fall secondary to a dilutional effect. However, this
ignores the potential for clearance of t-PA across the vascular bed (43),
and stimulation of its release by shear stress and flow (44,45). Without
measuring the arteriovenous concentration gradient across the forearm,
net tissue release can only be derived and estimated. However, arterial
sampling requires the insertion of large bore cannulae which do not
lend themselves to multiple cannulations within the same subject.
There is also the potential to introduce artefact from the presence of a
larger thrombogenic surface given that activated factor Xa is the most
Fig. 1 Dose ranging study: percen¬
tage change and absolute forearm
blood flow responses to incremental
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Fig. 2 Dose ranging study: venous plasma tissue plasminogen activator
(t-PA) antigen (O) and activity (□), and plasminogen activator inhibitor type 1
(PAI-1) antigen (A) and activity (❖) concentrations in the infused (closed sym¬
bols) and non-infused (open symbols) forearms in response to substance P
infusions (n = 7). Maximum substance P dose was 64 pmol/min in 5 subjects
and 128 pmol/min in 2 subjects, p <0.001 for all t-PA concentrations (ANOVA)
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Fig. 3 Local forearm study: venous plasma tissue plasminogen activator
(t-PA) antigen (O) and activity (□), and plasminogen activator inhibitor type 1
(PAI-1) antigen (A) and activity (❖) concentrations in the infused (closed
symbols) and non-infused (open symbols) forearms in response to sodium
nitroprusside and substance P infusions (n = 12). * p <0.001 (ANOVA)
potent stimulant for t-PA release yet known (3). Rather than assessing
arteriovenous differences, we have compared venous plasma t-PA
concentrations between infused and non-infused arms and have used
very fine gauge arterial cannulae for drug administration only. This
method may potentially underestimate the net release of t-PA and fail to
detect a modest effect due to the potential flow dependent, dilutional
changes in venous concentrations. However, typical resting arterio¬
venous differences are only -10% of the total venous concentra¬
tion (42, 46) and the basal constitutive release of t-PA antigen is
-0.9 ng/100 ml of tissue/min in the forearm (42). Thus, in the presence
of large increases in t-PA release, the dilutional effect of increased blood
flow on constitutive t-PA release will be reduced. Indeed, using this
bilateral venous sampling methodology, we have been able to demon¬
strate a substantial, dose-dependent release of t-PA from the forearm
vascular bed in response to substance P infusion. Moreover, despite in
vitro evidence that t-PA release may be influenced by shear stress
(44, 45), we have found that the endothelium independent nitric oxide
donor, sodium nitroprusside, has no significant effect on the venous
t-PA concentrations despite comparable increases in blood flow to
those with substance P. Sodium nitroprusside is known to have no
direct effect on the endothelial cell release of t-PA and PAI-1 in vitro
(47) and, therefore, it is likely that either shear stress and flow depen¬
dent stimulation of endothelial cell t-PA release is counterbalanced by
the potential dilutional effects of increased flow, or that this theoretical
flow dependence of venous concentrations is negligible. This also
indicates that increases in nitric oxide and blood flow are not sufficient
in themselves to release t-PA from the endothelium. However, it
remains a possibility that the L-arginine : nitric oxide pathway plays a
role in substance P-induced t-PA release and requires further studies
using a combined infusion of substance P and a nitric oxide synthase
inhibitor such as L-/V°-monomethyl arginine.
Although we have produced substantial increases in both t-PA
activity and antigen, we did not detect release of PAI-1, or the coagula¬
tion factors, vWf and factor VIII: C. This would indicate that these
agents are not stored in a rapidly translocatable pool within the endo¬
thelial cells of the forearm vascular bed or that they are not released in
response to substance P over the time course and at the doses used here.
However, protracted endothelial cell stimulation may release these
factors (7, 9). In this respect, it is interesting to note the time dependent
reduction in PAI-1 concentrations seen in our studies, although these
only achieved statistical significance in the non-infused arm during
the dose ranging study. The most likely explanation for a reduction in
PAI-1 is that the released and active t-PA is complexed by circulating
PAI-1 and subsequently cleared from the circulation by the liver (48).
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Thus, substantial local t-PA release will tend to reduce systemic PA1-1
concentrations in the short term, as seen with the administration of
pharmacological doses of t-PA (49).
As anticipated, local substance P infusion did not affect the rate of
release of hepatically derived factor VIII: C. In contrast, it is perhaps
surprising that we did not observe a rise in plasma vWf concentrations
to accompany the release of t-PA. To date, stimulation of t-PA release
using a wide range of secretagogues such as thrombin, vasopressin,
bradykinin, histamine and desmopressin, has invariably been accompa¬
nied by concomitant vWf release (7,50, 51). However, we were unable
to detect an acute local release of vWf even in the presence of high lo¬
cal concentrations of substance P in the dose ranging study. This novel
selectivity suggests that the endothelium is able to mobilise different
cytoplasmic storage pools in response to specific (NK,) receptor
stimulation. Further studies with more prolonged infusions of substance
P would be required to determine whether the endothelial cell vWf or
PA1-1 release is delayed or is truly not influenced by substance P.
In summary, brief, locally active and subsystemic infusions of intra¬
arterial substance P produce a rapid and substantial increase in plasma
t-PA activity and antigen concentrations across the forearm bed which
appear to act via a flow and nitric oxide independent mechanism. This
model provides a powerful method of assessing the in vivo capacity of
the endothelium to acutely release t-PA within the forearm vascular bed
and would be applicable to the assessment of diseases associated with
endothelial dysfunction, such as hypercholesterolemia (52).
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Abstract
Objective: Effective endogenous fibrinolysis requires rapid release of endothelial tissue plasminogen activator (t-PA). Using the nitric
oxide synthase inhibitor, t-JV*' monomethylargininc (l-MMMA), we examined the contribution of endogenous nitric oxide to 3ubstancc
P-induced t-PA release in vivo in man. Methods: Blood flow and plasma fibrinolytic and haemostatic factors were measured in both
forearms of 8 healthy male volunteers who received unilateral brachial artery infusions of substance P (2-8 pmol/min) and l-NMMA
(1-4 p.g/min). Results: Substance P caused dose-dependent increases in blood flow (P < 0.001) and plasma t-PA antigen (P = 0.04)
and activity (P< 0.001) concentrations confined to the infused forearm, but had no effect on plasminogen activator inhibitor type 1
(PA1-1) or von Willebrand factor concentrations. In the presence of l-MMMA, substance P again caused significant increases in blood
flow (P < 0.001) and t-PA antigen (P = 0.003) and activity (P < 0.001) concentrations but these increases were significantly less than
with substance P alone (P < 0.001, P = 0.05 and P < 0.01, respectively). l-NMMA alone significantly reduced blood flow in the infused
arm, but had no measurable effect on t-PA or PAI-1 concentrations. Conclusions: The L-arginine/nitric oxide pathway contributes to
substance P-induced t-PA release in vivo in man. This provides an important potential mechanism whereby endothelial dysfunction
increases the risk of atherothrombosis through a reduction in the acute fibrinolytic capacity. © 1998 Elsevier Science B.V. All rights
reserved.
Keywords: Thrombolysis; Endothelial factor; Nitric oxide; Blood flow; Endothelial function
1. Introduction
The endogenous fibrinolytic system can have important
clinical effects as exemplified by the observation that in
~ 30% of patients with an acute myocardial infarction, the
infarct-related artery spontaneously reperfuscs within 12 h
[1-3]. The ability of the endothelium to release tissue
plasminogen activator (t-PA) rapidly is crucial if endoge¬
nous fibrinolysis within the arterial circulation is to be
effective, with thrombus dissolution being much more
effective if t-PA is incorporated during, rather than after,
thrombus formation [4,5]. Epidemiological studies in a
healthy male population and patients with ischaemic heart
disease have shown a relationship between plasma fibri¬
nolytic parameters and future cardiovascular events, such
as stroke or myocardial infarction [6-9]. However, the
capacity of endothelial cells to release t-PA from intra¬
cellular storage pools, and the rapidity with which this can
be mobilised, may not be reflected in the basal circulating
plasma concentrations of t-PA antigen or activity [10],
Endothelial cell culture techniques have limitations in
the investigation of t-PA release and may not be truly
representative of the in vivo function of these cells. The
amount of t-PA released in culture is small and necessi-
Corresponding author. Tel.: +44 (131) 332-1205; Fax: +44 (131)
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tates prolonged incubation periods and sensitive assays.
Moreover, the phenotype of endothelial cells in culture,
and the ability to release t-PA, changes with increasing
passages. In contrast, under in vivo physiological condi¬
tions, the endothelium is arranged within a non-planar
three-dimensional vascular bed, has a more favourable
volume to surface area ratio, and is exposed to pulsatile
blood flow and pressure changes. We have recently de¬
scribed an in vivo model to assess acute t-PA release in
man [11], Using intra-brachial infusions of substance P, we
have shown a dose-dependent release of t-PA from the
human forearm without causing significant release of von
Willebrand factor (vWf) or plasminogen activator inhibitor
type 1 (PAI-1). This suggests either a selective action of
substance P or the lack of a rapidly translocatabie pool of
PAI-1 and vWf. However, we have previously used only
brief (~ 10 min) substance P infusions [11] and protracted
stimulation may release these factors [12-14].
Substance P causes endothelium dependent vasodilata¬
tion [15] which is mediated by the endothelial cell neu¬
rokinin type 1 receptor [16] and is, in part, related to the
release of nitric oxide [17-19]. However, because t-PA
release is not seen with infusions of the nitric oxide donor
and vasodilator, sodium nitroprusside [11,20], an increase
in nitric oxide and blood flow together do not release t-PA
from the endothelium. Nevertheless, it remains a possibil¬
ity that the l-arginine/nitric oxide pathway contributes to
substance P-induced t-PA release.
Therefore, the aims of the current study were two-fold:
first, to ascertain whether prolonged substance P infusion
can cause vWf or PAI-1 release; and second, to determine
whether nitric oxide synthase inhibition using l-AG-mono-




Eight healthy men aged between 20 and 33 years
participated in three studies which were undertaken with
the approval of the local research ethics committee and in
accordance with the Declaration of Helsinki. The written
informed consent of each subject was obtained before
entry into the study. None of the subjects received vasoac¬
tive or non-steroidal anti-inflammatory drugs in the week
before each phase of the study, and all abstained from
alcohol for 24 h, and from food, tobacco and caffeine-con¬
taining drinks for at least 5 h, before each study. All
studies were performed in a quiet, temperature-controlled
room maintained at 23.5-24.5°C.
2.2. lntra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannu-
lated with a 27-standard wire gauge steel needle (Cooper's
Needle Works, Birmingham, UK) under 1% lignocaine
(Xylocaine; Astra Pharmaceuticals, Kings Langley, UK)
local anaesthesia. The cannula was attached to a 16-gauge
epidural catheter (Portex, Hythe, UK) and patency main¬
tained by infusion of saline (0.9%: Baxter Healthcare,
Thetford, UK) via an IVAC PI000 syringe pump (IVAC,
Basingstoke, UK). The total rate of intra-arterial infusions
was maintained constant throughout all studies at 1
ml/min. Pharmaceutical-grade substance P (Clinalfa,
Laufelfmgen, Switzerland) and l-AG-monomethylarginine
(l-NMMA; Clinalfa) were administered following dissolu¬
tion in saline.
2.3. Forearm bloodJlow and blood pressure
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic strain
gauges applied to the widest part of the forearm [21],
During measurement periods, the hands were excluded
from the circulation by rapid inflation of the wrist cuffs to
a pressure of 220 mmHg using E20 Rapid Cuff Inflators
(D.E. Hokanson, Washington, USA). Upper arm cuffs
were inflated intermittently to 40 mmHg for 10 s in every
15 s to achieve venous occlusion and obtain plethysmo-
graphic recordings. Analogue voltage output from an EC-4
Strain Gauge Plethysmograph (D.E. Hokanson) was pro¬
cessed by a MacLab analogue-to-digital converter and
Chart v3.3.8 software (AD Instruments, Castle Hill, Aus¬
tralia) and recorded onto a Macintosh Classic II computer
(Apple Computers, Cupertino, USA). Calibration was
achieved using the internal standard of the plethysmo¬
graph.
Blood pressure was monitored in the non-infused arm at
intervals throughout each study using a semi-automated
non-invasive oscillometric sphygmomanometer [22]
(Takeda UA 751, Takeda Medical, Tokyo, Japan).
2.4. Venous sampling and assays
Venous cannulae (17-gauge) were inserted into large
subcutaneous veins of the antecubital fossa in both arms as
described previously [23], Ten ml of blood was withdrawn
simultaneously from each arm and collected into acidified
buffered citrate (Biopool Stabilyte, Umea, Sweden; for
t-PA assays) and citrate (Monovette, Sarstedt, Niimbrecht,
Germany; for PAI-1 assays) tubes, and kept on ice before
being centrifuged at 2000 g for 30 min at 4°C. Platelet-free
plasma was decanted and stored at — 80°C before assay.
Plasma PAI-1 and t-PA antigen concentrations were
determined using an enzyme-linked immunosorbent assay
(ELISA); Coaliza PAI-1 [24] and Coaliza t-PA [25] (Chro-
mogenix AB, Molndal, Sweden) respectively. Plasma PAI-
1 and t-PA activities were determined by a photometric
method, Coatest PAI-1 [26] and Coaset t-PA [27] (Chro-
mogenix). Intra-assay coefficients of variation were 7.0
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and 5.5% for t-PA and PAI-1 antigen, and 4.0 and 2.4%
for activity, respectively. Inter-assay coefficients of vari¬
ability were 4.0, 7.3, 4.0 and 7.6%, respectively. The
sensitivities of the assays were 2.5 ng/ml, 0.5 ng/ml, 5
AU/ml and 0.10 lU/ml, respectively. vWf antigen was
determined [28] using an EL1SA (Dako, Glostrup, Den¬
mark) with a sensitivity of 0.05 IU/ml. The intra-assay
and inter-assay coefficients of variability were 5.2 and
7.3%, respectively. Factor VIIPC procoagulant activity
was determined using a standard one-stage assay on an
ACL-3000 + coagulometer (Instrumentation Laboratory,
Warrington, UK). Haematocrit was determined by capil¬
lary tube centrifugation of blood anticoagulated by ethy¬
lene diamine tetraacetic acid and was obtained from the
infused forearm at baseline and at 120 min.
2.5. Study design
On 3 separate occasions, at 09.00 h, subjects attended
fasted and rested recumbent throughout each study. Strain
gauges and cuffs were applied and the brachial artery of
the non-dominant ami cannulated. Throughout all proto¬
cols, measurements of forearm blood flow were made
every 10 min. Saline was infused for the first 30 min to
allow time for equilibration and the final blood flow
measurement during saline infusion was taken as the basal
forearm blood flow. Thereafter, subjects underwent the
following protocols, in random order, each separated by at
least 1 week: protocol 1, each subject received intra-arterial
substance P at 2, 4 and 8 pmol/min, for 10 min at each
dose, followed by a continuous infusion of 8 pmol/min
for a further 90 min; protocol 2, l-NMMA was co-infused
at 4 p.mol/min for 10 min before and throughout the same
substance P infusion as protocol 1; and protocol 3, subjects
received intra-arterial l-NMMA at 1, 2 and 4 p,mol/min
for 10 min at each dose followed by a continuous infusion
of 4 p.mol/min for a further 90 min. Venous samples
were withdrawn from each arm at baseline and at 10, 20,
30, 50, 80 and 120 min after the start of substance P (for
protocols 1 and 2) or l-NMMA infusion (protocol 3).
2.6. Data analysis and statistics
Plethysmography data were extracted from the Chart
data files and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel v4.0; Microsoft, Cambridge,
USA). Recordings from the first 60 s after wrist-cuff
inflation were not used because of the reflex vasoconstric¬
tion this causes [21]. Usually, the last five flow recordings
in each 3-min measurement period were calculated and
averaged for each arm. Estimated net release of t-PA
activity and antigen was defined previously [11] as the
product of the infused forearm plasma flow (based on the
mean haematocrit, HCt, and the infused forearm blood
flow, FBF) and the concentration difference between the
infused ([t-PA]inf) and non-infused arms ([t-PA]non.inf).
Estimated net t-PA release
= FBF X {1 - HCt} X {[t-PA]inf
- [t-PA]non.inf}
Data were examined, where appropriate, by two-way
analysis of variance (ANOVA) with repeated measures
and two-tailed paired Student's /-test using Excel v4.0
(Microsoft). Tachyphylaxis was assessed by comparing the
30-min (peak) and 120-min (final) values with a two-tailed
paired Student's /-test. Area under the curve (AUC) was
calculated for the estimated net release of t-PA across the
study period. All results are expressed as mean + s.e.nr.
Statistical significance was taken at the 5% level.
3. Results
All subjects were normotensive and there were no
significant changes in blood pressure, heart rate or blood
flow in the contralateral arm throughout any of the studies
(Table 1). Haematocrit decreased slightly in each study
(Table 1). Between the 3 protocols, there were no signifi¬
cant differences in the baseline values of blood pressure,
Table I
Haemodynamics and haematocrit at baseline and completion of the 3 study protocols
Substance P alone l-NMMA alone Substance P + l-NMMA
Basal Final Basal Final Basal Final
Blood pressure (mmHg)
Systolic 137 ± 3 136 + 3 135 + 5 136 + 5 133 + 6 132 + 6
Diastolic 71 ±2 71 ±3 68 + 3 71+3 69 + 4 70 + 5
Heart rate (/min) 65 ±4 61+3 59 + 2 58 + 3 60 + 3 61 ±3
Absolute forearm blood flow (ml/100 ml/min)
Non-infused arm 3.1 +0.3 3.7 + 0.5 3.4 + 0.7 3.6 + 0.6 3.6 + 0.5 4.9 + 0.
Infused arm 3.6 + 0.4 12.1 ±1.3" 3.9 + 0.7 2.1+0.2 4.2 + 0.7 9.3 + 1.
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heart rate, forearm blood flow, haematocrit or plasma
concentrations of t-PA and PAI-1 antigen and activity.
3.1. Isolated infusions of substance P and L-NMMA
Substance P increased blood flow in the infused arm
(P < 0.001) in a dose-dependent manner (Fig. 1 and Table
2) reaching a maximum increase of 15.9+ 1.9 ml/100
ml/min after 10 min at 8 pmol/min. Following prolonged
infusion, substance P-induced vasodilatation demonstrated
tachyphylaxis and decreased to 12.1 + 1.3 ml/100 ml/min
after 100 min of substance P at 8 pmol/min (P < 0.003
vs. 10 min). In comparison to the non-infused arm, sub¬
stance P caused a dose-dependent increase in venous
plasma t-PA activity (P < 0.001) and antigen (P<0.04)




significant tachyphylaxis (Fig. 2). Concentrations of plasma
PAI-1 activity were also reduced in the infused arm (P =
0.04; Fig. 2). In contrast, there were no significant changes
in plasma PAI-1 antigen, vWf or factor VIII:C concentra¬
tions in either arm (Fig. 2 and Table 2).
l-NMMA decreased blood flow in the infused arm
(P < 0.001) in a dose-dependent manner (Fig. 1 and Table
2) reaching 2.1 + 0.2 ml/100 ml/min after 100 min at 4
p,mol/min. There were no significant changes in the
concentrations of plasma t-PA and PAI-1 antigen or activ¬
ity in either arm during infusion of l-NMMA (Fig. 2).
3.2. Co-infusion of L-NMMA and substance P
In the presence of l-NMMA, substance P increased
blood flow in the infused arm {P < 0.001) in a dose-de-
Time (min)
Fig. 1. Infused forearm blood flow and estimated net release of t-PA antigen and activity during protocol 1 (substance P alone, O), protocol 2 (substance P
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Table 2
Blood flow and plasma von Willebrand's factor and factor VIU:C activity concentrations in both arms during isolated substance infusion: protocol 1
Baseline Time (min)
10 20 30 50 80 120
Substance P dose (pmol/min) 0 2 4 8 8 8 8
Absolute forearm blood flow (ml/100 ml/min)
Non-infused arm 3.1 ±0.3 3.3 ±0.3 3.4 ±0.4 3.3 ±0.3 3.5 ±0.3 3.8 ± 0.4 3.7±0.5
Infused arm 3.6 + 0.4 11.8± 1.8 13.8 ± 1.9 15.9 ± 1.9 14.5 ±1.7 12.6 ±1.2 12.1 ±1.3°
von Willebrand's factor (IU/ml)
Non-infused arm 0.84 + 0.13 0.64 ±0.10 0.85 ±0.13 0.60 ±0.09 0.95 ±0.18 0.80±0.10 1.20 ±0.16
Infused arm 0.73 ±0.09 0.72 ±0.15 0.73 ±0.11 0.86±0.20 0.98 ±0.16 0.99±0.17 1.03 ±0.17
Factor V11LC (Ill/ml)
Non-infused arm 0.50 ±0.06 0.48 ±0.04 0.51 ±0.05 0.51 ±0.05 0.58 ±0.09 0.65±0.10 0.72 ±0.09
Infused arm 0.50 ±0.05 0.50 ±0.05 0.51 ±0.07 0.52 ±0.07 0.64 ±0.07 0.64 ±0.08 0.69 ±0.10
"P< 0.001.
pendent manner (Fig. 1) reaching a maximum increase of
13.7 ± 1.7 ml/100 ml/min after 10 min at 8 pmol/min.
This response underwent tachyphylaxis and decreased to
9.3 + 1.4 ml/100 ml/min after 100 min of substance P at
8 pmol/min (P < 0.002 vs. 10 min). In comparison, with
the non-infused arm, substance P co-infused with l-NMMA
caused a dose-dependent increase in plasma t-PA activity
(P < 0.001) and antigen (P < 0.003) concentrations of the
infused arm which did not undergo significant tachyphy¬
laxis (Fig. 2). l-NMMA caused a significant attenuation of
substance P-induced increases in blood flow (P < 0.001)
and plasma t-PA activity concentrations (P < 0.003) in the
infused forearm, but not plasma t-PA antigen.
3.3. Estimated net t-PA production
l-NMMA infused alone had no significant effects on
t-PA release: 95% confidence intervals for t-PA antigen
and activity release are 0.31 to —0.68 ng/100 ml/min
and 0.27 to —0.06 IU/100 ml/min, respectively. Sub-
Fig. 2. Plasma concentrations of t-PA and PA1-1 antigen (solid lines) and activity (dashed lines) in the infused (• and ■, respectively) and non-infused
(O and □, respectively) arms in the 3 protocols. * P < 0.001; ^P < 0.003; ^ P < 0.04 (ANOVA).
490 D.E. Newby el at. / Cardiovascular Research 38 (1998) 485-492
stance P caused dose-dependent increases in the estimated
net release of t-PA antigen and activity in the presence or
absence of l-NMMA (P < 0.001) which did not undergo
significant tachyphylaxis. However, the magnitude of the
increase in release of both t-PA antigen (P=0.05) and
activity (Z5 < 0.01) was significantly reduced in the pres¬
ence of l-NMMA (Fig. 1). l-NMMA reduced the AUC for
the substance P-induced release of t-PA antigen and activ¬
ity by 40 and 46% respectively.
4. Discussion
We have shown that intra-brachial substance P infusion
increases forearm blood flow and plasma t-PA concentra¬
tions for up to 2 h without a demonstrable effect on plasma
PAI-1 or vWf concentrations. Although the nitric oxide
synthase inhibitor, l-NMMA, significantly reduced fore¬
arm blood flow without affecting basal t-PA release, it
inhibited the increases in blood flow, plasma t-PA concen¬
trations and t-PA release produced by substance P adminis¬
tration in the forearm. These data suggest that the l-
arginine/nitric oxide pathway contributes to substance
P-induced t-PA release in vivo in man. In contrast, we [11]
and others [20] have shown previously that t-PA release is
not seen with the large local increases in nitric oxide
delivery and blood flow associated with infusions of the
nitric oxide donor, sodium nitroprusside. Taken together,
these findings indicate that increases in nitric oxide and
blood flow are not sufficient per se to release t-PA but,
through the l-arginine/nitric oxide pathway, are able to
enhance substance P-induced t-PA release.
The permissive role of intracellular mediators in the
mechanism of t-PA release has been described previously.
In the rat perfused hindlimb model, increasing intracellular
calcium alone is insufficient to cause t-PA release whilst it
is essential for bradykinin induced t-PA release [29]. How¬
ever, the regulation of t-PA release is complex and may
involve several signal transduction pathways [30]. This is
reflected by the diversity of mediators, such as thrombin,
bradykinin and desmopressin, which can release t-PA and
increase t-PA activity [12,13,31,32]. One can, therefore,
only speculate as to whether our findings extend to the
acute t-PA release seen with in situ thrombosis. However,
both nitric oxide mediated endothelial dysfunction [33-36]
and abnormalities of endogenous fibrinolysis [6-9] have
been described in many atherosclerotic diseases and the
associated risk factors. Thus, the coupling of acute t-PA
release to the l-arginine/nitric oxide pathway provides an
important potential mechanism whereby endothelial dys¬
function might increase the risk of atherothrombosis
through a reduction in the acute fibrinolytic capacity. Our
initial findings would suggest that this model could be
applied to the assessment of the acute fibrinolytic capacity
of patients with endothelial dysfunction such as those with
hypercholesterolaemia and a smoking habit [35,36], and to
the examination of the subsequent effect of L-arginine
supplementation.
Substance P-induced vasodilatation undergoes tachy¬
phylaxis [37] which may relate to internalisation of the
neurokinin type 1 receptor from the endothelial cell sur¬
face membrane [38], It has been suggested from ex vivo
animal studies [15,39] that the residual vasodilatation fol¬
lowing the development of tachyphylaxis is almost com¬
pletely nitric oxide-dependent. In the present study, the
degree of inhibition of substance P-induced vasodilatation
by l-NMMA was less than we [18] and others [17] have
previously described and may reflect the higher potency
and doses used in this study. Whilst we have readily
demonstrated tachyphylaxis of substance P-induced vaso¬
dilatation, the co-infusion of l-NMMA did not affect the
development of tachyphylaxis and did not abolish the
residual substance P-induced vasodilatation following its
development. Thus, in contrast to animal studies, residual
vasodilatation after the development of tachyphylaxis does
not appear to be predominantly nitric oxide mediated in
the human forearm. In addition, we were unable to detect
significant tachyphylaxis of substance P-induced increases
in plasma t-PA antigen and activity concentrations, sug¬
gesting that not all the actions of substance P undergo
tachyphylaxis.
The substance P-induced reductions in plasma PAI-1
activity of the infused arm without significant alterations
in PAI-1 antigen concentrations are consistent with acute
t-PA release in the absence of PAI-1 release [40], PAI-1
binds to the newly released t-PA to form an inactive
PAI-1 /t-PA complex, thereby reducing the plasma PAI-1
activity. The trend for PAI-1 antigen concentrations to fall
in both arms as the study progressed is consistent with
systemic (hepatic) clearance of the PAI-1/t-PA complex
[40-42], However, this trend was also seen with isolated
l-NMMA infusion in which there was no significant re¬
lease of t-PA consistent with a circadian fall of PAI-1
antigen during the morning [43].
Despite reducing foreann blood flow by half, l-NMMA
did not significantly affect the constitutive release or plasma
concentrations of t-PA and PAI-1 antigen and activity. The
95% confidence intervals indicates that if l-NMMA has an
effect on basal t-PA or PAI-1 release then it is rather
small. This suggests that the l-arginine/nitric oxide path¬
way does not play a major role in the basal release of t-PA
or PAI-1 in the peripheral vasculature of man.
4.1. Study limitations
Since the derivation of t-PA release is a function of
plasma flow, it could be argued that the inhibition by
l-NMMA of substance P-induced t-PA release reflects the
simultaneous reduction in blood flow. However, the reduc¬
tion in absolute blood flow was only modest (15-20%) in
comparison to the reduction in t-PA release (40-46%) and
the plasma t-PA activity concentrations in the infused
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forearm were also significantly reduced by co-infusion of
l-NMMA. The findings of the present study would be
strengthened by utilising a control vasoconstrictor and
demonstrating a neutral effect on substance P-induced
t-PA release. However, standard receptor coupled vasocon¬
strictors used in forearm studies, such as noradrenaline,
vasopressin and angiotensin II, are known to stimulate
t-PA and PAI-1 release [12,14,32,44] and would not help
in interpreting the influence of l-NMMA on substance
P-induced t-PA release.
We have previously been unable to detect an acute local
release of either vWf or PAI-1 during 10-min infusions of
substance P given at 8-fold higher concentrations [11]. In
the present study, substance P did not cause significant
vWf or PAI-1 release, despite infusion times of up to 120
min, suggesting that the dissociation of substance P-in-
duced t-PA release from vWf is not a temporal effect.
However, this dissociated release does not appear to be
unique to substance P since this has also been recently
described with local forearm infusions of desmopressin
[45]. These findings are, however, limited to the peripheral
forearm vascular bed and the endothelium in other tissue
beds may respond differently to substance P stimulation.
The extension of this model to vascular beds associated
with atherosclerosis such as the coronary circulation, will
be of crucial relevance in determining the influence of
atheroma and endothelial dysfunction on the acute local
release of t-PA during thrombotic occlusion and plaque
rupture.
In summary, in the forearm vascular bed in vivo, we
have shown for the first time that the l-arginine/nitric
oxide pathway contributes to substance P-induced t-PA
release in man. This coupling of acute t-PA release to the
l-arginine/nitric oxide pathway provides an important
potential mechanism whereby endothelial dysfunction in¬
creases the risk of atherothrombosis through a reduction in
the acute fibrinolytic capacity.
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Endothelin-1 does not contribute to
the release of tissue plasminogen
activator in vivo in man
D.E. Newby, F.E. Strachan, N.R. Johnston, D.J. Webb
Clinical Pharmacology Unit and Research Centre, University ol Edinburgh, Western General Hospital, Edinburgh, UK
Summary Objectives: Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with autocrine and
paracrine actions. Tissue plasminogen activator (t-PA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1),
are also released from the vascular endothelium and play a pivotal role in endogenous fibrinolysis. We, therefore,
examined the effects of exogenous and endogenous endothelin-1 on t-PA and PAI-1 release in vivo in man.
Design: Open investigative study.
Settings. Clinical Research Centre, University of Edinburgh.
Subjects: Fourteen healthy male volunteers.
Interventions: Unilateral brachial artery infusions of endothelin-1 at 2.5 and 10 pmol/min, and the selective endothelin
type B (ETb) receptor antagonist, BQ-788, at 1 nmol/min.
Main outcome measures: Blood, flow and plasma fibrinolytic factors were measured in both forearms using venous
occlusion plethysmography and venous blood samples withdrawn from the antecubital fossae.
Results: Endothelin-1 caused a slow onset dose-dependent forearm vasoconstriction (P<0.001) with a maximal
reduction in blood flow of 40 ± 4% and 63 ± 3% at 2.5 and 10 pmol/min respectively. BQ-788 also caused a slow onset
reduction in forearm blood flow (P<0.001) reaching a maximum of 21 ± 3%. However, BQ-788 and endothelin-1 did not
affect plasma concentrations of t-PA or PAI-1 in the venous effluent of the infused forearm.
Conclusions: Despite sustaining significant vasoconstriction, neither endogenous nor exogenous endothelin-1
influences the release of t-PA or PAI-1 in the forearm vascular bed of man. This suggests that endothelin-1 does not
provide a major contribution to the regulation of endogenous fibrinolysis in man. © Harcourt Publishers Ltd 1999
INTRODUCTION
Endothelial cells in the precapillary arterioles and post¬
capillary venules' synthesize and release t-PA and PAI-1
both basally and in response to stimulation by various
coagulation factors and stimulants. The time course of t-
PA release is important since clot dissolution is much
more effective if t-PA is incorporated during clot forma¬
tion rather than following completion.23 The acute
release of t-PA results from the rapid translocation of a
dynamic intracellular storage pool4 and plays a pivotal
•role in endogenous fibrinolysis.
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Endothelin-1 is a potent endothelium-derived vaso¬
constrictor peptide with autocrine and paracrine actions.
It is continuously released by the endothelium and con¬
tributes to the maintenance of basal vascular tone5 and
blood pressure.6 There are two main endothelin receptor
subtypes, ETA and ETB, but only the ETB receptors are pre¬
sent on the endothelium. Endothelin-1 causes vasocon¬
striction mainly through stimulation of the smooth
muscle cell ETA receptor, although smooth muscle ETB
receptors may also contribute in some vessel types. This
vasoconstrictor response is modulated by autocrine
endothelial cell ETB receptor-mediated generation of the
endothelium-derived vasodilators, nitric oxide and
prostacyclin.
The importance of endogenous t-PA release is exempli¬
fied by the high rate of spontaneous reperfusion in the
infarct-related artery after acute myocardial infarction,
occurring in around 30% of patients within the first 12 h.7-9
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Following an acute myocardial infarction, plasma endothe¬
lial concentrations are elevated and provide an important
prognostic marker of survival at 1 year.10 Furthermore, on
the basis of in vitro studies, it has been suggested that
endothelin-1 may contribute to the regulation of endoge¬
nous fibrinolysis and t-PA release.11"13 However, the evi¬
dence is contradictory, with endothelin-1 being found to
either inhibit13 or stimulate"12 endothelial cell t-PA release.
The role of endothelin-1 in the regulation of endogenous
fibrinolysis in man is currently unknown.
We,1415 and others,1617 have shown, using bilateral fore¬
arm venous occlusion plethysmography and unilateral
brachial artery infusions, that the forearm release of t-PA
and PAI-1 can be determined in vivo in man. Therefore,
the aim of the current study was, using synthetic
endothelin-1 peptide and the selective ETB receptor
antagonist, BQ-788, to determine whether endothelin-1,
of exogenous or endogenous origin, acts via the
endothelial ETB receptor to regulate the release of t-PA or
PAI-1 in vivo in man.
MATERIALS AND METHODS
Subjects
Fourteen healthy men aged between 20 and 33 years
participated in three studies which were undertaken with
the approval of the local research ethics committee and
in accordance with the Declaration of Helsinki. The writ¬
ten informed consent of each subject was obtained
before entry into the study. None of the subjects received
vasoactive or non-steroidal anti-inflammatory drugs in
the week before each phase of the study, and all
abstained from alcohol for 24 h, and from food, tobacco
and caffeine-containing drinks for at least 9 h, before
each study. All studies were performed in a quiet, tem¬
perature-controlled room maintained at 23.5-24.5°C.
Intra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannu-
lated with a 27-standard wire gauge steel needle
(Cooper's Needle Works Ltd, Birmingham, UK) under 1%
lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings
Langley, UK) local anaesthesia. The cannula was attached
to a 16-gauge epidural catheter (Portex Ltd, Hythe, UK)
and patency maintained by infusion of saline (0.9%:
Baxter Healthcare Ltd, Thetford, UK) via an IVAC PI000
syringe pump (IVAC Ltd, Basingstoke, UK). The total rate
of intra-arterial infusions was kept constant throughout
all studies at 1 mL/min. Endothelin-1 (Clinalfa AG,
Laufelfingen, Switzerland) and BQ-788 (American Peptide
Company, Sunnyvale, USA) were administered following
dissolution in saline.
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Forearm blood flow and blood pressure
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
strain gauges applied to the widest part of the fore¬
arm.1819 During measurement periods the hands were
excluded from the circulation by rapid inflation of the
wrist cuffs to a pressure of 220 mmHg using E20 Rapid
Cuff Inflators (D.E. Hokanson Inc, Washington, USA).
Upper arm cuffs were inflated intermittently to 40 mmHg
for 10 s in every 15 s to achieve venous occlusion and
obtain plethysmography recordings. Analogue voltage
output from an EC-4 Strain Gauge Plethysmograph p.E.
Hokanson) was processed by a MacLab* analogue-to-dig¬
ital converter and Chart i>3.3.8 software (AD Instruments
Ltd, Castle Hill, Australia) and recorded onto a Macintosh
Classic II computer (Apple Computers Inc, Cupertino,
USA). Calibration was achieved using the internal stan¬
dard of the plethysmograph.
Blood pressure was monitored in the non-infused arm
at intervals throughout each study using a semi-auto-
mated non-invasive oscillometry sphygmomanometer
(Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).20
Venous sampling and assays
Venous cannulae (17G) were inserted into large subcuta¬
neous veins of the antecubital fossa in both arms. Ten mL
of blood was withdrawn simultaneously from each arm
and collected into acidified buffered citrate (Biopool*
Stabilyte™, Umea, Sweden; for t-PA assays) and citrate
(Monovette", Sarstedt, Numbrecht, Germany; for PAI-1
assays) tubes, and kept on ice before being centrifuged at
2000 g for 30 min at 4°C. Platelet-free plasma was
decanted and stored at -80°C before assay.21
Plasma PAI-1 and t-PA antigen concentrations were
determined using an enzyme-linked immunosorbent
assay (ELISA); Coaliza* PAI-1 [22] and Coaliza* t-PA23
(Chromogenix AB, Molndal, Sweden) respectively. Plasma
t-PA activities were determined by a photometric method,
Coaset* t-PA24 (Chromogenix AB). Intra-assay coefficients
of variation were 7 and 5.5% for t-PA and PAI-1 antigen,
and 4% for t-PA activity respectively. Inter-assay coeffi¬
cients of variability were 4, 7.3 and 4% respectively. The
sensitivities of the assays were 2.5 ng/mL, 0.5 ng/mL and
0.10 lU/mL respectively. Haematocrit was determined by
capillary tube centrifugation of blood anticoagulated by
ethylene diamine tetraacetic acid and was obtained from
the infused forearm at baseline and at 120 min.
Study design
On each study day, subjects attended fasted and rested
recumbent throughout the study. Strain gauges and cuffs
© Harcourt Publishers Ltd 199i


















Fig. 1 Absolute (mL/100 mL of tissue/min: upper panel) and
percentage (% relative to the non-infused forearm: lower panel)
change of blood flow in the infused forearm during intra-arterial
infusion of BQ-788 (1 nmol/min;0) and endothelin-1 (2.5
pmol/min:0 and 10 pmol/min: •).
were applied and the brachial artery of the non-domi¬
nant arm cannulated. Throughout each of the studies,
measurements of forearm blood flow were made every 10
min. Before drug administration, saline was infused for
30 min to allow time for equilibration and the final blood
flow measurement during saline infusion was taken as
the basal forearm blood flow.
Eight subjects received an intra-brachial infusion of
endothelin-1 at 2.5 and 10 pmol/min for 120 min, given
in random order, on two separate occasions, at least 1
week apart. Eight subjects (two had also attended for
endothelin-1 infusions) received an intra-brachial infu¬
sion of BQ-788 at 1 nmol/min for 120 min. Venous sam¬
ples were withdrawn from each arm at baseline and at 10,
20, 30, 50, 80 and 120 min after the start of endothelin-1
or BQ-788 infusion.
Data analysis and statistics
Plethysmography data were extracted from the Chart
data files and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel t>5; Microsoft Corporation,
Cambridge, USA). Recordings from the first 60 s after
wrist cuff inflation were not used because of the reflex
vasoconstriction this causes.1819 Usually, the last five flow
recordings in each 3 min measurement period were cal¬
culated and averaged for each arm. To reduce the vari¬
ability of blood flow data, the ratio of flows in the two
arms was calculated for each time point: in effect using
the non-infused arm as a contemporaneous control for
the infused arm.1819 Percentage changes in the infused
forearm blood flow were calculated'819 as follows:
% Change in blood flow =
100 x (1,/NI,—Ib/NIb) /
W,
Where I. and NI. are the infused and non-infused fore-
b b
arm blood flows at baseline (time 0) respectively, and It
and NI, are the infused and non-infused forearm blood
flows at a given time point respectively.
Estimated net release of t-PA activity and antigen was
defined previously1" '5 as the product of the infused fore¬
arm plasma flow (based on the mean haematocrit, HCt,
Table 1 Systemic haemodynamics, forearm blood flow and haematocrit at baseline and after intra-arterial infusion for 120 min.
BQ-788 1 nmol/min
Basal Final
Endothelin-1 2.5 pmol/min Endothelln-1 10 pmol/min
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'PS0.001 (two-way ANOVA; infused vs non-infused)
$P<0.001 (one-way ANOVA)
$P<0.05 (paired t-test; basal vs final)
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and the infused forearm blood flow, FBF) and the con¬
centration difference between the infused ([t-PA]mf) and
non-infused arms ([t-PA]Non inf).
Estimated net t-PA release =
FBF x {1-HCt} x {[t-PA]Inf - [t-PA]Non inf}
Data were examined by two way analysis of variance
(ANOVA) with repeated measures and two-tailed paired
Student's t-test using Excel v5.0 (Microsoft) where appro¬
priate. All results are expressed as mean ± SEM. Statistical
significance was taken at the 5% level. Based on previous
data,1415 the study had 90% power to detect a 20%
change in plasma t-PA concentrations between treatment
periods at the 5% level.
RESULTS
All subjects were normotensive and there were no signif¬
icant changes in blood pressure, heart rate or blood flow
in the contralateral arm throughout any of the studies
(Table 1). Haematocrit decreased slightly in each
endothelin study (Table 1). Between the 3 protocols there
were no significant differences in the baseline values of
blood pressure, heart rate, forearm blood flow, haemat¬
ocrit or plasma concentrations of t-PA and PAI-1.
Endothelin-1 infusions
Endothelin-1 decreased blood flow in the infused arm
(PCO.OOl) in a dose-dependent manner (Fig. 1) reaching a
minimum of 2.5 + 0.3 mL/100 mL/min at 2.5 pmol/min
and 1.6 + 0.1 mI7100 mL/min at 10 pmol/min, after 120
min. This corresponds to a relative reduction in forearm
blood flow of 40 ± 4% and 63 ± 3% respectively. The
plasma concentrations of t-PA and PAI-1 did not change
in the infused arm (Fig. 2) during endothelin-1 infusion
at either concentration (P=NS; one-way ANOVA). In com¬
parison to the non-infused arm, there was a trend
(,P=0.06; two-way ANOVA) for the infused forearm
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Fig. 2 Plasma concentrations of tissue plasminogen activator (t-
PA) antigen (ng/mL; solid lines) and activity (lU/mL; dashed lines)
in the infused (solid circles) and non-infused (open circles) forearm
during intra-arterial infusion of BQ-788 (1 nmol/min) and
endothelin-1 (2.5 and 10 pmol/min).
pmol/min of endothelin-1. However, there were no
significant differences in plasma concentrations of PAI-1
antigen (Table 2) or t-PA activity between the forearms.
Table 2 Plasma plasminogen activator inhibitor type 1 (PAI-1) concentrations (ng/mL) during endothelin-1 (ET-1) and BQ-788 infusion.
Mean ± SEM.
Time (min)
Baseline 10 20 30 50 80 120
BQ-788 (1 nmol/min)
infused arm 39 ± 15 37 ± 13 43 ± 15 41 ± 13 37 ± 12 37 ±12 29 ± 9
non-infused arm 38 ± 13 40 ± 14 43+ 14 41 + 13 37 ± 13 33 ±9 32 + 9
ET-1 (2.5 pmol/min)
infused arm 28 + 7 27 ±5 26 + 6 26 ±5 25 + 5 21 ± 5 20 + 5
non-infused arm 27 ±5 29 + 6 29 ±6 27 ±5 28 ± 7 25 + 5 23 ±4
ET-1 (10 pmol/min)
infused arm 25 + 5 26 + 4 27 ±5 26 ±5 23 ±5 21+4 22 + 5
non-infused arm 27 ±5 27 ±5 26 ±5 25 + 4 24 ±5 ' 23 ±5 22 ±4
Endothclin-1 10 pmol/min
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Fig. 3 Theoretical components of venous plasma t-PA
concentration under basal conditions and during increases (upper
panel) and decreases (lower panel) in blood flow with and without
direct stimulation of t-PA release. Open bars: circulating or arterial
t-PA; grey bars: basal 'constitutive' t-PA released from the tissue
bed; black bars: stimulated 'facultative' t-PA released from the
tissue bed
BQ-788 infusion
In comparison to the non-infused arm, BQ-788 decreased
blood flow in the infused forearm after 120 min (relative
reduction of 21 ± 3%) although the absolute blood flow
was unchanged (Fig. 1 and Table 1). The plasma concen¬
trations of t-PA and PAI-1 (Fig. 2 and Table 2) did not
change in the infused forearm (.P=NS; one-way ANOVA)
or in comparison to the non-infused forearm (F^NS; two-
way ANOVA).
There was no significant net release of t-PA with infu¬
sions of either endothelin-1 or BQ-788 (Table 3).
DISCUSSION
We have demonstrated that, despite causing significant
reductions in blood flow, neither endogenous nor exoge¬
nous endothelin-1 influences the release of t-PA or PAI-1
in the forearm vascular bed of man. This suggests that
endothelin-1 does not contribute to the regulation of
endogenous fibrinolysis in man.
Endothelial cell culture techniques have limitations in
the investigation of t-PA release and may not be truly
representative of the in vivo function of these cells. The
amount of t-PA released in culture is small and necessi¬
tates prolonged incubation periods and sensitive assays.
Moreover, the phenotype of endothelial cells in culture,
and the ability to release t-PA, changes with increasing
passages. This may account for the disparity of our find¬
ings with previous endothelial cell culture studies.13
Studies in intact whole animals have suggested that
systemic endothelin-1 infusion is associated with stimu¬
lation of t-PA release,12 although plasma t-PA concentra¬
tions are not increased by low sub-pressor doses of
endothelin-1 in man.25 Systemic endothelin-1 administra¬
tion, particularly at pressor doses, will induce changes in
cardiac function and regional blood flow as well as hav¬
ing widespread effects on disparate tissues. Thus, the
consequent changes in systemic fibrinolytic parameters
will be a combination of many factors, potentially includ¬
ing hepatic production and clearance of t-PA and PAI-1.
One approach, to avoid these confounding systemic
effects, has been to use the isolated perfused rat
hindlimb model. This ex vivo model has been reported to
demonstrate that endothelin-1 infusion stimulates mod¬
est amounts of t-PA release." However, this increased
'release' may, in part, reflect the concentrating effects of a
reduction in blood flow associated with endothelin-1
infusion and the concentrations of endothelin-1 adminis¬
tered. In studies conducted to date,"-13 endothelin-1 has
been administered in nanomolar concentrations.
Table 3 Estimated net release of tissue plasminogen activator (t-PA) antigen across the forearm during endothelin-1 (ET-1) and BQ-788
infusion. Mean (95% confidence intervals)
Time (min)
Baseline 10 20 30 50 80 120
t-PA release (ng/100 mL/min)
BQ-788 (1 nmol/min) 1.1 0 0.4 0.3 -0.2 0.1 0.1
(-0.1 to 2.3) (-1.6 to 1.6) (-1.0 to 1.8) (-1.5 to 2.1) (-1.8to 1.4) (-1.3 to 1.5) (-1.7 to 1.9)
ET-1 (2.5 pmol/min) 0.1 1.4 2.5 1 2 1.7 0
(-0.7 to 0.9) (-0.6 to 3.4) (0.5 to 4.5) (-0.8 to 2.6) (-1.0 to 5.0) I o cn (-0.2 to 0.2)
ET-1 (10 pmol/min) 1.3 0.5 0.9 0.3 0.9 0.1 0.8
(-0.3 to 2.9) (-0.4 to 1.9) (0.1 to 1.7) (-0.4 to 1.7) (-0.1 to 1.9) (-0.7 to 0.9) (0.0 to1.6)
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Although local abluminal concentrations may be high,
normal human plasma endothelin-1 concentrations are
in the femtomolar range. Indeed, in the present study,
assuming a total forearm blood flow of 30-50 mL/min,
the forearm tissue concentration of endothelin-1 during
the 10 pmol/min infusion will be 200-300 fmol/mL. The
previous ex vivo animal studies," therefore, represent
some 4-5 orders of magnitude higher concentrations
and the release of t-PA is likely to represent a pharmaco¬
logical rather than physiological effect.
We have not detected a significant release of t-PA from
the forearm with endothelin-1 infusion despite a 63%
reduction in blood flow at the higher dose. Basal t-PA
release is of the order of -0.9 ng/100ml of tissue/min in
the forearm16 and the apparent trend for an increase in t-
PA antigen concentrations may, in part, reflect the reduc¬
tion in blood flow associated with the marked forearm
vasoconstriction (see Fig. 3). This is borne out by the
unchanged t-PA activity, because it would be anticipated
that plasma PAI-1 and t-PA antigen concentrations would
increase proportionately with reductions in blood flow.
ETb receptor antagonism causes both inhibition of
endothelium-derived vasodilators such as nitric oxide,
and potential hyperstimulation of the unopposed ETA
receptor. However, as with endothelin-1, BQ-788 did not
affect plasma concentrations of t-PA or PAI-1 in the
infused forearm.
Forearm release of t-PA has been demonstrated using
various endothelial cell stimulants including metha-
choline,16-26 noradrenaline17 and desmopressin.27 Using
the same .technique as in the present study, we have pre¬
viously demonstrated in vivo t-PA release of up to 80
ng/100 mL of tissue/min across the human forearm using
intrabrachial substance P infusion14 and this release is
sustained for at least 2h.15 In contrast, stimulation or
antagonism of the endothelial ETB receptor, with
endothelin-1 and BQ-788 respectively, does not appear to
influence forearm t-PA release. It is, therefore, unlikely
that endothelin-1 provides a major contribution to the
regulation of t-PA release in man, although we cannot
exclude a small stimulatory effect.
Study limitations
In the forearm, typical resting arterio-venous differences
are only -10% of the total venous t-PA concentration
and the basal constitutive release of t-PA antigen is -0.9
ng/100 mL of tissue/min.16 We have measured
venous-venous differences between the infused and
non-infused arms which, unlike the measurement of
arterio-venous differences of the infused arm, has the
disadvantage of not being able to correct for blood-flow-
dependent changes in venous plasma t-PA concentra¬
tions. Theoretically (see Fig. 3), in the absence of an
Fibrinolysis & Proteolysis (1999) 13(4/5), 185-191
alteration in t-PA release, a 60% reduction in blood flow
would be anticipated to increase total venous plasma
t-PA concentrations by only -7%, whereas a 200%
increase in flow would reduce t-PA concentrations to the
same degree (-7%). In the presence of stimulated t-PA
release, these small flow-dependent changes are propor¬
tionately reduced even further.
The measurement of arterio-venous differences neces¬
sitates arterial sampling and the insertion of large-bore
cannulae (19-20 gauge) which do not lend themselves to
multiple cannulations within the same subject.
Moreover, there is also the potential to introduce artefact
from the presence of a larger thrombogenic surface,
given that activated factor Xa is the most potent stimu¬
lant for t-PA release yet known.28 To minimize arterial
trauma and facilitate repeated studies in the same sub¬
jects, we have used 27-gauge arterial cannulae which
permit drug infusion but not arterial blood sampling.
However, we would suggest that flow-dependent
changes in venous t-PA concentrations are small, within
the variability of the t-PA assays (-5-7%) and are not of
practical importance. Interestingly, a significant fall in
the arterio-venous difference, or venous plasma concen¬
tration, of t-PA has not been detected during blood
flow increases of up to 600% with sodium nitroprusside
infusion.1416-29
Measurement of venous-venous and arterio-venous
differences both have the potential limitation that they
can only estimate the net release of t-PA from the fore¬
arm and are unable to take account of clearance of t-PA
within the forearm. However, the majority of t-PA is
removed from the circulation by the liver30 and the con¬
tribution of forearm clearance of t-PA is, therefore, likely
to be very small.
During the present study, we did not see changes in
heart rate or blood pressure to suggest systemic effects of
endothelin-131 or BQ-788 infusion.32 However, measuring
venous concentrations bilaterally will control for any
potential systemic effects which may go unrecognized if
arterio-venous differences are measured in isolation.
Once a drug has a systemic rather than a local effect,
there is always the concern that subsequent t-PA release
may be influenced or mediated by the release of other
humoral factors, such as catecholamines. Moreover, if
the main mechanism of t-PA release is mediated by a sys-
temically released intermediate factor, then measuring
arterio-venous differences could fail to detect this since
arterial concentrations may remain unchanged and
venous concentrations will rise in both forearms.
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Abstract
Objectives: Angiotensin II and bradykinin are potent endogenous vasoactive peptides which may play a role in the regulation of
endogenous fibrinolysis and, thereby, contribute to the beneficial actions of ACE inhibitors. The aims of the study were to determine the
acute effect of angiotensin II and bradykinin on the local vascular release of tissue plasminogen activator (t-PA) and its inhibitor,
plasminogen activator inhibitor type 1 (PAI-1), and the endothelium derived haemostatic factor, von Willcbrand factor (vWf) from the
forearm. Methods: Blood flow, and plasma haemostatic and fibrinolytic factors, were measured in both forearms of sixteen healthy men:
eight subjects received intra arterial angiotensin II (5, 50 and 500 pmol/min) which was coinfusod with sodium nitropruooide (SNP; 0.3,
1.5 and 7.5 p.g/min, respectively), and eight received intra-arterial bradykinin at 10-3000 pmol/min. Results: Despite substantial rises in
plasma angiotensin II concentrations (P<0.001) which caused pressor effects (P<0.003) at the highest dose, angiotensin II infusion did
not affect local plasma t PA, PAI-1 or vWf concentrations. In contrast, bradykinin caused substantial doso dependent increases in blood
flow and t-PA release (>100 ng/100 ml of tissue/min) in the infused forearm (P<0.001 for both) without affecting plasma PAI-1 or vWf
concentrations. Conclusions: Despite high local concentrations with breakthrough of significant systemic effects, angiotensin II did not
affect acute endothelial cell t PA, PA1 1 or vWf release in healthy men. In contrast, bradykinin is a potent vasodilator and selective
stimulus for acute local t-PA release. This may, at least in part, explain the fibrinolytic actions of ACE inhibitors in heart failure and
ischaemic heart disease. © 2000 Elsevier Science B.V. All rights reserved.
Keywords: Thrombolysis; Endothelial Factors; Blood Flow; Angiotensin
This article is referred to in the Editorial by L. Dezsi
(pages 642-644) in this issue.
1. Introduction
Tissue plasminogen activator (t-PA), and its inhibitor,
plasminogen activator inhibitor type 1 (PAI-1), are poten¬
tially important endothelium derived mediators that are
intimately linked to the risk of thrombosis. Acute t-PA
Corresponding author. Tel. +44-131-536 2749; fax: +44-131-536
2744.
E-mail address: d.e.newby@ed.ac.uk (D.E. Newby).
release results from the rapid translocation of a dynamic
intracellular storage pool present in the endothelium [1] of
the precapillary arterioles and post capillary venules [2],
The time course of t-PA release is important since clot
dissolution is much more effective if t-PA is incorporated
during clot formation rather than following completion
[3,4].
In patients with hypertension, an elevated plasma renin
activity for a given urinary sodium excretion is indepen¬
dently associated with an increased risk of acute myocar¬
dial infarction [5], Moreover, large scale clinical trials in
patients with heart failure, ischaemic heart disease or a
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recent myocardial infarction suggest a reduction in rein-
farction rates with angiotensin converting enzyme (ACE)
inhibitor therapy. The mechanisms underlying the associa¬
tion of renin-angiotensin system activation with coronary
thrombotic events are unknown but may relate, in part, to
an effect on fibrinolytic parameters. Indeed, activation of
the renin-angiotensin system by sodium depletion causes
an increase in early morning plasma PA1-1 concentrations
that can be reversed by ACE inhibition [6], Furthermore,
in patients with heart failure [7] or a recent myocardial
infarction [8,9], ACE inhibitor therapy causes marked
reductions in plasma PAI-1 concentrations.
The renin-angiotensin and kinin systems have a direct
influence on the regulation of the fibrinolytic system. Cell
culture studies demonstrate marked up-regulation and
release of PAI-1 in response to angiotensin II administra¬
tion [10,11] whilst ex vivo animal models have suggested
that bradykinin is one of the most potent stimulants for the
release of t-PA [12,13]. Studies in man have also indicated
that systemic infusions of angiotensin II and bradykinin are
associated with elevated levels of PAI-1 [14] and t-PA
[15.16], However, systemic drug administration of vasoac¬
tive agents can change blood pressure and regional blood
flow, as well as having widespread effects on many tissues.
Thus, altered systemic fibrinolytic parameters might be
attributable, for instance, to changes in hepatic release and
clearance of t-PA and PAI-1, and the concomitant release
of other stimulatory, vasoactive and humoral mediators
[15.17], To avoid these potentially confounding systemic
effects, the use of locally active intra-arterial infusion of
drugs can be used to investigate the acute local release of
t-PA and PAI-1 in the forearm of man [18-24],
We have previously been able to demonstrate that
substance P, an endothelium-dependent vasodilator, causes
a selective dose-dependent release of t-PA from the human
forearm without causing significant release of PAI 1 or the
endothelium-derived haemostatic factor, von Willebrand
factor (vWf) [21,22]. In contrast, despite causing equiva¬
lent increases in blood flow, the potent endothelium-in-
dependent vasodilator, sodium nitroprusside, does not
affect t-PA release from the forearm [19,21,24], The aim of
the present study was, therefore, to determine the local
effect of intra-arterial angiotensin II and bradykinin ad¬




Sixteen healthy male non-smokers, aged between 21 and
35 years, participated in the study which was undertaken
with the approval of the local research ethics committee
and in accordance with the Declaration of Helsinki. The
written informed consent of each subject was obtained
before entry into the study. None of the subjects received
vasoactive or non-steroidal antiflammatory drugs in the
week before each phase of the study, and all abstained
from alcohol for 24 h, and from food and caffeine-con¬
taining drinks for at least 12 h before each study. All
studies were carried out in a quiet, temperature controlled
room maintained at 22-24°C.
2.2. Drugs
Pharmaceutical grade bradykinin (Clinalfa, Laufelfing-
en, Switzerland), angiotensin II (Celinalfa) and sodium
nitroprusside (Nipride; Roche, Welwyn Garden City, UK)
were administered following dissolution in saline (0.9%:
Baxter Healthcare, Thetford, UK).
2.3. Intra-arterial administration
The brachial artery of the non-dominant arm was
cannulated with a 27-standard wire gauge steel needle
(Cooper's Needle Works, Birmingham, UK) under 1%
lignocaine (Xylocaine: Astra Pharmaceutical, Kings Lan-
gley, UK) local anaesthesia and attached to a 16-gauge
epidural catheter (Portex, Hythe, UK). Patency was main¬
tained by infusion of saline via an IVAC PI000 syringe
pump (1VAC, Basingstoke, UK). The total rate of intra¬
arterial infusions was maintained constant throughout all
studies at 1 ml/min.
2.4. Measurements
2.4.1. Forearm blood flow and haemodynamics
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic strain
gauges applied to the widest part of the forearm [25].
During measurement periods, the hands were excluded
from the circulation by rapid inflation of the wrist cuffs to
a pressure of 220 mmHg using E20 rapid cuff inflators
(D.E. Hokanson,Washington, USA). Upper arm cuffs were
inflated intermittently to 40 mmHg for 10 s in every 15 s
to achieve venous occlusion and obtain plethysmographic
recordings. Analogue voltage output from an EC-4 strain
gauge plethysmograph (D.E. Hokanson) was processed by
a MacLab® analogue-to-digital converter and chart™
v3.3.8 software (AD Instruments, Castle Hill, Australia)
and recorded onto a Macintosh Classic 11 computer (Apple
Computers, Cupertino, CA, USA). Calibration was
achieved using the internal standard of the plethysmog¬
raph.
Blood pressure and heart rate were monitored in the
non-infused arm at intervals throughout each study using a
semi-automated non-invasive oscillomctric sphygmo¬
manometer (Takeda UA 751, Takeda Medical, Tokyo,
Japan) [26].
2.5. Assays
Venous cannulae (17G) were inserted into large subcuta-
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neous veins of the antecubital fossa in both arms. A 10-20
ml volume of of blood was withdrawn simultaneously
from each arm and collected into acidified buffered citrate
(Biopool® Stabilyte™, Umea, Sweden; for t-PA assays),
citrate (Monovette®, Sarstedt, Niimbrecht, Germany; for
PA 1-1 and vWf assays) and 0.45% o-phcnanthroline-
4.65% disodium ethylene diamine tetraacetic acid (for
angiotensin II assays) tubes, and kept on ice before being
centrifuged at 2000 g for 30 min at 4°C. Platelet free
plasma was decanted and stored at — 80°C before assay
[27],
Plasma PAI-1 and t-PA antigen concentrations were
determined using an EL1SA; Coaliza® PAI-1 [28] and
Coaliza® t-PA [29] (Chromogenix, Molndal, Sweden),
respectively. Plasma PAI-1 and t-PA activities were de¬
termined by a photometric method, Coatest® PAI-1 [30]
and Coaset® t-PA [31] (Chromogenix). Intra-assay co¬
efficients of variation were 5.5 and 7.0% for t-PA and
PA 1-1 antigen, and 2.4 and 4.0% for activity, respectively.
Inter-assay coefficients of variability were 4.0, 7.3, 4.0 and
7.6%, respectively. The sensitivities of the assays were 0.5
ng/nrl, 2.5 ng/ml, 0.10 I.U./ml and 5 AU/ml, respective¬
ly. Determination of vWf antigen [32] was undertaken
using an ELISA (Dako, Glostrup, Denmark) with a
sensitivity of 0.05 I.U./ml. The intra-assay and inter-assay
coefficients of variability were 5.2 and 7.3%, respectively.
Following extraction using Bond Elut® columns (Varian,
Harbor City, CA, USA), plasma angiotensin II (Peninsula
Labs. Europe, St. Helens, UK) concentrations were de¬
termined by radioimmunoassay as previously described
[33]. The intra- and inter-assay coefficients of variability
were 7.2 and 9.3%, respectively. Haematocrit was de¬
termined by capillary tube centrifugation of blood an-
ticoagulated by ethylene diamine tetraacetic acid and was
obtained from the infused forearm at baseline and at the
end of the study protocol.
2.6. Study design
Subjects rested recumbent, and strain gauges and cuffs
were applied. The brachial artery of the non-dominant arm
was cannulated and forearm blood flow measured every 10
min or between 3 and 6 min for shorter (6 min) infusion
periods during the bradykinin protocol. Before bradykinin
or combined angiotensin II and sodium nitroprusside
administration, saline was infused for 30 min to allow time
for equilibration. The final blood flow measurement during
saline infusion was taken as the basal forearm blood flow.
2.6.1. Angiotensin 11 protocol
There is a modest basal release of t-PA from the forearm
and, in the presence of a reduction in blood flow, an
apparent rise in t-PA concentrations may occur without a
change in the rate of t-PA release [34], To correct for any
flow dependent effects, sodium nitroprusside, which does
not cause t-PA release [19,21,24], was coinfused with
angiotensin II to offset the angiotensin II mediated vas¬
oconstriction and maintain forearm blood flow greater than
or equal to that during saline infusion. Eight subjects
received three incremental infusions of angiotensin II and
sodium nitroprusside for 30 min at each dose in the
following order: angiotensin II 5 pmol/min + sodium nitro¬
prusside 0.3 ptg/min; angiotensin II 50 pmol/min + sodium
nitroprusside 1.5 p,g/min; and angiotensin II 500 pmol/
min+ sodium nitroprusside 7.5 p.g/min. The doses of
sodium nitroprusside were determined from preliminary
pilot studies (data on file). Venous blood samples were
obtained from both forearms at baseline and every 10 min
thereafter.
2.6.2. Bradykinin protocol
Eight subjects received an incremental infusion of
bradykinin at 10, 30, 100, 300, 1000 and 3000 pmol/min
followed by a 20-min saline infusion. Venous blood
samples were obtained from both forearms at baseline,
during bradykinin infusion at 30, 300 and 3000 pmol/min,
and 10 and 20 min after cessation of the final bradykinin
infusion of 3000 pmol/min. Bradykinin was infused for 6
min at each dose but was extended to 10 min at the 30, 300
and 3000 pmol/min doses because of venous sampling
following blood flow measurements.
2.7. Data analysis and statistics
The study population size, based on power calculations
derived from previous studies [21], gives 90% power of
detecting a 21% difference in t-PA release at a significance
level of 5%. Coefficients of repeatability [35] for plasma
concentrations of t-PA antigen and activity during sub¬
stance P infusion at 8 pmol/min are 1.6 ng/ml and 1.4
I.U./ml, respectively (data on file).
Plethysmographic data were extracted from the chart
data files. Forearm blood flows were calculated for in¬
dividual venous occlusion cuff inflations by use of a
template spreadsheet (excel v5.0; Microsoft, Cambridge,
USA). Recordings from the first 60 s after wrist cuff
inflation were not used because of the variations in blood
flow that this causes. Usually, the last five flow recordings
in each 3-min measurement period were calculated and
averaged for each arm. Estimated net release of t-PA
activity and antigen was defined previously [21] as the
product of the infused forearm plasma flow (based on the
mean haematocrit, Hct, and the infused forearm blood
flow, FBF) and the concentration difference between the
infused ([t-PA]lnf) and non-infused arms ([t-PA]Non.inf)
Estimated net t-PA release = FBF X {1 -Hct}
X {[t-PA]Inf — [t-PA]No„_inf}
Data were examined, where appropriate, by multifactorial
analysis of variance (ANOVA) with repeated measures and
two-tailed paired Student's /-test using excel v5.0 (Mi¬
crosoft). All results are expressed as mean±standard error





Age (years) 26±2 25±2
Height (m) 1.85 ±0.02 l.78±0.03
Weight (kg) 81 ±2 81 ±4
Body mass index (kg/m2) 23 ± 1 25± 1
Body surface area (m2) 2.03 ±0.04 1.99±0.06
Heart rate (/min) 63 ±3 68 ±6
Blood pressure Systolic (mmHg) 132±5 132±7
Diastolic (mmHg) 74±2 78±4
Haematocrit Basal 0.38±0.00 0.40±0.02
Final 0.38±0.01 0.41 ±0.01
of the mean. Statistical significance was taken at the 5%
level.
3. Results
Subject characteristics are shown in Table 1.
3.1. Angiotensin 11 protocol
There were no significant changes in blood pressure,
heart rate or blood flow in the non-infused arm throughout
the study protocol except during the final 30 min infusion
(Fig. 1).
In comparison with the preceding 30-min infusion
periods, administration of angiotensin II 500 pmol/min
with sodium nitroprusside 7.5 p.g/min was associated with
an increase in mean arterial pressure (four-way ANOVA,
P<0.003), and infused (four-way ANOVA, P<0.001) and
non-infused (four-way ANOVA, P = 0.05) forearm blood
flow without a change in heart rate.
Venous plasma angiotensin II concentrations increased
in the infused (ANOVA, /5<0.001 for all doses) and
non-infused (ANOVA, P<0.001 at 500 pmol/min only)
forearms (Table 2). In comparison to the non-infused arm,
plasma angiotensin II concentrations were substantially
greater in the infused arm (Table 2; two-way ANOVA,
P< 0.001). However, despite substantial increases in local
angiotensin II concentrations, there were no significant
changes in plasma t-PA, PA1-1 or vWf antigen concen¬
trations in either arm (Table 2).
3.1.1. Bradykinin protocol
Consistent with the actions of other kinins [21], transient
and patchy flushing and skin oedema of the infused arm





















| Saline | 10 | 30 | 100 | 300 |l000| 3000 | Saline
-30 -20 -10 0 6 16 22 32 38 48 58 68
[ Saline | Ang II 5 + SNP 0.3 | Ang II 50 + SNP 1.5 | Ang II 500 + SNP 7.5 |
I 1 1 1 1 1 1 1 1 1 1 1 1
-30 -20 -10 0 10 20 30 40 50 60 70 80 90
Time (min)
Fig. 1. Mean arterial pressure (solid squares), heart rate (open squares), and blood flow in the infused (solid circles) and non-infused (open circles) forearms
during saline, bradykinin (pmol/min), and combined angiotensin II (Ang 11, pmol/min) and sodium nitroprusside (SNP, p.g/min) infusions. Paired /-test:*,
P<0.001, f, P^0.02, J, P<0.05 (vs. baseline); One-way ANOVA: P<0.001 for infused forearm blood flow (bradykinin and angiotensin II infusions).
Two-way ANOVA:/><0.001 (infused vs. non-infused forearm blood flow, bradykinin and angiotensin II infusions); P = 0.006, J, P = 0.02 (saline vs.
angiotensin II 500 pmol/min); four-way ANOVA: t> /5<0.003, J, P = 0.05 (four groups: saline, angiotensin II 5 pmol/min, angiotensin II 50 pmol/min
and angiotensin II 500 pmol/min).
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Table 2
Estimated net release and plasma concentrations of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen, and
venous plasma von Willebrand factor (vWf) and angiotensin II concentrations during angiotensin II and sodium nitroprusside infusion
Baseline Angiotensin II 5 pmol/min Angiotensin II 50 pmol/min Angiotensin II 500 pmol/min
+ + +
sodium nitroprusside sodium nitroprusside sodium nitroprusside
0.3 p.g/min 1.5 pg/min 7.5 pg/min
Time (min) 0 10 20 30 40 50 60 70 80 90
t-PA antigen (ng/ml)
Infused arm 3.4±0.4 3.7±0.4 3.6±0.3 3.4±0.4 3.4i0.4 3.6i0.3 3.5i0.4 3.4i0.2 3.4±0.3 3.5±0.:
Non-infused arm 3.7±0.5 3.4±0.3 3.3±0.4 3.6±0.4 3.4±0.4 3.4i0.3 3.3i0.3 3.5i0.3 3.4±0.2 3.3±o.:
Concentration difference between forearms — 0.3±0.1 0.3±0.2 0.3±0.1 — 0.2±0.1 0.0 + 0.1 0.2i0.1 0.2i0.1 — 0.1 ±0.1 0.0+0.1 0.1 ±0.
Estimated net release of t-PA (ng/100 ml/min) — 0.4±0.2 0.4±0.2 0.4±0.2 -0.2±0.1 — 0.1 iO.2 0.3i0.1 0.3i0.2 — 0.1 ±0.2 0.1 ±0.2 o.3±o.:
PAI-1 antigen (ng/ml)
Infused arm 16±4 16±5 15±4 15±3 12i3 13i4 13i3 11 ±3 13 + 3 12±3
Non-infused arm 14+4 15±4 14±4 14±4 13i3 12i4 13i3 12±3 11 ±3 11 ±3
Concentration difference between forearms 2± 1 2±2 1 + 1 1 ± 1 0+0 lit 0i2 0+1 1 ± 1 1±1
Estimated net release of PAI-1 (ng/100 ml/min) 3±2 2±2 Oil Oil — 1 i 1 2i2 0i3 -1+2 2± 1 3±3
vWf Antigen (I.U./ml)
Infused arm 0.7+0.1 0.6±0.1 0.6+0.1 0.7i0.1 0.7i0.1 0.7+0.1 0.7i0.1 0.8±0.2 0.8±0.2 0.7±0.
Non-infused arm 0.8±0.2 0.8±0.2 0.7±0.2 0.7i0.2 0.6i0.1 0.8i0.2 0.8i0.2 0.8±0.2 0.9 + 0.1 0.9±0.l
Plasma angiotensin 11 concentration (fmol/ml)a
Infused arm 8±3 - 92 +11 f - - 174±3f - - 219±23J -t
Non-infused arm 12±5 - 11 ±4 - - 46i26 - - 126± 19J -t
J
n = 4.
One-way ANOVA: t, P— 0.001. Two-way ANOVA: f, P <0.001 (infused vs. non-infused forearm). Paired /-test: P^0.01 (vs. baseline).
min. The oedema had an urticarial appearance, taking the
form of a raised wheal with a yellow hue. The extent of
oedema varied between subjects, beginning at the level of
the elbow and extending distally with increasing dose.
However, there was no associated pruritis or tenderness
and the oedema resolved completely within 1-2 h of
stopping the infusion. No local effects were seen with
angiotensin II and sodium nitroprusside infusions.
There were no significant changes in blood pressure,
heart rate or blood flow in the non-infused arm throughout
the study protocol (Fig. 1). Bradykinin increased blood
flow in the infused arm (ANOVA, P< 0.001) in a dose
dependent manner (Fig. 1) reaching a maximum increase
of 22.8±2.7 ml/100 ml/min at 3000 pmol/min.
Bradykinin caused a dose-dependent increase in venous
plasma t-PA activity and antigen concentrations of the
infused (ANOVA, T3<0.001) and non-infused (ANOVA,
.P = 0.01) forearms (Fig. 2). In comparison to the non-
infused arm, plasma t-PA antigen and activity concen¬
trations were substantially greater in the infused arm (two-
way ANOVA, P<0.001), consistent with a marked net
local release of t-PA (ANOVA, PC0.001; Table 3).
Baseline plasma PAI-1 antigen, PAI-1 activity and vWf
concentrations were 36±4 ng/ml, 12±2 and 0.64±0.05
I.U./ml in the infused arm, and 40±4 ng/ml, 13± 1 and
0.67±0.09 l.U./ml in the non-infused arm, respectively.
There were no significant changes in plasma PAI-1 an¬
tigen, PAI-1 activity or vWf concentrations in either arm
during bradykinin infusion (data on file).
4. Discussion
We have shown that, despite very high local concen¬
trations, ultimately causing significant systemic pressor
effects, angiotensin II infusion does not directly affect
acute local endothelial cell t-PA or PAI-1 release. In
contrast, we found that the potent vasodilator, bradykinin,
is a selective stimulus for acute local t-PA release. These
findings suggest that bradykinin, but not angiotensin II,
may contribute to the acute local regulation of endogenous
fibrinolysis in man. This may, in part, contribute to altered
endogenous fibrinolysis seen with the use of ACE inhibitor
therapy [8,9].
In vitro studies have suggested that angiotensin II
influences endothelial [11] and vascular smooth muscle
cell [10] PAI-1 synthesis and release. However, in vitro
cell techniques have limitations because the phenotype of
cells in culture, and the ability to release PAI-1, may
change, particularly with increasing passages. There has
been conflicting in vivo evidence with regard to the role of
angiotensin II in the regulation of endogenous fibrinolysis,
with angiotensin II either increasing plasma PAI-1 con¬
centrations without affecting t-PA [14] or increasing
plasma t-PA concentrations without affecting PAI-1 [16].
However, systemic neurohumoral responses to the infusion
of vasoactive agents may contribute to, or even mediate,
the subsequent fibrinolytic response [17], To avoid these
confounding systemic effects, locally active intra-arterial
infusion of drugs can be used to investigate the acute local
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Fig. 2. Plasma tissue plasminogen activator (t-PA) antigen (solid lines;
upper panel) and activity (dashed lines; lower panel) concentrations in the
infused (solid circles) and non-infused (open circles) forearms during
saline and bradykinin infusions. One-way ANOVA: infused arm; P<
0.001 for t-PA antigen and activity. Non-infused arm; P — 0.003 for t-PA
antigen, /? = 0.01 for t-PA activity. Two-way ANOVA: infused vs. non-
infused arm; /><0.001 for t-PA antigen and activity. Paired Mest: *,
P<0.05, f, /5<0.001 (vs baseline).
release of l-PA in the forearm circulation of man [18-24].
Using high but locally vasoactive doses of angiotensin II
(5 and 50 pmol/min), we were unable to detect alterations
in plasma t-PA or PAI-1 concentrations in the forearm
vascular bed. Moreover, the absence of a fibrinolytic
response is unlikely to be a temporal effect since the blood
vessels of the infused forearm were exposed to markedly
elevated plasma angiotensin II concentrations for 90 min.
In order to counteract the development of forearm
vasoconstriction and subsequent flow-dependent changes
in plasma t-PA concentrations [34], sodium nitroprusside
was co-infused with angiotensin II. Sodium nitroprusside
is unlikely to have influenced the fibrinolytic response to
angiotensin II infusion because a number of previous in
vitro [36] and in vivo studies [19-21,24] have failed to
demonstrate any effect of sodium nitroprusside administra¬
tion on the acute release of t-PA or PAI-1. At the highest
dose, angiotensin II did not affect plasma t-PA or PAI-1
concentrations despite increasing systemic blood pressure
and increasing forearm blood flow in the non-infused arm.
Increased blood flow of the infused forearm may, at least
in part, reflect relative dominance of the vasodilatation
associated with sodium nitroprusside co-infusion. How¬
ever, vasodilatation of the non-infused forearm with sys¬
temic pressor doses of angiotensin II is consistent with
previous work [37] and is related to the relatively greater
vasoconstrictor response to angiotensin II infusion in other
resistance vascular beds, such as the splanchnic circulation.
In addition to potential actions on plasma fibrinogen
[38] and platelet function [39], the major benefits associ¬
ated with ACE inhibitor therapy may, at least in part, be
mediated through actions on endogenous fibrinolytic func¬
tion. Following myocardial infarction, basal fibrinolytic
parameters are improved by the use of ACE inhibitors
[8,9], principally through a reduction in plasma PAI-1
concentrations. The absence of a direct effect of high local
concentrations of angiotensin II in the forearm circulation
suggests that this is not mediated by a direct action of
angiotensin 11 on the endothelium. However, PAI-1 is
synthesised and released by many tissues, including
megakaryocytes, liver and vascular smooth muscle, and the
present study does not exclude a systemic role of angioten¬
sin II in the regulation of endogenous fibrinolysis.
Animal models suggest that bradykinin is an extremely
potent stimulus for the release of t-PA from the vascular
endothelium in vitro [1], ex vivo [13] and in vivo [40]. We
have been able to demonstrate marked and substantial
release of t-PA with intra-arterial infusions of bradykinin in
humans. Assuming a forearm volume of -1000 ml [25],
3000 pmol/min of bradykinin caused the release of over 1
p.g/min of t-PA from the infused forearm. Plasma t-PA
concentrations, but not blood flow, increased in the non-
infused forearm at the highest dose of bradykinin, sug¬
gesting the release of t-PA from the infused forearm
exceeded the capacity to clear it immediately from the
systemic circulation.
Recently, Brown et al. [41] have described the forearm
release of t-PA with intra-arterial bradykinin infusion using
doses up to 400 pmol/min. Using similar techniques, we
have confirmed their findings, shown a greater release of
t-PA at higher doses of bradykinin, and extended these
observations to demonstrate the absence of vWf release. In
contrast to the animal studies [13], bradykinin does not
appear to release vWf from the forearm circulation in man.
This finding is consistent with similar observations ob¬
tained with substance P [21] and desmopressin infusions
[20], and suggests the presence of separate and distinct
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One-way ANOVA: *, P<0.001.
Paired /-test: f, P<0.05, J, P^O.001 (vs. baseline).
endothelial storage pools and release mechanisms for t-PA
and vWf.
Small areas of denudation and thrombus deposition are a
common finding on the surface of atheromatous plaques
[42,43] and are usually sub-clinical. However, in the
presence of an imbalance in the coagulation or fibrinolytic
systems, such microthrombi may propagate, ultimately
leading to arterial occlusion. Bradykinin is not only an
inflammatory mediator but is also released during the
contact phase of coagulation when high-molecular-weight
kininogen is cleaved by kallikrein to produce a disulphide-
linked light and heavy chain [44,45], This liberation of
bradykinin may represent an important negative feedback
loop in which bradykinin induced l-PA release inhibits
thrombus formation within the vascular lumen when
localised endothelial denudation occurs. Furthermore,
given that bradykinin induced forearm vasodilatation is
potentiated by ACE inhibition [46], such actions may be
enhanced in the presence of ACE inhibition and may, in
part, explain the anti-ischaemic action of this therapy [47],
However, although inferred, the potentiation of bradykinin
induced t-PA release by ACE inhibition has yet to be
established.
In conclusion, it would appear that bradykinin, but not
angiotensin 11, is a potent vasodilator and selective
stimulus for acute local t-PA release. This may, in part,
explain the beneficial fibrinolytic actions of ACE inhibition
in heart failure and ischaemic heart disease.
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PUBLICATION 5
Bradykinin Receptor Antagonism and Endothelial Tissue
Plasminogen Activator Release in Humans
Fraser N. Witherow, Pamela Dawson, Christopher A. Ludlam, David J. Webb,
Keith A.A. Fox, David E. Newby
Objective—We sought to assess pharmacodynamic responses to the bradykinin antagonist B9340 and to determine the
contribution of the endothelial bradykinin receptor to stimulated tissue plasminogen activator (t-PA) release in humans.
Methods and Results—Bilateral forearm blood flow and plasma fibrinolytic variables were measured in 8 volunteers
during 100 minutes of intrabrachial infusions of saline placebo, B9340 at 4.5 nmol/min, or B9340 at 13.5 nmol/min. On
each occasion, intra-arterial bradykinin (30 to 3000 pmol/min) and substance P (4 to 16 pmol/min) were coinfused for
10 minutes at each dose. To assess the onset and offset of action, 6 additional subjects on 2 occasions received
intra-arterial bradykinin (100 pmol/min) for 60 minutes with a coinfusion of either saline placebo or B9340 (13.5
nmol/min) for 12 minutes. During placebo infusion, bradykinin and substance P caused dose-dependent vasodilatation
in the infused forearm (PCO.OOl). B9340 caused a dose-dependent inhibition of bradykinin-induced forearm
vasodilatation and t-PA release (P<0.001) without affecting substance P-induccd vasodilatation or t-PA release
(P=NS). B9340 caused a reversible inhibition of bradykinin-induccd vasodilatation (P<0.001) with a rapid onset and
offset of action.
Conclusions—B9340 is a potent, reversible, and selective competitive receptor antagonist of bradykinin-induccd
vasodilatation and t-PA release in humans. (Arterioscler Thromb Vase Biol. 2003;23:1667-1670.)
Key Words: bradykinin ■ blood flow ■ tissue plasminogen activator ■ receptor antagonism
Bradykinin is an endogenous, vasoactive, nonapeptidemediator involved in many physiologic processes. It is
cleaved from high-molecular-weight kininogen during the
contact phase of blood coagulation,' resulting in endotheli-
um-dependent vasodilatation and stimulation of tissue plas¬
minogen activator (t-PA) release from human endothelial
cells.2 It has a brief duration of action (plasma half-life of 15
to 30 seconds) owing to its rapid degradation by several
enzymes, principally angiotensin-convcrting enzyme (ACE).
Bradykinin appears to contribute to the vascular effects of
ACE inhibitor therapy in hypertension1 and heart failure.4
Bradykinin receptor antagonists have been developed from
peptide analogues of bradykinin. The most widely used
bradykinin receptor antagonist is HOE-140, or icatibant,
which demonstrates high selectivity for the B2 receptor.
Recently, a third-generation synthetic peptide antagonist of
bradykinin, B9340, has been synthesized. It has a similar
chemical structure to HOE-140 and differs by replacement of
the «-(2-indanyl)glycine at position 7 of the molecule with a
tetrahydroisoquiniline-3-carboxylic acid moiety. In compari¬
son with HOE-140, B9340 retains similar potency of inhibi¬
tion at the bradykinin B, receptor (median inhibitory concen¬
tration [IC50] of 0.158 nmol/L for both) but has greater
inhibition at the B| receptor (IC50 of 1000 nmol/L and 7.9
nmol/L for HOE-140 and B9340, respectively).5
The purpose of this study was to assess pharmacodynamic
responses to the novel bradykinin antagonist B9340 and to
determine the contribution of the endothelial bradykinin
receptor to stimulated t-PA release in vivo in humans. To
assess the selectivity of B9340, we compared the vasomotor
and fibrinolytic responses of bradykinin with those of sub¬
stance P, a bradykinin receptor independent, endothelium-
dependent vasodilator and stimulator of t-PA release.6
Methods
Study Subjects
Fourteen healthy, male volunteers were recruited into the study,
which was performed with approval of the local ethics committee, in
accordance with the Declaration of Helsinki and the written, in¬
formed consent of each subject. Each volunteer was studied at the
same time of day and had been fasting for at least 4 hours before each
study. All subjects avoided alcohol for 24 hours and caffeine-
containing products for 5 hours before study. No medications or
vasoactive drugs were taken in the 7 days before each study.
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Intra-Arterial Administration
All studies were performed in a quiet, temperature-controlled (22°C
to 25°C) room. On each occasion, the brachial artery of the
nondominant arm was cannulatcd with a 27-gauge needle (Cooper's
Needle Works Ltd) after 1% lidocaine local anesthesia. The needle
was attached to a 16-gaugc epidural catheter (Portcx Ltd), and needle
patency was maintained by an infusion of 0.9% saline at 1 mL/min.
The total rate of intra-arterial infusions was maintained constant
throughout all studies at 1 mL/min.
FBF and Blood Pressure
Forearm blood flow (FBF) was measured by mcrcury-in-silicone
elastomer strain-gauge venous-occlusion plethysmography, as previ¬
ously described.7-8 Immediately after each FBF measurement, pulse
and blood pressure were measured noninvasivcly in the noninfuscd
arm throughout each study with a scmiautomatcd digital sphygmo¬
manometer (UA-731, A&D Engineering). Mean arterial pressure
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Figure 1. Infused FBF during substance P (left) and bradykinin
(right) infusion with saline placebo (circles), B9340 at 4.5 nmol/
min (squares), and B9340 at 13.5 nmol/min (triangles). P<0.001,
ANOVA, for all blood flow responses; P<0.001, ANOVA, for
comparisons between saline placebo and B9340 administration
for bradykinin infusion (right) only
Drugs
Pharmaceutical-grade B9340 (Clinalfa AG), substance P (Clinalfa),
and bradykinin (Clinalfa) were dissolved in 0.9% saline before
infusion. All solutions were freshly prepared on the day of study.
Venous Sampling and Assays
Venous cannulas (17 gauge) were inserted into large subcutaneous
veins of the antecubital fossa in both arms, as described previously.9
Ten milliliters of blood was withdrawn simultaneously from each
arm and collected into acidified, buffered citrate (Biopool Stabilytc)
and citrate (Monovcttc. Sarstedt) tubes and kept on ice before being
ccntrifugcd at 2000g for 30 minutes at 4°C. Platclct-frcc plasma was
decanted and stored at —80°C before assay. Plasma t-PA antigen and
activity concentrations were determined by EL1SA (Coaliza t-PA,
Chromogenix AB) and a photometric method (C'oatest t-PA, Chro-
mogenix AB), respectively, as described previously."'
Study Design
Protocol 1: Efficacy and Selectivity of B9340
Eight healthy, male volunteers attended on 3 occasions at least I
week apart. After 30 minutes' equilibration with saline infusion,
intra-arterial placebo (0.9% saline), B9340 at 4.5 nmol/min, or
B9340 at 13.5 nmol/min was infused for 100 minutes on separate
occasions in a randomized, double-blind, aseending-dose design.
Placcbo/B9340 was coinfuscd with saline for 10 minutes; bradykinin
at 30, 300, and 3000 pmol/min for 10 minutes at each dose; and after
a 30-minutc saline infusion, substance P at 4, 8, and 16 pmol/min for
10 minutes at each dose. FBF and mean arterial pressure were
measured every 10 minutes for the duration of the study. Venous
samples were obtained at baseline, after 10 minutes of B9340/
placebo infusion, and after each dose of bradykinin and substance P.
Protocol 2: Onset and Offset of B9340 Action
Six additional healthy, male volunteers attended on 2 occasions at
least 1 week apart. After 30 minutes' equilibration with saline
infusion, intrabrachial bradykinin was infused at 100 pmol/min for
60 minutes. After 12 minutes of bradykinin infusion, B9340 (Cli¬
nalfa) at 13.5 nmol/min or placebo (saline vehicle) was coinfuscd for
12 minutes in a randomized, double-blind manner. FBF and mean
arterial pressure were measured every 6 minutes for the duration of
the study.
Data Analysis and Statistics
Plethysmography data were extracted from the software (Chart) data
files, and FBF was calculated for individual venous-occlusion cuff
inflations by use of a template spreadsheet (Excel 97, Microsoft).
The last 5 How recordings in each 3-minute measurement period
were calculated and averaged for each arm. The effective dose
causing a 100% increase in FBF (ED,,K>) was calculated to assess the
degree of bradykinin antagonism. The percentage increase in blood
llow was determined from the ratio of the FBFs, as described
previously.8
Estimated net release of t-PA antigen and activity was defined as the
product of the infused forearm plasma How (based on the hematocrit
1 Hct | and the infused FBF) and the concentration difference between the
infused (|t-PA||,,f) and noninfuscd forearms (|l-PA|Nol,i„f): estimated net
t-PA rcleasc=FBFX(I -HCt)X(|tPA|„,f-[tPA]N™,f).
Data were examined, where appropriate, by ANOVA with re¬
peated measures and 2-tailed, paired Student's t test with commer¬
cially available software (Excel 97). All results are expressed as
mcan±SEM. Statistical significance was taken at the 5% level.
Results
The infusions were well tolerated with no major adverse
events. There were no significant changes in FBF in the
noninfiised arm, heart rate, or blood pressure during the
infusions (data not shown).
Protocol I: Efficacy and Selectivity of B9340
Subjects were aged 25±5 years with a body mass index of
22 ±2 kg/m2.
Forearm Blood Flo in
Baseline blood flow during saline infusion was 2.0±0.2 nrL
• 100 niL"1 • min"' in the infused arm and 2.0±0.1 ml ■ 100
ml"1 • min"1 in the noninfused arm. In comparison with
placebo, B9340 infusion alone caused no significant change
in the infused FBF from baseline at either dose (placebo,
— 7.4±3.7%; B9340 at 4.5 nmol/min, 8.1 ±7.6%; and B9340
at 13.5 nmol/L, 3.8±5.5%; ANOVA, P=0.8). During pla¬
cebo infusion, bradykinin and substance P caused dose-
dependent vasodilatation in the infused forearm (ANOVA,
P<0.001 for both; Figure 1). At doses of 4.5 and 13.5
nmol/min, B9340 caused 7-fold and 18-fold increases in the
ED,,,, for bradykinin, respectively (ANOVA, P<0.001 for
both; Figure 1). In contrast, B9340 had no effect on substance
P induced vasodilatation (Figure 1).
Estimated Net t-PA Release
Baseline plasma t-PA antigen and activity concentrations
during saline infusion were 3.4±0.4 ng/mL and 1.3±0.3
IU/mL in the infused arm and 3.6±0.3 ng/mL and 1.3±0.3
lU/mL in the noninfused arm, respectively. B9340 infusion
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Figure 2. Estimated net t-PA antigen (closed symbols, top) and
activity (open symbols, bottom) release during substance P (left)
and bradykinin (right) infusion with saline placebo (circles),
B9340 at 4.5nmol/min (squares), and B9340 at 13.5 nmol/min
(triangles). P<0.05, ANOVA, for all t-PA responses; P<0.001,
ANOVA, for comparisons between saline placebo and B9340
administration for bradykinin infusion (right) only.
alone produced no change in plasma t-PA antigen or activity
(ANOVA, P=0.9). Both bradykinin and substance P pro¬
duced a dose-dependent increase in plasma t-PA antigen and
activity concentrations in the infused forearm (ANOVA,
/,<0.001). Both doses of B9340 completely inhibited t-PA
antigen and activity release at 300 pmol/min bradykinin and
reduced t-PA antigen and activity release at 3000 pmol/min
by 4- to 8-fold (ANOVA, P<0.001 for both doses; Figure 2).
There was no effect of B9340 on substance P induced t-PA
release (Figure 2).
Protocol 2: Onset and Offset of B9340 Action
Subjects were aged 30±2 years with a body mass index of
21 ±2 kg/nf. Baseline blood flow during saline infusion was
3.4±1.0 mL • 100 mL"1 • mill-1 in the infused ann and
2.7±0.6 mL • 100 mL-1 • mill"' in the noninfused arm.
Bradykinin infusion caused a 288±7% increase in the infused
FBF that was sustained for 60 minutes (ANOVA, P<0.001;
Figure 3). Compared with placebo, B9340 coinfusion caused
a rapid onset and offset of inhibition of bradykinin-induced
vasodilatation (ANOVA, P<0.001; Figure 3).
Discussion
We have confirmed our earlier findings11-12 that intrabrachial
bradykinin infusion causes marked forearm vasodilatation
-12 -6 0 6 12 18 21 30 3« 42 48 54 60
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Figure 3. Infused-arm FBF with bradykinin infusion (black bar;
100 pmol/min) during placebo (open circles) or B9340 (closed
circles; 13.5 nmol/min) coadministration (gray bar).
and endothelial t-PA release. We have demonstrated that
B9340 is a potent and competitive antagonist of bradykinin-
induced vasodilatation and endothelial t-PA release in vivo in
humans. B9340 appears to be a selective and reversible
bradykinin receptor antagonist with a rapid onset and offset
of action.
B9340 caused dose-dependent inhibition of bradykinin-
induced vasodilatation and t-PA release, suggesting that it
acts as a competitive receptor antagonist and that both
vascular effects are mediated through bradykinin receptors.
Previous clinical studies13-14 have used systemic intravenous
administration of the selective B2 receptor antagonist FlOE-
140, combined with intrabrachial bradykinin infusions. Flow-
ever, systemic dmg administration might have ancillary
effects, and the antagonist effects of F1OE-140 could have
been mediated through intermediary pathways. In contrast,
here we have demonstrated a direct, local, dose-dependent
inhibition of the vascular actions of bradykinin with intra-ar-
terial infusions ofB9340. Moreover, those previous studies of
systemic F1OE-140 administration cither lacked a control
vasodilator14 or used the endothelium-independent vasodila¬
tor sodium nitroprusside.13 We have more rigorously demon¬
strated the selectivity of bradykinin antagonism by B9340
through comparison with the tachykinin substance P, which
acts through the endothelial neurokinin type 1 receptor to
cause endothelium-dependent vasodilatation6 and t-PA re¬
lease. The antagonist action of B9340 cannot, therefore, be
attributed to a nonspecific effect on the vascular endothelium
and appears to be selective for bradykinin receptors.
Bradykinin is thought to exert its vasodilatory effects by
activating the B2 receptor on vascular endothelium. This
results in release of nitric oxide15-16 and endothelium-derived
hyperpolarizing factor to produce vasorelaxation.1713 How
ever, although inhibition of nitric oxide synthase with N°-
monomcthyl-L-arginine attenuates the vasodilatation to bra¬
dykinin, it does not affect endothelial t-PA release.13 This
would suggest that bradykinin-stimulated t-PA release is
mediated through a nitric oxide synthase-independent path¬
way and that the endothelium regulates blood flow and t-PA
release through distinct pathways. Indeed, we have recently
demonstrated that direct, local, endothelial t-PA release can
be induced by tumor necrosis factor-a in the absence of
alterations in blood flow in the human forearm.19 Thus,
bradykinin-induced t-PA release appears to be dependent on
the endothelial bradykinin receptors and to act through a
second-messenger pathway that is distinct from the regulation
of vasomotion.
B9340 had no effect on basal FBF or plasma t-PA
concentrations, suggesting that in healthy humans, bradykinin
does not contribute to the basal maintenance of vascular tone
or t-PA release. However, this does not preclude a potential
role for bradykinin in pathophysiologic conditions, such as
inflammation,20 or instances where ACE inhibitor therapy is
used.4-21
Although B9340 antagonizes the B2 receptor at concentra¬
tions nearly 2 orders of magnitude greater than those at the B,
receptor, B9340 might still produce some blockade of the B,
receptor. The B| receptor was previously thought to be
inactive in the vascular system unless upregulated during
1670 Arterioscler Thromb Vase Biol. September 2003
inflammation. Raidoo et al20 have recently shown that B,
receptors are present in large numbers on the vascular
endothelium and are further upregulated around atheroscle¬
rotic plaques. However, the functional significance of the B,
receptor on the endothelium is unknown, and the work by
Brown et al13 using HOE-140 would suggest that the ob¬
served effects are mediated principally through blockade of
the B2 receptor.
Conclusions
B9340 is a potent, reversible, and selective competitive
inhibitor of bradykinin-induced vasodilatation and t-PA re¬
lease in humans. This compound is a potentially useful
investigational tool in dissecting out the physiologic and
pathophysiologic role of bradykinin in vivo in humans.
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Inhibition of thrombin activatable fibrinolysis inhibitor
augments fibrinolysis in human whole blood
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Exogenous thrombolytic therapy fails to achieve repcrfusion of
the infarcl-related artery in approximately a third of patients
with acute myocardial infarction [l]. Thrombin-activatable
fibrinolysis inhibitor (TAFI) is a plasma procarboxypeptidase
that may contribute to this resistance to thrombolysis. TAFI is
converted to the active form, TAFIa, in the presence of
activated coagulation factors, thrombin and thrombomodulin,
and once activated, cleaves lysine groups from the C-terminal
of partially degraded fibrin, thereby preventing the binding of
plasminogen [2], This greatly reduces the ability of tissue-type
plasminogen activator (t-PA) to convert plasminogen to
plasnrin and inhibits the process of t-PA mediated fibrinolysis.
Although elevated plasma concentrations of TAFIa have been
reported during thrombolysis administration [3], it remains
unclear whether TAFIa contributes to resistance to thrombo¬
lysis in man.
Potato carboxypeptidase inhibitor (PCI) is a specific inhib¬
itor of TAFIa in blood that been shown to accelerate t-PA
mediated fibrinolysis both in vitro [2,4-6] and in animal models
[7,8]. Previous in vitro studies, however, were based on the
dynamics of preformed or de novo clot dissolution in the
presence of specific blood products, or at best plasma.
Thromboelastography is a global assay of fibrinolytic function
that measures the viscoelastic properties of clotting blood over
time and has been used to assess the fibrinolytic activity of
exogenous thrombolytic agents in whole blood [9,10[. We
investigated the effects of the specific TAFIa inhibitor, PCI, on
t-PA mediated fibrinolysis using thromboclastography of
human whole blood.
Studies were performed with the approval of the local
research ethics committee and informed consent ofeach subject
in accordance with the Declaration of Helsinki. Six healthy,
male non-smokers aged 20-40 years were recruited. Using a
17-gauge needle, 9 mL venous blood was collected from an
antecubital vein into plain, additive-free tubes (Sarstedt
(Niimbrecht, Germany)) and immediately applied to a Throm-
boelastograph® Coagulation Analyser 5000C (Haenroscope
Corporation, Skokie, IL, USA). Thromboelastography was
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performed on 360 pL of samples consisting of 320 pL ofwhole
blood, 10 pL of tissue factor (manufacturer's recommended
concentration; Haemoscope Corporation) and 30 pL of nor¬
mal saline containing the study drugs. Incremental doses of
recombinant t-PA (final cup concentration: 0-560 ng mL-1;
Boehringer Ingelheim, Ingelheim, Germany) were applied with
saline placebo, PCI (27 pg mL-1; Calbiochem, Darmstadt,
Germany) or tranexamic acid (420 ng mL"1; Pharmacia,
Milton Keynes, UK) during tissue factor-initiated thrombo¬
elastography of human whole blood. Maximum amplitude
(MA) and clot lysis at 30 (Ly30) and 60 (Ly60) minutes were
determined using Thromboelastograph® software.
In the presence of saline placebo, t-PA caused a dose-
dependent reduction in MA (P < 0.0001; one-way anova)
and increases in Ly30 (P < 0.0001; one-way anova; Fig. 1)
and Ly60 (P < 0.0001; one-way anova; Fig. 1). PCI aug¬
mented t-PA mediated lysis, causing a leftward shift in the t-PA
dose response curve for both Ly30 and Ly60 (P < 0.001 for
both; PCI vs. placebo; Fig. 1). In contrast, tranexamic acid
inhibited t-PA mediated lysis, shifting the t-PA dose response
curves for Ly30 and Ly60 rightwards compared with placebo
[P < 0.001 for both; tranexamic acid (TA) vs. placebo; Fig. 1].
In the absence of t-PA, there were no significant differences in
MA (57 ± 2 vs. 58 ± 2 vs. 57 ± 1 mm), Ly30 (2.5 ± 0.9 vs.
2.0 ± 0.7 vs. 2.9 ± 0.8%) or Ly60 (7.0 ± 0.9 vs. 6.1 ± 1.2
vs. 7.4 ± 1.3%) between saline placebo, PCI and tranexamic
acid respectively.
We have demonstrated that inhibition of TAFIa augments
t-PA mediated fibrinolysis in human whole blood. Thrombo¬
elastography has a number of potential advantages over
traditional clot-based and turbidity-time course assays in that
it allows incorporation of t-PA during, rather than after,
thrombus formation [11] and is more likely to reflect physiolo¬
gical concentrations of TAFIa, given that TAFI activation
occurs at sites of active clot formation where local thrombin
concentrations are greatest [12], It has been suggested that
platelet derived TAFI may play a key role in the resistance ofclot
to thrombolysis [13]. Thromboelastography encompasses all of
the constituents of blood involved in thrombus propagation
including the cellular components absent from plasma-based
assays. The demonstration that tranexamic acid, a competitive
inhibitor of plasminogen activation, inhibits t-PA mediated
fibrinolysis confirms the validity of thromboelastography as a
method by which to assess fibrinolytic activity in human whole
© 2005 International Society on Thrombosis and Haemostasis
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Fig. 1. Tissue factor initialed thromboelastography of human whole
blood (h = 6 for each data point): effect of incremental doses of t-PA [final
cup concentration (ng mL ')] on Lyju and Ly6u In the presence of saline
placeho (solid squares), potato carboxypeptidase inhibitor (PCI,
27 pg mL"1; solid triangles) or tranexamic acid (TA, 420 ng mL"1; open
circles). Compared with placebo, PCI caused a significant leftward shift
and tranexamic acid caused a significant rightwards shift in the Ly30 and
Ly60 t-PA dose response curves (P < 0.001 for all). Data are expressed as
mean ± SEM.
blood. We believe, therefore, that thromboelastography pro¬
vides a robust and representative assessment of the clot
dynamics anticipated at sites of thrombus formation in the
human circulation.
To our knowledge, this is the first study to examine the
functional effects of TAFla inhibition in human whole blood.
The concentrations of t-PA used in this study reflect plasma
concentrations achieved during systemic thrombolysis for acute
myocardial infarction (approximately 100-200 ng mL-1) [14],
Our findings are in keeping with previous data demonstrating
PCI mediated augmentation of clot lysis in a plasma-based
assay at similar concentrations of t-PA [6], Moreover, consis¬
tent with our data, PCI had no effect on lysis at higher
concentrations of t-PA (1000 and 5000 ng mL-1), possibly as
the authors suggest, because of loss of fibrin dependence [6],
Inhibition of TAFla may also have a role in the secondary
prevention of coronary heart disease. Low circulating endog¬
enous fibrinolytic activity is associated with an increased risk of
myocardial infarction in young men [15] and predicts which
patients with unstable angina will progress to myocardial
infarction [16], Acute endothelial t-PA release is impaired in
smokers [17] and in patients with coronury urtcry disease, and
the degree of impairment correlates with atheromatous plaque
load [18], In patients with atheromatous vascular disease,
TAFla inhibition may augment endogenous fibrinolytic nctiv
ity, swinging the balance in favor of clot dissolution rather than
propagation, and interrupting the cycle of subclinical thrombus
formation, organization and vessel remodeling that underlies
chronic atheromatous plaque growth.
In summary, we have demonstrated that inhibition of
TAFla augments t PA mediated fibrinolysis in human whole
blood. Our findings provide functional evidence of TAFI
activity in man and suggest that TAFla inhibition may be both
a potential adjuvant to thrombolytic therapy in patients with
acute myocardial infarction, and a novel therapeutic strategy in
the secondary prevention of thrombotic vascular events in
patients with atherosclerosis.
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Fast kinetic assay for the determination of procarboxypeptidase
U (TAFI) in human plasma
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Carboxypeptidase U (CPU, TAFIa) is a recently discovered
enzyme present in the circulation as its zymogen, procarb¬
oxypeptidase U (proCPU, TAFI). CPU was first described by
Hendriks et cil. [1,2] as an interference in the assay of
carboxypeptidase N, a basic carboxypeptidase constitutively
active in human plasma. After extensive research in the last
15 years, CPU is now regarded as an important link between
coagulation and fibrinolysis [3-5]. Given that the proCPU
concentration in plasma is far below its K„, for activation by the
thrombin-thrombomodulin (T-Tm) complex the formation of
CPU will be dependent both on the T-Tm concentration as
well on the proCPU concentration [6,7], A low or a high
proCPU plasma concentration might therefore tip the balance
between profibrinolytic and antifibrinolytic pathways and
thereby cause a predisposition to bleeding or thrombosis.
ProCPU levels in plasma can be measured using both
immunological assays (ELISA) or activity-based assays. The
intrinsic instability of CPU and the difference in stability
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between isoforms are major drawbacks of activity-based assays
and were solved in the past by using very high substrate
concentrations (which stabilize the active enzyme), incubating
for short periods of time or by incubating at room temperature
[8,9]. Another possibility of solving this is making use of a
kinetic method, which enables the determination of accurate
initial velocities even at very low substrate concentrations. We
recently published a kinetic assay for the efficient characteri¬
zation of physiological and synthetic CPU substrates with a
C-terminal arginine [8], We now adapted this assay for use in a
plasma environment. The reaction mechanism is shown in
Fig. 1.
In order to determine plasma proCPU concentrations a
reaction mixture is prepared consisting of 5.6 mmol L_l
MgS04, 22.2 mmol L_l KC1, 4.9 mmol L~' phosphoenol-
pyruvate, 1.1 mmol L_l NADH, 5.6 mmol IT1 ATP
9000 U L_l of both pyruvate kinase and lactate dehydroge¬
nase, 18 000 U L_1 arginine kinase and 11 mmol L-1 hippu-
ryl-L-arginine substrate in HEPES buffer adjusted to pH 8.0.
Prior to its addition to the reaction mixture, the pyruvate
kinase/lactate dehydrogenase suspension is centrifuged for
5 min at 14 000 g, and the pellet is redissolvcd ex tempore in an
equal amount of 100 mmol L~' HEPES buffer pH 8.0. Plasma
is diluted 1/20 in 20 mmol L~' HEPES buffer pH 7.4 and
activated in Eppendorf tubes (using final concentrations of
T-Tm of 8 and 16 nmol L ', respectively) and transferred to
microtiter plates at room temperature. To 55 pL of activated
plasma, 45 pL reaction mixture is added (37 °C). The micro¬
titer plate is incubated for 3 min in a water bath at 37 °C to
© 2005 International Society on Thrombosis and Haemostasis
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Direct Vascular Effects of Protease-Activated Receptor
Type 1 Agonism In Vivo in Humans
Ingibjorg J. Gudmundsdottir, MD; Ian L. Megson, PhD; Jillian S. Kell, BSc;
Christopher A. Ludlam, MD; Keith A.A. Fox, MD; David J. Webb, MD; David E. Newby, MD, PhD
Background—Protease-activaied receptor type 1 (PAR-1) has been proposed as the principal thrombin receptor in humans,
although its actions in vivo have not been defined. The aim of the present study was to determine the direct vascular
actions of PAR-1 agonism in humans.
Methods and Results—Dorsal hand vein diameter was measured by the Aellig technique in 14 healthy volunteers during
local intravenous SFLLRN (PAR-1 agonist; 0.05 to 15 nmol/min) and SLIGKV (PAR-2 agonist; 1.6 to 160 nmol/min)
infusions. The venous effects of SFLLRN were further assessed in the presence or absence of norepinephrine or the
glycoprotein llh/llla antagonist tirofiban Forearm blood flow was measured by venous occlusion plethysmography in
16 volunteers during infusion of SFLLRN (1 to 50 nmol/min), SLIGKV (160 to 800 nmol/min), and the
endothelium-dependent vasodilator bradykinin (100 to 1000 pmol/min). Platelet-monocyte binding (a sensitive measure
of platelet activation) and plasma tissue plasminogen activator (tPA), plasminogen-activator inhibitor 1, and von
Willebrand factor concentrations were measured at intervals throughout the study. SFLLRN caused dose-dependent
venoconstriction (/'<().001) that was unaffected by norepinephrine or tirofiban co-infusion. In forearm resistance
vessels, SFLLRN increased forearm blood flow (P<0.()01), tPA release (P<0.001), and platelet-monocyte binding
(PC0.0001) without affecting plasma plasminogen-activator inhibitor 1 or von Willebrand factor concentrations.
SLIGKV caused venous (P<0.001) and arterial (P<0.01) dilatation without tPA release.
Conclusions—We have demonstrated that PAR-1 agonism causes platelet activation, venous constriction, arterial
dilatation, and tPA release in vivo in humans. These unique and contrasting effects provide important insights into the
physiological and pathophysiological role of thrombin in the human venous and arterial circulations. (Circulation. 2006;
114:1625-1632.)
Key Words: platelets ■ blood flow ■ veins ■ arteries ■ receptor, PAR-1 ■ receptor, PAR-2
Thrombin is a powerful physiological stimulant in thecardiovascul r system. Apart from its central enzymatic
role in the coagulation cascade, it directly activates platelets,
leukocytes, and vascular smooth muscle and endothelial
cells.1 Thrombin is therefore a vital link between thrombosis,
cellular activation, and inflammation, key pathogenic factors
in atherothrombotic disorders.
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Given the apparent direct cellular effects of thrombin,
cloning methods2-1 were used to conduct an extensive search
for its receptor. This led to the identification of G-protein-
coupled protease-activated receptors (PARs) characterized by
a unique mechanism of activation whereby proteolytic cleav¬
age unmasks a short peptide sequence that remains tethered
and activates the receptor.2-4 Four different types of PARs
have been identified. PAR-1, -3, and -4 are all activated by
thrombin. The type I receptor has been proposed as the
principal thrombin receptor in humans.5-6 In contrast, the
PAR-2 receptor is activated by trypsin, by tryptase, and to a
lesser extent by coagulation factors upstream of thrombin.7 It
appears to be of importance in inflammatory conditions that
induce endothelial PAR-2 expression and vasodilatation.
PAR-1 receptor agonism has been extensively studied in
vitro and is associated with platelet activation and aggrega¬
tion,8 vasodilatation,9 and angiogenesis.10 Although studies in
small animals suggest that PAR-1 and PAR-2 agonism induces
vasodilatation,"-12 there is significant species heterogeneity, and
rodent models are of limited relevance to humans.13 Exploring
the role of PAR-1 receptors in the hurrum vasculature would
deepen our understanding of the physiological role of thrombin
and would be of interest in the development of new therapeutic
strategies such as PAR-1 receptor antagonists'4-15 and direct
thrombin inhibitors.16-17
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TABLE 1. Baseline Characteristics of Study Volunteers
Male, % 79 (41/52)
Age, y 24±0.5
Body mass index, kg/m2 23±0.4
Heart rate, bpm* 67±2




White cell count, X109/L* 4.98±0.37
Platelets, x109/L* 213 + 11
Values are mean±SEM.
'Data from vascular studies only.
Therefore, the aims of the present study were to determine
the direct in vivo vascular effects of PAR-1 agonism in the
human vasculature. Specifically, we wished to assess the
direct role of PAR-1 activation on platelet activation and
aggregation, venous and arterial tone, and the release of
endothelium-derived factors in vivo in humans.
Methods
Subjects
Fifty-two healthy male and female nonsmokers (age, 20 to 38 years)
were recruited into the study (Table 1). Participants had not been
taking any regular medications, over-the-counter medications, herbal
supplements, or vitamins. They did not have clinically significant
coexisting conditions, including hypertension, hyperlipidemia, dia¬
betes mellitus, asthma, and coagulopathy, and had not suffered a
recent infective or inflammatory condition. The study was approved
by the local research ethics committee and conducted in accordance
with the Declaration of Helsinki and with the written informed
consent of all volunteers.
Platelet Studies
Protocol I: Platelet Aggregoinetry
Blood was sampled with a 19-gauge needle from the antecubita!
fossa into a 50-mL syringe, transferred into lubes containing 3.8%
citrate, and centrifuged at I30g for 20 minutes at room temperature
to obtain platelet-rich plasma. Blood was centrifuged at 1200g for 10
minutes to obtain platelet-poor plasma for reference samples. Platelet
aggregation was measured at 37°C using standard optical platelet
aggregometry.18-1'2
Preliminary in vitro platelet studies were carried out to construct
concentration-response curves to define the concentration of the PAR-1
agonist SFLLRN-NH, that caused platelet activation and aggregation.
SFLLRN-NHj fAuspep. Parkville Victoria. Australia) was compared with
the thromboxane A- agonist U46619 (Sigma, Gillingham, UK) in both
platelet-rich plasma and washed platelets.18 To assess the specificity of the
PAR-1-activating peptide, both SFLLRN-NH2- and U46619-induced




4-difluorobenzenepropanamide; American Peptide Co, Sunnyvale, Calif) in
washed platelets. SFLLRN-NH,-induced platelet aggregation was also
assessed in tire presence of the direct thrombin inhibitor lepirudin (0.1 and
1.0 mg/mL; Schering, Burgess Hill, UK).
We chose the concentration of SFLLRN-NH, that caused nearly
maximal platelet aggregation and assumed that the vascular and
platelet PAR 1 receptor sensitivities were equivalent. However,
before progressing to in vivo infusions, we defined the dose of
tirofiban that would completely inhibit platelet aggregation using the
clinical-grade preparation of SFLLRN-NH,. Platelet-rich plasma was
incubated for 5 minutes in the presence or absence of tirofiban
(Merck, Sharp and Dohme. Hoddesdon, UK) at 50 ng/mL.20 Platelet
aggregation was measured after administration of 0.06 to 12 pmol/L
of the PAR-l-activating peptide SFLLRN-NH, (Clinalfa, Laufelfin-
gen, Switzerland) by a 4-channel platelet aggregometry profiler
(PAP-4D, Bio/Data Corp, Horsham, Pa) linked to PC interface
software (Platelet Aggregation Profiler, version 2.3, Bio/Data Corp).
Protocol 2: Platelet-Monocyte Binding
Venous blood (5 mL) was collected through a 19-gauge needle and
transferred into a tube containing the direct thrombin inhibitor
D-phenylalanyl-L-propyl-L-arginine chloromethylketone. For in
vitro studies, blood was collected into 2 D-phenylalanyl L propyl-L-
arginine chloromethylketone tubes containing either tirofiban (50
ng/mL) or SFLLRN-NH, (0.06 to 6 grmol/L). Five minutes after
sampling, blood was incubated with appropriate monoclonal anti¬
bodies labeled with fluorochromes for 20 minutes, and platelel-
monocyte aggregates were measured as described previously.21
Vascular Studies
All studies were carried out in a quiet, temperature-controlled room
(22°C to 24°C). Participants were semirecumbent (venous studies) or
supine (arterial studies) and had abstained from alcohol for 24 hours
and from food and caffeine-containing drinks for at least 4 hours
before the study.
Venous Studies
A 23-gauge needle was sited in a dorsal hand vein, and the total
infusion rate was kept constant at 0.25 mL/min in all studies. The
hand was supported above the level of the heart and an upper arm
cuff inflated to 40 mm Hg to obstruct venous return. The internal
diameter of the dorsal hand vein was measured by the Aellig
technique.22 In brief, a magnetized lightweight rod rested on the
summit of the infused vein =1 cm downstream from the tip of the
infusion needle. The rod passed through a core of a linear variable
differential transformer, supported above the hand by a small tripod.
Changes in vein diameter caused vertical displacement of the rod,
leading to a linear change in the voltage generated by the linear
variable differential transformer. This enabled calculation of abso¬
lute changes in vein size.
Protocol 3: Effect on Venous Tone
Because dorsal hand veins do not have resting tone, norepinephrine
(1 to 128 ng/min) was used to induce and maintain a 50% to 70%
reduction in vein diameter throughout the study to allow detection of
either venodilatation or venoconstriction. This was followed by
co-infusion of the PAR-l-aclivating peptide SFLLRN-NH2 (0.05 to
5 nmol/min) or the PAR-2-activating peptide SLIGKV-NH, (1.6 to
160 nmol/min; Clinalfa).
Protocol 4: Effect ofGlycoprotein llb/IIla Receptor Antagonism
The effects of SFLLRN-NIL (0.05 to 15 nmol/min) in the presence
and absence of the glycoprotein Ilb/llla inhibitor tirofiban (250
ng/min) and norepinephrine (1 to 128 ng/min) were assessed to
determine the importance of platelet aggregation on PAR 1 mcdi
ated alterations of venous tone. The doses of tirofiban and SFLLRN-
NH, were chosen to achieve end-organ concentrations equivalent to
those with efficacy in in vitro studies (protocol 1) and assumed a
dorsal hand vein flow of 5 mL/min.
Arterial Studies
All subjects underwent brachial artery cannulation with a 27-
standard-wire-gauge steel needle under controlled conditions. Intra¬
arterial infusion rate was kept constant at 1 mL/min throughout all
studies. Forearm blood flow was measured in the infused and
noninfused arms by venous occlusion plethysmography using
mercury-in-Silastic strain gauges as described previously.2-1-24 Su¬
pine heart rate and blood pressure were monitored at intervals
throughout ouch study using a scminutomated noninvasive oscillo
metric sphygmomanometer. Tirofiban (1.25 pig/min) was co-infused
during PAR-1 activation to inhibit in vivo potential platelet aggre-
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Figure 1. Induction of platelet aggrega¬
tion by the PAR-1-activating peptide
SFLLRN-NH2 (A) and the thromboxane
A2 agonist U46619 (B; P<0.001 for both,
1-way ANOVA). The PAR-1 antagonist
RWJ-58259 inhibited aggregation
induced by SFLLRN-NH2 (C; P<0.001,
1-way ANOVA) but not by U46619 (D;
P=NS). Values are mean±SEM.
gation. The doses of tirofiban and SFLLRN-NIL were chosen to
achieve end-organ concentrations equivalent to those with efficacy in
in vitro studies (protocol 1) and assumed a brachial artery blood flow
of 25 mL/min.
Blood Sampling
Venous cannulas (17 gauge) were inserted bilaterally into the
antecubital fossae. Blood samples were drawn simultaneously from
each arm during infusion of saline, tirofiban, and each dose of the
PAR-aclivating peptides and bradykinin. They were collected into
acidilied buffered citrate (Stabilyte, Trinity Biotech Pic, Co Wicklow,
Ireland: for tissue plasminogen activator [tPA] assays) and into citrate
(BD Vacutainer, BD UK Ltd, Oxford, UK; for plasminogen activator
inhibitor type 1 [PAI-1] and von Willebrand factor [vWF] assays).
Samples were kept on ice before centrifugation at 2(XX)g for 30 minutes
at 4"C. Platelet-free plasma was decanted and stored at — 80"C before
assay. Plasma tPA antigen and activity (tPA Combi Actibind Elisa Kit,
Tcchnoclone, Vienna, Austria) and PAI-1 antigen and activity
(ElileslPAI-1 Antigen and Zymutest PAI-1 Activity, Hyphen Biomed,
Neuville-Sur-Oise, France) concentrations were determined by ELISAs.
Full blood count was measured at baseline and at the end of the study.
Blood was also collected from each arm to determine platelet-monocyte
binding (see protocol 2) at baseline, at the highest dose of SFLLRN-
Nl I,, during saline washout, and at the highest dose of bradykinin.
Protocol 5: PAR-1 Activation
After a 20-minute baseline saline infusion, tirofiban (1.25 pig/min)
was infused throughout the study. Thirty minutes after the tirofiban
infusion was started, the PAR-l-activating peptide SFLLRN-NH,
was co-infused at 5, 15, and 50 nmol/min for 8 minutes at each dose
separated by 6 minutes of saline washout infusions. This was
followed by a 30-minute washout period before co-infusion of
bradykinin (an endothelium-dependent vasodilator that releases tPA;
Clinalfa) at 100, 300, and 1000 pmol/min25 for 8 minutes at each
dose.
Protocol 6: PAR-2 Activation
After a 20-minute baseline saline infusion, the PAR-2-activating
peptide SLIGKV-NH, was infused at 160, 360, and 800 nmol/min
for 8 minutes at each dose separated by 6 minutes of saline washout
infusions. This was followed by a 30-minutc saline infusion before
bradykinin was infused at 100, 300, and 1000 pmol/min25 for 8
minutes at each dose.
Data and Statistical Analyses
Dorsal hand venous26 and forearm plethysmography23 data were
analyzed as described previously. Variables arc reported as
mean±SEM and analyzed using repeated-measures 1- or 2-way
ANOVA with post-hoc Bonfcrroni corrections and 2-tailed Student
/ test as appropriate. Statistical analysis was performed with Graph-
Pad Prism (GraphPad Software, Inc, San Diego, Calif). Statistical
significance was taken at P<0.05.
The authors had full access to the data and take responsibility for their
integrity. All authors have read and agree to the manuscript as written.
Results
In Vitro Effects of PAR Agonism on Platelets
Both SFLLRN-NH2 and U46619 caused dose-dependent
platelet aggregation (median effective concentration
rEC50]= 1.26 and 0.78 pimol/L, respectively; Figure 1A and
IB; n = 8). The PAR-1 antagonist RWJ-58259 selectively and
fully inhibited SFLLRN-NH2-induced (Figure 1C; n = 8;
P<0.001, 1-way ANOVA) but not U466I9-induced (Figure
ID; n = 8: P=NS) platelet aggregation. In contrast, the direct
thrombin inhibitor lepirudin had no effect on SFLLRN-NFL-
induced platelet aggregation (n=6; P=NS; data not shown).
The clinical-grade SFLLRN-NH, also caused a dose-
dependent increase in platelet aggregation (EC50=0.66 /xmoI/L)
that was inhibited by tirofiban (Figure 2A; n=6; P<0.001,
2-way ANOVA). In contrast, PAR-1 activation caused a dose-
dependent increase in whole-blood platelet-monocyte binding
(EC5o=0.23 pmol/L) that was not affected by tirofiban (Figure
2B; n=6; /J=NS, 2-way ANOVA). As anticipated, PAR-2
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Figure 2. PAR-1 -activating peptide
(SFLLRN-NH2) induced platelet aggrega¬
tion (A) and platelet-monocyte binding
(B) in the presence (*) or absence (□) of
tirofiban (50 ng/mL). Values are
mean±SEM. A, P<0.0001 (2-way
ANOVA) vs tirofiban; B, P=NS (2-way
ANOVA) vs tirofiban.
activation with SLIGKV-NH, induced neither platelet aggrega¬
tion nor platelet-monocyte binding (n>3; data not shown).
In Vivo Effects of PAR Agonism on Dorsal
Hand Veins
After venoconstriction (50% to 70%) was induced and main¬
tained with norepinephrine, SFLJLRN-NTT and SLIKGV-Nf I,
caused dose-dependent venoconstriction (n=8; P<0.00l. I-way
ANOVA) and venodilatation (n=6; PC0.001, 1-way ANOVA),
respectively. In the absence of norepinephrine, SFLLRN-NH2
caused a dose-dependent venoconstriction (P<0.001, 1-way
ANOVA) that was able to induce complete constriction of the
venous segment. This was not mediated by platelet aggregation
because co-infusion of tirofiban had no effect on SFLLRN-
NH.-induced venoconslriction (Figure 3). SFLLRN-NH2 was
well tolerated by all subjects with no adverse effects. Vein
patency was maintained at all times with no clinically apparent
in situ thrombus formation.
In Vivo Effects of PAR Agonism on Forearm
Resistance Vessel Tone
There was no change in heart rate, blood pressure, or
noninfused forearm blood flow throughout either study.
Intra-arteria! tirofiban had no effect on resting forearm blood
(low (P=NS). Both PAR-1 activation with SFLLRN-NH,
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Figure 3. The PAR-1-activating peptide
SFLLRN-NH2 causes concentration-
dependent venoconstriction (■; n=6 to 8;
P<0.001, 1-way ANOVA) that is unaf¬
fected by norepinephrine (A, B) or tirofi¬
ban (C, D) infusion, whereas the PAR-2-
activating peptide SLIGKV-NH2 (E)
induces venodilatation (□; n = 6; P<0.001,
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Figure 4. Forearm vasodilatation induced
by the PAR-1-activating peptide
SFLLRN-NH2 (A; ■; n = 8; P<0.001,
1 -way ANOVA), the PAR-2-activating
peptide SLIGKV-NH2 (C; a; n=8; P<0.01,
1-way ANOVA), and bradykinin (B, •; D,
o; n=8; P<0.001, 1-way ANOVA). Values
are mean±SEM. *P<0.05, **P<0.01,
*"P<0.001.
dependent vasodilatation (Figure 4A and 4C; n = 8; P<0.00I
and P<0.01, respectively, 1-way ANOVA) with a rapid onset
and offset of action. As anticipated, bradykinin increased
forearm blood flow (Figure 4B; P<0.001, 1-way ANOVA)
and was unaffected by lirofiban co-infusion (Figure 4D;
P=NS versus no tirofiban).
In Vivo Effects of PAR Agonism on
Endothelium-Derived Factors
Plasma tPA antigen and activity concentrations increased in a
dose-dependent manner during SFLLRN-NFF and bradykinin
but not SLIGKV-NH2 infusion (Figure 5; PC0.001 for all).
Plasma PAI-1 antigen and activity and vWF concentrations
were unaffected by all infusions (P=NS for all; Table 2).
Although there was an apparent rise in plasma PAI-1 antigen
concentration at 50 nmol/min SFLLRN-NFI2, it did not
achieve statistical significance (P=0.08, paired r test versus
baseline) and was not associated with increases in PAI-1
activity or vWF. There were no differences in peripheral
blood hematocrit (0.416±0.006 versus 0.426±0.008) or
platelet counts (213±16X109 versus 216± 15X109/L) at
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Figure 5. Plasma tPA antigen (solid lines)
and activity (dashed lines) during infusion
of the PAR-1-activating peptide
SFLLRN-NH2 (■) and bradykinin (•). Val¬
ues are mean±SEM.
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TABLE 2. Plasma PAI-1 Antigen and Activity and vWF Antigen Concentrations in the Infused and
Noninfused Arms During Brachial Artery Infusion of SFLLRN-NH2 and Bradykinin
PAI-1 Antigen, ng/mL PAI-1 Activity, U/mL vWF Antigen, ng/mL
Infused Arm Noninfused Arm Infused Arm Noninfused Arm Infused Arm Noninfused Arm
Baseline 27.3±5.5 27.7±5.6 0.58±0.14 0.51 ±0.13 0.72±0.08 0.72±0.07
Tirofiban 25.6+5.5 24.5±4.4 0.40±0.09 0.43±0.12 0.69±0.04 0.62±0.08
SFLLRN-NHZ, nmol/min
5 23.0±4.7 24.9±4.4 0.44+0.12 0.47 ±0.11 0.62±0.06 0.67 ±0.08
15 24.3±4.5 23.8±4.4 0.41 ±0.10 0.41 ±0.11 0.67±0.06 0.74±0.10
50 33.8±6.8 26.9±5.3 0.37+0.09 0.42±0.09 0.73±0.08 0.76±0.08
Washout 22.9±4.2 23.1 ±3.6 0.32±0.08 0.33±0.08 0.67±0.09 0.74±0.09
Bradykinin, pmol/min
100 19.6+3.7 21 3±3.9 0.27±0.07 0.35±0.09 0.80±0.08 0.64 ±0.09
300 19.5±4.4 19.5±4.9 0.25±0.06 0.26±0.07 0.73±0.08 0.70±0.07
1000 19.5+3.2 19.1+2.9 0.16±0.03 0.25±0.05 0.76±0.07 0.67±0.07
n=8 for all. Values are mean±SEM.
vivo platelet-monocyte binding (from 16±5% to peak of
74±5%; Figure 6; PC0.0001, 1-way ANOVA) that declined
toward baseline with time.
The PAR-2-activating peptide SL1GKV-NH, had no effect
of plasma tPA concentrations (P=NS for all; data not
shown).
Discussion
In a series of clinical studies, we have, for the first time,
described the direct vascular effects of PAR-1 agonism and
established the induction of in vivo platelet activation, veno-
eonstriclion, vasodilatation, and tPA release, as well as
confirming the vasodilatory effects of PAR-2 agonism. These
unique and contrasting effects of PAR-1 activation provide
important insights into the physiological and pathophysiolog¬
ical roles of thrombin in the venous and arterial circulations
of humans.
Platelet Effects of PAR-Activating Peptides
Inhibition of platelet activation has been of major benefit in
the prevention and treatment of cardiovascular diseases.
Thrombin is one of the most potent physiological stimulants
of platelet activation that appears to be mediated largely
through the PAR-1 receptor, although major contributions are
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Figure 6. Platelet-monocyte binding during the infusion of the
PAR-1 agonist SFLLRN-NH2 in the infused (open bars) and non¬
infused (gray bars) arms. Values are mean±SEM.
date, strategies to reduce the action of thrombin have focused
on direct inhibition of its enzymatic activity. Recently,
PAR-1 antagonists have been developed as potential anti¬
platelet agents15 that do not affect the coagulation cascade. It
is therefore important to define the in vitro and in vivo effects
of PAR-1 agonism in humans. As anticipated, we have
demonstrated that PAR-1 but not PAR-2 agonism caused
concentration-dependent platelet activation and aggregation.
Moreover, in the presence of complete inhibition of platelet
aggregation with the glycoprotein lib/Ilia receptor antagonist
tirofiban, PAR-1 agonism continued to induce platelet acti¬
vation as measured by platelet-monocyte binding both in
vitro and in vivo. This is consistent with our previous findings
that although glycoprotein Ilb/IIla receptor antagonism inhib¬
its platelet aggregation, it does not affect platelet activation or
platelet-monocyte binding.27
Vascular Effects of PAR-Activating Peptides
PAR-1 appears to be the principal receptor responsible for the
vascular actions of thrombin and includes the regulation of
vasomotion, platelet aggregation, inflammation, and angio-
genesis. However, investigation of the in vivo vascular
effects of thrombin presents challenges because of the direct
activation of the coagulation cascade and platelets that may
result in intravascular thrombosis. Here, we have chosen to
use PAR-activating peptides that cause direct cellular stimu¬
lation without enzymatic activation of the coagulation
cascade.
The direct vascular effects of PAR-1 receptor agonism
have not been previously reported in humans. Our study
protocol was vigilant to minimize any potential prothrom-
botic effects associated with PAR-l-induced platelet aggre¬
gation. We defined the in vitro concentrations of glycoprotein
llb/IIIa receptor antagonism that would permit the direct in
vivo intravascular infusion of PAR-1-activating peptide
without inducing platelet aggregation and potential thrombo¬
sis. This appears to have been successfully achieved, given
the absence of significant adverse clinical side effects or
thrombosis.
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Venous Effects of PAR-Activating Peptides
Thrombin and the PAR-I agonist SFLLRN-NH2 have previ¬
ously been shown to cause endothelium- and nitric oxide-
dependent venous and arterial dilatation in canine and porcine
ring segments.28'29 Although confirming previous observa¬
tions of PAR-2-mediated venodilatation,30 we have rather
unexpectedly described a dose-dependent venoconslriction
with PAR-1 activation. This may be mediated by platelet
activation, release of endothelium-derived vasoconstrictors,
or a direct effect on venous smooth muscle cells. Neither
norepinephrine nor tirofiban co-infusion appeared to affect
this potent venoconstrictor effect. In combination with the
apparent absence of in situ thrombosis, this suggests that
PAR-1-induced venoconstriclion was not mediated by plate¬
let aggregation, although we cannot exclude an effect of
platelet activation.
Arterial Effects of PAR-Activating Peptides
In contrast to the venous effects, both PAR-1 and PAR-2
activation caused dose-dependent vasodilatation of forearm
resistance vessels. We have not assessed the mechanism of
this vasodilatation, but animal and clinical models suggest
that this is likely to be endothelium and nitric oxide depen¬
dent n"10 However, data from animal studies have limited
relevance in humans because of the wide species variability
in PAR-1 receptor expression and function. The mechanism
of PAR-1-induced vasodilatation needs to be addressed in
future clinical studies.
PAR receptor expression varies between endothelial cell
cultures originating from different human blood vessels,31
which may partly explain the contrasting responses between
PAR-1 and PAR-2 in the arterial and venous circulations. Our
findings that PAR-2 activation causes venous and arterial
dilatation are consistent with previous findings30 and support
the vascular role of PAR-2 receptors in inflammatory
conditions.
Effects of PAR-Activating Peptides on
Endothclium-Derivecl Factors
Intra-arterial PAR-1 but not PAR-2 agonism caused an acute
dose-dependent increase in local endothelial tPA release. In
contrast to in vitro human endothelial culture studies,32 this
occurred in the absence of the release of other endothelium-
derived factors such as PAI-1 and vWF. However, there was
an apparent rise in plasma PAI-1 antigen (/J=0.08) with
high-dose PAR-1 agonism, but given the absence of an effect
on PAI-1 activity and vWF, this may reflect the associated
platelet activation and release of platelet-derived PAI-1.
PAI-1 is stored in platelet a-granules, where its activity is
*=5% of plasma because of the absence of the stabilizing
effect of vitronectin. Thus, PAR-1 agonism appears to have a
selective profibrinolytic effect on the arterial endothelium.
Physiological Significance of Vascular
PAR-1 Activation
We have, for the first time, described the unexpected and
contrasting vascular effects of PAR-1 agonism in vivo in
humans. How do we interpret these effects? In an intact
normal vessel, homeostatic mechanisms attempt to maintain
vessel patency and minimize intravascular thrombus forma¬
tion. Dorsal hand veins do not have resting tone, and the
induction of venodilatation will not affect venous blood flow.
Therefore, in the presence of developing venous thrombosis,
venodilatation would not be beneficial, whereas venocon-
striction will potentially limit thrombus propagation and
embolization. In contrast, it would be anticipated that increas¬
ing blood flow and endogenous fibrinolysis would limit
arterial thrombosis by ensuring rapid clearance and dissolu¬
tion of a developing thrombus. We therefore propose that the
vascular effects of PAR-1 agonism in vivo in humans can be
understood in terms of limiting intravascular thrombosis and
maintaining vessel patency. We speculate that these physio¬
logical effects may be disturbed in patients with cardiovas¬
cular disease or prothrombotic disorders.
Conclusions
PAR-1 agonism causes platelet activation, venoconstriction,
vasodilatation, and tPA release in vivo in humans. This has
important implications in our understanding of the physio¬
logical vascular effects of thrombin and the pathogenesis of
thromboembolic and atherothrombotic disorders.
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CLINICAL PERSPECTIVE
In addition to its well-known central enzymatic role within the coagulation cascade, thrombin is a powerful direct cellular
activator of platelets, leukocytes, and vascular smooth muscle and endothelial cells. It is therefore a vital link between
thrombosis and inflammation, key pathogenic factors in atherothrombotic disease. It has recently been discovered that
thrombin causes direct cellular activation through a group of G-protein-coupled protease-activated receptors (PARs).
Although the PAR-1 receptor is believed to mediate most of the receptor-mediated effects of thrombin, the cellular actions
of PAR-1 activation have not been described in vivo in humans. In the present study, we establish for the first time the in
vivo vascular effects of PAR-1 activation and demonstrate that it causes venous constriction, arterial dilatation, platelet
activation, and release of endogenous tissue plasminogen activator. These intriguing and contrasting effects of PAR-1
agonism demonstrate the diverse nature of the vascular consequences of thrombin activation in humans. We suggest that,
in the presence of a developing intravascular thrombosis, venoconstriction would limit thrombus propagation and
embolization, whereas in the arterial circulation, increasing blood flow and endogenous fibrinolysis would limit arterial
thrombosis by ensuring thrombus clearance and dissolution. We therefore propose that the vascular effects of PAR-1
agonism in vivo in humans can be understood in terms of limiting intravascular thrombosis and maintaining vessel patency.
This has potential implications for applying novel PAR-1 receptor antagonists that are currently under clinical development
as potential antiplatelet therapies.
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Acute Effects of Glucocorticoids on Endothelial
Fibrinolytic and Vasodilator Function in Humans
Anna R. Dover, PhD, Patrick W. F. Hadoke, PhD, Brian R. Walker, MD, and David E. Newby, PhD
Abstract: Acute coronary events occur most commonly in the
morning, when circadian variations dictate that endogenous fibri¬
nolytic activity is low and Cortisol levels are high. We hypothesized
that glucocorticoids would impair the acute fibrinolytic capacity of
the endothelium because chronic glucocorticoid excess is associated
with a prothrombotic state and endothelial vasomotor dysfunction.
Twelve healthy subjects attended on 3 occasions and received oral
metyrapone followed by intravenous saline or low-dose or high-dose
hydrocortisone. Forearm blood flow and fibrinolytic indices were
measured using venous occlusion plethysmography during intra-
brachial bradykinin, acetylcholine, and sodium nitroprussidc infusion.
Hydrocortisone infusion had no effect on systemic concen¬
trations of plasminogen activator inhibitor type 1 (PAT-1) or tissue
plasminogen activator (t-PA; P = 0.10 and 0.95, respectively).
Bradykinin caused a dose-dependent increase in plasma t-PA concen¬
trations (P < 0.0001) that was unaffected by systemic hydrocortisone
administration. Intrabrachial infusions of bradykinin, acetylcholine,
and sodium nitroprusside all caused dose-dependent increases in
forearm blood flow (P < 0.05) that were unaltered by hydrocortisone
infusions.
Short-term variations in plasma Cortisol concentrations within
the physiological range do not affect endothelial fibrinolytic or
vasomotor function in healthy volunteers. These findings suggest that
glucocorticoids do not exert acute effects on endothelial function
in vivo in humans.
Key Words: glucocorticoids, endothelium, vasodilatation, fibrinoly¬
sis, human
(J Cardiovasc Pharmacol™ 2007;50:321-326)
INTRODUCTION
The incidence of acute coronary events exhibits
circadian variation, peaking in the morning.1'2 The mecha¬
nisms underlying this pattern are not understood but
may include variations in endogenous fibrinolysis, either
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systemically or locally within the blood vessel wall.3 In
particular, circadian fluctuations in the plasma concentrations,
or activity, of circulating fibrinolytic factors, such as tissue
plasminogen activator (t-PA), and their inhibitors [eg, plas¬
minogen activator inhibitor type 1 (PAI-1)] result in atten¬
uation of fibrinolysis in the morning.4 Indeed, the efficacy
of exogenous thrombolytic therapy also exhibits circadian
variation, with treatment success (as judged by coronary
arterial patency) achieved less commonly in the morning.5
The pattern of glucocorticoid secretion may contribute
to the diurnal patterns of cardiovascular events and fibrinolytic
function. Plasma Cortisol concentrations are highest on waking
and reach a nadir before sleep. Acute cardiac events and
sudden cardiac deaths are more common in the aftermath of
stressful environmental triggers (eg, earthquake6), when acute
elevations of Cortisol concentrations are predicted. Moreover,
chronic glucocorticoid excess is associated with an increased
incidence of cardiovascular events.7,8 This may be due, at least
partially, to direct effects of glucocorticoids on fibrinolysis,
either systemically or locally at the vascular endothelium.
Glucocorticoid excess, either endogenous or exogenous, is
associated with elevations in PAI-1, von Willebrand factor, and
factor VIII concentrations, favoring a hypofibrinolytic and
hypercoagulable state.9"13 Indeed, glucocorticoids enhance
PAI-1 expression in cultured rat hepatocytes14 and human
adipose tissue,15 which is significant because these organs may
constitute major sources ofplasma PAI-1.16,17 Glucocorticoids
potentiate vasoconstrictor responses to norepinephrine and
angiotensin II,18,19 and impair endothelium-dependent vaso¬
dilatation.20-21 However, any acute influence ofglucocorticoids
on the capacity of the endothelium to release fibrinolytic
factors, such as t-PA, has not been explored previously.
Here, we tested the hypothesis that acute elevations in
plasma glucocorticoid concentrations (within the physiolog¬
ical range) adversely influence the systemic fibrinolytic




Twelve healthy non-smoking men were enrolled in the
study, which was undertaken with the approval of the local
research ethics committee, in accordance with the Declaration
of Helsinki, and with the written informed consent of each
subject. Subjects were excluded if they were taking vasoactive
or antiinflammatory medication or if they had biochemical
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evidence of hyperglycemia or significant hepatic, renal, or
thyroid dysfunction at an initial screening visit.
Study Design
We aimed to compare basal physiological and moder¬
ately stressed levels of glucocorticoids with glucocorticoid
depletion. Subjects attended on 3 occasions separated by
a washout period of at least 1 week. On each occasion, subjects
were permitted a light breakfast but refrained from all
medications for 7 days, alcohol for 24 hours, and caffeine
for at least 4 hours before the start of the study. In order to
suppress endogenous adrenal glucocorticoid synthesis, sub¬
jects received 750 mg of 11 [3-hydroxylase inhibitor, metyr-
apone (Metopirone, Alliance Pharmaceuticals, UK) at
midnight before the study day and again at 8:00 am on the
day of the study. Subjects attended for each study visit at 8 am
and rested recumbent in a quiet, temperature-controlled room.
A 17-G cannula was inserted into the antecubital vein of each
arm to allow blood sampling, and a dorsal foot vein was
cannulated with a 23-G cannula for intravenous drug adminis¬
tration. Subjects received either (1) intravenous 0.9% saline
(depletion ofendogenous glucocorticoid), (2) low-dose (2.8 mg
of priming bolus and 1.8 mg/hr infusion), or (3) high-dose
(9.4 mg of priming bolus and 6.1 mg/hr infusion) intravenous
hydrocortisone (Solu-Cortef, Pfizer UK) in a randomized,
double-blind crossover design. During each phase, systemic
t-PA and PAI-1 concentrations, local endothelial t-PA release
and forearm vasodilator responses were measured between
3 and 5 hours of intravenous infusion as described below.
Vasomotor Responses
Forearm venous occlusion plethysmography studies
were commenced 3 hours after the initiation of intravenous
drug administration. The brachial artery of the nondominant
arm was cannulated with a 27-G steel needle (Cooper's Needle
Works Ltd, Birmingham, UK) under 1% lignocaine (Xylo-
caine; Astra Pharmaceuticals Ltd, Kings Langley, UK) local
anaesthesia. The cannula was attached to a 16-gauge epidural
catheter (Portex Ltd, Llythe, UK) and patency was maintained
by infusion of saline via an I VAC PI 000 syringe pump (IVAC
Ltd, Basingstoke, UK). The total rate of intraarterial infusion
was maintained constant throughout all studies at 1 mL/min.
After a 30-minute equilibration period (during which intra¬
arterial saline was administered), subjects received intraarterial
infusions of bradykinin at 100, 300, and 1000 pmol/min
(bradykinin, an endothelium-dependent vasodilator which
releases t-PA22,23; Merck Biosciences AG, Liiufelfingen,
Switzerland), acetylcholine at 5, 10, and 20 p,g/min (acetyl¬
choline, an endothelium-dependent vasodilator which does not
release t-PA24,25; Novartis UK Ltd) and sodium nitroprusside
at 2, 4, and 8 p,g/min (sodium nitroprusside, an endothelium-
independent vasodilator24 27; David Bull Laboratories, UK).
Each intraarterial drug was administered for 6 minutes (or
10 minutes in the case of bradykinin) at each dose, with drugs
separated by 20-minute saline washout periods. Drugs were
administered in random order, although the order was the same
in all 3 phases for each subject. Forearm blood flow (FBF) was
measured 3 minutes after the start of each drug dose and every
6 to 10 minutes throughout the washout periods.
Blood flow was measured in both forearms by venous
occlusion plethysmography as previously described.27 29
Mercury-in-silastic strain gauges applied to the widest part
of the forearm were used to measure changes in forearm
circumference.30 During measurement periods, the hands were
excluded from the circulation by rapid inflation of the wrist
cuffs to a pressure of 200 mm Hg using E20 Rapid Cuff
Inflators (D.E. Hokanson Inc, Washington, USA). Upper arm
cuffs were inflated intermittently to 40 mm Hg pressure for
8 s in every 11 s to achieve venous occlusion and obtain
plethysmographic recordings. Analogue voltage output from
an EC-4 strain gauge plethysmograph (D.E. Hokanson) was
processed by a PowerLab analogue-to-digital converter and
Chart v4.1.2 for Windows software (AD Instruments Ltd,
Castle Hill, Australia). Calibration was achieved using the
internal standard of the plethysmograph. Blood pressure and
pulse were monitored in the non-infused arm at intervals
throughout each study using a semi-automated non-invasive
oscillometric sphygmomanometer (Takeda UA 751, Takeda
Medical Inc, Tokyo, Japan). Mean arterial pressure (MAP)
was defined as the diastolic pressure plus a third of the pulse
pressure.
Endogenous Fibrinolytic Responses
Venous blood (8 mL) was withdrawn simultaneously
from each arm at intervals throughout the study and collected
into tubes containing potassium ethylene diamine tetraacetic
acid (EDTA; Monovette, Sarstedt, Niimbrecht, Germany), lith¬
ium heparin (Monovettc, Sarstedt, Niimbrecht, Germany), acid¬
ified buffered citrate (Biopool Stabilyte, Umea, Sweden), and
trisodium citrate (Monovette, Sarstedt, Niimbrecht, Germany)
for estimation of haematocrit, Cortisol, t-PA, and PAI-1,
respectively. Citrate and acidified buffered citrate samples were
centrifuged at 2000 x g for 30 min at 4°C, and lithium heparin
samples at 1000 x g for 10 min at 20°C. Platelet-free plasma
was decanted and stored at — 80°C before assay.
Estimated net release of t-PA antigen was defined as the
product of the infused forearm plasma flow (based on the
hematocrit and the infused FBF) and the concentration
difference between the infused arm ([t-PA]inf) and noninfused
arm ([t-PA]Non_inr) as previously described.27,31
Laboratory Measurements
Plasma Cortisol was determined using an enzyme-linked
immunosorbent assay (DRG Instalments GmbH, Germany)
with <2% crossreactivity for 11-deoxycortisol. Plasma PAI-1
and t-PA antigen concentrations and t-PA activities were
determined as previously described32,33 using enzyme-linked
immunosorbent assays (Elitest PAI-1 antigen and Zymutest
t-PA antigen; Hyphen-Biomed, France; Combi Actibind t-PA
activity; Technoclone, UK). Haematocrit was determined
using an automated Coulter counter (Beckman-Coulter ACt.8,
High Wycombe, UK).
Data Analysis and Statistics
Data were examined where appropriate by repeated
measures analysis of variance (ANOVA) and post-hoc 2-tailed
paired Student t test using GraphPad Prism (GraphPad
Software, California, USA). Data are expressed as
322 © 2007 Lippincoll Williams & Wilkins
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mean ± standard error of the mean. Differences were
considered statistically significant if P < 0.05.
RESULTS
The participants were men aged 28 ± 3 years (age range,
21-48 years), with body mass index of 25 ± I kg/m2 and
baseline random glucose concentrations of 5.1 ± 0.2 mM.
Oral, intravenous, and intra-arterial drugs were well tolerated
with no adverse events.
Plasma Cortisol Concentrations
An increase in plasma Cortisol was evident after both
low-dose and high-dose intravenous hydrocortisone compared
with placebo (P < 0.0001; Figure 1).
Hemodynamic Effects
Baseline MAP, heart rate, and FBF were similar on all
3 visits (Table 1). There was no change in pulse during the
studies, although mean arterial pressure rose during the study
to a similar degree in all 3 phases (from 88 ± 4 mm Fig to
101 ± 2 mm Hg with placebo, 89 ± 3 mm Hg to 97 ± 3 mm Hg
with low-dose hydrocortisone, and 92 ± 2 mm Hg to 101 ±
2 mm Hg with high-dose hydrocortisone; P < 0.001 for all).
Bradykinin, acetylcholine, and sodium nitroprusside
all caused dose-dependent increases in FBF in the infused
arm without affecting blood flow in the noninfused arm
(Figure 2). There were no differences among saline and the
2 hydrocortisone infusions in FBF during intraarterial
infusion of bradykinin, acetylcholine, or sodium nitroprusside
(Figure 2).
Plasma Fibrinolytic Variables
Baseline plasma t-PA antigen concentrations and t-PA
activity in the infused and noninfused arm were unchanged by
systemic hydrocortisone infusion (P = 0.95 for noninfused
Time (minutes)
FIGURE 1. Plasma Cortisol concentrations. Plasma Cortisol
concentration during the study in subjects (n = 12) treated with
intravenous saline (closed circles), low-dose hydrocortisone
(closed squares) and high-dose hydrocortisone (closed trian¬
gles). Significant differences in plasma Cortisol were observed
among all 3 groups (P < 0.0001). Shaded area represents
forearm plethysmography study.
TABLE 1. Baseline Hemodynamic Characteristics
Low-Dose High-Dose P
Placebo Hydrocortisone Hydrocortisone Value*
Heart rate (/min) 67 ± 3 63 ± 3 68 -+■ 4 0.30
Mean Arterial
Pressure (mm Hg) 88 -+• 4 89 -r- 3 92 ± 2 0.59
Forearm blood flow,
infused
(mL/100 mL/min) 2.0 0.3 3.0 ± 0.5 2.4 ± 0.3 0.12
Forearm blood flow,
non-infused
(mL/100 mL/min) 1.8 0.2 2.8 0.4 2.3 0.3 0.08
♦Repeated measures ANOVA comparing treatment phases.
arm; Figure 3). Bradykinin caused dose-dependent increases
in infused arm total and active plasma t-PA concentrations that
did not differ between treatment groups when comparing
either plasma t-PA concentration (ng/mL, P = 0.74; Figure 3)
or estimated net t-PA release (ng/100 mL tissue/min; P - 0.88,
Figure 3).
There was a trend towards an increase in infused arm
plasma PAI-1 concentrations with increasing intravenous
hydrocortisone dose that did not reach statistical significance
(P = 0.10 versus noninfused arm; Table 2). There was no
significant change in plasma PAI-1 concentrations during
intrabrachial bradykinin infusion in the infused (P = 0.45) or
noninfused (P = 0.71) arm (Table 2).
DISCUSSION
These data show that acute variations in plasma
glucocorticoid concentrations alter neither the systemic
fibrinolytic balance nor the capacity for the endothelium to
release t-PA acutely in response to bradykinin. Furthermore, in
contrast to prolonged administration of pharmacological
glucocorticoids,20 short-term manipulation of plasma gluco¬
corticoid concentrations does not alter endothelial vasomotor
function in vivo in humans.
Vasomotor Function
Previous studies have shown that prolonged adminis¬
tration (5 days) of hydrocortisone results in hypertension and
impairment of endothelium-dependent vasodilatation.20 The
effects of glucocorticoids on vascular responsiveness have
been attributed to impairment of nitric oxide bioavailabil¬
ity,20,21'34 although the exact mechanisms remain elusive.
Glucocorticoids also potentiate vasoconstrictor responses to
noradrenaline and angiotensin II.18,19 The findings that Cortisol
can induce hypertension within 24 hours and that ACTF1
infusion produces an elevation in blood pressure within 2 to
8 hours35 suggest that cortisol-mediated effects on vascular tone
might be apparent in the acute setting. However, the present
data suggest that, despite nearly 6-fold differences in plasma
Cortisol concentrations, no difference in endothelial vasomotor
function was apparent over 3 to 5 hours. These findings are
consistent with recently published data showing that systemic
administration of pharmacological doses of hydrocortisone
(200 mg infused over 3 hours) has no effect on plasma
© 2007 Lippincolt Williams & Wilkins 323


































FIGURE 2. Forearm blood flow (FBF) responses to vasodilators.
Infused (closed symbols) and noninfused (open symbols,
dotted line) FBF in response to increasing doses of (A)
bradykinin, (B) acetylcholine, and (C) sodium nitroprusside
in subjects (n = 12) treated with intravenous saline (circles),
low-dose hydrocortisone (squares), and high-dose hydrocor¬
tisone (triangles). P < 0.001 for FBF in infused arm, P = ns for
comparisons among groups.
nitrate/nitrite activity or forearm vascular responsiveness to
acetylcholine.36 Taken together with evidence that direct
intraarterial short-term Cortisol infusion does not alter vascular
resistance in the human forearm vascular bed,36,37 these
findings suggest that Cortisol does not acutely alter basal vas¬
cular tone, nitric oxide generation, or vasodilator responses.
There are a number of possible explanations for the
lack of effect of short-term hydrocortisone infusion on
endothelium-dependent vasodilatation. It may be that there
are no direct effects of glucocorticoids on endothelial cell
function in humans. This conclusion is supported by
observations that in vitro incubation of human subcutaneous
resistance arteries with Cortisol (30 p,M for 3 hours) had no
effect on endothelium-dependent vascular reactivity (Hadoke
PWF, unpublished observations). Alternatively, the acute
effects of glucocorticoids on endothelial function may be
mediated through de novo gene transcription, which takes
more than 3 hours to become evident. Whilst glucocorticoid-
mediated effects on the generation of reactive oxygen spe¬
cies by mononuclear cells38 and on muscle sympathetic nerve
activity are evident within 3 hours, effects on generation of
reactive oxygen species and nitric oxide availability in
human umbilical vein endothelial cells are manifest only after
6 hours.21
Metyrapone was administered to all subjects in each
treatment phase. Whilst it is possible that this drug had an
effect on endothelial function that confounded the effects of
glucocorticoids (for example, due to elevated levels of the
precursor mineralocorticoid 11-deoxycortisol), this is unlikely
because previous studies have shown no effect of this drug on
either basal FBF in vivo or endothelial nitric oxide release
in vitro.39
Fibrinolytic Function
Although glucocorticoid excess has been associated
with elevated plasma PAI-1 concentration and a hypofibrino-
loytic and hypercoagulable state,9-13 there have been no
studies to date investigating whether physiological variations
in glucocorticoid concentrations influence the local fibrino¬
lytic capacity of the endothelium. The mechanisms regulating
acute t-PA release and plasma PAI-1 concentrations are likely
to involve the nitric oxide pathway.28 Augmentation of t-PA
release is seen after acute inflammation,40 and impairment of
fibrinolytic activity is predictive of increased cardiovascular
risk.41 Considering the antiinflammatory properties of gluco¬
corticoids, their ability to inhibit nitric oxide production by
iNOS, and their association with cardiovascular risk, one
might predict an adverse effect ofglucocorticoids on the acute
capacity of the endothelium to release t-PA. However, the
present study has demonstrated that short-term systemic
administration of hydrocortisone had no effect on basal or
bradykinin-stimulated acute release of t-PA from the
endothelium.
In addition to the lack of effect of hydrocortisone on
acute t-PA release, we also found no change in plasma PAI-1
concentrations after short-term hydrocortisone administration.
These results parallel those from a recent study that showed no
change in plasma PAI-1 levels in healthy volunteers treated
with dexamethasone (6 mg) daily for 5 days.42 However,
elevations in PAI-1 levels have been demonstrated in patients
with endogenous glucocorticoid excess10 and in those
receiving long-term glucocorticoid therapy after heart13 and
renal transplantation.12 These elevations in PAI-1 improve
upon surgical correction of Cushing syndrome10 or steroid
withdrawal.9 Furthermore, studies in vitro14,43"^8 and in animal
models in vivo49'50 have also demonstrated an augmentation of
PAI-I release after glucocorticoid treatment. The lack of effect
324 © 2007 Lippincott Williams & Wilkins







FIGURE 3. t-PA concentrations dur¬
ing intrabrachial bradykinin infusion.
Plasma concentrations (/mL; left
panels) and estimated net release
(/100mL tissue/min; right panels) of
total (ng) and active (iU) t-PA
antigen in infused (closed symbols)
and noninfused (open symbols, dot¬
ted line) arms during intrabrachial
bradykinin infusion in subjects trea¬
ted with intravenous saline (circles),
low-dose hydrocortisone (squares),
and high-dose hydrocortisone (tri¬
angles). P < 0.001 for t-PA dose
response in infused arm and net



































of short-term hydrocortisone on PAI-l concentrations in our
study suggests that, in contrast to studies of chronic steroid
excess and studies in vitro, PAI-I is not released in response to
hydrocortisone over the time course and at the physiological
doses used in the present study.
CONCLUSIONS
We conclude that short-term variations in piasma
glucocorticoid levels within the physiological range do not
alter the systemic fibrinolytic balance or endothelial fibrino¬
lytic and vasomotor function. If there are direct effects of
glucocorticoids on endothelial cell function in vivo, it may be
that they require a longer duration to become manifest. It
therefore appears unlikely that circadian variations in Cortisol
are responsible for variations in fibrinolytic function, although
it remains possible that either of these pathways contribute to
the circadian variation in cardiovascular disease events.
TABLE 2. Plasma PAI-1 Concentrations Before and During
Bradykinin Administration After Intravenous Placebo or
Hydrocortisone
0 pniol/min 1000 pmol/min
Arm Bradykinin Bradykinin
Placebo
Infused (ng/mL) 18.8 ± 1.7 18.5 ± 1.6
Noninfused (ng/mL) 19.3 ± 1.0 19.9 ± 2.7
Low-dose hydrocortisone
Infused (ng/mL) 22.2 ± 2.9 21.7 ± 1.9
Noninfused (ng/mL) 20.9 ± 2.6 24.3 ± 2.0
High-dose hydrocortisone
Infused (ng/mL) 26.4 ± 3.5 24.0 ± 3.0
Non-infused (ng/mL) 24.0 ± 4.1 24.7 ± 3.3
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OBJECTIVES The purpose of this study was to investigate in vivo the effects of acute systemic inflammation
on the endogenous fibrinolytic capacity in men.
BACKGROUND Systemic inflammation and endogenous fibrinolysis play a major role in the pathogenesis of
coronary arteiy disease. Although previous studies have shown impaired endothelium-
dependent vasomotor function, the effects of inflammation on the endothelial release of the
fibrinolytic factor tissue plasminogen activator (t-PA) are unknown.
METHODS In a double-blind randomized placebo-controlled crossover trial, we administered a mild
inflammatory stimulus, Salmonella typhi vaccine, or saline placebo to eight healthy men on
two separate occasions. Six hours after vaccination, blood flow and plasma fibrinolytic
variables were measured in both arms during intrabrachial infusions of bradykinin (40 to
1,000 pmoL/min), acetylcholine (5 to 20 p.g/min), and sodium nitroprusside (2 to 8 ptg/min).
RESULTS Compared with placebo, the S. typhi vaccination caused a rise in white cell count (11.1 ± 0.5
X1071 vs. 7.9 ± 0.8 X109/l; p = 0.004) and plasma interleukin-6 concentrations (6.9 ± 1.4
pg/ml vs. 1.6 ± 0.4 pg/ml; p = 0.01) in addition to a significant augmentation of t-PA
antigen (45 ± 9 ng/100 ml/min at peak dose vs. 24 ± 8 ng/100 ml/min at peak dose; p =
0.016, analysis of variance) and activity (104 ± 15 IU/100 ml/min vs. 54 ± 12 IU/100
ml/min; p = 0.006, analysis of variance) release during bradykinin infusion. Forearm blood
flow increased in a dose-dependent manner after bradykinin, acetylcholine and sodium
nitroprusside infusions (p < 0.001), but this was unaffected by vaccination.
CONCLUSIONS Our results showed that acute systemic inflammation augmented local forearm t-PA release
in men, which suggests that acute inflammation may invoke a protective response by
enhancing the acute endogenous fibrinolytic capacity in healthy men. Further studies arc
needed to clarify whether this response is impaired in patients with cardiovascular
disease. (J Am Coll Cardiol 2003;41:333-9) © 2003 by the American College of
Cardiology Foundation
Atherosclerosis is widely recognized to be an inflammatory
disease process involving dysfunction of the vascular endo¬
thelium (1). This dysfunction leads to increased expression
of leukocyte adhesion molecules, reduced anticoagulant
activity and the release of growth factors, inflammatory
mediators, and cytokines. Continued inflammation leads to
leukocyte and monocyte recruitment, arterial damage, and
atherogenesis. Additional cycles of damage cause plaque
expansion and disruption that may lead to angina, crescendo
angina, and acute coronary syndromes.
Recent epidemiological and observational studies have
suggested a link between systemic inflammation and coro¬
nary artery disease. Infections by organisms, such as Chla¬
mydia pneumoniae and herpes simplex virus type 1, appear to
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be associated with an increased risk of cardiovascular mor¬
tality (2), and approximately 4% of bacteremic patients will
develop acute myocardial infarction within a month of
infection (3). Increased cardiovascular mortality also is seen
after respiratory tract infections (4), severe illnesses requir¬
ing intensive care (5), and surgery (6). Markers of systemic
inflammation, such as C-reactive protein (CRP), serum
amyloid A, interleukin-6 (IL-6), and tumor necrosis factor-
alpha, are elevated in patients with cardiovascular disease and
are associated with an adverse prognosis and recurrent coronary
events (7-10). Moreover, in previously healthy individuals,
elevated plasma CRP and IL-6 concentrations predict the
development of cardiovascular disease (11-13). Indeed, reflect¬
ing its anti-inflammatory action, the preventative benefits of
aspirin in reducing cardiovascular risk are proportional to the
plasma CRP concentration (11). These data collectively sug¬
gest two patterns of association: a link between chronic
inflammation and the slow process of atherogenesis and an
association between acute systemic inflammation and a tran¬
siently increased risk of an acute cardiovascular event.
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Abbreviations and Acronyms
ANOVA = analysis of variance
CRP = C-reactive protein
FBF = forearm blood flow
IL-6 = interleukin-6
PAI-1 = plasminogen activator inhibitor type 1
t-PA = tissue-type plasminogen activator
The vascular endothelium plays a vital role in the control
of blood flow, hemostasis, fibrinolysis, and inflammation
(14), and impaired endothelial function is implicated in the
pathogenesis ol coronary artery disease. Tissue plasminogen
activator (t-PA) is a fibrinolytic factor released from the
endothelium through the translocation of a dynamic intra¬
cellular storage pool and regulates the degradation of intra¬
vascular fibrin (15). If endogenous fibrinolysis is to be
effective, then the rapid mobilization of t-PA from the
endothelium is essential because thrombus dissolution is
much more effective if t-PA is incorporated during, rather
than after, thrombus formation (16,17). However, in the
presence of pro-inflammatory states or an imbalance in
endogenous fibrinolysis, such microthrombi may propagate,
ultimately leading to arterial occlusion and tissue infarction
(18).
We have previously described an in vivo model to assess
the acute release of t-PA in men (19) and demonstrated an
association between t-PA release and endothelial dysfunc¬
tion (20,21). Hingorani et al. (22) also have recently shown
that acute inflammation causes dysfunction of endothelium-
dependent vasodilation in humans. However, there have
been no studies to assess directly the acute local fibrinolytic
capacity after acute inflammation. Therefore, the aim of this
study was to test the hypothesis that the acute fibrinolytic
capacity is altered by a mild systemic inflammatory response
generated by typhoid vaccination.
METHODS
Subjects. Eight healthy nonsmoking men between 20 and
27 years of age participated in the study, which was
undertaken with the approval of the local research ethics
committee and in accordance with the Declaration of
Helsinki. The written informed consent of each subject was
obtained before entry into the study.
All subjects were normotensive without a history of
diabetes mellitus and vascular or coronary artery disease.
None of the subjects had undergone typhoid vaccination in
the previous year or received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before the study. All
subjects abstained from alcohol for 24 h and from food and
caffeine-containing drinks for at least 4 h before each
forearm study. All studies were performed in a quiet,
temperature-controlled room maintained at 22 to 25°C.
Drugs. An inflammatory response was generated with a
typhoid vaccination using Salmonella typhi capsular polysac¬
charide vaccine 0.025 mg (Typhim Vi, Aventis Pasteur
MSD, Berkshire, United Kingdom). Pharmaceutical-grade
bradykinin (Clinalfa, Laufelfingen, Switzerland), acetylcho¬
line (Clinalfa), and sodium nitroprusside (David Bull Lab¬
oratories, Faulding, United Kingdom) were administered
after dissolution in saline (0.9%; Baxter Healthcare Ltd.,
Berkshire, United Kingdom). All solutions were freshly
prepared on the day of study.
Hemodynamic measurements. Blood flow was measured
in both forearms by venous occlusion plethysmography
using mercury-in-silastic strain gauges as previously de¬
scribed (19-21). Blood pressure was monitored in the
noninfuscd arm at intervals throughout each study with a
scmiautomated noninvasive oscillometric sphygmomanom
eter (Takeda UA 751, Takeda Medical Inc., Tokyo, Japan).
Blood sampling and assays. Blood was withdrawn simul
taneously from each arm and collected into acidified buff¬
ered citrate (Biopool Stabilyte, Umea, Sweden) for t-PA
assays and trisodium citrate, ethylene diamine tetraacetic
acid, and serum bead tubes (Monovette, Sarstedt, Ntim-
brecht, Germany) for plasminogen activator inhibitor type 1
(PAI-1), IL-6, and CRP assays, respectively, and kept on
ice before being centrifuged at 2,000g for 30 min at 4°C.
Platelet-free plasma was decanted and stored at — 80°C
before assay. Plasma t-PA, PAI-1, IL-6, and CRP concen¬
trations were determined using specific enzyme linked im
munosorbent assays (Coaliza t-PA and Coaliza PAI-1,
Chromogenix AB, Molndal, Sweden; Quantikine human
IL-6 immunoassays, R&D Systems, United Kingdom;
C-reactive protein enzyme-linked immunosorbent assay,
Eurogenetics, Belgium, respectively) and plasma t-PA ac¬
tivity using a photometric method (Coatest t-PA, Chro¬
mogenix AB, Molndal, Sweden). Hematocrit and white cell
count were determined using an automated Coulter counter
(Bcckman-Coulter ACt.8 Coulter Counter, High Wy¬
combe, United Kingdom).
Study design. The S. typhi vaccine or saline placebo were
injected into the deltoid muscle of each subject's dominant
arm at 8:30 AM in a randomized, balanced block, double-
blind crossover manner at least two weeks apart. Previous
reports have indicated that vaccination induced endothelial
dysfunction is transient and resolves within 32 h (22).
Six hours after vaccination and after a 4-h fast, strain
gauges and cuffs were applied. The brachial artery of each
subject's nondominant arm was cannulated with a 27-
standard wire gauge steel needle (Cooper's Needle Works
Ltd., Birmingham, United Kingdom) under 1% lidocaine
(Xylocaine; Astra Pharmaceuticals, Wayne Pennsylvania)
local anesthesia and attached to a 16-gauge epidural catheter
(Portex Ltd., Hythe, United Kingdom). Patency was main¬
tained by infusion of saline via a MS2000 syringe infusion
pump (Graesby Medical, Watford, United Kingdom). Ve¬
nous 17-gauge cannulae were inserted into large subcuta¬
neous veins of the antecubital fossae of both arms. Forearm
blood flow (FBF) was measured every 6 to 10 min. After 30
min of equilibration with saline infusion, intra-arterial
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bradykinin was administered at 40, 200, and 1,000 pmol/
min for 10 min at each dose, acetylcholine at 5, 10, and 20
/xg/min, and sodium nitroprusside at 2, 4, and 8 /xg/min for
6 min at each dose. The drugs were separated by 20 min of
saline infusion and administered in a randomized order that
was kept constant for each individual. Venous samples were
taken at baseline and during infusion of each bradykinin
dose but not during sodium nitroprusside or acetylcholine
infusion because they do not affect plasma t-PA or PAI-1
concentrations in this forearm model (19,23). White cell
count, hematocrit, IL-6, and CRP were determined 6 h
after vaccination and hematocrit was repeated at the end of
the forearm study.
Data analysis and statistics. Plethysmography data were
extracted from the chart data files, and FBF was calculated
for individual venous occlusion cuff inflations by use of a
template spreadsheet (Microsoft Excel 97). Recordings for
the first 60 s after wrist cuff inflation were not used because
of the variability in blood flow this initial inflation causes.
The last five linear plethysmographic recordings in each
3-min measurement period were calculated and averaged for
each arm. The estimated net release of t-PA antigen and
activity was defined previously (19) as the product of the
infused forearm plasma flow (based on the mean hematocrit
and the infused FBF) and the concentration difference
between the infused ([t-PA]inf) and noninfused ([t-
PAJnoninf) arms and is shown as follows:
Estimated net t-PA release = FBF X (1 — Hct)
X ([t-PA],„y - [t-PA]
The area under the curve (AUC) was calculated for
estimated net t-PA antigen and activity release during
bradykinin infusion.
Data were examined, where appropriate, by analysis of
variance (ANOVA) with repeated measures and two-tailed
paired Student t test using Excel 97 (Microsoft). All results
are expressed as mean ± SEM. Statistical significance was
assigned at the 5% level.
RESULTS
Inflammatory response. All subjects remained healthy
throughout the study and reported no localized discomfort
or systemic side effects after vaccination. Compared with
placebo injection, there was a marked elevation in white cell
count (11.1 ± 0.5 X 109/1 vs. 7.9 ± 0.8 X 109/1; p = 0.004,
t test) and plasma IL-6 concentrations (6.9 ±1.4 pg/ml vs.
1.6 ± 0.4 pg/ml; p = 0.01, t test) 6 h after typhoid
vaccination, although serum CRP concentrations (1.8 ±1.2
/xg/ml vs. 1.0 ± 0.6 pg/ml; p = NS, t test) and temperature
(p = NS, /-test) (Table 1) were unchanged.
Assessment of endothelium-dependent vasomotion.
There were no significant effects of vaccination on heart
rate, blood pressure, or baseline FBF. There were no
significant changes in heart rate, blood pressure, or nonin¬
fused FBF during drug infusion on either study day.
Table 1. Baseline Characteristics
Vaccination Placebo
Temperature (°C) 37.0 0.1 36.9 ± 0.1
Systolic blood pressure (mm Hg) 131 4 129 ± 5
Diastolic blood pressure (mm Hg) 62 -4- 3 66 ± 3
Heart rate (beats/min) 57 -4- 1 57 ± 2
Hematocrit 0.41 -4- 0.01 0.41 ± 0.01
Infused forearm blood flow 3.0 -4- 0.6 2.8 ± 0.6
(ml/100 ml tissue/min)
Forearm blood flow increased in a dose-dependent manner
during bradyldnin, acetylcholine, and sodium nitropruccide
infusions (p < 0.001, ANOVA), but there was no change in
the blood flow response after vaccination (p = NS,
ANOVA) (Fig. 1).
Assessment of fibrinolytic activity. After vaccination,
there were no changes in baseline plasma t-PA and PAI-1
antigen concentrations nor plasma t-PA activity concentra¬
tion. Compared with the noninfused arm, bradykinin
caused dose-dependent increases in plasma t-PA antigen
and activity (p < 0.001 for both, ANOVA) concentrations
in the infused arm that were significantly higher after
vaccination (p < 0.03, ANOVA) (Table 2). The S. typhi
vaccination caused a significant augmentation in the net
release of t-PA antigen (45 ± 9 vs. 24 ± 8 ng/100 ml/min
at peak dose; p = 0.016, ANOVA) and activity (104 ± 15
vs. 54 ± 12 IU/100 ml/min; p = 0.006, ANOVA) during
bradykinin infusion, and a two- to threefold increase in the
AUC for net t-PA antigen (37 ± 12 ng/100 ml/min vs. 13
± 9 ng/100 ml/min; p = 0.14, t test) and activity (70 ± 12
IU/100 ml/min vs. 36 ± 8 IU/100 ml/min; p = 0.037, t
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Figure 1. Infused forearm blood flow during bradykinin (circles), acetyl¬
choline (trianglco), and sodium nitropruccidc (squares) infusions in cub
jects who were administered typhoid vaccination (closed symbols) and
saline placebo (open symbols). Analysis of variance, p < 0.001 for all
(dose-response).
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Table 2. Plasma t-PA and PAI-1 Antigen and t-PA Activity/Concentrations
Typhoid Vaccination Placebo Injection
Hradykinin Infusion
(pmol/min) 0 40 200 1,000 0 40 200 1,000
t-PA antigen (ng/ml)
Noninfused arm 2.3 -t- 0.3 2.7 ± 0.5 2.9 ± 0.5 3.5 ± 0.5 2.8 ± 0.6 3.2 ± 0.8 3.6 ± 0.7 4.4 ± 0.8
Infused arm 3.0 + 0.5 3.2 ± 0.5 3.9 ± 0.5 6.7 + 0.7* 2.8 ± 0.6 3.0 ± 0.7 3.8 ± 0.8 6.1 ± 0.9*
Concentration differences 0.7 ± 0.4 0.5 ± 0.4 1.0 ± 0.6 3.3 0.8§ 0.0 ± 0.2 -0.1 ± 0.4 0.2 ± 0.3 1.7 ± 0.5§f
between forearms
t-PA activity (IU/ml)
Noninfused arm 1.3 0.2 1.4 ± 0.2 1.7 ± 0.2 2.6 ± 0.4 1.1 ± 0.2 1.2 ± 0.2 1.5 ± 0.2 2.5 ± 0.5
Infused arm 1.1 -t- 0.2 1.6 ± 0.3 3.3 ± 0.6 9.9 ± 1.2* 1.0 ± 0.2 1.3 ± 0.2 2.5 ± 0.5 6.5 ± 1.3*+
Concentration differences -0.2 0.1 0.2 ± 0.1 1.6 ± 0.5 7.4 ± 1.0* -0.1 ± 0.1 0.1 ± 0.1 0.9 ± 0.5 3.9 ± 1.0*4
between forearms
PAI antigen (ng/ml)
Noninfused arm 17 4 16 2 15 ± 2 16 ± 3
Infused arm 18 + 5 14 2 16 ± 3 15 ± 2
Concentration differences 1.3 ■+ 2.4 -1.2 H- 1.3 0.4 ± 0.8 -0.5 ± 1.7
between forearms
One-way analysis of variance (ANOVA): *p < 0.001, §p < 0.01 (dose-response). Two-way ANOVA: fp = 0.026, < 0.01 (vaccination vs placebo); p < 0.001 for all
(dose-response).
PAI-1 = plasminogen activator inhibitor type 1; t-PA = tissue-type plasminogen activator.
concentrations did not change during bradykinin infusion
(Tabic 2).
DISCUSSION
We have demonstrated that an acute mild systemic inflam¬
matory stimulus causes potentiation of bradykinin-induced
t-PA release. We conclude that acute systemic inflamma¬
tion enhances local endothelial t-PA release in men. This
may reflect an adaptive mechanism of the vascular endothe¬
lium to augment its fibrinolytic response under circum¬
stances of acute inflammation.
Endothelium-dependent vasoinotion. We assessed basal
and stimulated FBF after intra-arterial infusions of the
endothelium-dependent vasodilators bradykinin and acetyl¬
choline, and the endothelium-independent vasodilator so¬
dium nitroprusside 6 to 8 h after vaccination. Bradykinin
and acetylcholine have both been widely used to investigate
the function of vascular endothelium. Impaired arterial
vasodilatory response to endothehum-dependent agonists
has been shown in patients with hypertension (24), diabetes
mellitus (25), and hypercholesterolemia (26). Flingorani et
al. (22) have previously reported that S. typhi vaccinations
generated an inflammatory response that was associated
with a temporary suppression of endothelium-dependent
vasodilation in the forearm circulation of six healthy volun¬
teers. Although we applied a similar protocol to their study
and included overlapping doses of both bradykinin and
acetylcholine, we did not replicate their findings of impaired
forearm endothelium-dependent vasodilation after vaccina¬
tion at 6 to 8 h (Fig. 1). This discrepancy may be partly
explained by the variability in vasodilatory response with
acetylcholine (27) and the higher maximal vasodilator dose
used in our studies, although we used a larger sample size
and a double-blind, randomized, placebo-controlled, cross¬
over trial.
Endogenous fibrinolysis. Tissue plasminogen activator,
the key enzyme in the initiation of fibrinolysis, is synthe
sized in endothelial cells and stored in small, dense vesicles.
It is secreted both basally and in response to thrombin and
several vasoactive agents through a calcium dependent and
G protein-coupled pathway (28) The regulated endogenous
release of t-PA plays a major role in the defense against
intravascular thrombosis, especially in the coronary circula
tion (18). Bradykinin is a vasoactive peptide and potent
stimulant for the acute release of t PA from the vasculature
(23,29-31) and is produced locally through activation of the
kallilcrcin ltinin system on the surface of endothelial cells
(32). 1n the present study, bradykinin-induced t-PA antigen
and activity release were augmented two to threefold after
typhoid vaccination in the absence of systemic hemody¬
namic effects (Fig. 2).
The underlying mechanisms for our findings are un¬
known. Inflammation is recognized to induce a protective
response towards tissue injury, and it functions as part of
normal host surveillance mechanisms. Various compounds
associated with the inflammatory response, including hista¬
mine, thrombin and endotoxin, have been shown to increase
cellular t-PA transcription and expression (33,34). How¬
ever, we did not observe an increase in the basal plasma
concentrations of either t-PA or PAI-1. The inflammatory
stimulus, therefore, appears to augment specifically the
storage or acute release of t-PA rather than a generalized
upregulation of protein synthesis and basal secretion. This
may be mediated by pro-inflammatory cytokines, such as
IL-6, that modulate cellular activation, leading to alter¬
ations in endothelial function. In particular, molecular and
pharmacologic evidence supports the role of bradykinin B2
receptors in the acute phase of inflammation, and upregu¬
lation of B2 receptors may account for the potentiation of
bradykinin-induced t-PA release.
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Figure 2. Estimated net release of tissue-type plasminogen activator (t-PA) antigen (solid line) and activity- (dotted line) in subjects who were administered
typhoid vaccination (closed circles and bars) and saline placebo (open circles and bars). Lower panel represents area under the curve for the response.
Analysis of variance, *p < 0.05; fp = 0.006 (vaccination vs. placebo); t test, tp < 0.05 (vaccination vs. placebo).
Clinical implications. The augmentation of acute t-PA
release after typhoid vaccination suggests that mild acute
inflammation may induce antithrombotic properties in the
forearm circulation. This may represent an adaptive re¬
sponse to inhibit intravascular thrombus deposition under
circumstances of acute vascular inflammation. This obser¬
vation is consistent with the increase in endogenous fibri¬
nolysis in systemic inflammation induced by experimental
endotoxemia in healthy subjects (35). However, in suscep¬
tible individuals, such as those with ischemic heart disease
and chronic inflammation, this adaptive and protective
acute response may fail or become depleted, leading to
thrombus propagation and vessel occlusion. The fibrinolytic
response to acute systemic inflammation in patients with
ischemic heart disease and the influence of anti¬
inflammatory therapies, such as aspirin, now needs to be
established. Indeed, recent evidence has suggested that
preventative treatment with aspirin is able to reverse
inflammation-induced endothelial dysfunction (36).
Epidemiologic studies have demonstrated an association
between the risk of future cardiovascular events and both
plasma inflammatory markers (11-13) and fibrinolytic fac¬
tors (37). Therefore, the current observations are consistent
with the suggestion that elevated plasma t-PA concentra-
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tions may provide a marker of vascular inflammation.
Irrespective of whether these common associations are
partly or wholly explained by inflammation-induced t-PA
release, understanding the regulation of both acute and
chronic t-PA release will have important clinical implica¬
tions and may help to develop more effective strategies in
the management of atherosclerotic disease.
Study limitations. There are some limitations to our study.
We administered the typhoid vaccination in the deltoid
muscle of each subject's dominant arm rather than the
gluteus muscle. However, because blood flow was assessed
in the forearm and intra-arterial vasodilators were adminis¬
tered in the contralateral nondominant arm, it would be
highly unlikely that the site of vaccination would have
affected the response in the infused forearm. It would also
have been preferable to assess the vascular responses imme¬
diately before and 6 to 8 h after vaccination on the same day.
However, this would require repeated arterial cannulations
within the same day, and we have previously demonstrated
that endothelium-dependent vasodilation and t-PA release
is reproducible when performed at least one week apart
(38.39). The study subjects were healthy and young, and we
acknowledge that the response in older subjects may be
quite different. Finally, we studied peripheral vascular func¬
tion; therefore, these findings may not be directly applicable
to other vascular beds. However, endothelial dysfunction is
often a generalized process, and we have previously shown
(21.40) consistent endogenous fibrinolytic responses be¬
tween the forearm and coronary circulation.
Conclusions. We have demonstrated that mild inflamma¬
tion generated by typhoid vaccination results in a significant
potentiation of bradykinin-induced t-PA release from the
vascular endothelium. Additional studies are now required
to determine the underlying mechanism and to assess the
effects of acute and chronic inflammation on endogenous
fibrinolysis in health and disease.
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PUBLICATION 10
Intra-Arterial Tumor Necrosis Factor-a Impairs
Endothelium-Dependent Vasodilatation and Stimulates Local
Tissue Plasminogen Activator Release in Humans
Stanley Chia, Motaz Qadan, Richard Newton, Christopher A. Ludlam,
Keith A.A. Fox, David E. Newby
Objective—Inflammation contributes to the pathogenesis of cardiovascular disease, potentially through the actions of
proinflammatory cytokines. We assessed the direct effects of local intra-arterial tumor necrosis factor-w (TNF-a),
interIeukin-6, and endotoxin on blood flow and endogenous tissue plasminogen activator (t-PA) release in vivo in
humans.
Methods and Results—In a double-blind, randomized, placebo-controlled trial, blood How, plasma cytokine, and
fibrinolytic parameters were measured using venous occlusion plethysmography and blood sampling. Ten subjects
received intrabrachial TNF-a, interleukin-6, and endotoxin infusions, and 8 additional subjects received intrabrachial
infusions of bradykinin, acetylcholine, and sodium nitroprusside after pretreatment with TNF-a. TNF-a but not
interleukin-6, endotoxin, or placebo caused a gradual and sustained «=20-fold increase in plasma t-PA concentrations
fP<0.001) that was associated with elevated plasma interleukin-6 concentrations (P<0.05) but without an effect on
blood flow or plasminogen activator inhibitor type I antigen. Compared with placebo, TNF-a pretreatment impaired
bradykinin- and acetylcholine-induced vasodilatation (F<0.03) and resulted in a doubling of bradykinin-induced t-PA
release (P<0.05).
Conclusions—Intra-arterial TNF-a causes an acute local vascular inflammation that is associated with impaired
endothelium-dcpendent vasomotion as well as a sustained and substantial increase in endothelial t-PA release. TNF-a
has potentially both adverse vasomotor and beneficial profibrinolytic effects on endothelial function. (Arterioscler
Thromb Vase Biol. 2003;23:695-701.)
Key Words: cytokines ■ endothelium ■ fibrinolysis ■ inflammation ■ vasodilatation
There is emerging evidence that systemic inflammationplays a major role in the pathogenesis of cardiovascular
disease. The proinflammatory cytokines, tumor necrosis
factor-a (TNF-«) and interleukin-6 (IL-6) in particular, have
been implicated in the initiation and maintenance of systemic
and vascular inflammation associated with atherosclerosis
and coronary artery disease. Indeed, plasma concentrations of
these cytokines are elevated in patients with ischemic heart
disease1-2 and have been shown to predict the future risk of
myocardial infarction in apparently healthy individuals.3
The vascular endothelium plays a vital role in the control
of blood flow, hemostasis, fibrinolysis, and inflammation,
and changes in endothelial function may underlie the associ¬
ation between inflammation and the risk of cardiovascular
disease.
Tissue plasminogen activator (t-PA) is a fibrinolytic factor
released from the endothelium and lyses intravascular fibrin.4
If endogenous fibrinolysis is to be effective, then the rapid
mobilization of t-PA from the endothelium is essential,
because thrombus dissolution is much more effective if t-PA
is incorporated during, rather than after, thrombus formation.''
However, in the presence of proinflammatory states or an
imbalance in endogenous fibrinolysis, intravascular thrombus
may propagate, ultimately leading to arterial occlusion and
tissue infarction.6
TNF-a and endotoxin have been reported to induce local
vascular inflammation and impair endothelium-dependent
vasodilatation in the venous circulation of humans.7 Although
mild systemic inflammation has also been shown to alter
endothelial function,8 the underlying mechanisms for these
observations have not been elucidated, and the direct in vivo
effects of cytokines and inflammatory stimuli on local arterial
endothelial vasomotor and fibrinolytic function are unknown.
The aims of this study were to investigate the acute effects
of local intra-arterial inflammatory cytokines (IL-6 and
TNF-a) and bacterial endotoxin (lipopolysaccharide [LPS])
exposure on vasomotor function and endothelial t-PA release
in vivo in humans.
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Methods
Subjects
Eighleen healthy nonsmoking men 21 to 25 years of age participated
in the study, which was undertaken with the approval of the local
research ethics committee in accordance with the Declaration of
Helsinki and the written informed consent of each subject. None of
the subjects had infective illnesses or received medication in the
week before study. All subjects abstained from alcohol for 24 hours
and from food and caffeine-containing drinks for at least 4 hours
before each study. All studies were performed in a quiet,
temperature-controlled room.
Cytokines and Drugs
TNF-cv (Knoll Pharmaceuticals),9 IL-6 (Novartis Pharma AG),'11
LPS (lot G-l, USPCI)." bradykinin (Clinalfa), acetylcholine
(Cibavision Ophtbalmios), and sodium nitrnprnsside (David Bull
Laboratories) were administered after dissolution in 0.9% saline.
TNF-a, IL-6, and LPS were prepared as stock solutions and stored at
—80°C in aliquols. All other drugs were freshly prepared on the
study day.
Hemodynamic Measurements
Blood flow was measured in both forearms by venous occlusion
plethysmography using mercury-in-silastic strain gauges, as previ¬
ously described.12 Blood pressure was monitored in the noninfused
arm at intervals throughout each study with a semiautomated
noninvasive oscillometric sphygmomanometer.
Venous Sampling and Assays
Venous blood (10 mL) was withdrawn simultaneously from each
arm and collected into tubes containing acidified buffered citrate (for
t-PA assays), trisodium citrate (for plasminogen activator inhibitor
type 1 fPAI-1] assays), and potassium ethylene diamine tetraacetic
acid (EDTA) (for cytokine assays). Citrate and acidified buffered
citrate samples were centrifuged at 2000g for 30 minutes at 4°C and
EDTA samples at lOOOg for 10 minutes at 20°C. Platelet-free plasma
was decanted and stored at — 80°C before assay. Plasma t-PA, PAI-1,
TNF-a, IL-6, and von Willebrand factor (vWF) antigen concentra¬
tions were determined as previously described1'-14 using enzyme-
linked immunosorbent assays (Coaliza t-PA and PAI-1, Chromoge-
nix AB; Quantikine human TNF and IL-6 immunoassays, R&D
Systems; and Dako A/S, respectively) and fibrinolytic activities
using a photometric method (Contest t-PA and PAI-1, C'homogenix
AB). Hematocrit and white cell count were determined using an
automated Coulter counter (Beckman Coulter ACt.8).
Study Design
Subjects rested recumbent, strain gauges and cuffs were applied, and
venous cannulas (17-G) were inserted into both antecubital fossae.
The brachial artery of the nondominant arm was cannulated with a
27-SWG needle under local anesthesia. The total rate of intra-arterial
infusion was maintained constant throughout at 1 mL/min. Forearm
blood flow was measured every 6 to 10 minutes.
Cytokine and Endotoxin Administration
In a randomized, double-blind study, 10 subjects attended on 3
occasions at least 1 week apart, and saline was infused for 30
minutes to allow time for equilibration. Subjects were then random¬
ized to receive inlra-arterial infusions of low-dose TNF-a (80
ng/min; n=6), high-dose TNF-a (240 ng/rnin; n = 6), IL-6 (30
ng/min; n=6), LPS (100 pg/min; n=6), or saline placebo (I mL/min;
n= 6) over 60 minutes. This was followed by an additional 60-minute
saline washout infusion. Venous samples were obtained at baseline,
10, 20, 40, and 60 minutes during drug infusion, and 30, 60, and 180
minutes after cessation of drug infusion. Cytokine and LPS doses
were chosen to achieve local concentrations comparable with healthy
volunteer studies7-"-15 and those seen in cardiovascular disease.'-"'
Effect of Tumor Necrosis Factor-a on Endothelial Function
Eight subjects attended on 2 occasions at least 1 week apart in a
randomized, double-blind, placebo-controlled, crossover trial. They
received an intra-arterial infusion of either TNF-a (80 ng/min) or
saline placebo (1 mL/min) over 60 minutes. After an additional 60
minutes of saline infusion, intra-arterial bradykinin was administered
at 100, 300, and 1000 pmol/min for 10 minutes at each dose,
acetylcholine at 5, 10. and 20 p.g/min, and sodium nitroprusside at 2,
4, and 8 yxg/min for 5 minutes at each dose. Infusions of the
vasoactive drugs were separated by 15-minute infusions of saline.
Venous samples were obtained at baseline, after 60 minutes of
TNF-a/placebo infusion, before and during each dose of bradykinin,
and 15 minutes after cessation of bradykinin infusion. Venous
samples were not obtained during acetylcholine or sodium nitroprus¬
side infusion, because they do not affect plasma t-PA or PAI-1
concentrations in this forearm model.l2-'7-"<
Data Analysis and Statistics
Plethysmography data were extracted from the chart data files, and
the last 5 linear recordings in each measurement period were
averaged. Estimated net t-PA antigen and activity release was
defined previously12 14 as the product of the infused forearm plasma
flow and the concentration difference between the infused and























Figure 1. Plasma concentrations of
TNF-a (top) and IL-6 (bottom) in the
infused (•) and noninfused (o) arms after
1 hour of intra-arterial infusion of TNF-a
at 80 ng/min (left) and 240 ng/min (right).
PsO.01 (ANOVA) for all responses
except IL-6 concentrations in the nonin¬
fused arm. P<0.05 (ANOVA, infused vs
noninfused arm) for all responses.
*P<0.05 (paired t test; vs baseline).
Time (hrs)
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TABLE 1. Forearm Blood Flow (mL/100 mL/min) During
TNF-a, IL-6, LPS, and Saline Placebo Infusion
TNF-a, TNF-a, IL-6, LPS,
80 ng/min 240 ng/min 30 ng/min 100 pg/min Saline
Infused arm
Baseline 2.2±0.2







tered by pretreatment with TNF-a, t-PA antigen and activity release
during bradykinin infusion was calculated by subtracting the mean
t-PA release before and 15 minutes after cessation of bradykinin
infusion.
Data were examined, where appropriate, by ANOVA with re¬
peated measures and 2-tailed paired Student's r test using Statview
(SAS Institute, Inc). All results are expressed as mean±SEM.
Statistical significance was assigned at the 5% level.
Results
All subjects remained well throughout the study and reported no
adverse effects. There were no effects on hematocrit, body temper¬
ature, or white cell count throughout all studies (data on file).
Cytokine and Endotoxin Administration
Cytokine Assays
Plasma TNF-a concentrations increased from 1±0 and 2±1
pg/ntL to 539±71 and 1 164±41 pg/mL in the infused arm
(/><0.001 for both) and to 20±2 and 62±8 pg/mL in the
noninfused arm (PCO.OOl for both) during 80 and 240
ng/min of TNF-a, respectively (Figure 1). This wa3 accom
panied by a gradual increase in plasma IL-6 concentrations
(Figure 1). In the infused arm, IL-6 infusion increased plasma
IL-6 concentrations from 2±1 to 14±3 pg/mL (P=0.01) and
LPS infusion increased plasma TNF-a and IL-6 concentra¬
tions from 1±3 to 7±1 pg/mL (/>=0.01) and from 1±0 to
6±2 pg/mL (P=0.02), respectively.
Hemodynamic Effects
Intra-arterial saline placebo, TNF-a, IL-6, and LPS infusions
had no effect on heart rate, blood pressure, or forearm blood
flow throughout all studies (data on file; Table 1).
Fibrinolytic and Hemostatic Assays
There were no changes in plasma t PA antigen concentrations
during IL-6, LPS, or saline placebo infusions (data on file).
Plasma t-PA antigen and activity concentrations increased in
the infused arm by up to 20-fold after both low- and
high-dose TNF-a infusions (P<0.001; Figure 2). Plasma
t PA concentrations incroasod slowly, being dctoctablc at 20
minutes and peaking at 60 minutes of infusion. Thereafter,
plasma t-PA concentrations fell but remained elevated 4
hours after initiation of tho infusion, with an apparently stable
elevation between 2 and 4 hours.
Plasma PA1-1 and vWF antigen concentrations were un¬
changed throughout all studies, although plasma PAI-1 activ¬
ity was reduced in the infused arm only after high-dose
TNF-a infusion (P=0.003; Table 2).
Effect of Tumor Necrosis Factor-a on
Endothelial Function
Cytokine Assays
Intra-arterial TNF-a infusion (80 ng/min) increased plasma
TNF-a concentrations in the infused and noninfused arm
from 2±1 and 2±1 pg/mL to 561 ±108 and 15±1 pg/mL,
respectively (P<0.001 for both).
Hemodynamic Effects
Intra-arterial TNF-a or placebo infusion had no significant
effects on heart rate, blood pressure, or basal forearm blood
flow up to 2 hours after commencement of the infusion
fP=NS for both). Forearm blood flow increased in a dose-
































Figure 2. Plasma concentrations of t-PA
antigen (solid lines) and activity (dashed
lines) in the infused (•) and noninfused
(o) arms after 1 hour of intra-arterial infu¬
sion of TNF-a at 80 ng/min (left) and 240
ng/min (right). PcO.001 (ANOVA) for all
responses except noninfused arm after
TNF-a 80 ng/min infusion. P<0.001
(ANOVA, infused vs noninfused arm) for
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TABLE 2. Plasma PAI-1 Antigen and Activity Concentrations
During TNF-a Infusion
TNF-a, 80 ng/min TNF-a.240 ng/min
Infused Noninfused Infused Noninfused
PAI-1 antigen, ng/mL
0 minutes 17±4 19±5 23±5 24±5
60 minutes 18 ±4 20±4 25 ±6 26±8
120 minutes 14±3 16+3 CO l+ cn 24+5
240 minutes 15±4 14 ± 3 21 ±5 36 17
PAI-1 activity, lU/mL
0 minutes 12 ±2 11+1 CM+lO 9±2
60 minutes 9±2 10±2 5±2* 12±3
120 minutes 11±1 14 ± 3 6+1* 10+2
240 minutes 8±1 11 ±2 4±1* 12 ± 1
Values are mean±SEM.
*P=0.003, ANOVA, infused vs noninfused arm.
dium nitroprusside infusions (P<0.02; Figure 3). Compared
with placebo, TNF-a infusion caused impaired endothelium-
dependent vasodilatation to bradykinin (P=0.029) and ace¬
tylcholine (P=0.01) but had no effect on endothelium-
independent vasodilatation to sodium nitroprusside (P=0.43;
Figure 3).
Fibrinolytic Assays
Plasma t-PA antigen and activity concentrations increased
from 3.5±0.6 to 8.5±1.6 ng/mL (P=0.004) and from
1.1 ±0.3 to 9.2± 1.9 IU/mL (P=0.003), respectively, after 60
minutes of TNF-a infusion. Again, this rise was sustained
with an apparently stable elevation between 2 and 3 hours, ie,
1 to 2 hours after cessation of TNF infusion (Figure 4).
Plasma t-PA antigen and activity concentrations were un¬
changed in the noninfused arm and during placebo infusion.
Plasma t-PA antigen and activity concentrations increased
in a dose-dependent manner during bradykinin infusion
(P<0.01). Compared with placebo, pretreatment with TNF-a
resulted in higher plasma t-PA antigen and activity concen¬
trations during bradykinin infusion (11.3±0.8 versus 6.8±0.5
ng/mL and 16.5±3.9 versus 6.6±2.0 lU/mL at peak brady¬
kinin dose; P<0.002) (Figure 4) and a marked augmentation
in the estimated net release of t-PA antigen and activity
(/>=0.018 and P=0.037, respectively; Figure 5). For the
30-minute bradykinin dose-response infusion, pretreatment
with TNF-a resulted in 83% and 132% increases in area
under the curve for t-PA antigen and activity release, respec¬
tively (P<0.05).
Discussion
We have demonstrated for the first time that local intra-arte-
rial TNF-a administration can be used to generate an in vivo
local vascular inflammatory model in humans that is associ¬
ated with endothelial dysfunction and a unique profile of
endogenous t-PA release. In contrast to IL-6 and LPS, TNF-a
causes a slow-onset, sustained, and selective release of t-PA
from the vascular endothelium in the absence of basal
vasomotor effects. Moreover, prctreatment with TNF-a at¬
























































^ = === = = ^1= = =: === = =^
2 4 8
Sodium Nitroprusside (gg/min)
Figure 3. Infused (solid line) and noninfused (dashed line) fore¬
arm blood flow responses to incremental doses of bradykinin
(a), acetylcholine (b), and sodium nitroprusside (c) in subjects
who were pretreated with TNF-a (•) or saline placebo (o).
Ps0.02 (ANOVA) for all infused arm responses. 'P<0.03
(ANOVA, TNF-a vs saline placebo).
acute bradykinin-induced t-PA release. These findings indi¬
cate that TNF-a and acute vascular inflammation have
complex effects on endothelial function. Although the profi-
brinolytic actions may reflect a protective mechanism in
acute inflammation, TNF-a also directly impairs cndotheli-
um-dependent vasomotor responses.
Model of Local Vascular Inflammation
We have here developed a model of local vascular inflam¬
mation in vivo in humans. Using unilateral intrabrachial
infusions, we achieved high local plasma TNF-a concentra¬
tions that were comparable to the plasma concentrations seen
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Figure 4. Plasma concentrations of t-PA antigen (solid lines)
and activity (dashed lines) in infused (•) and noninfused (o) arms
after 1 hour of intra-arterial infusion of TNF-a (circles) or saline
placebo (triangles) and during bradykinin infusion. P<0.001
(ANOVA) for all infused arm responses. P<0.001 (ANOVA,
infused versus noninfused arm) for all responses. P<0.001
(ANOVA, TNF-« vs saline placebo) for infused arm responses.

























































Figure 5. Estimated net t-PA antigen (solid lines) and activity
(dashed lines) release during bradykinin infusion corrected for
baseline t-PA concentrations in subjects who were pretreated
with TNF-a (•) or saline placebo (o). P<0.001 (ANOVA) for all
responses. *P<0.05 (ANOVA, TNF-a vs saline placebo).
tP^O.05 (paired f test; TNF-a vs saline placebo).
in patients with severe heart failure."' A direct local vascular
and endothelial inflammatory response was confirmed by the
local rise in plasma 1L-6 and t-PA concentrations. However,
the fibrinolytic effects of TNF-a were not mediated through
1L-6 release, because isolated 1L-6 infusion had no effect on
t-PA release. Indeed, in pilot studies, we found that high-dose
intrabrachial 1L-6 infusion sufficient to increase plasma IL-6
concentrations to >100 pg/mL have also failed to produce
significant effects on forearm blood flow or t-PA release.
Effects of TNF-a on t-PA Release
The profile of t-PA release during local intra-arterial TNF-a
administration is unique and has not been previously de¬
scribed in vivo in humans. Previous studies in healthy
volunteers have reported changes in plasma fibrinolytic15 and
coagulation20 factors during systemic TNF-a administration.
TNF-a has pleiotropic effects and may cause these effects
through actions on specific tissues or via secondary mediators
released from organs such as the liver. In the present smdy,
we have assessed local peripheral vascular responses to direct
intra-arterial TNF-a and have shown that it causes selective
endothelial t-PA release in the forearm without demonstrable
effects on plasma vWF or PA1-1 antigen concentrations.
Although there was a modest rise in the IL-6 and t-PA
concentrations in the noninfused arm, this may represent
overspill from the infused arm, where the concentrations
increased by up to 20-fold. In contrast to previous systemic
studies,15-20 subjects here remained asymptomatic and there
was no associated pyrexia, consistent with the absence of a
major systemic response.
We12 and others1718 have previously reported acute rapid
t-PA release during intra-arterial substance P, bradykinin. and
methacholine infusions. Using these agents, there is a near-
instantaneous onset and offset of action with no sustained
increase in t-PA release after cessation of administration.
Moreover, there is always an associated change in vascular
tone and regional blood flow, because these agents also cause
vasodilatation. In contrast, TNF-a administration had no
effect on basal blood flow and caused a slow onset and
sustained release of t-PA that was not apparent until 20
700 Arlerioscler Thromb Vase Biol. April 2003
minutes after commencement of the infusion and continued
for at least 3 hours after its cessation.
Endothelial cells synthesize and secrete t-PA both consti-
tutively and facultatively. The facultative release of t-PA
occurs in response to stimulation by several physiological
agonists, including thrombin and bradykinin.19 This large and
rapid release arises from the translocation of a dynamic
intracellular storage pool of t-PA.4-'9 Agonists such as bra¬
dykinin are likely to stimulate t-PA release via exocytosis
of these granules because of the near-instantaneous release of
t-PA and the ex vivo animal evidence that inhibition of
protein synthesis by cycloheximide has no effect on
bradykinin-induced acute t-PA release.19 The profile of t-PA
release seen with TNF-a is distinct from this pathway.
Although the mechanism has not been elucidated in our
study, we speculate that it may arise from an increase in de
novo t-PA synthesis and its constitutive release rather than
through the previously described facultative pathways. How¬
ever, the initial detectable rise in t-PA release seen at 20
minutes may be too early for protein synthesis to occur. Other
potential mechanisms such as activation of adherent leuko¬
cytes may cause the generation of secondary mediators that
enhance t-PA release.
Infusion of TNF-a seems to cause an isolated increase in
local t-PA release without affecting other endothelium-
dcrived fibrinolytic or hemostatic factors, namely PAI-1 and
vWF, respectively. This suggests a selective and specific
action of TNF-a on the endothelium and forearm vascular
bed. The fall in plasma PAI-1 activity seen in the infused arm
during high-dose TNF-a infusion is likely to reflect the
magnitude of the local t-PA released and its immediate
binding with PAI-1. Although other investigators have re¬
ported elevated plasma PAI-1 antigen concentrations within 3
hours of systemic administration of TNF-a and endotox¬
in, i5.2i we <jid n0( detect any changes in PAI-1 antigen
concentrations. This suggests that cytokine-induced increases
in PAI-1 release are mediated through a systemic mechanism,
such as hepatic or adipocyte synthesis, or produced in
response to markedly elevated systemic plasma t-PA
concentrations.
Effects of TNF-a on Endothelium-
Dcpendent Vasomotion
Bhagat and Vallance7 have previously shown that TNF-a
directly induced endothelial dysfunction in the venous circu¬
lation of healthy volunteers. We have extended these findings
and demonstrated that TNF-a also impairs resistance vessel
endothelium-dependent vasodilatation, possibly through the
development of acute arterial endothelial injury. The effects
of TNF-a were specific for the endothelium, because endo-
thelium-independent vasodilatation to the nitric oxide donor,
sodium nitroprusside, was unaltered.
TNF-a may alter endothelial vasomotor responses through
various mechanisms including decreased constitutive nitric
oxide synthase expression,22 increased inducible nitric oxide
synthase expression,22 and enhanced production of reactive
oxygen species.23 Additional studies are needed to clarify the
precise mechanism, although it is tempting to speculate that
TNF-a may, in part, be responsible for inducing endothelial
dysfunction in cardiovascular conditions associated with
inflammation.
Effects of TNF-a on Acute Endogenous Fibrinolysis
We have additionally demonstrated that TNF-a potentiates
bradykinin-induced endothelial t-PA release despite reduced
endothelium-dependent vasodilatation. This suggests that
acute local vascular inflammation induces antithrombotic
properties that may represent an adaptive response to inhibit
intravascular thrombus deposition at sites of vascular injury.
In particular, molecular and pharmacological evidence sup¬
ports the role of bradykinin B2 receptors in the acute phase of
inflammation, and upregulation of B2 receptors by TNF-a
may account for the observed profibrinolytic effect. The
augmented bradykinin response is also likely to reflect the
proposed increase in de novo t-PA production induced by
TNF-a pretreatment.
Clinical Implications
There is a consistent link between endothelial dysfunction
and cardiovascular disease, with impaired endothelium-
dependent vasodilatation having been described in athero¬
sclerotic conditions24 and its associated risk factors, such as
hypercholesterolemia.25 The major findings of our study will
be particularly pertinent to cardiovascular conditions, such as
acute coronary syndromes and congestive heart failure, in
which inflammation and impaired cndothelium-depcndent
vasodilatation occur.
We have found that although TNF-a adversely affects
certain aspects of endothelial function, such as cndothclium-
dependent vasodilatation, it enhances other protective mech¬
anisms, such as the endogenous fibrinolytic capacity. This
reflects (lie complex and pleiotropic nature of TNF-a, which
functions as part of the normal host surveillance mechanisms
and responses to tissue injury. These diverse effects may
explain some of the contradictory findings of recent clinical
studies. For example, in patients with heart failure, TNF-a
antagonism causes marked improvement in endothelium-
dependent vasodilatation26 but has failed to demonstrate
clinical benefit in the RECOVER and RENAISSANCE
randomized controlled trials.27 Thus, the benefits of restoring
endothelium dependent vasomotor function byTNF a-antag¬
onism may be counterbalanced by inhibiting other potentially
beneficial effects such as enhancing acute endogenous t-PA
release.
Conclusions
This is the first study to delineate the direct effects of
intra-arterial TNF-a administration on local vascular tone and
endogenous fibrinolysis in vivo in humans. It supports the
crucial role of TNF-a in cardiovascular disease and provides
evidence for its direct and pleiotropic effects on the circula¬
tion and endogenous fibrinolysis. Our findings have particu¬
lar implications for the future development of effective
anticytolcine and anti inflammatory strategies in cardiovascu¬
lar disease.
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Clinical Investigation and Reports
Endothelial Dysfunction, Impaired Endogenous Fibrinolysis,
and Cigarette Smoking
A Mechanism for Arterial Thrombosis and Myocardial Infarction
David E. Newby, BA, BSc, BM, MRCP; Robert A. Wright, MB, ChB, MRCP;
Catherine Labinjoh, BSc, MB, ChB, MRCP; Christopher A. Ludlam, PhD, FRCP, FRCPath;
Keith A.A. Fox, BSc, MB, ChB, FRCP, FESC;
Nicholas A. Boon, MD, FRCP; David J. Webb, MD, FRCP, FRCPE, FFPM
Background—Effective endogenous fibrinolysis requires rapid release of tissue plasminogen activator (tPA) from the
vascular endothelium. Smoking is a known risk factor for arterial thrombosis and myocardial infarction, and it causes
endothelial dysfunction. We therefore examined the effects of cigarette smoking on substance P-induced tPA release
in vivo in humans.
Methods and Results—Blood flow and plasma fibrinolytic factors were measured in both forearms of 12 smokers and 12
age- and sex-matched nonsmokers who received unilateral brachial artery infusions of substance P (2 to 8 pmol/min).
In both smokers and nonsmokers, substance P caused dose-dependent increases in blood flow and local release of
plasma tPA antigen and activity (7><0.001 for all) but had no effect on the local release of plasminogen activator
inhibitor type 1. Compared with nonsmokers, increases in forearm blood flow (P=0.03) and release of tPA antigen
(P=0.04) and activity (P<0.001) caused by substance P were reduced in smokers. The area under the curve for release
of tPA antigen and activity decreased by 51% and 53%, respectively.
Conclusions—Cigarette smoking causes marked inhibition of substance P-induced tPA release in vivo in humans. This
provides an important mechanism whereby endothelial dysfunction may increase the risk of athcrothrombosis through
a reduction in the acute fibrinolytic capacity. (Circulation. 1999;99:1411-1415.)
Key Words: plasminogen activators ■ endothelium ■ endothelium-derived factors ■ blood flow
Acute rupture of a coronary atheromatous plaque andsubsequent coronary artery thrombosis causes the ma¬
jority of sudden cardiac deaths and myocardial infarctions.1-2
Cigarette smoking not only is strongly associated with ath
erosclerosis1 and ischemic heart disease4 but also is a major
risk factor for acute coronary thrombosis.1-5 Indeed, 75% of
sudden cardiac deaths due to acute thrombosis are in cigarette
smokers.1 Smoking causes endothelial dysfunction6 and is
associated with increased platelet thrombus formation.5 Small
areas of denudation and thrombus deposition are a common
finding on the surface of atheromatous plaques7-8 and are
usually subclinical. However, in the presence of an imbalance
in the coagulation or fibrinolytic systems, such microthrombi
may propagate, ultimately leading to arterial occlusion.
The importance of endogenous tissue plasminogen activa
tor (tPA) release is exemplified by the high rate of sponta¬
neous reperfusion in the infarct-related artery after acute
myocardial infarction, occurring in «=30% of patients within
the first 12 hours.9-11 It would be anticipated that high plasma
tPA concentrations should protect against subsequent coro¬
nary events. However, in epidemiological studies of patients
with ischemic heart disease1"' n and in a healthy male popu¬
lation (US Physicians Study),14 higher total plasma tPA
(antigen) concentrations positively predict future coronary
events. This is explained by the concomitant elevation of
plasminogen activator inhibitor type 1 (PAI-1), which forms
a complex with tPA and thereby causes an overall reduction
in free tPA "activity."15-16 It is this free and unbound tPA that
is physiologically active and leads to endogenous fibrinolysis.
However, the capacity of endothelial cells to release tPA from
intracellular storage pools and the rapidity with which this
can be mobilized may not necessarily be reflected in the basal
circulating plasma concentrations of tPA antigen or activity.17
Using the endothelium-dependent vasodilator substance P
to stimulate tPA release, we recently described an in vivo
model to assess the acute fibrinolytic capacity of the human
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forearm.18 Moreover, we have been able to demonstrate a
reduction in tPA release after inducing experimental "endo¬
thelial dysfunction" with nitric oxide synthase inhibition.19
We therefore hypothesized that cigarette smoking might
impair endogenous fibrinolysis by reducing the capacity of
the endothelium to release tPA acutely. The aim of the study
was to compare substance P-induced tPA release from the




Twelve healthy smokers (5 to 20 cigarettes/d) and 12 age- and
sex-matched nonsmokers between 25 and 55 years old participated in
the study, which was undertaken with the approval of the local
research ethics committee and in accordance with the Declaration of
Helsinki. The written informed consent of each subject was obtained
before entry into the study.
All subjects were normotensive without a history of diabetes
mellitus or vascular disease. Female subjects were premenopausal
and not receiving hormonal contraceptives. They were clinically well
and taking no regular medications. Control subjects were lifelong
nonsmokers and were not exposed to regular environmental tobacco
smoke. Smokers had a history of regular daily cigarette smoking of
at least 5 years' standing and maintained their normal smoking habits
in the week before attendance. None of the subjects received
vasoactive or nonsteroidal anti-inflammatory drugs in the week
before the study, and all abstained from alcohol for 24 hours before
and from food, tobacco, and caffeine-containing drinks on the day of
the study. All studies were performed in a quiet, temperature-
controlled room maintained at 23.5°C to 24.5°C.
Intra-Arterial Drug Administration
The brachial artery of the nondominant arm was cannulated with a
27-standard wire gauge steel needle (Cooper's Needle Works Ltd)
under local anesthesia. The cannula was attached to a 16-gauge
epidural calhclci (Puitcx Lid), and patency was maintained by
infusion of saline (0.9%: Baxter Health Care Ltd) via an 1VAC
PI000 syringe pump (IVAC Ltd). The total rate of intra-arterial
infusions was maintained constant throughout all studies at 1
tllL/mili. Pharmaceutical-glade substance P (Clinulfa AG) was ad¬
ministered after dissolution in saline.
Measurements
Blood flow was measured in both forearms by venous occlusion
plethysmography as previously described.18-20 Blood pressure was
monitored in the noninfused arm at intervals throughout each study
with a semiautomated noninvasive oscillomctric sphygmomanome¬
ter (Takeda UA 751, Takeda Medical Inc).
Venous cannulas (17-gauge) were inserted into large subcutaneous
veins of the antecubital fossae of both arms. Blood (10 mL) was
withdrawn simultaneously from each arm and collected into acidified
buffered citrate (Biopool Stabilyte, for tPA assays) and citrate
(Monovette, for PAI-1 assays) tubes and kept on ice before being
centrifuged at 2000g for 30 minutes at 4°C. Platelet-free plasma was
decanted and stored at — 80°C before assay. Plasma PAI-1 and tPA
antigen and activities were determined as previously described18-1''
with an EL1SA (Coaliza PA1-1 and Coaliza tPA, Chromogenix AB)
and a photometric method (Coatest PAI-1 and Coaset tPA, Chro¬
mogenix AB). Hematocrit was determined by capillary tube centrif-
ugation at baseline and during infusion of 8 pmol/min of substance
P. Plasma lipid fractions were measured by an enzymatic colorimet-
ric method (Boehringer Mannheim GmbH Diagnostica). LDL cho¬
lesterol was derived according to the method of Friedewald et al.21
TABLE 1. Baseline Subject Characteristics
Nonsmokers Smokers
Age, y 35±3 34±2
Sex, male:female 10:2 10:2
Body mass index, kg/m2 23.9±0.5 24.5 ±1.1
Mean arterial pressure, mm Hg 92 ±2 91+2
Heart rate, bpm 59±3 66+2
Fasting plasma glucose, mmol/L 5.3±0.1 5.4+: 0.1
Total cholesterol, mg/dL 189±14 200±16
LDL cholesterol, mg/dL 113 + 13 130± 16
HDL cholesterol, mg/dL 48±3 37 ±2*
Triglycerides, mg/dL 138±16 163±27
Baseline hematocrit 0.41 ±0.01 0.43±0.01
*P=0.01 (unpaired (test, smokers vs nonsmokers).
Study Design
At 9 AM, subjects attended fasted and then rested recumbent
throughout each study. Strain gauges and cuffs were applied, and the
brachial artery of the nondominant arm was cannulated. Forearm
blood flow was measured every 10 minutes. Saline was infused for
the first 30 minutes to allow time for equilibration. The final blood
flow measurement during saline infusion was taken as the basal
forearm blood flow. Thereafter, subjects received intra-arterial sub¬
stance P at 2, 4, and 8 pmol/min for 10 minutes at each dose.
Data Analysis and Statistics
This study's population size, on the basis of power calculations
derived from previous studies, gives 90% power of detecting an 18%
difference in tPA release at a significance level of 5%. Coefficients
of repeatability22 for plasma concentrations of tPA antigen and
activity during substance P infusion at 8 pmol/min are 1.6 ng/mL and
1.4 HJ/mL, respectively (data on file).
Plethysmography data were extracted from the Chart data files,
and forearm blood flows were calculated for individual venous
occlusion cuff inflations by use of a template spreadsheet (Excel
version 5.0; Microsoft Corp). Recordings from the first 60 seconds
after wrist cuff inflation were not used because of the reflex
vasoconstriction this causes.20 Usually, the last 5 flow recordings in
each 3 minute measurement period were calculated and averaged for
each arm. Estimated net rclcusc of tPA activity and antigen war
defined previously18 as the product of the infused forearm plasma
flow (based on the mean hematocrit, Hct, and the infused forearm
blood flow, FBF) and the concentration difference between the
infused ([tPA]tof) and noninfused ([tPA]Noninl) arms: Estimated net
tPA re!ease=FBFX(] — Hct)X([tPA]lnl- -[tPA]Nolmlf).
Data were examined, where appropriate, by 2-way ANOVA with
repeated measures and 2-tailed Student's t test using Excel version
5.0 (Microsoft). The area under the curve was calculated for the
estimated net release of tPA across the study period. All results are
expressed as mcaniSEM. Statistical significance was taken at the
5% level.
Results
There were no significant differences in baseline character¬
istics, except that smokers had a slightly lower HDL concen¬
tration (Table 1). There were no significant changes in blood
pressure, heart rate, hematocrit, or blood flow in the nonin¬
fused forearm during the study (data on file; Table 2). In the
noninfused arm, plasma tPA antigen concentrations were
higher in smokers than nonsmokers (P=0.02; Table 2). There
were no significant differences in plasma PAI-1 antigen and
activity between the groups.
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10 20 30 10 20 30
Substance P dose, pmol/min 0 2 4 8 0 2 4 8
Absolute forearm blood flow,
mL • 100 mL_1 • mirr'
Noninfused arm 2.8±0.3 2.9±0.4 2.9±0.4 ro CO l+ o CO 2.8±0.2 2.9±0.3 2.9±0.3 3.0±0.3
Infused arm CO l+ O 4^- 11.2+1.1 13.5+1.3 16.2 =± 1.5+ 3.6+0.3 9.4±0.4 11.5±0.7 14.2±0.8*t
tPA antigen, ng/mL
Noninfused arm 3.3±0.5 3.4±0.5 3.4±0.5 3.7±0.5 4.0±0.5 4.3+0.5 4.4±0.5 4.4±0.6f
Infused arm 3.2±0.5 4.1 ±0.6 4.4±0.6 6.2±0.8* 4.1 ±0.5 4.5+0.6 5.2±0.7 5.9±0.9*
tPA activity, lU/mL
Noninfused arm 0,8±0.2 0.91:0.2 1.0 + 0.2 1.3±0.2 0.7 ±0.1 0.7 + 0.1 0.8±0.1 1.0+0.2
Infused arm CMO+lCOo 2.1 ±0.5 2.8±0.5 4.6±0.6* 0.7 ±0.1 1.1 ±0.2 1.7±0.4 3.0±0.5*f
PAI-1 antigen, ng/mL
Noninfused arm 29±7 29±6 28±7 28+6 29±6 26 ±5 25±5 26±5
Infused arm 28±6 28±7 27±6 28 ±5 26±5 27 ±6 26±6 26±5
PAI-1 activity, AU/mL
Noninfused arm 11.8+1.7 11.8+1.7 12.1±1.6 11.4+1.8 12.0+2.0 11.0±1.7 9.2 ±1.4 10.2±1.3
Infused arm 10.7+1.6 8.8+1.5 10.8 ± 1.7 9.3±1.5 12.5± 1.9 10.6± 1.5 10.5 ±1.2 8.5± 1.1
One-way ANOVA: *P<0.001; 2-way ANOVA (nonsmokers vs smokers): tP<0.05; %P= 0.001.
Substance P caused dose-dependent increases in forearm
blood flow in the infused arm in both smokers and nonsmok¬
ers (Table 2, Figure), but the increase in blood flow was
greater in nonsmokers (/5=0.03; 2-way ANOVA, nonsmok¬
ers versus smokers). Compared with the noninfused arm
(2-way ANOVA), substance P caused dose-dependent in¬
creases in plasma concentrations of tPA antigen (/><0.001)
and activity (/5<0.001) in the infused arm of both smokers
and nonsmokers (Table 2). There were no significant changes
in plasma PAI-1 antigen or activity in either group. The
increase in plasma tPA activity in the infused arm was greater
in the nonsmokers (P=0.001; 2-way ANOVA, nonsmokers
versus smokers).
Substance P increased the net release of tPA antigen
(P=0.009) and activity (P<0.001) in smokers (Figure). In
nonsmokers, substance P increased the net release of tPA
antigen (P<0.001) and activity (PCO.OOl) significantly more
than in smokers (P=0.04 and P<0.001, respectively; 2-way
ANOVA, nonsmokers versus smokers). Compared with the
nonsmokers, the area under the curve for net tPA antigen and
activity release was reduced by 51% and 53%, respectively,
in the smokers.
Subgroup analysis after exclusion of female subjects did
not alter the magnitude or the statistical significance of the
above findings. Qualitatively, the responses in female smok¬
ers and nonsmokers were similar to those observed in the
male subjects.
Discussion
We have shown here, for the first time, that despite higher
basal plasma tPA antigen concentrations, cigarette smokers
have a markedly impaired capacity of the endothelium to
release tPA acutely. This establishes an important mechanism
whereby cigarette smoking can lead to arterial thrombosis
and myocardial infarction.
The rapid mobilization of tPA front the endothelium is
crucial if endogenous fibrinolysis within the arterial circula¬
tion is to be effective, with thrombus dissolution being much
more effective if tPA is incoiporated during, rather than after,
thrombus formation.23-2'' The increased risk of spontaneous
thrombosis seen in smokers may therefore plausibly relate to
the propagation of thrombus, which would otherwise undergo
lysis and remain subclinical. Although cigarette smokers have
a higher overall mortality from myocardial infarction than
nonsmokers,25 the in-hospital mortality is lower.26 28 This
apparent paradox can be explained by the observation that the
infarct-related artery is more than twice as likely to become
patent in current smokers as in nonsmokers after thrombolytic
therapy for acute myocardial infarction.28-30 Indeed, it has
been suggested30 that thrombolytic therapy should only be
given to smokers and that alternative strategies such as
primary angioplasty should be used in nonsmokers. These
observations are consistent with the present findings because
it might be anticipated that patients with impaired endothelial
cell tPA release would benefit most from thrombolytic
therapy, whereas those with a normal endogenous fibrinolytic
capacity are more likely to have tPA-resistant thrombus,
which would respond less favorably.
Our findings in smokers are consistent with the previous
observational data12-'4 that increased basal plasma concentra¬
tions of tPA antigen are associated with future coronary
events. The assessment of endogenous fibrinolysis has pre¬
viously relied on measurement of basal plasma tPA concen¬
trations and the acute release of tPA in response to venous
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Infused forearm blood flow and the net release of tPA antigen
and activity in smokers (•) and nonsmokers (O). P<0.001
(1-way ANOVA) for all responses. Two-way ANOVA (nonsmok¬
ers vs smokers): *P<0.05; fP<0.001.
occlusion, systemic desmopressin infusion, or exercise.31 34
However, because of confounding systemic effects and the
nonuniformity of the stimuli applied, these responses can be
variable and give only a relatively crude measure of fibrino¬
lytic capacity. Moreover, although it has previously been
shown that systemic desmopressin infusion causes less tPA
release in smokers,31 this effect may not be directly endothe¬
lium-dependent.35 In contrast, we have used locally active
doses of substance I' to provide a more precise pharmacolog¬
ical stimulus to the endothelium and to cause a substantial
and dose-dependent local release of tPA.18-19 This has al¬
lowed us to demonstrate a distinct and marked inhibition of
stimulated endothelial tPA release in smokers.
Although thrombin is more physiologically relevant to
acute tPA release than substance P, we have used the latter
because its vascular actions are endothelium-dependent,36
mediated in part through nitric oxide,37 and its administration
intra-arterially is safe and well tolerated.38 Consistent with
previous workers,1<tf».4o We have also found an attenuation of
the endothelium-dependent forearm blood flow responses in
smokers. This inhibition of both the blood flow and tPA
response may, in part, relate to an impairment of the
i.-arginine:nilric oxide pathway in smokers.19'3' Although
differences exist,41 the forearm model may provide a useful
surrogate for the coronary vascular bed42-43 and permits a
readily accessible and reliable assessment of endothelial cell
function. However, the present findings need to be confirmed
in the coronary circulation.
We have studied the sustained effect of chronic smoking in
a selected healthy and predominantly male population at a
single time point. Although total and LDL cholesterol con¬
centrations were similar in smokers and nonsmokers, HDL
cholesterol concentrations were slightly lower in smokers.
This is not unexpected, because cigarette smoking is known
to be associated with a selective reduction in HDL cholesterol
concentrations.44-45 However, the application of this model to
other conditions associated with endothelial dysfunction,
such as dyslipidemia, is warranted. Finally, because hormonal
status influences fibrinolytic parameters,46 the assessment of
the acute fibrinolytic capacity in premenopausal and post¬
menopausal women and the modulating effect of hormonal
therapy will also be of particular interest.
In conclusion, we have demonstrated a major impairment
of tPA release from the vascular endothelium of smokers. Our
findings suggest that the fundamental mechanism whereby
cigarette smoking causes arterial thrombosis and myocardial
infarction relates, at least in part, to impairment of the acute
endogenous fibrinolytic capacity.
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ABSTRACT
We assessed forearm blood flow and plasma fibrinolytic factors in eight healthy males who
received unilateral brachial artery infusions of the endothelium-dependent vasodilator,
substance P, and the endothelium-independent vasodilator, sodium nitroprusside. These
measurements, together with platelet aggregation studies, were performed on four occasions
after double-blind randomized ingestion of placebo, methionine (0.1 mg/kg), vitamin C (2 g) and
methionine plus vitamin C. Blood flow and platelet aggregation responses were unaffected by
methionine loading. Substance P caused dose-dependent increases in plasma tissue plasminogen
activator (t-PA) antigen (from 3.0 + 0.1 to 4.7 + 0.4 ng/ml; P < 0.001) and activity (from 1.2 + 0.2
to 4.2 + 0.4 i.u./ml; P< 0.001), which were augmented during acute methionine loading
(4.7 + 0.4 to 5.6 + 0.5 ng/ml and 4.2 + 0.4 to 5.5 + 0.9 i.u./ml respectively; P< 0.05). Moreover,
the estimated net release of t-PA was enhanced during methionine loading (two-way ANOVA;
P = 0.02), but this was unaffected by vitamin C supplementation. We conclude that, in the
absence of alterations in endothelium-dependent vasomotion or platelet aggregation, substance
P-induced t-PA release is enhanced following methionine loading. This suggests that the acute
endogenous fibrinolytic capacity is augmented during acute hyperhomocysteinaemia in healthy
humans via an oxidation-independent mechanism.
INTRODUCTION
Elevated plasma homocysteine concentrations are an
independent risk factor for myocardial infarction [1], are
associated with thrombophilia, and confer a more than
20-fold increased risk of coronary artery disease [2].
Severe hyperhomocysteinaemia is rare, but moderate
hyperhomocysteinaemia is more common [3-5] and is
present in ~ 30% of patients with premature coronary
artery disease [2], In contrast with serum lipid fractions,
homocysteine concentrations are correlated only weakly
with the extent of coronary atheroma [6], suggesting that
the association with coronary events is more likely to
represent thrombogenicity or plaque rupture rather than
atherogenicity.
It has been recognized for over 20 years that elevated
plasma concentrations of homocysteine cause endothelial
cell injury and denudation in animal models [7,8].
However, more recent studies have confirmed that
endothelial dysfunction is also present in human subjects
with hyperhomocysteinaemia [9-12], and that this may
be reversed by lowering plasma homocysteine concen¬
trations using pyridoxine and folate therapy [13], The
mechanism whereby hyperhomocysteinaemia produces
Key words: blood flow, endothelium, hyperhomocysteinaemia, plasminogen activators, platelet aggregation.
Abbreviations: t-PA, tissue plasminogen activator; PA1, plasminogen activator inhibitor; a.u., arbitrary units.
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endothelial dysfunction may, in part, relate to oxidative
stress and superoxide generation [14]. Indeed, acute
antioxidant administration using vitamin C appears to
reverse the impairment of flow-associated vasodilatation
induced by methionine loading in healthy volunteers
[15].
The fibrinolytic factor tissue plasminogen activator (t-
PA) and its inhibitor, plasminogen activator inhibitor
type 1 (PAI-1), are potentially important endotheiium-
derived mediators that are intimately linked to the risk of
thrombosis. The time course of t-PA release is important,
since clot dissolution is much more effective if t-PA is
incorporated during clot formation rather than following
completion [16,17]. Plowever, the capacity of endothelial
cells to release t-PA from intracellular storage pools, and
the rapidity with which it can be mobilized, may not
necessarily be reflected in the basal circulating plasma
concentrations of t-PA antigen or its activity [18,19]. We
have shown, using bilateral forearm venous occlusion
plethysmography and unilateral brachial artery infusions,
that the forearm release of t-PA can be determined in
vivo in humans [20]. This model permits a more precise
pharmacological stimulus to be applied to the endo¬
thelium in a well defined and reproducible manner.
Moverover, on applying this model to healthy subjects
with a smoking habit, we have shown that, despite higher
basal plasma antigen concentrations, cigarette smokers
have a markedly impaired capacity to release t-PA acutely
[18].
In a longitudinal study of stroke patients, plasma t-PA
concentrations were found to be an independent dis¬
criminator, and were correlated directly with plasma
homocysteine concentrations [21], Moreover, methion¬
ine loading causes more pronounced alterations in basal
fibrinolytic parameters of patients with premature vas¬
cular disease [22], Although it would appear that hyper-
homocysteinaemia may be associated with alterations in
endogenous fibrinolysis, it is not known whether changes
in plasma homocysteine concentrations can influence the
acute release of t-PA from the endothelium.
In addition to procoagulant effects on the vessel wall,
hyperhomocysteinaemia may induce vascular occlusion
through platelet actions [23,24], Animal studies [23,25]
indicate that hyperhomocysteinaemia enhances platelet
aggregation. However, the effects of acute elevations of
plasma homocysteine concentrations on the activity of
platelets in humans are currently unknown.
We hypothesized that experimental hyperhomo¬
cysteinaemia, produced by methionine loading, would
impair substance P-induced forearm vasodilatation and
t-PA release, and enhance platelet aggregation. Moreover,
given the potential role of oxidative stress, we further
hypothesized that vitamin C supplementation would
reverse these potential derangements in endothelial and
platelet function. Therefore the aims of the present study
were to examine the effects of increased plasma homo¬
cysteine concentrations, following an oral methionine
load, on acute endogenous t-PA release, endothelium-
dependent vasomotion and platelet aggregation, and to




Eight healthy male non-smokers, aged between 20 and 42
(mean 30) years, participated in a four-phase study,
which was undertaken with the approval of the local
research ethics committee and in accordance with the
Declaration of Helsinki (1989) of the World Medical
Association. The written informed consent of each
subject was obtained before entry into the study.
Volunteers were normotensive, with normal serum chol¬
esterol, folate and vitamin Br2 levels. None of the subjects
received vasoactive or non-steroidal anti-inflammatory
drugs in the week before each phase of the study, and all
abstained from alcohol for 24 h, and from caffeine-
containing foods for at least 12 h, before each study. All
studies were carried out in a quiet, temperature-con¬
trolled room maintained at 22—24 °C.
Drugs
Pharmaceutical-grade substance P (Clinalfa AG,
Laufelfingen, Switzerland) and sodium nitroprusside
(Nipride; Roche, Welwyn Garden City, U.K.) were
administered following dissolution in 0.9 % saline (Baxter
Healthcare Ltd, Thetford, Norfolk, U.K.). In order to
maintain blinding, methionine (0.1 mg/kg; Evans Medi¬
cal Ltd, Leatherhead, Surrey, U.K.) [12], vitamin C (2 g;
Redoxen; Roche) and placebo were administered fol¬
lowing dissolution in an orange-flavoured drink con¬
taining no vitamin C.
Intra-arterial administration
The brachial artery of the non-dominant arm was
cannulated with a 27-standard wire gauge steel needle
(Cooper's Needle Works Ltd, Birmingham, U.K.) under
1 % lignocaine (Xylocaine; Astra Pharmaceutical Ltd,
Kings Langley, Herts., U.K.) local anaesthesia, and
attached to a 16 gauge epidural catheter (Portex Ltd,
Hythe, Kent, U.K.). Patency was maintained by infusion
of saline via an IVAC P1000 syringe pump (IVAC Ltd,
Basingstoke, Hants., U.K.). The total rate of intra-arterial
infusion was maintained constant throughout all studies
at 1 ml/min.
Forearm blood flow and haemodynamics
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
© 2001 Ihe Biochemical Society and the Medical Research Society
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strain gauges applied to the widest part of the forearm
[26]. During measurement periods, the hands were
excluded from the circulation by rapid inflation of wrist
cuffs to a pressure of 220 mmHg using E20 Rapid Cuff
Inflators (D. E. Hokanson Inc., Washington, DC,
U.S.A.). Upper-arm cuffs were inflated intermittently to
40 mmHg for 10 s in every 15 s to achieve venous
occlusion and obtain plethysmography recordings. Ana¬
logue voltage output from an EC-4 Strain Gauge
Plethysmograph (D. E. Hokanson Inc.) was processed
by a MacLab® analogue-to-digital converter and Chart®
v3.3.8 software (AD Instruments Ltd, Castle Hill, NSW,
Australia) and recorded on to a Macintosh Classic II
computer (Apple Computers Inc.). Calibration was
achieved using the internal standard of the plethysmo¬
graph.
Blood pressure and heart rate were monitored in the
non-infused arm at intervals throughout each study using
a semi-automated non-invasive oscillometry sphygmo¬
manometer (Takeda UA 751; Takeda Medical Inc.,
Tokyo, Japan) [27],
Assays
t-PA and and PAI-I
Venous cannulae (17G) were inserted into large sub¬
cutaneous veins of the antecubital fossa in both arms. A
10 ml blood sample was withdrawn simultaneously from
each arm and collected into acidified buffered citrate
(Biopool®; Stabilyte, Umea, Sweden; for t-PA assays)
and citrate (Monovette®; Sarstedt, Niimbrecht,
Germany; for PAI-l assays) tubes, and kept on ice before
being centrifuged at 2000 g for 30 min at 4 °C. Platelet-
free plasma was decanted and stored at — 80 °C before
assay [28],
Plasma PAI and t-PA antigen concentrations were
determined using ELISAs: Coaliza® PAI-l [29] and
Coaliza® t-PA [30] (Chromogenix AB, Molndal,
Sweden) respectively. Plasma PAI and t-PA activities
were determined by a photometric method: Coatest®
PAI-1 [31] and Coatest® t-PA [32] (Chromogenix AB).
Intra-assay coefficients of variation were 7.0% and 5.5 %
respectively for t-PA and PAI-1 antigen, and 4.0% and
2.4 % respectively for activity. Inter-assay coefficients of
variation were 4.0%, 7.3 %, 4.0% and 7.6% respectively.
The sensitivities of the assays were 0.5 ng/ml, 2.5 ng/ml,
0.10 i.u./ml and 5 arbitrary units (a.u.)/ml respectively.
The haematocrit was determined from the infused fore¬
arm at baseline and during infusion of 8 pmol of
substance P/min.
Homocysteine and vitamin C
Plasma total homocysteine concentrations were
measured, as described previously [33], in blood collected
in lithium/heparin (Monovette®). In brief, following
addition of 2-mercaptoethylamine and reduction with
tri-n-butylphosphine, plasma was deproteinized using
10% trichloroacetic acid and derivatized with 7-
fluorobenzo-2-oxa-l,3-diazole-4-sulphonic acid at 60 °C
for 1 h. Derivatized thiols were separated by HPLC (C18
columns; Millipore, Milford, MA, U.S.A.; mobile phase
6% acetonitrile in 0.1 mol/1 KH2P04 adjusted to pTI
2.15 with H3P04; flow rate 0.8 ml/min) and detected in
a fluorescence detector (Perkin Elmer LS30; excitation
385 nm, emission 515 nm). Chromatograms were
analysed using computer software (JCL 6000 Chromato¬
graphy Data System; Jones Chromatography,
Lakewood, CO, U.S.A.) and expressed as the quotient of
the homocysteine peak area (retention time 5.3 min) and
the internal standard peak area (retention time 3.3 min).
The peak ratio showed a linear relationship with homo¬
cysteine concentration in spiked plasma samples (< 2.5
to >40/(mol/I; r® = 0.997). Inter- and intra-assay
coefficients of variation were <12% and <8% re¬
spectively.
Blood samples in lithium/heparin (Monovette®) were
centrifuged immediately, and 500 /d of plasma was
separated before being rapidly snap-frozen following
addition of 500/(1 of 5% metaphosphoric acid. Plasma
vitamin C concentrations were determined using an
enzymic colorimetric method, as previously described
[34] (Cobas Bio centrifugal analyser equipped with a
fluorescence attachment).
Platelet aggregometry
A 30 ml sample of blood was collected into trisodium
citrate tubes (Monovette®) and immediately centrifuged
at 120 g for 10 min to obtain platelet-rich plasma, which
was aspirated and pre-warmed to 37 °C. Aggregation
studies were performed, 30-40 min after blood sampling,
using a standard optical technique (Chronolog Ca560
aggregometer; Labmedics, Stockport, U.K.) as described
previously [35], The maximum aggregation attained
within 7 min of the addition of each ADP concentration
(1-8 /(mol/1) was recorded, and expressed as a percentage
of the response to 8/tmol/l ADP. Measurement of
platelet counts and haematocrit were performed using an
automated Coulter counter (ACt.8 Coulter Counter;
Beckman-Coulter, High Wycombe, U.K.).
Study design
All subjects attended at 08.00 hours on each of four study
days at least 1 week apart, and participated in each of the
four study phases: double placebo, methionine plus
placebo, vitamin C plus placebo, and methionine plus
vitamin C. Blood samples were obtained for the measure¬
ment of plasma homocysteine concentrations and platelet
aggregation before and 6 h after the ingestion of double
placebo, methionine plus placebo, vitamin C plus placebo
or methionine plus vitamin C, administered in a double-
© 2001 The Biochemical Society and the Medical Research Society
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Table I Absolute blood flow in the infused and non-infused forearms during substance P infusion: endothelium-dcpendent
vasomotion
SP, substance P. The significance of substance P dose-response relationships in the infused arm was assessed by one-way ANOVA. Differences between placebo and
methionine were not significant by two-way ANOVA.
Blood flow (ml • min"1 • 100 ml"')
Infused arm Non-infused arm
Treatment [SP] (pmol/min)... 0
Placebo supplementation
Placebo 5.8+1.0 13.9 + 0.9 17.4+1.2 22.1 + 1.9 < 0.001 3.5 + 0.3 4.3 + 0.5 4.1 + 0.4 4.4 + 0.5
Methionine 4.9 + 0.5 12.8+1.4 14.9+1.3 17.0 + 1.8 < 0.001 3.2 + 0.3 3.2 + 0.2 2.9 + 0.3 3.7 + 0.4
Vitamin C supplementation
Placebo 4.6 + 0.8 12.2 + 2.1 14.7 + 2.2 18.2 + 2.8 < 0.001 3.2 + 0.5 3.4 + 0.5 3.5 + 0.4 3.6 + 0.4
Methionine 4.7 + 0.9 12.3+1.5 15.6 + 2.3 20.3 + 3.2 < 0.001 3.2 + 0.4 3.6 + 0.5 3.6 + 0.5 3.9 + 0.6
blind randomized manner. The studies were timed to
coincide with the peak plasma homocysteine concen¬
tration, which occurs between 4 and 8 h [12,36],
At 13.30 hours on each study day, subjects rested
recumbent; strain gauges and cuffs were applied and the
brachial artery of the non-dominant arm was cannulated.
Measurements of forearm blood flow were made every
10 min, between 3 and 6 min into each infusion period.
Before substance P and sodium nitroprusside adminis¬
tration, saline was infused for 30 min to allow time for
equilibration, and the final blood flow measurement
during saline infusion was taken as basal forearm blood
flow. Substance P was infused at 2, 4 and 8 pmol/min for
10 min at each dose [18,20], and sodium nitroprusside
was infused at 2, 4 and 8 ycg/min for 10 min at each dose
[20]. The order of substance P and sodium nitroprusside
administration was randomized, although for each sub¬
ject the order was maintained on each of the four
occasions. Plasma fibrinolytic parameters were assessed
at baseline and at the end of each dose of substance P, but
not during sodium nitroprusside infusion, since the latter
does not affect plasma t-PA or PAI-1 concentrations in
this model [20].
Data analysis and statistics
The study population size, based on power calculations
derived from previous studies [20], gives 90% power of
detecting a 21 % difference in t-PA release at a signifi¬
cance level of 5%. Coefficients of repeatability [37] for
plasma concentrations of t-PA antigen and activity
during substance P infusion at 8 pmol/min are 1.6 ng/ml
and 1.4 i.u./ml respectively (results not shown).
Plethysmographic and aggregometry data were
extracted from the Chart®" data files. Forearm blood
flows were calculated for individual venous occlusion
cuff inflations by use of a template spreadsheet (Excel
v5.0; Microsoft Corp.). Recordings from the first 60s
© 2001 The Biochemical Society and the Medical Research Society
after wrist cuff inflation were not used, because of the
variability in blood flow this causes. Usually, the last five
flow recordings in each 3 min measurement period were
calculated and averaged for each arm. Estimated net
release of t-PA activity and antigen was defined pre¬
viously [20] as the product of the infused forearm plasma
flow [based on the mean haematocrit (HCt) and the
infused forearm blood flow (FBF)] and the concentration
difference between the infused ([t-PA]Inr) and non-
infused ([t-PA]Non.inr) arms:
Estimated net t-PA release = FBF x (1 —HCt) x
([t-PA]Inf— [t-PA]Nonln[)
Data were examined, where appropriate, by two-way
ANOVA for repeated measures and two-tailed paired
Student's t-test using Excel v5.0 (Microsoft). All results
are expressed as means + S.E.M. Statistical significance
was taken at the 5% level.
RESULTS
There were no significant differences in baseline blood
pressure, heart rate, haematocrit (results not shown) or
forearm blood flow between the four study days (Tables 1
and 2). On each of the study days, blood pressure, heart
rate, haematocrit (results not shown) and non-infused
forearm blood flow (Tables 1 and 2) did not change
during the study. However, plasma homocysteine con¬
centrations (Figure 1) were elevated in all subjects
following methionine plus placebo or methionine plus
vitamin C {P = 0.01; paired r-test), but not after double
placebo or placebo plus vitamin C. Plasma vitamin C
concentrations increased after vitamin C plus placebo or
vitamin C plus methionine (P < 0.001), but not after
double placebo or placebo plus methionine (Figure 1).
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Table2 Absolute blood flow in the infused and non-infused forearms during sodium nitroprusside infusion: endothelium-
independent vasomotion
SNP, sodium nitroprusside. The significance of sodium nitroprusside dose-response relationships in the infused arm was assessed by one-way ANOVA. Differences between
placebo and methionine were not significant by two-way ANOVA.
Blood flow (ml-min-1 • 100 ml"')
Infused arm Non-infused arm
Treatment SNP (ytg/min)... 0
Placebo supplementation
Placebo 4.2 + 0.3 16.9 + 3.9 20.2 + 4.1 20.7±3.l < 0.001 3.4 + 0.2 3.7 + 0.3 3.9 + 0.4 3.6 + 0.3
Methionine 4.1+0.4 10.8 + 0.7 14.0+ I.I 16.9+1.4 < 0.001 3.1 + 0.2 3.0 + 0.2 3.5 + 0.3 3.1 + 0.3
Vitamin C supplementation
Placebo 3.6 + 0.4 11.5 + 2.3 15.9 + 2.9 20.6 + 4.4 < 0.001 2.6 + 0.2 2.7 + 0.2 2.8 + 0.2 3.1 + 0.5
Methionine 4.1+0.4 13.2 + 3.3 17.3 + 3.9 20.8 + 3.4 < 0.001 3.2 + 0.3 3.3 + 0.4 3.5 + 0.4 3.5 + 0.3
Figure I Plasma homocysteine (upper panel) and vitamin C
(lower panel) concentrations at baseline (□) and 6 h post-
ingestion (■) of double placebo, methionine plus placebo,
vitamin C plus placebo or methionine plus vitamin C
Significance of differences (paired /-test): "P^ 0.01, < 0.001.
Endothelium-dependent and -independent
vasomotion
Sodium nitroprusside and substance P caused dose-
dependent increases in blood flow of the infused forearm
(ANOVA: P < 0.001 for all; Tables 1 and 2) on all four
study days. The blood flow responses to both sodium
nitroprusside and substance P were similar on each of the
study days, with no significant differences in the mag¬
nitude of the responses. There was no time order effect of
the blood flow responses to substance P or sodium
nitroprusside.
Endogenous fibrinolysis
There were no significant differences between baseline
plasma t-PA and PAI-1 concentrations on each of the
four study days. Substance P caused dose-dependent
increases in plasma t-PA antigen concentration and
activity in the infused, but not the non-infused, forearm
on each of the four study days (Table 3). Moreover, the
concentration difference between the infused and non-
infused forearms also increased significantly with sub¬
stance P infusion (Table 3). Estimated net release of t-PA
antigen and activity demonstrated dose-dependent
increases (ANOVA: P < 0.001 for all; Figure 2), which
were unaffected by co-administration of vitamin C.
Substance P-induced increases in t-PA plasma concen¬
trations and forearm release were significantly greater
following methionine loading than after placebo (Table 3
and Figure 2).
At 6 h after administration of double placebo, meth¬
ionine plus placebo, vitamin C plus placebo and meth¬
ionine plus vitamin C, basal plasma PAI-1 antigen
concentrations were 20+ 5, 18 + 3, 20 + 2 and 16 + 2 ng/
ml respectively, and PAI-1 activities were 8 + 1, 7 + 2,
8+1 and 7 +1 a.u./ml respectively. There were no
significant differences between the study days.
Platelet aggregation
There were no differences in platelet counts before or 6 h
after the administration of double placebo
[(442 + 27) x lO'/l and (415+ 17) x 10"/1 respectively] or
methionine plus placebo [(429 + 32) x 10"/1 and
(411 ±25) x 10"/1 respectively]. There were no significant
changes in the concentration-response curves for ADP-
induced platelet aggregation in platelet-rich plasma 6 h
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Table 3 Plasma t-PA antigen concentration and activity in the infused and non-infused forearms during substance P infusion
in the presence and absence of vitamin C supplementation
SP, substance P; NS, not significant. Estimated net release is expressed as ng or i.u. per min per 100 ml of tissue, /"values are given for the substance P dose-response
relationship (one-way ANOVA). P values are also given for comparisons of placebo with methionine (two-way ANOVA)
Placebo Methionine
SP infusion (pmol/min) 0 2 4 8 P 0 2 4 8 P P (2-way)
Placebo supplementation
t-PA antigen (ng/ml)
Infused arm 3.0 + 0.1 3.5 + 0.2 3.9 + 0.2 4.7 + 0.4 g 0.001 3.3 + 0.2 4.1+0.5 4.5+ 0.2 5.6 + 0.5 g 0.01 sg 0.01
Non-infused arm 3.1+0.1 3.4 + 0.2 3.4 + 0.2 3.5 + 0.2 NS 3.3 + 0.2 3.2 + 0.1 3.3 + 0.2 3.7 + 0.2 NS
Forearm difference — 0.1 ±0.1 0.1 + 0.2 0.5 + 0.2 1.2 + 0.3 g 0.001 0.0 + 0.2 0.8 + 0.4 1.2 + 0.2 1.9 + 0.5 g 0.01 sg 0.01
Net release -0.4 + 0.2 0.8+1.9 5.8 + 2.0 15.8 + 4.0 g 0.001 0.1+0.6 5.8 + 2.5 11.4 + 3.0 20.4 + 5.7 g 0.01
(ng - min-1 • 100 ml"1]1
t-PA activity (i.u./ml)
Infused arm 1.2 + 0.2 2.1+0.4 2.6 + 0.4 4.2 + 0.4 g 0.001 1.5 + 0.3 2.4 + 0.4 3.5 + 0.6 5.5 + 0.9 g 0.001 sg 0.05
Non-infused arm 1.5 + 0.3 1.7 + 0.5 1.5 + 0.2 1.9 + 0.2 NS 1.5 + 0.3 1.6 + 0.2 1.9 + 0.4 2.3 + 0.4 NS
Forearm difference -0.3 + 0.1 0.4 ± 0.2 1.1 + 0.2 2.3 + 0.4 g 0.001 -0.1+0.2 0.8 + 0.3 1.6 + 0.4 32.2 + 0.7 g 0.001 sg 0.05
Net release - 1.0 + 0.7 3.3+1.9 11.6 + 2.4 31.6 + 7.1 g 0.001 -0.4 + 0.4 6.8 + 2.6 14.4 + 4.0 32.2 + 7.6 g 0.001
(i.u. ■ min"1 ■ 100 ml"
Vitamin C supplementation
t-PA antigen (ng/ml)
Infused arm 3.1 + 0.2 3.6 + 0.2 3.9 + 0.3 4.3 + 0.4 g 0.05 3.1+0.3 3.5 + 0.4 4.1 + 0.5 5.1+0.7 g 0.05
Non-infused arm 3.4 + 0.2 3.3 + 0.2 3.4 + 0.2 3.6 + 0.3 NS 3.2 + 0.4 3.1+0.4 3.4 + 0.4 3.5 + 0.3 NS
Forearm difference -0.3 + 0.1 0.3 + 0.1 0.5 + 0.3 0.7 + 0.3 g 0.05 -0.1 ±0.1 0.4 + 0.1 0.7 + 0.2 1.6 + 0.5 g 0.001 sg 0.05
Net release -0.8 + 0.2 2.2+1.0 5.1+2.8 8.9 + 4.0 g 0.05 -0.2 + 0.2 3.3+1.1 5.0+1.4 17.7 + 5.4 eg 0.001
(ng ■ min"1 • 100 ml"' )
t-PA activity (i.u./ml)
Infused arm 1.3 + 0.3 2.2 + 0.3 2.9 + 0.5 4.0 + 0.6 g 0.001 1.5 + 0.2 2.8 + 0.4 3.7 + 0.9 5.1+0.9 g 0.01 sg 0.11
Non-infused arm 1.5 + 0.3 1.5 + 0.3 1.4 + 0.3 1.8 + 0.3 NS 1.3 + 0.2 1.6 + 0.3 1.6 + 0.3 2.0 ± 0.4 NS
Forearm difference -0.2 + 0.1 0.7 + 0.2 1.5 + 0.5 2.3 + 0.6 g 0.001 0.2 + 0.1 1.2 + 0.3 2.1+0.8 3.1+0.8 g 0.01 sg 0.11
Net release -0.5 + 0.2 5.6 + 2.4 15.7 + 5.8 29.7 + 9.1 g 0.01 0.4 + 0.4 7.6+1.8 14.9 + 5.0 34.7 + 10.0 g 0.01
after oral administration of double placebo or methionine
plus placebo (Figure 3). Maximal aggregation (theoretical
maximum 80 mV) induced by 8 /tM ADP was 68 + 4 and
65±3mV following placebo and methionine adminis¬
tration respectively.
DISCUSSION
In the absence of alterations in endothelium-dependent
vasomotion and platelet aggregation, we report, for the
first time, a modest enhancement of substance P-induced
t-PA release following methionine loading. This effect
does not appear to be mediated through oxidative stress,
since co-administration of vitamin C had no effect on this
response. Thus it would appear that the acute endogenous
fibrinolytic capacity is augmented during acute hyper-
homocysteinaemia in healthy humans.
The importance of endogenous t-PA release is exempli¬
fied by the high rate of spontaneous reperfusion in the
infarct-related artery after acute myocardial infarction;
this occurs in around 30% of patients within the first
12 h [38—40]. It would be anticipated that high plasma
t-PA concentrations should protect against subsequent
coronary events. However, in epidemiological studies of
patients with ischaemic heart disease [41,42], and in
prospective studies in healthy populations [43,44], higher
total plasma t-PA (antigen) concentrations positively and
independently predict future coronary events. This may,
in part, be explained by the concomitant elevation of
PAI-1, which forms a complex with t-PA and thereby
causes an overall decrease in free t-PA 'activity' [45,46],
It is the free and unbound t-PA which is physiologically
active and leads to endogenous fibrinolysis. Moreover, in
the Northwick Park Heart Study [46] small changes
(25%) in fibrinolytic activity were associated with
significant increases in the risk of sustaining a myocardial
infarction or sudden cardiac death.
The findings of the present study suggest that acute
hyperhomocysteinaemia potentiates stimulated t-PA
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Figure 2 Estimated net release of t-PA during incremental
substance P infusion
Upper panel: □, placebo plus placebo or vitamin C (n = 16); ■. methionine
plus placebo or vitamin C (n = 16). Lower panel: O. double placebo (n = 8);
0, methionine plus placebo (/? = 8). Significance of differences: one-way ANOVA,
P < 0.001 for all (substance P dose-response); two-way ANOVA, ' P — 0.02,
\P = 0.06 (placebo compared with methionine)
release. This may be a consequence of acute endothelial
cell injury or perturbation, which results in an enhanced
response on further provocation. However, chronic
hyperhomocysteinaemia may have very different effects,
which may include chronic endothelial injury, desen-
sitization and a reduced t-PA response. The results of the
present study cannot be extrapolated to chronic hyper¬
homocysteinaemia, and this requires further careful
investigation.
In general, platelet aggregation is sensitive to defects in
platelet function rather than to increased platelet activity.
However, previous animal studies have indicated that
acute methionine loading can enhance platelet aggre¬
gation in response to ADP and thrombin [25], In the light
of these findings, we felt that assessment of platelet
aggregation could be a useful indicator in our clinical
study. However, we have found no evidence of an effect
of methionine loading on platelet aggregation in response
to ADP. This suggests that hyperhomocysteinaemia is
unlikely to alter platelet activity in humans.
In contrast with previous workers [12,15], we have not
found an impairment of endothelium-dependent vaso-
motion in acute hyperhomocysteinaemia. This is despite
the use of a comparable regimen of oral methionine
loading and a large rise in plasma homocysteine concen¬
trations. However, previous studies [12,15] have used
flow-associated dilatation as a non-invasive method of
assessing conduit artery endothelial function. In the
present study, we have predominantly assessed the
function of endothelium within the resistance vessel bed,
in terms of the capacity both to release t-PA and to
increase forearm blood flow. Conduit artery and micro¬
vascular endothelial cells have distinct phenotypic
differences, and this may contribute to the apparent
disparity in the responses to the same acute insult.
Moreover, responses to mechanical rather than phar¬
macological stimuli may also differ.
Recently, two studies [47,48] have assessed
endothelium-dependent resistance vessel function fol¬
lowing acute methionine loading. Using the endo¬
thelium-dependent vasodilator acetylcholine, these
studies have demonstrated either an impairment of [47],
or no effect on [48], forearm resistance vessel endothelial




Figure 3 Platelet aggregation in response to incremental doses of ADP at baseline (#) and 6 h post-ingestion of double
placebo or methionine plus placebo (A)
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function. These apparently contradictory findings may,
in part, reflect the differing study designs. Using a study
design similar to that of Kanani and colleagues [47], we
achieved similar increases in plasma homocysteine
concentrations with acute methonine loading, but failed
to detect a significant difference in endothelium-de-
pendent vasodilatation using substance P. This may be
explained by the differing signal transduction pathways
involved in acetylcholine- and substance P-induced
vasodilatation [49,50]. Indeed, previous studies assessing
endothelial function, using both substance P and acetyl¬
choline administration, have documented either con¬
cordant [51,52] or discordant [53,54] responses that are,
in part, dependent upon the disease processes under
investigation. Moreover, we chose to use substance P as
an endothelial cell stimulant because acetylcholine does
not induce the acute release of t-PA in the human forearm
[55]. These observations highlight the important
differences between the various agents used to stimulate
the endothelium, as well as the differing manifestations of
endothelial dysfunction that are dependent on the nature
of the underlying cellular injury.
In summary, we have found a modest and selective
enhancement of substance P-induced t-PA release fol¬
lowing methionine loading. It would appear that the
acute endogenous fibrinolytic capacity is augmented
during acute hyperhomocysteinaemia in healthy humans
via an oxidation-independent mechanism.
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Abstract
Objective: Cigarette smoking impairs peripheral endothelium-dependent vasodilatation and acute tissue plasminogen activator (t-PA)
release in man. The aim of the study was to determine if this endothelial dysfunction is, in part, mediated by the effects of nicotine.
Methods: Blood flow and plasma fibrinolytic factors were measured in both forearms of eight healthy male non-smokers during unilateral
brachial artery infusion of the endothelium-dependent vasodilator, substance P (2 to 8 pmol/min). Endothelium-independent vasodilat¬
ation was assessed using intra-arterial infusion of sodium nitroprusside (2 to 8 p.g/min). Subjects attended after 7 days treatment with
transdermal nicotine or placebo in a double blind randomised crossover design. Results: Plasma cotinine concentrations rose from
0.4±0.1 (placebo) to 125±25 ng/ml during nicotine administration (PCO.OOl). On both treatment days, substance P caused dose-
dependent increases in blood flow and plasma t-PA antigen and activity concentrations (P<0.00l for all) but had no effect on plasma
plasminogen activator inhibitor type I (PA1-1) concentrations. Compared with placebo, nicotine administration increased the substance-P-
induced release of t-PA antigen and activity {P<0.05 for both) without an effect on endothelium-dependent or -independent
vasodilatation. Conclusions: Short-term transdermal nicotine treatment does not affect endothelium-dependent vasomotion but does
increase substance-P-induced t-PA release in vivo in man. This suggests that nicotine administration alters specific aspects of endothelial
function and enhances the acute endogenous fibrinolytic capacity in vivo. The long-term effects of nicotine exposure, including the
potential to cause depletion of endothelial t-PA stores, now needs to be assessed. © 2001 Elsevier Science B.V. All rights reserved.
Keywords: Blood flow; Endothelial function; Thrombolysis
1. Introduction
Cigarette smoking is a major risk factor for cardiovascu¬
lar disease [1] and is associated with acute coronary
thrombosis and sudden cardiac death [2], The mechanisms
underlying these associations are unknown although previ¬
ous studies have demonstrated that regular smokers have
impaired endothelium-dependent vasodilatation in both the
peripheral [3] and coronary circulations [4], Endothelial
dysfunction may, therefore, contribute to the thrombotic
consequences and complications of cigarette smoking.
However, whilst endothelium-dependent regulation of vas¬
*Corresponding author. Cardiovascular Research, Department of Car¬
diology, Royal Infirmary, Edinburgh EH3 9YW, Scotland, UK. Tel./fax:
+ 44-131-536-2550.
E-mail address: d.e.ncwby@ed.ac.uk (D.E. Newby).
cular tone is important, this may not reflect other crucial
aspects of endothelial function such as haemostasis and
fibrinolysis.
Focal areas of endothelial denudation and thrombus
deposition are a common finding on the surface of
atheromatous plaques and usually remain subclinical.
However, in the presence of an imbalance in the haemos¬
tatic or fibrinolytic system such microthrombi may prop¬
agate ultimately leading to arterial occlusion [5]. The
degradation and clearance of intravascular thrombus is
regulated by tissue-type plasminogen activator (t-PA), a
serine protease that is released from the endothelial cells
through the translocation of a dynamic intracellular storage
pool. The efficacy of plasminogen activation and fibrin
degradation is determined by the relative balance between
Time for primary review 32 days.
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the acute release of t-PA and its subsequent inhibition
through formation of complexes with its inhibitor, plas¬
minogen activator inhibitor type 1 (PA1-1). Thus, through
the acute release of t-PA, endothelial function may have a
central role in the regulation of intravascular thrombus
formation and, if impaired, may contribute to the patho¬
genesis of acute myocardial infarction and sudden cardiac
death. We have previously described an in vivo model to
assess the acute release of t-PA from the endothelium in
the forearm vascular bed of man [6]. Using this approach,
we have been able to demonstrate that cigarette smoking
markedly impairs the acute peripheral release of t-PA [7],
However, the mechanism of this attenuated endothelial
response was not established.
Nicotine is a major component of cigarette smoke that is
rapidly absorbed following inhalation. Nicotine replace¬
ment therapy (NRT), either as a gum or patch preparations,
has become freely available for over-the-counter sale as a
medication to assist in smoking cessation. A number of
reports of thrombotic cardiovascular events have been
reported amongst individuals regularly using NRT [8], Cell
culture and in vivo animal 3tudic3 [9 12] have indicated
that nicotine is directly toxic to endothelial cells and may
have an effect on the fibrinolytic balance. There is
currently little information about its impact on endo-
thclium-dependent vasodilatation or acute t-PA release in
vivo in man. Therefore, the aims of this study were to
determine whether nicotine impairs endothelium-depcndent
vasodilatation and whether it affects the endogenous
fibrinolytic capacity in the peripheral circulation of man.
2. Methods
2.1. Subjects
Eight healthy male non-smokers participated in the
study which was undertaken with the approval of the local
research ethics committee and in accordance with the
Declaration of Helsinki. The written informed consent of
each subject was obtained before entry into the study.
None of the subjects received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before the study, and
all abstained from alcohol for 24 h before, and from food
and caffeine-containing drinks on the day of, the study. All
studies were performed in a quiet, temperature-controlled
room maintained at 22-25°C.
2.2. Intro-arterial drug administration
The brachial artery of the nondominant arm was cannu-
lated with a 27-standard wire gauge steel needle (Cooper's
Needle Works Ltd., Sheffield, UK) under local anaesthesia.
The cannula was attached to a 16-gauge epidural catheter
(Portex Ltd., Kent, UK) and patency was maintained by
infusion of saline (0.9% Baxter Healthcare Ltd., Norfolk,
UK) via an IVAC PI000 syringe pump (IVAC Ltd.,
Basingstoke, UK). The total rate of intra-arterial infusions
was maintained constant throughout all studies at 1 ml/
min. Pharmaceutical grade substance P (Clinalfa AG,
Laufelfingen, Switzerland) and sodium nitroprusside
(Faulding DBL Pharmaceutical, Leamington, UK) were
administered following dissolution in saline.
2.3. Measurements
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury in silastic strain
gauges applied to the widest part of the forearm [13],
During measurement periods, the hands were excluded
from the circulation by rapid inflation of the wrist cuffs to
a pressure of 220 mmHg using E20 Rapid Cuff Inflators
(D.E. Hokanson, Washington, USA). Upper arm cuffs were
inflated intermittently to 40 mmHg for 10 s in every 15 s
to achieve venous occlusion and obtain plethysmography
recordings. Analogue voltage output from an EC-4 Strain
Gauge Plethysmograph (D.E. Hokanson) was processed by
a MacLab analogue-lo-digital converter and Chart™ v3.3.8
software (AD Instruments, Castle Hill, Australia) and
recorded onto a Macintosh Classic II computer (Apple
Computers, Cupertino, USA). Calibration was achieved
using the internal standard of the plethysmograph.
Blood pressure was monitored in the non-infused arm at
intervals throughout each study with a semi-automated
non-invasive oscillometry sphygmomanometer (Takeda
UA 751, Takeda Medical, Tokyo, Japan).
Venous cannulae (17-gauge) were inserted into the deep
large subcutaneous veins of the antccubital fossae of both
arms. Blood (10 ml) was withdrawn simultaneously from
each arm and collected into acidified buffered citrate
(Biopool Slabilyte, Umea, Sweden for t-PA assays) and
citrate (Monovette, Sarstedt, Niimbrecht, Germany for
PAI-1 assays) tubes, and kept on ice before being cen-
trifuged at 2000Xg for 30 min at 4°C. Platelet-free plasma
was decanted and stored at — 80°C before assay. Plasma
PALI antigen and t PA antigen were dotormincd as previ
ously described [6,7] using ELISA (Coaliza PAI-1 and
t-PA, Chromogenix AB) and t-PA activity was measured
using a photometric method (Coaset t-PA, Chromogenix
AB). Haematocrit was determined by an Ac T Counter
(Coulter Corporation, Miami, USA) at baseline and during
infusion of 8 pmol/min of substance P. Plasma lipid
fractions were measured by an enzymatic colorimetric
method (Boehring Mannheim GmbH Diagnostica, Ger¬
many). LDL cholesterol was derived according to the
method of Friedewald et al. [14], Plasma cotinine was
determined by gas-liquid chromatography as previously
described [15].
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2.4. Study design
Suhjects attended on two occasions separated by at least
1 week. Topical nicotine or placebo patches were applied
for 7 days prior to the study day in a double blind
randomised crossover design. The dose of nicotine ad¬
ministered was 17.5 mg (Nicotinell TTS® 10) but was
increased to 35 mg (Nicotinell TTS® 20) for the final 4
days if well tolerated. 'High dose' placebo patches were
administered in a similar manner such that double blinding
was maintained. On the study day, subjects attended fasted
and rested recumbent throughout. Strain gauges and cuffs
were applied, and the brachial artery of the non-dominant
arm was cannulated as described above. Forearm blood
flow was measured every 10 min. Saline was infused for
the first 30 min to allow time for equilibration with the
final measurement taken as the baseline blood flow, time 0.
Thereafter, the subjects received intra-arterial substance P
at 2, 4 and 8 pmol/min for 10 min at each dose. After a
30-min washout of saline infusion, the subjects received
also an intra-arterial infusion of sodium nitroprusside
(SNP) at 2, 4 and 8 p.g/min for 10 min at each dose to
assess endothclium-independent vasodilatation. Tissue-
plasminogen activator was measured at baseline and with
each dose of substance P. Plasminogen activator inhibitor
was measured at baseline and at substance P 8 pmol/min.
In this model, SNP infusion does not affect fibrinolytic
variables [6,16] and was, therefore, not measured. The
order of the substance P and SNP infusions was random¬
ised between subjects in each study but remained constant
for each subject. Plasma cotinine concentrations were
measured at baseline on each 3tudy day.
2.5. Data analysis and statistics
Plethysmographic data were extracted from the Chart1"
data files and forearm blood flow (FBF) was calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel v5.0; Microsoft Corporation,
Cambridge, USA). Recordings from the first 60 s after
wrist cuff inflation were not used because of the variability
in blood flow this causes [13], The average of the last five
recordings from a 3-min interval of FBF measurement
were used for analysis. The percentage change from
baseline blood flow in the infused arm was calculated, as
previously described [13], from the ratio of the infused and
non-infused arm blood flow:
(J. INI. - L/NL)
% change in blood flow = 100 X , ..
where 7b and NJb are the infused and non-infused forearm
blood flows at baseline (time 0) respectively, and /, and NI{
are the infused and non-infused forearm blood flows at a
given time point, respectively.
Estimated net release of t-PA activity and antigen was
previously defined [6,7] as the product of the infused
forearm plasma flow (based on the mean haematocrit, Hct,
and the infused forearm blood flow, FBF) and the con¬
centration difference between the infused ([t-PA],nf) and
non-infused arms ([t-PA]Non.inl)
estimated net t-PA release = FBF X {1 — Hct}
X{[t-PA]lnf-[t-PA]Non.inr}.
Data were examined, where appropriate, by two-way
analysis of variance (ANOVA) with repeated measures and
two-tailed paired Student's Mest using Excel v5.0 (Mi¬
crosoft). All results are expressed as mean±standard error
of the mean (S.E.M.). Statistical significance was taken at
the 5% level.
3. Results
All subjects were normotensive with a normal serum
lipid profile and plasma glucose concentration (Table 1).
Nicotine administration significantly increased plasma
cotinine levels from 0.4±0.1 to 125±25 ng/ml (P-CO.OOl,
paired /-test). There were no significant changes in blood
pressure, heart rate, haematocrit or blood flow in the
non-infused forearm during each of the study days (Table
2). During nicotine administration, the heart rate and the
non-infused and infused forearm blood flows were con¬
sistently higher than during placebo (Table 2). Two
subjects were unable to tolerate the higher dose of nicotine
and returned to the 17.5 mg nicotine patch for the
remainder of the 7 days.
Substance P and SNP caused dose-dependent increases
in FBF during placebo and nicotine administration (P<
0.001 for all, ANOVA). Because of baseline differences,
absolute FBF during substance P and SNP infusion were
greater with nicotine administration (P<0.05, two-way
ANOVA). However taking account of these baseline
differences, there were no significant differences in the
percentage increase in FBF with substance P or SNP
infusion during nicotine administration (Table 2).
Table 1
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Table 2
Forearm blood flow and systemic haemodynamics during nicotine and placebo administration




Heart rate (/min) 69±3 69±3 67±3 71±3 71±3 70±3 73±5 73±4*
Mean arterial pressure (mmHg) 92±4 92±4 94±4 92±3 95±3 94±4 96±4 95±4
Absolute forearm blood flow
(ml/100 ml/min)
Non-infused arm 4.8±0.7 5.2±0.8 5.1+0.8 5.2 + 0.9 5.3±0.9 5.1±0.9 5.6+1 4.8±0.8*'
Infused arm 5±0.6 13±0.7 15.5±0.9 18.7± 1.3* 5.2±0.8 11.2±0.9 15+1.4 18± 1,7*t
Percentage change in 0 159±25 217±34 281+46* 0 I64±40 227±55 368±80*
forearm blood flow
Placebo administration
Heart rate (/min) 68±3 63±2 62±1 68±3 68±3 69±2 66±1 71±2'
Mean arterial pressure (mmHg) 90±3 91 ±3 92±2 92±2 95±2 93±3 92±3 91 ±2
Absolute forearm blood flow
(ml /100 ml/min)
Non-infused arm 3.5±0.5 3.8±0.5 3.5±0.6 4±0.5 4.1+0.6 3.810.5 3.510.4 3.410.3*1
Infused arm 3.910.8 1110.9 12.311.1 15.211* 4.310.7 10.510.7 1211.2 15.411.3*'
Percentage change in 0 211144 300166 309152* 0 178123 242130 337145*
forearm blood flow
*f<0.001 one-way ANOVA; 'P<0.05 two-way ANOVA (nicotine vs. placebo administration).
Compared with the non-infused arm, substance P caused
dose-dependent increases in plasma concentration of t-PA
antigen and activity in the infused arm during nicotine and
placebo administration (Table 3). The infused arm plasma
concentrations and estimated net release of t-PA antigen
and activity were greater with nicotine administration in
comparison to placebo (Fig. 1 and Table 3). There were no
significant changes in plasma PA1-1 concentrations either
between treatment groups or before and after substance P
infusion (Table 3).
4. Discussion
In healthy male volunteers, short-term nicotine adminis¬
tration, sufficient to increase plasma cotinine concentra¬
tions to those observed in cigarette smokers [3,17], was
associated with an increase in substance-P-induced t-PA
release, but had no effect on endothelium-dependent
vasodilatation. This suggests that short-term nicotine ad¬
ministration alters specific aspects of endothelial function
and enhances the acute endogenous fibrinolytic capacity in
Table 3
Plasma tissue plasminogen activator (l-PA) tind plasminogen activator inhibitor type 1 (PA.1 1) concentrations during nicotino and placebo administration
Nicotine Placebo




Non-infused arm 4.5 + 0.3 4.4 + 0.2 5.0±0.5 4.5±0.2 4.2±0.3 4.2±0.4 4.2±0.4 4.4±0.5
Infused arm 3.9±0.3 4.3+0.3 4.9±0.2 6.4±0.6* 4.1 ±0.4 4.6+0.4 4.8±0.4 5.8±0.7*
Forearm difference — 0.6±0.2 — 0.1 ±0.3 0.1+0.4 1.9±0.6* — 0.1 ±0.1 0.4±0.1 0.6±0.2 1.4±0.4'
Plasma t-PA activity
(HJ/ml)
Non-infused arm 1.9+0.1 2.2±0.2 2.3±0.2 2.3±0.2 1.9 ±0.1 2.0±0.2 2.1 ±0.2 2.3±0.2
Infused arm 1.9±0.1 2.4 + 0.2 3.8±0.7 7.1 + 1.7* 1.8 ±0.1 2.2 + 0.2 2.8±0.5 4.0±0.7*'
Forearm difference 0.0±0.1 0.2±0.1 1.5 rt 0.5 4.8 + 1.6' 0.0±0.1 0.1 ±0.2 0.7±0.5 1.7±0.6"
Plasma PAI-1 antigen
(ng/ml)
Non-infused arm 32+6 - — 30±6 35 ± 8 - - 40 ±6
Infused arm 30 + 6 - — 31+5 37±9 - - 34 ±8
*P<0.05 two-way ANOVA (infused vs. non-infused arm); 1P<0.05 two-way ANOVA (nicotine vs. placebo); 'PCO.OOl one-way ANOVA.




































Fig. 1. Net release of tissue plasminogen activator (t-PA) antigen (solid
lines) and activity (dashed lines) during placebo (open circles) and
nicotine (closed circles) administration. One-way ANOVA: P<0.001 for
all responses. Two-way ANOVA: *P<0.05; 1P<0.001 (nicotine vs.
placebo).
vivo. The long-term effects of nicotine exposure, including
the potential to cause depletion of endothelial t-PA stores,
now needs to be assessed, particularly in recent ex-smok¬
ers.
There are many potentially toxic chemicals in cigarette
smoke but there has been continued concern that nicotine
may have direct injurious effects, especially given anecdot¬
al reports of thrombotic cardiovascular events amongst
individuals regularly using NRT [8], Although species
differences exist, in vitro studies have shown that acute
nicotine administration increases t-PA release from bovine
aortic endothelial cells [11] while in vivo rodent studies
suggest chronic nicotine exposure depletes the free pool of
brain capillary t-PA antigen [12]. The act of smoking
acutely releases t-PA causing an elevation in plasma t-PA
concentrations [18] that appears to be blunted in chronic
cigarette smokers [19]. Indeed, chronic smoking causes a
reduction in the subsequent ability to release t-PA when
challenged with desmopressin [20] or venous occlusion
[21]. These findings are consistent with our observations of
enhanced acute t-PA release with short-term nicotine
exposure and our previous findings [7] of increased basal
plasma t-PA concentrations in chronic cigarette smokers
but a reduced acute release of t-PA. However, further
studies are now required to assess how rapidly the impair¬
ment of t-PA release reverses on cessation of cigarette
smoking, and what effect nicotine supplementation has in
recent ex-smokers.
The mechanisms of action of nicotine on t-PA release
are unknown, but may be mediated by induction of gene
expression [11] or processing of t-PA antigen at the post-
transcriptional level [12], As with cigarette smoking, there
does appear to be an important difference between the
effects of nicotine during acute and chronic administration
[11,12], and whilst short-term nicotine administration
appears to potentiate acute t-PA release, chronic adminis¬
tration may cause a reduction. This may be a consequence
of the depletion of intracellular t-PA stores, desensitisation
of the endothelium to further stimulation, or paradoxically
a reduction in the acute storage pool due to preferential
up-regulation of constitutive t-PA release. In the present
investigation, short-term nicotine exposure significantly
increased the capacity of the endothelium to release t-PA
when challenged by substance P infusion. However, we
did not observe a rise in basal plasma concentration of
t-PA antigen to accompany this associated increase in acute
stimulated t-PA release. This suggests that nicotine may
require a more protracted period of administration or
necessitate synergy with a stimulus for t-PA release, such
as other gas-phase components of cigarette smoke.
Epidemiological studies of long-term nicotine treatment
have not been conducted but relevant information can be
inferred from studies of chewing tobacco or snuff users
where there is systemic absorption of nicotine but not of
other combustion products. These studies have found no
evidence of an increased risk of myocardial infarction or
sudden cardiac death [22,23]. Two prospective studies
involving treatment of smokers with known cardiovascular
disease using transdermal nicotine have also failed to find
an association between nicotine use and the risk of acute
cardiovascular events [24,25]. Indeed, one study of smok¬
ers [25] reported more adverse events with placebo than
nicotine patches suggesting a protective role of nicotine.
Moreover, an experimental study of smokers with known
coronary artery disease demonstrated that nicotine supple¬
mentation caused a substantial reduction in exercise-in¬
duced reversible myocardial perfusion defects as assessed
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by quantitative SPECT scanning [26], Although there are
differences between epidemiological and experimental
studies, these results suggest that nicotine in itself is not a
direct cause of tobacco-related cardiovascular disease.
In contrast to previous in vivo studies [27-29], we did
not find an attenuation in blood flow responses to the
endothelium-dependcnt vasodilatation during nicotine ad¬
ministration. This disparity may be due to species differ¬
ences [27] or to the study populations investigated [29].
Sarabi et al. [29] assessed the effects of nicotine supple¬
mentation in habitual smokers and reported a difference in
a derived index of endothelial function. However, no direct
comparisons were made of the blood flow responses to
methacholine. In addition, nicotine treatment was associ¬
ated with a change in systemic blood pressure and the
authors conceded that this may have accounted for their
findings. These contrasting observations may also be
explained by the differing signal transduction pathways
involved in muscarinic and substance-P-induced vasodilat¬
ation [30,31]. Indeed, previous studies assessing endotheli¬
al function, using both substance P and acetylcholine
administration, have documented cither concordant [32,33]
or discordant [34,35] responses that are, in part, dependent
upon the disease processes under investigation. Moreover,
we chose to use substance P as an endothelial cell
stimulant because acetylcholine does not induce the acute
release of t-PA in the human forearm [36]. These observa¬
tions highlight the important differences between the
various agents used to stimulate the endothelium as well as
the differing manifestations of endothelial dysfunction that
are dependent on the nature of the underlying cellular
injury.
Another finding of the present study is that nicotine
administration was associated with an increase in basal
forearm blood flow suggesting a vasodilator effect of
nicotine on the peripheral vascular bed. The cardiovascular
effects of systemic nicotine administration arc complex
and include actions of nicotine on the central and peripher¬
al nervous systems. Of the studies that have examined the
direct effect of nicotine on vascular reactivity, all have
suggested a vasodilator action. Ex vivo studies indicate
that nicotine induces a neurally and nitric oxide-mediated,
endothelium-independent, vasodilatation [37,38]. This has
been confirmed by an in vivo canine model [39] that
demonstrated that the intracarotid injection of nicotine
increased cerebral blood flow through the release of nitric
oxide from vagal nerve terminals. Moreover, Fewings et
al. [40] have reported that intra-arterial nicotine infusion
increases forearm blood flow in man. Our findings suggest
that short-term nicotine administration does not impair
endothelium-dcpendent vasomolion but does cause sys¬
temic vasodilatation as indicated by an elevation in resting
forearm blood flow and heart rate.
In conclusion, we have demonstrated, for the first time,
that nicotine administration alters specific aspects of
endothelial function and enhances the acute endogenous
fibrinolytic capacity in vivo. Future studies are now needed
to assess the effects of long-term nicotine exposure,
including the potential to cause depletion of endothelial
t-PA stores, particularly in recent ex-smokers.
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Objective: To assess acute tissue plasminogen activator (t-PA) release in vivo in patients with hyper¬
cholesterolaemia in the presence and absence of lipid lowering treatment and in matched normocho-
lesterolaemic controls.
Design: Parallel group comparison and double blind randomised crossover.
Setting: University hospital.
Patients: Eight patients with hypercholesterolaemia (> 7.8 mmol/l) and eight matched normocholes-
terolaemic controls (< 5.5 mmol/l).
Methods: Blood flow and plasma fibrinolytic factors were measured in both forearms during unilateral
brachial artery infusions of the endothelium dependent vasodilator substance P (2-8 pmol/min) and the
endothelium independent vasodilator sodium nitroprusside (1-4 pg/min).
Interventions: In patients, measurements were made on three occasions: at baseline and after six
weeks of placebo or pravastatin 40 mg daily administered in a double blind randomised crossover
design.
Main outcome measures: Acute release of t-PA.
Results: Compared with patients, in normocholesterolaemic control subjects substance P caused
greater dose dependent increases in forearm blood flow (p < 0.05) but similar increases in plasma t-PA
antigen and activity concentrations. During pravastatin treatment in patients, total serum cholesterol fell
by 22% from a mean (SEM) of 8.1 (0.3) to 6.4 (0.4) mmol/l (p = 0.002) and substance P induced
vasodilatation was no longer significantly impaired in comparison with controls. However, despite
reproducible responses, pravastatin treatment was not associated with significant changes in basal or
substance P induced t-PA release.
Conclusions: Hypercholesterolaemia and lipid lowering treatment cause no demonstrable effects on
acute substance P induced t-PA release in vivo. This suggests that the preventative benefits of lipid low¬
ering treatment are unlikely to be mediated by improvements in endogenous fibrinolysis.
Hypercholesterolaemia impairs endothelial cellfunction,'"' predisposes vessels to damage, and contrib¬utes to vascular occlusion.'' Previous stu ies have shown
that endothelium dependent nitric oxide mediated vasodilata¬
tion is impaired irt patients with hypercholesterolaemia,1"' an
effect that is reversed by lipid lowering treatment.'"' Although
other endothelial cell markers have been described,*'' the
fibrinolytic factor tissue plasminogen activator (l -PA) and its
inhibitor, plasminogen activator inhibitor type 1 (PA1-1), are
potentially important markers that are intimately linked to
the risk of atherothrombosis.'" "
Endothelial cells in the precapillary arterioles and postcap¬
illary venules" synthesise and release t-PA and PA1-1 both
basally and in response to various coagulation factors and
stimulants. The rapid mobilisation of t-PA from the endothe¬
lium is crucial if endogenous fibrinolysis within the arterial
circulation is to be effective, with thrombus dissolution being
much more effective if t-PA is incorporated during, rather than
after, thrombus formation." '" The importance of endogenous
t-PA release is exemplified by the high rate of spontaneous
reperfusion in the infarct related artery after acute myocardial
infarction, which occurs in around 30% of patients within the
(irst 12 hours."
Epidemiological studies examining total plasma t-PA and
PA1-1 concentrations in patients with ischaemic heart disease
have observed a positive correlation with coronary events.'" "
It would be anticipated, however, that high t-PA concentra¬
tions would protect against subsequent coronary events rather
than the reverse. This paradoxical association is, in part,
explained by the concomitant increase of PAI-), which
complexes with t-PA and therefore causes an overall reduction
in free t-PA "activity"." " It is this free and unbound t-PA that
is physiologically active and central to endogenous fibrinoly¬
sis. However, the capacity of endothelial cells to release t-PA
from intracellular storage pools and the rapidity with which
this can be mobilised may not necessarily be reflected in the
basal circulating plasma concentrations of t-PA antigen or its
activity." " We have recently described an in vivo model to
assess the acute release of t-PA in the forearm of humans.2"
Using intrabrachial infusions of substance P, we have shown a
dose dependent release of t-PA without causing a significant
release in PA1-1. Moreover, we have also reported2' that t-PA
release is inhibited by nitric oxide synthase inhibition with
L-W'-monomethylarginine, suggesting that endothelial dys¬
function may impair the release of t-PA.
Given that substance P induced vasodilatation has
been reported to be impaired in patients with
Abbreviations: ELISA, enzyme linked immunosorbent assay; FBF,
forearm blood flow; Hcl, Haemotocrit; LDf, low density lipoprotein; PAI-1,
plasminogen activator inhibitor type 1; t-PA, tissue plasminogen activator;
WOSCOPS, west of Scotland coronary prevention study
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hypercholesterolaemia,' the aims of the present study were to
determine whether there is also an impairment of t-PA release
in patients with hypercho 1ei:terobemia and whether treat
merit with pravastatin5 could enhance t-PA release in these
patients.
METHODS
Patients and control subjects
Eight patients with primary hypercholesterolaemia were
recruited from the clinic if their serum cholesterol concentra¬
tions exceeded 7.8 mmol/1 (> 296 mg/dl). Following screening
with clinical examination, repeated questioning for symp¬
toms, clinical chemistry screen (liver enzymes, electrolytes,
urea, and creatine), haematology screen (full blood and
differential counts), urinalysis, and 12 lead ECG, patients were
excluded if they had diabetes mellitus, hypertension, ischae-
mic heart disease, peripheral vascular disease, an abnormal
resting ECG, or other clinically significant disease. Patients
were matched witli nornlochOleSterolaermc (< 5.5 mmol/1;
< 209 mg/dl) healthy control subjects for age, sex, and smok¬
ing habit. All studies were undertaken with the approval of
the local research ethics committee and in accordance with
the Declaration of Helsinki. The written informed consent of
each subject was obtained before entry into the study. None of
the subjects was receiving vasoactive or non-steroidal anti¬
inflammatory drugs in the week before each phase of the
study, and all abstained from alcohol for 24 hours and from
food, tobacco, and drinks containing caffeine for at least nine
hours before each study. All studies were performed in a quiet
temperature controlled room maintained at 23.5-24.5°C.
Infra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannitlated
with a 27 standard wire gauge steel needle (Cooper's Needle
Works I.td, Birmingham. UK) under 1% lignocaine (Xylocaine;
Astra Pharmaceuticals Ltd. Kings Langley. UK) local anaesthe¬
sia. The cannula was attached to a 16 gauge epidural catheter
(Portex Ltd, Hylhe, UK) and patency was maintained by infu¬
sion of saline (0.9%; Baxter Healthcare Ltd, Thetford, UK)
through an IVAC P1000 syringe pump (1VAC Ltd, Basingstoke,
UK). The total rate of intra-arterial infusions was maintained
constant throughout all studies at 1 ml/min. Pharmaceutical
grade substance P (Clinalfa AG, Laufelfingen, Switzerland)
and sodium nitroprusside (David Bull Laboratories, Warwick,
UK) were administered following dissolution in saline.
Forearm blood flow and blood pressure
Blood How was measured in both forearms by venous
occlusion plethysmography using mercury in silastic strain
gauges applied to the widest part of the forearm." During
measurement periods the hands were excluded from the
circulation by rapid inflation of the wrist cuffs to a pressure of
220 lltm Hg using E20 rapid cull iiiflatuis (DE Ilukansuii lite,
Bellevue, Washington, USA). Upper at in cuffs were inflated
intermittently to 40 mm Hg for 10 s in every 15 s to achieve
venous occlusion and obtain plethysmography recordings.
Analogue voltage output from an EC-4 strain gauge plelhys-
tuugiaph (DE Hukanson) was processed by a MacLub
analogue to digital converter and Chart version 3.3.8 software
(AD Instruments Ltd, Castle Hill, Australia) and lccuidcd un
to a Macintosh Classic II computet (Apple Computet s hie,
Cupertino, California USA). Calibration was achieved using
the internal standard of the plethysmography
Blood pressure was monitored in the non-infused arm at
intervals throughout each study using a semiautomaled non¬
invasive oscillometric sphygmomanometer (Takeda UA 751,
Takeda Medical Inc. Tokyo, Japan)."
Venous sampling and assays
Venous cannulne (17 gauge) were inserted into large
subcutaneous veins of the antecubital fossa in both arms. Ten
millilitres of blood was withdrawn simultaneously from each
arm and collected into acidified buffered citrate (Biopool Sta-
bilyte, Umca, Sweden, for t-PA assays) and citrate (Monovctte,
Sarstedt, Numbrecht, Germany, for PAI-1 assays) tubes, and
kept on ice before being centrifuged at 2000 4 for 30 minutes
at 4°C. Platelet free plasma was decanted and stored at -80°C
before assay. '4
Plasma t-PA and PAI-1 antigen concentrations were
determined using an enzyme linked immunosorbent assay
(EL1SA): Coaliza t-PA" and Coaliza PAI-11* (Chromogenix AB,
Molndal, Sweden), respectively. Plasma l-PA and PAI-1 activi¬
ties were determined by a photometric method: Coaset t-PA
and Coatest PAI-1 (Chromogenix AB), respectively." Plasma
PAI-1 activity is determined by a back titration method and
represents the total t PA inhibitory activity of the plasma." All
fibrinolytic assays were performed in duplicate and the mean
value was taken. Intra-assay coefficients of variation were
7.0% and 5.5% for t-PA and PAI-1 antigen and 4.0% and 2.4%
for activity, respectively. Internssny coefficients of variability
were 4.0%, 7.3%, 4.0% and 7.6%, respectively. The limits of
sensitivity of the assays were 0.5 ng/ml, 2.5 ng/rnl, 0.10 tU/ml,
and 5 AU/rnl, respectively. Haematocrit (Hct) was determined
by capillary tube centrilugation of blood anticoagulated by
ethylene diamine tetra acetic acid and was obtained from the
infused forearm at baseline and at 8 pmol/min of substance P
Serum cholesterol and triglyceride concentrations were deter
mined by an enzymatic colorimetric method (Boehringer
Mannheim GmbH Diagnostica, Mannheim, Germany). Low
density lipoprotein (LDL) cholesterol was determined by ihe
method of Friedewald and colleagues."'*
Study design
All patients attended on each of the three study days: baseline
and following six weeks' treatment with placebo and six
weeks' treatment with pravastatin 40 mg daily. Placebo and
pravastatin treatments were given in a randomised double
blind crossover design. Control subjects attended on one occa
sion only.
On each study day, subjects attended fasted at 0900 and
rested recumbent throughout. Strain gauges and cuffs were
applied and the brachial artery of the non-dominant arm was
cannulated. Throughout all protocols, forearm blood flow
(FBF) was measured every 10 minutes. Before administration
of substance P and sodium nitroprusside, saline was infused
for 30 minutes to allow time for equilibration and the final
blood How measurement during saline infusion was taken as
the basal Fltr. Substance Pvvas infused at 2,4, and 8 pmol/min
for 10 minutes at each dose14""'1 and sodium nitroprusside was
infused at 1, 2, and 4 jug/min for 10 minutes at each dose."'0 The
order of administration of substance P and sodium nitroprus
side was randomised.
Data analysis and statistics
Plethysmography data were extracted from the Chart data
files and FBFs were calculated for individual venous occlusion
cuff inflations by use of a template spreadsheet (Excel version
5.0; Microsoft Corporation, Redmond, Washington, USA).
Recordings from the first 60 seconds after wrist cuff inflation
were not used because of the variability in blood flow that this
causes." Usually the last five flow recordings in each three
minute measurement period were calculated and averaged for
each arm. lb reduce the variability of blood flow data, the ratio
of flows in the two arms was calculated for each time point, in
effect using the non-infused arm as a contemporaneous con¬
trol for the infused arm." Percentage changes in the infused
FBF were calculated" as follows:
% change in blood flow = 100 x (1,/NI, - lb/NIJ / Ib/Nlb
where I,, and NL, are the infused and non-infused FBFs at
baseline (time 0), respectively, and 1, and Nl, are the infused
and non-infused FBFs at a given time point, respectively.
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Table 1 Lipid profile, haemodynamics, a asolute Forearm blood flow, and
haematocrit at baseline and during placebo and pravastatin treatment
Patients
Controls Baseline Placebo Pravastatin
Age (years) 43 (3) 46 (3) - -
Sex (maleifemale) 5:3 5:3 - -
Body mass index (kg/m^) 24(1) 25(1) - -
Smokers 3 3 - -
Total cholesterol (mmol/l) 5.0 (0.2)*** 8.1 (0.3) 8.2 (0.3) 6.4 (0.4)**
LDL cholesterol (mmol/l) 3.2 (0.2)*** 5.8 (0.5) 6.1 (0.5) 4.3 (0.4)*
HDL cholesterol (mmol/l) 1.1 (0.1) 1.1 (0.1) 1.1 (0.2) 1.2 (0.2)
Triglycerides (mmol/l) 1.5 (0.4) 2.7 (0.4) 2.3 (0.4) 1.9 (0.3)
Mean arterial pressure (mm Hg) 88 (5) 87 (2) 87 (4) 87 (2)
Heart rate (beats/min) 64 (2) 62 (3) 63 (5) 62 (4)
Basal blood flow (mlL/100 ml/min)
Non-infused arm 3.0 (0.5) 2.4 (0.3) 2.9 (0.3) 2.4 (0.3)
Infused arm 3.7 (0.7) 3.6 (0.3) 3.2 (0.3) 2.5 (0.3)
Haematocrit 0.39 (0.01) 0.43 (0.01) 0.42 (0.01) 0.41 (0.01)
Data are mean (SEM). Unpaired /test * **p<0.001 (controls versus patients at baseline); *p=0.04,
**p=0.003 (patients: pravastatin versu controls); Paired / test *p=0.02, **p<0.003 (patients: placebo
versus pravastatin); Analysis of variance *p=0.04, * p<0.002 (three way analysis of variance for patient
groups).
HDL, high density lipoprotein; LDL, low density lipoprotein.
Estimated tut release of t PA activity and antigen was
defined previously'"1 as the product of the infused forearm
plasma flow (based on the mean Hct and the infused FBF) and
the concentration difference between the infused ([ t- PA ] lll()
arid non-infused arms (ft-PA]Nol,.,„,):
estimated net t-PA release = FBF x (1 - Hct) x ([t-PA],, -
[t-PAL„J
Data were examined, where appropriate, by two way analysis
of variance with repeated measures and two tailed paired Stu¬
dent's t test using Excel version 5.0. Reproducibility of the
responses to substance P infusion was assessed by comparing
the baseline data with placebo treatment study days using the
method of Bland and Altman."' Coefficients of reproducibility
were determined for 95% confidence intervals using the Stu¬
dent's t distribution. All results are expressed as mean (SEM).
Significance was taken at the 5% level. On tiie basis of previ¬
ous data-'" the study had 90% power to detect a 20% change in
plasma t-PA concentrations between treatment periods at the
5% level.
RESULTS
Table 1 shows patient and control subject characteristics. The
groups were well matched for age, sex, body mass index,
smoking habit, blood pressure, heart rate, Hct, and FBF. final
cholesterol and LDL cholesterol concentrations were signifi¬
cantly higher in the patient group and fell during pravastatin
but not placebo treatment (table 1). On each of the study days
in the patient and control groups, blood pressure, heart rate,
Hct, blood flow, and t-PA concentrations of the non-infused
forearm did not change.
Blood flow responses
Substance P caused dose dependent increases in blood flow of
the infused forearm in both patients and controls (p < 0.001
for both, analysis of variance; fig 1). In comparison to the con¬
trol group, the substance P induced increases in blood flow
were significantly less in the patient group (p < 0.05, two way
analysis of variance; fig 1). During pravastatin treatment, sub¬
stance P appeared to cause a slightly greater increase in blood
flow but this was not significantly different from baseline
responses (p = 0.30, two way analysis of variance, baseline
www.heartjnl.com
versus pravastatin) although it was no longer significantly
different from control group responses (p = 0.24, two way
analysis of variance).
Sodium nitroprusside also caused dose dependent increases
in blood flow of the infused forearm (p < 0.001, analysis of
<1>
CD
Substance P infusion Sodium nitroprusside infusion
(pmol/min) (pg/min)
Figure 1 Forearm blood flow responses to substance P and sodium
nitroprusside administration in control subjects (open circles, upper
panels) and patients at baseline (closed circles, upper panels), and
in patients during placebo (open squares, lower panels) and during
pravastatin treatment (closed squares, lower panels), p < 0.001 for
each forearm blood flow response (one way analysis of variance).
*p < 0.05 (two way analysis of variance, controls versus patients).
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Table 2 Plasma tissue plasminogen activator (t-PA) antigen and activity in patients











0 5.0 (0.5) 4.6 (0.8) 4.7 (0.6) 4.5 (0.6)
2 5.6 (0.7) 5.4 (0.8) 5.4 (0.6) 5.0 (0.4)
4 7.4 (0.8) 5.7 (0.9) 6.0 (0.9) 5.8 (0.6)
8 8.0 (1.3) 7.4(1.1) 7.5 (1.3) 7.6(1.1)
0 4.7 (0.5) 4.8 (0.7) 4.5 (0.6) 4.6 (0.6)
2 4.6 (0.4) 4.8 (0.7) 4.5 (0.5) 4.5 (0.6)
4 5.8 (0.6) 5.1 (0.8) 4.5 (0.8) 4.6 (0.6)
8 5.7 (0.6) 5.0 (0.8) 5.1 (0.6) 4.8 (0.6)
0 0.6 (0.1) 0.5 (0.1) 0.6 (0.1) 0.5 (0.1)
2 1.7 (0.5) 1.3 (0.5) 1.1 (0.4) 1.6 (0.8)
4 2.7 (1.0) 2.0 (0.6) 1.7 (0.9) 2.2 (1.1)
8 4.5 (1.5) 3.4(1.1) 3.9 (1.4) 3.1 (1.2)
0 0.7 (0.1) 0.4 (0.1) 0.5 (0.1) 0.4 (0.1)
2 0.8 (0.1) 0.5 (0.1) 0.6 (0.2) 0.5 (0.1)
4 1.1 (0.2) 0.6 (0.1) 0.7 (0.2) 0.6 (0.1)
8 1.7 (0.5) 0.7 (0.2) 0.8 (0.2) 0.7 (0.2)
Data are mean (SEMJ. *p<0.001, one way analysis of variance in the infused forearm for each group.
variance; fig 1), which were similar in patient and control
groups. Neither pravastatin nor placebo treatment influenced
the response to sodium nitroprusside infusion.
Fibrinolytic factor responses
Substance P caused dose dependent increases in plasma t-PA
antigen and activity concentrations in the infused forearm of
both patients and controls (p < 0.001 for both, analysis of
variance; table 2). Substance P induced increases in plasma
t-PA concentrations were similar in both groups and, in the
patient group, were unaffected by pravastatin or placebo
treatment. The concentration differences between the fore¬
arms and the estimated net release of t-PA antigen and activ¬
ity also increased dose dependently (p < 0.001, analysis of
variance; fig 2), which did not differ between the patient and
control groups or during pravastatin and placebo treatment.
There were no significant differences in plasma PA1-1 antigen
and activity concentrations at baseline, although there
appeared to be a trend for plasma PA1-1 antigen concentra¬
tions to be lower in the control group (p > 0.12, unpaired
l test; table 3). Plasma PA1-1 concentrations were unaffected
by substance P infusion or pravastatin treatment (table 3).
Reproducibility of substance P responses
Comparison of responses at baseline and during placebo
treatment shows good reproducibility for substance P induced
increases in plasma t-PA concentrations and FBF (table 4).
DISCUSSION
Despite impaired endothelium dependent forearm vasodilata¬
tion, we have shown that in patients with hypercholesterol-
aemia intrabrachial substance P infusions are associated with
a normal capacity to release t-PA acutely. Moreover, pravasta¬
tin treatment, sufficient to reduce cholesterol concentrations
by 22%, had no significant effects on acute t-PA release. This
suggests that, despite the presence of endothelial dysfunction,
hypercholesterolaemia does not influence the acute fibrino¬
lytic capacity of the endothelium and that the preventative
benefits of lipid lowering treatment are unlikely to be
mediated by improvements in endogenous fibrinolysis.
Consistent with previous findings,' we have shown that in
patients with hypercholesterolaemia, endothelium dependent
vasodilatation in response to substance P infusion is impaired.







Substance P infusion (pmol/min)
Figure 2 Concentration difference between infused and
non-infused forearms (upper panels) and estimated net release (lower
panels) of plasma tissue plasminogen activator antigen (solid lines,
left panels) and activity (dashed lines, right panels) during substance
P administration in controls (open circles) and patients at baseline
(closed circles), and during placebo (open squares) and pravastatin
(closed squares) treatment, p < 0.001 for each response (one way
analysis of variance).
release that we have recently described in cigarette smokers/"
hypercholesterolaemia and lipid lowering treatment do not
appear to influence substance P induced l-PA release. These
findings suggest that although smoking is associated with
impaired endogenous fibrinolysis, hypercholesterolaemia is
not. This is consistent with the observations that the patency
rate of the infarct related artery following thrombolytic treat¬
ment during myocardial infarction is enhanced in cigarette
www.heartjnl.com
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Table 3 Plasma plasminogen activator inhibitor type 1 (PAI-1) antigen and activity




(pmol/min) Controls Baseline Placebo Pravastatin
PAI-1 antigen (ng/ml)
Infused arm 0 23 (9| 40 (10) 47(12) 48 (15)
2 24(8) 43 (10) 47(11) 44 (13)
4 24 18) 41 (9) 46 (11) 51 (16)
8 29 (10) 39 (9) 46 (12) 46 (14)
Non-infused arm 0 22 (8) 44 (11) 50 (13) 50 (16)
2 23 (8) 40 (9) 51 (12) 51 (18)
4 26 (9) 39 (9) 51 (14) 46 (14)
8 28 (8) 38 (9) 48 (11) 46 (14)
PAI-1 activity (AU/ml)
Infused arm 0 9(3) '3 (2) 15 (3) 13(3)
2 10(4] 10(2) 16(3) 13 (2)
4 9(4) 9(3) 13 (3) 14(2)
8 " (-51 11 (3) 13(3) 13(2)
Non-infused arm 0 12(3) 14 (3) 14(3) 15(3)
2 8(4) 13 (2) 16(3) 13 (2)
4 11 (5) 10(3) 14(2) 13 (3)
8 9(4) 12 (3) 13(3) 12(3)
Data are mean (SEM).
Table 4 Repeatabi ity of t-PA and blood flow responses to substance P
administration in the nfused forearm baseline versus placebo
Substance P dose Placebo Mean of Coefficient of
(pmol/min) Baseline mean mean differences repeatability
t-PA antigen (ng/ml) 0 4.6 (0.8) 4.7 (0.6) 0.5 0.4
2 5.4 (0.8) 5.4 (0.6) 0.1 1.4
4 5.7 (0.9) 6.0 (0.9) 0.6 1.4
8 7.4(1.1) 7.5 (1.3) 0.1 1.6
t-PA activity (lU/ml) 0 0.5 (0.1) 0.6 (0.1) 0.0 0.2
2 1.3 (0.5) 1.1 (0.4) 0.3 0.6
4 2.0 (0.6) 1.7 (0.9) 0.4 1.2
8 3.4(1.1) 3.9 (1.4) 0.3 1.4
Absolute forearm blood 0 3.5 (0.3) 3.2 (0.3) 0.3 0.6
flow (ml/100 ml/min)
2 11.2 (0.7) 10.3 (1.3) 0.9 3.0
4 14.4 (1.8) 12.6 (1.5) 1.7 4.6
8 15.7 (1.1) 14.9 (1.5) 0.8 3.4
Change in forearm blood 2 206 (20) 240 (30) 35 48
flow (%)
4 300 (39) 300 (36) 0 68
8 402 (49) 384 (58) 17 76
Data are mean (SEM).
smokers,""3 but not in patients with hypercholesterolaemia,11
and that cigarette smoking is associated with thrombotic
occlusion whereas hypercholesterolaemia is linked to athero-
genesis and plaque rupture,'1 This would also indicate that
endothelial dysfunction can be manifest in separate distinct
pathways depending on the nature of the insult.
The WOSCOPS (west of Scotland coronary prevention
study)" was the first major randomised controlled trial to
show the primary preventative benefits of lipid lowering
therapy. We therefore chose to examine the effects of pravas¬
tatin 40 mg daily on endothelial and fibrinolytic function in a
well defined and otherwise healthy hypercholesterolaemic
population. Although the total cholesterol was reduced by 22%
and pravastatin was used at doses that have been shown to
confer major preventative benefits in several large scale clini¬
cal trials," the total serum cholesterol concentration
remained significantly higher than that in the normocholes-
terolaemic population. It may be that a greater reduction in
cholesterol concentrations would have facilitated a significant
improvement in endothelium dependent vasodilatation. How¬
ever, the mean cholesterol concentrations of the patients in
WOSCOPS were similar to those in the present study and the
relative risk reduction in ischaemic events is the same across a
broad range of cholesterol concentrations." Moreover, it
appears that statins do not just lower cholesterol and may
have many ancillary vascular actions." Finally, since we did
not observe a significant difference in t-PA release between
hypercholesterolaemic and normocholesterolaemic subjects, it
is unlikely that additional reductions in lipid concentrations,
brought about by higher doses of pravastatin or more potent
statins, would influence the acute release of t-PA.
The influence of lipid lowering therapy on endothelial dys¬
function was initially studied in patients with hypercholes-
terolaetnia following treatment for 3-6 months." However,
more recent studies have shown that endothelial dysfunction
can be reversed by statin treatment for six" or even lour
weeks.3 Indeed, two hour treatment with plasma LDL aphaer-
esis is associated with rapid and immediate reversal of
endothelial dysfunction.1" It is therefore unlikely that the
absence of an effect of pravastatin treatment is caused by the
length of treatment and is consistent with a recent
preliminary report from the WOSCOPS that showed no
www.heartjnl.com
Hypercholesterolaemia and endogenous fibrinolysis 53
changes in basal plasma t-PA concentrations despite 12
months' treatment with pravastatin.40 Moreover, in contrast to
previous studies, we have used a randomised double blind
crossover study design that provides a greater sensitivity to
detect potential differences in responses. The coefficients of
reproducibility are consistent with our previous studies'0 " and
indicate a power sufficient to detect an approximately 20%
change in blood flow and fibrinolytic responses.
In summary, whereas endothelium dependent vasodilata¬
tion is abnormal in both cigarette smoking and hypercholes¬
terolaemia, acute t-PA release appears to be impaired only by
cigarette smoking.19 These observations support the concept
that endothelial dysfunction is not a homogeneous condition
and may be manifested in differing ways depending on the
nature of the injury. Moreover, the benefits of lipid lowering
treatment in the primary1'' and secondary'5prevention of
coronary events are unlikely to be mediated by improvements
in endogenous fibrinolysis.
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Diesel Exhaust Inhalation Causes Vascular Dysfunction and
Impaired Endogenous Fibrinolysis
Nicholas L. Mills, MRCP*; Hakan Tornqvist, MD*; Simon D. Robinson, MRCP;
Manuel Gonzalez, MD; Kareen Darnley, RN; William MacNee, MD;
Nicholas A. Boon, MD; Ken Donaldson, PhD; Anders Blomberg, MD, PhD;
Thomas Sandstrom, MD, PhD; David E. Newby, DM, PhD
Background Although the mechanisms aro unknown, it liar, boon suggested that transient exposure to traffic derived air
pollution may be a trigger for acute myocardial infarction. The study aim was to investigate the effects ofdiesel exhaust
inhalation on vascular and endothelial function in humans.
Methods and Results In a double blind, randomized, cross over study, 30 healthy men were exposed to diluted dicscl
exhaust (300 /xg/m3 particulate concentration) or air for 1 hour during intermittent exercise. Bilateral forearm blood How
and inflammatory factors were measured before and during unilateral intrabrachial bradykinin (100 to 1000 pmol/min),
acetylcholine (5 to 20 /xg/min), sodium nitroprusside (2 to 8 /xg/min), and verapamil (10 to 100 /xg/min) infusions 2 and
6 hours after exposure. There were no differences in resting forearm blood flow or inflammatory markers after exposure
to diescl exhaust or air. Although there was a dose dependent increase in blood flow with each vasodilator (PC0.0001
for all), this response was attenuated with bradykinin (P<0.05), acetylcholine (P<0.05), and sodium nitroprusside
(P<0.001) infusions 2 hours after exposure to diesel exhaust, which persisted at 6 hours. Bradykinin caused a
dose-dependent increase in plasma tissue plasminogen activator (P<0.0001) that was suppressed 6 hours after exposure
to diesel (P<0.001; area under the curve decreased by 34%).
Conclusions At levels encountorod in an urban environment, inhalation of dilute diescl exhaust impairs 2 important and
con iplemeinaty aspects of vascular function in humans, the regulation of vascular tone and endogenous fibrinolysis.
These important findings provide a potential mechanism that links air pollution to the pathogenesis of atherothrombosis
and acute myocardial infarction. (Circulation. 2005;112:3930-3936.)
Key Words: air pollution ■ endothelium ■ blood How ■ fibrinolysis
Air pollution is a major eauso of cardiovascular morbidityand mortality. Short term increases in air pollution
exacerbate cardiorespiratory disease, leading to hospitaliza¬
tion for conditions including acute myocardial infarction.1
Long-term repeated exposure increases the risk of cardiovas¬
cular mortal it v, vvith deaths attributable to ischemic heart
disease, arrhythmias, and heart failure.2 These associations
are strongest for fine particulate air pollutants (PM25),3 of
which the combustion-derived nanoparticulates of diesel
exhaust are an important component.4 Although significant
improvements in air quality have occurred during the last 50
years, the association between PM25 and mortality is evident
below current air quality standards.3
Clinical Perspective p 3936
Despite the strength of the epidemiological evidence and
the emergence of promising hypotheses,7 the important
constituents and biological mechanisms responsible for tho
cardiovascular effects of uir pollution arc largely unknown. It
was recently reported that transient exposure to road traffic
may increase the risk of acute myocardial infarction.8 Long-
term exposure to traffic in those living within 100 m of a
major road significantly increased cardiopulmonary mortnli
ty.9 These important observations suggest that the
combustion-derived particulates in PM25 may be critical in
determining the cardiovascular effects of air pollution.
Abnormal endothelial function has been widely recognized
in patients with atherosclerosis and its risk factors.'0 " Endo¬
thelial dysfunction can also predict the likelihood of future
cardiovascular events and death in patients with coronary
artery disease17 and in at risk individuals with normal coro
nary arteries.'3 We have previously demonstrated endothelial
dysfunction in both the peripheral and coronary circulations
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of cigarette smokers.10 " Given the potential for common
etiologic factors contained within polluted air and cigarette
smoke, we hypothesized that the adverse cardiovascular
effects of air pollution are a result of combustion-derived
particulates and are mediated by an impairment of normal
vascular function. Using a carefully characterized exposure
system, we sought to assess the effect of diluted diesel




Thirty healthy, male nonsmokers between 20 and 38 years old
participated in these studies, which were performed with the ap¬
proval of the local research ethics committee, in accordance with the
Declaration of Helsinki, and the written, informed consent of all
volunteers. Subjects taking regular medication and those with clin¬
ical evidence of atherosclerotic vascular disease, arrhythmias, dia¬
betes mellitus, hypertension, renal or hepatic failure, asthma, signif¬
icant occupational exposure to air pollution, or an intercurrent illness
likely to be associated with inflammation were excluded from the
study. Subjects had normal lung function and reported no symptoms
of respiratory tract infection for at least 6 weeks before or during the
study.
Study Design
Subjects attended the experimental sessions on 2 occasions 2 weeks
apart and received either filtered air or diesel exhaust in a random¬
ized, double-blind, cross-over design. Each subject was exposed for
1 hour in a specially built diesel exposure chamber according to a
previously described standard protocol.14 During each exposure, they
performed moderate exercise (minute ventilation, 25 L • min"' • m 2)
on a bicycle ergometer that was alternated with rest at 15-minute
intervals.
Based on previous exposure15 and systemic inflammatory16 stud¬
ies, vascular assessments were performed in 15 subjects at 6 to 8
hours after diescl or air exposure. In light of our findings from this
6- to 8-hour study, we subsequently determined vascular function in
another 15 subjects at an earlier time point of 2 to 4 hours after
exposure to diesel exhaust or air. All subjects abstained from alcohol
for 24 hours and from food, tobacco, and caffeine-containing drinks
for at least 4 hours before each vascular study. Studies were carried
out in a quiet, temperature-controlled room maintained at 22°C to
24°C with subjects lying supine. All subjects remained indoors
between the exposure and vascular assessment to minimize addi¬
tional exposure to particulate air pollution.
Diesel Exposure
The diesel exhaust was generated from an idling Volvo dicsel engine
(Volvo TD45, 4.5 L, 4 cylinders, 680 rpm) as described previously.15
More than 90% of the exhaust was shunted away, and the remaining
part was diluted with air and fed into the exposure chamber at a
steady-state concentration. The air in the exposure chamber was
continuously monitored for nitrogen oxides (NO, N02), carbon
monoxide (CO), particulates (number/cm3), and total hydrocarbons.
The exposures were standardized by keeping the particulate concen¬
tration at 300 p.g/m3 and were associated with concentrations of N02
of 1.6 ppm; of NO, 4.5 ppin; of CO, 7.5 ppm; of total hydrocarbons,
4.3 ppin; of formaldehyde, 0.26 pg/m3; and of suspended particles,
1,2X 106/cm3. The lempcrature and humidity in the chamber were
controlled at 20°C and 50%, respectively.
Vascular Studies
All subjects underwent brachial artery cannulation with a 27-
standard wire gauge steel needle under controlled conditions. After a
30-minute baseline saline infusion, acetylcholine at 5, 10, and 20
p.g/min (endothelium-dependcnt vasodilator that does not release
tissue plasminogen activator [t-PA]; Merck Biosciences); bradykinin
at 100, 300, and 1000 pmol/min (endothelium-dependent vasodilator
that releases t-PA; Merck Biosciences); and sodium nitroprusside at
2, 4, and 8 /rg/min (endothelium-independent vasodilator that does
not release t-PA; David Bull Laboratories) were infused for 6
minutes at each dose. The 3 vasodilators were separated by 20-
minute saline infusions and given in a randomized order. In the
second cohort with the early (2- to 4-hour) vascular assessment,
verapamil at 10, 30, and 100 pg/min (endothelium- and NO-
independent vasodilator that does not release t-PA) was infused at
the end of the study protocol.17
Forearm blood flow (FBF) was measured in infused and nonin-
fused arms by venous occlusion plethysmography with a mercury-
in-silicone elastomer strain gauges as described previously.18 Supine
heart rate and blood pressure in the noninfused arm were monitored
at intervals throughout each study with a semiautomated, noninva¬
sive, oscillometry sphygmomanometer.
Venous cannulas (17 gauge) were inserted into large subcutaneous
veins of the antecubital fossae of both arms. Blood (10 mL) was
withdrawn simultaneously from each arm at baseline and during
infusion of each dose of bradykinin and collected into acidified
buffered citrate (Stabilyte tubes, Biopool International) for t-PA
assays and into citrate (BD Vacutainer) for plasminogen activator
inhibitor type 1 (PAI-1) assays. Samples were kept on ice before
being ccntrifuged at 2000g for 30 minutes at 4°C. Platelet-free
plasma was decanted and stored at — 80°C before assay. Plasma t-PA
and PAI-1 antigen concentrations were determined by ELISAs
(TintElize t-PA, Biopool EIA; Coaliza PAI-1, Chromogenix AB).
Hematocrit was determined by capillary tube centrifugation at
baseline and during infusion of bradykinin at 1000 pmol/min.
Blood samples were taken immediately before and at 2 and 6
hours after exposure and analyzed for total cells, differential cell
counts, and platelets by an autoanalyzcr. Plasma interleukin-6 (IL-6)
and tumor necrosis factor-a (TNF-o) were measured with commer¬
cially available ELISAs (Quantikine, R&D Systems). Plasma immu-
noreactive big endothelin (ET)-l and ET-1 concentrations were
measured according to an acetic acid extraction technique by use of
a modified commercial radioimmunoassay with rabbit anti-human
big ET-1 or ET-1 (Peninsula Laboratories Europe), as described
previously.19 Serum C-reactive protein (CRP) concentrations were
measured with an immunonephelometric assay (Behring BN fl
ncphelometer).
Data Analysis and Statistics
Plethysmography data were analyzed as described previously.10 The
estimated net release of t-PA antigen was defined as the product of
the infused forearm plasma flow (based on the mean hematocrit and
the infused FBF) and the concentration difference between the
infused and noninfused arms.10 Continuous variables are reported as
mean±SEM. Statistical analyses were performed with GraphPad
Prism (Graph Pad Software) by ANOVA with repeated measures and
2-tailed Student t test, where appropriate. The area under the curve
was calculated for the estimated net release of t-PA during the
forearm study period. Statistical significance was taken at P<0.05.
Results
There were no differences in resting heart rate, blood pres¬
sure, or baseline FBF after exposure to diesel exhaust or air in
either cohort (Table 1). Leukocyte, neutrophil, and platelet
counts; plasma IL-6, TNF-tr, big ET-1, and ET-1; and serum
CRP concentrations were not altered by diesel or air exposure
(Table 2).
Bradykinin, acetylcholine, and sodium nitroprusside caused
dose-dependent increases in FBF after both air and diesel
exhaust exposure (PCO.OOOl; Figure 1). The increase in blood
flow was blunted 2 hours after exposure to diesel exhaust in
response to infusion of bradykinin (P<0.05), acetylcholine
(P<0.05), and sodium nitroprusside (PcO.OOl), and this dimin-
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TABLE 1. Baseline Hemodynamics Variables
Air Diesel Significance
2 Hours, n= 15
Heart rate, bpm 64±3 65 ±2 P=0.64
Systolic blood pressure, mm Hg 140±4 148 ±4 P=0.13
Diastolic blood pressure, mm Hg 71 ±3 77 ±4 P=0.08
Infused FBF, mL/100 mL tissue per min 3.3±0.6 3.1 ±0.4 P=0.45
Noninfused FBF, mL/100 mL tissue per min 2.3±0.2 2.6±0.4 P=0.30
Hours, n=15
Heart rate, bpm 61 ±2 60 ±2 P=0.66
Systolic blood pressure, mm Hg 138+5 138 ±3 P=0.39
Diastolic blood pressure, mm Hg 75 ±2 76 ±4 P=0.87
Infused FBF, mL/100 mL tissue per min 3.1 ±0.5 2.5±0.2 P=0.25
Noninfused FBF, mL/100 mL tissue per min 2.2+0.1 2.4 + 0.3 P 0.65
Values are reported as mean±SEM, 2-tailed paired T test.
ished response persisted at 6 hours (Figure 2). In contrast,
verapamil induced vasodilatation was unaffected after exposure
to air or diesel exhaust (P=NS).
Bradykinin caused a dose-dependent increase in plasma
t-PA antigen concentrations (P<0.0001; Table 3) that was
reduced 6 hours after diesel exposure (P<0.001). The esti¬
mated net t-PA antigen release was reduced by 34% 6 hours
after exposure to diesel (P<0.05; Figure 3) but was unaf¬
fected at the earlier time point of 2 hours.
TABLE 2. Systemic Effects of Exposure to Diesel Exhaust
Before Exposure 2 Hours 6 Hours
Air
Leucocytes, x 109 cells/L 5.1 ±0.2 5.6+0.3 5.3 + 0.3
Neutrophils, X109 cells/L 2.8±0.2 3.3±0.2 3.0± 0.2
Platelets, ><109 ccllc/L 217 + 12 216±9 218 +: 12
IL-6, pg/mL 2.6± 1.3 3.4+ 0.8
TNF-cr, pg/mL 16.9±1.1 17.8+ 1.2
CRP, mg/L 0.9±0.3 0.8±:0.2
PAI-1 antigen, ng/mL 20.2±3.9 19.2+2.8 18.5±: 3.7
t-PA antigen, ng/mL 6.6±0.6 7.0±0.6 6.0+:0.5
ET-1, pg/mL 4.9 + 0.5 4.9±0.5 4.9 + 0.4
Big ET-1, pg/mL 28.8+1.5 29.6±2.5 32.2± 2.5
Diesel
Leucocytes, X109 cells/L 5.6±0.3
Neutrophils, x 10° cells/L 2.8±0.2
Platelets, X109 cells/L 228±14
IL-6, pg/mL 2.7±0.7
TNF-re, pg/mL 15.3 ±0.5
CRP, mg/L 1.0±0.4
PAI-1 antigen, ng/mL 16.1 ±3.0
t-PA antigen, ng/mL 6.0±0.6
ET-1, pg/mL 4.5±0.4


















Values are reported as mean±SEM.
Discussion
This is the first study to demonstrate that inhalation of diesel
exhaust, a common urban air pollutant, can impair vascular
function in humans. Using a robust and powerful study
design, we have assessed 2 important and complementary
aspects of vascular function: the regulation of vascular tone
and endogenous fibrinolysis. Both are impaired and plausibly
related to the well-documented cardiovascular effects of air
pollution. These important findings provide a plausible mech¬
anism that links air pollution to the pathogenesis of alhero
thrombosis and acute myocardial infarction.
Vasomotor Function
Impaired endolhelium-dependent and -independent vasomo¬
tor function in the forearm vascular bed is associated with an
increased risk of acute cardiovascular events, including car¬
diac death.12 We have demonstrated that inhalation of diesel
exhaust impairs vasomotor responses to both endothelium
dependent and -independent vasodilators at 6 hours. On the
basis of this initial study, it is unclear whether the impairment
is primarily mediated by the vascular endothelium or is a
result of smooth muscle dysfunction. However, reduced NO
bioavailability in the presence of increased systemic or
vascular oxidative stress is an attractive hypothesis.
The endothelium is a major target of oxidative stress, and
this interaction plays an important role in the pathophysiol¬
ogy of vascular disease.20 Superoxide radicals, produced as a
consequence of oxidative stress, combine with NO to form
peroxynitrite, thus reducing NO bioavailability in the vessel
wall and shifting the balance toward vasoconstriction. In
vascular smooth muscle cells, superoxide inhibits the activity
of enzymes such as soluble guanylyl cyclase21 and cGMP-
dependent protein kinase,22 thereby reducing both endotheli-
um-dependent and -independent NO-mediated vasodilation.
We hypothesized that our initial findings were due to the
oxidative effects of diesel exhaust, and as such, vascular
impairment would occur early. In the subsequent study, we
have demonstrated an acute impairment to endothelium-
dependent and -independent vasodilators, but we were also
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Figure 1. Infused FBF in subjects 2 to 4
hours after diesel exposure (•) and air
(o) during intrabrachial infusion of brady¬
kinin, acetylcholine, sodium nitroprus-
side, and verapamil. For all dose
responses, P<0.0001. For diesel expo¬
sure (•) vs air (o), bradykinin P<0.05,
acetylcholine P<0.05, sodium nitroprus-
side P<0.001, and verapamil P=NS.
able to show that vasodilation to the calcium channel antag¬
onist verapamil was unaffected. This suggests that the mech¬
anism of vascular dysfunction involves increased consump¬
tion of NO, whether it be endogenously derived from
endothelial NO synthase or from an exogenous source, such
as sodium nitroprusside. Indeed, in vitro studies provide
support for this mechanism, with Ikeda el al23 demonstrating
that incubation of aortic ring preparations with diesel exhaust
particles resulted in a dose-dependent inhibition of
acetylcholine-mediated relaxation, an effect abolished by
coincubation with superoxide dismutase.
Our findings of an acute effect of exposure to air pollution
are consistent with recent epidemiological studies that report
a significant increase in risk of acute myocardial infarction as
little as 2 hours after exposure to road traffic8 or an increase
in PMiy.1 Our studies add to those of Brook et al,24 who
demonstrated a reduction in brachial artery diameter imme¬
diately after exposure to a mixture of concentrated ambient
particles and ozone. In contrast, they did not find an effect on
endothelium-dependent or -independent vasodilation by
flow-mediated and nitroglycerine-induced dilation. This may
relied differences in the potency of the pollution models used
or the technique used to assess vascular function. Exposures
to concentrated ambient particulates are inherently variable in
magnitude and composition, whereas in our study, each
volunteer received a standard exposure to combustion-
derived particulates of known toxicity. Alternatively, it is
possible that the vascular effects of particulate matter are
mediated primarily in the resistance vessels, as assessed by
plethysmography, rather than in the conduit arteries, as
assessed by ultrasound of the brachial artery.
Fibrinolytic Function
Acute endogenous t-PA release from the endothelium regulates
the dissolution of intravascular thrombus and is a critical
determinant of cardiovascular outcome. This is exemplified by
the clinical observation that in =30% of patients with acute
myocardial infarction, spontaneous reperfusion occurs within 12
hours of vessel occlusion. The increased risk of atherothrombo-
sis and myocardial infarction in cigarette smokers is at least in
part explained by impaired fibrinolytic capacity.1" '1
We have described an impairment in acute endogenous
fibrinolytic capacity after diesel exhaust inhalation. This
abnormality may have prothrombotic consequences that
could plausibly result in acute cardiovascular events.8 t-PA
release was reduced 6 hours after exposure but not at the
earlier time point, suggesting that this impairment is mediated
by an inducible pathway or a change in protein synthesis.
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Figure 2. Infused FBF in subjects 6 to 8
hours after diesel exposure (•) and air
(o) during intrabrachial infusion of brady¬
kinin, acetylcholine, and sodium nitro¬
prusside. For all dose responses,
P<0.0001. For diesel exposure (•) vs air
(o), bradykinin P<0.05, acetylcholine
P=0.07, and sodium nitroprusside
P<0.001.
Indeed, culture of human umbilical vein endothelial cells with
particulate matter for 6 hours inhibits both the synthesis and
release of t-PA in a dose-dependent manner.25 Ciiven that
cigarette smoking and air pollution share common toxicolog-
ical properties, the present findings are consistent with
previous observations in the peripheral"' and coronary"
circulations of cigarette smokers and suggest a potential
common etiologic factor.
TABLE 3. Plasma t-PA Antigen Concentrations After Air and Diesel Exposure
Air (Bradykinin, pmol/min) Diesel (Bradykinin, pmol/min)

























































































Values are reported as mean±SEM.
AN0VA (dose response), *P<0.0001; AN0VA (air vs diesel), fP<0.05, tP<0.001.


















Figure 3. Net release of t-PA antigen in subjects 6 hours after
diesel exposure (•) and air (o) during intrabrachial infusion of
bradykinin. For both dose responses, P<0.0001. For diesel
exposure (•) vs air (o), P<0.05.
Air Pollution, Oxidative Stress, and Inflammation
A substantial body of evidence supports a role for oxidative
stress in determining the toxicity of ambient pollution26 and
in the proinflammatory effects of diesel exhaust particles.27-2S
Reactive oxidant species arise not only from the redox
potential of the pollutants themselves but also from the
activation of alveolar epithelial cells or resident macrophage
and the recruitment of circulating neutrophils.
The potential for inhaled nanopartieulate air pollution to
cause local inflammation is not in doubt, and airway neutro¬
philia has been demonstrated in a healthy volunteer study
with the same concentration of diesel particulate and expo¬
sure system.15 In our study, inhaled diesel exhaust was not
associated with an increase in blood leukocytes, plasma 1L-6
and TNF-a, or serum CRP concentrations, but this does not
rule out the influence of other circulating inflammatory
factors, oxidized lipids, or proteins.
Population Risk and Exposure
As an important source of combustion-derived particulate,
diesel exhaust is strongly implicated in the observed adverse
effects of air pollution.4-29-30 Particulate matter concentrations
can regularly reach levels of 300 p.g/m3 in heavy traffic,
occupational settings, and the world's largest cities.31 Expo¬
sure to 300 p.g/m3 for 1 hour increases a person's average
exposure during a 24-hour period by only 12 pg/m3. Changes
of this magnitude occur on a daily basis in even the least
polluted of cities and are associated with increases in cardio¬
respiratory mortality.3 Our model is therefore relevant in both
the composition and magnitude of exposure for the assess¬
ment of short-term health effects in humans.
Diesel exhaust is a complex mixture of gases and particles,
and from our findings, we cannot exclude a nonparliculate
cause of the adverse vascular effects. However, in epidemi¬
ological studies, particulate matter has been held responsible
for the majority of the adverse health effects of air pollution.32
Ambient N02 can be considered a surrogate for traffic-
derived pollution,29 but it has little adverse effect in con¬
trolled chamber studies, even at the exposure levels seen
here.33 There are no reports of the potential adverse cardio¬
vascular effects of toxins such as hydrocarbons or formalde¬
hyde. We therefore suggest that the vascular effects described
herein are mediated primarily by diesel exhaust particulates
and not its other components, but this needs to be more
definitively addressed.
Conclusions
Exposure to increased levels of combustion-derived air pol¬
lution for as little as I hour can impair vasomotor function
and endogenous fibrinolysis in humans. We provide evidence
that this may be the result of reduced NO bioavailability in
the vasculature and postulate that this effect is mediated by
oxidative stress induced by the nanoparliculate fraction of
diesel exhaust. These data provide a plausible mechanistic
link to explain the association between air pollution and acute
myocardial infarction.
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CLINICAL PERSPECTIVE
Air pollution is a serious problem in the world's major cities owing to the combustion of fossil fuels such as diesel oil. In
particular, there has been recent interest in the consistent association between increased levels of air pollution and
cardiovascular morbidity and mortality. The World Health Organization estimates that a quarter of the world's population
is exposed to unhealthy concentrations of air pollutants. The American Heart Association recently issued a scientific
statement highlighting the increased cardiovascular risk associated with exposure to air pollution and emphasized the
importance of establishing a mechanistic link to explain these epidemiological observations. We have previously
demonstrated vascular dysfunction in cigarette smokers. Because combustion products and particulate matter are common
to both polluted air and cigarette smoke, we hypothesized that air pollution would cause detrimental vascular effects. This
is the first study to demonstrate that inhalation of diesel exhaust, a common urban air pollutant, can impair vascular
function in humans. Using a double-blind, randomized, cross-over study design, we have assessed the effects of diesel
exhaust inhalation on 2 important and complementary aspects of vascular function: the regulation of vascular tone and
endogenous fibrinolysis. We were able to demonstrate that both are impaired and plausibly related to the well-documented
adverse cardiovascular effects of air pollution. These important findings provide a plausible mechanism that links air
pollution to the pathogenesis of atherothrombosis and acute myocardial infarction.
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Rationale-. Exposure to combustion-derived air pollution is associ¬
ated with an early (1-2 h) and sustained (24 h) rise in cardiovascular
morbidity and mortality. We have previously demonstrated that
inhalation of diesel exhaust causes an immediate (within 2 h) im¬
pairment of vascular and endothelial function in humans
Objectives: To investigate the vascular and systemic effects of diesel
exhaust in humans 24 hours after inhalation.
Methods- Fifteen healthy men were exposed to dicsel exhaust (par
ticulate concentration, 300 pg/m!) or filtered air for 1 hour in a
Houhle-hlind, randomized, crossover study I wenty tour hours after
exposure, bilateral forearm blood flow, and inflammatory and fi¬
brinolytic markers were measured before and during unilateral
intrahrachial hradykinin (100-1,000 pmol/min), acetylcholine (5-
zu ng/min'), sodium niiroprusside (2-8 pg/'min), and verapamil
(10-100 nq/min) infusions
Measurements and Main Results: Resting forearm blood flow, blood
pressure, and basal fibrinolytic markers were similar 24 hours after
either exposure. Diesel exhaust increased plasma cytokine concen¬
trations (tumor necrosis factor-ix and interleukin-6, p < 0.05 for
both) but appeared to reduce acetylcholine (p = 0.01), and brady-
kinin (p = 0.08) induced forearm vasodilatation. In contrast, there
were no differences in either endothelium-independent (sodium
nitroprusside and verapamil) vasodilatation or bradykinin-induced
acute plasma tissue plasminogen activator release.
Conclusions: Twenty-four hours after diesel exposure, there is a se¬
lective and persistent impairment of endothelium-dependent vaso¬
dilatation that occurs in the presence of mild systemic inflammation.
These findings suggest that combustion-derived air pollution may
have important systemic and adverse vascular effects for at least
24 hours after exposure.
Keywords: air pollution; endothelium; blood flow; inflammation; diesel
exhaust
The link between ambient particulate matter (PM), air pollution,
and increased cardiorespiratory mortality and morbidity is well
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The link between ambient particulate matter air pollution
and cardiorespiratory mortality and morbidity is well estab¬
lished. However, the biological mechanisms underlying the
cardiovascular effects of particulate matter air pollution
are largely unknown.
What This Study Adds to the Field
Exposure to diesel exhaust causes a selective impairment
of vascular endothelial function, which persists Up to 24
hours after exposure. Adverse cardiovascular effects of
combustion-derived pollution may be mediated through
prolonged detrimental vascular effects.
established (1). Short-term exposure to traffic and ambient air
pollution is associated with an increased risk of early (1-2 h)
and delayed (24 h) presentation with acute myocardial infarction
(2, 3), or rehospitalization for myocardial ischemia in patients
with prior myocardial infarction (4). Long-term repeated expo¬
sure to PM pollution increases the risk of cardiovascular mortal¬
ity, with deaths attributable to ischemic heart disease, arrhyth¬
mia, heart failure, and cardiac arrest (3-7). These associations
are strongest for fine particulate air pollutants (=s 2.5 (im in
diameter; PM25) (8). Diesel exhaust emissions are a significant
source of PM2iS in urban environments, particularly in Europe
where the use of diesel engines in transport has increased steadily
in recent years (9). As a consequence, diesel exhaust exposures
have been used as models of PM pollution in experimental stud¬
ies (10-12).
The biological mechanisms underlying the cardiovascular ef¬
fects of PM air pollution are largely unknown, although it has
been suggested that pulmonary inflammation results in systemic
consequences that adversely affect the cardiovascular system
(13). In vitro studies, animal models, and human exposures have
clearly established the oxidant and proinflammatory nature of
combustion-derived PM and implied a role for oxidative stress
in determining the toxicity of ambient air pollution and the
proinflammatory effects of diesel exhaust particulates (14-16).
At levels encountered in an urban environment, we have pre¬
viously demonstrated that exposure to diesel exhaust causes
pronounced airway inflammation, including recruitment of in¬
flammatory cells, the up-regulation of vascular endothelial adhe¬
sion molecules, and the enhanced epithelial expression of cyto¬
kines. These effects are associated with the up-regulation of
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important oxidative stress-related transcription factors and
mitogen-activated protein (MAP) kinases in the bronchial epi¬
thelium (l'l, 12, 17-20).
Endothelial dysfunction is widely considered to represent the
earliest pathologic process in atherosclerosis (21), with estab¬
lished risk factors for cardiovascular disease adversely affecting
endothelial function (22,23). In recent studies, we have demon¬
strated an immediate impairment of vascular and endogenous
fibrinolytic function in young healthy volunteers after exposure
to diesel exhaust (24). In the absence of systemic inflammation
up to 6 hours after exposure, we suggested that these early vascular
effects were determined by oxidative stress. The duration of these
adverse vascular effects are unknown, and the potential for devel¬
oping later pulmonary and systemic inflammatory effects to po¬
tentiate vascular dysfunction requires further investigation.
The aim of the present study was to investigate whether there
is systemic inflammation and sustained vascular dysfunction in
healthy volunteers 24 hours after exposure to diesel exhaust.
METHODS
Study Design
Fifteen healthy male nonsniokers (mean age. 26 yr; range, 18-38 yr)
participated in the study. Subjects were exposed to filtered ambient air
or diesel exhaust at a particulate concentration of 300 p.g/m', in a
randomized, double-blind, crossover fashion for 1 hour, according to
a previously described standard protocol (11). During each exposure,
subjects alternated moderate exercise on a bicycle ergometer and rest
at 15-minute intervals. Vascular assessments were performed 24 hours
after each exposure, with at least 2 weeks allowed between exposures.
Subjects also underwent an identical vascular assessment 2 to 4 hours
after each exposure; the results of this assessment are reported in
full elsewhere (24). The study was performed in accordance with the
Declaration ofHelsinki, with the approval of the local ethics committee,
and with the written, informed consent of each volunteer.
Diesel Exposure
The diesel exhaust was generated from an idling Volvo diesel engine
as described previously (10, 11). The air in the exposure chamber was
continuously monitored for gaseous pollutants, with exposures stan¬
dardized on levels of nitrogen oxides to deliver a particulate concentra¬
tion of 300 pg/m'. The temperature and humidity in the chamber were
controlled at 20°C and 50%, respectively.
Vascular Study
The vascular studies were carried out in a quiet temperature-controlled
room (22°-24°C) with subjects resting in the supine position. All subjects
underwent unilateral brachial artery cannulation with a 27-standard
wire gauge steel needle under controlled conditions. After a 30-minute
saline infusion, acetylcholine at 5, 10, and 20 pg/minute (endothelium-
dependent vasodilator that does not release tissue plasminogen activator
[t-PA]); bradykinin at 100, 300, and 1,000 pmol/minute (endothelium-
dependent vasodilator that releases t-PA); and sodium nitroprusside
at 2, 4, and 8 pg/minute (endothelium-independent vasodilator that
does not release t-PA) were infused for 6 minutes at each dose. The
three vasodilators were separated by 20-minute saline infusions and
given in a randomized order. Verapamil at 10, 30, and 100 pg/minute
(endothelium and nitric oxide-independent vasodilator that does not
release t-PA) was infused for 6 minutes at each dose at the end of the
study protocol (25). Forearm blood flow was measured in both arms
by venous occlusion plethysmography as described previously (23).
Supine heart rate and blood pressure in the noninfused arm were
monitored at regular intervals.
Venous cannulae (17-gauge) were inserted into both arms. Blood
was drawn simultaneously from each arm at baseline and during the
infusion of each dose of bradykinin, and collected for estimation of
plasma t-PA and plasminogen activator inhibitor type 1 (PA1-1) concen¬
trations. Hematocrit was determined at baseline and after infusion of
bradykinin at 1,000 pmol/minute.
Systemic Inflammation and Oxidative Stress
Blood samples were taken before and 24 hours after the exposure and
analyzed for total cells and differential and platelet counts. Plasma and
serum were prepared for the measurement of cytokines (tumor necrosis
factor JTNFJ-o, 1L-6), C-reactive protein, nitrite, total antioxidant ca¬
pacity of plasma, soluble P-selectin, and soluble intercellular adhesion
molecule 1 (slCAM-1). Diesel exhaust particles were collected on Teflon
filters during exposures, and electron paramagnetic resonance (EPR)
was used to establish the oxidative radical generation of particulate
(see the online supplement for details).
Data Analysis and Statistics
Plethysmography data were analyzed as described previously (23).
Estimated net release of t-PA antigen was defined as the product of
the infused forearm plasma flow and the concentration difference be¬
tween the infused and noninfused arms (26). Continuous variables are
reported as mean ± SEM. Statistical analyses were performed with
GraphPad Prism (Graph Pad Software, Inc., San Diego, CA) using
analysis of variance with repeated measures and two-tailed Student's
I test where appropriate. Statistical significance was taken at p < 0.05.
RESULTS
There were no differences in resting heart rate, blood pressure,
or baseline forearm blood flow between or during the two study-
visits (Table 1).
Vascular Function
After both air and diesel exhaust exposures, there were dose-
dependent increases in the infused forearm blood flow with all
vasodilators (p < 0.001 for all). After exposure to diesel exhaust,
endothelium-dependent vasodilatation was reduced with acetyl¬
choline (p = 0.01) and appeared to be reduced with bradykinin
(p = 0.08; Figure 1). In contrast, there were no effects on endothe-
lium-independent vasodilatation: peak blood flow responses to
sodium nitroprusside (14.2 ± 1.2 vs. 12.8 ± 0.8 ml/100 ml/min)
and verapamil (14.6 ± 0.9 vs. 13.4 ± 0.9 ml/100 ml/min) were
similar.
Venous plasma concentrations of nitrite were not effected
by exposure (Table 2).
Bradykinin caused a dose-dependent increase in plasma
t-PA concentrations (p < 0.001; Table 3), which was unaffected
by diesel exhaust exposure. The estimated net t-PA antigen
release was similar after exposure to both diesel exhaust and
filtered air (Figure 2).
All subjects also underwent an identical early vascular assess¬
ment at 2 to 4 hours after exposure, the results of which are
published in full elsewhere (24). Peak forearm blood flow re¬
sponse to endothelium-dependent vasodilators correlates well
between the early (2^1 h) and late (24-26 h) vascular assessments
for bradykinin (r = 0.60, p < 0.05) and acetylcholine (r = 0.72,
p < 0.05). There was also a relationship between the magnitude
of impairment caused by exposure to diesel exhaust (difference
between peak forearm blood flow after diesel exhaust and filtered
TABLE 1. BASELINE HEMODYNAMIC VARIABLES 24 HOURS
AFTER EXPOSURE
Air Diesel Significance
Heart rate, beats/min 62 2 61 ± 2 p = 0.73
Systolic blood pressure, mm Hg 144 -+- 3 143 ± 3 p = 0.63
Diastolic blood pressure, mm Hg 71 ± 2 75 ± 2 p = 0.16
Infused FBF, ml/100 ml tissue/min 3.6 ± 0.5 3.2 ± 0.4 p = 0.15
Noninfused FBF, ml/100 ml tissue/min 2.5 0.2 2.7 0.2 p = 0.48
Definition of abbreviation-. FBF — forearm blooci flow.
Values are reported as mean ± SEM, two-tailed paired t test.
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Figure 1. Infused forearm blood flow in subjects after
diesel exposure (solid circles) and filtered air (open circles)
during intrabrachial infusion of bradykinin and acetyl¬
choline. p < 0.001 for all dose responses in the infused
arm. For diesel exposure versus air: bradykinin (p =




air) at the early and late time points for bradykinin (r ~ 0.58,
p < 0.05), but not for the other vasodilators.
Systemic Inflammation and Oxidative Stress
Twenty-foui hours after the exposures, there were no differences
in leukocyte and neutrophil counts or plasma sICAM-1, t-PA,
and PAI-1 antigen concentrations (Table 2). Exposure to diesel
exhaust increased plasma IL-6 (2.2 ± 0.2 vs. 1.5 ± 0.2 pg/ml, p =
0.02) and TNF a (0.99 ± 0.07 vs. 0.88 ± 0.07 pg/ml, p - 0.02)
concentrations compared with air. Total platelet numbers were
not affected by exposure, but concentrations of soluble P-selectin
were increased 24 hours after exposure to diesel exhaust (3fS.5 ±
1 4 vs. 37 7 ± 1.8 ng/ml, p = 0.02). Total antioxidant capacity
of plasma (TEAC [Trolox equivalent antioxidant capacity]) was
also greater 24 hours after exposure to diesel exhaust compared
with filtered air (Table 2).
The majority of inflammatory markers were significantly re¬
duced at 24 hours when compared with baseline after exposure
to both filtered air and diesel exhaust. This consistent response
across exposures is due to an effect of one or more of the study
interventions, which included a period of aerobic exercise, a
TABLE 2. SYSTEMIC EFFECTS 24 HOURS AFTER EXPOSURE
TO AIR AND DIESEL EXHAUST
Air Diesel Significance
Leukocytes, x 109 cells/L 5.2 ± 0.4 5.2 0.3 0.84
Neutrophils, x 109 cells/L 2.8 ± 0.2 2.8 ± 0.2 0.57
IL-6, pg/ml 1.5 ± 0.2 2.2 0.2 0.02
TNF-a, pg/ml 0.88 ± 0.07 0.99 0.07 0.02
CRP, fi.g/ml 0.75 ± 0.20 0.70 0.19 0.97
sICAM-1, ng/ml 171 ± 6 181 + 8 0.76
Nitrite, nM 108.1 ± 6.8 117.7 8.1 0.45
TEAC, mM 6.0 ± 0.2 7.1 ± 0.3 0.003
sP-selectin, ng/ml 33.7 1.8 36.5 ± 1.4 0.02
Platelets, x 109 cells/L 221 ± 12 219 ± 14 0.57
t-PA antigen, ng/ml 5.9 ± 0.5 6.2 ± 0.6 0.63
PAI-1 antigen, ng/ml 16.8 ± 2.1 19.8 -F 3.5 0.45
Definition of abbreviations: CRP = C-reactive protein; IL-6 = interleukin-6;
PAI-1 - plasminogen activator-1; sICAM-1 = soluble intercellular adhesion mole¬
cule 1; sP-selectin = soluble P-selectin; TEAC = Trolox equivalent antioxidant
capacity; t-PA = tissue plasminogen activator; TNF-ot = tumor necrosis factor-u.
Values are reported as mean ± SEM.
regulated healthy diet, a prolonged fast, and repeated blood
sampling. Significant differences between exposures occurred
with absolute measures at 24 hours and change from baseline
in IL-6, TNF-a, TEAC, and soluble P-selectin concentrations
were consistent and clue to modification of these pathways
evoked by exposure to diesel exhaust. These data are presented
in full in the online supplement.
Suspensions of diesel exhaust particles showed a time-
dependent increase in the characteristic three peak EPR spec
trum for a spin-adduct with the unpaired electron in the vicinity
of a nitrogen atom (i.e., 4 oxo tempo, the oxidized form of
Tempnne-Ff) (Figure 7a) The signal increased at a constant rate
over the 60 minute period. EPR measurements wore approxi
matcly fivefold higher in suspensions that contained diesel filters
(blank, 1,144 units; diesel, 5,864 units: t = 60 min; Figure 3b).
Superoxide dismutase (SOD) inhibited the EPR signal from
diesel, causing a 30.2% reduction in signal. This concentration
of SOD had a similar magnitude of cflcct on the diesel signal
TABLE 3. FOREARM BLOOD FLOW AND PLASMA TISSUE
PLASMINOGEN ACTIVATOR ANTIGEN CONCENTRATIONS
Bradykinin (pmol/min)
0 100 300 1,000
Air
FBF, ml/100 ml/min
Noninfused arm 2.2 ± 0.2 2.3 ± 0.2 2.2 0.1 2.6 -4- 0.3
Infused arm 4.8 ± 1.0 12.3 ± 1.4 14.8 ± 1.5 20.2 ± 2.0*
t-PA antigen, ng/ml
Noninfused arm 6.2 0.5 6.0 ± 0.5 6.0 ± 0.6 7.8 + 0.6
Infused arm 6.0 ± 0.5 7.9 ± 0.7 10.1 ± 0.8 14.0 ± 0.9*
Diesel
FBF, ml/100 ml/min
Noninfused arm 2.6 ± 0.3 2.6 ± 0.2 2.5 ± 0.2 2.5 ± 0.3
Infused arm 4.1 ± 0.7 10.7 ± 1.0 13.8 ± 1.1 18.8 ± 1.2*
t-PA antigen, ng/ml
Noninfused arm 6.0 ± 0.6 6.4 ± 0.5 6.7 ± 0.6 8.4 ± 0.6
Infused arm 6.2 ± 0.6 7.8 ± 0.7 10.6 ± 1.0 14.7 ± 1.3*
Definition of abbreviations: FBF - forearm blood flow; t-PA = tissue plasminogen
activator.
Values are reported as mean ± SEM.
*
p < 0.001, analysis of variance (dose response).




















Figure 2. Net release of tissue plasminogen activator (t-PA) antigen in
subjects after diesel exposure (solid circles) and filtered air (open circles)
during intrabrachial infusion of bradykinin. p < 0.001 for both dose
responses, p = 0.34, diesel exposure versus air.
as il did to thai of the superoxide generator pyrogallol (34.7%
reduction; Figure 3b).
DISCUSSION
Twenty-four hours after a transient 1-h exposure to diesel ex¬
haust, there is a selective and persistent impairment of endothelium-
dependent vasodilatation that occurs in the presence of mild
systemic inflammation after a period ofpotential oxidative stress.
These findings suggest that combustion-derived air pollution
may have important adverse systemic and vascular effects for
at least 24 hours after exposure. This may accounl for the epide¬
miologic observations of recent time-series studies suggesting
both an acute (1-2 h) and a sustained peak in adverse cardiovas¬
cular outcomes after exposure to air pollution.
Exposure to air pollution causes airway inflammation and
has an important negative effect on respiratory health. Diesel
exhaust causes neutrophilic airway inflammation 6 to 24 hours
after exposure (11.12,27), increases airway antioxidant defenses,
and activates redox-sensitive transcription factors in vivo, consis¬
tent with oxidative stress-induced and cytokine-niediated in¬
flammation (20, 28). It is increasingly recognized that these ef¬
fects may induce important systemic effects (12, 29), including
vascular inflammation (30).
We hypothesized that our initial observations of an imme¬
diate (within 2 h) impairment of vascular function were due
to the oxidative effects of diesel exhaust (24). After exposure
to diesel exhaust, endothelium-dependent and endothelium-
independent nitric oxide donors caused reduced vasodilatation,
whereas the endothelium- and nitric oxide-independent vasodi¬
lator verapamil caused normal vasodilatation. This pattern of
vascular dysfunction suggested increased consumption of nitric
oxide, whether it be endogenously derived from endothelial ni¬
tric oxide synthase or from an exogenous source, such as sodium
nitroprusside.
In the current study, we demonstrate a persistent endothelium-
dependent vascular dysfunction 24 hours after an hour-long expo¬
sure to diesel exhaust. Although vasodilatation to both endothe¬
lium-dependent agonists appeared to be impaired, this only
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Figure 3. (a) Sample electron paramagnetic resonance (EPR) spectra
generated from suspensions of blank and dicscl particulate coated fil¬
ters, as well as the superoxide generator pyrogallol. EPR spectra were
generated in the presence (grey lines) and absence (black lines) of super¬
oxide dismutase (SOD), (b) Amplitude of EPR spectra (in arbitrary units)
over a 60-minute incubation period in the presence (open symbols) and
absence (closed symbols) of SOD. Diesel particulate (square symbols)
caused a large increase in EPR intensity in comparison to suspension from
the blank filter (circles). SOD caused an approximate 30% reduction in
the EPR signal from diesel particulate and a similar reduction in signal
to the superoxide generator pyrogallol (diamonds).
reached statistical significance for acetylcholine. Bradykinin
causes vasodilatation through the release of various endothelium-
derived factors, including nitric oxide, although it is believed that
hyperpolarizing factor is the primary mediator of this response in
humans (31). It is possible that differences in acetylcholine-
and bradykinin-mediated vasodilatation may be explained by
variation in the relative contribution of nitric oxide to the vaso¬
motor response of these agonists. The mechanism of this selec¬
tive impairment of endothelium-dependent vasodilatation has
not been determined, but we suggest that this may be due to
modification of endothelial homeostatic pathways after an initial
oxidative burst.
The role of vascular oxidative stress in mediating endothelial
dysfunction in this clinical model requires confirmation. How¬
ever, the mechanism is supported by in vitro studies (32-34), as
well as human exposure studies by our own group (25) and
others (35).
The endothelium is a major target of oxidative stress and this
interaction plays an important role in the pathophysiology of
vascular disease (36). Incubation of aortic ring preparations with
diesel exhaust particles inhibits acetylcboline-mediated relax¬
ation, an effect that can be reversed by coincubation with the
free radical scavenger SOD (32). Furthermore, diesel exhaust
particles can induce oxidative modification of low-density lipo¬
protein, themajor determinant of atheromatous vascular disease
(37).
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Diesel exhaust is a complex mixture of gases and particles,
and from our findings we cannot exclude a role for nonparliculate
or soluble components. The mo3t abundant gaseous pollutants
produced in the combustion of diesel fuel are oxides of nitrogen.
In epidemiologic studies, ambient nitrogen dioxide (NCb) is con
sideieii a suiiogutc for traffic-derived pollution, with PM held
responsible for the majority of the adverse health effects of air
pollution (38). Although the direct effect of N02 on vascular
function has not been studied to date, exposure to N02 alone
at a higher concentration and for a longer duration than used
here docs not induce an inflammatory response in the airway
mucosa (39). In contrast, exposure to dilute dicscl exhaust for
1 hour at similar particulate concentrations to the present study
lesulted in pronounced airway mucosal inflammation with up
regulation of neutrophils, mast cells, and T lymphocytes (11).
Allliuugli this suggests that the particulate phuse of dilute dicsel
exhaust is responsible for the adverse inflammatory (11) and
vascular effects of diesel exhaust (24), further proof is required
with additional control exposures to nitrogen oxides und filtered
diesel exhaust. Recent findings by Campen and colleagues, in
which incubation with soluble components of diesel exhaust
caused vascular dysfunction in isolated coronary artery rings
from mice, highlight the need for further controlled exposure
studies (40).
Whether diescl particulates or soluble components of the
exposure, including organic hydrocarbons and transition metals,
can directly affect the systemic vascular endothelium after inha¬
lation also requires clarification. Although evidence that inhaled
nanoparticles can translocate into the circulation in humans re¬
mains controversial (41,42), it is not in doubt that diesel exhaust
particulates are capable of inducing oxidative stress in vitro, with
reactive oxidant species arising from the redox potential of the
particles themselves and from the activation of inflammatory
cells. Using EPR, we demonstrate that diesel exhaust particulate
is capable of generating oxidative free radicals without prior interac¬
tion with pulmonary or vascular tissue. Furthermore, coincubation
of diesel particles with SOD partially prevented this response,
indicating a contribution of superoxide to this oxidative signal.
However, measuring systemic oxidative stress in vivo is difficult,
because the oxidative state is modulated by a range of antioxi¬
dant defenses (17). Interestingly, we demonstrate an increase in
the antioxidant capacity of plasma 24 hours after exposure to
diesel exhaust, perhaps suggesting up-regulation of antioxidant
defense mechanisms after earlier systemic oxidative stress.
In contrast to our previous study, stimulated release of endo¬
thelial t-PA from the forearm circulation was not impaired at
24 hours (24). In health, the vascular endothelium delicately
balances regulatory pathways controlling coagulation, fibrinoly¬
sis, and inflammation, as well as regulating vascular tone. It is
perhaps not surprising that these complex dynamic functions are
altered by exposure to diesel exhaust at different time points.
Endogenous fibrinolytic function was impaired at 6 to 8 hours
in our previous studies, but normalized at 24 hours, suggesting
that this aspect of endothelial homeostasis recovers earlier than
vasomotor function after exposure to air pollution.
We did not find evidence of a systemic cellular inflammatory
response, but we did identify changes in proinflammatory cyto¬
kines IL-6 and TNF-tx, raising the possibility that ongoing airway
inflammation is contributing to the state of vascular dysfunction.
Observational studies have strongly implicated systemic inflamma¬
tion as a key pathological mechanism in the health effects of
PM (7). In panel and population studies, increased PM exposure
is associated with an acute-phase response with raised serum
C-reactive protein concentrations (43), increased plasma viscos¬
ity (44), as well as altered hematologic indices (45) and plasma
fibrinogen (46,47). It is possible that, in a susceptible population.
in which inflammatory pathways may be up-regulated and anti
oxidant defenses may be depleted, an hour-long exposure to
diesel exhaust would be sufficient to cause a greater systemic
inflammatory response. Likewise, repeated exposure over a
number of days or weeks may result in inflammation, with pro
longed vascular dysfunction contributing to the pathogenesis of
atherosclerosis. Indeed, in an apolipoprotein E-deficient (apoE ')
mouse model, long term exposure to low concentrations of PM^,
altered vasomotor lone, induced vascular inflammation, and
potentiated atherosclerosis (30).
Endothelial dysfunction, characterized as an impaired vasodi
latation to acetylcholine, predicts the likelihood of future cardio
vascular events und death in patients with coronary artery dis
ease (48) and in al risk individuals with normal coronary arteries
(49). Although the mechanism of this association has not been
precisely identified, this vascular dysfunction clearly has impor
tant clinical implications. Our findings of endothelial dysfunction
24 hours after diesel exhaust inhalation suggest that the adverse
cardiovascular effects of combustion derived air pollution are
mediated through persistent detrimental vascular effects.
Conclusions
In healthy volunteers, inhalation of diesel exhaust for 1 hour,
at particle concentrations encountered in an urban setting, causes
mild systemic inflammation and an impairment of vascular endo¬
thelial function that persisted for up to 24 hours after the expo
sure. This occurred in the absence of alterations in endogenous
fibrinolytic capacity. These findings provide a plausible explana
lion for the observed increase in acute cardiovascular events
24 hours after a peak in traffic-related PM air pollution.
Conflict of Interest Statement: None of the authors has a financial relationship
with a commercial entity that has an interest in the subject of this manuscript.
Acknowledgment: The authors thank Pamela Dawson, Chris Ludlam, Frida
Holmstrom, Annika lohansson, Maj-Cari Ledin, Jamshid Pourazar, Ann-Britt
Lundstrom, Margot Johansson, Mona Svensson, Ester Roos-Engstrand, and all the
staff in the Department of Respiratory Medicine and Allergy and Clinical Research
Facility, University Hospital, Umea, and Wellcome Trust Clinical Research Facility,
Edinburgh, for their assistance with the studies.
References
1. Brunekreef B, Holgate ST. Air pollution and health. Lancet 2002;360:
1233-1242.
2. Peters A, Doekery DW, Muller JE, Miltleman MA. Increased particulate
air pollution and the triggering of myocardial infarction. Circulation
2001;103:2810-2815.
3. Peters A, von Klot S, Heier M, Trentinaglia I, Hormann A, Wichmann
HE. Lowel H: Cooperative Health Research in the Region of Augs¬
burg Study Group. Exposure to traffic and the onset of myocardial
infarction. N Engl J Med 2004;351:1721-1730.
4. von Klot S, Peters A, Aatto P. Bcllander T, Berglind N, DTppoliti D,
Elosua R. Hormann A, Kulmala M. Lanki T, et al., for the Health
Effects of Particles on Susceptible Subpopulations (HEAPSS) Study
Group. Ambient air pollution is associated with increased risk of
hospital cardiac readmissions of myocardial infarction survivors in live
European cities. Circulation 2005;112:3073-3079.
5. Hock G, Brunekreef B, Goldbohm S. Fischer P, van den Brandt PA.
Association between mortality and indicators of traffic-related air pol¬
lution in the Netherlands: a cohort study. Lancet 2002;360:1203-1209.
6. Pope CA 111, Burnett RT, Thurston GD. Thun MJ, Calle EE, Krewski
D. Godleski JJ. Cardiovascular mortality and long-term exposure to
particulate air pollution, epidemiological evidence of general patho¬
physiological pathways of disease. Circulation 2004;109:71-77.
7. Brook RD. Franklin B, Cascio W, Hong Y. Howard G, Lipsett M,
Luepker R, Mittleman M, Samet J, Smith SC Jr, et al. Air pollution
and cardiovascular disease: a statement for healthcare professionals
from the Expert Panel on Population and Prevention Science of the
American Heart Association. Circulation 2004;109:2655-2671.
8. Laden F. Neas LM, Dockery DW, Schwartz J. Association of fine particu¬
late matter from different sources with daily mortality in six EJ.S. cities.
Environ Health Perspect 2000;108:941-947.
400 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 1 76 2007
9. Charron A, Harrison RM. Fine (PM2J) and coarse (PM^u) particulate
matter on a heavily trafficked London highway: sources and processes.
Environ Sci TechnoI 2005;39:7768-7776.
10. Rudell B, Sandstrom T, Hammarstrom U, Ledin ML, Horstedt P,
Sternberg N. Evaluation of an exposure setup for studying effects of
diesel exhaust in humans, hit Arch Occup Environ Health 1994;66:
77-83.
11. Salvi S, Blomberg A, Rudell B, Kelly F, Sandstrom T, Holgate ST, Frew
A. Acute inflammatory responses in the airways and peripheral blood
after short-term exposure to diesel exhaust in healthy human volun¬
teers. Am J Respir Crit Care Med 1999;159:702-709.
12. Stenfors N. Nordenhall C, Salvi SS, Mudway 1, Soderberg M, Blomberg
A, Helleday R, Levin JO, Holgate ST, Kelly FJ, et al. Different airway
inflammatory responses in asthmatic and healthy humans exposed to
diesel. Eur Respir J 2004;23:82-86.
13. Seaton A, MacNee W, Donaldson K, Goclden D. Particulate air pollution
and acute health effects. Lancet 1995;345:176-178.
14. Donaldson K, Stone V, Borm PJ, Jimenez LA, Gilmour PS, Schins RP,
Knaapen AM. Rahman 1, Faux SP, Brown DM, et al. Oxidative stress
and calcium signaling in the adverse effects of environmental particles
(PM,„). Free Radic Biol Med 2003;34:1369-1382.
15. Donaldson K, Tran L, Jimenez LA. Duffin R, Newby DE, Mills N.
MacNee W, Stone V. Combustion-derived nanoparticles: a review
of their toxicology following inhalation exposure. Part Fibre Toxicol
2005 ;2:10.
16. Nel AE, Diaz-Sanchez D, Li N. The role of particulate pollutants in
pulmonary inflammation and asthma: evidence for the involvement
of organic chemicals and oxidative stress. Curr Opin Pulm Med 2001 ;7:
20-26.
17. Behndig AF, Mudway IS, Brown JL, Stenfors N, Helleday R, Duggan
ST, Wilson SJ, Boman C, Cassee FR, Frew AJ, et al. Airway antioxi¬
dant and inflammatory responses to diesel exhaust exposure in healthy
humans. Eur Respir J 2006;27:359-365.
18. Salvi SS, Nordenhall C, Blomberg A, Rudell B, Pourazar J, Kelly FJ,
Wilson SJ, Sandstrom T, Holgate ST, Frew AJ. Acute exposure to
diesel exhaust increases IL-8 and GRO-a production in healthy human
airways. Am J Respir Crit Care Med 2000;161:550-557.
19. Pourazar J, Frew AJ, Blomberg A, Helleday R, Kelly FJ, Wilson S,
Sandstrom T. Diesel exhaust exposure enhances the expression of
IL-13 in the bronchial epithelium of healthy subjects. Respir Med
2004;98:821-825.
20. Pourazar J, Mudway IS, Samet JM, Helleday R, Blomberg A, Wilson
SJ, Frew AJ, Kelly FJ, Sandstrom T. Diesel exhaust activates redox-
sensitive transcription factors and kinases in human airways. Am J
Physiol Lung Cell Mol Physiol 2005;289:L724-L730.
21. Weissberg P. Mechanisms modifying atherosclerotic disease: from lipids
to vascular biology. Atherosclerosis 1999;147:S3-S10.
22. Newby DE, McLeod AL, Uren NG. Flint L, Ludlam CA, Webb DJ, Fox
KA, Boon NA. Impaired coronary tissue plasminogen activator release
is associated with coronary atherosclerosis and cigarette smoking:
direct link between endothelial dysfunction and atherothrombosis.
Circulation 2001;103:1936-1941.
23. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA,
Webb D.T. Endothelial dysfunction, impaired endogenous fibrinolysis,
and cigarette smoking: a mechanism for arterial thrombosis and myo¬
cardial infarction. Circulation 1999;99:1411-1415.
24. Mills NL, Tornqvist H, Robinson SD, Gonzalez M, Darnley K, MacNee
W, Boon NA, Donaldson K, Blomberg A, Sandstrom T, et al. Diesel
exhaust inhalation causes vascular dysfunction and impaired endoge¬
nous fibrinolysis. Circulation 2005;112:3930-3936.
25. Robinson SD, Ludlam CA, Boon NA, Newby DE. Phosphodiesterase
type 5 inhibition does not reverse endothelial dysfunction in patients
with coronary heart disease. Heart 2006;92:170-176.
26. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An
in vivo model for the assessment of acute fibrinolytic capacity of the
endothelium. Thromb Hae.most 1997;78:1242-1248.
27. Nordenhall C, Pourazar J, Blomberg A, Levion JO, Sandstrom T,
Adelroth E. Airway inflammation following exposure to diesel ex¬
haust: a study of time kinetics using induced sputum. Eur Respir J 2000;
15:1046-1051
28. Mudway IS, Stenfors N, Duggan ST, Roxborough H, Ziclinski H,
Marklund SL, Blomberg A, Frew AJ, Sandstrom T, Kelly FJ. An in
vitro and in vivo investigation of the effects of diesel exhaust on human
airway lining fluid antioxidants. Arch Biochem Biophys 2004,423:200-
212.
29. Nemery B, Abraham E. Environmental health and the AJRCCM. Am
./ Respir Crit Care Med 2005;172:1484-1485.
30. Sun O, Wang A, Jin X, Natanzon A, Dtiquaine D, Brook RD, Aguinaldo
JG, Fayad ZA, Fuster V, IJppmann M, et al. Long-term air pollution
exposure and acceleration of atherosclerosis and vascular inflamma¬
tion in an animal model. JAMA 2005;294:3003-3010.
31. Honing MLH, Smits P. Morrison PJ, Rabelink TJ. Bradykinin-induced
vasodilation of human forearm resistance vessels is primarily mediated
by endothelium-dependent hyperpolarization. Hypertension 2000;35:
1314-1318.
32. Ikeda M, Suzuki M, Watarai K, Sagai M, Tomita T. Impairment of
endothelium-dependent relaxation by diesel exhaust particles in rat
thoracic aorta. Jpn J Pharmacol 1995;68:183-189.
33. Ikeda M, Watarai K, Suzuki M, Ito T, Yamasaki H, Sagai M. Tomita T.
Mechanism of pathophysiological effects of diesel exhaust particles
on endothelial cells. Environ Toxicol Pharmacol 1998;6:117-123.
34 Sun Y, Taguchi K, Sumi D, Yamano S, Kumagai Y. Inhibition of endothe
lial nitric oxide synthase activity and suppression of endothelium-
dependent vasorelaxation by 1,2-naphthoquinone, a component of
diesel exhaust particles. Arch Toxicol 2006;80:280-285.
35. Brook RD, Brook JR, Urch B, Vincent R, Rajagopalan S, Silverman F.
Inhalation of fine particulate air pollution and ozone causes acute
arterial vasoconstriction in healthy adults. Circulation 2002; 105:1534-
1536.
36. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction.
Am J Physiol Cell Physiol 2001 ;280:C719-C741.
37. Ikeda M, Shitashige M, Yamasaki H, Sagai M, Tomita T. Oxidative
modification of low density lipoprotein by diesel exhaust particles.
Biol Pharm Bull 1995:18:866-871.
38. Schwartz J. What are people dying of on high air pollution days? Environ
Res 1994;64:26-35.
39. Blomberg A. Krishna MT, Bocchino V, Biscione GL, Shule JK, Kelly
FJ, Frew AJ, Holgate ST, Sandstrom T. The inflammatory effects of
2 ppm NOj on the airways of healthy subjects. Am J Respir Crit Care
Med 1997;156:418-424.
40. Campen MJ, Babu NS, Helms GA. Pett S, Wernly J, Mehran R,
McDonald JD. Nonparticulate components of dicsel exhaust promote
constriction in coronary arteries from ApoE-/- mice. Toxicol Sci 2005;
88:95-102.
41. Mills NL, Amin N, Robinson SD, Anand A, Davies J, Patel D, de la
Fuente JM, Cassee FR, Boon NA, MacNee W, et al. Do inhaled carbon
nanoparticles translocate directly into the circulation in humans? Am
J Respir Crit Care Med 2006;173:426-431.
42. Nemmar A, Hoet PH, Vanquickenborne B, Dinsdale D, Thomeer M,
Hoylaerts MF, Vanbilloen H, Mortelmans L, Nemery B. Passage of
inhaled particles into the blood circulation in humans. Circulation
2002;105:411-414.
43. Peters A, Frohlich M, Doring A, Immervoll T, Wichmann HE,
Hutchinson WL, Pepys MB, Koenig W. Particulate air pollution is
associated with an acute phase response in men: results from the
MONICA-Augsburg Study. Eur Heart J 2001 ;22:1198-1204.
44. Peters A, Doring A, Wichmann HE, Koenig W. Increased plasma viscos¬
ity during an air pollution episode: a link to mortality? Lancet
1997;349:1582-1587.
45. Seaton A, Soutar CA, Crawford V, Elton R, McNerlan S, Cherrie J,
Watt M, Agius R, Stout R. Particulate air pollution and the blood.
Thorax 1999;54:1027-1032.
46. Pekkanen J, Brunner EJ, Anderson HR, Tiittanen P, Atkinson RW.
Daily concentrations of air pollution and plasma fibrinogen in London.
Occup Environ Med 2000;57:818-822.
47. Ghio AJ, Kim C, Devlin RB. Concentrated ambient air particles induce
mild pulmonary inflammation in healthy human volunteers. Am J
Respir Crit Care Med 2000;162:981-988.
48. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial
dysfunction, oxidative stress, and risk of cardiovascular events in pa¬
tients with coronary artery disease. Circulation 2001;104:2673-2678.
49. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw
MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular





Clinical Investigation and Reports
Impaired Coronary Tissue Plasminogen Activator Release
Is Associated With Coronary Atherosclerosis and
Cigarette Smoking
Direct Link Between Endothelial Dysfunction and Atherothroinbosis
David E. Newby, PhD, DM, MRCP; Andrew L. McLeod, MB, ChB, MRCP;
Neal G. Uren, MD, MRCP; Laura Flint, RGN; Christopher A. Ludlam, PhD, FRCPath;
David J. Webb, MD, DSc, FRCP; Keith A.A. Fox, MB, ChB, FRCP; Nicholas A. Boon, MD, FRCP
Background-—The aim of the study was to establish the influence of proximal coronary artery atheroma and smoking habit
on the stimulated release of tissue plasminogen activator (tPA) from the heart.
Methods and Results—After diagnostic coronary angiography in 25 patients, the left anterior descending coronary artery
(LAD) was instrumented, and the proximal LAD plaque volume was determined by use of intravascular ultrasound
(IVUS). Blood flow and fibrinolytic responses to selective LAD infusion of saline, substance P (10 to 40 pmol/min;
endothclium-dcpendent), and sodium nitroprusside (5 to 20 /xg/min; endothelium-independent) were measured by
intracoronary IVUS and Doppler, combined with arterial and coronary sinus blood sampling. Mean plaque burden was
5.5±0.8 mmVmm vessel (range 0.6 to 13.7 mm3/mm vessel). LAD blood flow increased with both substance P and
sodium nitroprusside (P<0.001), although coronary sinus plasma tPA antigen and activity concentrations increased only
during substance P infusion (P<0.006 for both). There was a strong inverse correlation between the LAD plaque burden
and release of active tPA (>'=—0.61, P=0.003). Cigarette smoking was associated with impaired coronary release of
active tPA (current smokers, 31 ±23 IU/min; ex-smokers, 50±33 IU/niin; nonsmokers 202±73 lU/min; P<0.05).
Conclusions Wc found that both the coronaiy atheromatous plaque burden and smoking habit arc associated with a
reduced acute local fibrinolytic capacity of the heart. These important findings provide evidence of a direct link between
endogenous fibrinolysis, endothelial dysfunction, and atherothrombosis in the coronary circulation and may explain the
greater efficacy of thrombolytic therapy for myocardial infarction in cigarette smokers. (Circulation. 2001; 103:1936-
1941.)
Key Words: thrombolysis ■ endothelium ■ coronary disease ■ ultrasonics
The fibrinolytic factor tissue plasminogen activator(tPA) is a serine protease that regulates the degrada¬
tion of intravascular fibrin and is released from the
endothelium through the translocation of a dynamic intra¬
cellular storage pool. If endogenous fibrinolysis is to be
effective, then the rapid mobilization of tPA from the
endothelium is essential, because thrombus dissolution is
much more effective if tPA is incorporated during, rather
than after, thrombus formation.1 The efficacy of plasmin¬
ogen activation and fibrin degradation is further deter¬
mined by the relative balance between the acute local
release of tPA and its subsequent inhibition through
formation of complexes with the serpin, plasminogen
activator inhibitor type 1 (PA1-1). This dynamic aspect of
endothelial function and fibrinolytic balance may be di¬
rectly relevant to the pathogenesis of atherothrombosis,
but only recently have robust methods to determine acute
tPA release been developed.2
Small areas of denudation and thrombus deposition are a
common finding on the surface of atheromatous plaques and
arc usually subclinical.' In the presence of an imbalance in
the fibrinolytic system, however, such microthrombi may
propagate, ultimately leading to arterial occlusion." Indeed, in
genetic murine models, tPA deficiency is associated with
myocardial necrosis and the development of regional wall
motion abnormalities.5 Recently. Rosenberg and Aird" pos¬
tulated that vascular bed specific defects in hemostasis exist
and that coronary thrombosis critically depends on the local
fibrinolytic balance. To date, however, no clinical studies
have directly assessed the acute local fibrinolytic capacity of
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the coronary vascular bed in patients with coronary artery
disease.
Using forearm venous occlusion plethysmography and the
endothelium-dependent agonist substance P, we recently
characterized a new model of assessing the acute release of
endogenous tPA in vivo in humans.2 This has allowed us to
show that cigarette smoking is associated with an impairment
of acute tPA release in the forearm circulation.1' We hypoth¬
esized that the acute local coronary release of tPA would be
influenced by both the extent of coronary atheroma and
smoking habit. Therefore, the aims of the present study were
first, to apply this approach to the coronary circulation and
thereby establish a method of assessing acute coronary tPA
release; second, to determine the relationship between the
extent of coronaiy artery atheroma, quantified by intravascu¬
lar ultrasound (IVUS), and the acute fibrinolytic capacity of
the coronary vascular bed; and third, to show whether




Patients were excluded if they had significant led main stem disease
or a minimal luminal diameter of <2 mm in the proximal left
anterior descending coronary artery (LAD). Coronary risk factors
were determined in all patients by standard clinical criteria. The
study was undertaken with the approval of the local research ethics
committee, in accordance with the Declaration of Helsinki, and with
the written informed consent of each subject.
Study Protocol
All patients discontinued their medication on the study day, attended
in the fasting state, and underwent diagnostic coronary angiography
at 8 am. The coronaiy sinus was cannulated from the femoral vein
with a preformed specific 6F catheter (Torcon NB catheter, C'ook)7
that was advanced beyond the posterior interventricular vein. Stable
and selective cannulation of the coronaiy sinus was achieved in all
but 3 subjects. Arterial samples were obtained through an BP
hemostatic sheath placed in the right femoral artery.
The left coronary artery was cannulated with a 7F guiding
catheter, and a 0.014-in 12.5-MHz Doppler wire (PloWire, Cardio-
metrics, findosonics) was passed into the LAD. A 3.2P Ultracross
20-MHz IVUS imaging catheter (Scimed, Boston Scientific Corp)
was advanced into the LAD over the Doppler wire. The IVUS
examination of the proximal artery was performed at 0.5 mm/s with
a motorized pullback device (Boston Scientific Corp). After the
pullback examination, the IVUS imaging catheter was repositioned
just distal to the ostium of the LAD. The Doppler guidewire was
retracted to the tip of the imaging catheter and maintained in a stable
position by the short monorail segment of the IVUS catheter."
Drug Administration
Pharmaceutical-grade substance P (C'linalfa AG), an endothelium-
dependent vasodilator, and sodium nitroprusside (David Bull Labo¬
ratories), an endothelium-independent vasodilator, were adminis¬
tered after dissolution in saline. Five-minute infusions were
administered at 1 mL/min via the 1VUS catheter flush port." The
agents were given in the following order: saline, substance P 10
pmol/mL, substance P 20 pmol/mL, substance P 40 pmol/mL,
sodium nitroprusside 5 pg/mL, and sodium nitroprusside 20 /xg/mL.
Measurement of Plaque Volume and Coronary
Blood Flow
Computerized 3D reconstructions of the proximal LAD were per¬
formed offline by a single blinded operator using the TomTec
computer system (Kchoscan, TomTec Imaging Systems). The prox¬
imal atheromatous plaque volume was calculated with a well-
validated edge-detection algorithm as previously described.7-10
The LAD cross-sectional area was measured by computerized
planimetry (Clcarvicw, Boston Scientific Inc) of the vessel lumen at
the onset of the QRS complex. Blood flow velocity was determined
by use of average peak velocity of the Doppler signal (FIoMap.
Cardiometrics). Blood flow in the LAD was previously defined as
half the product of the average peak velocity and the cross-sectional
area" and was determined from the mean of 5 measurements made
in the final minute of each infusion period.
Blood Sampling and Plasma Assays
Ten milliliters of arterial and 10 mL of coronary sinus blood were
obtained simultaneously at the end of each infusion period and
collected into acidified buffered citrate (Biopool Stabilyte) and
citrate (Monovette, Sarstedt) tubes, and plalelet-lrec plasma was
decanted and stored at —80°C before assay. Coronaiy sinus oxygen
saturations were determined at the end of each infusion period with
an automated oximeter (Oxicam 300, Watco Services). Plasma tPA











Serum lipid profile, mg/dL
Total cholesterol 221 ±10
LDL cholesterol 121 ±7
HDL cholesterol 51 ±3
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and PAI-1 antigen and activity concentrations were determined with
ELISAs and a photometric method as previously described.26
Data Analysis and Statistics
Coronary tPA release was defined as the product of the LAD plasma
llow and the plasma arterial and coronary sinus concentration
differences. To compare vasomotor and fibrinolytic responses with
proximal atheromatous plaque volume, the area under the curve
(AUC) was calculated for each response: coronary blood flow,
plasma arterial and coronary sinus tPA concentration differences,
and estimated net tPA release.
Data were examined by ANOVA with repeated measures, Stu¬
dent's t test, and univariate and multivariate regression analysis with
StatView v5.0.1 (SAS Institute Inc). Where ANOVA demonstrated
significant differences in responses, post hoc comparisons were
made by use of the Fisher protected least significant difference test
(StatView v5.0.1). Multivariate regression analysis was performed
only on those factors that were shown to have a significant
association by univariate analysis. All results are expressed as
mean±SEM. Statistical significance was taken at the 5% level.
Results
Baseline patient characteristics are shown in Table 1. In
keeping with the anticipated profile of patients undergoing
coronary angiography, the study population was predomi¬
nantly male and middle-aged and had a combination of risk
factors. Throughout the study, there were no significant
changes in heart rate, mean arterial pressure, or hematocrit
(0.40±0.01).
Plaque Volume and Blood Flow Responses
The proximal 29±1 mm of the LAD was reconstructed and
found to contain 160±24 mm1 of atheromatous plaque: a
plaque burden of 5.5±0.8 mm'/mm vessel (range, 0.6 to 13.7
mm3/mm vessel). There was a significant linear correlation
between the plaque burden and the serum total cholesterol-
:MDL cholesterol ratio (>-=0.55, P=0.004).
LAD blood flow increased with both substance P and
sodium nitroprusside infusion (/><0.001, ANOVA; see Table
2). There was a significant linear correlation between the
percentage increase in coronary sinus oxygen saturations and
LAD flow (r=0.46, P<0.001). There was no correlation,
however, between the plaque burden and the AUC for the
coronary blood flow responses to substance P or sodium






















y=-109 ln(x) + 255
Figure 1. Prevalence of risk factors and influence on coronary
blood flow responses to substance P infusion.
Plaque Burden
(mm3 per mm of vessel)
Figure 2. Correlation of plaque burden of LAD with AUC for
arteriovenous concentration differences (top) and estimated net
release (bottom) of tPA activity.
between the number of risk factors for atherosclerosis and the
coronary blood flow responses to substance P (Figure l:
r=-0.42, P<0.05).
Plasma Fibrinolytic Parameters
There was a significant increase in plasma tPA antigen and
activity concentrations from the coronary sinus during sub¬
stance P infusion (Table 2: ANOVA, PCO.OOl and P<0.006,
respectively) but not during sodium nitroprusside infusion.
There was a significant inverse correlation between the
plaque burden and the AUC for active tPA release (Figure 2:
>-= -0.61, P=0.003) and a trend for the AUC for tPA antigen
release (r=—0.34, P=0.15). There was also an inverse linear
correlation between the basal coronary sinus plasma tPA
antigen concentration and the AUC for active tPA release
(>•=—0.58, PC0.005).
Current smokers had a higher basal plasma tPA antigen
concentration despite similar plasma PAI-1 concentrations
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TABLE 2. Hemodynamics, Coronary Blood Flow, and tPA and PAI-1 Concentrations During Substance P and Sodium
Nitroprusside Infusion
Substance P, pmol/min Sodium Nitroprusside, /ug/min
Saline 10 20 40 Saline 5 20
Heart rate, bpm 65 ±2 64±3 64±3 64 + 3 69+3 69±3 68±4
Mean arterial pressure, mm Hg 98±3 99+3 98±3 98±3 94±3 96±5 90±4
Coronary sinus oxygen saturation, % 44±2 48+2 48±3 46±2 44±3 54 ±4
IVUS and Doppler
Luminal cross-sectional area, mm2 15.7 ±1.0 16.4 ±1.0* 16.5±1.0* 16.9± 1.0* § 14.9± 1.1 15.4±1.1* 16.1 ±1.3* II
Average peak velocity, cm/s 21,4±1.6 27.3±2.2f 27.5+2.4* 28.0+2.3* § 22.7 ±2.2 27.0+2.2* 47.1 ±4.6* §
Absolute coronary blood flow, mL/min 103 ±=12 CO co [+ CO ++ 140± 19* 143±18* § 109+18 131 ±20* 242 + 42* §
Change in coronary blood flow, % 0 36+6* 37 ±7* 46 ±: 10* § 0 29±9* 140 + 24* §
Plasma tPA antigen, ng/mL
Coronary sinus concentration 7.9±0.5 8.8±0.7* 8.8±0.6* 9.1+0.7* § 8.1 + 1.0 8.7 ±1.0
Arterial concentration 7.7+0.5 8.0±0.5 8.1 ±0.6 8.1 ±0.6 8.1 + 1.0 8.9+1.3
Arteriovenous concentration difference 0.3±0.2 0.8±0.3 0.7 ±0.3 1,0± 0.3* 0.0±0.2 -0.1 ±0.4
Plasma tPA activity, ILI/mL
Coronary sinus concentration 0.5±0.1 1.1 ±0.3* 0.8±0.2 1.0+0.2* § 0.7±0.2 0.7 ±0.2
Arterial concentration 0.4+0.1 0.5+0.1 0.6±0.2 0.7±.0.2* § 0.5+0.1 0.8±0.3
Arteriovenous concentration difference 0.1+0.1 0.6+0.2* 0.2 ±0.1 0.3±0.2 II 0.2±0.1 I o o l+ o o
Plasma PAI-1 antigen, ng/mL
Coronary sinus concentration 70±7 70±7 68±7 68±7 68+11 67+ 12
Arterial concentration 71 ±8 70±8 67±7 67±7 70±12 67±12
Arteriovenous concentration difference -0+ 2 -1 + 1 1±1 0±1 -1 + 1 0+ 1
Plasma PAI-1 activity, AU/mL
Coronary sinus concentration 21 ±4 21 ±3 19±4 17+3 24±8 23±9
Arterial concentration 20±3 19±3 20±3 19±3 26±1 31 ±6
Arteriovenous concentration difference 1±1 1±1 -0±0 —2±1 1±1 0±0
All indicates arbitrary units. n=14 for sodium nitroprusside responses; n=22 for fibrinolytic parameters (except PAI-1 activity; n = 13).
*Ps0.05; *fe0.01; *fe0.001, Fisher's protected least significant difference test (vs baseline).
§Ps0.007; ||fe0.05, ANOVA with repeated measures.
and coronary arterial plaque burden (Table 3). Current and
ex-smokers released significantly less active tPA than non-
smokers (Figure 3; ANOVA, Z'<0.05). Hypercholesterol¬
emia, hypertension, diabetes mellitus, and a family history of
premature coronary artery disease did not appear to influence
active tPA release, although some of the subgroup sample
sizes were small.
There were no significant changes in plasma PAI-1 antigen
and activity concentrations throughout the study (Table 2).
Basal coronary sinus plasma PAI-1 antigen concentrations
correlated positively with plaque burden (r=0.47, P<0.03)
and negatively with release of active tPA (r= — 0.44,
P=0 04)
Multivariate regression analysis identified plaque burden
and basal coronary sinus tPA antigen concentrations as the
independent variables that were significantly associated with
release of active tPA (P£0.02 for both).
Discussion
For the first time, we have shown a direct relationship
between both the coronary atheromatous plaque burden and
smoking habit and the acute stimulated fibrinolytic capacity
of the heart. These important findings suggest that both
atherosclerosis and smoking habit adversely influence the
local fibrinolytic balance in the coronary circulation and
provide a direct link between endothelial dysfunction, athero-
thrombosis, and myocardial infarction.
This is the first clinical study to attempt to directly assess
the acute release of tPA in the coronary circulation and to
have found it to be sensitive to the presence of atheroma: a
rapid decline in release of active tPA associated with an
increasing plaque burden. The reduction in acute fibrinolytic
capacity appears to reflect both an impairment of acute tPA
release and an elevation of plasma PAI-1 concentrations. The
mechanisms underlying this relationship remain to be estab¬
lished but arc likely to involve chronic endothelial cell injury
and possibly an impairment of the L-argininc nitric oxide
pathway.12 In addition, this association may reflect a chronic
stimulation and upregulation of basal tPA release caused by
arterial denudation and atheroma." The subsequent depletion
of endothelial cell tPA stores, the associated increases in
PAI-1 concentrations, and the overall reduction of the acute
dynamic fibrinolytic response would potentially limit the
capacity of the vasculature to lyse intraluminal thrombus.
This is consistent with the epidemiological observations of a
positive correlation between plasma tPA and PAI-1 antigen
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concentrations and future coronary events,7.14.15 aj well as our
findings of an inverse correlation of active tPA release with
basal coronary sinus tPA and PA1-1 antigen concentrations.
Questions of cause and effect cannot be resolved by the
present study. Indeed, our observations are consistent with a
reduced fibrinolytic activity causing enhanced atherogenesis.
Detailed postmortem studies have shown that plaque growth
is induced by episodic subclinical plaque disruption and
thrombus formation.16 The prolonged presence of residual
thrombus over a disrupted or eroded plaque will provoke
smooth muscle migration and the production of new connec¬
tive tissue, leading to plaque expansion.3-17 This is consistent
with the enhanced macrovascular fibrin deposition and
atherogenesis seen in genetic murine models of tPA and
plasminogen deficiency.5-18 It is likely, however, that both
processes, impaired fibrinolysis and atherogenesis, cooperate
and interact to damage vascular function and structure.
Consistent with our previous work in the peripheral circu¬
lation,6 we have observed an elevated basal plasma tPA
antigen concentration and an impaired coronary release of
active tPA in cigarette smokers. These observations suggest
that impaired endogenous fibrinolysis may contribute to the
increased risk of coronary thrombosis seen in smokers
through propagation of thrombus that would otherwise un¬
dergo lysis and remain subclinical. Although cigarette smok¬
ers have a higher overall mortality from myocardial infarction
than nonsmokers, the in-hospital mortality has consistently
been shown to be lower. This so-called "smokers' paradox"
can be explained by the observation that the infarct-related
artery is more than twice as likely to become patent in current
smokers than in nonsmokers after thrombolytic therapy for
acute myocardial infarction.19 Indeed, it has been provoca¬
tively suggested that thrombolytic therapy should be given
only to smokers and that such alternative strategies as
Ne! Release of
Aclive l-PA PI"tP"' Volume
(lU.min"1) (mm5.mm1)
Smokers Ex-sniukers Non-smokers
Figure 3. Influence of smoking status on AUC for net release of
active tPA (open bars) and plaque volume (solid bars). P<0.05
ANOVA; *P=0.03 Fisher's protected least significant difference
test, current or ex-smokers vs nonsmokers.
primary angioplasty be used in nonsmokers.2" Our findings
may account for these observations, because it might be
anticipated that patients with impaired coronary endothelial
cell tPA release would benefit most from thrombolytic
therapy.
Quantitative coronary angiography21 has suggested that
there is a direct association between coronary atherosclerosis
and endothelium-dependent vasodilation. Quantitative coro¬
nary angiography, however, has several inherent limitations
and inaccuracies22 that occur because it can assess only the
arterial lumen and is unable to take account of "Glagovian"
arterial remodeling.23 In contrast, 1VUS provides a more
accurate assessment of intracoronary plaque volume that has
been extensively validated.9-1" Using this methodology, we
did not find an association between the atherosclerotic plaque
burden and the magnitude of the substance P-induced vaso¬
dilation. This is, in part, likely to reflect the independent
influence of atherosclerotic risk factors on endothclium-
dependent vasomotion and is borne out by the correlation of
the vasodilation to substance P with the prevalence of these
risk factors.
Study Limitations
This study was conducted in the necessary clinical setting of
patients with a combination of risk factors and concomitant
therapies undergoing diagnostic coronary angiography. The
modest sample size means that this study lacks sufficient
power to address the influence of all the individual variables
associated with coronary artery disease. In particular, because
the number of patients with diabetes mellitus or normocho-
lesterolemia was small, our study may have failed to detect
potential associations between these factors. Moreover, it is
difficult to assess the effect of hypercholesterolemia and
hypertension given the high incidence of treatment with
TABLE 3. Influence of Smoking Status on Plaque Burden and








Plaque burden, mm3/mm 5.2+1.1 6.5+1.2 4.5+1.6
Plasma tPA antigen, ng/mL
Coronary sinus concentration 9.4±1.3f 8.2±0.4 6.3±0.7*
Arterial concentration 9.0±1.4f 7.84:0.3 6.3±0.8*
Plasma tPA activity, lU/mL
Coronary sinus concentration 0.34:0.1 0.6±0.2 0.6±0.2J
Arterial concentration 0.3±0.0 0.5±0.1 0.5 + 0.2f
Plasma PAI-1 antigen, ng/mL
Coronary sinus concentration 88±15 67±9 59+14
Arterial concentration 84±15 70 + 11 60±15
Plasma PAI-1 activity, AU/mL
Coronary sinus concentration 14±6 25±5 24+ 8
Arterial concentration 12±5 26+4 23+8
AU indicates arbitrary units.
*P<0.04; fP=0.06, ANOVA with repeated measures.
fP-0.01, Fisher's protected least significant difference test (nonsmokers vs
current smokers).
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lipid-lowering and antihypertensive therapy. Given the con¬
cordance between our previous findings in the forearm
circulation of smokers,6 however, the influence of such risk
factors as diabetes mellitus and hypercholesterolemia may be
more readily assessed in the peripheral circulation.
In conclusion, we have demonstrated, for the first time, a
direct association between both the coronary atheromatous
plaque burden and smoking habit with the acute local
fibrinolytic capacity of the coronary circulation. These im¬
portant findings may provide the main link between endothe¬
lial dysfunction and athcrothrombosis, as well as an explana¬
tion for the smokers' paradox. Interventions aimed at the
enhancement of the local coronary fibrinolytic capacity could
potentially be of major clinical importance.
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Preserved endothelial vasomotion and fibrinolytic function in patients with
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Abstract
Introduction: Acute stent thrombosis and in-stent restenosis are serious complications of percutaneous coronary intervention (PCI) and may
be associated with vascular or platelet abnormalities. We aimed to assess endothelium-dependent vasomotion, endogenous fibrinolysis and
platelet function in patients with acute stent thrombosis or in-stent restenosis. Materials and methods: Thirty-six subjects were enrolled into
four groups: acute stent thrombosis, in-stent restenosis, uncomplicated PCI with stent implantation and healthy matched controls. Forearm
blood flow was measured using bilateral venous occlusion plethysmography during intra-brachial acetylcholine, substance P and sodium
nitroprusside infusion. Venous blood samples were withdrawn for estimation of plasma fibrinolytic variables and platelet aggregometry.
Results: Acetylcholine, substance P and sodium nitroprusside caused dose-dependent increases in blood flow (P<0.001) and substance P
caused a dose-dependent increase in tissue-type plasminogen activator (t-PA) release (P< 0.001) in all groups. Thrombin, collagen, adenosine
diphosphate (ADP) and the thromboxane A2 analogue, U46619, caused dose-dependent platelet aggregation (P<0.001) in all groups. There
were no significant between group differences in these responses except that, in keeping with aspirin therapy, collagen-induced platelet
aggregation was impaired in patient groups compared with healthy controls (/><0.01). Post-hoc analysis demonstrated a significant
impairment of acute t-PA release in current smokers compared to non-smokers (P<0.05). Conclusions: Despite previous reports suggesting
impaired vascular function, endothelium-dependent vasomotion, endogenous fibrinolysis and platelet aggregation do not appear to play a
major role in the pathogenesis of acute stent thrombosis or in-stent restenosis.
© 2003 Elsevier Ltd. All rights reserved.
Keywords: Endothelial function; Platelets; In-stent restenosis; Stent thrombosis; Fibrinolysis
Coronary artery stent implantation is a valuable adjunct to
percutaneous transluminal coronary angioplasty. It reduces
the absolute incidence of restenosis compared with balloon
angioplasty by 10-15% and improves 6-month event free
survival by 10-20% [1,2]. However, there is a small but
significant risk of acute coronary stent thrombosis [3] and in-
stent restenosis that can have devastating consequences
Abbreviations: ADP, adenosine diphosphate; ANOVA. analysis of
variance; AUG. area under the curve; PAI-I, plasminogen activator
inhibitor type 1; PCI, percutaneous coronary intervention; t-PA, tissue-
type plasminogen activator.
* Corresponding author. Tel.: +44-131-242-6422; tax: +44-131-242-
6422.
E-mail address: d.e.newby@ed.ac.uk (D.E. Ncvvby).
0049-3848/$ - see front matter <0 2003 Elsevier Ltd. All rights reserved,
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including myocardial infarction and death [4], Whilst pro¬
cedure-related complications such as persistent dissection,
longer stent length and final minimal lumen diameter may be
implicated in some cases of stent thrombosis or restenosis
[3], no underlying precipitant can be identified in many
patients.
Stent thrombus formation is principally initiated by
platelet aggregation, which, in the absence of effective
endothelium-derived vasoregulation and fibrinolysis, is
then stabilised by the deposition of a fibrin mesh. The
chronology of in-stent restenosis has been described as
early thrombosis, followed by thrombus endothelialization
and infiltration by lymphocytes and monocytes, and finally
smooth muscle cell migration and proliferation within the
resolving thrombus [5—7]. The initiation, propagation and
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stabilization of acute stent thrombosis and in-stent reste¬
nosis are therefore dependent on several components:
platelet aggregation, endothelial function, coagulation and
fibrinolysis.
The purpose of the present study was to identify
potential factors that may be implicated in the predisposi¬
tion to acute stent thrombosis or in-stent restenosis using a
case-control methodology. We assessed endothelium-de-
pendent vasomotion, platelet aggregation and the acute
endogenous fibrinolytic capacity in patients who have
developed thrombotic complications following percutane¬
ous coronary intervention (PCI) and stent implantation.
1. Materials and methods
1.1. Subjects
Twenty-six patients who had undergone PCI with stent
implantation at least 6 months previously and 10 age- and
sex-matched healthy control subjects were recruited into the
study. In the patient group, 16 had developed complications
of acute stent thrombosis within 48 h of stent implantation
(// = 6) or in-stent restenosis within 6 months of intervention
(n= 10), and 10 had no clinical evidence of stent thrombosis
or restenosis at least 1 year following the procedure.
Patients with procedural complications or suboptimal stent
insertion were excluded. All patients received thienopyri-
dine therapy for 4 weeks after undergoing PCI and none
received a glycoprotein llb/llla receptor antagonist during
the procedure.
All subjects abstained from alcohol for 24 h, and from
food and caffeine-containing drinks for at least 4 h before the
study, and medications were withheld on the day of the
study. All studies were performed in a quiet, temperature-
controlled room maintained at 22-25 °C. The investigation
was performed with the approval of the local ethics com¬
mittee and conformed with the principles outlined in the
Declaration of Helsinki, and with the written informed
consent of each subject.
1.2. Di-ugs administration
Pharmaceutical-grade substance P (Clinalfa, Laufelfin-
gen, Switzerland), acetylcholine (Cibavision Ophthalmics,
Southampton, UK) and sodium nitroprussidc (David Bull
Laboratories, Faulding, UK) were administered following
dissolution in saline (0.9%: Baxter Healthcare). All solutions
were freshly prepared on the day of study.
1.3. Hemodynamic measurements
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
strain gauges as previously described [8,9]. Blood pres¬
sure was monitored in the non-infused arm at intervals
throughout each study with a semiautomated noninvasive
oscillometric sphygmomanometer (Takeda UA 751, Takeda
Medical).
1.4. Fibrinolytic assays
Venous blood (10 ml) was withdrawn simultaneously
from each arm and collected into acidified buffered
citrate (Biopool® Stabilyte™, Umea, Sweden; for t-PA
assays) and trisodium citrate (Monovette®, Sarstedt,
Niimbrecht, Germany; for PAJ-1 assays) tubes and centri-
fuged at 2000 xg for 30 min at 4 °C. Platelet-free
plasma was decanted and stored at — 80 °C before
assay. Plasma tissue-type plasminogen activator (t-PA)
and plasminogen activator inhibitor type 1 (PAI-1) anti¬
gens were determined as previously described [8] using
enzyme-linked immunosorbent assays (Coaliza t-PA and
Coaliza PAI-1, Chromogcnix, Molndal, Sweden) and
plasma t-PA activity using a photometric method (Coatest
t-PA, Chomogenix).
1.5. Platelet aggregometrv and thrombophilia screen
Fasting venous blood (30 ml) was collected into trisodium
citrate tubes (Monovcttc®) and immediately centrifuged at
120 x g for 10 min to obtain platelet-rich plasma, which was
aspirated, adjusted to give a platelet count of 250 x 109/I and















Sex (male/female) 2:4 9:1 8:2 9:1
Age 65 ±3 62 ± 2 63 ± 2 58 ±3
Current smoker, % (n) 17 (1) 20 (2) 20 (2) 20 (2)
Diabetes mellitus, % (n) 17 (1) 30 (3) 20 (2) 0(0)
Hypertension, % (/?) 50 (3) 60 (6) 30 (3) 0(0)
Three-vessel disease, % (/t) 33 (2) 30 (3) 20 (2) 0(0)
Normal or mild left 84 (5) 90 (9) 80 (8) 100 (10)
ventricular impairment,
% (n)
Average stent diameter, mm 3.3 ±0.2 3.0 ±0.1 3.2 ± 0.2
Average stent length, mm 16 ±2 18 ± 2 20 ±2
Medical therapy
Aspirin, % (;/) 100 (6) 100(10) 100 (10) 0 (0)
^-adrenoceptor 50 (3) 50 (5) 60 (6) 0 (0)
antagonists, % (n)
Angiotensin-converting 33 (2) 60 (6) 40 (4) o (0)
enzyme inhibitors, % (n)
Statins, % (/?) 100 (6) 80 (8) 80 (8) 0(0)
Calcium channel 50 (3) 60 (6) 10(1) 0(0)
blockers, % (n)
Oral nitrates, % (n) 50(3) 30 (3) 20 (2) 0(0)
Mean ± S.E.M.
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Table 2
Infused forearm blood flow during substance P, acetylcholine and sodium
nitroprusside infusion
Drug Infused forearm blood flow (ml/100 ml/min)
infusion » . . .
Acute stent In-stent Control Healthy
thrombosis restenosis patients subjects
(" = 6) (n- 10) (n— 10) ("- 10)
Baseline 1.7 + 0.4 2.5 ± 0.3 2.4 ± 0.2 2.8 + 0.5
Substance P (pmol/min)
4 8.6 + 0.5 9.6+1.1 9.7 ± 1.2 7.9+ 1.0
8 9.7 ± 0.7 10.6+ 1.1 11.0+ 1.1 9.7+ 1.3
16 11.6+1.3* 11.3 ± 1.4* 13.2+ 1.6* 12.4+ 1.9*
Acetylcholine (pg/inin)
5 7.7+1.8 5.7+ 1.2 6.2 ± 0.9 6.2+ 1.3
10 9.7 + 2.3 6.3 ± 1.4 6.9+ 1.0 7.3 ± 1.1
20 14.4 + 3.1' 9.2 ± 2.0* 9.0+ 1.5* 9.4 + 2.1*
Sodium nitroprusside (pg/min)
2 9.7 ± 2.9 7.3 ± 1.0 7.3 ± 0.6 8.4 ± 0.9
4 11.6 + 2.7 11.1 ± 1.2 10.1 ± 0.9 10.9+ 1.3
8 13.3 + 2.6' 13.4 ± 1.4* 12.6+ 1.4* 14.4 + 2.1*




on the platelct-rich plasma, 30-40 min after blood sampling,
using a standard optical technique (Chronolog C'a560 aggreg-
ometer; Labmedics, Stockport, UK) as described previously
[10], using the following agonists: adenosine diphosphate
(ADP, 0.5-10 pmol/1), the thromboxane A2 analogue
U46619 (0.5-6 pmol/1), thrombin (200-1000 mU/1) and
collagen (1-5 pg/ml). Responses were for 5 min after
addition of agonists, and the peak response recorded and
adjusted for platelet count (250 x 1109/l). Platelet count
and hematocrit were measured using an automated Coulter
counter (Act. 8 Coulter Counter; Beckman-Coulter, High
Wycombe, UK).
Venous blood (12 ml) were collected in potassium EDTA
and trisodium citrate (Monovette®*) tubes and screened for
anti-thrombin, protein S and protein C deficiencies, factor V
(Leiden) and prothrombin A20210G genotypes and anti-
phospholipid antibodies.
1.6. Study design
Subjects attended following a 4-h fast and then rested
recumbent throughout the study. Strain gauges and cuffs
were applied, and the brachial artery of the non-dominant
arm was cannulated with a 27-standard wire gauge steel
needle (Cooper's Needle Works, Birmingham, UK) under
1% lidocaine (Xylocaine; Astra Pharmaceuticals) local an¬
esthesia and attached to a 16-gauge epidural catheter (Por-
tex). Patency was maintained by infusion of saline via a
MS2000 syringe infusion pump (Graesby Medical, Watford,
UK). Venous cannulae (17-gaugc) were inserted into large
Table 3
Plasma t-PA and PA I-1 concentrations and release during substance P infusion
Substance P Acute stent thrombosis In-stent restenosis Control patients Healthy subjects
(pmol/min) (n = 6) (n= 10) (" =10) (n - 10)
Infused arm Non-infused Infused arm Non-infused Infused arm Non-infused Infused arm Noil-infused
arm ami ami arm
t-PA antigen (ng/ml) Baseline 4.9 ± 0.9 4.8 ± 0.9 4.3 ± 0.7 4.1 ± 0.6 4.7 ± 0.3 4.9 ± 0.5 5.1 ± 0.4 5.4 ± 0.5
4 7.2+ 1.1 5.2 ± 1.2 5.4 + 0.8 4.2 ± 0.6 5.8 ± 0.5 4.7 ± 0.4 6.1 ± 0.6 5.4 + 0.5
8 7,9+ 1.1 4.9 ± 1.2 6.0 ± 0.7 4.7 + 0.6 6.5 + 0.6 4.7 ± 0.4 7.0 ± 0.8 5.5 + 0.5
16 10.3 + 0.8* 5.6+ 1.3 8.8+ 1.5* 4.7 ± 0.6 7.6 ± 0.8' 4.9 + 0.4 8.5 ± 1.3 7.6+ 1.5
Estimated t-PA antigen Baseline 0.1 ± 0.5 0.2 ± 0.4 - 0.4 ± 0.4 - 0.5 ± 0.4
release (ng/100 ml/min) 4 11.2 + 4.1 6.8 ± 2.5 6.9 + 2.8 3.1 ± 1.3
8 18.7 ± 7.7 6.9 ± 2.5 12.2 + 3.3 7.8 + 3.3
16 34.4 ± 10.1* 25.3 ± 7.5* 19.6+3.3' 5.9 + 2.1*
Net t-PA antigen release (AUC) 47.1 ± 13.9 26.4 ± 6.6 28.6+8.0 13.6 + 4.1
t-PA activity (lU/ml) Baseline 2.1 ±0.5 1.8 ± 0.4 2.0 ± 0.3 2.1 ±0.5 1.2 ± 0.2 1.2 ± 0.2 0.8 ± 0.2 1.0 ± 0.2
4 5.3+ 1.0 2.2 ± 0.4 4.6 ± 0.8 2.5 ± 0.6 2.4 ± 0.5 1.29 ± 0.2 2.3 ± 0.5 1.0 ± 0.2
8 6.7+ 1.1 2.1 ± 0.4 4.7 + 0.9 2.7 ± 0.6 3.0 + 0.6 1.88 + 0.3 3.8+ 1.2 1.4 ± 0.3
16 7.6+ 1.1* 3.8 ± 0.8 7.0 + 0.9' 3.6 ± 0.9 5.5+ 1.0' 2.04 ± 0.4 5.9+ 1.7 1.7 + 0.4
Estimated t-PA activity release Baseline 0.1 ±0.2 -0.1 ±0.4 0.0 + 0.1 -0.3 + 0.1
(IU/10O ml/min) 4 16.8 ± 4.6 11.1 + 3.6 6.6 + 2.8 5.6+ 1.8
8 27.9 ± 5.9 11.3 + 3.8 6.1 ± 2.3 16.1 ± 8.5
16 25.5 ± 5.5' 18.3 + 4.2' 25.8 ± 5.3' 31.5 ± 13.6*
Net t-PA activity release (AUC) 57.5 ± 10.9 31.5 ± 8.2 25.6 ± 7.7 37.0 ± 16.7
PA 1-1 antigen (ng/ml) Baseline 33 ± 4 36 + 4 28 + 7 30 ± 7 43 ± 8 43 + 7 36 + 5 36 + 5
16 28 + 2 33 ± 4 32 + 7 33 ± 7 42 + 7 46 ± 8 36 ± 5 34 + 5
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subcutaneous veins of the antecubital fossae of both arms.
After 30 min equilibration with saline infusion, intra-arterial
substance P was administered at 4, 8, 16 pmol/min, acetyl¬
choline at 5, 10, 20 |xg/min and sodium nitroprusside at 2, 4,
8 gg/min for 10 ruin at each dose [8,11]. The drugs were
separated by 20 min of saline infusion and administered in a
randomized order. All infusions were given at a constant
infusion rate of 1 ml/min. Venous samples were taken at
baseline and during infusion of each substance P dose but
not during sodium nitroprusside or acetylcholine infusion
since they do not affect plasma t-PA or PAI-1 concentrations
in this forearm model [8,10,12],
1.7. Data analysis and statistics
Plethysmography and aggregonietry data were extracted
from the Chart data files and forearm blood flow was
calculated for individual venous occlusion cuff inflations
by use of a template spreadsheet (Excel 97, Microsoft).
Estimated net release of t-PA antigen and activity was
defined previously [8] as the product of the infused forearm
plasma flow (based on the mean hematocrit and the infused
forearm blood flow) and the concentration difference be¬
tween the infused and noninfused arms. Data was examined,
where appropriate, by analysis of variance (ANOVA) with
repeated measures and two-tailed paired Student's /-test
using Statvicw (SAS Institute). All results are expressed
as mean ± S.E.M. Statistical significance was taken at the
5% level.
2. Results
The baseline characteristics of all subjects arc shown
in Table 1. The patient groups are matched for age,
smoking history, diabetes mellitus, hypertension and se¬
verity of coronary artery disease although there appeared
to be a greater proportion of female subjects in the acute
stent thrombosis group. No significant abnormalities were
demonstrated in the thrombophilia screen in all study
subjects.
2.1. Endothelium-dependent vasomotion
There were no significant changes in heart rate, blood
pressure and non-infused forearm blood flow during drug
infusion in all studies. Forearm blood flow increased in a
dose-dependent manner during substance P, acetylcholine
and sodium nitroprusside infusions (P<0.05, ANOVA)
(Table 2). However, there were no significant differences
between the four groups.
2.2. Endogenous fibrinolysis
Compared to the non-infused arm, substance P caused
dose-dependent increases in plasma t-PA antigen and
activity concentrations in the infused ami in all subjects
(P<0.05, Table 3), but this increase was not different
between the groups. Patients with acute stent thrombosis
had an apparently higher t-PA antigen release but this
did not achieve statistical significance nor was this seen
with t-PA activity. Post-hoc analysis demonstrated a
significant reduction of t-PA antigen and activity release
in current smokers compared to non-smokers (P<0.05,
Fig. 1).
2.3. Platelet aggregation
All patients were on aspirin therapy and had reduced
platelet aggregation in response to collagen (P<0.01)
compared to healthy volunteers (Fig. 2). There was no
significant difference in platelet aggregation to thrombin,
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Fig. 1. F.stimated net release of t-PA antigen and activity in current smokers
(black), ex-smokers (grey) and non-smokers (white). Lower panel represents
area under the curve (AUC) for the response. ANOVA for smoking status
*P<0.01, 'pc0.05.
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Fig. 2. Platelet aggregation in response to thrombin, collagen. ADP and U46619 in patients with acute stent thrombosis (open inverted triangles), in-stent
restenosis (closed triangles) and uncomplicated PCI with stent implantation (open circles), and healthy matched controls (closed circles). P< 0.001 for each
dose response. */><0.01 controls vs. patients.
However, platelet aggregation was increased in patients
with acute stent thrombosis in response to ADP compared
to in-stent restenosis (P<0.001), although this was
not significant when compared to the control group
(P=0.19).
3. Discussion
We have assessed three critical aspects of vascular
function in patients who have undergone PCI. We have
found no evidence to indicate that endothelial vasomotor
or fibrinolytic function plays a major role in the patho¬
genesis of acute stent thrombosis or in-stent restenosis.
Moreover, in vitro platelet function appeared to be normal
with little evidence of alterations in platelet sensitivity to a
number of agonists. In contrast, we have been able to
confirm our previous findings [9,13] of the marked inhi¬
bition of acute t-PA release in current smokers. We
conclude that endothelial and platelet function do not
appear to be major determinants of acute stent thrombosis
or in-stent restenosis.
3.1. Endothelial vasomotor Junction
The endothelium plays a critical role in the regulation of
vasomotor tone [14,15] and its injury or dysfunction is an
important contributing factor in athcrothrombosis. There is
progressive impairment of endothelium-dcpendcnt vasodila¬
tation with the development of coronary atherosclerosis [16]
and its associated risk factors, such as hypercholesterolemia
[17], smoking [9] and diabetes mellitus [18]. In this study,
we assessed forearm blood flow following intra-arterial
infusions of the endothelium-dependent vasodilators, sub¬
stance P and acetylcholine, and the cndothelium-indepen-
dent vasodilator, sodium nitroprusside. We found no
differences in the forearm blood flow responses either
between the patient groups or comparing the patient and
healthy control groups. Given the absence of risk factors and
clinically evident disease, one would have anticipated greater
endothelium-dependent vasodilatation in the healthy control
subjects. However, ageing has a marked effect on the
regulation of basal [19] and stimulated [20] endothclium-
dependent vascular tone and we studied a predominantly
elderly population with a mean age of 62 years. Moreover.
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we recognise that subjects who are apparently healthy in this
age group commonly have subclinical atherosclerosis that
cannot be excluded in the absence of invasive investigation
such as coronary angiography.
3.2. Endogenous fibrinolysis
The regulated release of endothelial t-PA is an important
mechanism in the defence against intravascular thrombosis
especially in the coronary circulation [21]. Several investi¬
gators have suggested that impaired endogenous fibrinolysis
is associated with restenosis after PCI [22,23], and in
particular, a rise in plasma PAI-1 antigen concentrations
[24], In the present study, we were unable to find any
evidence of impaired endogenous fibrinolysis in our patients
with no apparent differences in plasma PAI-1 antigen con¬
centrations or acute endothelial t-PA release. However, when
stratifying the subjects according to smoking habit, post-hoc
analysis indicated that acute t-PA release was markedly
impaired in smokers compared to non-smokers. This con¬
firms our previous findings of impaired t-PA release in
smokers [9,13] and gives support to our conclusions that,
rather than a lack of power, there appears to be no major
impairment of endogenous fibrinolysis in patients with acute
stent thrombosis or in-stent restenosis.
3.3. Platelet function
Platelet adherence to the arterial wall occurs within
minutes of arterial injury. Pathological studies [25] in both
porcine coronary arteries and in human saphenous vein
grafts have shown that the earliest vascular response to stent
implantation is extensive platelet deposition. However, de¬
spite important reductions in periprocedural events [26,27],
the glycoprotein Ilb/lIIa receptor antagonist abciximab does
not reduce in-stent restenosis [28], Consistent with this
observation, platelet aggregation in response to thrombin,
A DP, the thromboxane A2 analogue U46619 or collagen was
unaffected in our study patient populations. In keeping with
long-term aspirin use, patients in all three groups demon¬
strated reduced collagen-dependent platelet aggregation in
comparison with healthy subjects. Again, this suggests that,
rather than a lack of power, there appears to be no major
difference in platelet aggregation in patients with acute stent
thrombosis or in-stent restenosis. Although assessment of
platelet function should ideally be performed after aspirin
has been withheld for at least 1 week, aspirin use was
unavoidable in our patient population.
3.4. Study limitations
There are several potential limitations to our clinical
study. First, complications from stent implantation may arise
due to procedural difficulties or suboptimal stent deploy¬
ment. However, we were careful to exclude such patients
with overt technical problems during the PCI procedure.
Second, acute stent thrombosis is a fortunately rare compli¬
cation of PCI but this makes recruitment of such patients
problematic. This is reflected in the modest number of
patients with acute stent thrombosis in our study and means
that we lack sufficient power to address the influence of all
the individual variables associated with thrombosis, partic¬
ularly given the higher proportion of female patients in this
group. The relatively low number of patients and subjects in
the whole study may also raise the potential possibility of a
type II error. Third, the assessment in our study is performed
at least 6 months following PCI and stent implantation in
order to exclude the development of late restenosis in the
control patient group. Whilst this avoids the influence of
acute confounding factors, we may have missed a transient
impairment in endothelial or platelet function. It is therefore
possible that changes in platelet behaviour, fibrinolysis or
vascular function may occur in the acute phase of stcnt-
thrombosis and this study does not definitely exclude that
changes in these factors contribute to the development of
acute stent thrombosis. Finally, we used a clinical diagnosis
of restenosis and cannot exclude a degree of subclinical
angiographic restenosis in the control patient group.
In conclusion, our study suggests that endothelial dys¬
function, platelet aggregation and endogenous fibrinolysis
do not appear to play a major role in the pathogenesis of
acute stent thrombosis or in-stcnt restenosis.
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Summary. Objectives: To determine if polymorphisms of the
tissue plasminogen activator (t-PA) gene influence acute
endogenous t-PA release in patients with coronary heart disease
(CHD). Methods: Forearm blood flow and plasma t-PA
concentrations were measured in response to intra-brachial
infusion of substance P and sodium nitroprusside in 96 patients
with stable CHD. Genotyping was performed using a Taqmttn
polymerase chain reaction assay specifically designed to detect
the polymorphisms of interest: (i) /1/rr-repeat insertion/deletion
sequence; (ii) C —> T substitution in an upstream enhancer
region (-7351 C/T); (iii) T —> C in exon 6 (20 099 T/C); and (iv)
T —> A (27 445 T/A) in intron 10. Results: Substance P and
sodium nitroprusside caused dose-dependent increases in
forearm blood flow in all patients (P < 0.001 for all) that were
independent of the four genetic polymorphisms. Similarly, there
were no differences in basal plasma t-PA antigen concentrations
or net l-PA release between genotypes. Compared to non-
smokers, smokers exhibited impaired substance P-induced
vasodilatation (P < 0.001) and t-PA release (P = 0.05).
Conclusions: Despite confirming our previous findings in
cigarette smokers, we have found no effect of polymorphisms
of the t-PA gene on two complementary aspects of endothelial
function. We conclude that genetic variation of the t-PA locus is
unlikely to have a major influence on acute t-PA release in
subjects with established CHD.
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olysis, genetic polymorphisms.
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Introduction
Coronary heart disease (CHD) and its risk factors, such as
cigarette smoking, hyperlipidemia and hypertension, are asso¬
ciated with impaired endothelium-dependent vasorelaxation
[1-3] and tissue plasminogen activator (t-PA) release [4-6].
These aspects of endothelial function are important as plasma
fibrinolytic variables and endothelium-dependent vasodilata¬
tion independently predict future cardiovascular risk [7,8].
Genetic factors influence plasma concentrations of a number
of hemostatic and fibrinolytic factors including t-PA, plasmi¬
nogen activator inhibitor type 1 (PAI-1) and fibrinogen [9]. A
common intronic polymorphism of the l-PA gene is generated
by the insertion of a 311 base pair Alu-repeat sequence [10],
Although not a consistent finding in all populations [11], there
is an independent association between the insertion (II)
genotype and the future risk of myocardial infarction (MI): a
relative risk of 2.24 in comparison with the deletion (DD)
genotype [12], This Alu intronic sequence is now known to be in
linkage disequilibrium (LD) with three single nucleotide
polymorphisms associated with t-PA release, within the
upstream enhancer region (7351 C —> T), in exon 6 (20 099
T —> C) and within intron 10 (27 445 T —> A) [13]. The C —> T
substitution within the enhancer region disrupts a binding site
for the Spl transcription factor and appears to be functionally
important [13,14] with TT homozygotes having an increased
risk of both MI [15] and lacunar stroke [16] compared to CC
homozygotes.
Genetic differences in t-PA release may alter the fibrinolytic
balance predisposing to local thrombus formation and an
increased likelihood of adverse athero-thrombotic events. Jern
and colleagues previously demonstrated a link between t-PA
release and both the Alu insertion/deletion and -7351 C/T
enhancer polymorphisms in healthy volunteers [13,17]. How¬
ever the functional importance of these genetic variants in
patients with established CHD is unknown. We hypothesized
that polymorphisms of the l-PA gene may influence endothelial
vasomotor and fibrinolytic function in patients with stable
CHD.
© 2006 International Society on Thrombosis and Haemoslasis
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Methods
Subjects
We recruited patients with CHD confirmed by angiography
(defined as > 70% luminal stenosis of at least one major
epicardial coronary vessel) or a history of Q-wave MI. All
patients had stable anginal symptoms and had not undergone
coronary revascularization within the preceding 3 months.
Exclusion criteria were significant cardiac failure, renal impair¬
ment, systolic blood pressure < 100 or >190 mmHg,
impaired fasting glucose (> 7 mmol L-1) or prior diagnosis
of diabetes mellitus. Self-reported smoking status was con¬
firmed using plasma cotinine levels [18]. All studies were
undertaken with the approval of the local Research Ethics
Committee, the written informed consent of each subject, and
in accordance with the Declaration of Helsinki.
Venous sampling and assays
Venous blood was collected into tubes containing acidified
buffered citrate (for t-PA), trisodium citrate (for PAI-1 and
cotinine), potassium ethylene diamine tetraacetic acid (forDNA
extraction) and serum gel tubes (for C-reactive protein; CRP).
Platelet-free plasma, serum and whole blood (DNA) were
stored at -80 °C before assay. Plasma t-PA and PAI-1 antigen
concentrations were determined using enzyme-linked immuno¬
sorbent assays (Coaliza®; Chromogenix, Molnoal, Sweden) [5]
with intra-assay and inter-assay coefficients ofvariation of7.0%
and 5.5%, and 4.0% and 7.3% for t-PA and PAI-1 antigen,
respectively [19], All fibrinolytic assays were performed in
duplicate and the mean value taken. Scrum CRP concentrations
were measured using particle-enhanced immunonephelometry
(Behring BN II nephelometer, Milton Keynes, UK). Plasma
cotinine concentrations were determined using high perform¬
ance liquid chromatography (ABS Laboratories Ltd, London,
UK) [18], Hematocrit was determined using an automated
Coulter counter (Beckman-Coulter ACt.8, High Wycombe,
UK). Biochemical assays were undertaken on the fasting venous
serum samples by the hospital clinical laboratory facility.
Cenotyping
Genomic DNA was isolated from whole blood. Lor the -7351
C —» T (upstream enhancer), 20 099 T —> C (exon 6), and
27 445 T —> A (intron 10) polymorphisms genotyping was
performed by allele discrimination analysis using the 5' nuclease
assay. Oligonucleotide primers and fluorescently labeled probes
were obtained from Applied Biosystems (Applied Biosystems,
Poster City, CA, USA) on the basis of previously published
DNA and primer sequences [13,15], In brief, polymorphic
target sequences were amplified by polymerase chain reaction
(PCR) in the presence of two fluorogenic probes specific for
each allele. Probes hybridize to their target during the annealing
step and the reporter dye is cleaved by the 5' nuclease activity of
Taq polymerase. Real lime quantitative PCR was performed in
an ABI PRISM® 7900HT Sequence Detector System (Applied
Biosystems). Thermal cycling conditions were two initial holds
(50 °C for 2 rnin and 95 °C for 10 min) followed by a 40-cycle
two-step program (95 °C for 15 s and 60 °C for 1 min) utilizing
a standardized operating protocol (WTCRP Genetics Core,
Edinburgh UK; http://www.wtcrf.ed.ac.uk; accessed 27 July
2006). The fluorescent contribution of each dye was determined
directly after the completion of PCR.
For the /1/w-intronic polymorphism, the insertion specific
sequence was submitted to the Applied Biosystems Assay-by-
design service. Gene expression assays consisted of unlabeled
PCR primers and TaqMan® MGB probes (FAM dye labeled).
Forward and reverse primers were 5'-CGTAACAGGACAG-
CTCACAGTT-3 and 5'-CCCTAGGAGAACTTCTCTTTA-
ACTTTGTT-3, respectively. The insertion specific probe was
labeled in its 5' end with FAM and in it 3' end with aNFQ (non-
fluorescent quencher): FAM-ACCCTATGAGATTAGAA-
CAC-NFQ. Real time quantitative PCR was performed with
a ABI PRISM® 7900HT Sequence Detector using the stan¬
dardized operating protocol described (WTCRF Genetics
Core; http://www.wtcrf.ed.ac.uk; accessed 27 July 2006). Alu-
insertion PCR products were normalized to threshold values
against an endogenous control (single copy RNase P gene).
Each sample was run in triplicate with both the gene of interest
and the RNase P control. Genotype for the /l/u-intronic
polymorphism was calculated from differences in the threshold
cycle between the RNAse P and /t/u-insertion sequence.
A confirmatory assay of Alu Ins/Del genotypes utilized PCR
amplification of the Ins fragment with primers designed to flank
the region of interest (PLAT.l 5' to 3' GTGAAAAGC-
AAGGTCTACCAG and PLAT.2 5' to 3' GACACCGAG-
TTCATCTTGAC). PCR was performed on a DNA engine
tetrad fromMJ Research (Bio-Rad Laboratories, Inc, Hercules,
CA, USA). Thermal cycling conditions were 94 °C for 2 min
followed by 35 cycles (30 s at 94 °C for and 30 s at 60 °C and
30 s at 72 °C) with a final extension step of 10 min at 72 °C. A
10-gL sample of this reaction was analyzed on a 2.5% agarose
gel and following electrophoresis DNA was visualized with
ethidium bromide and UV transillumination. Amplification of
the products produces a 570 bp fragment from chromosomes
with the Ins allele and a 260-bp fragment from those without
(Del). All genolyping was performed by an individual without
information on case status or vascular study data.
Drugs
Substance P (2, 4 and 8 pmol min-1; Clinalfa AG, Switzerland)
and sodium nitroprusside (2, 4 and 8 pg min-'; David Bull
Laboratories, Warwick, UK) were administered following
dissolution in 0.9% saline. All solutions were freshly prepared
on the day of study.
Forearm study protocol
Subjects were requested to abstain from alcohol for 24 h,
and food, caffeine-containing drinks and tobacco for at least
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4 h before each study. Cardioactive medications were
withheld on the morning of each study visit. All studies
were conducted in a quiet temperature controlled room
maintained at 22-25 °C. Patients rested recumbent, strain
gauges and cuffs were applied. A 17-G venous cannula was
inserted into the antecubital vein of each arm and the
brachial artery of the non-dominant arm was cannulated
with a 27-SWG needle (Cooper's Needle Works Ltd,
Birmingham, UK).
Forearm blood flow was measured in both forearms by
venous occlusion plethysmography as previously described
[5,20], Following a 30-min saline infusion to allow equilibration
and recording of resting blood flow, intra-arterial substance P
at 2, 4 and 8 pmol min"1 (cndothelium-dependent vasodilator
releasing t-PA) and sodium nitroprusside at 2, 4 and
8 |ig min- (endothelium independent vasodilator which docs
not release t-PA) [20] were each administered for 6 min in a
randomized order with a 15 min saline washout period
between each agent. Forearm blood flow was measured at
baseline and with each dose of vasodilator. Venous blood
sampling for determining plasma t-PA and PA1-1 antigen
concentrations was undertaken at baseline and following the
recording of blood flow response to each dose of substance P.
Blood pressure and heart rate were measured throughout each
study using a semi automated non invasive sphygmomanom
eter (Omron 705 IT; Omron Healthcare UK, Milton Keynes,
UK).
Statistical analysis
Plethysmographic data were extracted from Chart data files
and forearm blood flow calculated for individual venous
occlusion cuff inflations by use of a template spreadsheet (Excel
2002®; Microsoft™, Seattle, WA, USA). The last five flow
recordings in each 3-min measurement period were calculated
and averaged for each arm. Estimated net release of t-PA
antigen was defined [5,20] as the product of the infused forearm
plasma flow (based on the hematocrit and the infused forearm
blood flow), and the concentration difference between the
infused and non-infused forearms. Area under the curves
(AUCs) for the dose-response of t-PA release were calculated
using the trapezoid rule.
Allele frequencies were estimated by gene counting. Chi-
squared test was used to evaluate deviations of genotype
distributions from the Hardy-Weinberg equilibrium. The
LD coefficient D' was calculated as previously described
[21], Baseline characteristics of the study population are
presented as frequencies or mean values and standard error
of mean. Differences between groups were compared by
Student's t-test, chi-squared test, and, where appropriate, by
analysis of variance (anova) with repeated measures. As
CRP values were not normally distributed they were log
transformed prior to analysis. All statistical calculations were
undertaken using c.raphpad prism (GraphPad Software,
San Diego, CA, USA). Statistical significance was assigned
at the 5% level.
Table 1 Allele frequencies and pairwise linkage disequilibrium (LD)
coefficient between polymorphisms at the tissue plasminogen activator
(t-PA) locus; (chi-squared, degrees of freedom), P < 0.01 for all
Allelic
frequency Alu -7351 20 099 27 445
Alu Ins -> Del 0.65/0.35 0.63 0.83 0.60
(67.4; 4) (107.8; 4) (76.7; 4)
-7351 C—>T 0.69/0.31 0.85 0.68
(93.7; 4) (82.3; 4)
20 099 T —> C 0.63/0.37 0.66
(98.5; 4)
27 445 T —» A 0.73/0.27
Results
A total of 96 patients were recruited with a cardiovascular risk
factor profile in keeping with their diagnosis ofCHD and most
were prescribed secondary preventative medications. The
genotype distributions for the Alu insertion/deletion (II 46%,
ID 36% and DD 18%),-7351 C/T enhancer (CC 54%, CT 32%,
and TT 14%), 20 099 T/C exon 6 (TT 42%, CT 43%, and CC
15%) and 27 445 T/A intron 10 (TT 56%, TA 34% and AA
10%) were in keeping with the Hardy-Weinberg equilibrium.
There was significant LD between the four polymorphisms
(Table 1) with allelic frequencies being similar to published
studies of European Caucasian subjects [13,17], There was
complete agreement between the two PCR methods in the
determination ofAlu insertion/deletion genotype. Three subjects
could be genotyped only for the Alu insertion/deletion variant.
Biometric variables were similar between genotypes
(Tables 2 and 3; data on file, University of Edinburgh,
Edinburgh, UK) although there were significantly fewer smok
ers in the -7351 heterozgote group (P = 0.01, chi-squared).
Hemodynamics and forearm blood flow
Resting heart rate, blood pressure and non-infused forearm
blood flow were similar in each group and these did not change
significantly during infusion of cither vasodilator (Tables 2 4;
data on file).
Substance P and sodium nitroprusside increased the infused
forearm blood flow in all subjects (P < 0.001, anova). None
of the genetic polymorphisms appeared to influence the
endothelium-dependent or -independent blood flow responses
(Fig. 1; data on file).
Plasma fibrinolytic variables
Baseline plasma t-PA and PAI-1 antigen concentrations were
similar for each genotype (Table 4; data on file). Substance P
caused a dose-dependent increase in plasma t-PA antigen
within the infused ami in all three groups (P < 0.01, anova)
whilst plasma PAI-1 antigen concentrations were unchanged
(data on file). There were no differences in substance P-induced
t-PA release between any of the genetic polymorphisms (Fig. 2;
data on file). Similarly, the AUC for net t-PA release over the
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Table 2 Clinical characterislics of subjects according to Alu insertion/
deletion genotype (n = 96)
Genotype
Table 3 Clinical characteristics of subjects according to -7351 C/T geno¬







(« = 17) P1
Age, years 59 ± 1 60 ± 1 59 ± 2 0.88
Gender, male/female 33/11 32/3 14/3 0.16
BMI, kg nT2 29 ± 1 28 ± 1 30 ± 1 0.27
Systolic BP, mrnHg 136 ± 3 128 ± 4 132 ± 4 0.23
Diastolic BP, mmHg 79 ± 2 75 ± 2 73 ± 2 0.30
Pulse, bpm 57 ± 1 58 ± 2 57 ± 3 0.96
Current smoker (%) 30 23 47 0.42
Co-morbidity (%)
Previous Ml 43 46 24 0.28
Hypertension 50 49 47 0.98
FHx CHD 52 37 29 0.74
Prior hyperlipidemia 93 94 94 1.00
Extent of coronary disease, (%)*
1 vessel 41 51 41 0.33
2 vessels 27 20 24 0.86
3 vessels 30 17 35 0.43
Medical therapy, (%)
Aspirin 100 100 94 0.10
Stalin therapy 91 97 94 0.52
ACE inhibitor, ARB 27 34 29 1.00
Urea, mrnol L-' 5.4 ± 0.2 5.6 ± 0.3 5.7 ± 0.4 0.70
Creatinine, pmol L_ 93.1 ± 2.5 94.6 ± 2.1 91.3 ± 2.6 0.72
Glucose, mmol L~' 5.6 ± 0.1 5.7 ± 0.2 6.0 ± 0.2 0.24
Total chol, mmol L~' 4.5 ± 0.2 4.4 ± 0.2 4.4 ± 0.2 0.89
LDL chol, mmol L_l 2.6 ± 0.1 2.5 ± 0.2 2.2 ± 0.2 0.28
Triglycerides, mmol L_l 1.7 ± 0.2 1.7 ± 0.2 2.3 ± 0.3 0.09
CRP, mg L~' 1.87 ± 0.18 1.92 ± 0.35 1.90 ± 0.41 0.97
Values are mean ± SEM.
•Angiographic data unavailable on five subjects. iP = anova or chi-
squared for difference between genotypes. BMI, body mass index;
bpm, beats per minute; CHD, coronary heart disease; Ml, myocardial
infarction; FHx, family history; chol, cholesterol; ACE, angiotensin







(« = 13) Px
Age, years 59 ± 1 59 ± 1 61 ± 3 0.82
Gender, male/female 38/12 27/3 11/2 0.28
BMI, kg irT2 29 ± 1 28 ± 1 29 ± 1 0.47
Systolic BP, mmHg 134 ± 3 131 ± 4 123 ± 6 0.27
Diastolic BP, mmHg 79 ± 2 75 ± 2 70 ± 3 0.07
Pulse, bpm 57 ± 1 57 ± 2 54 ± 3 0.57
Current smoker (%) 46 13 38 0.01
Co-morbidity (%)
Previous Ml 44 43 38 0.89
Hypertension 46 40 62 0.43
FHx CHD 32 37 31 0.23
Prior hyperlipidemia 92 93 92 0.98
Extent of coronary disease, (%)*
1 vessel 40 50 38 0.64
2 vessels 24 23 23 0.99
3 vessels 30 20 38 0.42
Medical therapy, (%)
Aspirin 100 97 100 0.35
Statin therapy 88 100 92 0.14
ACE inhibitor, ARB 28 23 54 0.98
Urea, mmol L~' 5.2 ± 0.2 5.7 ± 0.2 6.1 ± 0.5 0.09
Creatinine, pmol L~' 93.3 ± 2.2 92.6 ± 2.1 92.3 ± 4.0 0.96
Glucose, mmol L~ 5.6 ± 0.1 5.6 ± 0.2 6.0 ± 0.3 0.26
Total chol, mmol L~' 4.6 ± 0.2 4.4 ± 0.2 4.2 ± 0.3 0.37
LDL chol, mmol L~ 2.7 ± 0.1 2.6 ± 0.1 2.0 ± 0.3 0.08
Triglycerides, mmol L~' 1.8 ± 0.2 1.6 ± 0.1 2.4 ± 0.3 0.08
CRP, mg L"' 2.02 ± 0.29 1.5 ± 0.3 2.3 ± 0.7 0.49
Values are mean ± SEM.
•Angiographic data unavailable on five subjects. 'P — anova or chi-
squared for difference between genotypes. BMI, body mass index;
bpm, beats per minute; CHD, coronary heart disease; Ml, myocardial
infarction; FHx, family history; chol, cholesterol; ACE, angiotensin
converting enzyme; ARB, angiotensin receptor blocker; CRP, C-
reaclive protein.
30-min period of substance P infusion was similar between
genotypes (data on file).
Smoking status was confirmed by plasma cotinine con¬
centration (median 307.8 vs. 0.6 ng mL~' in smokers and
non-smokers respectively). Subgroup analysis revealed an
interaction between smoking status and vascular function.
Consistent with our previous findings, cigarette smokers had
impaired forearm blood flow (FBF) responses (P < 0.001,
anova) and net t-PA release (P = 0.05, anova; Fig. 3)
compared to non-smokers. In light of the uneven distribution
of smokers across -7351 genotypes and the interaction between
smoking and t-PA release, we performed a post hoc analysis of
t-PA release according to smoking status. However, we found
no difference in the AUC for net t-PA release between CC, CT
and TT -7351 genotypes in either smokers (111 [48-174]; 167
[94-240]; 193 [5-382]; P = 0.41 anova) or non-smokers (187
[114-260]; 160 [100-220]; 188 [50-325]; P = 0.83) respectively
(mean [95% confidence intervals]).
Discussion
This is the first study to assess directly the role of t-PA genetic
polymorphisms in determining acute t-PA release in patientswith
CHD. Using a validated and reproducible technique [22], we
have found no difference in the basal concentration, or net release
of, plasma t-PA antigen between genotypes. These important
findings suggest that, in patients with established coronary
atherosclerosis, variation at the t-PA gene locus does not
substantially influence acute endogenous fibrinolytic capacity.
Tissue plasminogen activator release from endothelial cells is
the major arbiter oflocal intravascular fibrinolysis [23] and will
influence vessel patency following acute coronary thrombosis
[24], Inter-individual differences in t-PA release may contribute
to a pro-thrombotic phenotype and determine the sequelae of
acute MI. Indeed, clustering of individuals with low rates of t-
PA release has been reported in families with a history of
thrombosis [25], Moreover, genetic murine models of t-PA
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Table 4 Elfect of A!u insertion/deletion and -7351 C/T genotypes on baseline forearm blood flow, tissue lype-plasminogen activator (t-PA) and
plasminogen activator inhibitor type 1 (PAI-1) antigen concentrations; P = ns between genotypes
Alu Insertion/deletion
11 ID DD CC
-7351 C/T
CT TT
Forearm blood flow (mL 100 mL tissue"
Infused arm 2.7 ± 0.1
Non-infused arm 2.7 ± 0.2
t-PA antigen (ng mL" )
Infused arm 9.1 ± 0.5
Non-infused arm 9.3 ± 0.5
PAI-1 antigen (ng mL"')
Infused arm 43.3 ± 4.2















































































Sodium Nitroprusside, pg min"
Fig. 1. Infused (solid line) and non-infused (dashed line) forearm blood
flow during inlra-brachial substance P (left) and sodium nilroprusside
(right) according to (A) Alu insertion/deletion, and (B) -7,351 C/T, geno¬
types. P < 0.001, anova, lor infused FBF response to both vasodilators.
deficiency show a reduced thrombolytic potential and an
increased thrombotic tendency [26]. We therefore wanted to
explore the potential genetic influences on t-PA release in at
risk patients with CHD.
The t-PA -7351C —» T enhancer site polymorphism has been
associated with an increased risk of first MI [15] and lacunar
stroke [16] although the data on non-lacunar stroke is
conflicting [16,27], The strong linkage between the -7351 C/T
enhancer and the /f/u-repeat polymorphisms may explain the
association between the (non-coding) Alu insertion/deletion
polymorphism and cardiovascular events [12,13], In healthy
volunteers (n = 51), both the Alu insertion/deletion and -7351
C —> T enhancer polymorphisms were associated with signifi¬
cant differences in basal t-PA release with II and CC homo-
zygotes having around 2-fold greater release rates than the DD
and TT homozygotes respectively [13,17], Of the genotypes
studied here, the 7351 C —> T substitution is thought to result in




























Substance P, pmol min
Fig. 2. Estimated net release of tissue plasminogen activator (t-PA)
antigen induced by intra-brachial substance P (2, 4 and 8 pmol min"1)
according to (A) Alu insertion/deletion, and (B) -7351 C/T, genotypes.
P < 0.001, anova, for dose response.
factor binding site which is negatively regulated by binding of
the thymidine allele [13]. However despite this difference in
basal l-PA release rate, acute t-PA release was similar between
all genotypes. Now, in a larger cohort of subjects (n = 96) with
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Fig. 3. Infused (solid line) and non-infused (dashed line) forearm blood
flow (A), and net l-PA release (B), in response to intra-brachial substance P
in smokers (filled circle) and non-smokers (hollow circle). *P < 0.001,
2-way anova, infused FBF response in smokers vs. non-smokers; **P =
0.05, 2-way anova, net l-PA release in smokers vs. non-smokers.
established CHD, wc have shown that there is no significant
relationship between basal plasma t-PA concentrations or acute
t-PA release, and these genetic polymorphisms. Furthermore,
endothelium-dependent vasodilatation, a complementary
measure of endothelial function, was similarly unaffected by
variation within the t-PA gene locus.
Regulatory control of t-PA release involves distinct path¬
ways from those controlling vessel culibre and indeed t PA
release can be induced without changes in forearm blood flow
[28], In view of previous work in healthy volunteers [13,17], we
chose to assess whether a number of t PA genetic polymor
phistns were associated with changes in vascular function in
patients with CHD. If t-PA genotype was important in
regulating endogenous t-PA release, certain alleles could favor
the continued presence of thrombus following atheromatous
plaque rupture. Organization of residual thrombus is known to
stimulate further plaque growth and expansion [29], disrupting
endothelial integrity that is critical to the regulation of vascular
tone and coagulation. Impaired endothclium-dependent vaso¬
dilatation is considered a surrogate of endothelial dysfunction
and has been widely studied as a bio-marker of atherosclerosis.
We therefore hypothesized that t-PA genetic polymorphisms
might also be associated with changes in endothelium-depend¬
ent vasodilatation through pathways linking coagulation,
atherogenesis, and endothelial dysfunction. However, we found
no evidence to support the contention that t-PA polymor¬
phisms influence endothelial function in patients with CHD. In
contrast, cigarette smoking and CHD are associated with
endothelial dysfunction as demonstrated by impaired endothe¬
lium-dependent vasodilatation [1] and endogenous t-PA release
[5,30], Our study confirms these previous findings in cigarette
smokers in a large cohort of patients with established CHD
maintained on secondary preventative medications. These
consistent findings would appear to reaffirm the validity of
our approach and suggest that environmental rather than
genetic factors have a more dominant influence on acute
endogenous t-PA release.
There are a number of differences between the current
study and previous reports demonstrating an interaction
between acute t-PA release and polymorphisms within the t-
PA gene locus. Our population comprised subjects with
established CHD recruited within the UK. In contrast, Jern et
al. [13,17] studied healthy Scandinavian volunteers free of
symptomatic atherosclerosis. A recent mcta analysis of studies
on genetic polymorphisms and CHD risk demonstrated
heterogeneity according to the population studied [31]. The
/f/u-repeat polymorphism was associated with an increased
incidence of acute MI in Dutch subjects [12] but not in studies
from North America [11] or the UK [32], Our subjects were all
of European Caucasian origin, recruited from within the same
geographical area, and had similar risk factor profiles. It
seems unlikely that biological variability or modulation from
environmental factors obscured true differences in t-PA
release between genotypes. Although our findings may not
be applicable to other racial groups, Rosenbaum and
colleagues [33] failed to demonstrate differences in acute
endogenous t-PA release between healthy black and white
Americans.
Study limitations
Although endothelium-dependent blood flow responses are
similar in the forearm and coronary circulations [34], we
cannot be sure that these polymorphisms of the t PA gene do
not influence fibrinolytic responses within the coronary
circulation. Indeed, there are limited data to suggest that,
although not apparent in the forearm circulation, angioten
sin-converting enzyme gene insertion/deletion polymorphism
can influence acute t-PA release in the coronary circulation
[35].
Jern and colleagues previously demonstrated a difference
in basal, though not stimulated, t-PA release according to t-
PA genotype [13,17], Whilst we cannot determine basal t-PA
release using the venovenous technique described, we have
found no relationship between t-PA genotype and stimulated
t-PA release. Calculation of net t-PA release provides an
accurate assessment of stimulated t-PA release with good
reproducibility [19], and basal release contributes only a
small proportion of the overall venous plasma t-PA
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concentration. In this study we did not find any difference in
acute t-PA release in response to substance P between t-PA
genotypes. However, our study protocol cannot exclude the
possibility that these polymorphisms might alter protein
transcription and endothelial storage, or the very early
(< 6 rnin) release of, t-PA in response to substance P
infusion [36],
In our cohort, there was an uneven distribution of smokers
between t-PA -7351 CC, CT and TT groups. Although we
found no difference in net t-PA release between these three
groups when analyzed according to smoking status, we accept
that the relationship between cigarette smoking and impaired l-
PA release may have obscured an association between t-PA
genotype and fibrinolytic function with the post hoc analysis
limited by the number of smokers and non-smokers within
each group.
Conclusion
Whilst we have confirmed previous findings showing that
cigarette smokers have impaired endothelial vasomotor and
fibrinolytic function, we have found no major effect of genetic
variation within the t-PA gene locus on either plasma t-PA
concentrations or acute t-PA release in subjects with stable
CHD.
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ABSTRACT
Hyperhomocysteinaemia is a prothrombotic condition that may cause oxidative endothelial injury
and impair endogenous fibrinolysis. Vitamin supplementation enhances endothelial function in hy-
perhomocysteinaemic patients, but responses in patients with co-existing coronary artery disease
have been variable. It is also unknown whether hyperhomocysteinaemia is associated with reduced
fibrinolytic responses in patients with coronary artery disease. The study aims were to test the
hypothesis that patients with recent myocardial infarction and hyperhomocysteinaemia have im¬
paired endothelium-dependent vasomotion and fibrinolysis that is rectified by vitamin supple¬
mentation. From a cohort of 120 patients admitted with acute myocardial infarction, 18 patients
were recruited from the upper (n = 9) and lower (n = 9) plasma homocysteine quartiles into a
randomized double-blind placebo-controlled crossover trial. Following a 4-week course of placebo
or folate/cyanocobalamin/pyridoxine supplements, FBF (forearm blood flow) was measured using
venous occlusion plethysmography during intra-arterial substance P (4-16 pmol/min), acetylcholine
(5-20 /zg/min) and sodium nitroprusside (2-8 yig/min) infusions. All vasodilators caused dose-
dependent increases in infused FBF (P < 0.05). Patients in the upper homocysteine quartile
(16.8 + 2.9 compared with 7.9 + 0.7 /zmol/T, P = 0.003) had reduced vasodilatation to acetylcholine
(P = 0.01) and substance P (P < 0.05), but not sodium nitroprusside. There were no differences
in substance P-induced tissue plasminogen activator release. Vitamin supplementation increased
serum folate and vitamin Bq concentrations (P < 0.05), but did not significantly lower homo¬
cysteine, or affect FBF or fibrinolytic responses. In patients with recent myocardial infarction,
hyperhomocysteinaemia is associated with impaired endothelium-dependent vasodilatation, but no
alteration in the acute fibrinolytic capacity. This endothelial vasomotor dysfunction is unaltered
by vitamin supplementation.
INTRODUCTION
Several prospective and case-control studies have shown
that elevated plasma homocysteine concentrations are an
independent risk factor for the development of athero-
thrombotic vascular disease as well as a prognostic marker
in ischaemic heart disease [1—3]. Plasma homocysteine
concentrations are consistently higher in patients with
premature peripheral and cerebrovascular diseases [4],
and almost a third of patients with premature coronary
Key words: endothelial dysfunction, fibrinolysis, homocysteine, myocardial infarction, vasodilatation, vitamin.
Abbreviations: CI, confidence interval; FBP, forearm blood flow; NS, not significant; I'AI-1, plasminogen activator inhibitor type 1;
t-PA, tissue plasminogen activator.
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artery disease are found to have hyperhomocysteinaemia
[1], In addition, apparently healthy men with plasma
homocysteine concentrations 12 % above the upper limit
of normal have a 3-fold increased risk of acute myocardial
infarction [2], and in patients with ischaemic heart disease
there is an increased mortality associated with plasma
concentrations greater than 9 /xmol/1 [5].
The vascular endothelium plays a central role in the
control of blood flow, haemostasis and endogenous fib¬
rinolysis, and endothelial dysfunction independently pre¬
dicts cardiovascular events [6,7], Although the mechan¬
ism of vascular damage is unclear, homocysteine may
promote atherogenesis through oxidative endothelial in¬
jury that is mediated by cytotoxic reactive oxygen species
[8-10]. Indeed, acute and chronic hyperhomocystein¬
aemia are associated with impaired endothelium-depen-
dent flow-mediated dilatation of the brachial artery
[10-12],
Hyperhomocysteinaemia is a prothrombotic state [3].
We [13] and others [14] have shown previously that hy¬
perhomocysteinaemia induced by oral methionine load¬
ing is associated with alterations in endogenous fibri¬
nolysis in healthy subjects and patients with premature
vascular disease. However, the influence of chronic
hyperhomocysteinaemia on the acute fibrinolytic capa¬
city is unknown and is the subject of debate [15]. Inter¬
estingly, there is an association between plasma homo¬
cysteine and t-PA (tissue plasminogen activator) antigen
concentrations in stroke patients [16].
Vitamin supplementation with folate, vitamin B(, and
vitamin B|2 is safe and may reduce plasma homocysteine
concentrations [17]. Although endothelial function is
enhanced following treatment with folate in patients
with hyperhomocysteinaemia [18,19] and hypercholes-
terolaemia [20], the response in patients with coronary
artery disease has been variable [21-25]. Furthermore,
it is unknown whether elevated plasma homocysteine
concentrations are associated with reduced resistance
vessel vasomotor responses in patients with established
coronary artery disease.
The aim of the present study was to test the hypo¬
theses that, in patients with recent myocardial infarction,
elevated plasma homocysteine concentrations are asso¬
ciated with impaired endothelium-dependent vasodilata¬
tion and endogenous fibrinolytic capacity, and that vita¬
min supplementation (with folate, vitamin B<; and vitamin




One hundred and twenty patients admitted with an acute
myocardial infarction were recruited into the trial. Myo¬
cardial infarction was defined as typical ischaemic cardiac
pain associated with elevation of cardiac markers (greater
than twice the upper limit of normal) and electrocardi¬
ographic evidence of myocardial ischacmia. Exclusion
criteria were atrial fibrillation on warfarin therapy, im¬
paired renal function (serum creatinine > 120 /xmol/1),
diabetes mellitus, requirement for folate supplementation
or pernicious anaemia. The written informed consent of
each subject was obtained before entry into the study. All
studies were undertaken with the approval of the local
Research Ethics Committee and in accordance with the
Declaration of Helsinki (1996).
Study design
Fasting plasma homocysteine concentrations were deter¬
mined in all patients on days 5-7 following acute myo¬
cardial infarction [26], From the upper and lower plasma
homocysteine concentration quartiles, nine patients in
each quartile were recruited into a randomized double-
blind balanced-block placebo-controlled crossover trial
at least 4 months after the index event. All patients rece¬
ived two separate 4-week courses of oral sucrose placebo
or vitamin supplementation (5 mg of folate/100 /xg of
cyanocobalamin/10 mg of pyridoxine), and attended at
the end of each 4-week treatment period. On each study
day, medications were withheld and subjects attended
after a 4-h fast and rested recumbent in a quiet temper¬
ature-controlled room maintained at 22-25 °C. Strain
gauges and cuffs were applied, and the brachial artery
of the non-dominant arm was cannulated. After 30 min
equilibration with saline infusion, intra-arterial substance
P (4-16 pmol/min), acetylcholine (5-20/xg/min) and
sodium nitroprusside (2-8 /xg/min) were administered
in a randomized order for 6-10 min at each dose and
separated by 20 min washout periods [27-29], Venous
samples were taken at baseline and during infusion of each
substance P dose for determination of t-PA and PAI-1
(plasminogen activator inhibitor type 1). Venous sam¬
pling was not performed during sodium nitroprusside or
acetylcholine infusion, since they do not affect t-PA or
PAI-1 release in this forearm model [13,27,30].
Intra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannu¬
lated with a 27-standard wire gauge steel needle (Cooper's
Needle Works, Birmingham, U.K.) under 1 % lidocaine
(Xylocaine; Astra Pharmaceuticals, Kings Langley,
Herts., U.K.) local anaesthesia and attached to a
16-gauge epidural catheter (Portex, Hythe, Kent, U.K.).
Patency was maintained by infusion of saline (0.9%
NaCl) via a MS2000 syringe infusion pump (Graseby
Medical, Watford, Herts., U.K.). The total rate of intra¬
arterial infusions was maintained constant throughout
all studies at 1 ml/min. Pharmaceutical grade substance
P (Clinalfa, Liiufelfingen, Switzerland), acetylcholine
(Cibavision Ophthalmics, Southampton, U.K.) and so¬
dium nitroprusside (David Bull Laboratories, Warwick,
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U.K.) were administered following dissolution in saline.
All solutions were freshly prepared on the day of study.
Haemodynamic measurements
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
strain gauges as described previously [27,28]. During
measurement periods, the hands were excluded from
the circulation by rapid inflation of the wrist cuffs to
220 mmHg using E20 rapid cuff inflators (DE Hokanson,
Bellevue, WA, U.S.A.). Upper arm cuffs were inflated
intermittently to 40 mmHg for 8 s in every 10 s to achieve
venous occlusion and obtain plethysmography record¬
ings. Blood pressure was monitored in the non-infused
arm at intervals throughout each study with a semi-
automated non-invasive oscillometry sphygmomano¬
meter (Takeda UA 751; Takeda Medical, Tokyo, Japan).
Venous sampling and assays
Venous cannulae (17-gauge) were inserted into large
subcutaneous veins of the antecubital fossae of both arms.
Venous blood was withdrawn simultaneously from
each arm and collected into acidified buffered citrate
(Biopool® Stabilyte1M, Umea, Sweden) for t-PA assays
and trisodium citrate and lithium heparin tubes
(Monovette®, Sarstedt, Niinrbrecht, Germany) for PAI-1
and homocysteine assays respectively. Samples were kept
on ice before being centrifuged at 2000 g. Platelet-free
plasma was decanted and stored at — 80°C before as¬
say. Plasma t-PA and PAI-1 antigens were determined as
described previously [27] using ELISA (Coaliza t-PA and
Coaliza PAI-1; Chromogenix, Molndal, Sweden),
and plasma t-PA activity was determined using a photo¬
metric method (Coatest t-PA; Chromogenix). Plasma
homocysteine (Axis® Plomocysteine EIA; Axis-Shield,
Oslo, Norway) and serum folate and vitamin B^ con¬
centrations (Bayer Immuno 1® automated immunoassay
analyser, Bayer, Leverkusen, Germany) were determined
using enzyme immunoassay.
Data analysis and statistics
Estimated net release of t-PA antigen and activity were
defined previously [27] as the product of the infused
forearm plasma flow [based on the mean haematocrit
(Hct) and the infused FBF (forearm blood flow)] and the
concentration difference between the infused ([t-PA];nf)
and non-infused ([t-PA]i\|un;nf) arms using the formula:
Estimated net t-PA release
= FBF x (1 - Hct) x ([t-PA];nf - [t-PA]Noninf)
Data were examined, where appropriate, by ANOVA
with repeated measures and two-tailed paired Student's
t test (SAS Institute). All results are expressed as means
(S.E.M.) or means [95% CI (confidence interval)]. Stat¬
istical significance was taken at the 5 % level.
Table I Patient characteristics
Values are means (S.E.H.), or numbers (percentage). ACE, angiotensin-converting
enzyme.
Patients in Patients in







Sex (male/female) 9/0 8/1
Mean arterial pressure (mmHg) 88 (5) 86 (2)
Heart rate (beats/min) 59 (2) 54 (2)
Type ol myocardial infarction
Anterior (n) 2 (22 %) 3 (33 %)
Inferior (n) 6 (67 %) 3 (33%)
Other (n) 1 (11%) 3 (33 %)
Peak creatine kinase (units/I) 790 (230) 1900 (550)
Received thrombolysis (n) 6 (67%) 6 (67%)
Medication
Antiplatelet therapy (n) 9 (100%) 9 (100%)
/f-Adrenoceptor antagonists (n) 8 (89%) 6 (67%)
ACE inhibitors (n) 5 (56%) 5 (56%)
HMG CoA reductase inhibitors (n) 8 (89%) 7 (77 %)
Risk factors
Smokers (n) 6 (67%) 3 (33 %)
History of hypertension (n) 3 (33 %) 2 (22%)
Hypercholesterolaemia (n) 8 (89%) 7 (77 %)
Diabetes mellitus (n) 0 (0%) 0 (0%)
RESULTS
Baseline and biochemical characteristics
From the upper and lower plasma homocysteine quar-
tiles, 18 patients (nine patients in each quartile) were
recruited into the randomized controlled trial. Apart
from plasma homocysteine concentrations (PcO.Ol, as
determined by Student's t test), which were significantly
different by design, there were no significant differences
between the baseline clinical characteristics or medi¬
cal therapies in the two groups of patients (Tables 1
and 2).
All subjects tolerated placebo and vitamin supplemen¬
tation and no side effects were reported or noted. Serum
folate and vitamin B12 concentrations were increased
following vitamin supplementation compared with
placebo in both patient groups (P < 0.001 and P< 0.05
respectively, as determined by Student's t test; Table 2).
Plasma homocysteine concentrations appeared to be re¬
duced by r»16% with active treatment in hyperhomo-
cysteinacmic patients, but this was not statistically signi¬
ficant (P = 0.3, as determined by Student's t test; Table 2).
Vitamin supplementation had no significant effects on
heart rate, blood pressure or basal FBF in either patient
group.
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Table 2 Plasma homocysteine, serum folate and vitamin
Bi2 concentrations following vitamin supplementation
Values are means (S.E.M.). " P < 0.01 compared with lower quartile, as determined































1; Upper limit of serum folate assay was 20 /cg/l; 13 patients had concentrations above
this after supplementation and were taken as 20 pcg/l.
Endothelium-dependent vasomotion
Substance P, acetylcholine and sodium nitroprusside
caused dose-dependent increases in blood flow in the
infused forearm in both patient groups on each study
day (P < 0.05, as determined by ANOVA; Figure 1).
In comparison with patients in the lower quartile, hy-
pcrhomocystcinaemic patients had significantly reduced
FBF responses to acetylcholine and substance P (P= 0.01
and P< 0.05 respectively, as determined by ANOVA;
Figure 1), but there were no significant differences in the
blood flow responses to sodium nitroprusside [P= NS
(not significant), as determined by ANOVA].
Neither endothelium-dependent nor endothelium-
independent vasodilatation were significantly influenced
by vitamin treatment in either patient group (P=NS
for all, as determined by ANOVA). For the hyperhomo-
cysteinaemic group, the mean difference for the res¬
ponse to vitamin treatment at the peak dose was 1.1 ml ■
100 ml-1 • min"1 (95% CI, —0.8 to +2.9) for substance
P, 0.3 ml • 100 ml"' • min"1 (95 % CI, — 1.3 to +1.8) for
acetylcholine, and — 0.3 ml ■ 100 ml"1 ■ min-' (95% CI,
— 2.8 to +2.1) for sodium nitroprusside. For the lower
quartile group, the mean difference for the response
to vitamin treatment at the peak dose was 2.0 ml ■
100ml"1 -min"1 (95% CI, —0.6 to +4.6) for substance
-2.9 to +1.2)
in"1 (95% CI,
P, -0.8 ml 100 ml"1 min"1 (95% CI,
for acetylcholine, and 1.7 ml • 100 ml"1 ■ n
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Fibrinolytic responses
Baseline plasma t-PA and PAI-1 antigen and t-PA activ¬
ity concentrations were similar in both groups (Table 3).
Substance P caused dose-dependent increases in plasma
t-PA antigen and activity concentrations in the infused
forearm of all patients (P < 0.05 for both, as determined
by ANOVA; Table 3). The responses were similar in
both patient groups and were not influenced by vitamin
Figure I Infused (solid line) and non-infused (dashed line)
FBF responses to incremental doses of substance P (upper
panel) and acetylcholine (lower panel) in patients in
upper (closed symbols) and lower quartiles (open symbols)
following placebo (left panel) and vitamin supplementation
(right panel)
P < 0.05 for all infused arm responses, as determined by ANOVA. * P < 0.05
compared with lower quartile, as determined by ANOVA.
supplementation (/5 = NS, as determined by ANOVA).
The mean difference of t-PA antigen release for the res¬
ponse to vitamin supplementation at the peak substance
P dose was — 2.7 ng ■ 100 ml"1 ■ min"1 (95 % CI, — 15.5
to +10.2; P = NS, as determined by Student's t test) in
the upper quartile group and — 7.4 ng • 100 ml"1 • min"1
(95% CI, —24.3 to +9.5, P = NS, as determined by
Student's t) in the lower quartile group. Plasma PAI-1
concentrations were unaffected by substance P infusion
or vitamin treatment (P = NS, as determined by Student's
t test).
DISCUSSION
In the present study, we have demonstrated that, in pati¬
ents with a recent myocardial infarction, elevated plasma
homocysteine concentrations arc associated with im¬
paired endothelium dependent vasodilatation without af
fecting acute endogenous t-PA release. However, vitamin
supplementation failed to significantly reduce plasma
homocysteine concentrations or improve endothelial
vasomotor function.
© 2005 The Biochemical Society
Homocysteine, endothelial function and fibrinolysis 69
Table 3 Plasma t-PA and PAI-I concentrations and release during substance P infusion
Values are means (S.E.M.). 'P < 0.05 for all responses during substance P infusion, as determined by ANOVA. AUC, area under curve; IU, international units.
Patients in the upper quartile Patients in the lower quartile
Placebo Treatment Placebo Treatment
Substance P Non-infused Non-infused Infused Non-infused Non-infused
(pmol/min) Infused arm arm Infused arm arm arm arm Infused arm arm
t-PA antigen (ng/ml) Baseline 7.7 (1.2) 8.6 (1.4) 7.5 (1.0) 8.2 (1.4) 6.5 (1.3) 7.2 (1.3) 7.6 (1.3)
4 9.8 (1.5) 8.3 (1.3) 9.2 (1.0) 7.7 (1.3) 7.0 (I.I) 8.1 (1.4) 7.6 (1.4)
8 9.4 (1.5) 8.1 (I.I) 10.3 (I.I) 7.8 (1.0) 7.1 (1.2) 8.9 (1.5) 7.6 (1.5)
16 12.7 (2.4)* 7.8 (0.9) ll.l (1.4)* 7.6 (I.I) r 6.7 (1.3) 10.5 (1.6) 7.9 (1.4)
Estimated t-PA antigen release Baseline - I.I (0.7) - 1.2 (I.I) - 0.3 (0.4)
(ng • 100 ml-1 • min-') 4 4.0 (3.2) 5.4 (3.4) 1.4 (1.5)
8 4.7 (4.1) ll.l (4.2) 5.9 (2.4)
16 21.6 (6.7)* 18.9 (5.2)* r 15.6 (3.9)*
Net t-PA antigen release (AUC) 18.9 (9.3) 25.4 (9.0) > 14.9 (4.2)
t-PA activity (lU/ml) Baseline 0.9 (0.2) 0.8 (0.2) 0.5 (0.1) 0.6 (0.1) ) 1.0 (0.3) 0.8 (0.2) 0.8 (0.3)
4 1.7 (0.6) 0.7 (0.2) 1.5 (0.3) 0.8 (0.1) ) 1.2 (0.4) 1.5 (0.6) 0.9 (0.2)
8 1.9 (0.7) 0.8 (0.3) 2.3 (0.4) 0.7 (0.2) ) 1.2 (0.4) 2.0 (0.9) 0.9 (0.2)
16 3.1 (0.8)* 1.0 (0.2) 2.9 (0.5)' 0.8 (0.2) r 1.5 (0.4) 2.7 (1.0)* 0.9 (0.2)
Estimated t-PA activity release Baseline 0.0 (0.1) -0.1 (0.1) ) 0.1 (0.2)
(IU ■ 100 ml"1 • min"1) 4 2.5 (1.4) 3.1 (1.3) i 2.2 (1.2)
8 3.6 (1.6) 7.0 (1.7) ) 4.6 (2.1)
16 9.3 (2.9)* 11.7 (3.6)* r 10.2 (3.4)*
Net t-PA activity release (AUC) 10.7 (4.2) 15.9 (4.7) > 12.0 (4.9)
PAI-I antigen (ng/ml) Baseline 47 (5) 48 (4) 44 (4) 48 (5) 46 (14) 44 (II) 46 (13)
16 48 (4) 54 (3) 45(4) 50 (5) 44 (15) 46 (12) 49 (15)
Endothelium-dependent vasodilatation
Previous studies have shown that homocysteine is asso¬
ciated with endothelial dysfunction. Lentz et al. [9] re¬
ported that, in monkeys with diet-induced hyperhomo-
cysteinaemia, endothelium-dependent vasodilatation is
impaired in carotid artery rings in vitro and hindlimb
resistance vessels in vivo. Celermajer et al. [11] documen¬
ted abnormal endothelium-dependent vasodilatation in
children with severe hyperhomocysteinaemia due to ho¬
mozygous homocystinuria. Impaired endothelium-de¬
pendent vasodilatation is detected in healthy subjects with
acute hyperhomocysteinaemia induced by oral methi¬
onine loading [10,31], as well as in patients with chronic
hyperhomocysteinaemia who are free from clinical mani¬
festations of atherosclerotic disease [12,18]. In the present
study, we have extended these findings to patients with
recent myocardial infarction and demonstrated impaired
vasomotor responses in those with elevated plasma
homocysteine concentrations.
The vascular endothelium plays a critical role in the
control of vascular homoeostasis by regulating vascular
tone, platelet activity, coagulation and fibrinolysis, and
endothelial dysfunction is believed to be an early step in
the pathogenesis and pathophysiology of atherosclerosis.
Although patients with coronary artery disease typically
demonstrate endothelial dysfunction, there is consider¬
able heterogeneity in the magnitude of impairment in
individuals with similar risk factor profiles. This is of
particular interest because the extent of coronary as well
as peripheral endothelial dysfunction independently pre¬
dicts the long-term risk of acute cardiovascular events, in¬
cluding sudden cardiac death, myocardial infarction and
revascularization procedures [6,7]. Recent prospective
data have indicated that, in patients with established
coronary artery disease, homocysteine is a significant
predictor of mortality independent of other traditional
risk factors [5,32]. Our present findings therefore support
the role of homocysteine as a secondary risk marker,
suggesting that this may be mediated through its effects
on endothelial function.
Endogenous fibrinolysis
Although homocysteine impairs endothelial vasomotor
function, it does not appear to have a major effect on
endothehum-dependent fibrinolytic capacity, as both
basal and stimulated release of t-PA or PAI-1 were not
significantly different between the two patient groups.
Hyperhomocysteinaemia is a prothrombotic condition
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and may interfere with the antithrombotic and fibrino¬
lytic mechanisms of the endothelium and alter endothelial
protein secretory pathways. Although endothelial cell-
associated t-PA activity is reduced in homocysteine-
treated cells [33], our present study failed to detect
reduced fibrinolytic activity in vivo. This is consistent
with data indicating that homocysteine might perturb the
intrinsic fibrinolytic potential by reducing the functional
binding site for t-PA without altering the catalytic
capability of t-PA or affecting t-PA synthesis and
secretion [33].
Effects of vitamin supplementation
on plasma homocysteine
Previous studies have shown that treatment with folate
and B vitamins can lower plasma homocysteine concen¬
trations to a varying degree. The Homocysteine Lower¬
ing Trialists' meta-analysis predicted a 20-30% reduction
in homocysteine in patients with plasma concentrations
above 12 /r.mol/1 taking folate, and a further small addi¬
tional effect with vitamin Bl2 but not B(l [17], However, a
more modest 11-14% reduction is seen in patients with
coronary artery disease who consumed fortified breakfast
cereals [34,35]. The limited homocysteine lowering seen
in our present study was probably related to the rela¬
tively mild hyperhomocysteinaemia and normal folate
concentrations in our study population as well as the
confounding effects of dietary folate fortification.
Effects of vitamin supplementation
on endothelial responses
We did not detect an improvement in endothelium-
dependent vasodilatation or endogenous fibrinolytic ca¬
pacity following vitamin supplementation in the present
study. Although this may not be surprising in the absence
of significant homocysteine reduction, Doshi et al. [22]
have suggested that the acute effects of folate on en¬
dothelial function may occur by a mechanism independ¬
ent of homocysteine lowering. Moreover, the evidence
of the beneficial effects of vitamin supplementation on
endothelial function is conflicting. Chambers et al. [21]
and Title et al. [24] demonstrated improved endothelial
function in patients with coronary artery disease follo¬
wing folate treatment without or with vitamin B]2. How¬
ever, our present findings are consistent with those of
other investigators who failed to detect improved endo¬
thelial function in a similar patient population, in healthy
siblings of patients with premature atherothrombotic
disease or in patients with renal impairment [23,25,36].
These contradictory findings may be related, in part, to
the presence of other cardiovascular risk factors such as
hypertension or hypercholesterolaemia, which may con¬
tribute to endothelial injury [37,38], but would not be
expected to respond to folate or B vitamins. The vascular
endothelium in patients with established coronary artery
disease may have also been subjected to chronic injury
and would therefore be less responsive to intervention.
Furthermore, although the above studies adopted flow-
mediated dilatation as a non-invasive method of assessing
conduit artery endothelial function, in the present and
other studies [28,39], we have focussed on the function of
endothelium within resistance vessels. Conduit artery and
microvascular endothelial cells have distinct phenotypic
differences, and responses to mechanical rather than
pharmacological stimuli may also differ, and may contri¬
bute to the apparent disparity in the responses.
There is further controversy regarding the effects of
vitamin supplementation on cardiovascular outcomes in
patients undergoing percutaneous coronary intervention.
Contrary to earlier reports that vitamin supplementation
may reduce the rate of restenosis and adverse out¬
comes following coronary artery angioplasty [40,41],
Lange et al. [42] have recently demonstrated that folate
therapy following coronary stenting may increase the
risk of in-stent restenosis. The underlying mechanism
for these findings remains uncertain, but it is possible
that the proliferative effects of folate may promote the
growth of neointimal cells within implanted stents.
Therefore more prospective data are needed before any
recommendations can be made regarding the use of
vitamin supplementation in coronary artery disease.
Study limitations
There are several potential limitations to our present
study. First, we studied peripheral vascular function and
thus these findings may not be directly applicable to other
vascular beds. However, endothelial dysfunction is often
a generalized process, and we have shown previously con¬
sistent vasomotor and endogenous fibrinolytic responses
between the forearm and coronary circulation [27,39].
Secondly, the failure to improve endothelial function may
be related to inadequate treatment duration, although
studies have suggested that a 4-6-week treatment with
folate can improve endothelial function [20,22]. Thirdly,
the size of the study was small and, although it was
powered to detect a 15-20% difference in t-PA release
or forearm vasodilatation, it is possible that a smaller
effect may have been missed. Fourthly, we used a
placebo-controlled crossover design and there was the
possibility of a carry-over effect of the vitamin therapy on
endothelial function during placebo administration, des¬
pite a significant difference in the serum concentrations
of folate and vitamin B]2. Finally, we cannot rule out that
homocysteine may be a marker of vascular injury rather
than a mediator of endothelial dysfunction, although
experimental data support the direct role of homocysteine
in causing endothelial damage [9,33].
In conclusion, we have demonstrated that endo-
thelium-dependent vasodilatation, but not endogenous
© 2005 The Biochemical Society
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1
fibrinolysis, is impaired in patients with recent myocar¬
dial infarction and elevated plasma homocysteine, and
that this endothelial vasomotor dysfunction is not recti¬
fied by vitamin supplementation. These results provide
further evidence for the role of homocysteine in vas¬
cular damage, but do not support the hypothesis that
vitamin supplementation improves endothelial function
in patients with established coronary artery disease.
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Objectives: To investigate whether sildenafil citrate, a selective phosphodiesterase type 5 inhibitor, may
improve endothelial vasomotor and fibrinolytic function in patients with coronary heart disease.
Design: Randomised double blind placebo controlled crossover study.
Patients and methods: 16 male patients with coronary heart disease and eight matched healthy men
received intravenous sildenafil or placebo. Bilateral forearm blood flow and fibrinolytic parameters were
measured by venous occlusion plethysmography and blood sampling in response to intrabrachial infusions
of acetylcholine, substance P, sodium nitroprusside, and verapamil.
Main outcome measures: Forearm blood flow and acute release of tissue plasminogen activator.
Results: Mean arterial blood pressure fell during sildenafil infusion from a mean (SEM) of 92 (1) to 82
(1) mm Hg in patients and from 94 (1) to 82 (1) mm Hg in controls (p < 0.001 for both). Sildenafil
increased endothelium independent vasodilatation with sodium nitroprusside (p < 0.05) but did not alter
the blood flow response to acetylcholine or verapamil in patients or controls. Substance P caused a dose
dependent increase in plasma tissue plasminogen activator antigen concentrations (p < 0.01) that was
unaffected by sildenafil in either group.
Conclusions: Sildenafil does not improve peripheral endothelium dependent vasomotor or fibrinolytic
function in patients with coronary heart disease. Phosphodiesterase type 5 inhibitors are unlikely to reverse
the generalised vascular dysfunction seen in patients with coronary heart disease.
The endothelium is important in the regulation of vascularfunction including local blood flow and endogenousfibrinolysis. Coronary heart disease (CHD) and its risk
factors, such as cigarette smoking, hyperlipidaemia, and
hypertension,'"' are associated with impaired endothelium
dependent vasorelaxation and reduced endothelial release of
the endogenous fibrinolytic factor tissue plasminogen acti¬
vator (t-PA)'• These aspects of endothelial function are
important, since plasma fibrinolytic variables and endothe¬
lium dependent vasodilatation independently predict future
cardiovascular risk.1'7
Nitric oxide is a key factor linked to the beneficial
protective effects of the endothelium and a decrease in nitric
oxide bioavailability favours atherogenesis." Nitric oxide
exerts many of its biological effects through generation of
cyclic guanosine monophosphate (cGMP) after activation of
soluble guanylate cyclase. Phosphodiesterase type 5 (PDE5)
inactivates cGMP within vascular smooth muscle and thus
negatively regulates nitric oxide mediated cellular actions.'7
Recently, highly selective PDE5 inhibitors that prolong the
action of cGMP and thereby enhance nitric oxide mediated
effects have become available for clinical use.
It has been suggested that the PDE5 inhibitor sildenafil
citrate (Viagra; Pfizer) can improve endothelial vasomotor
function in the peripheral circulation of healthy cigarette
smokers'" and the coronary circulation of patients with
CHD." Although we have previously reported a link between
nitric oxide and acute t-PA release," the potential beneficial
effects of sildenafil on t-PA and its inhibitor, plasminogen
activator inhibitor type 1 (PA1-1), are unknown.
We therefore hypothesised that sildenafil would favour¬
ably alter endothelium dependent vasomotor function
and acute t-PA release in patients with stable CHD. If so,
PDE5 inhibitors may become a useful adjunctive treatment




Sixteen male patients with stable CHD and eight age
matched healthy control men participated in the study. The
investigation was undertaken with the approval of the local
research ethics committee, with the written informed
consent of each patient, and in accordance with the principles
outlined in the Declaration of Helsinki.
A history of CHD was confirmed by angiographic evidence
of > 50% luminal stenosis of at least one major epicardial
coronary vessel or a history of myocardial infarction (con¬
firmed by a serial rise in creatine kinase of twice the upper
limit of the normal reference range and the development of
pathological Q waves in at least two contiguous leads of the
ECG). Nitrate medications were withdrawn for 48 hours
before each visit and other medications were withheld on the
morning of study. Patient exclusion criteria were significant
cardiac failure, renal impairment, systolic blood pressure
< 100 or > 190 mm Hg, and diabetes mcllitus. Control
subjects were healthy norrnotensive euglycaemic non-smo-
kers without any history of cardiorespiratory or vascular
disease and were not taking any regular medications. No
participant had received sildenafil or other phosphodiesterase
inhibitors before or during participation in this study.
Abbreviations: cGMP, cyclic guanosine monophosphate; CHD,
coronary heart disease; FBF, forearm blood flow; PA1-1, plasminogen
activator inhibitor type 1; PDE5, phosphodiesterase type 5; t-PA, tissue
plasminogen activator
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Measurements
Forearm blood (low (FBF) was measured in both forearms by
venous occlusion plethysmography with mercury in silastic
strain gauges applied to the widest part of the forearm as
previously described.IJ U During measurement periods the
hands were excluded from the circulation by rapid inflation
of the wrist cuffs to a pressure of 220 mm Hg with E20 rapid
cuff inflators (DE Hokanson Inc, Bellevue, Washington,
USA). Upper arm cuffs were inflated intermittently to
40 mm Hg for 10 seconds in every 15 seconds to achieve
venous occlusion and obtain plethysmographic recordings.
Analogue voltage output from an EC-4 strain gauge
plethysmograph (DE Hokanson) was processed by an
analogue to digital converter and Chart version 5 software
(AD Instruments Ltd, Chalgrove, UK). Instruments were
calibrated with the internal standard of the plethysmograph.
Blood pressure and heart rate were monitored in the non-
infused arm by a semiautomated non-invasive sphygmo¬
manometer (Agilent V24; Phillips Medical Systems). Mean
arterial pressure was defined as the diastolic pressure plus a
third of the pulse pressure.
Plasma t-PA and PAI-1 antigen concentrations were
measured as previously described with enzyme linked
immunosorbent assays (Coaliza t-PA and PAI-1;
Chromogenix AB, Mdlndal, Sweden) at baseline, after
sildenafil or placebo, and during intra-arterial substance
P." " '* Haematocrit was determined by an automated Coulter
counter (ACt.8; Beckman-Coulter, High Wycombe, UK).
Biochemical assays were undertaken on the lasting venous
samples by the hospital clinical laboratory facility.
Study design
Participants were requested to abstain from alcohol for 24
hours and from food, caffeine-containing drinks, and tobacco
for at least four hours before each study. All studies were
carried out in a quiet temperature controlled room main¬
tained at 22-25°C. Each participant attended at 9 am on two
separate occasions at least two weeks apart and received
matched placebo and sildenafil in a randomised double blind
crossover design.
While participants rested recumbent, strain gauges and
cuffs were applied. A 17 gauge venous cannula was inserted
into the antecubital vein ol each arm and a li gauge cannula
into the dorsal foot vein for the administration of either
intravenous sildenafil or matched placebo. The brachial
artery ol the non-dominant arm was cannulated wun a 27-
SWG needle (Cooper's Needle Works Ltd, Birmingham, UK)
under local anaesthesia. The intra-arterial infusion rale was
maintained constant at 1 ml/min throughout the study with
an 1VAC syringe pump (Alaris Medical Ltd, Basingstoke, UK).
Saline was infused intra-arterially for the first 20 minutes
to allow recording of resting FBF, blood pressure, and heart
rate. After this period, sildenalil or matched placebo (Pltzer
UK Ltd, Sandwich, Kent, UK) was administered intrave¬
nously as a single 26.25 mg bolus over five minutes, then as a
continuous infusion ol 10 mg/hour to achieve stable plasma
concentrations equivalent to the peak concentration of a
single 100 mg oral dose (pharmacokinetic data, Pfizer UK
Ltd). Twenty minutes after the sildenafil or placebo infusion
was started, basal FBF was determined and thereafter
acetylcholine (5, 10, and 20 pg/ntin; Novartis UK Ltd,
Farnborough, UK), substance P (2, 4, and 8 pmol/min;
Clinalfa AG, Laufelfingen, Switzerland), sodium nilroprus-
side (2, 4, and 8 pg/min; David Bull Laboratories, Warwick,
UK), and verapamil (10, 30, and 100 pg/min; Abbott UK Ltd)
were infused inlra-arterially for six minutes at each dose.
Acetylcholine, substance P, and sodium nitroprusside were
given in a random order and separated by 20 minute saline
washout periods but, because of its prolonged vasodilator
Table 1 Baseline characteristics
Patients Controls
Age (years) 57 (2) 54 (2)
Body mass index (kg/m2) 27(1) 27(1)
Co-morbidity
Myocardial infarction 10 0
Hypertension 12 0
Diabetes mellitus 0 0




P Adrenergic blocker 13 0
Calcium antagonist 3 0
Long acting nitrate/nicorandil 2 0
ACE inhibitor, AT II antagonist 5 0
Lipid lowering agent 16 0
Serum urea (mmol/l) 5.5 (0.3) 5.1 (0.4)
Serum creatinine (pmol/l) 92 (3) 95 (4)
Glucose (mmol/l) 5.6 (0.2) 5.5 (0.3)
Total cholesterol (mmol/l) 4.2 (0.2) 5.5 (0.2)*
HDL cholesterol (mmol/l) 1.0 (0.0) 1.1 (0.1)
Triglycerides (mmol/l) 1.7 (0.2) 1.2 (0.2)
Placebo visit
Heart rate (beats/min) 55(1) 61 (3)*
MAP (mm Hg) 95 (2) 95 (4)
FBF (ml/100 ml/min)
Infused arm 2.5 (0.2) 2.2 (0.2)
Non-infused arm 2.3 (0.2) 2.1 (0.4)
Sildenafil visit
Heart rate (beats/min) 55(1) 65 (3)*
MAP (mm Hg) 95 (2) 91 (3)
FBF (ml/100 ml/min)
Infused arm 2.5 (0.2) 2.6 (0.3)
Non-infused arm 2.5 (0.2) 2.4 (0.3)
Data are mean (SEM) or number.
•pcO.001 unpaired / test, patients v controls.
ACE, angiotensin converting enzyme; AT II, angiotensin II type I receptor;
FBF, forearm blood Row; HDt, high density lipoprotein; MAP, mean
arterial pressure.
action, verapamil was infused last. The order of the infusions
was maintained constant for each participant across both
visits.
Statistical analysis
Plethyr.mographic data were extracted from Churl data files
from which the last five linear recording in each measure¬
ment period were averaged and FBF was calculated.
Estimated net l PA antigen wan defined as the product of
the infused forearm plasma flow (based on the haematocrit
and the infused FBF) and the concentration dif¬
ference between the infused ([ t -PA ] ijjt) and non-inlused
([t-PA]Non.irlr) forearms,12 where estimated net t-PA release
= FBF x( 1 —haematocrit) x ([ t-PA]inf) — ([ l-PA J N„n.inf).
Data were examined, where appropriate, by analysis of
variance with repeated measures and two tailed Student's I
test by GraphPad Prism (GraphPad Software, San Diego,
California, USA). All results are expressed as mean (SEM).
Significance was assigned at the 5% level. On the basis of a
previous study,,s this study had an 80% power to detect a 23%
change in plasma t-PA concentrations and a 22% difference
in FBF in patients with CHD between sildenafil and placebo
at the 5% level.
RESULTS
Most patients with CHD had a history of myocardial
infarction, hypertension, and hyperlipidaemia (table 1).
Reflecting concomitant treatment, mean resting heart rate
(55 (1) v63 (2) beats/min, respectively, p < 0.001, unpaired /
test) and serum total cholesterol concentration (4.2 (0.2) v
5.5 (0.2) nnnol/1, p < 0.001) were lower in patients with
CHD than in controls. Baseline mean arterial pressure,
www.heartjnl.com






















Figure 1 (A) Heart rate and (B) mean arterial pressure (MAP) during
sildenafil (closed circles, solid line) or placebo (open circles, dashed line)
infusion (shaded box) in patients with coronary heart disease (CHD).
*p < 0.001 analysis of variance, sildenafil versus matched placebo.
Control subject data on file (p < 0.001, analysis of variance, MAP
sildenafil versus matched placebo).
resting heart rate, baseline FBF, or haematocrit did not differ
between the two study visits. Infusions were well tolerated
and there were no serious adverse events. For technical
reasons, one control subject was unable to complete both
visits.
Haemodynamic effects
Over the course of the study, the average mean arterial
pressure was lower during sildenafil than placebo infusion in
patients with CHD (82 (1) v 92 (1) mm Hg, p < 0.001 paired
l test sildenafil versus placebo) (fig 1) and control subjects
(82 (1) v 94 (1) mm Hg, p < 0.001 paired t test). It returned
to baseline after discontinuation of infusion (data not
shown). Heart rate rose transiently after the sildenafil bolus






























Figure 2 Infused (solid line) and non-infused (dashed line) forearm
blood flow in paiienis with CHD (•) and conirols (O) during
inlrabrachial acetylcholine (panel A), sodium nitroprusside (panel B),
and verapamil (panel C) with placebo infusion, p < 0.001 analysis of
variance, dose response in infused arm; *p = 0.005 analysis of
variance patients with CHD versus controls.
Placebo visit
Acetylcholine caused a dose dependent increase in FBF in
both groups, although this rise was significantly less in
patients with CHD than in controls (p = 0.005, analysis of
variance) (fig 2). FBF responses did not differ between the
two groups during sodium nitroprusside and verapamil
infusions (fig 2). There were no significant changes in the
non-infused FBF.
Sildenafil and vascular function
Compared with placebo, administration of sildenafil caused
no significant difference in the infused FBF during intra¬
arterial infusion of acetylcholine (at 20 pg/rnin, mean
difference 0.1 ml/100 ml/min, 95% confidence interval (CI)
-0.2 to 0.4), substance P (at 8 pmol/min, mean difference
0.5 ml/100 ml/min, 95% CI 0.00 to 0.9), or verapamil (at
8 pmol/min, mean difference 0.3 ml/100 ml/min, 95% CI
—0.1 to 0.7). However, sildenafil augmented the vasodilata¬
tion to sodium nitroprusside in both patients with CHD
(p < 0.05, analysis of variance) (fig 3) and control subjects
(p < 0.001, analysis of variance) (fig 4).
Plasma fibrinolytic variables
Baseline plasma l-PA antigen concentrations were
unchanged by sildenafil in either group (table 2, fig 5).
Substance P caused a dose dependent increase in plasma t PA
concentrations in both patients and controls (p < 0.01 for
both, analysis of variance) (table 2). The substance P induced
increase in plasma t-PA concentrations did not differ during
the sildenafil or placebo infusion (at 8 pmol/min, mean
difference 0.02 ng/ml, 95% CI —1.15 to 1.18) (table 2) and
www.heartjnl.com











Figure 3 Infused (solid line) and non-infused (dashed line) forearm
blood flow in patients with CHD during intrabrachial sodium
nitroprusside (panel A), acetylcholine (panel B), and verapamil (panel C)
with sildenafil (•) and matched placebo (O) infusion, p < 0.001
analysis of variance, dose response in infused arm; *p < 0.05 analysis
of variance, sildenafil versus matched placebo.
Figure 4 Infused (solid line) and non-infused (dashed line) forearm
blood flow in heulll ly conhuls during irttrubrueliiul sodium nitroprusside
(panel A), acetylcholine (panel B), and verapamil (panel C) witn
sildenafil (•! and matched placebo (O) infusion, p < 0.01 analysis of
variance, dose response in infused arm; "p < 0.001 analysis of
variance, sildenafil versus matched placebo.
plasma PAI-1 concentration:) did not change significantly
throughout either study.
DISCUSSION
We have shown that sildenafil, a selective PDE5 inhibitor,
does not modify endothelium dependent vasodilatation or
acute t-PA release in men with stable CHD. However,
sildenafil did augment the vasodilator effect of the exogenous
nitric oxide donor sodium nitroprusside. Thus, while our
study confirms the well described interaction of sildenafil
with nitric oxide donors,'" we have found no evidence to
support the contention that PI)E5 inhibitors improve
endothelium dependent vasomotor or fibrinolytic function
in patients with CHD.
Compared with matched controls, patients with CHD
exhibited impaired endothelium dependent responses to
acetylcholine while having preserved vasodilator responses to
the endothelium independent agonists sodium nitroprusside
and verapamil. This prognostically significant impairment' "
was evident in patients who were already receiving standard
antianginal, antiplatelet, and lipid lowering treatments.
Sildenafil had no effect on peak How mediated dilatation
of the brachial artery in patients with CHD" and reports on
the vasomotor responses of the coronary vessels to sildenafil
are conflicting. Herrmann ct alfound no change in coronary
artery diameter, blood flow, or coronary vascular resistance,
whereas Halcox el al" reported enhanced coronary artery
vasodilatation to acetylcholine. Unlike previous studies, we
used a more robust double blind randomised placebo
controlled crossover study design and have shown that
PDE5 inhibition does not alter either endothelium depend¬
ent vasomotor or fibrinolytic function in patients with
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Table 2 Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor
type 1 (PAI-1) concentrations at baseline and during sildenafil and matched placebo
infusion in patients with coronary heart disease
0 Bolus Continuous infusion (10 mg/h)
Sildenafil/placebo
Substance P dose (pmol/min) 2 4 8
Placebo
Plasma t-PA antigen (ng/ml)
Infused arm 9.0 (0.7) 8.7 (0.6) 9.3 (0.6) 9.8 (0.7) 10.5 (0.8)*
Non-infused arm 9.0 (0.6) 9.1 (0.6) 9.1 (0.6) 8.9 (0.6) 9.1 (0.6)
Plasma PAI-1 antigen (ng/ml)
Infused arm 46.8 (6.9) 43.1 (6.0) 0 0 34.4 (5.4)
Non-infused arm 45.2 (7.1) 45.5 (7.6) 0 0 36.4 (6.3)
Sildenafil
Plasma t-PA antigen (ng/ml)
Infused arm 9.0 (0.6) 8.7 (0.6) 9.1 (0.6) 9.4 (0.6) 10.5 (0.7)*
Non-infused arm 9.1 (0.6) 8.8 (0.6) 9.0 (0.6) 8.9 (0.6) 9.0 (0.6)
Plasma PAI-1 antigen (ng/ml)
Infused arm 44.0 (5.6) 39.6 (4.6) 0 0 36.0 (3.8)
Non-infused arm 47.9 (5.6) 43.2 (4.9| 0 0 38.6 (4.2)
*p<0.001, anal/sis of variance for t-PA response.
Control subject data on file (p = 0.003, analysis of variance for t-PA response)
CUD ui in aye matched controls. Moreover, we used a
bolus and continuous intravenous sildenafil infusion to
minimise variations in plasma concentrations duriny the













Figure 5 Infused (solid line) and non-infused (dashed line) forearm
blond flow (panel A) and estimated net release of tissue plasminogen
activator (t-PA) antigen (panel B) at baseline, during sildenafil {•) and
matched placebo (O) infusion (shaded box), and subsequently with
intrabrachial substance P (2, 4, 8 pmol/min) in patients with CHD.
p < 0.01 analysis of variance for all, dose response for infused arm FBF
and net t-PA release.
is an important study consideration given the short hall life
of sildenafil in humans.
We observed a decrease in mean arterial pressure in both
patients and controls during administration of sildenafil that
presumably reflected an augmentation of the vascular effects
of basal vascular nitric oxide release and is mediated through
an increase in cGMP. Our findings are consistent with the
published hacmodynomic data from both healthy volun
leers'" and patients with CHD1"" and confirm that we
achieved a physiological effect with sildenafil infusion. The
consistent vasodilatory response to the nitric oxide indepen
dent agonist verapamil makes it unlikely that administration
of the PDE5 inhibitor impaired vascular smooth muscle
function or obscured potentially beneficial effects on
endothelial function. Moreover, both acetylcholine and
substance P produced similar, consistent, and reproducible
responses on both study days. This suggests that prolonging
cGMP actions in patients with established atherosclerosis
would not reverse endothelial dysfunction. As would be
predicted frurn its mechanism of action, sildenafil augmented
the responses to sodium nitroprusside, an exogenous nitric
oxide donor, in both controls and patients with CHD.
There are several potential reasons for tfie differences
observed in the effect of sildenafil on the acetylcholine and
sodium nitroprussidc responses. The modest decrease in
acetylcholine induced vasodilatation'1 " seen after nitric
oxide synthase inhibition suggests that non-nitric oxide
dependent pathways such as endothelium derived hyper
polarising factor (EDHF) may predominate particularly in the
presence of endothelial dysfunction." " Furthermore, differ¬
ences in the relative contribution of endothelium derived
nitric oxide across vascular beds may explain some of the
previously conflicting data on the vascular responses to
sildenafil."""' As well as endothelial dysfunction, athero¬
sclerosis is associated with high concentrations of free
radicals such as superoxide anion that rapidly react with
nitric oxide to generate peroxynilrite, a powerful oxidant
species that induces significant cellular damage and directly
inhibits soluble guanylate cyclase.'7 Elegant studies in
animals with specific knockouts of nitric oxide dependent
pathways also suggest that tissue specific downregulation of
nitric oxide/cGMP, including cGMP dependent protein
kinase, may be an early feature of endothelial dysfunction
in atherosclerotic conditions.""" PDE5 inhibition would not
be anticipated to influence changes irt oxidative stress or
directly affect cGMP independent nitric oxide molecular
targets that contribute to endothelial dysfunction and
www.heartjnl.com
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atherogenesis. Therefore, the contrasting effects of silde¬
nafil on acetylcholine and sodium nitroprusside induced
vasodilatation are likely to reflect a major dependence on
non-nitric oxide mediated pathways, increased oxidative
stress, and decreased nitric oxide bioavailability associated
with CHD.
Although the precise mechanism underlying acute t-PA
release remains uncertain, several reports have previously
suggested involvement of nitric oxide and cyclic nucleotides
regulated by phosphodiesterases. In animals, pentoxifylline
and its analogues, non-selective phosphodiesterase inhibi¬
tors, increased acute t-PA release50 and potentiated the effects
of thrombolytic treatment." We and others have reported
acute endothelial t-PA release during intra-arterial substance
P," M bradykinin,u and methacholine" infusions, as well as
an inverse relation between acute t-PA release and athero¬
sclerotic plaque burden within the coronary circulation/' In
the present study, we have again shown a rise in both plasma
t-PA antigen concentrations and net t-PA release with local
intra-arterial substance P infusion. However, infusion of
sildenafil did not change basal plasma t-PA concentrations or
substance P induced t-PA release. Therefore, enhancement of
cGMP apparently does not directly augment endothelial t-PA
release in humans.
Although we found no such change in acute t-PA release
with substance P, sildenafil may improve the response
to other agonists such as bradykinin, which causes B2
receptor mediated prostacyclin and nitric oxide generation."
However, the dominant mechanism of t-PA release with
bradykinin appears to be nitric oxide and prostacyclin
independent with coupling of the B2 receptor to the calcium
dependent Gq/phospholipase C-beta pathway.36 Some of the
conflicting results on the effect of nitric oxide synthase
inhibitors on t-PA release may suggest that there is
physiological redundancy within the nitric oxide dependent
pathways which contribute to the regulation of acute t-PA
release in humans.
Study limitations
In light of the haemodynamic changes seen in our study,
intrabrachial infusion of sildenafil in subsystemic locally
active doses would be one approach to assess the direct
vascular actions of PDE5 inhibition. However, sildenafil is
metabolised by the liver to an active metabolite that accounts
for nearly half of its phosphodiesterase inhibitory activity.
Local intra-arterial infusion would not assess the action of
this important metabolite. The effect of long term PDE5
inhibitor therapy remains unclear, and further studies with
women and patients with diabetes mellitus would be of
interest, as these groups may show differences within nitric
oxide dependent pathways." 5K
Conclusion
Despite being highly effective in the management of erectile
dysfunction, sildenafil docs not modify endothelium depen¬
dent vasomotor or fibrinolytic function in patients with CHD.
Phosphodiesterase inhibitors have already shown promise as
novel treatments for conditions such as chronic heart failure"
and pulmonary hypertension,59 and these areas clearly
warrant further research. However, on the basis of our
results, we believe that PDE5 inhibitors are unlikely to
reverse the generalised vascular dysfunction seen in patients
with CHD.
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IMAGES IN CARDIOLOGY
Pseudo-supraventricular tachycardia
A79 year old man with dilated phase of ahypertrophic cardiomyopathy and ahistory of anteroseptal myocardial
infarction was admitted because of frequent
episodes of tachyarrhythmia requiring cardio¬
version. A 12 lead EGG demonstrated small
positive waves (closed circles) followed by
larger positive waves (open circles) in limb
leads and leads V4-6, which, at first glance,
seemed to represent P waves followed by QRS
complexes (panel A). A closer look indicated
that the presumed P waves (closed circle) in
leads V4-6 corresponded to R waves (arrow¬
head) in leads VI and V2 as well as
dissociation of true P waves (arrows) from
QRS complexes. The diagnosis of ventricular
tachycardia was confirmed by electrophysio¬
logic study, which revealed that the first and
second positive wave corresponded to the
local ventricular potential recorded from the
apex of right and left ventricle, respectively
(panel B). Catheter ablation of the ventricular
tachycardia was not possible because the
tachycardia was not stable. The patient was
treated with mexiletine and followed
uneventfully.
This case re-emphasises the importance of
recording a 12 lead ECG for the diagnosis of
arrhythmia, even when the diagnosis from
an ECG with fewer leads such as telemetry
seems to be straightforward (sinus tachy¬
cardia or supraventricular tachycardia in this
case).
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Vascular and fibrinolytic effects of intra-arterial
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ABSTRACT
Elevated plasma t-PA (tissue plasminogen activator) and serum CRP (C-reactive protein) concen¬
trations are associated with an adverse cardiovascular risk. In the present study, we investigated
whether acute local inflammation causes vascular dysfunction and influences t-PA release in
patients with stable coronary heart disease. Serum CRP, plasma t-PA and PAI-I (plasminogen
activator inhibitor type I) concentrations were determined in 95 patients with stable coronary
heart disease. A representative subpopulation of 12 male patients received an intra-brachial
infusion of TNF-a (tumour necrosis factor-a) and saline placebo using a randomized double-
blind cross-over study design. Forearm blood flow and plasma fibrinolytic and inflammatory
variables were measured. Serum CRP concentrations correlated with plasma t-PA concentrations
(r = 0.37, PcO.OOl) and t-PA/PAI-l ratio (r= —0.21, P < 0.05). Intra-arterial TNF-a caused a
rise in t-PA concentrations (PcO.OOl) without affecting blood flow or PAI-I concentrations.
TNF-or pretreatment impaired acetylcholine- and sodium nitroprusside-induced vasodilatation
(P < 0.001 for both) whilst doubling bradykinin-induced t-PA release (P— 0.006). In patients with
stable coronary heart disease, plasma fibrinolytic factors correlate with a systemic inflammatory
marker and local vascular inflammation directly impairs vasomotor function whilst enhancing
endothelial t-PA release. We suggest that the adverse prognosis associated with elevated plasma
t-PA concentrations relates to the underlying causative association with vascular inflammation and
injury.
INTRODUCTION
In epidemiologic studies of patients with CHD (coronary
heart disease) [1] and in prospective studies in healthy
populations [2], higher plasma concentrations of the
pro-fibrinolytic factor t-PA (tissue plasminogen activ¬
ator) positively and independently predict future cardio¬
vascular events. It would be anticipated that high t-PA
concentrations would protect against subsequent cardio¬
vascular events rather than the reverse. This paradoxical
association is, in part, explained by the concomitant
elevation of PAI-1 (plasminogen activator inhibitor
Key words: coronary disease, endothelial function, fibrinolysis, inflammation, tumour necrosis factor-a (TNF-a), vasodilation.
Abbreviations: BP, blood pressure; CHD, coronary heart disease; CRP, C-reactive protein; F1 + 2, fragment 1 and 2; FBF, forearm
blood flow; HR, heart rate; hs-CRP, highly sensitive CRP; IL-6, intcrleukin-6; IU, international units; NO, nitric oxide; eNOS,
endothelial NO synthase; ns, not significant; PAI-1, plasminogen activator inhibitor type 1; SBP, systolic blood pressure; SNP,
sodium nitroprusside; TNF-a, tumour necrosis factor-a; t-PA, tissue plasminogen activator.
Correspondence: Dr Simon D. Robinson (email simon.robinson@cd.ac.uk).
© 2006 The Biochemical Society
S. D. Robinson and others
type 1) which complexes with, and inactivates, t-PA.
However, the precise stimulus for this increased t-PA re¬
lease remains unclear.
Areas of endothelial denudation and thrombus
deposition are a common finding on the surface of athero¬
matous plaques and are usually subclinical. Through
t-PA release, endogenous fibrinolysis is usually able to pre¬
vent thrombus propagation, although organization of the
residual thrombus may lead to plaque growth and ex¬
pansion [3], The adverse prognosis conferred by elevated
plasma t-PA antigen concentrations may, therefore,
reflect the extent of occult atheroma and subclinical
plaque rupture stimulating t-PA release.
Markers of systemic inflammation, such as CRP (C-
reactive protein) and TNF-u (tumour necrosis factor¬
ed), arc elevated in patients with cardiovascular disease
[4,5]. Indeed, serum CRP concentrations predict the
development of cardiovascular disease independently of
other risk factors. Previous studies have indicated a
direct relationship between serum CRP and plasma t-PA
concentrations [6,7]. This raises the question of whether
vascular inflammation is causally related to the elevation
in plasma t-PA concentrations or whether CRP and t-PA
are independently increased by a common factor related
to the atherosclerotic process itself, such as acute plaque
rupture.
Abnormalities of endothelial function have been
demonstrated in patients with atherosclerosis [8] and
vascular inflammation [9,10]. In patients with CHD, re¬
storation of cndothclium-dcpcndcnt vasomotor function
occurs when there is normalization of CRP concen¬
trations [11], whereas ongoing chronic inflammation
is associated with an impaired fibrinolytic response
to venous occlusion [12]. As the endothelium is the
major source of plasma t-PA, abnormalities of endo¬
thelial function may therefore mediate the potential
inflammation-induced elevations in plasma t-PA concen¬
trations.
It therefore remains unclear whether elevated t-PA
concentrations arc implicated in the mechanisms con¬
tributing to, or arise as a consequence of, athcrothrom-
botic events.
The aims of the present study were, in patients with
stable CHD, to confirm the previous association between
plasma CRP and t-PA concentrations and to determine
the effect of acute local vascular inflammation provoked
by direct intra-artcrial infusion of TNF-a on vasomotor
function and endothelial t-PA release.
METHODS
Patients
We recruited patients with CHD confirmed by angio¬
graphy (defined as > 70 % luminal stenosis of at least one
major epicardial coronary vessel) or a previous history
of Q-wave myocardial infarction. All patients had stable
anginal symptoms and had not undergone coronary
revascularization within the preceding 3 months. Ex¬
clusion criteria were significant cardiac failure, renal
impairment, SBP [systolic BP (blood pressure)] < 100
or >190mmHg, diabetes mcllitus, history or clinical
features of recent infective illness and immuno¬
suppressive or non-steroidal anti-inflammatory medi¬
cation (excluding 75 mg/day aspirin). All studies were
undertaken with the approval of the local Research Ethics
Committee and in accordance with the Declaration of
Helsinki. Written informed consent was obtained from
each subject.
Venous sampling and assays
Plasma t-PA, PAI-1 (Coaliza®; Chromogenix), pro¬
thrombin F1 + 2 (fragment 1 and 2; Enzygnost F1 +2;
Dade Behring), TNF-a (Quantikinc; R&D Systems) and
IL-6 (interleukin-6; Dako) concentrations were deter¬
mined using ELISAs, and t-PA activity using a photo¬
metric method (Coatest t-PA; Chomogenix) [13-15].
Assays of hs-CRP (highly sensitive CRP) were under¬
taken using the method of particle-enhanced immuno-
ncphelometry (BN II nephclomctcr; Bchring). Venous
blood was collected into tubes containing acidified buf¬
fered citrate (for t-PA), trisodium citrate (for PAI-1 and
prothrombin F1 +2), potassium EDTA (for cytokines)
and serum gel tubes (for CRP). Platelet-free plasma and
scrum were stored at — 80"C before assay. Hacmatocrit
and white cell count were determined using an automated
Coulter counter. Biochemical assays were undertaken
on fasting venous samples by the hospital Clinical
Laboratory facility.
Drugs
TNF-a (Knoll Pharmaceuticals), bradykinin (Clinalfa),
acetylcholine (Novartis) and SNP (sodium nitroprusside;
David Bull Laboratories) were administered following
dissolution in 0.9% saline.
Study design
All subjects abstained from alcohol for 24 h and from
food, tobacco and caffeine-containing drinks for at least
4 h before each study visit. A venous blood sample was
taken from all patients for estimation of serum CRP and
plasma t-PA and PAI-1 antigen concentrations. Twelve
representative male patients were then recruited into a
randomized double-blind placebo-controlled cross-over
study comparing the effect of direct intra-brachial in¬
fusion of TNF-a and saline placebo.
Forearm study protocol
All studies were carried out at 09:00 hours in a quiet
temperature-controlled room maintained at 22-25"C.
Patients rested recumbent and strain gauges and cuffs
were applied. A 17-gauge venous cannula was inserted
into the antccubital vein of each arm, and the brachial
artery of the non-dominant arm was cannulated with a
© 2006 The Biochemical Society
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27-SWG (standard wire gauge) needle (Cooper's Needle
Works). FBF (forearm blood flow) was measured in both
forearms by venous occlusion plethysmography using
mercury in silastic strain gauges as described previously
[16]. BP and HR (heart rate) were measured using a semi-
automated non-invasive sphygmomanometer (Omron
705 IT).
Subjects (n = 12) attended on two occasions at least
two weeks apart and received an intra-arterial infusion of
either TNF-a (80 ng/min) or saline placebo over 60 min,
followed on each occasion by a further 60 min of saline in¬
fusion. Thereafter intra-arterial bradykinin (100, 300 and
1000 pmol/min), acetylcholine (5, 10 and 20 /rg/min)
and SNP (2, 4 and 8 /rg/min) were administered at
1 ml/min with a 15 min saline washout period between
each agent. The dose of TNF-a was chosen to achieve
local cytokine concentrations comparable with healthy
volunteer studies [13] and those seen in cardiovascular
disease [17],
Venous blood samples for t-PA antigen and activity
and PAI-1 antigen were obtained at baseline, after
60 min of TNF-a/placcbo infusion, following the 60 min
infusion of saline, before and during each dose of
bradykinin and 15 min after the end of bradykinin
infusion. Plasma cytokines, hs-CRP and prothrombin
F1 + 2 were assessed prior to and following the TNF-a/
placebo and saline infusions and at the end of each study.
Statistical analysis
Estimated net release of t-PA was defined previously as
the product of the infused forearm plasma flow and the
concentration difference between the infused and non-
infused forearms [16]. Because basal t-PA concentrations
were altered by pretrcatmcnt with TNF-a, net release
of t-PA during bradykinin infusion was calculated by
subtracting the mean t-PA release before and 15 min
after cessation of bradykinin infusion [13]. The area
under the curve was calculated for the estimated net
release of t-PA in response to bradykinin. Data were
examined, where appropriate, by ANOVA with repeated
measures, followed by post-hoc Student's t tests adjusted
with a Bonfcrroni correction for multiple comparisons.
Spearman's correlation was used to compare CRP and
plasma levels of fibrinolytic factors. As serum CRP
concentrations have a skewed distribution, they were
logarithmically transformed.
All statistical calculations were undertaken using
GraphPad Prism (GraphPad Software). Results arc ex¬
pressed as means ± S.E.M., unless otherwise stated, and
statistical significance was assigned at the 5 % level.
RESULTS
Patients had a typical cardiovascular risk factor profile
in keeping with their diagnosis of CHD and most were
Table I Baseline characteristics of the 95 subjects with
stable CHD
Values are means ± 5.D. or n (%). ACE, angiotensin-converting enzyme; ARB,
angiotensin II receptor blocker; LDL, low-density lipoprotein. "Angiographic data
were unavailable on one subject.
Characteristics
Age (years) 59 + 7
Body mass index (kg/m!) 29 ±5
Male gender (n) 79 (83 %)
Previous myocardial infarction (n) 39 (41%)
Extent of coronary artery disease (n)*
One vessel 42 (44 %)
Two vessels 24 (25 %)
Three vessels 28 (29%)
Previous coronary revascularization (n) 64 (67%)
Co-morbidity (n)
Hypertension 46 (48%)
Previous hyperlipidaemia 89 (94%)
Family history of premature CHD 32 (34%)




Statin 90 (95 %)
ACE-inhibitor/ARB 30 (32 %)
Serum urea (mmol/l) 5.6 ± 1.3
Serum creatinine (/xmol/l) 93+13
Plasma glucose (mmol/l) 5.7 ±0.9
Total cholesterol (mmol/l) 4.5 + 0.9
LDL-cholesterol (mmol/l) 2.5 ±0.7
Triacylglycerols (mmol/l) 1.8 ±0.9
prescribed secondary preventative medications (Tables 1
and 2). Themajority of the subjects were male, two-thirds
had previously undergone coronary revascularization
and approx. one-third were habitual smokers.
Plasma fibrinolytic factors and
correlation with CRP
In the cohort of 95 patients with stable CHD, scrum
hs-CRP concentrations correlated with plasma t-PA
antigen concentrations (r = 0.37, P< 0.001) and plasma
PAI-1 antigen concentrations (r = 0.28, P = 0.006) and
inversely with the ratio of t-PA/PAI-1 antigen (r =
— 0.21, P< 0.05). As anticipated, plasma t-PA antigen
concentrations correlated with plasma PAI-1 anti¬
gen concentrations (r = 0.49, P < 0.001).
Effect of acute inflammation on vascular
and fibrinolytic function
Those subjects who received TNF-a and saline placebo
had similar baseline characteristics to the main cohort and
all were receiving statin and aspirin therapy. There were
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Table 2 Baseline characteristics oF 12 patients receiving
TNF-a and saline placebo in a randomized double-blind
cross-over study design
Values are means + S.E.M or n (%). ACE, angiotensin-converting enzyme; LDL,
low-density lipoprotein. 'Angiographic data were unavailable on one subject.
Characteristics
Age (years) 60 ±2
Body mass index (kg/m2) 24 ± 1
Male gender (n) 12 (100%)
Previous myocardial infarction (n) 5 (42 %)
Extent of coronary disease (n)*
One vessel 5 (42%)
Two vessels 4 (33%)
Three vessels 2 (17%)
Previous coronary revascularization (n) 9 (75%)
Co-morbidity (n)
Hypertension 3 (25%)
Family history of premature CHD 1 (8%)




Anti-anginal 11 (92 %)
Statin 12 (100%)
ACE-inhihitor 1 (8%)
Serum urea (mmol/l) 5.9 + 0.3
Serum creatinine (/tmol/l) 93 ±2
Plasma glucose (mmol/l) 5.2 ±0.1
Total cholesterol (mmol/l) 3.9 + 0.2
EDL-cholesterol (mmol/l) 2.1+0.2
Triacylglycerols (mmol/l) 1.3 ±0.2
Placebo visit
HR (beats/min) 56 ±2
SBP (mmHg) 145 + 6
Diastolic BP (mmHg) 83 + 4
FBF (ml ■ 100 ml"1 of tissue ■ min-')
Infused arm 2.1 + 0.2
Non-infused arm 2.0 ± 0.2
TNF-a visit
HR (beats/min) 56 + 3
SBP (mmHg) 142 + 4
Diastolic BP (mmHg) 81+2
FBF (ml ■ 100 ml-1 of tissue ■ min-')
Infused arm 2.0 ± 0.2
Non-inlused arm 2.1+0.2
no differences in resting arterial pressure, HR or FBF
between the two study visits (Table 2).
There was no change in HR or BP during infusion
of cither TNF-a or placebo. Haematocrit, temperature,
white cell count and hs-CRP were similar on both study
visits [P = ns (not significant); results not shown]. The
study protocol was well tolerated with no major adverse
effects.
TNF-a Saline
0 12 3 4
Time, hours
Figure I Plasma TNF-a concentrations in the infused (solid
line) and non-infused arm (dashed/dotted line) after 60 min
of intra-arterial TNF-a (•) and saline placebo (O)
P < 0.001 for the TNF-o? dose-response in the infused arm, as determined by
AN0VA; PcO.OOl when TNF-cr compared with saline placebo in the infused
arm, as determined by AN0VA.
Plasma cytokine concentrations
Intra-arterial infusion of TNF-a increased plasma TNF-
a concentrations from 1.4 + 0.2 to 164.5 + 26.8 pg/ml in
the infused arm and from 1.3 + 0.1 to 33.3 + 5.6 pg/ml
in the non-infused arm (P < 0.001; Figure 1). At 1 h after
TNF-a infusion, plasma IL-6 concentrations increased
from 4.1 + 1.9 to 6.4+ 2.3 pg/ml in the infused arm
(P < 0.001, as determined by ANOVA), but were un¬
changed in the non-infused arm (4.0 + 1.9 to 3.7 + 1.3 pg/
ml). Placebo infusion had no effect on plasma IL-6
concentrations in the infused arm (3.9+1.7 to 4.3 +
1.3 pg/ml; P=ns). Serum CRP concentrations were
unchanged following the 60 min infusion of TNF-a and
saline placebo.
Vasomotor and fibrinolytic responses
There was no significant change in resting FBF in the 2 h
after the start of cither TNF-a or placebo infusion. After
60 min of TNF-a, plasma t-PA antigen and activity con¬
centrations in the infused arm had increased from 9.4 +
1.1 to 11.3 + 1.2 ng/ml and 0.3 + 0.1 to 2.1 + 0.6 IU (in¬
ternational units)/ml respectively (P < 0.001), and these
remained elevated in the 2 h following discontinuation
of the TNF-a infusion (Figure 2). There was no change
in plasma PAI-1 antigen concentrations in the infused
arm and no change in either plasma t-PA or PAI-1
concentrations in the non-infused arm during the study
(results not shown). Prothrombin F1 +2 concentrations
in the infused arm were unaltered following either saline
placebo (0.9 + 0.1 to 0.9 + 0.1 ng/ml; P = ns) or TNF-a
infusion (0.9 + 0.1 to 1.0 + 0.1 ng/ml; P = ns).
There was a dosc-depcndent increase in FBF during
bradykinin, acetylcholine and SNP infusion (P $5 0.01,
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' at peak dose; P < 0.05) and
compared with 98.8 + 21.0 IU •
Figure 2 Plasma t-PA activity (upper panel) and antigen
(lower panel) concentrations in the infused (•) and
non-infused (O) arms after 60 min infusion of intra-arterial
TNF-a
<0.001 when infused compared with non-infused arms, as determined by
AN0VA. "P < 0.05 and ""P< 0.001, as determined by post-hoc Student's I
test for treatment effect.
as determined by ANOVA). Compared with the saline
placebo, TNF-a pretreatment impaired acetylcholinc-
and SNP-induced vasodilatation (P < 0.001 for both), but
did not alter the response to bradykinin (Figure 3).
Plasma t-PA concentrations increased in a dosc-dcpcn-
dent manner during bradykinin infusion on both study
visits (P < 0.001). Pretreatment with TNF-a augmented
the bradykinin-induced rise in plasma t-PA antigen and
activity concentrations (T5 < 0.001 for both; Figure 4)
and significantly increased estimated net release of t-PA
antigen (63.7+14.8 compared with 120.6 + 26.1 ng •
100 ml of tissue • min
activity (54.8 + 14.8
100 ml-1 of tissue ■ min'1 at peak dose;P < 0.05). Over the
30 min period of bradykinin infusion, TNF-a increased
the area under the curve for net t-PA antigen and activity
release by 120% and 188% respectively (P = 0.006).
Subgroup analysis showed a significant impairment
of cndothelium-dependent vasodilatation as well as
bradykinin-induced t-PA response in cigarette smokers.
Qualitatively the effect of intra-arterial TNF-a on the
blood flow and fibrinolytic responses was similar in both
smokers and non-smokers.
DISCUSSION
In the present study, we have confirmed the direct asso¬
ciation between plasma t-PA and serum CRP concen¬
trations in patients with stable CHD. For the first time,
we have extended this observation using an acute local
vascular inflammatory model and demonstrated that
direct intra-arterial infusion of TNF-a causes a slow
onset and sustained increase in basal t-PA release. This
arterial inflammation was also associated with increased
stimulated t-PA release in the presence of impaired
vasomotor function. Our findings arc consistent with
the suggestion that t-PA is released during vascular
inflammation and endothelial injury and this may, in part,
explain the adverse prognosis associated with increased
plasma t-PA concentrations.
The link between markers of inflammation and plasma
t-PA concentrations suggests that vascular inflammation




















Figure 3 Infused (solid line) and non-infused (dashed/dotted line) FBF during incremental doses of acetylcholine (left-hand
panel), SNP (middle panel) and bradykinin (right-hand panel) following pretreatment with TNF-a (9) or saline placebo (O)
P ^ 0.01 for all infused arm responses, as determined by ANOVA. fP<0.00l when TNF-a compared with saline placebo treatments, as determined by ANOVA.
'P < 0.05, as determined by post-hoc Student's t test for treatment effect.
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Figure 4 Plasma concentrations of t-PA antigen (left-hand panel) and t-PA activity (right-hand panel) during bradykinin
infusion following pretreatment with TNF-cr (•) or saline placebo (O)
fP < 0.001 when TNF-cr compared with saline placebo treatments, as determined by ANOVA. "P < 0.05 and **P < 0.01, as determined by post-hoc Student's t
test lor treatment effect.
release. However, this association may arise from com¬
mon aetiological factors and does not establish a causal
relationship. A recent meta-analysis has suggested that
increases in plasma t-PA concentrations largely reflect the
presence of concomitant cardiovascular risk factors [7],
We therefore sought to induce vascular inflammation in a
representative sample of our study population. Inducing
systemic inflammation will have many biological actions
and could be confounded by indirect or extra-vascular
effects. This may explain some of the differences between
our present results and those of previous work in healthy
volunteers using Salmonella typhi vaccination [9,10]. We
chose to employ an acute local inflammatory model
[13] to assess the direct effects of intra-arterial TNF-ty
administration on t-PA release. We were able to induce
local vascular inflammation with a rise in local plasma
IL-6 concentrations to levels comparable with those seen
in patients with unstable angina [17], without evidence
of a systemic inflammatory response or change in plasma
t-PA or PA1-1 concentrations in the non-infused arm.
This local vascular inflammation caused a slow onset and
sustained increase in plasma t-PA concentrations that
continued for at least 2 h after cessation of the TNF-u
infusion. This establishes that vascular inflammation
directly causes endothelial t-PA release in humans.
The mechanism of TNF-a-induced t-PA release has
not been established. Inflammatory cytokines, such as
TNF-a, may cause t-PA release via induction of local
thrombus formation, activation of specific cellular recept¬
ors or through generation of secondary mediators within
the local vasculature. The former seems unlikely given
that we observed no increase in prothrombin F1 + 2,
a sensitive marker of in vivo thrombin generation [15].
Although it is likely that plasma t-PA concentrations
are increased by inducing endothelial injury, smooth
muscle cells, macrophages and monocytes also express
t-PA mRNA following stimulation by inflammatory
cytokines within atherosclerotic plaques [18] and could
theoretically contribute to this fibrinolytic response.
Effects of TNF-a on vasomotor function
Impaired vasodilator responses to acetylcholine [19,20]
and SNP [20] in patients with cardiovascular risk fac¬
tors predict an increased risk of adverse cardiovascular
events. Previous studies in healthy volunteers have
shown acute systemic inflammation is associated with
a transient impairment in vasomotor function [9]. In the
present study, we have now shown that, in patients with
CHD, acute local vascular inflammation decreases the
vasomotor response to both acetylcholine and SNP.
Acetylcholine is known to stimulate NO (nitric oxide)
production via activation of cNOS (endothelial NO
synthase) and, together with the impaired SNP response,
these findings suggest that local arterial inflammation
can decrease NO bioavailability. Interestingly, impaired
vasodilator responses to both acetylcholine and SNP
have been correlated with plasma TNF-a concentrations
in patients with rheumatoid arthritis, a chronic inflam¬
matory condition which is itself associated with an excess
cardiovascular risk [21]. Furthermore, intra-arterial in¬
fusion of the free radical scavenger vitamin C restores
forearm blood flow responses in patients with CHD and
elevated serum levels of CRP [22].
Our results suggest that acute inflammation is
associated with impaired NO-dependent smooth muscle
relaxation in response to direct NO donors such as SNP
or endogenously derived NO following stimulation of
eNOS. Several lines of evidence support the contention
that cytokines, such as TNF-a, may impair NO-
dependent signalling. TNF-a decreases eNOS expression
[23] as well as increasing reactive oxygen species, such as
superoxide anion, that rapidly inactivate NO and are dir¬
ectly cytotoxic to vascular tissues. TNF-a also increases
plasma ADMA (asymmetric dimcthylarginine), an endo¬
genous inhibitor of cNOS that inhibits cndothclium-
dependent vasodilatation [24]. Finally, inflammatory
states may increase iNOS (inducible NO synthase) ex¬
pression which is associated with receptor uncoupling
and endothelial dysfunction [25].
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Bradykinin-induced vasodilatation was unaltered by
pretreatment with TNF-a. Previous work has suggested
that NO contributes only a small proportion (approx.
15%) to bradykinin-induccd vasodilatation [26,27] and
docs not contribute to the mechanism of bradykinin-
induced t-PA release [28]. Moreover, in patients with vas¬
cular dysfunction, there may be an increased contribution
of EDHF (endothclium-dcrived hypcrpolarizing factor)
to smooth muscle vasorelaxation [29], particularly if NO
is consumed by free radicals generated by locally active
inflammatory cells. These observations arc consistent
with our present findings of impaired acetylcholine- and
SNP-induced vasodilatation, but preserved bradykinin
responses.
Effects of TNF-a on acute endogenous
fibrinolysis
Despite the presence of higher baseline plasma t-PA
concentrations in patients with atherosclerosis [7], we
have shown in the present study that direct intra¬
arterial TNF-a infusion increases bradykinin-induccd
t-PA release in patients with stable CHD. Thus, although
vasorelaxation was impaired, acute inflammation initiates
a sustained increase in both basal and stimulated t-PA
release. The mechanism of this effect is unknown, but
may involve direct endothelial injury, up-regulation of
t-PA synthesis or alterations in bradykinin receptor
expression.
Under some circumstances, increases in t-PA may
protect against the propagation of intravascular throm¬
bosis and thereby avoid the development of an acute
coronary syndrome. However, elevations in plasma t-PA
concentrations may reflect more widespread endothelial
dysfunction and a dominant pro-inflammatory vascular
response that may overwhelm any locally protective pro-
fibrinolytic effect. Indeed, the pro-fibrinolytic actions
of vascular inflammation may potentiate degradation of
extracellular matrix and aggravate plaque instability [30].
The clinical outcome of acute vascular inflammation may,
therefore, depend upon the relative balance between the
protective antithrombotic actions and potential plaque
dcstabihzation associated with increased vascular t-PA
release.
In the present study, all patients who received TNF-
a and placebo infusion were already receiving secondary
preventative therapy, including aspirin and lipid-lowering
medications. Although these may have influenced the
vascular response to TNF-a, it was considered unethical
to withhold these and, in clinical practice, a large
proportion of patients presenting with acute coronary
syndromes and raised inflammatory markers are already
established on such therapies. As our study design was
focused on the question of the link between vascular
inflammation and t-PA release in patients with CHD, we
did not include a control population of healthy subjects.
However, we have shown previously [13] that intra¬
arterial TNF-a enhances cndothelium-dcpcndcnt t-PA
release by a similar degree in younger healthy volunteers.
Although we have again demonstrated that smokers
have impaired endothelial responses, including t-PA re¬
lease [14], intra-arterial TNF-a increased plasma t-PA
concentrations to a similar degree in both smokers and
non-smokers with established CHD.
We have found that, although TNF-a adversely affects
NO-dcpcndent vasodilatation, it enhances other pro¬
tective mechanisms, such as the endogenous fibrinolytic
capacity. This reflects the complex and pleiotropic nature
ofTNF-a which functions as part of the normal host sur¬
veillance mechanisms and response to tissue injury.
Although we only determined the effect of acute vas¬
cular inflammation in 12 patients, our results may explain
some of the contradictory findings of previous clinical
studies. For example, in patients with heart failure,
TNF-a antagonism causes marked improvements in
endothehum-dependent vasodilatation [31], but has
failed to demonstrate clinical benefit in randomized con¬
trolled trials [32]. Thus the benefits of restoring endo-
thelium-dependcnt vasomotor function by TNF-a ant¬
agonism may be counterbalanced by inhibiting other
potentially beneficial acute effects, such as enhancing
endogenous t-PA release.
Conclusions
In the present study, we have shown that, in patients with
stable CHD, plasma fibrinolytic factors are correlated
with CRP, a sensitive and prognostically relevant marker
of vascular inflammation.We have also demonstrated that
acute vascular inflammation directly impairs vasomotor
function whilst enhancing endothelial t-PA release.
We suggest that the adverse prognosis associated with
elevated plasma t-PA concentrations reflects a causative
association with vascular inflammation and injury, rather
than representing a marker of occult plaque rupture.
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KEYWORDS Abstract
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Myocardial infarction; Introduction: Thrombolytic therapy fails to achieve reperfusion in almost a third of
Reperfusion patients with acute myocardial infarction. Thrombin activatable fibrinolysis inhibitor
(TAFI) and soluble CD40 ligand (sCD40L) are novel endogenous fibrinolytic and
atherothrombotic factors that determine clot stability. We investigated whether
admission plasma thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40
ligand (sCD40L) concentrations predicted reporfusion following thrombolytic therapy
in patients with acute myocardial infarction.
Materials and methods: Prior to administration of thrombolytic therapy, venous
blood was collected from 110 patients presenting with acute ST segment elevation
myocardial infarction and plasma assayed for tissue plasminogen activator (t-PA)
antigen and activity, plasminogen activator inhibitor type-1 antigen (PAI-1), TAFI
antigen and activity, C-reactive protein (CRP) and sCD40L concentrations. Reperfu¬
sion was determined using continuous ST segment monitoring.
Results: Reperfusion occurred in 77 (70%) patients with a mean treatment to
reperfusion time of 83 ±46 min. Peak creatine kinase was significantly lower in
patients who reperfused (1578±1199 versus 2200± 1744 U/L; P<0.05) and
correlated with time to reperfusion (r = 0.44 [95% CI: 0.23 - 0.61], P = 0.0001).
Abbreviations: CRP, C-reactive protein; ELISA, Enzyme-linked immunosorbent assay; PAI-1, Plasminogen activator inhibitor type-1;
sCD40L, Soluble CD40 ligand; t-PA, Tissue-type plasminogen activator; TAFI, Thrombin activatable fibrinolysis inhibitor.
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There was a modest correlation between plasma TAFI antigen and activity (r = 0.3
[95% CI: 0.04 — 0.53]; P<0.05). There were no significant associations between
coronary reperfusion and plasma concentrations of t-PA, PAI-1, TAFI, CRP or sCD4QL.
Conclusions: Systemic plasma TAFI, sCD40L and CRP concentrations do not predict
reperfusion in patients receiving thrombolytic therapy for acute ST elevation
myocardial infarction.
© 2005 Elsevier Ltd. All rights reserved.
Introduction
Thrombolytic therapy is an established treatment
for acute ST elevation myocardial infarction [1], In
almost a third of patients thrombolysis fails to
achieve timely reperfusion of the infarct-related
artery and this is associated with a greater mortality
and morbidity [2], Arterial thrombosis is a complex,
dynamic process that is dependent on a number of
variables including endogenous fibrinolytic activity,
vascular inflammation and platelet activation.
These latter factors may play an important role in
determining successful reperfusion following throm¬
bolytic therapy.
Endogenous fibrinolytic activity is largely depen¬
dent on the balance between tissue plasminogen
activator (t-PA) and its inhibitor, plasminogen acti¬
vator inhibitor type-1 (PAI-1) [3]. In both healthy
individuals [4] and patients with cardiovascular
disease [5], reduced plasma fibrinolytic activity is
associated with an increased risk of myocardial
infarction. Evidence that the endogenous fibrino¬
lytic system may be important in the acute phase of
myocardial infarction is exemplified by the obser¬
vation that in a third of patients, the infarct-related
artery spontaneously reperfused within 12 h [6].
Moreover, baseline plasma PAI-1 concentrations
appear to predict reperfusion following thromboly¬
sis [7,8],
Thrombin activatable fibrinolysis inhibitor (TAFI)
is a recently described pro-carboxypeptidase that,
once activated, removes the C-terminal lysine
residues from partially degraded fibrin, thereby
preventing the binding of plasminogen and inhibiting
fibrinolysis [9]. Thrombin activatable fibrinolysis
inhibitor circulates in plasma as an inactive precur¬
sor but in the presence of the thrombin-thrombo¬
modulin complex undergoes proteolytic conversion
to its active form, TAFIa [9]. In man, plasma TAFI
antigen concentration is largely under genetic
control [10] and elevated concentrations have been
reported in patients with stable ischemic heart
disease, although this finding has not been universal
[11,12], In animal models, inhibition of TAFI
potentiates t-PA mediated fibrinolysis [13], and in
healthy man, plasma TAFI correlates with clot lysis
time in vitro [14],
Inflammation, fibrinolysis and thrombosis are
intimately interlinked [15], C-reactive protein
(CRP) is an established marker of inflammation
that has pro-thrombotic actions. In patients with
acute myocardial infarction, increased plasma CRP
concentrations are associated with a poorer out¬
come [16] and appear to predict successful
reperfusion following thrombolytic therapy [17].
Novel inflammatory mediators, such as CD40/CD40
ligand dyad, have recently been described. CD40
ligand, a member of the tumour necrosis factor
family, is expressed along with its receptor, CD40,
on a wide range of atheroma-associated cells [18].
In addition to the cell-associated form, CD40
ligand is also present in plasma as the biologically
active fragment, soluble CD40 ligand (sCD40L)
[18]. The CD40/CD40 ligand dyad mediates a wide
range of pro-inflammatory and pro-thrombotic
processes [18] including expression of cytokines,
chemokines, cell adhesion molecules and tissue
factor [19]. In addition, sCD40L acts as a platelet
agonist [20] and is necessary for the stability of
arterial thrombi [21], As with CRP, plasma sCD40L
concentrations are associated with an increased
risk of recurrent events in patients with acute
coronary syndromes [22],
The aim of this study was to establish whether
the novel fibrinolytic and vascular inflammatory
factors, TAFI and sCD40L, as well as plasma t-PA,
PAI-1 and CRP concentrations are associated with
successful reperfusion following thrombolytic ther¬




One hundred and ten consecutive patients pre¬
senting with acute ST elevation myocardial infarc¬
tion fulfilling the European Society of Cardiology
clinical and electrocardiographic criteria for
thrombolytic therapy [1] in whom informed con¬
sent was obtained were recruited. Patients with
severe intercurrent illness, overt malignancy,
active inflammatory disease or left bundle branch
block on the electrocardiogram at presentation
Plasma TAFI and soluble CD40 ligand 191
were excluded. The study was performed with the
approval of the local research ethics committee in
accordance with the Declaration of Helsinki.
Protocol
Immediately prior to administration of thrombolyt¬
ic therapy (streptokinase or recombinant tissue-
type plasminogen activator), 10 mL venous blood
was collected from an antecubital vein using a 21-
gauge needle and continuous ST segment monitor¬
ing was initiated. Where possible, streptokinase
(1.5 million units) was the thrombolytic agent of
choice. Recombinant t-PA (100 mg) was adminis¬
tered in place of streptokinase when patients had
previously received streptokinase, had a systolic
blood pressure <90 mm Hg or had evidence of
extensive anterior infarction on the admission
electrocardiogram. All patients received three
hundred milligrams of aspirin prior to thrombolysis.
Reperfusion of the infarct-related artery was
determined non-invasively as a fall in ST segment
elevation >50% or the onset of idioventricular
rhythm [23,24],
Blood samples and assays
Blood was collected into acidified buffered citrate
(Biopool Stabilyte, Umea; for t-PA assays) and
citrate (Monovette, Sarstedt; for PAI-1, CRP, TAFI
and sCD40L). Samples were kept on ice before
being centrifuged at 2000 xg for 30 min at 4 °C.
Platelet-free supernatant was decanted and
stored at -80 °C before assay. Plasma t-PA antigen
and activity, and PAI-1 antigen concentrations
were determined using enzyme-linked immunosor¬
bent assay (ELISA) and a photometric method as
previously described [25], The intra-assay coeffi¬
cients of variation were 5.5% and 2.4% for t-PA
antigen and activity, respectively and 7.0% for PAI-
1 antigen. The inter-assay coefficients of variation
were 4.0%, 4.0% and 7.3%, respectively. The
sensitivities of the assays were 0.5 ng/ml_, 0.1
lU/mL and 2.5 ng/mL, respectively.
Plasma CRP concentrations were measured using
ultra-sensitive particle enhanced immunonephelo-
metry (Dade Behring UK Ltd). Plasma TAFI antigen
(Hyphen Biomed) and sCD40L (Bender MedSystems)
concentrations were determined using commercial¬
ly available ELISA kits. The total amount of
activatable TAFI present in plasma was measured
using a commercially available chromogenic assay
(Actichrome). Plasma TAFI antigen concentrations
are expressed as a percentage of normal pooled
plasma. For technical reasons, plasma TAFI antigen
and activity and sCD40L concentrations were only
available for the latter 56 patients enrolled in the
study. The intra-assay coefficients of variation
were 2% for CRP, 5% for TAFI antigen, 6% for TAFI
activity and 7% for sCD40L. The inter-assay coeffi¬
cients of variation were 4%, 5%, 9% and 14%,
respectively. The sensitivities of the assays were 1
mg/L, 1.4%, 0.2 p.g/mL and 12 pg/mL, respectively.
Based on previous data [25,26,27], the present
study had 80% power to detect a difference of 0.6
ng/mL, 0.3 lU/mL, 8 ng/mL, 0.1 pg/mL and 0.7
Hg/mL with a significance level of P<0.05 for t-PA
antigen and activity, PAI-1 antigen, sCD40L and
TAFI activity, respectively.
Statistical analysis
Data are reported as mean ± standard deviation
for normally distributed data and median [inter¬
quartile range] for non-Gaussian data. Statistical
analysis was performed using the chi-squared test,
unpaired t-test for Gaussian data, and the Mann-
Whitney U test for non-Gaussian data. The rela¬
tionship between variables was assessed by linear
regression analysis and is expressed as coefficient,
significance value and the 95% confidence inter¬
vals for this relationship.
Results
Patients were predominantly male with a mean
age of 66 years (Table 1). Twenty-six (24%)
patients were receiving treatment for hyperten¬
sion. Ten patients (9%) had a previous diagnosis of
diabetes mellitus and 46 patients (42%) were
current smokers. Anterolateral ST segment eleva¬
tion was present in 40 patients (36%) and inferior
elevation in 70 (64%). Intravenous streptokinase
was administered in 70 patients (64%) and recom¬
binant t-PA in 40 (36%). There was no difference in
the percentage of patients that reperfused fol¬
lowing treatment with streptokinase compared to
recombinant t-PA (48 (69%) versus 29 (73%)
patients, P = 0.7). There were no differences in
the time of admission between the reperfusion
and no reperfusion groups (Table 1).
Reperfusion of the infarct-related artery oc¬
curred in 77 (70%) patients (Table 1). The mean
time from initiation of thrombolysis to reperfusion
was 83 ±46 min. There was no difference in the
time from onset of symptoms to treatment be¬
tween the reperfusion and no reperfusion groups
(230±180 versus 231 ±201 min, respectively,
P = 1.0). Peak plasma creatine kinase concentra¬
tions were lower with reperfusion compared to no
reperfusion (1578±1199 versus 2200±1744 U/L,
respectively, P<0.05, n = 110; 1690 ±1317 versus
192 N.L.M. Cruden et al.
Table 1 Patient demographics for all 110 patients and for the 56 patients in whom plasma soluble CD40 ligand and
thrombin activatabte fibrinolysis inhibitor concentrations were measured
All Reperfusion No reperfusion P' All Reperfusion No reperfusion P*
(n = 110) (n = 77) (n = 33) (f = 56) (n = 37) (n = 19)
Age, years (range) 66 (37- 86) 65 (37- 82) 69 (48- 86) 0.1 68 (37- 84) 66 (37- 79) 71 (50- 84) 0.2
Male, n (%) 71 (65) 53 (69) 18 (54) 0.2 34 (61) 25 (68) 9 (47) 0.14
Time to treatment 2301186 2301180 231 1201 1.0 243 1 207 2321204 2651215 0.6
(min)
Risk factors, n (%)
Hypertension 26 (24) 19 (25) 7 (21) 0.2 12 (21) 9 (24) 3 (16) 0.5
Diabetes mellitus 10 (9) 6 (8) 4(12) 0.5 5 (9) 2 (5) 3 (16) 0.2
Current smoker 46 (42) 33 (43) 13 (39) 0.2 18 (32) 11 (30) 7(37) 0.6
Prior aspirin use 30 (27) 21 (27) 9(27) 1.0 17 (30) 11 (30) 6 (32) 0.9
Time of treatment,
n (X)
00:00 -08:00 16 (15) 13 (17) 3 (9) 0.3 4 (7) 3 (8) 1 (5) 0.7
08:00 -16:00 66 (60) 45 (58) 21 (64) 0.6 41 (73) 25 (68) 16 (84) 0.2
16:00 -24:00 18 (25) 19 (25) 9 (27) 0.7 11 (20) 9 (24) 2 (11) 0.2
Data are expressed as mean± SD or as indicated. -Reperfusion versus no reperfusion (unpaired t test or chi squared).
2715 ± 1983, respectively, P<0.05, n = 56) and
correlated with the time to reperfusion (r = 0.44
[95% CI; 0.23 to 0.61], P = 0.0001, n = 110, Fig. 1;
r = 0.53 [95% CI; 0.25 to 0.73], P<0.05, n = 56).
Fibrinolytic factors
There were no differences in plasma concentra¬
tions of t-PA antigen and activity, TAFI antigen and
activity, and PAI-1 antigen between the reperfu¬
sion and no reperfusion groups (Table 2). There
were no associations between time to reperfusion
and plasma concentrations of t-PA, PAI-1 and TAFI
(Fig. 2). For patients enrolled within six hours of
the onset of symptoms, there were no differences
in plasma t-PA, PAI-1 and TAFI concentrations
between the reperfusion and no reperfusion
groups (data not shown). There was a modest
correlation between TAFI antigen and activity
(r = 0.3, [0.04- 0.53]; P<0.05; Fig. 2).
C-reactive protein and soluble CD40
ligand
There were no differences in plasma CRP or
sCD40L concentrations between the reperfusion
and no reperfusion groups (Table 3). Plasma CRP
concentrations were significantly lower in patients
presenting within six hours of symptom onset
compared to those with symptoms of greater than
six hours duration (1.6 [0.8— 4.0] versus 4.5 [1.2 —
19.5] mg/L, respectively; P<0.01). There were no
associations between time to reperfusion and
either plasma CRP (data not shown) or sCD40L
(Fig. 2) concentrations. There were no differences
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Figure 1 (a) Peak serum creatine kinase concentrations in patients who do (triangles) and do not (squares) reperfuse
following thrombolytic therapy, and (b) correlation between time to reperfusion and peak serum creatine kinase
concentrations (R = 0.44 [95% CI: 0.23 — 0.61]; P = 0.0001).
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Table 2 Plasma concentrations of endogenous fibrinolytic factors in patients presenting with acute ST elevation
myocardial infarction
AH Reperfusion No reperfusion P* Difference* [95% CI]
t-PA antigen (ng/mL) 14.3 ± 6.8 14.3 ± 0.8 14.0± 5.9 0.8 -0.3 [-2.7 to 3.3]
t-PA activity (lU/mL) 1.6 ± 3.0 1.7+3.2 1.6 ± 2.3 1.0 0.0 [-1.3 to 1.2]
PAI-1 antigen (ng/mL) 72 + 32 73 ±31 69 ±34 0.6 -3.2 [-10.1 to 16.4]
t-PA: PAI-1 ratio 0.3 ± 0.3 0.2 + 0.3 0.3 ± 0.3 0.2 0.0 [-0.1 to 0.1]
TAFI antigen (%)f 117 ± 20 118 + 29 116 ±24 0.8 1.7 [ 13.8 to 17.1]
TAFI activity (ng/mL)t 14.5 + 3.3 14.5 ± 3.4 14.4 ± 3.3 0.9 -0.1 [-1.8 to 2.1]
Data are expressed as mean±SD. The difference between means [95% Confidence Interval (CI)] is also given. t-PA, tissue
plasminogen activator; PAI-1, plasminogen activator inhibitor type 1; TAFI, thrombin activatable fibrinolysis inhibitor. "Reperfusion
versus no reperfusion (unpaired t test), f (r> = 56).
sCD40L (data not shown) between the reperfusion
and no reperfusion groups for patients enrolled
within six hours of the onset of symptoms.
Discussion
This is the first study to examine the relationship
between plasma concentrations of TAFI and sCD40L
and the response to thrombolytic therapy in
patients with acute ST segment elevation myocar¬
dial infarction. We found no association between
coronary reperfusion and plasma concentrations of
the endogenous fibrinolytic factors, t-PA, PAI-1 and
TAFI, the inflammatory marker, CRP, or the ather-
othrombotic mediator, sCD40L. We conclude that
systemic plasma TAFI and sCD40L concentrations do
not appear to influence the efficacy of therapeutic
thrombolysis.
Reperfusion and creatine kinase
In keeping with previous work [28], peak creatine
kinase concentrations were lower in patients who
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R=0.3 [95% CI, 0.04 - 0.53]; P<0.05
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Figure 2 Comparison of time to reperfusion with plasma concentrations of (a) TAFI antigen, (b) TAFI activity, and (c)
soluble CD40 ligand. (d) Relationship between plasma TAFI antigen and activity concentrations in all patients (R = 0.3
[95% CI: 0.04- 0.53]; P<0.05).
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Table 3 Plasma concentrations of C-reactive protein and soluble CD40 ligand in patients presenting with acute ST
elevation myocardial infarction
All Reperfusion No reperfusion P* Difference* [95% CI]
CRP (mg/L) 2.0 [0.9-5.2] 1.9 [0.8-4.7] 2.7 [0.9-6.5] 0.7 0.37 [-0.42 to 1.75]
CRP (mg/L; symptoms<6 h)f 1.6 [0.8- 4.0] 1.6 [0.7-4.0] 1.9 [0.8- 4.3] 0.8 -0.02 [—0.9 to 0.7]
Soluble CD40 ligand (pg/mL) ' 0.9 + 0.8 0,9±0.7 0.9± 1.0 08 0.1 [-0,5 to 0.4]
Data are expressed as median [interquartile range] or mean±SD. The difference between means [95% confidence interval (CI)] is
also given. CRP, C-reactive protein. 'Reperfusion versus no reperfusion (unpaired t test or Mann-Whitney U test); 'plasma C-
reactive protein concentrations in patients presenting within 6 h of symptom onset (n = 87). *(n = 56).
therapy. Moreover, peak creatine kinase concentra¬
tions correlated with time to reperfusion, consis¬
tent with a reduction in infarct size associated with
more rapid coronary reperfusion [29],
Endogenous fibrinolysis
We found no association between systemic plasma
t-PA or TAFI concentrations and the response to
thrombolysis. These data are consistent with the
observation that neither plasma t-PA nor TAFI
concentrations predict reperfusion of the infarct-
related artery in patients receiving thrombolytic
therapy for acute stroke [30], Flowever, this does
not exclude the possibility that local, in this case
intra-coronary, activity of t-PA and TAFI may
determine the stability of thrombus or sensitivity
to thrombolysis. The vascular endothelium is re¬
sponsible for the synthesis and release of t-PA into
the circulation and when acutely stimulated, is
capable of achieving local concentrations normally
associated with exogenous thrombolytic therapy
[31], However, systemic plasma concentrations may
not reflect local coronary vascular activity because
of the substantial dilutional effect of blood passing
into the systemic circulation, and the rapid removal
of t-PA from the circulation by the liver (half-life -5
min) [32]. Obtaining blood samples from the
coronary sinus in patients with acute myocardial
infarction prior to reperfusion therapy might pro¬
vide a clearer picture of local fibrinolytic condi¬
tions but would be challenging to obtain.
Plasmin can cleave and inactivate TAFI in vitro
[33] and it has been suggested that this mechanism
may account for the reduced plasma TAFI activity
and associated bleeding abnormalities observed in
patients with acute promyelocytic leukaemia [34],
Local plasmin concentrations are likely to be
significantly elevated following treatment with
thrombolysis and this mechanism may offer an
alternative explanation for our finding that system¬
ic TAFI concentrations do not predict reperfusion.
Elevated thrombin concentrations at sites of
thrombus formation are likely to favour maximal
activation of local TAFI. Using the Actichrome
assay, we have measured the total amount of
activatable TAFI present in plasma. However, it is
not clear whether this reflects the actual concen¬
tration of TAFIa at sites of thrombus formation
within the coronary circulation. In addition, we
found a relatively weak correlation between TAFI
antigen and activity concentrations. This may
reflect differences in the stability or activity of
polymorphisms of the TAFI gene [35].
We found no association between baseline
plasma PAI-1 concentrations and the response to
thrombolytic therapy in acute myocardial infarc¬
tion in keeping with the findings of Paganelli et al.
[36], This is not a universal finding, however, and
our data are in contrast to those of Barbash et al.,
who reported that plasma PAI-1 concentrations
correlated with patency of the infarct-related
artery [7]. This apparent disparity is likely to
reflect differences in the incidence of coronary
artery reocclusion due to the timing of assessment
of coronary artery patency. Barbash assessed
coronary artery patency at 72 h, whereas we
determined reperfusion within 4 h of the admin¬
istration of thrombolysis. Early reocclusion of the
infarct-related coronary artery occurs in -10% of
patients receiving thrombolytic therapy for myo¬
cardial infarction [37] and has been associated
with elevated PAI-1 concentrations. Indeed, in 60
patients receiving streptokinase for acute myocar¬
dial infarction, Sinkovic found that elevated
baseline PAI-1 concentrations predicted coronary
artery reocclusion but not reperfusion [8].
C-reactive protein
Although plasma CRP concentrations appeared to
be lower in patients who reperfused, this was not
statistically significant. In contrast, in a recent
study of 319 patients receiving thrombolysis for
acute myocardial infarction, elevated plasma CRP
concentrations were associated with a failure to
reperfuse, determined both non-invasively 2 h after
admission and by coronary angiography performed
within 7 days [17]. This difference may reflect the
larger sample size, the greater incidence of car-
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diovascular risk factors or the differing non-inva¬
sive criteria for myocardial reperfusion when
compared to our study [17].
It has been suggested that elevated plasma CRP
concentrations may simply reflect the extent of
underlying myocardial necrosis and associated
acute phase response [38]. On this basis, it would
not be surprising if plasma CRP concentrations were
higher in patients who fail to reperfuse. To control
for this possibility we analysed the data excluding
patients presenting with symptoms of greater than
six hours duration, since this represents the mini¬
mum time taken for an acute increase in plasma
CRP concentrations to occur. Plasma CRP concen¬
trations were lower in this restricted population,
and we again found no association with failure to
reperfuse following thrombolysis.
Soluble CD40 ligand
We found no association between plasma sCD40L
concentrations and the response to thrombolytic
therapy in patients with acute ST elevation myo¬
cardial infarction. These data are consistent with
the observations of Andre et al. [21], which
demonstrate that the instability of arterial thrombi
observed in CD40 knockout mice do not appear to
be due to differences in fibrin formation. The
mechanism by which CD40 ligand stabilises thrombi
is unclear but appears to be dependent on CD40
ligand-platelet interactions, in particular those
mediated via the glycoprotein lib/Ilia receptor
[39]. The platelet glycoprotein lib/Ilia receptor is
capable of binding sCD40L directly, whilst glyco¬
protein lib/Ilia receptor antagonists inhibit SCD40L
release from activated platelets [40], These data
suggest a positive feedback loop whereby sCD40L
stabilizes platelet—thrombus interactions under
high shear rates [39], In support of this, there was
a strong correlation between platelet activation
and plasma sCD40L concentrations in patients
presenting with an acute coronary syndrome [22].
Given the central role of platelets in CD40 ligand-
mediated signalling, it is not surprising that sCD40L
concentrations predict the response to the glyco¬
protein lib/Ilia inhibitor, abciximab, but not throm¬
bolytic agents in patients with acute myocardial
infarction.
Study limitations
Although coronary angiography remains the gold
standard for predicting TIMI 3 flow in the infarct-
related artery, it is widely accepted that ST segment
resolution is a reliable non-invasive predictor of
myocardial reperfusion and prognosis following
thrombolysis [23,24,41]. We believe, therefore,
that continuous ST segment monitoring is an appro¬
priate non-invasive method with which to assess
reperfusion for the purposes of this study.
Whilst there were no significant differences in
the presence of major risk factors for ischemic heart
disease between the reperfusion and no reperfusion
groups, we acknowledge that associated comorbid¬
ity and concomitant therapies may influence both
plasma concentrations of the factors measured and
the success or otherwise of reperfusion therapy.
However, the present study was not powered to
examine the relationship between the many poten¬
tial clinical variables and reperfusion.
Finally, we have examined the relationship
between endogenous fibrinolytic and vascular in¬
flammatory factors and reperfusion following
thrombolysis for acute myocardial infarction. Given
that elevated baseline PAI-1 concentrations pre¬
dicted coronary artery reocclusion but not reper¬
fusion [8], it remains possible that plasma
concentrations of TAFI and sCD40L may influence
the incidence of early re-infarction following reper¬
fusion. Further studies are required to address this
hypothesis.
Summary
We have demonstrated that systemic plasma
concentrations of TAFI, sCD40L and CRP, as well
as established endogenous fibrinolytic factors, do
not predict reperfusion in patients receiving
thrombolytic therapy for acute ST elevation myo¬
cardial infarction. Further work is required to
determine whether these findings can be extrap¬
olated to the local endogenous fibrinolytic activity
within the coronary circulation at the time of
thrombotic arterial occlusion.
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Endothelial Fibrinolytic Capacity Predicts Future Adverse
Cardiovascular Events in Patients With Coronary
Heart Disease
Simon D. Robinson, Christopher A. Ludlam, Nicholas A. Boon, David E. Newby
Objective—The endothelium-derived fibrinolytic factor tissue plasminogen activator (t-PA) is a major determinant of
vessel patency after coronary plaque rupture and thrombosis. We assessed whether endothelial fibrinolytic capacity
predicts atherothrombotic events in patients with coronary heart disease.
Methods and Results—Plasma t-PA and plasminogen activator inhibitor (PAI)-I concentrations were measured during
intrabrachial substance P infusion in 98 patients with angiographically proven stable coronary heart disease. Forearm
blood flow was measured during infusion of substance P and sodium nitroprusside. Cardiovascular events (cardiovas¬
cular death, myocardial infarction [MI], ischemic stroke [CVA], and emergency hospitalization for unstable angina)
were determined during 42 months of follow-up. Patients experiencing a cardiovascular event (n=19) had similar
baseline characteristics to those free of events. Substance P caused a dose-dependent increase in plasma t-PA
concentrations (PCO.OOl). However, net t-PA release was 72% lower in the patients who experienced death. Ml, or
CVA, and 48% lower in those who suffered death, Ml, CVA or hospitalization for unstable angina (P<0.05). Major
adverse cardiovascular events were most frequent in those with the lowest fibrinolytic capacity (P=0.03 for trend);
patients with the lowest quartile of t-PA release had the highest rate of adverse events (P=0.01).
Conclusion—Endothelial fibrinolytic capacity, as measured by stimulated t-PA release, predicts the future risk of adverse
cardiovascular events in patients with coronary heart disease. We suggest that endothelial fibrinolytic capacity is a
powerful novel determinant of cardiovascular risk. (Arterioscler Thromb Vase Biol. 2007;27:1651-1656.)
Key Words: coronary heart disease ■ endothelium ■ fibrinolysis ■ survival ■ vasodilation
The endogenous fibrinolytic system protects the circula¬tion from i travascular fibrin for ation and rombosis.
In the presence of developing thrombus, the fibrinolytic
factor tissue plasminogen activator (t-PA) is rapidly released
from the vascular endothelium by the coagulation factors
thrombin and factor Xa1 and causes a 1000-fold increase in
the enzymatic conversion of plasminogen to plasmin.--1 This
ensures that rapid plasmin generation, fibrin degradation, and
clot dissolution are tightly regulated and localized to sites of
vascular injury and thrombus formation. Thus, the rapidity
and extent of acute t-PA release from the endothelium is a
critical factor in determining the efficacy of local endogenous
fibrinolysis.4-5
Areas of endothelial denudation and thrombus deposition
are a common finding on the surface of atheromatous plaques
and are often subclinical.6 Through t-PA release, endogenous
fibrinolysis is usually able to prevent thrombus propagation,
vessel occlusion, and tissue infarction, although organization
of the residual thrombus may lead to plaque growth and
expansion.6 The resolution of thrombus after atheromatous
plaque rupture, and the resulting clinical sequelae, may
therefore be critically dependent on the efficacy on endoge¬
nous fibrinolysis.7 Accordingly the capacity of the endothe¬
lium to release t-PA may predict the outcome of individual
plaque events and long-term cardiovascular risk.
Intraarterial infusion of substance P8 and bradykinin9 cause
a rapid and sustained release of t-PA from the endothelium,
and acute stimulated t-PA release has been measured within
the forearm8-10 and coronary"1- circulations of man. Previous
studies have demonstrated impaired forearm t-PA release in
cigarette smokers13 and patients with hypertension14 who are
at particular risk of coronary thrombosis and myocardial
infarction (MI).1516 Although this suggests that endogenous
fibrinolysis plays an important role in the pathogenesis of
coronary thrombosis, the relationship between the capacity to
release t-PA and the future risk of adverse cardiovascular
events is unknown. The aim of the present study was,
therefore, to determine whether endothelial fibrinolytic ca¬
pacity predicts the future risk of alherothrombotic events in
patients with stable coronary heart disease (CHD).
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Methods
Patients
We recruited patients with angiographically proven CHD defined as
&50% luminal stenosis of at least one major epicardial coronary
vessel. All patients had stable anginal symptoms and had not
undergone coronary revascularization within the preceding 3
months. Exclusion criteria were significant cardiac failure, renal
impairment, systolic blood pressure <100 or >190 mm Hg, or
diabetes mellitus. All studies were undertaken with the approval of
the local Research Ethics Committee, the written informed consent
of each subject, and in accordance with the Declaration of Helsinki.
Venous Sampling and Assays
Venous blood was collected into tubes containing gel, ethylene
diamine tctra-acetic acid, acidified buffered citrate, and trisodium
citrate. Platelet-free plasma and serum were stored at — 80°C before
assay. Plasma t-PA and PAI type 1 (PA1-1) antigen concentrations
(Coaliza, Chromogenix) were determined using enzyme-linked im¬
munosorbent assays."-13 Highly sensitive assays of C-reactive protein
(/i.r-CRP) were undertaken on serum using the method of particle-
enhanced immunonephelometry (Behring BN 11 ncphelometer).
Serum biochemical analysis and hematocrit estimations were under¬
taken by the hospital Clinical Biochemistry and Hematology Labo¬
ratories, respectively.
Forearm Study Protocol
Subjects abstained from alcohol for 24 hours and from food, tobacco,
and caffeine-containing drinks for at least 4 hours before each study
visit. Cardioactive medications were withheld on the morning of
each study. All studies were carried out in a quiet temperature
controlled room maintained at 22 to 25°C. Patients rested recumbent,
strain gauges and cuffs were applied. A 17-G venous cannula was
inserted into the antecubilal vein of each arm and the brachial artery
of the nondominant arm was cannulated with a 27-G needle
(Cooper's Needle Works Ltd). Forearm blood (low (FBF) was
measured in both forearms by venous occlusion plethysmography
using mercury-in-silastic strain gauges as previously described.81-1
Blood pressure and heart rate were measured using a semiautomated
noninvasive sphygmomanometer.
After a 30-minute saline infusion, intraarterial substance P (Cli-
nalfa) at 2, 4, and 8 pmol/min (cndothclium-dependent vasodilator
releasing t-PAR) and sodium nitroprusside (David Bull Laboratories)
at 2, 4, and 8 pig/min (endothelium-independent vasodilator which
does not release t-PA8-'7) were infused intraarterially for 6 minutes at
each dose. The vasodilators were administered in a randomized order
with a 15-minute saline washout period between each agent. Forearm
blood flow was measured at baseline and with each dose of
vasodilator. Venous blood sampling for plasma t-PA and PAI-1
antigen concentration estimation was undertaken before and after
each 6-minute infusion period of substance P doses 2, 4, and
8 pmol/min.
Long-Term Follow-Up
Atherothrombotic cardiovascular events, defined as death from a
cardiovascular cause, MI, ischemic stroke (CVA), and emergency
hospitalization for unstable angina, were determined through the
Information and Statistics Division of the National Health Service in
Scotland and the General Register Office in Scotland. These data¬
bases combine high quality data and consistency, with national
coverage and the ability to link data to allow patient based analysis
and follow-up. These systems have been successfully applied to
evaluate cardiovascular morbidity and mortality for subjects resident
within Scotland.18 Diagnostic criteria for acute myocardial infarction
and unstable angina were as previously validated in the GRACE
(Global Registry of Acute Coronary Events) registry,1'' a prospective
multi-center observational study of patients with the full spectrum of
acute coronary syndromes (full criteria shown in data supplement
online, please sec http://atvb.ahajournals.org). Patients with unstable
symptoms who were hospitalized for <1 day and patients with
perioperative associated acute myocardial infarction were excluded.
Statistical Analysis
Data of baseline characteristics are expressed as mean±SD or
frequency (n, %) and compared using 2-tailcd Student r test and
Fisher exact test where appropriate. Responses to substance P and
sodium nitroprusside were examined by analysis of variance
(ANOVA) for repeated measures. Forearm blood flow responses to
the vasodilators were analyzed as the ratio between the infused and
control arms expressed as a percentage of the ratio measured during
the baseline control period.20 Estimated net release of t-PA was
defined previously as the product of the infused forearm plasma
flow, and the concentration difference between the infused and
noninfused forearms.5-8-1-1 Cumulative event rates were estimated by
Kaplan-Meier survival curves, and probability values were deter¬
mined with the log-rank test. In those patients who experienced
multiple events, survival analysis was restricted to the first event. For
Kaplan-Meier analyses, subjects were divided into quartilcs atcoid-
ing to estimated net release of t-PA antigen. All statistical analysis
was completed using GraphPad Prism (GraphPad Software) with
statistical significance being assigned at the 5% level.
Results
Endothelial fibrinolytic capacity was measured in 98 subjects
with angiographically proven CUD who were followed up for
a median of 42 months (range 5 to 51 months). Over the
follow-up period, 2 patients died from cardiovascular disease,
2 suffered a Ml, 2 hud an ischemic CVA, and 13 had an
emergency admission for unstable angina. In general, patients
experiencing cardiovascular events had similar baseline char¬
acteristics and use of secondary preventative medications to
those free from events (Table), although plasma glucose
levels were slighter higher in those subsequently experienc¬
ing clinical events (6.1 ±0.9 versus 5.6±0.8 nrmol/L, respec¬
tively, P=0.03).
Substance P caused a dose-dependent increase in plasma
t-PA (P<0.001, ANOVA) but not PAI-1 (P=ns) concentra¬
tions. The concentration differences of t-PA antigen between
the forearms and estimated net release of t-PA both increased
dose dependently (P<().()01 for both, ANOVA) although this
increase was reduced in subjects who subsequently experi¬
enced cardiovascular events (P<0.05, ANOVA; Figure 1).
Specifically, net release of t-PA during substance P infusion
was 72% lower in those subjects suffering cardiovascular
death, MI, or CVA (P=0.02, ANOVA), and 48% lower in
those with cardiovascular death, Ml or CVA, or hospitaliza¬
tion for unstable angina (P=0.008, ANOVA). Major adverse
cardiovascular events were most frequent in (hose with the
lowest fibrinolytic capacity (P=0.03 for trend) such that
patients with the lowest quartile of t-PA release had the
highest rate of adverse events (P=0.01; Figure 2).
Although baseline parameters were similarly distributed
between subjects with and without events, baseline plasma
PAI-1 antigen and female gender were positively cor¬
related with t-PA release (P<0.05), whereas cigarette
smoking was associated with a reduction in substance
P-induced t-PA release (P=0.05). There was no associa¬
tion between acute t-PA release and plasma glucose concen¬
trations (I59±24 versus 168±26. P=0.80: area under the
curve for t-PA release in subjects±versus>median glucose
concentration).








Age, years 59+7 62 ±8 59 + 7 0.10
Sex, male/female 80/18 17/2 63/16 0.51
BMI, kg/m2 29+4 28±4 29±5 0.27
Systolic BP, mm Hg 134±18 138±20 133 ±17 0.26
Diastolic BP, mm Hg 75±10 77±10 74 ± 10 0.71
Pulse, bpm 57+9 56±8 57 ±9 0.70
Cigarette smoker, % 31 32 30 1.00
Co-morbidity, %
Previous Ml 42 53 39 0.31
Hypertension 48 47 48 1.00
FHx CHD 33 47 29 0.17
Symptomatic CVD 4 11 3 0.17
Extent of coronary disease, %
1 vessel 46 47 46 0.73
2 vessels 26 26 26 0.84
3 vessels 28 26 28 0.98
Medical therapy, %
Aspirin 99 100 99 0.62
Lipid lowering therapy 93 95 92 0.72
ACE inhibitor, ARB 31 37 29 0.51
Urea, mmol/L 5.6±1.3 5.3±1.4 5.6±1.3 0.41
Creatinine, /imol/L 94 ±13 96±16 93 ±12 0.29
Glucose, mmol/L 5.7±0.9 6.1 ±0.9 5.6 + 0.8 0.03*
Total chol, mmol/L 4.5 + 1.0 4.5 + 1.1 4.5±.0.9 0.88
LDL chol, mmol/L 2.5 + 0.8 2.5+ 1.1 2.5±0.6 0.95
t-PA antigen, ng/mL 9.7+3.9 10.1+5.0 9.6±3.6 0.62
PAI-1 antigen, ng/mL 43.7+24.5 36.3±17.9 45.4±25.6 0.16
C-reactive protein, mg/L 1.91+1.87 1.98 ±1.84 1.90 ±1.84 0.92
Values are mean±SD.
"Unpaired ttest or Fishers exact test for subjects with, vs without, events (death from a cardiovascular cause, Ml,
ischemic CVA, hospitalisation for unstable angina). As C-reactive protein values were not normally distributed they
were log transformed before statistical analysis.
BMI indicates body mass index; bpm, beats per minute; Ml, myocardial infarction; CHD, coronary heart
disease; FHx, family history; CVD, cerebrovascular disease; ACE, angiotensin converting enzyme; ARB,
angiotensin receptor blocker; chol, cholesterol; t-PA, tissue plasminogen activator; PAI-1, plasminogen activator
inhibitor-1.
There was no difference in resting forearm blood flow
between those subjects with and without atherothrombotic
events (2.9±0.3 niL/100 mL tissue/min versus 2.8±0.3
mL/100 mL tissue/min, respectively; P=0.37). Substance P
and sodium nitroprusside caused dose-dependent increases in
infused forearm blood flow in all subjects (P<0.001,
ANOVA). There were no differences in either endolhelium-
dependent or -independent blood flow responses between
subjects in either group (Figure 3).
Discussion
This is the first study to assess the relationship between
endothelial fibrinolytic capacity and the future risk of athero¬
thrombotic cardiovascular events. The population that we
chose to study was a homogenous cohort of patients with
stable CHD and a typical distribution of conventional cardio¬
vascular risk factors. Even though this was a relatively low
risk population receiving optimal secondary preventative
therapy, endothelial fibrinolytic capacity has emerged as a
powerful novel determinant of future cardiovascular risk.
In a metaanalysis of prospective observational studies,21
the risk of CHD is increased in subjects with plasma t-PA
antigen concentrations in the highest lertile compared with
those in the lowest tertile. This may seem counterintuitive but
in part reflects the concomitant rise of plasma PAI-1 concen¬
trations and the associated reduction in t-PA activity. More¬
over, in the basal state, the endogenous fibrinolysis system is
effectively inactive and does not influence in situ thrombus
formation. Neither basal plasma t-PA nor PAI-1 concentra¬
tions control the local vascular fibrinolytic capacity, which is
























Figure 1. Concentration differences between the forearms of
plasma tissue plasminogen activator (t-PA) antigen (lower pan¬
els) and estimated net release of t-PA antigen (upper panels) in
subjects with (•), and without (O), death, Ml, or CVA (left hand
panels) or death, Ml, CVA, or hospitalization for unstable angina
(right hand panels). *P=0.02, ANOVA (•) vs (O); |P=0.004,
ANOVA (•) vs (O); *P=0.008, ANOVA (•) vs (O).
determined by the acute release of t-PA from the endotheli¬
um.4 This underscores the importance of assessing the patho¬
physiological^ relevant measure of acute stimulated endo¬
thelial t-PA release.
The positive association between forearm t-PA release and
female gender is in keeping with previous reports.22-23 Fur¬
thermore, we and others have also previously demonstrated
that cigarette smoking"-'3-24 but not hypercholesterolemia25 is
associated with a characteristic and substantial reduction in
endothelial t-PA release. There is a good correlation and
consistency between the endothelial fibrinolytic capacity of
the forearm13-26 circulation and the coronary vascular bed.1112
Although the forearm vascular bed is relatively protected
from the development of atheroma, it therefore seems likely
that changes in its fibrinolytic capacity are indicative of a
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Figure 2. Cumulative proportion of patients without cardiovas¬
cular events during follow-up (Kaplan-Meier). Subjects are
divided into quartiles for estimated net release of t-PA antigen.






Figure 3. Forearm blood flow (FBF) during incremental doses of
substance P (left), sodium nitroprusside (right) in subjects with
(•) and without (O) death. Ml, CVA, or hospitalization for unsta¬
ble angina. P<0.001, ANOVA dose response; P=ns, (•) vs (O),
for both vasodilators.
considerations are, therefore, in keeping with the hypothesis
that atherosclerosis is a systemic disorder, and that acute t-PA
release should be considered a distinct marker of endothelial
function.
Intravascular thrombus formation is a key feature of
clinical atherosclerotic events associated with eroded or
unstable coronary plaques. The importance of endogenous
t-PA release is exemplified by the high rate of spontaneous
reperfusion in the infarct related artery after acute myocardial
infarction, occurring in up to 30% of patients within the first
12 hours.27 29 Any reduction in the acute dynamic fibrinolytic
response decreases the capacity to lyse intraluminal thrombus
and the likelihood of restoring vessel patency. In this pro¬
spective observational cohort study, we have further demon¬
strated that the capacity to release t-PA appears to be a major
determinant of the risk of cardiovascular events and suggests
that endothelial fibrinolytic capacity has a crucial role in the
pathogenesis of atherothrombosis.
Endothelial dysfunction is characterized by the disruption
of multiple homeostatic pathways predisposing to vasocon¬
striction, platelet activation, and thrombosis. To date, most
clinical studies on endothelial function have focused on
endothelium-dependent vasomotion with decreased responses
associated with an increased incidence of future adverse
events.30 32 Although a useful surrogate marker, the patho¬
physiological mechanism linking impaired endothelium-
dependent vascular smooth muscle relaxation and future
atherothrombotic events remains unclear. Moreover, the reg¬
ulation of vessel tone may not be the facet of vascular
function most closely allied to the future risk of atherothrom¬
botic events. In this current study, we did not observe a
difference in endothelium-dependenl or -independent blood
flow responses between subjects with, and without, subse¬
quent cardiovascular events. This disparity may reflect a lack
of power or the use of differing endothelium-dependent
vasodilators. Thus far, studies assessing the prognostic value
of endothelium-dependent vasodilatation have used acetyl¬
choline. We chose to use substance P because this is a potent
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stimulant of endothelial t PA release, and acetylcholine does
not cause demonstrable t-PA released Reports of preserved
endolhelium-dependent vasodilatation in smokers33 and in
patients with hypertension34 despite reduced acute t-PA
release24-35 suggest that, in some circumstances, reduced t-PA
release may be a more sensitive marker of endothelial
dysfunction.5 These data also highlight the complexity of
vascular biology and demonstrate that endothelial dysfunc¬
tion is not a single clinical entity encompassing a unifoiiu
pathophysiological response to vascular injury.
Study Limitations
Although we cannot determine basal t-PA release using the
venovenous technique described.5 calculation of net t-PA
release provides an accurate assessment of stimulated t-PA
release with good reproducibility25 and basal release contrib¬
utes only a small proportion ol the overall venous plasma
t-PA concentration. Furthermore, previous work has demon¬
strated that basal plasma l-PA concentrations do not control
the local vascular fibrinolytic capacity which is in fact
determined by the acute release of t-PA from the
endothelium.4
Plaque growth is induced by episodic subclinical plaque
disruption6 and if local t-PA release is impaired, the contin¬
ued presence of thrombus may favor smooth muscle migra¬
tion. the production of new connective tissue, and plaque
expansion.36 In keeping with this hypothesis, genetic murine
models of plasminogen deficiency37-38 as well as PAl-l
overexpression39 have shown that reduced fibrinolytic poten¬
tial is associated with enhanced macrovascular fibrin deposi¬
tion and accelerated atherogenesis. As we do not have
follow-up angiographic data, we do not know whether those
subjects with the lowest local t-PA release or recurrent
cardiovascular events exhibited a greater progression of
angiographic disease over me study period. We have previ¬
ously demonstrated an inverse correlation between acute
coronary t-PA release and local atheromatous plaque bur¬
den," and prospective studies of coronary t-PA release and
quantification of disease progression and would be of interest.
Comparable numbers of patients in each group were
receiving secondary preventative medications including ACE
inhibitors. Although treatment with ACE inhibitors enhances
bradykinin-mediated t-PA release,4H-41 these do not influence
t-PA release in response to infusion of substance P.40 In
keeping with the risk factor profile and use of secondary
preventative therapies in our study cohort, relatively few
events occurred over the study period. Despite this, similar
results were noted for outcomes regardless of whether hos¬
pitalization for unstable angina was included. Although the
risk factor profile and severity of coronary artery disease were
similar in those patients with or without events during
follow-up, the relatively modest study numbers and follow-up
period mean we were unable to explore in detail potential
interactions and independence of endothelial fibrinolytic
capacity with conventional cardiovascular risk factors or the
extent of coronary artery disease. Indeed, given the modest
number of subjects and clinical end points, our results should
be interpreted with caution. It would be desirable to increase
subject numbers and clinical end points further, but the
invasive nature and complexity of undertaking such detailed
physiological studies presents many challenges when at¬
tempting to apply this technique to larger population-based
clinical studies.
Conclusion
t-PA release from the endothelium is a distinct marker of
endothelial function. In patients with stable CHD, we have
shown that a reduction in acute t PA release predicts an
increased risk of adverse cardiovascular events. Further
studies of the factors modifying the endogenous fibrinolytic
capacity have the potential to provide major new insights into
the pathophysiology of CHD and to shape future therapeutic
interventions.
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ABSTRACT
BACKGROUND
Exposure to air pollution from traffic is associated with adverse cardiovascular events.
The mechanisms for this association are unknown. We conducted a controlled expo¬
sure to dilute diesel exhaust in patients with stable coronary heart disease to determine
the direct effect ofair pollution on myocardial, vascular, and fibrinolytic function.
METHODS
In a double-blind, randomized, crossover study, 20 men with prior myocardial infarc¬
tion were exposed, in two separate sessions, to dilute diesel exhaust (300 /u.g per cubic
meter) or filtered air for 1 hour during periods of rest and moderate exercise in a con-
trolled-exposure facility. During the exposure, myocardial ischemia was quantified
by ST-segment analysis using continuous 12-lead electrocardiography. Six hours after
exposure, vasomotor and fibrinolytic function were assessed by means of intraarte¬
rial agonist infusions.
RESULTS
During both exposure sessions, the heart rate increased with exercise (P<0.001); the
increase was similar during exposure to diesel exhaust and exposure to filtered air
(P = 0.67). Exercise-induced ST-segment depression was present in all patients, but
there was a greater increase in the ischemic burden during exposure to diesel exhaust
(-22±4 vs. -8±6 millivolt seconds, PcO.OOl). Exposure to diesel exhaust did not ag¬
gravate preexisting vasomotor dysfunction, but it did reduce the acute release of en¬
dothelial tissue plasminogen activator (P=0.009; 35% decrease in the area under the
curve).
CONCLUSIONS
Brief exposure to dilute diesel exhaust promotes myocardial ischemia and inhibits
endogenous fibrinolytic capacity in men with stable coronary heart disease. Our find¬
ings point to ischemic and thrombotic mechanisms that may explain in part the ob¬
servation that exposure to combustion-derived air pollution is associated with adverse
cardiovascular events. (ClinicalTrials.gov number, NCT00437138.)
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(WHO) estimates that air pollution is re¬
sponsible for 800,000 premature deaths
worldwide each year.1 Short-term exposure to air
pollution has been associated with increases in car¬
diovascular morbidity and mortality, with deaths
due to ischemia, arrhythmia, and heart failure.2
In a large cohort study from the United States,
Miller et al. recently reported that long-term ex¬
posure to air pollution increases the risk of death
from cardiovascular disease by 76%.3 These asso¬
ciations are strongest for fine particulate air pol¬
lutants (particulate matter of less than 2.5 /im in
aerodynamic diameter [PM2 J), ofwhich the com¬
bustion-derived nanoparticulate in diesel exhaust
is an important component.4 Substantial improve¬
ments in air quality have occurred in the developed
world over the past 50 years, yet the association
between PM2 5 and mortality has no apparent
threshold and is evident below current air-quality
standards.5
Preclinical models ofexposure to particulate air
pollution demonstrate accelerated atherosclerotic
plaque development6 and increased in vitro7 and
in vivo" platelet aggregation. Epidemiologic and
observational clinical studies suggest that expo¬
sure to air pollution may worsen symptoms of
angina,9 exacerbate exercise-induced myocardial
ischemia,10'11 and trigger acute myocardial infarc¬
tion.12'13 These clinical findings are limited by
imprecision in the measurement of pollution ex¬
posure, the effect of potential confounding envi¬
ronmental and social factors, and the lack of
mechanistic data.14 Controlled exposures to air
pollutants can help address these shortcomings by
providing a precisely defined exposure in a regu¬
lated environment that facilitates investigation
with validated biomarkers and surrogate measures
of cardiovascular health. Using a carefully charac¬
terized exposure system, we have previously shown
that exposure to dilute diesel exhaust in healthy
volunteers causes lung inflammation,15 depletion
of airway antioxidant defenses,16 and impairment
of vascular and fibrinolytic function.17
To our knowledge, there have been no con¬
trolled exposures in patients with coronary heart
disease, an important population that may be par¬
ticularly susceptible to the adverse cardiovascular
effects of air pollution. We assessed the effect of
inhalation of dilute diesel exhaust on myocardial,
vascular, and fibrinolytic function in a population
of patients with stable coronary heart disease.
METHODS
SUBJECTS
Twenty men with stable coronary artery disease
participated in this study, which was performed
with the approval of the local research ethics com¬
mittee, in accordance with the Declaration ofHel¬
sinki, and with the written informed consent of
all participants.
All the men had proven coronary heart disease,
with a previous myocardial infarction (>6 months
before enrollment) treated by primary angioplasty
and stenting, and were receiving standard second¬
ary preventive therapy. Men with angina pectoris
(Canadian Cardiovascular Society class >2), a his¬
tory ofarrhythmia, diabetes mellitus, uncontrolled
hypertension, or renal or hepatic failure, as well
as those with unstable coronary disease (acute
coronary syndrome or symptoms of instability
3 months before enrollment), were excluded.
All eligible volunteers were invited to a prestudy
screening for exercise stress testing; subjects who
were unable to achieve stage 2 of the Bruce pro¬
tocol or who had marked changes on an electro¬
cardiogram (left bundle-branch block, early ST-
segment depression >2 mm) and those in whom
hypotension developed were excluded. Current
smokers and men with asthma, substantial occu¬
pational exposure to air pollution, or an intercur¬
rent illness were also excluded from the study.
STUDY DESIGN
Using a randomized, double-blind, crossover study
design, we evaluated the subjects in two 8 a.m.
sessions at least 2 weeks apart. In each session,
the subjects were exposed to controlled amounts
of dilute diesel exhaust or filtered air. Each sub¬
ject was exposed for 1 hour in an exposure cham¬
ber, as previously described.15 During each expo¬
sure, the subjects performed two 15-minute periods
of exercise on a bicycle ergometer separated by
two 15-minute periods of rest. For each subject,
the ergometer workload was calibrated to achieve
a ventilation of 15 liters per minute per square
meter of body-surface area to ensure a similar ex¬
posure on both occasions. The workload was con¬
stant for both exposures and was equivalent to
stage 2 of the Bruce protocol (range, 110 to 150
watts; 5 to 7 metabolic equivalents). All subjects
were fitted with 12-lead Holter electrocardiograph¬
ic monitors (Medical Lifecard 12 Digital Holter
Recorder, Del Mar Reynolds). In accordance with
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previous exposure studies in healthy volunteers,
vascular assessments were made 6 to 8 hours af¬
ter exposure to diesel exhaust or filtered air.17
DIESEL-EXHAUST EXPOSURE
The diesel exhaust was generated from an idling
Volvo diesel engine (Volvo TD45, 4.5 liters, 4 cylin¬
ders, 680 rpm) from low-sulfur gas-oil E10 (Preem),
as described previously.15 More than 90% of the
exhaust was shunted away, and the remainder di¬
luted with filtered air heated to 20°C (relative hu¬
midity approximately 50%) before being fed into a
whole-body exposure chamber (3.0 m by 3.0 m by
2.4 m) at a steady-state concentration.
The chamber was monitored continuously for
pollutants, with exposures standardized with the
use of nitrogen oxide concentrations to deliver a
particulate matter concentration of 300 /xg per
cubic meter (median particle diameter, 54 nm;
range, 20 to 120). There was little variation be¬
tween exposures in the mean (±SE) number of
particles (1.26±0.01xl06 particles per cubic centi¬
meter) or in the concentrations of nitrogen oxide
(4.4510.02 ppm), nitrogen dioxide (1.0110.01 ppm),
nitric oxide (3.4510.03 ppm), carbon monoxide
(2.910.1 ppm), and total hydrocarbon (2.810.1
ppm). The predominant polycyclic aromatic hydro¬
carbons (approximately 90% of the total) were
phenanthrene, fluorene, 2-methyIfluorene, diben-
zothiophene, and different methyl-substituted
phenanthrenes. Only a minor fraction of polycy¬
clic aromatic hydrocarbons (3.5%) was associated
with particulate matter: 0.04% total particulate
matter and 0.06% particulate-matter organic frac¬
tion. The concentration of particulate matter of
less than 10 (im in aerodynamic diameter (PMI0)
in the exposure chamber exceeded the WHO air-
quality standard of 50 /xg per cubic meter by a
factor of 6, and the nitrogen dioxide concentra¬
tion exceeded the WHO standard of 0.105 ppm by
a factor of 10.ls
VASCULAR STUDY
All subjects underwent brachial-artery cannulation
with a 27-standard wire-gauge steel needle. After
a 30-minute baseline saline infusion, subjects were
given infusions of acetylcholine at rates of 5, 10,
and 20 /xg per minute (endothelium-dependent va¬
sodilator, Clinalfa), bradykinin at rates of 100,
300, and 1000 pmol per minute (endothelium-
dependent vasodilator that releases tissue plasmin¬
ogen activator [t-PA], Clinalfa), and sodium nitro-
prusside at rates of 2, 4, and 8 /xg per minute












Time since index infarction (mo) 35±4
Coronary angiographic findings




Culprit lesion (no. of subjects)
Left anterior descending coronary artery 14
Circumflex coronary artery 4






Fasting glucose (mg/dl) 102±6




ACE inhibitor or angiotensin-receptor blocker)- 4
* Plus-minus values are means ±SE. The body-mass index is the weight in kilo¬
grams divided by the square of the height in meters. LDL denotes low-density
lipoprotein, HDL high-density lipoprotein, and ACE angiotensin-converting
enzyme. To convert the values for cholesterol to millimoles per liter, multiply
by 0.02586. To convert the values for triglycerides to millimoles per liter, mul¬
tiply by 0.01129. To convert the values for glucose to millimoles per liter, mul¬
tiply by 0.05551.
■\ ACE inhibitor therapy was withdrawn 7 days before each vascular study. All
other regular medications were continued throughout the study.
(endothelium-independent vasodilator, David Bull
Laboratories); each infusion was given for 6 min¬
utes. Infusions of the three vasodilators were
separated by 20-minute saline infusions and given
in a randomized order. Therapy with angioten-
sin-converting-enzyme inhibitors was withdrawn
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Table 2. Effect of Exercise on Heart Rate and ST Segment in the 20 Subjects







Heart rate — bpm
Baseline 63±2 61±2 0.24
Maximum 87±3 86±3 0.67
Maximum ST-segment change (pV)
Lead II —28±13 -56±10 0.03
Lead V2 -28±10 —41±12 0.18
Lead V5 -14±8 -3 3 ±9 0.04
Change in ischemic burden (mVsec)
Lead II —11±5 -23 ±4 0.004
Lead V2 -13±5 —21±6 0.04
Lead V5 —4±3 —12±4 0.01
Exercise phase 2
Heart rate (bpm)
Baseline 67±2 65 ±2 0.35
Maximum 91±3 87±3 0.12
Maximum ST-segment change (pV)
Lead II -17±15 —49±12 0.006
Lead V2 -18±12 —41±13 0.04
Lead V5 -7±9 —28±10 0.02
Change in ischemic burden (mVsec)
Lead II -8±6 —22±4 0.0007
Lead V2 -11±5 -20±6 0.02
Lead V5 —2±3 —12±5 0.006
* Plus-minus values are means ±SE; mVsec denotes millivolt seconds,
•j- P values were calculated with Student's t-test.
7 days before each vascular study, because it aug¬
ments bradykinin-induced release of endothelial
t-PA.19 All other medications were continued
throughout the study.
Forearm blood flow was measured in both
arms by venous occlusion plethysmography with
the use of mercury-in-Silastic strain gauges, as
described previously.20 Heart rate and blood pres¬
sure in the noninfused arm were monitored at in¬
tervals throughout each study while the subject
was in the supine position, with the use of a semi-
automated, noninvasive oscillometric sphygmoma¬
nometer.
FIBRINOLYTIC AND INFLAMMATORY MARKERS
Blood (10 ml) was withdrawn into acidified buff¬
ered citrate (Stabilyte tubes, Biopool International)
for t-PA assays and into citrate (BD Vacutainer) for
plasminogen activator inhibitor type 1 (PAI-1) as¬
says. Plasma t-PA and PAI-1 antigen concentrations
were determined by means of enzyme-linked
immunosorbent assays (TintElize t-PA, Biopool
EIA; Coaliza PAI-1; and Chromogenix AB). Serum
C-reactive protein concentrations were measured
with an immunonephelometric assay (BN II neph-
elometer, Dade Behring).
DATA ANALYSIS
Electrocardiographic recordings were analyzed
with the use of the Medical Pathfinder Digital 700
Series Analysis System (Del Mar Reynolds). ST-seg-
ment deviation was calculated by comparing the
ST segment during each 15-minute exercise test
with the average ST segment for the 15-minute
period immediately before the start of the expo¬
sure. The ST-segment amplitude was determined
at the J point plus 80 msec. The ischemic burden
during each exercise test was calculated as the
product of the change in ST-segment amplitude
and the duration of exercise. Leads II, V2, and V5
were selected a priori for ST-segment analysis to
reflect separate regions ofmyocardium. The max¬
imum ST-segment depression and ischemic bur¬
den were determined for these leads individually
and as a composite.
Plethysmographic data and net t-PA release were
determined as described previously.20'21
STATISTICAL ANALYSIS
Continuous variables are reported as means ±SE.
Analysis of variance with repeated measures and
a two-tailed Student's t-test were performed as ap¬
propriate with the use ofGraphPad Prism software.
A two-sided P value of less than 0.05 was consid¬
ered to indicate statistical significance.
RESULTS
Subjects were all middle-aged men with predom¬
inantly single-vessel coronary artery disease (Ta¬
ble 1). They reported no symptoms ofangina and
had no major arrhythmias during exposure or in
the subsequent 24 hours.
MYOCARDIAL ISCHEMIA
The heart rate increased with exercise during ex¬
posures to diesel exhaust and filtered air (P<0.001
for both comparisons with the baseline rates; P=
0.67 for the comparison of rates during exposure
to diesel exhaust and during exposure to filtered
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air) (Table 2). Myocardial ischemia was detected
during exercise in all subjects, with greater max¬
imum ST-segment depression during exposure to
diesel exhaust than during exposure to filtered air
(Table 2 and Fig. 1A and IB) (P<0.05). The ische¬
mic burden induced by exercise was greater dur¬
ing exposure to diesel exhaust (Fig. 1C).
VASOMOTOR FUNCTION
There were no significant differences in resting
heart rate, blood pressure, or baseline blood flow
in the noninfused forearm between or during the
two study visits. Although there was a dose-depen¬
dent increase in blood flow with each vasodilator
(PcO.OOl for all comparisons), neither endothelium-
dependent nor endothelium-independent vasodi¬
latation was affected by inhalation of diesel ex¬
haust (Fig. 2). Comparison of these data with the
findings in a contemporary reference population
ofhealthy male volunteers (mean age, 53±4 years)
showed impaired vasodilatation in response to
acetylcholine (P = 0.02) but not to sodium nitro-
prusside (Fig. 2).
FIBRINOLYTIC AND INFLAMMATORY MARKERS
There were no significant differences in basal plas¬
ma concentrations of t-PA (10.5±1.0 and 9.511.0 ng
per milliliter, respectively) or its endogenous in¬
hibitor, PA1-1 (18.813.0 and 17.012.0 ng per milli¬
liter, respectively), 6 hours after exposure to either
diesel exhaust or filtered air. Likewise, leukocyte,
neutrophil, and platelet counts and serum C-reac-
tive protein concentrations were not altered at
6 or 24 hours by exposure to diesel exhaust or fil¬
tered air. Bradykinin caused a dose-dependent in¬
crease in plasma t-PA concentrations (data not
shown) and net t-PA release (Fig. 3) in the infused
arm (PcO.OOl for both comparisons) that was sup¬
pressed after exposure to diesel exhaust (P=0.009;
35% decrease in the area under the curve).
DISCUSSION
We have demonstrated that transient exposure to
dilute diesel exhaust, at concentrations occurring
in urban road traffic, exacerbates exercise-induced
myocardial ischemia and impairs endogenous fi¬
brinolytic capacity in men with coronary heart dis¬
ease. These findings provide a plausible explana¬
tion for the epidemiologic observation thatexposure



































Figure 1. Myocardial Ischemia during 15-Minute Intervals of Exercise-
Induced Stress and Exposure to Diesel Exhaust or Filtered Air in the 20
Subjects.
Panel A shows the average change in the heart rate and in the ST segment
in lead II. Panel B shows the maximum ST-segment depression during in¬
halation of diesel exhaust as compared with filtered air (P = 0.003), and
Panel C shows the total ischemic burden during inhalation of dicscl cx
haust as compared with filtered air (P<0.001); the values in Panels B and C
are averages of the values in leads II, V2, and V5. In all three panels, red in¬
dicates exposure to diesel exhaust, and blue exposure to filtered air. T bars
denote standard errors, and mVsec millivolt seconds.
Concentrations of particulate matter can regu¬
larly reach levels of 300 fig per cubic meter in
heavy traffic, in occupational settings, and in the
world's largest cities.22 A major proportion of this
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inhalation of diesel exhaust. This reproducible ef¬
fect was present despite extensive use of mainte¬
nance beta-blocker therapy in patients without
limiting angina. Thus, we have established that
inhalation of diesel exhaust has an immediate,
proischemic effect, and we believe this provides
an important mechanism for the observed in¬
crease in myocardial infarction in the hour after
exposure to traffic.13
Small areas of denudation and thrombus de¬
position are common findings on the surface of
atheromatous plaques and are usually subclinical.
Rosenberg and Aird have postulated that vascular-
bed-specific defects in hemostasis exist and that
propagation of coronary thrombosis is critically
dependent on the local fibrinolytic balance.26 The
magnitude and rapidity of t-PA release from the
vascular endothelium regulate the generation of
plasmin and thus determine the efficacy of endog¬
enous fibrinolysis.
We have previously reported impaired t-PA re¬
lease in healthy volunteers 6 hours after inhalation
of diesel exhaust, although this effect was not seen
2 hours after exposure.17 We have now confirmed
similar reductions in acute t-PA release 6 hours
after inhalation of diesel exhaust in patients with
coronary heart disease. This delayed effect on
endogenous fibrinolysis cannot explain our find¬
ings of immediate myocardial ischemia but is
consistent with the observations of Peters and
colleagues, who reported a second peak in the
incidence of myocardial infarction 5 to 6 hours
after exposure to traffic.13 Preclinical thrombotic
models also lend support to our findings. Nem-
mar and colleagues reported that in a hamster
model, instillation of diesel-exhaust particulate
into the lungs increases venous and arterial throm¬
bus formation at sites of vascular injury.27 Taken
together, these findings indicate an important
thrombotic effect of diesel-exhaust inhalation that
may promote coronary thrombosis.
Although we found important adverse effects of
diesel exhaust on vascular fibrinolytic function,
we did not detect an effect on vasomotor func¬
tion. However, vasomotor function was assessed
6 hours after exposure and 5 hours after we docu¬
mented an increase in the ischemic burden. We
have previously demonstrated that exposure to
diesel exhaust impairs vasomotor function in
healthy volunteers.17 This effect was most marked
at 2 hours but was still present 6 hours after ex¬

















Figure 2. Forearm Blood Flow 6 to 8 Hours after Exposures to Diesel
Exhaust and Filtered Air.
Values for infused (solid lines) and noninfused (dashed lines) forearm
blood flow are shown for 17 subjects after exposure to diesel exhaust (red)
and after exposure to filtered air (blue), as well as for a reference popula¬
tion of matched healthy controls (orange), during intrabrachial infusion of
acetylcholine or sodium nitroprusside. P<0.001 for dose response to both
drugs in the infused arm. Among the 17 subjects, P = 0.54 for exposure to
diesel exhaust versus filtered air during infusion of acetylcholine, and
P = 0.56 during infusion of sodium nitroprusside. For the comparison of the
subjects with healthy controls, P = 0.02 during acetylcholine infusion, and
P = 0.72 during sodium nitroprusside infusion.
mass is attributable to combustion-derived nano-
particles from traffic, ranging from 20% at remote
monitoring sites23 to 70% in a road tunnel.24 Ex¬
posure to 300 /ag of particulate matter per cubic
meter for 1 hour increases a person's average ex¬
posure over a 24-hour period by only 12 pig per
cubic meter. Changes of this magnitude occur on
a daily basis, even in the least polluted cities, and
are associated with increases in the rate of death
from cardiorespiratory disorders.23 Our model is
therefore highly relevant, in terms ofboth the com¬
position and the magnitude of exposure, to the
assessment of short-term health effects in men.
Given potential safety concerns, we recruited
patients who had stable and symptomatically well-
controlled coronary heart disease, with good exer¬
cise tolerance on formal stress testing. The study
participants were closely monitored throughout
the exposure and reported no adverse effects. De¬
spite similar changes in the heart rate during ex¬
posure to diesel exhaust and to filtered air, we
documented asymptomatic myocardial ischemia
that was increased by a factor of up to three after
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ity of a detrimental vasomotor effect in patients
at an earlier point in time.
Patients with coronary heart disease are known
to have impaired endothelial function,28 and we
confirm the presence of endothelial dysfunction
in our patients. This may have hindered our abil¬
ity to demonstrate a further impairment of vas¬
cular function after exposure to diesel exhaust.
In addition, we performed our assessments while
the subjects were taking medications that are
known to influence endothelial vasomotor func¬
tion.29 Furthermore, Brook and colleagues report¬
ed that air pollution does not have an effect on
endothelium-dependent vasodilatation.30
We have identified two distinct and potentially
synergistic adverse cardiovascular effects of air
pollution in patients with coronary heart disease.
These effects may contribute to the increased in¬
cidence ofmyocardial infarction after exposure to
traffic. However, the precise mechanisms by which
diesel-exhaust inhalation induces these ischemic
and thrombotic effects have not been established
in our study and will need to be determined in
future work.
Our findings are consistent with epidemiologic
studies showing associations between ambient
particulate air pollution and increased myocardial
ischemia during formal exercise testing.10'11 Myo¬
cardial ischemia occurs as a consequence of re¬
duced myocardial oxygen supply, increased de¬
mand, or both. We hypothesize that oxidative
stress and microvascular dysfunction in the re¬
sistance vessels of the myocardium may, in part,
explain the adverse ischemic effects of exposure
to dilute diesel exhaust. In vitro studies, animal
models, and studies of exposures in humans have
clearly established the oxidant and proinflamma¬
tory nature of combustion-derived particulate
matter.31 Indeed, the pattern of vascular dysfunc¬
tion in our previous studies suggested that oxi¬
dative stress and reduced nitric oxide availability
may play a role in mediating the adverse vascular
effects of diesel-exhaust inhalation.17
Diesel exhaust is a complex mixture of gases
and particles, and from our findings, we cannot
rule out a nonparticulate cause of the adverse car¬
diovascular effects. However, on the basis of epi¬
demiologic studies,32 particulate matter is thought
to be responsible for the majority of the adverse
health effects ofair pollution.33 This view is sup¬
ported by the recent observations of Miller and
colleagues, who found that cardiovascular out-
Figure 3. Release of Tissue Plasminogen Activator
(t-PA) Antigen 6 to 8 Hours after Exposures to Diesel
Exhaust and Filtered Air in 17 Subjects.
As compared with filtered air (blue), inhalation of die¬
sel exhaust (red) reduced the net release of t-PA anti¬
gen (calculated as the product of forearm plasma flow
and the difference in t-PA concentrations between the
two arms) by 35% (P=0.009).
comes were strongly associated with long-term
exposure to particulate matter but not with gas¬
eous pollutants.3 Ambient nitrogen dioxide can be
considered a surrogate for pollution from traffic,
but it has little adverse effect in controlled-cham-
ber studies, even at the exposure levels in our
study.34 We therefore suggest that the cardiovas¬
cular effects described here are mediated primar¬
ily by the particulates in diesel exhaust and not
by its other components. This argues for the use
of diesel-exhaust particle traps to limit the adverse
health effects of traffic emissions. However, the
causative role of particulates must first be defini¬
tively established, and the efficacy of particle traps
confirmed.
Brief exposure to dilute diesel exhaust increas¬
es myocardial ischemia and impairs endogenous
fibrinolytic capacity in men with stable coronary
heart disease. Our findings suggest mechanisms
for the observation that exposure to combustion-
derived air pollution is associated with adverse
cardiovascular events, including acute myocar¬
dial infarction. Environmental health policy inter¬
ventions targeting reductions in urban air pollu¬
tion should be considered in order to decrease the
risk of adverse cardiovascular events.
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Effects of Acute Angiotensin II Type 1 Receptor Antagonism
and Angiotensin Converting Enzyme Inhibition on Plasma
Fibrinolytic Parameters in Patients With Heart Failure
Nicholas E.R. Goodfield, MB, ChB, MRCP; David E. Newby, BA, BSc, BM, MRCP;
Christopher A. Ludlam, MB, ChB, PhD, FRCP, FRCPath; Andrew D. Flapan, MB, ChB, MD, MRCP
Background—Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an
improvement in plasma fibrinolytic parameters. The aim of the present study was to determine whether acute ACE
inhibition and angiotensin II type 1 (AT,) receptor antagonism have similar effects in patients with heart failure.
Methods and Results—Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan
50 mg on 2 separate occasions in a single-blind, randomized, crossover design. Plasma tissue plasminogen activator
(t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen and activity were measured at baseline and 6 hours
after the dose. Acute administration of losartan but not of enalapril reduced plasma t-PA (11%; P=0.003) and PAI-1
(38%; P<0.001) antigen concentrations, which was associated with increases in t-PA (29%; P=0.03) and decreases in
PAI-1 (48%; P=0.01) activity. Changes in plasma fibrinolytic parameters were more marked during losartan treatment
(P<0.02), with a 3-fold greater reduction in plasma PAI-1 antigen concentrations (P<0.05).
Conclusions—Acute AT, antagonism in patients with heart failure is associated with a significant improvement in plasma
fibrinolytic parameters that is greater than during ACE inhibition. These beneficial effects of AT, antagonism and ACE
inhibition would therefore appear to be mediated principally through suppression of angiotensin II. (Circulation.
1999;99:2983-2985.)
Key Words: angiotensin ■ plasminogen activators ■ heart failure ■ fibrinolysis
It would be anticipated that high tissue plasminogen acti¬vat r ( t-PA) concentrations would protect against subse¬
quent coronary events. However, paradoxically, epidemiolog¬
ical studies of total t-PA (antigen) concentrations in patients
with ischemic heart disease'-2 have observed a positive
correlation with future coronary events. This may be ex¬
plained by the concomitant elevation of plasminogen activa¬
tor inhibitor type 1 (PAI-1), which complexes with t-PA and
therefore causes an overall reduction in free t-PA "activi¬
ty."1-4 It is this free and unbound t-PA that is physiologically
active and leads to endogenous fibrinolysis.
Several large-scale heart failure and post-myocardial in¬
farction trials (VHEFT-II [Veterans Administration Heart
Failure Trial II], SAVE [Survival And Ventricular Enlarge¬
ment], SOLVD [Studies Of Left Ventricular Dysfunction],
AIREX [Acute Infarction Ramipri! Efficacy extension
Study], TRACE [TRAndolapril Cardiac Evaluation], and
SMILE [Survival ofMyocardial Infarction: Long-term Eval¬
uation]) have suggested a reduction in reinfarction rates in
patients treated with ACE inhibitors. The mechanisms under¬
lying this reduction in coronary thrombotic events are un¬
known. However, given that angiotensin II5 and bradykinin''
are known to induce the release of PAI-1 and t-PA, respec¬
tively, the benefits ofACE inhibitor therapy may be mediated
through increases in bradykinin-induced t-PA release or a
reduction in angiotensin II-mediated PAI-1 release or both.
Indeed, the use of ACE inhibitors after myocardial infarction
is associated with a decrease in PAI-1 concentrations and a
potential increase in t-PA activity.7-K However, the effects of
ACE inhibition on plasma fibrinolytic factors have not been
assessed in patients with heart failure, and it is unknown
whether these beneficial effects are also seen with angioten¬
sin II type 1 (AT,) receptor antagonism. The aim of the
present study, therefore, was to determine whether acute ACE
inhibition and AT, receptor antagonism have similar effects
in patients with heart failure.
Methods
Subjects
Twenty patients with New York Heart Association (NYI1AJ grade II
to III chronic heart failure and objective evidence of left ventricular
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TABLE 1. Patient Characteristics
Age, y (meaniSEM) 65±2
Sex, malefemale 13:7
Etiology, n














impairment (left ventricular ejection fraction <40%, shortening
fraction <20%, or left ventricular end-diastolic diameter >5.5 cm)
were recruited with the approval of the local research ethics
committee and in accordance with the Declaration of Helsinki. The
written informed consent of each subject was obtained before entry
into the study. No patient had previously received ACE inhibitor or
AT, receptor antagonist therapy or had a myocardial infarction
within 3 months of the study. Concomitant therapy was omitted on
the day of attendance.
Measurements
Supine heart rate and blood pressure were monitored at intervals
throughout each study with a semiautomated, noninvasive oscillo-
metric sphygmomanometer9 (Takeda UA 751, Takeda Medical Inc).
Ten milliliters of blood was withdrawn from the antecubital fossa
of the forearm and collected into acidified buffered citrate (Biopool
Stabilyte for t-PA assays) and citrate (Monovctte for PA1-1 assays)
tubes and kept on ice before being centrifuged at 2000g for 30
minutes at 4°C. Platelet-free plasma was decanted and stored at
-B0°C before assay.1" Plasma PA1-1 and t-PA antigen and activities
and atrial natriuretic peptide (ANP) concentrations were determined
by ELlSAs and a photometric method as previously described.1112
All assays were performed by blinded independent operators.
Study Design
Patients attended the clinic at 9 am and rested recumbent for 20











Changes in plasma t-PA (white bars) and PAI-1 (black bars)
antigen (solid bars) and activity (hatched bars) after single oral
dose of enalapril and losartan in patients with heart failure.
*P=0.016 (2-way ANOVA for changes in 4 plasma fibrinolytic
parameters; losartan vs enalapril); 1~P=0.047 (f test for changes
in plasma PAI-1 antigen; losartan vs enalapril).
received a single-blind, randomized oral dose of enalapril 10 mg or
losartan 50 mg followed by a light lunch at midday. After an
additional 20-minute period of supine rest at 4 pm, repeated mea¬
surements were taken to coincide with peak plasma concentrations of
the active metabolites (enalaprilat and E3174, respectively). To
allow for a sufficient washout of enalaprilat and E3174, patients
reattended 2 days later to undergo the same protocol but crossed over
to receive the alternate therapy.
Data Analysis and Statistics
Data were examined by ANOVA and 2-tailed paired Student's / test
with Excel version 5.0 (Microsoft). All results are expressed as
mean±SEM. Statistical significance was taken at the 5% level.
Results
Patient characteristics are shown in Table 1. Baseline predose
hemodynamic, plasma ANP, and fibrinolytic parameters were
similar on the 2 study days, with no significant differences
(Table 2) or time order effects.
After losartan therapy, plasma t-PA and PAI-1 antigen
concentrations fell by 11% (P= 0.003) and 38% (P<0.001),
respectively (Table 2; Figure). Plasma t-PA activity increased
by 29% (P=0.03), whereas PAI-1 activity fell by 48%
(P=0.01). Enalapril therapy was associated with similar
changes in fibrinolytic parameters (—6%, —14%, 21%, and
— 17%, respectively), but they were not statistically signifi¬
cant (P=0.1 to 0.4). Changes in plasma fibrinolytic parame-
TABLE 2. Effect of Losartan and Enalapril on Systemic Hemodynamics and Plasma ANP and Fibrinolytic Parameters
Enalapril Losartan
Predose Postdose P Predose Postdose P
Mean arterial pressure, mm Hg 93±4 83±5
' 91+3 88±4 '
Heart rate, bpm 70±3 64±3 ' 71 ±2 66±3 •
t-PA antigen, ng/mL 7.6±0.8 7.1 ±0.8 7.2±0.5 6.4±0.4 *
t-PA activity, lll/mL 1.0+0.1 1.2±0.2 1.1+0.2 1.4±0.2 t
PAI-1 antigen, ng/mL 47.7±5.9 40.8±4.7 54.6±6.4 33.9±3.8 *
PAI-1 activity, AU/mL 11.3+1.8 9.3±2.0 13.8±2.5 7.2±1.6 t
ANP, ng/mL 17.5±3.1 13.6± 1.7 17.4 =t 3.0 11.0+1.1 t
Values are mean±SEM.
*As0.003; tP^O.03; fP=0.06 (paired / test; pre- vs post-dose).
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ters were more marked during losartan treatment (P=0.016;
2-way ANOVA, enalapril versus losartan), with a 3-fold
greater reduction in plasma PAI-1 antigen concentrations
(P=0.047; I test, enalapril versus losartan). There were no
significant effects on plasma ANP concentrations (Table 2).
Discussion
We have shown that acute AT, receptor antagonism in
patients with heart failure is associated with a significant
improvement in plasma fibrinolytic parameters. Moreover,
this improvement was greater than with ACE inhibition,
which suggests that these effects are mediated directly
through suppression of angiotensin II.
Previous studies have shown the beneficial effects of ACE
inhibition on fibrinolytic parameters in patients after an acute
myocardial infarction.7-8 In the present study, we assessed the
acute effects in patients with heart failure, and our results are
consistent with these post-myocardial infarction studies. This
suggests that the benefits of ACE inhibition are not limited to
the immediate postinfarction period but may also be achieved
in patients with heart failure. Additionally, we have directly
assessed l-PA activity and have confirmed that the changes in
basal t-PA and PAI-1 antigen concentrations are associated
with an increase in t-PA activity.
It has been suggested that the changes in fibrinolytic
parameters seen with ACE inhibitors may be mediated
through augmentation of bradykinin, because t-PA release is
induced by bradykinin infusions during systemic ACE inhi¬
bition.6 However, the present study would suggest that
bradykinin is not involved in basal t-PA release because of
the similar effects of AT, receptor antagonism on the profile
of plasma t-PA and PAI-1 concentrations. Moreover, given
the greater efficacy of AT| receptor antagonism, particularly
on PAI-1 concentrations, it would appear that angiotensin II
is the principal mediator of this effect. This is consistent with
the in vitro1-' and in vivo-' release of PAI-1 with angiotensin
II administration. Furthermore, these observations may pro¬
vide one potential explanation for the findings of the ELITE
[Evaluation of Losartan in The Elderly] study, in which AT,
receptor antagonism was associated with reduced mortality
compared with ACE inhibition in patients with heart failure.14
Plasma t-PA and PAI-1 concentrations undergo diurnal
variations, which have a complementary and inverse sinusoi¬
dal relationship.15 Such diurnal variation may contribute in
part to the observed changes in fibrinolytic parameters,
although this does not explain the differential effects of ACE
inhibition and AT| receptor antagonism, especially on PAI-1.
In addition, the doses of losartan14 and enalapril16 were
chosen on the basis of the major published heart failure trials,
and the observed differences are unlikely to reflect a dose
effect because the resultant hemodynamic effects were
similar.
In conclusion, the present study suggests that in patients
with heart failure, acute angiotensin II inhibition with AT,
receptor antagonism produces a marked improvement in
basal fibrinolytic balance through a reduction in PAI-1.
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Tissue Plasminogen Activator Release
by Angiotensin-Converting Enzyme Inhibition
Catherine Labinjoh, BSc, MB, ChB (Hons), MRCP,*
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Neil R. Johnston, MSc,* Nicholas A. Boon, BA, MB, BChjr, MA, MD, FRCP,t
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Edinburgh, United Kingdom
OBJECTIVES The aim of the present study was to determine the effect of angiotensin-converting enzyme
(ACE) inhibition on the local stimulated release of tissue plasminogen activator (t-PA) from
the endothelium.
BACKGROUND Angiotensin-converting enzyme inhibitor therapy may exert a beneficial effect on the
endogenous fibrinolytic balance.
METHODS Blood flow and plasma fibrinolytic factors were measured in both forearms of eight healthy
males who received unilateral brachial artery infusions of the endothelium-dependent
vasodilators substance P (2 to 8 pmoL/min) and bradykinin (100 to 1,000 pmol/min), and the
endothelium-independent vasodilator sodium nitroprusside (2 to 8 p.g/min). These measure¬
ments were performed on each of three occasions following one week of matched placebo,
quinapril 40 mg or losartan 50 mg daily administered in a double-blind randomized crossover
design.
RESULTS Sodium nitroprusside, substance P and bradykinin produced dose-dependent increases in the
blood flow of infused forearm (analysis of variance [ANOVA], p < 0.001 for all). Although
sodium nitroprusside did not affect plasma t-PA concentrations, they were increased
dose-dependently in the infused forearm by substance P and bradykinin infusion (ANOVA,
p < 0.001 for both). Bradykinin-induced release of active t-PA was more than doubled
during treatmentwith quinapril in comparison to placebo or losartan (two-way ANOVA: p <
0.003 for treatment group, p < 0.001 for t-PA response and p = ns for interaction), whereas
the substance P response was unaffected.
CONCLUSIONS We have shown a selective and marked augmentation of bradykinin-induced t-PA release
during ACE inhibition. These findings suggest that the beneficial clinical and vascular effects
of ACE inhibition may, in part, be mediated through local augmentation of bradykinin-
induced t-PA release. (J Am Coll Cardiol 2001;38:1402-8) © 2001 by the American
College of Cardiology
The fibrinolytic factor tissue plasminogen activator (t-PA)
is a serine protease that regulates the degradation of intra¬
vascular fibrin and is released from the endothelium through
the translocation of a dynamic intracellular storage pool
(1,2). If endogenous fibrinolysis is to be effective then the
rapid mobilization of t-PA from the endothelium is essen¬
tial, because thrombus dissolution is much more effective if
t-PA is incorporated during, rather than after, thrombus
formation (3). The efficacy of plasminogen activation and
fibrin degradation is further determined by the relative
balance between the acute local release of t-PA and its
subsequent inhibition through formation of complexes with
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the serpin plasminogen activator inhibitor type 1 (PAI-1).
This dynamic aspect of endothelial function and fibrinolytic
balance may be directly relevant to the pathogenesis of
atherothrombosis, but only recently have robust methods to
determine acute t-PA release been developed (4-7).
Small areas of denudation and thrombus deposition are a
common finding on the surface of atheromatous plaques
(8,9) and are usually subclinical. However, in the presence of
an imbalance in the coagulation or fibrinolytic systems, such
microthrombi may propagate, ultimately leading to arterial
occlusion (10). Bradykinin is released during the contact
phase of coagulation, when high-molecular-weight kinino-
gen is cleaved by kallikrein to produce a disulphide-linked
light and heavy chain (11,12). Although an inflammatory
mediator, bradykinin is also a potent endothelial cell stim¬
ulant that can induce the acute release of t-PA from the
endothelium (7,13) through a B2 receptor mechanism (14).
Thus, following activation of the intrinsic coagulation
pathway, the liberation of bradykinin may represent an
important negative feedback loop in which bradykinin-
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November 1, 2001:1402-8
Labinjoh et al. 1403
ACE Inhibition and Bradykinin-lnduced t-PA Release
Abbreviations and Acronyms
ACE = angiotensin-converting enzyme
ANOVA = analysis of variance
AT, = angiotensin II type 1
PAI-1 == plasminogen activator inhibitor type 1
t-PA = tissue plasminogen activator
induced t-PA release inhibits thrombus formation within
the vascular lumen when localized endothelial denudation
occurs. Furthermore, given that bradykinin-induced fore¬
arm vasodilatation is potentiated by angiotensin-converting
enzyme (ACE) inhibition (15), such actions may be en¬
hanced in the presence of ACE inhibition and may, in part,
explain the anti-ischemic action of this therapy in vascular
disease (16). However, although inferred, the potentiation
of bradykinin-induced t-PA release by ACE inhibition has
yet to be established. Therefore, the aim of the present study
was to determine whether systemic ACE inhibition could
augment acute local t-PA release from the endothelium in
vivo in humans.
METHODS
Subjects. Eight healthy male nonsmokers, ages between 21
and 30 years, participated in the study, which was under¬
taken with the approval of the local research ethics com¬
mittee, in accordance with the Declaration of Helsinki and
with the written informed consent of each subject. Except
for study medication, none of the subjects received vasoac¬
tive drugs in the week before each phase of the study, and all
abstained from alcohol for 24 h and from food and caffeine-
containing drinks for at least 4 h before each study. All
studies were carried out in a quiet, temperature-controlled
room maintained at 22°C to 24°C.
Measurements. FOREARM BLOOD FLOW AND HEMODY¬
NAMICS. Blood flow was measured in both forearms by
venous occlusion plethysmography using mercury-in-silastic
strain gauges applied to the widest part of the forearm as
previously described (17). Analogue voltage output from an
EC-4 Strain Gauge Plethysmograph (D.E. Hokanson Inc.,
Bellevue, Washington) was processed by a MacLab
analogue-to-digital converter and Chart v3.3.8 software
(AD Instruments Ltd., Castle Hill, Australia) and recorded
onto a Macintosh Classic II computer (Apple Computers
Inc., Cupertino, California). Calibration was achieved using
the internal standard of the plethysmograph.
Blood pressure and heart rate were monitored in the
noninfused arm at intervals throughout each study using a
semiautomated noninvasive oscillometric sphygmomanom¬
eter (Takeda UA 751, Takeda Medical Inc., Tokyo, Japan).
ASSAYS. Venous cannulae (17G) were inserted into large
subcutaneous veins of the antecubital fossa in both arms.
Ten to 20 ml of blood was withdrawn simultaneously from
each arm and collected into acidified buffered citrate
(Biopool Stabilyte, Umea, Sweden, for t-PA assays), citrate
(Monovette, Sarstedt, Numbrecht, Germany, for PA1-1
assays) and lithium heparin (for ACE activity assays) tubes,
and kept on ice before being centrifuged at 2,000 g for
30 min at 4°C. Platelet-free plasma was decanted and stored
at —80°C before assay (18).
Plasma t-PA and PAI-1 antigen and activity concentra¬
tions were determined using enzyme-linked immunosor¬
bent assays and a photometric method as previously de¬
scribed (5,19). Plasma ACE activity was determined using a
spectophotometric technique (Sigma Chemical Corpora¬
tion, St. Louis, Missouri) (20). Hematocrit was determined
by capillary tube centrifugation of blood anticoagulated by
ethylene diamine tetraacetic acid.
Study design. Subjects attended on each of three study
days, two weeks apart, having received matched placebo,
quinapril 40 mg and losartan 50 mg (an angiotensin II type
1 (ATj) receptor antagonist) once daily for the seven days
before attendance. The subjects received each of the medi¬
cations in a double-blind randomized crossover design. On
each study day, the final dose of placebo, quinapril or
losartan was taken at 08.00 hr. Six hours later, the subjects
rested recumbent, and strain gauges and cuffs were applied
to the forearms. The brachial artery of the nondominant
arm was cannulated with a 27-standard wire gauge steel
needle (Cooper's Needle Works Ltd., Birmingham, United
Kingdom) under 1% lidocaine (Xylocaine: Astra Pharma¬
ceutical Ltd., Kings Langley, United Kingdom) local anes¬
thesia. The total rate of intra-arterial infusions was main¬
tained constant at 1 ml/min and forearm blood flow was
measured every 10 min throughout all studies. Intrabrachial
infusions of substance P (Clinalfa AG, Laufelfingen, Swit¬
zerland; endothelium-dependent vasodilator) at 2, 4 and
8 pmol/min (5,19), sodium nitroprusside (David Bull Lab¬
oratories, Warwick, United Kingdom; endothelium-
independent vasodilator) at 2, 4 and 8 /ng/min (5,7) and
bradykinin (Clinalfa AG; endothelium-dependent vasodila¬
tor) at 100, 300 and 1,000 pmol/min were given for 10 min
at each dose in that order. Saline was infused for 30 min
before the substance P, sodium nitroprusside and bradyki¬
nin infusions.
Data analysis and statistics. Plethysmography data were
extracted from the Chart data files. Forearm blood flows
were calculated for individual venous occlusion cuff infla¬
tions by a template spreadsheet (Excel v5.0; Microsoft
Corporation, Cambridge, Massachusetts) as previously de¬
scribed (5,7,19). Estimated net release of t-PA activity and
antigen was previously defined (5,7,19) as the product of the
infused forearm plasma flow (based on the mean hematocrit
and the infused forearm blood flow) and the concentration
difference between the infused and noninfused arms. Data
were examined, where appropriate, by analysis of variance
(ANOVA) with repeated measures and two-tailed paired
Student t test using Excel v5.0 (Microsoft). All results are
expressed as mean ± standard error of the mean. Statistical
significance was taken at the 5% level.
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Figure 1. Infused forearm blood flow response to intrabrachial infusion of substance P, sodium nitroprusside and bradykinin during placebo (open circles),
quinapril (closed circles) and losartan (closed squares) administration, p < 0.001 (analysis of variance) for all blood flow responses.
RESULTS
Oral and intra-arterial drag administrations were well tol¬
erated without significant adverse effects. Consistent with
previous studies (7), transient patchy flushing and skin
edema of the infused arm occurred with bradykinin infusion
at doses &300 pmol/min. There were no significant changes
in heart rate, blood pressure and noninfused forearm blood
flow (data on file) during or between study days. In
comparison to placebo and losartan, plasma ACE activity
was suppressed during quinapril administration (14.1 ±
0.8 IU/ml, 17.9 ± 2.4 IU/ml and 7.6 ± 1.6 IU/ml
respectively: p < 0.004, ANOVA).
Forearm blood flow responses. Substance P, sodium ni¬
troprusside and bradykinin produced dose-dependent fore¬
arm vasodilatation during each study visit (one-way
ANOVA: p < 0.001 for all) (Fig. 1). There were no
significant differences between the magnitude of the fore¬
arm blood flow responses during placebo, quinapril or
losartan administration (two-way ANOVA: p = ns for
treatment group, p < 0.001 for forearm blood flow re¬
sponse, p = ns for interaction). There was a modest trend
for bradykinin-induced vasodilatation to be greater during
quinapril administration, but this was not statistically sig¬
nificant (two-way ANOVA: p = 0.12 for quinapril vs.
placebo, p < 0.001 for forearm blood flow response, p = ns
for interaction).
Plasma fibrinolytic parameters. Substance P and bradyki¬
nin caused dose-dependent increases in plasma t-PA anti¬
gen and activity concentrations in the infused arm during
each study visit (one-way ANOVA: p < 0.001 for all)
(Table 1). There was a modest but significant increase in
plasma t-PA concentrations in the noninfused arm during
infusion of bradykinin, but not substance P. Despite sub¬
stantial increases in blood flow, sodium nitroprusside had no
effect on plasma t-PA concentrations in either arm. During
quinapril administration, there was a significant increase in
bradykinin, but not substance P, induced increases of
plasma t-PA antigen (two-way ANOVA: p = 0.05 for
treatment group, p < 0.001 for t-PA response, p = ns for
interaction) and activity (p < 0.001 for treatment group,
p < 0.001 for t-PA response, p = ns for interaction)
concentrations in the infused forearm (Table 1).
There were no significant differences in basal plasma
PAI-1 antigen concentrations during placebo, quinapril or
losartan administration, or stimulated release of PAI-1
during substance P, sodium nitroprusside or bradykinin
infusion (data on file).
Release of t-PA. Substance P and bradykinin caused dose-
dependent increases in the plasma t-PA antigen and activity
concentration differences between the forearms, and the
estimated net release of t-PA antigen and activity during
each study visit (one-way ANOVA: p < 0.001 for all)
Table1.EffectofPl cebo,QuinaprilandLos rtanPlasmat-PAAntigenndctivi yConcentrationsithInf dN in iisF r sD gSubst n,d u NitroprussideanBradykininInfusio Placebo Plasmat-PAantigen(ng/ l) Infusedarm Noninfusedarm Plasmat-PAactivity(IU/ l) Infusedarm Noninfusedarm Quinapril Plasmat-PAantigen(ng/ l) Infusedarm Noninfusedarm Plasmat-PAactivity(IU/ l) Infusedarm Noninfusedarm Losartan Plasmat-PAantigen(ng/ l) Infusedarm Noninfusedarm Plasmat-PAactivity(IU/ l) Infusedarm NoninfusedarmSubstanceP(pmol/min)SodiuNitroprusside(fXg/min)Bradykini(pmol i ) 02481 03, 00 3.9±0 8 4.0±0 94.8: 5.3:0.8 1.55.8 4.1:0.7 :0.87.5±1.1* 4.6±1 03.3±0 4 3.9±0 83.1±0 5 3.7±0 82.8±0 7 3.8±0 73.8±0 7 3.4±0 6
3.6±0 3.3±0 5




1.8±0 2 1.9±0 2











1.5±0 2 1.7±0 2
2.5±0 3 1.8±0 2
4.5±0 9 2.2±0
8.5±2.0* 2.4±0.4+






3.0±0 3 3.0±0 1
3.0±0 4 2.8±0 3
2.6±0 3 3.0±0 2
2.9±0 5 2.9±0 1
3.2±0 4 2.9±0 1
8.0±0 8 4.4±0 6
11.7±. 6.2±1 6
19.6±6.5*§ 10.0±4.3t






1.6±0 2 1.4±0 2












4.4±0 7 3.6±0 4
6.3±1 6 3.8±0.4
7.6±1.3* 4.9±0 6
3.7±0 5 3.6±0 3
3.2±0 3.2±0 3
3.5±0 4 3.4±0 3
3.7±0 2 3.2±0
















1.4±0 1 1.4±0 1
1.5±0 1 1.6±0 2
3.3±0 4 1.7±0 1
5.3±0 7 1.8±0 1
7.4±1.4* 2.2±0.3+
*p<0.001;t. 5+p;§=0. 5.One-wayanalysisofvariancedosere ponse;Tw -wayan lysifv ri nc :qui a rilversulosa t ndpl c b(<0. 01f t-PAresp sea d=ninter ctio ). t-PA=issueplasminog nactivator.
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Figure 2. Forearm concentration difference (left) and estimated net release (right) of tissue plasminogen activator (t-PA) antigen (upper, solid lines) and
activity (lower, dashed lines) in response to intrabrachial infusion of bradykinin during placebo (open circles), quinapril (closed circles) and losartan
(closed squares) administration, p < 0.001 (analysis of variance, ANOVA) for all responses, *p = 0.003, +p = 0.03, £p = 0.09, §p = 0.13 two-way
ANOVA: quinapril versus losartan and placebo (p < 0.001 for t-PA response and p = ns for interaction).
(Fig. 2). During quinapril administration, there was a
significant increase in bradykinin- but not substance
P-induced release of active t-PA (two-way ANOVA: p =
0.003 for treatment group, p < 0.001 for t-PA response,
p = ns for interaction) (Fig. 2) and a trend for t-PA antigen
(two-way ANOVA: p = 0.09 for treatment group, p <
0.001 for t-PA response, p = ns for interaction) (Fig. 2).
Quinapril increased the area under the curve for the net
release of active t-PA by 135% and 125% in comparison to
placebo and losartan respectively.
DISCUSSION
For the first time, we have shown that in contrast to AT,
receptor antagonism, ACE inhibition potentiates bradykinin-
induced endogenous t-PA release from the endothelium.
However, this potentiation appears to be specific to brady¬
kinin because ACE inhibition did not appear to influence
substance-P-induced t-PA release. These findings suggest
that the beneficial clinical and vascular effects of ACE
inhibition (16) may, in part, be mediated through the acute
local augmentation of bradykinin-induced t-PA release.
Endogenous fibrinolysis and acute coronary syndromes.
The endogenous fibrinolytic system can have important
clinical effects, as exemplified by the observation that in a
third of patients with an acute myocardial infarction, the
infarct-related artery spontaneously reperfuses within 12 h
(21-23). Moreover, a low fibrinolytic activity is associated
with an increased risk of myocardial infarction in young
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men (24) and predicts which patients with unstable angina
will develop myocardial infarction (25). Clinical studies of
patients with unstable angina have also indicated that there
is enhanced activation of the kallikrein system and that
bradykinin release is increased (26). Given this augmenta¬
tion of bradykinin generation and the activation of the
intrinsic coagulation pathway in acute coronary syndromes,
ACE inhibition may have major beneficial effects on the
acute local fibrinolytic balance by markedly enhancing
bradykinin-induced t-PA release in areas of intravascular
thrombus formation.
ACE inhibition, bradykinin metabolism and t-PA re¬
lease. More than 95% of bradykinin metabolism occurs
through ACE, whereas plasma substance P is metabolized
by several additional enzymes including dipeptidyl(amino)-
peptidase IV and aminopeptidase M (27). Moreover, the
tissue and cellular metabolism of substance P is performed
almost exclusively by neutral endopeptidase 24.11 (27).
Consistent with this, and with previous work in the forearm
circulation (28), we did not detect a significant influence of
ACE inhibition on substance-P-induced vasodilatation.
Indeed, ACE inhibition did not appear to influence
substance-P-induced t-PA release. This indicates that the
augmentation of bradykinin-induced t-PA release reflects
the inhibition of bradykinin metabolism rather than a
general enhancement of the capacity of the endothelium to
release t-PA acutely. Given the recent report (29) of even
greater reductions in cardiovascular events with omapatrilat,
a combined ACE and neutral endopeptidase inhibitor, the
potentiation of bradykinin-induced t-PA release may be
enhanced even further by such compounds. This requires
further investigation.
In contrast to the marked potentiation of t-PA release,
we failed to detect a significant increase in bradykinin-
induced vasodilatation during ACE inhibition. Benjamin et
al. (15) have previously reported that local ACE inhibition
causes a potentiation of the increases in blood flow associ¬
ated with bradykinin infusion in the human forearm.
However, there did appear to be a trend toward an enhanced
blood flow response, and it is likely that our study lacked
sufficient power to detect this difference. This would also
suggest that, in comparison to vasomotor responses, ACE
inhibition has a proportionately greater effect on the en¬
hancement of bradykinin-induced t-PA release given more
than a doubling of the release of active t-PA. In addition, it
is unlikely that the augmentation of active t-PA release by
ACE inhibition is due to the potentially greater increase in
blood flow because vasodilatation and increased blood flow
do not appear, by themselves, to cause t-PA release, as
demonstrated by the absence of an effect with sodium
nitroprusside infusion. This latter observation is in agree¬
ment with our previous studies (5) and work by other groups
(4,6).
Conclusions. We have demonstrated a specific augmenta¬
tion of bradykinin-induced t-PA release by ACE inhibition.
This effect appears to be independent of angiotensin II
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action because ATj receptor antagonism did not influence
the acute release of t-PA. These findings suggest that the
beneficial clinical and vascular effects of ACE inhibition
may, in part, be mediated through the acute local augmen¬
tation of bradykinin-induced t-PA release.
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OBJECTIVES The aim of the present study was to assess the contribution of angiotensin-converting enzyme
(ACE) inhibitor therapy to bradykinin-induced tissue-type plasminogen activator (t-PA)
release in patients with heart failure (HF) secondary to ischemic heart disease.
BACKGROUND Bradykinin is a potent endothelial cell stimulant that causes vasodilatation and t-PA release.
In large-scale clinical trials, ACE inhibitor therapy prevents ischemic events.
METHODS Nine patients with symptomatic HF were evaluated on two occasions: during and following
seven-day withdrawal of long-term ACE inhibitor therapy. Forearm blood flow was
measured using bilateral venous occlusion plethysmography. Intrabrachial bradykinin (30 to
300 pmol/min), substance P (2 to 8 pmol/min), and sodium nitroprusside (1 to 4 pmol/min)
were infused, and venous blood samples were withdrawn from both forearms for estimation
of fibrinolytic variables.
RESULTS On both study days, bradykinin and substance P caused dose-dependent vasodilatation and
release of t-PA from the infused forearm (p < 0.05 by analysis of variance [ANOVA]).
Long-term ACE inhibitor therapy caused an increase in forearm vasodilatation (p < 0.05 by
ANOVA) and t-PA release (p < 0.001 by ANOVA) during bradykinin, but not substance
P, infusion. Maximal local plasma t-PA activity concentrations approached 100 IU/ml, and
maximal forearm protein release was —4.5 p.g/min.
CONCLUSIONS Long-term ACE inhibitor therapy augments bradykinin-induced peripheral vasodilatation
and local t-PA release in patients with HF due to ischemic heart disease. Local plasma t-PA
activity concentrations approached those seen during systemic thrombolytic therapy for acute
myocardial infarction. This may contribute to the primary mechanism of the anti-ischemic
effects associated with long-term ACE inhibitor therapy. (J Am Coll Cardiol 2002;40:
961-6) © 2002 by the American College of Cardiology Foundation
Bradykinin is a potent endothelium-dependent vasodilator
that has a brief duration of action due to its rapid degrada¬
tion by angiotensin-converting enzyme (ACE). In addition
to acting as an inflammatory mediator, bradykinin is closely
involved in fibrinolytic and coagulation cascades. During the
See page 967
contact phase of blood coagulation, it is released after cleavage
of high-molecular-weight kininogen by kallikrein (1). It is also
a potent stimulant for the release of tissue-type plasminogen
activator (t-PA) from the endothelium (2). Thus, when plaque
rupture or erosion activates the intrinsic coagulation pathway,
liberation of bradykinin may represent an important negative
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feedback loop in which bradykinin-induced t-PA release in¬
hibits intravascular thrombus formation.
Large-scale clinical trials of patients with heart failure
(HF) or ischemic heart disease indicate a reduction in
recurrent infarction rates with ACE inhibitor therapy (3).
The mechanisms underlying this anti-ischemic benefit may
relate, in part, to the effects on endogenous fibrinolysis.
Inhibition of ACE enhances bradykinin-induced vasodila¬
tation and endothelial t-PA release in healthy volunteers
(2). However, to date, there has been no assessment of the
effect of long-term ACE inhibition on acute endogenous
t-PA release in patients with HF or ischemic heart disease.
Therefore, the aim of this study was to determine whether
long-term ACE inhibition potentiates acute t-PA release in
patients with HF secondary to ischemic heart disease.
METHODS
Patients. Nine patients with New York Heart Association
functional class II or III HF secondary to ischemic heart
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Abbreviations and Acronyms
ACE = angiotensin-converting enzyme
ANOVA = analysis of variance
d.f. = degree of freedom
HF = heart failure
MI = myocardial infarction
PAI-1 = plasminogen activator inhibitor type 1
t-PA = tissue-type plasminogen activator
Table 1. Patient characteristics (n = 9)
disease participated in the study, which was undertaken
with the approval of the local Research Ethics Committee,
in accordance with the Declaration of Helsinki, and each
subject gave written, informed consent. All subjects had
been maintained on a maximally tolerated dose of an ACE
inhibitor for more than six months, and they abstained from
alcohol for 24 h and from food and caffeine-containing
drinks for at least 4 h before each study.
Measurements. FOREARM BLOOD FLOW AND HEMODY¬
NAMICS. Blood flow was measured in both forearms by
venous occlusion plethysmography using mcrcury-in-
Silastic strain gauges applied to the widest part of the
forearm, as previously described (2,4). Blood pressure and
heart rate were monitored in the noninfuscd arm at intervals
throughout each study by using a semi-automated nonin¬
vasive oscillometric sphygmomanometer (Takeda UA 751,
Takeda Medical Inc., Tokyo, Japan).
ASSAYS. Venous cannulae (17-gauge) were inserted into
large subcutaneous veins of the antecubital fossa in both
arms. Ten to 20 ml of blood was withdrawn simultaneously
from each arm and collected into acidified buffered citrate
(Biopool Stabilyte, Umea, Sweden; for t-PA assays) and
citrate (Monovette, Sarstedt, Niimbrecht, Germany; for
plasminogen activator inhibitor type 1 [PAI-1] assays) tubes
and kept on ice before being centrifuged at 2,000 g for 30
min at 4°C. Platelet-free plasma was decanted and stored at
— 80°C before assay. Plasma t-PA and PAI-1 antigen and
activity concentrations were determined using enzyme-
linked immunosorbent assays and a photometric method, as
previously described (2,4).
Study design. Patients were evaluated at 9 AM on two
occasions: during and after seven-day withdrawal of long-
term ACE inhibitor therapy. On the appropriate study day,
oral ACE inhibitor therapy was administered at 8 AM. The
brachial artery of the nondominant arm was cannulated with
a standard 27-gauge steel-wire needle (Cooper's Needle
Works Ltd., Birmingham, UK) under local anesthesia. The
total rate of intra-arterial infusions was maintained constant
at 1 ml/min, and forearm blood flow was measured every 10
min throughout all studies. Intrabrachial infusions of sub¬
stance P (Clinalfa AG, Laufelfingen, Switzerland) at 2, 4,
and 8 pmol/min, bradykinin (Clinalfa AG) at 30, 100, and
300 pmol/min, and sodium nitroprusside (David Bull Lab¬
oratories, Warwick, UK) were given at 1, 2, and 4 p.g/min
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Data are presented as the number of patients or mean value ± SEM. 'Diastolic
pressure + one-third of pulse pressure.
ACE = angiotensin-converting enzyme; LVEDD = left ventricular end-diastolic
diameter; Visit 1 = during long-term ACE inhibition; Visit 2 = after seven-day
withdrawal of long-term ACE inhibition.
was infused for 30 min before the substance P, sodium
nitroprusside, and bradykinin infusions.
Data analysis and statistics. Forearm blood flow was
calculated for individual venous occlusion cuff inflations, as
previously described (2,4). Estimated net release of t-PA
activity and antigen was previously defined as the product of
the infused forearm plasma flow (based on the mean
hematocrit and infused forearm blood flow) and the con¬
centration difference between the infused and noninfused
arms (2,4). Data were examined, where appropriate, by
analysis of variance (ANOVA) with repeated measures and
the two-tailed paired Student t test, using Microsoft Excel
97. All results are expressed as the mean value ± SEM.
Statistical significance was set at the 5% level.
RESULTS
Patient characteristics are shown in Table 1. After with¬
drawal of ACE inhibitor therapy, baseline mean arterial
pressure appeared to rise, but this was not statistically
significant. There were no significant changes in heart rate,
blood pressure or noninfused forearm blood flow (Table 1,
Fig. 1) (data on file, University of Edinburgh) during or
between the study days.
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Figure 1. Effect of intra-arterial bradykinin and substance P infusions on blood flow and plasma tissue-type plasminogen activator (t-PA) antigen (solid
lines) and activity (dashed lines) concentrations in the infused (solid symbols) and noninfused (open symbols) arms in the presence (left) or absence (right)
of angiotensin-converting enzyme (ACE) inhibition. *p < 0.05 by analysis of variance (ANOVA). tp < 0.001 by ANOVA for long-term ACE inhibition
versus no ACE inhibition.
Forearm blood flow responses. Sodium nitroprusside
(data on file), substance P, and bradykinin caused dose-
dependent forearm vasodilatation during each study visit
(ANOVA for blood flow response, p < 0.001 for all; n = 9
at baseline and with the three doses, degree of freedom
(d.f.) = 3) (Fig. 1). In the presence of long-term ACE
inhibition, forearm vasodilatation was augmented during
bradykinin (ANOVA for ACE inhibition vs. no ACE
inhibition, p < 0.05; n = 9 for blood flow at baseline and
with the three doses, d.f. = 1), but not substance P or
sodium nitroprusside (p = NS) infusion.
Plasma fibrinolytic variables. Bradykinin and substance P
caused dose-dependent increases in plasma t-PA antigen
and activity concentrations in the infused arm (ANOVA for
plasma t-PA concentrations, p < 0.05 for all; n = 9 at
baseline and with the three doses, d.f. = 3) (Fig. 1). Plasma
t-PA antigen and activity concentrations were significantly
augmented during bradykinin (ANOVA for ACE inhibi¬
tion vs. no ACE inhibition, p < 0.001; n = 9 for plasma
t-PA concentrations at baseline and with the three doses,
d.f. = 1), but not substance P (p = NS) infusion in the
presence of long-term ACE inhibition.
Basal plasma PA1-1 antigen concentrations were lower in
the presence (38 ± 6 ng/ml) than in the absence (48 ± 7
ng/ml) of ACE inhibitor therapy (paired t test for ACE
inhibition vs. no ACE inhibition, p < 0.02; n = 9 for
plasma PAI-1 concentrations, d.f. = 1). Bradykinin and
substance P administration had no effect on plasma PAI-1
concentrations (data on file, University of Edinburgh).
Release of t-PA. Substance P and bradykinin caused dose-
dependent increases in the plasma t-PA antigen and activity
concentration differences between the forearms, as well as
the estimated net release of t-PA antigen and activity during
each study visit (ANOVA for t-PA release, p < 0.01 for all;
n = 9 for t-PA release or concentration difference at
baseline and with the three doses, d.f. = 3) (Fig. 2). During
ACE inhibition, there was a massive increase in
bradykinin-induced (ANOVA for ACE inhibition vs. no
ACE inhibition, p < 0.001; n = 9 for t-PA release at
baseline and with the three doses, d.f. = 1) (Fig. 2), but
not substance P-induced (p = NS), release of t-PA
antigen and activity (increases in the area under the curve
of 520% and 877%, respectively). Post-hoc analysis iden¬
tified no significant effect of other concomitant medica-
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Figure 2. Estimated net release of tissue-type plasminogen activator (t-PA) antigen (solid lines) and activity (dashed lines) during bradykinin (right) and
substance P (left) infusions in the presence (solid circles) or absence (open circles) of angiotensin-converting enzyme (ACE) inhibition, p < 0.01 by
analysis of variance (ANOVA) for all responses. *p < 0.001 by ANOVA for long-term ACE inhibition versus no ACE inhibition.
tions on substance P-induced or bradykinin-induced
t-PA release.
DISCUSSION
For the first time, to the best of our knowledge, we have
shown that in patients with PIF secondary to ischemic heart
disease, long-term ACE inhibition markedly potentiates
bradykinin-induced endogenous t-PA release from the en¬
dothelium. However, this potentiation appears to be specific
to bradykinin, because ACE inhibition did not influence
substance P-induced t-PA release. These findings suggest
that the beneficial clinical and vascular effects of ACE
inhibition may be partly mediated through the acute local
augmentation of bradykinin-induced t-PA release.
Magnitude of t-PA release. Long-term ACE inhibition
produced a massive augmentation of bradykinin-induced
t-PA release across the forearm vascular bed. The approx¬
imate fivefold increase in t-PA antigen release and the
~20% reduction in plasma PAI-1 antigen concentrations
led to the approximate ninefold increase in the release of
active t-PA. Our group has previously shown that
bradykinin-induced t-PA release is augmented by ACE
inhibition in healthy volunteers, but this was modest at
approximately twofold only (2). The dramatic potentiation
of active t-PA release in the present study is exemplified by
the observation that the maximal local forearm concentra¬
tions of active t-PA (99 IU/ml at 300 pmol/min of
bradykinin) approached those observed during systemic
thrombolysis during acute myocardial infarction (MI) (100
to 1,000 IU/ml) (5). Moreover, it also underscores the large
capacity of the endothelium to release t-PA quickly—up to
4.5 /xg or 16,000 IU/min from the infused forearm at 300
pmol/min of bradykinin. Indeed, using intrabrachial sub¬
stance P infusions, we have previously demonstrated sub¬
stantial and sustained release of t-PA for up to 2 h (6).
Minai et al. (7) have recently reported that ACE inhibi¬
tion produces an approximate twofold increase in
bradykinin-induced t-PA release in the coronary circulation
of patients with atypical chest pain and angiographically
normal coronary arteries. This is consistent with our previ¬
ous findings in the peripheral circulation of healthy volun¬
teers (2) and suggests that comparable endothelial fibrino¬
lytic effects exist between the peripheral and coronary
circulations (8). The present study extends these previous
findings, because we have demonstrated a more marked
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augmentation of peripheral t-PA release in patients with
HF secondary to ischemic heart disease.
Mechanism of bradykinin-induced t-PA release. In
keeping with our previous work (2) and that by others (9),
ACE inhibition augmented the vasodilatation induced by
bradykinin but did not affect the vasodilatation or t-PA
release produced by substance P. This suggests that the
effect of ACE inhibition does not appear to reflect a
generalized enhancement of vascular function but is specific
to bradykinin. Brown et al. (10) and Gainer et al. (11) have
previously investigated the mechanism of bradykinin-
induced t-PA release in the human forearm. Bradykinin
induces t-PA release through a B2 receptor-dependent,
nitric oxide synthase-independent, and cyclooxygenase-
independent pathway (10). Brown et al. (10) have suggested
that bradykinin-induced t-PA release may be caused by an
endothelium-derived hyperpolarizing factor, although other
mediators may be involved. This group has also described a
potential interaction between the vascular responses to
bradykinin and the ACE gene insertion/deletion polymor¬
phism (11). We have not explored this interaction because
of the small sample size of our study, but this may markedly
influence the fibrinolytic response to long-term ACE inhi¬
bition in patients with HF or vascular disease, and it
requires further investigation.
Inflammation plays an important role in the pathogenesis
of HF (12), with elevated plasma concentrations of circu¬
lating cytokines such as tumor necrosis factor-alpha (13).
Bradykinin receptor expression is altered by ACE inhibition
(14,15), inflammation (16), and chronic HF (14,15,17) and
may partly explain the proportionately greater and massive
release of t-PA from the endothelium.
Endothelial function, endogenous fibrinolysis, and
HF. The endothelium plays a vital role in the control of
blood flow, hemostasis, fibrinolysis, and inflammation.
Consequently, the maintenance and regulation of tissue
perfusion critically depends on the integrity of endothelial
function and the release of potent endothelium-derived
factors. After the seminal work of Furchgott and Zawadski
(18), it has been widely recognized that an array of media¬
tors can influence vascular tone through endothelium-
dependent actions, and there is now extensive evidence of
abnormal endothelium-dcpendent vasomotion that is re¬
versed by ACE inhibition in patients with HF (19,20).
However, although endothelium-dependent vasomotion is
important, it may not be representative of other aspects of
endothelial function, such as the regulation of endogenous
fibrinolysis.
Tissue plasminogen activator is a serine protease that
regulates the degradation of intravascular fibrin and is
released from the endothelium through the translocation of
a dynamic intracellular storage pool. If endogenous fibrino¬
lysis is to be effective, then the rapid mobilization of t-PA
from the endothelium is essential, because thrombus disso¬
lution is much more effective if t-PA is incorporated during,
rather than after, thrombus formation (21). This dynamic
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aspect of endothelial function and fibrinolytic balance may
be directly relevant to the pathogenesis of atherothrombosis
and is not necessarily reflected by the basal plasma concen¬
trations of t-PA (22-24).
Clinical relevance. The endogenous fibrinolytic system
can have important clinical effects, as exemplified by the
observation that in one-third of patients with an acute MI,
the infarct-related artery spontaneously reperfuses within
12 h (25-27). Moreover, low fibrinolytic activity is associ¬
ated with an increased risk of MI in young men (28) and
predicts which patients with unstable angina will develop
MI (29). Clinical studies of patients with unstable angina
have also indicated that there is an enhanced activation of
the kallikrein system and that bradykinin release is increased
(30). Given this augmentation ofbradykinin generation and
activation of the intrinsic coagulation pathway in acute
coronary syndromes, ACE inhibition may have major ben¬
eficial effects on the acute local fibrinolytic balance by
markedly enhancing bradykinin-induced t-PA release in
areas of intravascular thrombus formation. This is consistent
with the observation that ACE inhibition improves the basal
fibrinolytic balance (31,32) and reduces myocardial troponin
release in patients with acute coronary syndromes (33).
Conclusions. Long-term ACE inhibitor therapy augments
bradykinin-induced peripheral vasodilatation and local
t-PA release in patients with HF due to ischemic heart
disease. Local plasma t-PA activity concentrations ap¬
proached those seen during systemic thrombolytic therapy
for acute ML This may contribute to the primary mecha¬
nism of the anti-ischcmic effects associated with long-term
ACE inhibitor therapy.
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Neutral Endopeptidase Inhibition Augments Vascular
Actions of Bradykinin in Patients Treated With
Angiotensin-Converting Enzyme Inhibition
Nicholas L.M. Cruden, Keith A.A. Fox, Christopher A. Ludlam, Neil R. Johnston, David E. Newby
Abstract—Angiotensin-converting enzyme and neutral endopeptidase (EC 3.4.24.11; neprilysin) are metallopeptidases
present on the endothelium that metabolize bradykinin. Inhibitors of angiotensin-converting enzyme potentiate
bradykinin-mediated vasodilatation and endothelial tissue plasminogen activator release. Combined angiotensin-
converling enzyme and neutral endopeptidase inhibition may have additional beneficial cardiovascular effects mediated
through bradykinin potentiation. We investigated the effects of local neutral endopeptidasc inhibition on the vascular
actions of bradykinin in heart failure patients maintained on chronic angiotensin-converting enzyme inhibition. Ten
patients received intrabrachial infusion of thiorphan (30 nmol/min), a neutral ondopeptidaso inhibitor, in a randomized
double-blind placebo-controlled crossover trial. Thiorphan was coinfused with Lys-des-Arg''-bradykinin (1 to 10
nmol/min), bradykinin (30 to 300 pmol/min), atrial natriuretic peptide (10 to 100 pmol/min), and sodium nitroprusside
(2 to 8 jag/min). Bradykinin, atrial natriuretic peptide, and sodium nitroprussidc caused dose dependent vasodilatation
(peak blood flow 14.4±2.2, 3.6±0.6, and 8.6±l.3 mL per 100 mL/min, respectively; P<0.0001). Bradykinin caused
dose-dependent increases in tissue plasminogen activator antigen and activity (peak concentration 31.8±3.4 ng/mL and
21.9±7.6 lU/mL, respectively; P<0.001) and estimated antigen and activity release (peak release 152±46 ng per 100
mL/min and 154±22 1U/100 mL/min, respectively; B<0.005). Compared with placebo, thiorphan augmented
bradykinin-mediated vasodilatation (1.4-fold; /><0.0001) and net tissue plasminogen activator release (1.5-fold;
P<0.005). Neutral endopeptidase contributes to bradykinin metabolism in heart failure patients maintained on
angiotensin converting enzyme inhibitor therapy. Our findings may explain some of the clinical effects of combined
angiotensin-converting enzyme and neutral endopeptidase inhibition, including the greater vasodepressor effect
observed with combined therapy when compared with angiotensin converting enzyme inhibition alone. (Hypertension.
2004;44:913-918.)
Key Words: heart failure ■ angiotensin-converting enzyme ■ bradykinin ■ endothelium
Bradykinin is a potent endothelium-dependent vasodilatorpeptide released at sites of inflammation and coagula
lion. Apart from vasodilatation, it also stimulates endothelial
release of the prolytic factor tissue-type plasminogen activa¬
tor (t-PA), and these effects are mediated by the constitulively
expressed B2 receptor.1'2 Removal of the C-tcrminal arginine
from bradykinin results in formation of des-Arg7-bradykinin,
the principal ligand for the B, kinin receptor in plasma.3
However, the most potent endogenous ligand for the B, kinin
receptor is Lys-des-Arg''-bradykinin.3 The vascular B, recep¬
tor is normally expressed very weakly but is markedly
upregulated in the presence of inflammation, cardiovascular
discaso, and angiotensin converting enzyme (ACE) inhibi
lion,4 whero it also mediates vasodilatation.3
ACE is the principal enzyme responsible for the rapid
turnover of bradykinin (plasma half life =15 seconds) and its
metabolites.3 It has been widely established that ACE inhib¬
itors improve morbidity and mortality in patients with heart
failure,-'' and these benefits may be due, at least in part, to
inhibition of bradykinin metabolism.6-7 ACE inhibition in¬
creases the plasma half lives of bradykinin and des-Arg7-
bradykinin =9 and 2-fold, respectively," and at a functional
level, potentiates the vascular actions of bradykinin in the
human foroarm19 and coronary1" circulations. Moreover,
bradykinin antagonism causes vasoconstriction7 and attcnu
ates the fall in blood pressure6 in patients treated with ACE
inhibitor therapy.
Neutral endopeptidase (EC 3.4.24.11; neprilysin [NEP]) is
a membrane bound metallopcptidasc that colocalizes with
ACE and metabolizes a number of vasodilator and vasocon
stridor peptides, including atrial natriuretic peptide, sub¬
stance P, endothelin-1. and bradykinin.11 NEP expression is
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upregulated in heart failure patients,1211 and in the presence
of ACE inhibition, the contribution of NEP to bradykinin
metabolism is increased.14 NEP inhibition potentiates the half
life of bradykinin15 and augments bradykinin-mediated vaso¬
dilatation in vitro.lh It is not known whether NEP inhibition
augments the half life of Lys-des-Arg9-bradykinin. Indeed, it
has been suggested that the Plie8 residue may protect B,
ligands from degradation by NEP.3 Although the effects of
NEP inhibition on systemic hemodynamics are variable,17-20
clinical improvements have been reported during NEP inhi¬
bition in heart failure patients.21
Coadministration of ACE and NEP inhibitors may confer
additional therapeutic efficacy. Combined ACE and NEP
inhibition attenuates bradykinin degradation more effectively
than either enzyme alone,22 and in animal models, improves
cardiac remodeling and survival to a greater extent than
isolated ACE inhibition.2-1 These caidioprotective effects aie
lost in transgenic mice lacking the B> kinin receptor.24 In
man, combined ACE and NEP inhibition reduces blood
pressure to a greater extent than inhibition of eilher enzyme
alone19-25 and is associated with symptomatic and hemody¬
namic improvements in heart failure patients.2'' The hypoth¬
esis that combined ACE and NEP inhibition may improve
symptoms and survival in heart failure patients to a greater
extent than ACE inhibition alone has been evaluated recently
in a large-scale clinical trial (Omapatrilat Versus Fnnlnpril
Randomized Tiial of Utility in Reducing Events
[OVERTURE]).27
We demonstrated previously that chronic ACE inhibition
potentiates bradykinin-mcdiatcd vasodilatation and endothe¬
lial release of t-PA in forearm circulation of heart failure
patients 1 The aims of this study were to investigate whether
local NEP inhibition augments the vascular actions of brady¬
kinin and to examine the effects of B, receptor agonism in




ten patients with symptomatic heart tailure and echocardiographic
evidence of left ventricular systolic dysfunction attended, fasted al
9 am on 2 occasions at least 2 weeks apart. The protocol was
performed with the approval of the local ethics committee, in
accordance with the Declaration of Helsinki and with the written
informed consent of each patient. Patients were maintained oil
maximally tolerated ACE inhibitor therapy (ramipril 10 mg daily
[n = 4J and 5 mg daily [n= 3]: enalapril 20 mg daily [n= I ] and 10 mg
daily [n= 1 ]; and lisinopril 40 mg daily [n= 1]) for at least 6 months
before recruitment On the morning of each visit, APF inhibitor
therapy was administered at 8 am and diuretics were withheld.
Measurements
Bilateral forearm blood flow was measured using venous occlusion
plethysmography.n7-9,28 Heart rate and blood pressure were recorded
in the iioiunluscd arm using a scriiiauloinatcd noninvasive oscillo¬
metry sphygmomanometer (Takeda UA 751: Takeda) at baseline
and in the final minute of each drug infusion period, after forearm
blood How measurements and venous sampling.
Venous cannulae (17-gauge) were inserted bilaterally into a large
antecubilal vein. Throughout each study, 10 mL of blood was
collected from each arm into acidified buffeted cluate (Blopool
Stabilyte; Umea; for t-PA assays) and citrate (Monovette, Sarstedl,
Numbrecht; for plasminogen activator inhibitor ! [ PA I -1 ] assays).
Platelet-free plasma was prepared as described previously1-28 and
stored at —80"C before assay. Plasma concentrations of t-PA and
PAI-1 antigen were determined using an ELISA, t-PA activity using
a photometric method,28 and ACE activity using colorimetric spec
trophotometry (reference range 8 to 55 U/L; Sigma).29
Study Protocol
A 27-gauge steel needle was inserted into the brachial artery of the
nondominant arm. After 15 minutes equilibration with an infusion of
0.9% saline, patients were randomized to receive an intrabrachial
infusion of thiorphan (30 nmol/min; Clinalfa AC) or saline placebo for
3 hours. The dose of thiorphan was chosen based on previous forearm
studies3" to achieve a local plasma concentration > 10-fold the 1C50 of
thiorphan for NEP in vitro. " Thiorphan or placebo was coinfused witli
bradykinin (30, 100, and 300 pmol/min: Clinalfa AG),7 Lys-des-Arg'1-
bradykinin (1, 3, and 10 nmol/min; Clinalfa AG), anial natriuretic
peptide (10, 30, and 100 pmol/min; Clinalfa AG),32 and sodium
nitroprusside (2, 4. and 8 /xg/min; David Bull Laboratories)28 for 10
minutes al each dose. There was a 20 minute washout infusion of 0.9%
saline between compounds. The order of infusion was randomized
between patients but was maintained lor both visits. The doses of
Lys-des-Arg'J-bradykinin were chosen based on binding affinity data33
und the hypotensive dose response in rodents and nonhuman pri
mates.34-35 The combined rate of infusion remained constant throughout
each study at 1 niL/min.
Data Analysis and Statistics
Plethysmography data were extracted from Chart data files, and
forearm blood Bow was calculated as described previously.1-28
Estimated net release of t-PA antigen und activity were calculated as
the product of infused forearm plasma flow and the t-PA concentra¬
tion difference between the infused and noninfused arms.128 Stalin
tical analyses were performed using ANOVA or, where appropriate,
paired i tests.
Results
There were no significant differences in heart rate, blood
pressure, or baseline forearm blood flow during or between
study days (Table I). Consistent with previous studies,2 1
subject developed transient upper limb edema with 300
pmol/min of bradykinin that rapidly resolved on cessation of
the infusion. There were no other reported side effects.
Plasma ACE Activity
Baseline plasma ACE activity was similar between tliiorphan
and placebo study visits (12.3rt2.6 versus 9.7±l.5 U/niL,
respectively: P=0.7). Compared with baseline, there were no
significant differences in plasma ACE activity measured after
90 minutes of thiorphan (I0.7±2.5 U/mL; P=0.3) or placebo
(I0.2±1.7 U/ntL; /J=0.3) coinfusion.
Forearm Blood Flow Responses
Bradykinin, atrial natriuretic peptido, and sodium nitroprus
side caused dose dependent increases in forearm blood flow
in all studies (PCO.OOOI for all; Figure 1). Forearm blood
flow did not change during Lys des Arg9 bradykinin infusion
(Figure I). Compared with saline placebo, coinfusion of
thiorphan augmented forearm vasodilatation to bradykinin
(P<0.0001; Figure 1) but not atrial natriuretic peptide or
sodium nitroprusside.
Plasma Fibrinolytic Factors
There were no significant differences in baseline plasma t PA
antigen (10.8±0.9 versus 9.8±0.9 ng/rnL), t-PA activity
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TABLE 1. Patient Characteristics and Baseline
Hemodynamics (n=10)
Variables All Patients (n=10) Units
Age (range) 64 (52-73)
Gender (male/female) 5/5
Diagnosis (IHD/DCM) 8/2
NYHA class (ll/lll) 6/4



















Ejection fraction 31 ±2
LVEDD 61 ±3
Baseline heart rate
Thiorphan visit 58 ±3
Placebo visit 56±2
Baseline mean arterial pressure
Thiorphan visit 92±5
Placebo visit 86±4














mL per 100 mL/min
Data are expressed as No. of patients or meanrtSEM.
Mean arterial pressure was calculated as diastolic pressure plus one third
pulse pressure.
IHD indicates ischemic heart disease; DCM, idiopathic dilated cardiomyop¬
athy; NYHA, New York Heart Association; LVEDD, left ventricular end diastolic
diameter.
(0.1 ±0.1 versus 0.4±0.1), or PA1-1 antigen concentrations
(37.3±3.7 versus 38.4±6.2 ng/mL) between thiorphan and
placebo, respectively. Bradykinin caused a dose-dependent
increase in plasma l-PA antigen and activity concentrations in
the infused arm (/><0.Q01 for all; Table 2) and the net release
of l-PA antigen and activity in all studies (P<0.005 for all;
Figure 2). Compared with placebo, thiorphan augmented the
increase in plasma t-PA activity concentration (21.9±2.4
versus 24.8 ±2.6 HJ/mL, respectively at bradykinin, 300
pmol/min; P<0.05; Table 2) in the infused arm and the net






















Figure 1. Effect of thiorphan (•) and placebo (O) on infused
forearm blood flow during infra-arterial infusion of bradykinin,
sodium nitroprusside, atrial natriuretic peptide, and Lys-des-
Arg9-bradykinin ("P<0.0001, ANOVA dose response;
tP<0.0001, ANOVA thiorphan vs placebo).
mL/min, respectively at bradykinin, 300 pmol/min; P<0.005;
Figure 2) and activity (155±22 versus 244±51 ng per I00
mL/min, respectively at bradykinin, 300 pmol/min; P<0.005;
Figure 2). There was a trend toward an increase in t PA
antigen in the infused arm during thiorphan infusion com¬
pared with placebo (32.5±3.4 versus 36.5±4.2 ng/mL, re¬
spectively at bradykinin, 300 pmol/min; P—0.058; Table 2).
Because of systemic overspill, bradykinin increased plasma
t-PA antigen and activity concentrations in the noninfused
arm (PCO.OI and P<0.05, respectively; Table 2) that, for
t-PA activity, was greater during thiorphan infusion (P<0.05;
Table 2). There were no significant changes in t-PA antigen,
activity, or net t-PA release during infusion of atrial natri¬
uretic peptide or Lys-des-Arg''-bradykinin.
There was a significant reduction in plasma PAI-1 antigen
concentrations in the infused ami duiiug btadykinin coinfu-
sion with thiorphan (baseline 33.3±3.5 versus 29.4±3.4
ng/mL al bradykinin, 300 pmol/min; P<0.05) but not pla¬
cebo. There were no significant changes in PAl-1 antigen
concentration during infusion of Lys-des-Arg9-bradykinin or
atrial natriuretic peptide.
Discussion
For the first time, we demonstrated that acute local NEP
inhibition augments bradykinin-mediated cndothelium-
dependent vasodilatation and endogenous t-PA release in
heart failure patients maintained on chronic ACE inhibitor
therapy. In addition, this is the first clinical study to show that
the B, receptor does not mediate vasodilatation or endothelial
t-PA release in these patients. Our findings support the
hypothesis that bradykinin may contribute to the systemic
hemodynamic differences observed between combined ACE
and NEP inhibition, and ACE inhibition alone.
Clinical Implications
There is now substantial evidence that bradykinin contributes
to the systemic hemodynamic and anti-ischemic effects of
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TABLE 2. Effect of Thiorphan and Placebo on Forearm Blood Flow (FBF) and Plasma Tissue Plasminogen Activator (t-PA) Antigen
and Activity Concentrations in the Infused and Noninfused Forearms During Coinfusion of Bradykinin, Atrial Natriuretic Peptide, and
Lys-des-Arg9-Bradykinin
Parameter Bradykinin pmol/min Atrial Natriuretic Peptide pmol/min Lys-des-Arg!'-Bradykinin nmol/min
Baseline 30 100 300 Baseline 10 30 100 Baseline 1 3 10
Thiorphan
infusion
FBF, mL per 100
mtVmin
Infused 2.1 ±0.2 8.2+0.7 13+1.5 19+ 2.2*f 2 ±0.3 2.4±0.4 3±0.4 3.8±0.6* 2.2 ± 0.3 2.1 ±0.3 2.2±0.3 2.1 ±0.3
Noninfused 1.5±0.3 2±0.4 1.9±0.3 1.7±0.3 1.4±0.2 1.5±0.3 1.6±0.3 1.7±0.3 1.6±0.3 1,5± 0.3 1.5± 0.3 1.6±0.3
t-PA antigen,
ng/mL
Infused 9.3±0.8 18.0+1.8 26.2±2.9 36.5±4.2* 10.8+0.9 10.7±0.8 10.2 it0.7 9.5+0.8 10.1 ±0.9 10.2± 0.9 10.1+0.8 9.8±0.8
Nonintused 9.6±0.7 10.8±1 12.9±1 17.6±2.5* 9.9±0.8 10.4 it 0.9 10.3±0.9 9.8±0.8 10.2±0.9 10.2±0.9 10±0.8 9.6±0.8
t-PA activity,
lU/mL
Infused 0.1+0.1 8.7±1.4 16.2 =t 2.4 24.8±2.6*§ 1.3+0.5 1.1 ±0.4 0.8±0.4 0.5±0.2 0.8±0.4 0.8±0.5 0.5±0.3 0.4±0.2
Noninfused 0.1 + 0.1 1.0 + 0.2 3.1 ±1 6+1.2f§ 0.6±0.2 0.7+0.3 0.5±0.3 0.4±0.3 0.7±0.3 0.2±0.2 0.4±0.3 0.3±0.2
Placebo infusion
FBF, mL per 100
mL/min
Infused 2±0.3 5.8±0.8 8.3±0.9 14.4 ± 2.2*4: 2.2±0.4 2.6±0.4 3±0.5 3.6±0.6" 2.5±0.3 2.6±0.3 2.7 ±0.4 2.7±0.4
Noninfused 1.9+0.3 2.1 + 0.4 2±0.3 2.1 ±0.4 2±0.4 2±0.3 2±0.3 2±0.3 1.8±0.2 1.9±0.3 1.9±0.3 1.9±0.3
t-PA antigen,
ng/mL
Infused 9.1+0.7 14.2+1 22.8+2.2 32.5+3.4" 9.8±0.8 9.4±0.7 9.2±0.7 9.5+0.8 9.6±0.8 9.7±0.8 9.5±0.8 9.4 ±0.8
Noninfused 9.3+0.8 9.8±0.7 11.2± 0.8 14.6+1.2* 10 ±0.7 9.8 ±0.6 10± 0.7 9.6±0.7 9.4 ±0.8 9.3± 0.8 9.2 + 0.7 9±9.7
t-PA activity,
lU/mL
Infused 0.3±0.1 4.6+1.3 12.6±2.4 21.9±2.4*§ 0.6+0.2 0.5±0.1 0.4±0.2 0.3±0.1 0.8±0.2 0.6±0.2 0.6 ±0.2 0.6±0.2
Noninfused 0.3+0.1 0.8+0.3 1.4 + 0.4 2.8±0.7f§ 0.2±0.1 0.3±0.1 0.2±0.1 0.1 ±0.1 0.3+10.1 0.3±0.1 0.3±0.1 0.3±0.2
ANOVA dose response *P<0.001, tP<0.05; ANOVA thiorphan vs placebo fP<0.001, §P<0.05.
ACE inhibitor therapy.'•6-7-36 Our findings suggest that
bradykinin-mediated vasodilatation may contribute to the
greater vasodepressor actions demonstrated with combined
ACE and NEP inhibition compared with isolated ACE
inhibition.19-25 Moreover, despite the marked increase in
bradykinin-induced t-PA release by ACE inhibition alone,1
additional NEP inhibition causes further substantial augmen¬
tation of acute t-PA release. Together, these hemodynamic
and profibrinolytic effects would be expected to have impor¬
tant therapeutic consequences. However, in the recent
OVERTURE trial27 of heart failure patients, treatment with
omapatrilat, a combined ACE and NEP inhibitor, failed to
reduce all-cause mortality when compared with enalapril,
although it did reduce the combined secondary end point of
cardiovascular death and hospitalization. Post hoc analysis
redefining end points according to the Studies of Left
Ventricular Dysfunction (SOLVD) criteria suggested that
omapatrilat may be more effective at preventing cardiovas¬
cular events than enalapril, but that the additional benefit was
substantially smaller than anticipated.27 This may. in part,
reflect the shorter duration of NEP inhibition compared with
ACE inhibition with omapatrilal.37 Given our findings, phar¬
macological strategies offering a more balanced and pro¬
longed duration of combined ACE and NEP inhibition may
confer greater cardiovascular benefits.
Augmentation of bradykinin-mediated vasodilatation
within the kidney may also contribute to the greater increase
in renal blood flow observed with combined ACE and NEP
inhibition than ACE inhibition alone.38 As a result, it has been
suggested that combined ACE and NEP inhibition may afford
greater renal protection than ACE inhibition alone.38 How¬
ever, it should be noted that potentiating the vascular actions
of kinins may have detrimental effects. Bradykinin has been
implicated in the pathogenesis of ACE inhibitor-mediated
angioedema.39 An even greater incidence of angioedema has
been reported after treatment with combined ACE and NEP
inhibition.40 Our findings are consistent with the suggestion
that bradykinin may contribute to this rare but potentially
life-threatening side effect.
Role of B, Receptor
We demonstrated that intra-arterial Lys-des-Arg''-bradykinin,
a potent and highly selective agonist at the human B, kinin
receptor, has no effect on blood flow or endothelial t-PA
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Figure 2. Effect of thiorphan (•) and placebo (O) on net tissue
plasminogen activator (t-PA) antigen (top) and activity (bottom)
release during intra-arterial infusion of bradykinin and atrial na¬
triuretic peptide (*P<0.005, ANOVA dose response; "fP<0.005,
ANOVA thiorphan vs placebo).
release in the forearm circulation of heart failure patients
maintained on long-term ACE inhibitor therapy. This is in
contrast to our previous findings that combined B, and B2
receptor blockade, but not isolated selective blockade of the
B: receptor causes vasoconstriction in heart failure patients
treated with ACE inhibition.7 We infused Lys-des-Arg9-
bradykinin at a dose that would achieve a local plasma
concentration 20X greater than those shown previously to
produce 50% of the maximal vasomotor response in human33
and animal studies,34-35 and therefore, our findings are un¬
likely to reflect an inadequate dose. Additional clinical
studies using a selective B, kinin receptor antagonist are now
required to more fully investigate the role of the vascular B,
receptor in man.
Atrial Natriuretic I'eptide and
Neutral Endopeptidase
Consistent with previous work demonstrating an impaired
forearm vasodilator response to atrial natriuretic peptide in
heart failure patients.32-41-42 atrial natriuretic peptide caused a
modest dose-dependent increase in forearm blood How that
was not augmented by local NEP inhibition. Although sup¬
pression of PA1-1 expression in endothelial cells has been
reported in vitro,43 we report for the first time that intra-ar¬
terial atrial natriuretic peptide does not directly alter either
plasma PA1-1 or t-PA antigen concentrations in vivo in man.
Local NEP inhibition did not potentiate atrial natriuretic
peptide-mediated forearm vasodilatation, in keeping with pre¬
vious data demonstrating that intrabrachial thiorphan (30 nmol/
min) does not increase endogenous plasma atrial natriuretic
peptide concentrations in human forearm circulation.30 At first,
this may appear surprising given that systemic NEP inhibition
augments plasma atrial natriuretic peptide concentrations in
heart failure patients.21 However, it is likely to reflect differences
in the rate of clearance of atrial natriuretic peptide and bradyki¬
nin from forearm circulation. The half life of atrial natriuretic
peptide (=5 minutes) is greater than that of bradykinin (=15
seconds). Assuming a transit time of the forearm vascular bed of
=30 seconds, NEP inhibition with intrabrachial thiorphan is
unlikely to result in sufficient local accumulation of atrial
natriuretic peptide to augment forearm vasomotor responses.
Moreover, the natriuretic peptide C receptor contributes equally
to the clearance of plasma atrial natriuretic peptide, and this
pathway is unaffected by NEP inhibition.
Study Limitation
Although selective for NEP, thioqrhan may cause some inhibi¬
tion of ACE activity, and theoretically, our findings could
represent further inhibition of ACE activity. Thiorphan exists as
2 enantiomers that, although cquipotent for NEP inhibition, have
differing potencies against ACE: selectivity of NEP compared
with ACE inhibition of =50-fold for 5-thiorphan and 200-fold
for W-lhiorphan." The preparation of thiorphan used in this
study contains equal proportions of both isomers." We do not
believe the effects of thiorphan were mediated through addi¬
tional inhibition of ACE activity because local thiorphan infu¬
sion did not alter plasma ACE activity. Moreover, in a previous
study30 using the same dose of thiorphan, there were no effects
on plasma angiotensin II concentrations in forearm circulation of
healthy volunteers treated acutely with enalapril. However, we
acknowledge that ACE inhibition by maximally tolerated doses
of an ACE inhibitor may be incomplete,44 and we cannot
completely exclude a contribution of additional ACE inhibition
to our study findings.
Perspectives
We have demonstrated that local NEP inhibition augments
bradykinin-mediated vasodilatation and endothelial t-PA re¬
lease in heart failure patients maintained on long-term ACE
inhibitor therapy. Using a potent B, receptor agonist, we have
shown that isolated stimulation of the B, kinin receptor does
not cause vasodilatation or endothelial t-PA release in man.
These findings confirm that NEP contributes to bradykinin
metabolism in heart failure patients and suggest that potenti¬
ation of the vascular and profibrinolytic actions of bradykinin
may explain some of the observed effects in recent clinical
trials of combined ACE and NEP inhibitor therapy.
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B1 Kinin Receptor Does Not Contribute to Vascular Tone
or Tissue Plasminogen Activator Release in the Peripheral
Circulation of Patients With Heart Failure
Nicholas L.M. Cruden, George H. Tse, Keith A.A. Fox, Christopher A. Ludlam,
lan Megson, David E. Newby
Objective—Vascular expression of ihe B, kinin receptor is markedly upregulated with left ventricular dysfunction and
angiotensin-converting enzyme (ACE) inhibition, but its function remains unclear. Inhibitors of ACE potentiate
bradykinin-mediated B, receptor-dependent vasodilatation and tissue plasminogen activator (tissue-type plasminogen
activator [t-PAj) release. We investigated the contribution of the B, receptor to the maintenance of vascular tone and
t-PA release in patients with heart failure.
Methods and Results—Eleven patients were treated with enalapril (10 mg twice daily) or losartan (50 mg twice daily) in
a randomized double-blind crossover trial. During week 6 of each treatment, patients received an intrabrachial infusion
of Lys-des-Arg9-bradykinin (B, agonist; 1 to 10 nmol/min), bradykinin (30 to 300 pmol/min), Lys-[Leu8]-des-Arg9-
bradykinin (B, antagonist; 1 to 10 nmol/min), and norepinephrine (60 to 540 pmol/min). Blood How and t-PA release
were measured using venous occlusion plethysmography and blood sampling. Bradykinin (PCO.OOl for all), but not
Lys-des-ArglJ-bradykinin, caused vasodilatation and t-PA antigen and activity release. Norepinephrine (P<0.001), but
not Lys-|Leu8]-des-Arg''-bradykinin, caused vasoconstriction. Compared with losartan, enalapril augmented bradykinin-
mediated vasodilatation (P<0.05) and t-PA release (PC0.01 for all) but had no effect on B, receptor-mediated
responses.
Conclusions—The B, kinin receptor does not have a major vasomotor or fibrinolytic role in patients with heart failure.
Augmentation of kinin-mediated vasodilatation and t-PA release by ACE inhibition is restricted to the B2 receptor.
(Arterioscler Thromb Vase Biol. 2005;25:772-777.)
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Bradykinin is the major effector for the kinin family ofpeptides in humans. It is released at sites of inflamma¬
tion and coagulation and contributes to the systemic hemo¬
dynamic1-2 and anti-ischemic3-4 effects of angiotensin-
converting enzyme (ACE) inhibitor therapy. Besides
vasodilatation, bradykinin stimulates endothelial release of
the pro-lytic factor, tissue plasminogen activator (t-PA), and
these effects are mediated by the constitutively expressed B2
kinin receptor.5
Des-Arg9-bradykinin is the principal ligand for the B, kinin
receptor in human plasma and is generated by carboxypepti-
dases after removal of the C-terminal arginine from bradyki¬
nin. The vascular B, receptor is normally expressed very
weakly but is markedly upregulated in the presence of
inflammation,6 ischemic left ventricular dysfunction,7 cardio¬
vascular disease,8 and ACE inhibition.9 In animal studies,
stimulation of the B, receptor produces vasodilatation and a
reduction in blood pressure.6-10"12 Intense endothelial B|
receptor expression has been demonstrated in atheromatous
human blood vessels,13 and B| receptor stimulation induces
dose-dependent vasodilatation in human coronary arteries in
vitro.14 Whether the B, receptor contributes to the vascular
effects of kinins in vivo in humans remains unknown.
ACE is the principal enzyme responsible for the rapid
breakdown of bradykinin (plasma half life "=15 seconds) to
its inactive metabolites.15 In addition to increasing plasma
bradykinin concentrations, ACE inhibition will favor brady¬
kinin breakdown by alternative metabolic pathways including
plasma carboxypeptidases, augmenting the generation of
des-Arg'-bradykinin, and thereby potentiating both B, and B,
receptor-mediated effects.15 B, receptor antagonism attenu¬
ates the vasodepressor effect of a single oral dose of captopril
in healthy volunteers and subjects with hypertension.2 In
patients with heart failure, the combined B, and B2 kinin
receptor antagonist, B9340. causes vasoconstriction in the
forearm circulation in the presence, but not absence, of ACE
inhibition,16 and when administered systemically, it attenu¬
ates the hemodynamic effects of chronic ACE inhibition.1
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However, the role of the B, receptor in patients with heart
failure and those treated with ACE inhibitor therapy remains
to be established.
Although des-Arg'-bradykinin is the principal B, agonist
present in plasma, it has only modest affinity for the human
B, receptor and retains some activity at the human B,
receptor.15 Indeed, des-Arg9-bradykinin is only 100-fold more
selective for the human B| receptor.15 In contrast, Lys-des-
Arg9-bradykinin, an endogenous tissue-based metabolite of
kallidin, has ^1000-fold greater affinity for the B, receptor
than des-Arg9-bradykinin and is inactive at the B, receptor in
humans.15'na8 Substitution of the Phe8 residue in Lys-des-
Arg9-bradykinin with Leu results in the formation of Lys-
[Leus]-des-Arg9-bradykinin, a synthetic peptide with potent
selective inhibitory activity at the human B| receptor.615
Using custom-manufactured, clinical-grade preparations
of Lys-des-Arg9-bradykinin and Lys-[Leu"]-des-Arg9-
bradykinin, the aims of this study were to investigate whether
the B| receptor contributes to the vascular actions of kinins in
the patients with heart failure treated with ACE inhibition.
Methods
This study was performed with the approval of the local research
ethics committee in accordance with the Declaration of Helsinki and
with the written infomied consent of each subject.
Drugs
Pharmaceutical grade bradykinin (Clinalfa AG, Liiufelfingen, Swit¬
zerland), Lys-dcs-Arg'-bradykinin (Clinalfa), Lys-[Leu8]-des-Arg9-
bradykinin (Clinalfa), HOE-140 (Clinalfa), B9340 (Clinalfa), and
norepinephrine (Abbott Laboratories Ltd, Maidenhead, UK) were
dissolved in physiological saline on the day of study. The doses of
bradykinin and norepinephrine were chosen based on the results of
previous studies.19 The doses of Lys-des-Arg''-bradykinin and Lys-
[Lcu*]-des-Arg'J-bradykinin were chosen based on the EC,,, (B,
receptor, 0.2 nmol/L: B, receptor, >30 000 nmol/L) and IC,0 (B,, 1.3
nmol/L; B2, >30 000 nmol/L), respectively, for human kinin recep¬
tors in vitro,15 data from human umbilical vein myography stud¬
ies,18'20 and the hypotensive dose response in rodents and nonhuman
primates.6"
Human Umbilical Vein Studies
To confirm the efficacy of the B, receptor agonist, Lys-des-Arg9-
bradykinin, and the B, antagonist, Lys-[Leu*j-des-Arg9-bradykinin,
human umbilical cord was obtained from women aged 16 to 40 years
undergoing routine cesarean section after uncomplicated pregnancy.
Immediately after delivery, 10 cm umbilical cord was excised
midway between placenta and child and placed in Krebs buffer
solution (NaCl 6.954 nmol/L, KC1 4.7 nmol/L, CaCL 2.5 nmol/L,
MgSO, 1.17 nmol/L, NaHCO, 2 nmol/L, KH2PO., 1.18 nmol/L,
EDTA 0.027 nmol/L, glucose 5.5 nmol/L; Fisher Scientific UK Ltd,
Loughborough UK). Human umbilical vein was dissected into 3-mm
rings as previously described.20
Myography
Three hours after delivery, umbilical vein rings were mounted on
wire myographs, suspended in organ baths containing 10 mL Krebs
solution, and stretched with an initial tension of 2 g (Multimyograph
System 700MO; JP Trading, Denmark). Krebs solution was main¬
tained at 37°C and continually bubbled with 95% (X/5% CCL.
Changes in tension were measured using an isometric transducer
(Mac Laboratory 8; Analog Digital Instruments Pty Ltd, Australia).
After 60-minute equilibration, during which the tension was
readjusted at 15-minute intervals, maximal contraction to KC1
(60 mmol/L) was determined on 3 occasions, interspersed by
15-minute washout periods. Tissue rings were incubated with cap-
topril (1 ptmol/L; Sigma Pharmaceuticals, St Louis, Mo) 30 minutes
before performing cumulative dose responses to bradykinin (B2
receptor agonist; 10"" to 10"6 mol/L) and Lys-des-Arg'-bradykinin (B,
receptor agonist; 10~" to 10"6 mol/L) in the presence or absence of
Lys-[Leu8]-des-Arg9-bradykinin (B, receptor antagonist; 1 /arnol/L),
HOE-140 (B2 receptor antagonist; 1 /itmol/L), or B9340 (combined
B,/B2 receptor antagonist; 1 pmol/L). Peptide antagonists were applied
10 minutes before agonists to ensure that equilibrium was obtained.
Maximal contraction to 60 mmol/L KG was determined on a final
occasion al the end of each experiment. A single concentration curve for
bradykinin and Lys-des-Arg'-bradykinin was obtained for each ring,
and experiments were performed in parallel with rings from the same
tissue.
Immunohistochemistry
After contractile studies, human umbilical vein rings were fixed in
formalin and embedded in paraffin wax. A hematoxylin and eosin
stain was performed for each tissue section. B, and B, receptors were
imnrunodetected using diaminobenzidine immunoprecipitation.
Briefly, tissue was boiled in 0.01 mol/L sodium citrate (pH 6.0) for
8 minutes to facilitate antigen retrieval. Nonspecific binding sites
were blocked with 1:100 donkey serum followed by 3% H,02. Tissue
sections were then incubated with the primary affinity purified goat
polyclonal antibody specific for human the B, or B, kinin receptor
(Santa Cruz Biotechnology, Inc), followed by the secondary anti¬
body (donkey anti-goat lgG; Santa Cruz Biotechnology Inc) or with
the secondary antibody alone (control). Finally, tissues were treated
with a peroxidase-antiperoxidase strepavidin-biotin conjugating
system (Dako K0690) and visualized by conventional light micros¬
copy using liquid diaminobenzidine precipitant (Dako K3465).
Clinical Study
Eleven patients with symptomatic heart failure (New York Heart
Association class II or III) and evidence of left ventricular systolic
dysfunction (ejection fraction <40%, shortening fraction <20%, or
left ventricular end diastolic dimension >55 mm) were recruited.
Patients were maintained on maximally tolerated ACE inhibitor
therapy for al least 6 months before enrollment. On study days,
patients who attended fasted for 4 hours and diuretics were withheld
for patient comfort.
When symptoms would allow, ACE inhibitor therapy was with¬
drawn for a period of 2 weeks (n=7). After this and in place of their
usual ACE inhibitor, patients were randomized to receive 6 weeks of
treatment with enalapril 10 mg21 twice daily or losartan 50 nig22
twice daily in a double-blind, crossover trial. One patient withdrew
because of worsening symptoms and was replaced. During week 2 of
ACE inhibitor withdrawal and weeks 6 and 12 of the crossover trial,
patients attended on 2 occasions at least 3 days apart and underwent
an agonist study on one occasion and an antagonist study on the
other. The study order was randomized between patients but re¬
mained constant for each patient.
Intra-Arterial Drug Administration
All studies were performed with patients lying supine in a quiet,
temperature-controlled (22°C to 25°C) room. Under local anesthesia,
a 27-gauge needle (Cooper Needle Works Ltd) was inserted into the
brachial artery of the nondominant arm. The rate of intra-arterial
drug infusion remained constant throughout at I mL/min.
Forearm Blood Flow and Blood Pressure
Forearm blood flow was measured at 10-minute intervals in both
arms using venous occlusion strain gauge plethysmography as
previously described.16-25 Heart rate and blood pressure were rec¬
orded in the noninfused arm al intervals throughout the study using
a semi-automated noninvasive oscillometric sphygmomanometer
(Takeda UA 751; Takeda Medical Inc, Japan).
Venous Sampling and Assays
During agonist studies only. 17-gaugc venous cannulae were inserted
bilaterally into a large antecubital vein. Ten milliliters of blood were
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wilhdrawn simultaneously IVom each arm at baseline and in the last
minute of each drug infusion period and collected into acidified
buffered citrate (Biopool Stabilyte, Umea) for t-PA assays and citrate
(Monovette, Sarstedt, Numbreeht) for plasminogen activator inhibi¬
tor (PAI) type-1 (PA1-1) assays. Samples were kept on ice before
being centrifuged at 2000g for 30 minutes at 4°C. Platelet-free
supernatant was decanted and stored at —80°C before assay. Plasma
t-PA and PAI-1 antigen concentrations were determined using
enzyme-linked immunosorbent assays and plasma t-PA activity by a
photometric method.23
Protocol Design
After 30-minute equilibration with 0.9% saline, patients received an
intra-brachial infusion of Lys-des-Arg'-bradykinin (I, 3, and 10
nmol/min) and bradykinin (30, 100, and 300 pmol/min) on one occasion
(agonist protocol), and Lys-[Leu8]-des-Arg''-bradykinin (1, 3, and 10
nmol/min) and norepinephrine (60, 180, and 540 pmol/min) on the other
(antagonist protocol). .Study drugs were infused in random order for 10
minutes at each dose and separated by a 20-minute infusion of 0.9%
saline.
Data Analysis and Statistics
Unless stated, all data are expressed as mean±SEM. Human umbil¬
ical vein responses are expressed as a percentage of the maximal
contraction to 60 mmol/L KC1 obtained at the end of each experi¬
ment. Plethysmography data were extracted from chart data files and
forearm blood flows were calculated as described previously.'6
Estimated net release of t-PA antigen and activity were defined as the
product of the infused forearm plasma flow (based on the mean
hematocrit and forearm blood flow) and the concentration difference
between the infused and noninfused arms.3-23 Statistical analyses
were performed using analysis of variance (ANOVA) and statistical
significance was taken at the 5% level.
Results
Human Umbilical Vein Studies
Immunohistochemistry confirmed intense immunolabeling of
both B, and B: receptors on human umbilical vein (Figure 1,
available online at http://atvb.ahajournals.org). Consistent
with previous work,18-20 bradykinin and Lys-des-Arg''-
bradykinin caused dose-dependent constriction of human
umbilical vein rings (Figure 1; P<0.001 for both). Lys-
[Leu*]-des-Arg',-bradykinin and B9340 caused -10-fold
rightward shift and F1OE-140 caused a modest leftward shift
in the dose response curve for Lys-des-Argv-bradykinin
(Figure la; P<0.001, /J<0.001, and P<0.05, respectively).
In contrast, HOE-140 and B9340, but not Lys-[Leu8]-des-
Arg''-bradykinin, caused a rightward shift in the dose re¬
sponse curve for bradykinin (Figure lb; P<0.001, P<0.001,
and P=not significant, respectively).
Clinical Study
Patients were predominantly male with mild to moderate
congestive heart failure caused by ischemic heart disease
(Table). There were no significant differences in heart rate,
blood pressure, or baseline forearm blood flow during or
between study days (Table I, available online at http://
atvb.ahajournals.org). Compared with losartan, plasma ACE
activity (42.2±11 versus 10.5 ±6.1 U/L, respectively;
P<0.05) and angiotensin II concentrations (24.4±6.3 versus
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Figure 1. Contraction of umbilical vein rings to (a) Lys-des-Arg9-
bradykinin (black circles, solid line) and (b) bradykinin alone (black
circles, solid line) or in the presence of Lys-[Leu8]-des-Arg9-
bradykinin (1 /xmol/L; white circles, fine dash), HOE-140 (1 p.mol/L;
white triangles, large dash), or B9340 (1 rtmol/L; white square,
intermittent dash), a, Lys-[Leu8]-des-Arg°-bradykinin and B9340
caused a rightward shift and HOE-140 caused a modest leftward
shift in the dose response curve for Lys-des-Arg9-bradykinin
(P<0.001, P<0.001, and P<0.05, respectively; ANOVA). b, HOE-
140 and B9340, but not Lys-[Leu8]-des-Arg9-bradykinin, caused a
rightward shift in the dose response curve for bradykinin (P<0.001,
P<0.001, and P=not significant, respectively; ANOVA).
Forearm Blood Flow
Bradykinin (P<0.000l for all), but not Ly.s-des-Arg9-
bradykinin (P=not significant for all), caused dose-
dependent vasodilatation in all studies (Figure 2).









































Data are expressed as number of patients or mean±SEM unless indicated.
ACE indicates angiotensin-converting enzyme; DCM, idiopathic dilated
cardiomyopathy; IHD, ischemic heart disease; LVEDD, left ventricular end
diastolic diameter; NYHA, New York Heart Association.
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Figure 2. Effect of bradykinin, Lys-des-Arg9-bradykinin, Lys-
[Leu8]-des-Arg9-bradykinin, and norepinephrine on forearm
blood flow in patients treated with enalapril (black circles), losar-
tan (white circles), or after ACE inhibitor withdrawal (crosses).
*P<0.05, |P<0.005 by ANOVA.
patients treated with enalapril compared with Iosartan
(/J<0.005; Figure 3) or ACE inhibitor withdrawal (P<0.05;
Figure 2).
Norepinephrine (P<0.0005 for all), but not Lys-[LcuB]-
des-Arg'-bradykinin (P= not significant for all), caused dose-
dependent vasoconstriction in all studies (Figure 2).
Fibrinolytic Factors
Release of t-I'A
Bradykinin (PC0.00I for all), but not Lys-des-Arg9-
bradykinin (P=not significant for all), caused dose-
dependent increases in plasma concentrations of t-PA antigen
and activity in the infused arm and net release of t-PA antigen
and activity in all studies (Figures 3 and 4). The bradykinin-
mediated increase in plasma t-PA antigen and activity in the
infused arm and net release of t-PA antigen and activity were
augmented in patients treated with enalapril compared with
losartan (P<0.()005 for all) or ACE inhibitor withdrawal
(P<0.005 for all; Figures 3 and 4).
Consistent with systemic overspill,3 bradykinin caused
dose-dependent increases in plasma t-PA antigen and activity
concentrations in the non-infused arm with enalapril therapy,
and plasma t-PA antigen alone after ACE inhibitor with¬
drawal (P<.0001 for all; Figure 3). Enalapril augmented the
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Figure 3. Effect of bradykinin and Lys-des-Arg9-bradykinin on
plasma t-PA antigen and activity concentrations in the infused
and noninfused arm in patients treated with enalapril (black cir¬
cles), losartan (white circles), or after ACE inhibitor withdrawal











Figure 4. Effect of bradykinin on net release of t-PA antigen and
activity in patients treated with enalapril (black circles), losartan
(white circles), or after ACE inhibitor withdrawal (crosses).
*P<0.0001 by ANOVA.
increase in t-PA compared with losartan therapy or ACE
inhibitor withdrawal (P<0.01 for both; Figure 3).
Plasma PAI-1 Antigen
There were no significant differences in basal PAI-1 antigen
concentrations between study days (data on file). Consistent
with an increase in PAI-l-mediated clearance after marked
t-PA release,24 and a potential time effect,25 plasma PAI-1
antigen concentrations declined during infusion of bradykinin
in both the infused (47.6±7.9 ng/mL at baseline versus
43.8±7 ng/mL during bradykinin 300 pmol/min; /J<0.05)
and noninfused arms (51 ±8.2 ng/mL at baseline versus
44.5±7 ng/mL during bradykinin 300 pmol/min; P<0.05) in
patients treated with enalapril but not losartan or during ACE
inhibitor withdrawal.
Discussion
This is the first study to characterize the potential vasomotor
and fibrinolytic role of the vascular B, kinin receptor in vivo.
We have demonstrated that the peptidic B, receptor agonist,
Lys-des-Arg9-bradykinin. and antagonist, Lys-[Leu"]-dcs-
Arg9-bradykinin, have no effect on vascular tone or endothe¬
lial t-PA release in the presence or absence of ACE inhibition.
In contrast, and consistent with our previous unblinded and
nonrandomized data,3 ACE inhibition markedly augmented
the vascular actions of bradykinin mediated via the B,
receptor. We conclude that the B, receptor does not appear to
have a major vasomotor or fibrinolytic role in the forearm
circulation of patients with heart failure treated with chronic
ACE inhibition.
Our findings are in contrast to previous in vitro and animal
work demonstrating vasodilatation after B, receptor slimula-
tion.6-9-'2 Before concluding that the B, kinin receptor does
not mediate vasodilatation or endothelial l-PA release in the
forearm circulation of patients with heart failure, we must
first consider the following possibilities: the doses of the
Lys-des-Argl,-bradykinin and Lys-[Leu8]-des-Arg9-
bradykinin used in this study were inadequate; the custom-
made peptides lacked biological activity; or the extent of
ACE inhibition was insufficient to upregulale B, receptor
expression.
We infused Lys-des-Arg9-bradykinin at a dose that was at
least 20-fold greater than that previously shown to produce
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50% of the maximal hypotensive response in both primate
(EC50 = 0.1 pmol/kg)6 and rodent studies (EC50 == 0.3
pmol/kgj." Similarly, Lys-| Leu8]-des-Arg9-bradykinin was
infused at a dose 20-fold greater than that previously shown
to abolish B, receptor-mediated vasomotor responses in
animal models in vivo.6 " To address the issue of biological
activity, we examined vasomotor responses to the custom-
manufactured B| agonist and antagonist in isolated human
umbilical vein.20 The concentration-response curves obtained
for Lys-des-Arg'-bradykinin and Lys-[Leu"]-des-Arg'J-
bradykinin were comparable with data from previous stud¬
ies18'20 and confirm efficacy at concentrations predicted to be
achieved in the infused human forearm circulation.
Previous rodent studies have demonstrated that besides
cardiovascular inflammation, chronic ACE inhibition upregu-
latcs functional vascular B, receptor expression.0 We have
examined B| receptor function in patients with heart failure
treated with an effective evidence based dose of enalapril.21
Moreover, plasma concentrations of angiotensin II and ACE
activity confirmed significant inhibition of the renin-angio¬
tensin system with enalapril at this dose. From our findings,
therefore, we can conclude that the B| kinin receptor does not
mediate vasodilatation or endothelial t-PA release in patients
with mild to moderate heart failure treated with long-term
ACE inhibitor therapy.
We have previously demonstrated that combined B, and B2
receptor blockade, but not B2 receptor blockade, causes
peripheral vasoconstriction in patients with heart failure
treated with ACE inhibition. In our current study, however,
selective B, receptor antagonism had no effect on peripheral
vascular tone. One potential explanation for this discrepancy
is that the B, receptor may only mediate the vasomotor effects
of kinins in the absence of B2 receptor-mediated signaling. In
support of this hypothesis, the B, and B2 kinin receptors are
coupled to similar G-protein subtypes and share the same
intracellular signaling pathways.15 In transgenic mice lacking
the B2 kinin receptor, the B, receptor is upregulated and
assumes vascular functions normally associated with the B2
receptor.26 Moreover, consistent with these data, we have
demonstrated that the B2 receptor antagonist, HOE-140,
augments the vasomotor responses to the B, agonist, Lys-des-
Arg'-bradykinin, in human umbilical vein in vitro. Future
studies examining the effects of B, receptor agonism and
antagonism during concomitant administration of HOE-140
may help clarify the issue of kinin receptor cross-talk in the
peripheral circulation of patients with heart failure.
Study Limitations
It has been suggested that the extent of the inflammatory
response in patients with congestive cardiac failure correlates
with the severity of underlying heart failure.27 We have
examined B, receptor function in patients with mild to
moderate (New York Heart Association class II or III) heart
failure. We cannot exclude the possibility that vascular B,
receptor expression may be restricted to patients with severe
end-stage heart failure. In addition, the B, kinin receptor has
been implicated in a number of alternative biological pro¬
cesses, including leukocyte trafficking28 and ischemia-
induced angiogenesis.29 It remains possible that B, receptors,
mediating processes other than vasodilatation or endogenous
fibrinolysis, may be present in the human forearm vascula¬
ture. Finally, we have examined B,-mediated responses in the
forearm circulation of patients with heart failure. Specific
vascular beds may differ in their response to B, agonists and
the current findings cannot be extrapolated to the entire
vasculature.
In conclusion, contrary to data from animal studies, we
have demonstrated for the first time to our knowledge that the
B, kinin receptor does not mediate vasodilatation or endothe¬
lial t-PA release in the peripheral circulation of patients with
heart failure treated with long-term ACE inhibition. Our
findings suggest that the beneficial vascular effects of ACE
inhibitor therapy attributed to kinins are restricted to those
mediated by the B2 receptor and do not support a major role
for the B, kinin receptor as a potential therapeutic target in
patients with heart failure.
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Summary
lntra-artcrial desmopressin caused dose and time dependent increas¬
es (p <0.00! for all) in forearm blood flow (all doses) and plasma
tissue plasminogen activator (t-PA) concentrations (desmopressin
>70 ng/min). Although plasma t-PA concentrations rose in both fore¬
arms, there was a modest local release of t-PA in the infused forearm
(14 ng/100 mL of tissue/min, p <0.05). At desmopressin doses
>300 ng/min, plasma von Willebrand faclor (vWf) and Factor VilPC
concentrations rose in both forearms (p <0.001) and correlated with
the rise in interleukin-6 concentrations (r = 0.92, p <0.001; r = 0.85,
p = 0.002 respectively). Neither desmopressin nor substance P caused
t-PA, vWfor Factor VIIPC release in the patients, although desmopres¬
sin increased plasma interleukin-6 concentrations as in healthy volun¬
teers. We conclude that desmopressin releases t-PA, vWf and Factor
VI11 :C predominantly via systemic mechanisms, possibly mediated by
cytokine release Patients with type 3 vWD appear to have a generalised
failure to release l-PA acutely despite a normal interleukin-6 response
to desmopressin infusion.
Introduction
Desmopressin (l-deamino-8-arginine vasopressin) increases plasma
levels of factor VIIPC, von Willcbrand factor (vWF) and tissue plasmi¬
nogen activator (t-PA) in healthy volunteers and patients with mild hae¬
mophilia A and mild von Willcbrand disease (vWD) (1, 2). Patients
with severe (type 3) vWD are usually (3), but not universally (4), unre¬
sponsive to desmopressin. Although the precise mode of action of
desmopressin remains incompletely understood, in vitro endothelial
cell culture studies have suggested that desmopressin at very high con¬
centrations induces endothelial vWF release by u mechanism which is
dependent on the presence of peripheral blood monocytes (5), possibly
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cular Research, Department of Cardiology, University of Edinburgh, Royal
Infirmary, Lauriston Place, Edinburgh, EH3 9YW, Scotland, UK - Tel.: +44-
131-536 2749; Fax: +44-131-536 2744; E-Mail: d.e.newby@ed.ac.uk
mediated by the production of a second messenger molecule (6). How¬
ever, the results of such in vitro experiments, must be interpreted with
caution, as they may fail accurately to reflect the function of the endo¬
thelium in vivo.
In addition to its haemostatic and fibrinolytic actions, desmopressin
causes vasodilatation and, when administered systemically, may lead to
facial flushing, an increase in heart rale and a fall in blood pressure. It
has been hypothesised that the consequent systemic neurohumoral re¬
sponse to desmopressin induced vasodilatation may contribute to, or
even mediate, the haemostatic and fibrinolytic response to desmopres¬
sin infusion (7). To avoid these confounding systemic effects, the use of
locally active intra-arterial infusion of drugs can be used to investigate
the acute local release of t-PA and vWf in the forearm circulation of
man (8-14). We have previously been able to demonstrate that sub¬
stance P, an endothelium- and neurokinin type 1 (NK,) receptor-depen¬
dent vasodilator (9), causes a selective dose-dependent release of t-PA
from the human forearm without causing significant release of vWf or
plasminogen activator inhibitor type I (PAI-1) despite prolonged infu¬
sions of up to 2 h (12,13). In contrast, intra-arterial infusions of desmo¬
pressin have either failed to find (8), or shown substantial (II), local re¬
lease of t-PA in the human forearm. The reasons for this apparent dis¬
parity, and the role of monocyte activation in this process, are unclear.
Endothelial cells arc able to store and rapidly release active vWf
multimers, especially after vascular injury (15). Increased plasma
concentrations of both Factor VIIPC and vWf have been associated
with chronic inflammatory conditions (16, 17) including atherosclero¬
sis (18-20). Moreover, the synthesis and release of Factor VIIPC may
be regulated by monokines and cytokines, such as interleukin-6 (1L-6)
(21), which, in part, mediate the acute phase response (22). Given the
apparent in vitro dependence of desmopressin induced vWf release on
the presence ofmonocytes, we hypothesised that IL-6 may mediate, or
contribute to, the haemostatic or fibrinolytic response to desmopressin
infusion.
The aims of the present study were to assess the acute release of
haemostatic (vWf and Factor VIIPC), fibrinolytic (t-PA and PAI-1) and
cytokine (IL-6) factors within the forearm vascular bed in response to
intra-arterial desmopressin using (a) an ascending dose design to define
the dose at which systemic effects intervene, and then (b) prolonged in¬
fusions of a locally (70 ng/min) and a systemically (700 ng/min) active
dose. In order to explore further the mechanism of haemostatic, fibrin¬
olytic and cytokine factors release, the responses to intra-arterial sub¬
stance P and desmopressin infusion were evaluated in two patients with
severe type 3 vWD.
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Methods
Subjects mil Patients
Sixteen healthy non-smoking men aged between 20 and 34 years and two
male patients with type 3 vWD aged 26 and 45 years participated in the studies
which were undertaken with the approval of the local research ethics commit¬
tee and in accordance with the Declaration of Helsinki. The written informed
consent of each subject was obtained before entry into the study. None of the
subjects received vasoactive or non-steroidal anti-inflammatory drugs in the
week before each phase of the study, and all abstained from alcohol for 24 h,
and from food and caffeine-containing drinks for at least 5 h, before each study.
All studies were performed in a quiet, temperature controlled room maintained
at 22-24° C.
Drugs and Intra-arterial Administration
The brachial artery of the non-dominant arm was cannulated with a 27-stan-
dard wire gauge steel needle (Cooper's Needle Works Ltd, Birmingham, UK)
under 1% lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings Langley,
UK) local anaesthesia and attached to a 16-gattge epidural catheter (Portex Ltd,
Hythe, UK). Patency was maintained by infusion of saline via an IVAC P1000
syringe pump (IVAC Ltd, Basingstoke, UK). The total rate of intra-artcrial in¬
fusions was maintained constant throughout all studies at 1 mL/min. Desmo¬
pressin (DDAVP* Ferring) and substance P (Clinalfa AG, Laufelfingen, Swit¬
zerland) were administered following dissolution in saline (0.9%: Baxter
Healthcare Ltd, Thetford, UK).
Forearm BloodFlow and Blood Pressure
Blood flow was measured in both forearms by venous occlusion plethys¬
mography using mercury-in-silastic strain gauges applied to the widest part of
the forearm (23, 24). During measurement periods the hands were excluded
from the circulation by rapid inflation of the wrist cuffs to a pressure of
220 mmllg using E20 Rapid Cuff Inflators (D. E. Hokanson Inc, Washington,
USA). Upper arm cuffs were inflated intermittently to 40 mmHg for 10 s in eve¬
ry 15 s to achieve venous occlusion and obtain plethysmography recordings.
Analogue voltage output from an EC-4 Strain Gauge Plethysmograph (D. E.
Hokanson) was processed by a PowcrLab® analogue-to-digital converter and
Chart'"" v3.5.7 software (AD Instruments Ltd, Castle Hill, Australia) and re¬
corded onto a Macintosh PowcrBook 520c computer (Apple Computers Inc,
Cupertino, USA). Calibration was achieved using the internal standard of the
plethysmograph.
Blood pressure was monitored in the non-infused arm at intervals through¬
out each study using a semi-automated non-invasive oscillometry sphygmom¬
anometer (Takeda UA 751, Takeda Medical Inc, Tokyo, Japan) (25).
Venous Sampling and Assays
Venous cannulae (17G) were inserted into large subcutaneous veins of the
antecubital fossa in both arms as described previously (14). Fifteen ml ofblood
was withdrawn simultaneously from each arm and collected into acidified buf¬
fered citrate (BiopooD Stabilytc™, Umea, Sweden; for t-PA assays), citrate
(Monovette*, Sarstedt, Numbrecht, Germany: for PA1-I, vWf and Factor
VIII:C assays) and ethylene diamine tetraacetic acid (Monovette®; for IL-6 as¬
says and determination of haematocrit) tubes, and kept on ice before being cen-
trifuged at 2,000 g for 30 min at 4° C. Platelet free plasma was decanted and
stored at -80° C before assay (26).
Plasma PA1-1, t-PA and IL-6 antigen concentrations were determined using
an enzyme-linked immunosorbent assay; Coaliza® PA1-1, Coaliza® t-PA
(Chromogenix AB, Mdlndal, Sweden) and Quantikinc® HS (R&D Systems
Europe, Abingdon, UK) respectively. Plasma PAI-1 and t-PA activities were
determined by a photometric method, Coatest® PAI-I and Coaset® t-PA (Chro¬
mogenix AB). lntra-assay coefficients of variation were 5.5%, 7.0% and 5.9%
for t-PA, PAI-1 and IL-6 antigen, and 2.4% and 4.0% for t-PA and PAI-1 activ¬
ity, respectively. Interassay coefficients of variability were 4.0%, 7.3%. 9.9%,
4.0% and 7.6% respectively. The sensitivities of the assays were 0.5 ng/ml,
2.5 ng/ml, 0.09 pg/mL, 0.10 lU/ml and 5 AU/ml respectively. Von Willebrand
factor (vWf) antigen was determined using an enzyme-linked immunosorbent
assay (Dako A/'S, Glostrup, Denmark), and vWf activity by the measurement of
platelet aggregation in response to ristocetin (ristocetin co-factor) (27), with as¬
say sensitivities of 0.10 lU/'mL and 0.10 lU/'mL respectively. The intra-assay
coefficients of variability were 5.2% and 6.6%, and interassay were 7.3% and
<8% respectively. Factor VllhC procoagulant activity was determined using a
standard one stage assay on an ACL-3000+ coagulometer (Instrumentation
Laboratory, Warrington, UK). Haematocrit was determined by capillary tube
ccntrifugation and was obtained from the infused forearm at baseline and at the
end of the study protocol.
Study Design
Subjects and patients rested recumbent throughout each study. Strain
gauges and cuffs were applied and the brachial artery of the non-dominant arm
cannulated. Measurements of forearm blood flow were made between 3 and
6 min of each infusion period unless otherwise stated. Before participating in
one of the following protocols, saline was infused for the first 30 min to allow
time for equilibration, with forearm blood flow measured every 10 min and the
final measurement taken as basal blood flow.
Healthy Volunteer Studies: Protocol I
Eight subjects received an incremental infusion of desmopressin at 10, 30,
100, 300 and 1000 ng/min for 6 min at each dose (total desmopressin dose of
13.08 pg) followed by a 20 tnin saline infusion. Venous blood samples were
obtained from both forearms at baseline, during desmopressin infusion at 10,
100 and 1000 ng/min, and 20 min after cessation of the final desmopressin in¬
fusion of 1000 ng/min. Venous sampling was performed following blood flow
measurements and necessitated extending the desmopressin infusion to 10 min
at the 10, 100 and 1000 ng/min doses.
Healthy Volunteer Studies: Protocol 2
Eight subjects received desmopressin infusion at 70 ng/min for 30 min fol¬
lowed by desmopressin at 700 ng/min for 30 min (total dose of 23.1 pg), before
infusing saline for the final 60 min. Venous blood samples were obtained from
both forearms at baseline, at 10. 20 and 30 min during each desmopressin infu¬
sion of 70 and 700 ng/min, and 20 and 60 min after cessation of the desmopres¬
sin infusion.
Patient Study
The two patients with type 3 vWD (patient I; vWf <0.10 lU/mL, ristocetin
co-factor <0.10 lU/mL, Factor VIILC 0.05 lU/mL; patient 2: <0.10 lU/mL,
<0.10 lU/mL, 0.04 lU/mL respectively) received an infusion of substance P at
4,8 and 16 pmol/min for 10 min at each dose (12) followed by 30 min infusions
of saline and desmopressin at 700 ng/min (total dose of 21 pg), before a final
infusion of saline for 60 min. Venous blood samples were obtained from both
forearms before, at 10, 20 and 30 min during substance P and DDAVP infu¬
sions and 20 and 60 min after cessation of the desmopressin infusion. On com¬
pletion of the study protocol, a bolus of Factor VIII concentrate (Haemate P,
Centeon, Eastbourne, UK) was administered prior to removal of the cannulae in
order to reduce the risk of bleeding.
Data Analysis andStatistics
Plethysmography data were extracted from the Chart™ data files and fore¬
arm blood flows were calculated for individual venous occlusion cuff inflations
by use of a template spreadsheet (Excel v5.0; Microsoft Corporation, Cam¬
bridge. USA). Recordings from the first 60 s after wrist cuff inflation were not
used because of the variability in blood flow responses that this causes (28).
Usually, the last five flow recordings in each 3 min measurement period were
calculated and averaged for each arm. Mean arterial pressure was defined as the
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Fig. I Mean arterial pressure (open squares), heart rate (solid squares), and blood flow in the infused (solid circles) and non-infused (open circles) forearms dur¬
ing saline and desmopressin infusion. Protocol 1, left panel; protocol 2, right panel. One-way ANOVA: p <0.001 for all responses except mean arterial pressure,
Two-way ANOVA: p = not significant (infused vs. non-infused forearms), paired t-test: *p <0.05 (vs. baseline)
sum of the diastolic blood pressure and a third of the pulse pressure. Estimated
net release of t-PA activity and antigen was defined as the product of the in¬
fused forearm plasma flow (based on the haematocrit, Met and the infused fore¬
arm blood flow, FBF) and the concentration difference between the infused
([t-PA]lnf) and non-infused arms ([t-PA]Non.inf).
Estimated net t-PA release = FBF X {1-Hctj X {[t-PA]lnf- [t-PA]Non.infJ
Data were examined, where appropriate, by analysis of variance (ANOVA)
with repeated measures, regression analysis and two tailed paired Student's
t-test using Excel v5.0 (Microsoft). All results arc expressed as mean ± standard
error of the mean. Statistical significance was taken at the 5% level.
Results
Healthy volunteer and patient characteristics are shown in Table
Healthy Volunteer Studies: Protocol I
Desmopressin infusion caused dose-dependent increases in blood
flow in the infused forearm (Fig. 1; ANOVA, p <0.001) at all doses and
in the non-infused forearm at doses >300 ng/min. Desmopressin also
caused an increase in heart rale (ANOVA, p <0.001) but no fall in mean
arterial pressure (ANOVA, p = 0.164) at doses >300 ng/min (Fig. 1).
Plasma t-PA antigen and activity concentrations increased in a dose-
dependent manner in both forearms (Fig. 2; ANOVA, p <0.001) during
desmopressin infusion and correlated with changes in heart rate (in¬
fused arm; r = 0.46, p = 0.003 and r = 0.69, p <0.001: non-infused arm;
r = 0.41, p = 0.009 and r = 0.64, p <0.001 respectively) and non-infused
forearm blood flow (infused arm; r = 0.45, p = 0.003 and r = 0.68,
p <0.001: non-infused arm; r = 0.55, p <0.001 and r = 0.72, p <0.001
respectively). Overall, there were no significant differences in plasma
Healthy Volunteers
Protocol 1 Protocol 2
Patients
Number 8 8 2
Age (years) 24 ± 2 25 ±2 36 ± 10
Height (m) 1.78 ± 0.03 1.85 ± 0.02 1.76 ±0.04
Weight (kg) 80 ± 3 80 ±2 86 ±4
Body Mass Index (kg/m2)
(m2)
25 ± 1 23 ± 1 28 ±0
Body Surface Area 2.02 ± 0.04 1.98 ±0.05 2.05 ± 0.07
Heart Kate (/min) 57 ± 3 61 ±3 61 ± 8
Blood Pressure Systolic (mmHg) 139 ± 2 134 ± 6 146 ± 2
Diastolic (mmHg) 67 ± 2 72 ±5 87 ±7
Haematocrit Basal 0.398 ± 0.009 0.375 ± 0.007 0.398 ± 0.015
Final 0.399 ± 0.010 0.376 ± 0.006 0.398 ± 0.015
Table 1 Healthy volunteer and patient characteristics
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Fig. 2 Plasma l-PA antigen (circles) and activity (squares) concentrations in the infused (solid symbols) and non-infused (open symbols) forearms during saline
and desmopressin infusion. Protocol 1, left panel; protocol 2, right panel. One-way ANOVA: p <0.001 for all responses, Two-way ANOVA: p = not significant





t-PA antigen and activity concentrations between the infused and non-
infused arms during protocol 1 (two-way ANOVA, p = 0.654 and 0.361
respectively). However, there was a small but significant increase in the
plasma t-PA antigen concentration difference between the forearms
(Table 2; ANOVA, p = 0.009) and in the net local release of t-PA
antigen and activity from the infused forearm (Table 2; ANOVA,
p <0.007).
Plasma vWf and Factor VllLC concentrations increased during, and
20 min following, the infusion of desmopressin at 1000 ng/min
(Fig. 3; ANOVA, p <0.001). There were no significant differences in
plasma vWf and Factor VU1:C concentrations between the infused and
non-infused arms (two-way ANOVA, p = 0.853 and 0.595) nor in the
concentration difference between the forearms or the estimated net lo¬
cal release. The rise in plasma vWf and Factor VII1:C concentrations
correlated with each other (r = 0.46, p <0.001) and appeared to lag
20-30 min behind the increases in plasma t-PA concentrations.
There were no significant changes in plasma PA1-1 antigen and ac¬
tivity concentrations during protocol 1 (Table 2).
Plasma 1L-6 concentrations increased in both forearms (Fig. 3;
ANOVA, p <0.001) during, and 20 min following, the infusion of
desmopressin at 1000 ng/min. The increase in plasma IL-6 concentra¬
tions appeared to be greater in the infused forearm but this was not sta¬
tistically significant (two-way ANOVA, p = 0.126 vs. non-infused fore¬
arm). Plasma IL-6 concentrations correlated with plasma vWf (r = 0.40,
p <0.001), Factor VllLC (r = 0.24, p = 0.030), and t-PA antigen
(r = 0.46, p <0.001) and activity (r = 0.46, p <0.001) concentrations.
The time course of the rise in mean plasma IL-6 concentrations ap¬
peared to be similar to that for mean plasma vWf (r = 0.92, p <0.001)
and Factor VllLC (r = 0.85, p = 0.002) concentrations.
Healthy Volunteer Studies: Protocol 2
Desmopressin infusion increased blood flow in the infused forearm
(Fig. 1; ANOVA, p <0.001) at both doses and in the non-infused fore¬
arm at 700 ng/min (ANOVA, p = 0.028). Compared with the blood
flow after 10 min, the infused forearm blood flow was greater after
30 min of 70 ng/min of DDAVP (paired t-test; p = 0.010) and lower
after 30 min of 700 ng/min (paired t-test; p = 0.035). There was an
increase in heart rate (ANOVA, p <0.001) without alteration in mean
arterial pressure during, and following, desmopressin infusion at
700 ng/min (Fig. 1).
Plasma t-PA antigen and activity concentrations increased in a time-
and dose-dependent manner in both the infused and non-infused fore¬
arms (Fig. 2; ANOVA, p <0.001) during desmopressin infusion. Al¬
though increases occurred in the infused forearm at both doses, plasma
t-PA concentrations rose in the non-infused forearm only during infu¬
sion of desmopressin at 700 ng/min. Overall, there were no significant
differences in plasma t-PA antigen and activity concentrations between
the infused and non-infused arms during the study (two-way ANOVA,
p = 0.443 and 0.515 respectively). However, there was a small but sig-
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Fig. 3 Plasma von Willebrand factor (circles), Factor V1II:C (squares) and interleukin-6 (triangles) concentrations in the infused (solid symbols) and non-infused
(open symbols) forearms during saline and desmopressin infusion. Protocol 1, left panel; protocol 2, right panel. One-way ANOVA: p <0.001 for all responses,
Two-way ANOVA: p = not significant (infused vs. non-infused forearms), Paired t-test: 'p <0.05, 'p = 0.07 (vs. baseline)
nificant increase in the plasma t-PA antigen and activity concentration
difference between the forearms (Table 3; ANOVA, p = 0.037 and
p = 0.003 respectively) and in the net local release of l-PA antigen and
activity from the infused forearm (Table 3; ANOVA, p <0.001 for
both).
Plasma vWf and Factor V111:C concentrations increased during, and
for up to 60 min following, the infusion of desmopressin at 700 ng/min
(Fig. 3; ANOVA, p <0.001). There were no significant differences in
plasma vWf and Factor Vlll.C concentrations between the infused and
non-infused arms (two-way ANOVA, p = 0.330 and p = 0.650 respec¬
tively) nor in the concentration difference between the forearms or the
estimated net local release. Again, the rise in plasma vWf and Factor
V111:C concentrations were closely correlated with each other (r = 0.76,
p <0.001) and appeared to lag 20-30 min behind the increases in plas¬
ma t-PA concentrations.
There were no significant changes in plasma PA1-1 antigen and ac¬
tivity concentrations during protocol 2 although there was a trend for a
reduction in plasma PAI-1 concentrations during the saline washout
(Table 3).
Plasma 1L-6 concentrations increased in both forearms (Fig. 3;
ANOVA, p <0.001) during, and for up to 60 min following, the infu¬
sion of desmopressin at 700 ng/min. The increase in plasma 1L-6 con¬
centrations appeared to be greater in the infused forearm but this was
not statistically significant (two-way ANOVA, p = 0.137 vs. non-in-
fused forearm). Plasma 1L-6 concentrations correlated with plasma
vWf (r = 0.59, p <0.001), Factor VIII:C (r = 0.50, p <0.001), and t-PA
antigen (r = 0.43, p <0.001) and activity (r = 0.24, p = 0.004) concentra¬
tions. The time course of the rise in mean plasma 1L-6 concentrations
appeared to be similar to that for plasma vWf (r = 0.87, p <0.001) and
Factor V111:C (r = 0.84, p <0.001) concentrations.
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Baseline Desmopressin Infusion Washout
Desmopressin (ng/min) 0 10 100 1000 0
Time (min) 0 10 26 42 62
t-PA Antigen Concentration Difference -0.0 ±0.1 0.0 ± 0.2 0.4 ± 0.1J 1.2± 0.3J -0.4 ±0.6 '
Between Forearms
(ng/mL)
Net Local (Infused) -0.0 ±0.1 -0.1 ± 0.5 2.7 ± 0.9J 13.5 ± 3.5J -4.4 ±2.9 «
Forearm Release
(ng/100 mL/min)
t-PA Activity Concentration Difference -0.0 ±0.1 0.5 ± 0.4 1.0± 0.4J 1.4 ± 0.6J -0.1 ±0.3 •
Between Forearms
(lU/mL)
Net Local (Infused) -0.1 ± 0.2 1.2 ± 1.0 6.4 ± 2.5J 15.2 ± 6.5 J -0.6 ±1.7 «
Forearm Release
(IU/100 mL/min)
PAI-1 Antigen i Non-infused Arm 19 ± 4 19 ± 3 20 ±5 17 ± 4 18 ± 5
(ng/mL)
Infused Arm 16 ± 3 18 ± 3 19 ± 4 17 ± 4 16 ± 4
PAI-1 Activity Non-infused Arm 5 ± 2 9 ± 2 7 ± 2 5 ±2 4 ± 2
(AU/mL)
Infused Arm 5 ± 1 6 ± 1 5 ± 1 4 ± 1 5 ± 2
Table 2 Healthy Volunteer Studies: Protocol 1. Differ¬
ence in forearm plasma tissue plasminogen activator
(t-PA) concentrations and estimated net release of t-PA
in the infused forearm, and plasma plasminogen activa¬
tor inhibitor type 1 (PAI-1) antigen and activity concen¬
trations in both forearms
One-way ANOVA: *p=s0.009, tp=0.056
Paired Mest: Jp<0.05 (v.v baseline)
Patient Studies
The study was well tolerated and there was no evidence of hematoma
formation at the sites of arterial or venous puncture in either patient. In
both patients, forearm blood flow appeared to increase only in the in¬
fused forearm with substance P infusion but in both forearms with de¬
smopressin infusion (Fig. 4). Baseline plasma PAI-1 antigen and activ¬
ity concentrations were 40 ± 10 ng/mL and 11 ± 2 AU/mL in the in¬
fused forearm, and 46 ± 8 ng/mL and 14 ± 3 AU/mL in the non-infused
forearm respectively. Baseline plasma vWf and Factor VIILC concen¬
trations were <0.01 lU/mL and 0.05 lU/mL respectively in both fore¬
arms. Throughout saline, substance P and desmopressin infusions, there
were no apparent changes in plasma t-PA (Fig. 5), PAI-1, vWf or Fac¬
tor VIILC concentrations. In contrast, plasma 1L-6 concentrations ap¬
peared to rise in both forearms following desmopressin but not sub¬
stance P infusion.
Discussion
We have shown that, at locally active doses (70-100 ng/min),
desmopressin causes a modest local release of t-PA in the forearm cir¬
culation without causing release of vWf or Factor VIILC. At doses
>300 ng/min, desmopressin causes systemic hacmodynamic effects and
marked increases in plasma t-PA, vWf and Factor VIILC concentra¬
tions. These systemic increases in vWf and Factor VIILC are closely
associated with changes in plasma IL-6 concentrations. Indeed, despite
the absence of a fibrinolytic or haemostatic response in patients with
type 3 vWD, plasma IL-6 concentrations were also elevated following
Saline 1 Substance P 1 Saline DDAVP Saline 1
■30 0 30 60 90 120 \i
Time (min)
Fig. 4 Mean arterial pressure (open squares), heart rate
(solid squares), and blood flow in the infused (solid cir¬
cles) and non-infused (open circles) forearms during sa¬
line, substance P (4, 8 and 16 pmol/min for 10 min at
each dose) and desmopressin (700 ng/min) infusion in
two patients with type 3 von Willebrand disease
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Fig. 5 Plasma tissue plasminogen activator (t-PA; cir¬
cles) antigen (solid lines) and activity (dashed lines), and
interleukin-6 (squares) concentrations in the infused
(solid symbols) and non-infused (open symbols) fore¬
arms during saline, substance P (4, 8 and 16 pmol/min
for 10 min at each dose) and desmopressin (700 ng/min)
infusion in two patients with type 3 von Willcbrand dis¬
ease
desmopressin, but not substance P, infusion. We conclude that desmo¬
pressin appears to release t-PA, vWf and Factor VII1:C predominantly
via systemic mechanisms which may, in part, be mediated by cytokine
release. The modest local release of t-PA induced by desmopressin may
be mediated by a ditecl action on the endothelium or indirectly via cy
tokines. Patients with type 3 vWD appear to have a generalised failure
to release t-PA acutely despite mounting a normal IL-6 response to
desmopressin infusion.
Our findings are al variance with those of Cash and colleagues (8)
who reported an absence of an effect of intra-arterial desmopressin
given at 100 ng/min for 10 min, although we detected a modest rise in
plasma t-PA concentrations (14% for antigen). Euglobulin clot lysis,
used by Cash, is a less sensitive method for detecting t PA release and
this may be the reason why his study failed to demonstrate an effect of
local intra-arterial desmopressin infusion. In agreement with a more
recent study (11), we find evidence of a modest local release of t-PA
Table 3 Healthy Volunteer Studies: Protocol 2. Difference in forearm plasma tissue plasminogen activator (t-PA) concentrations and estimated net release of
t-PA in the infused forearm, and plasma plasminogen activator inhibitor type 1 (PA1-1) antigen and activity concentrations in both forearms
Time (min)
Baseline Desmopressin 70 ng/min





t-PA Antigen Concentration Difference 0.2 ±0.1 0.3 ± 0.2 0.4 ± 0.2 0.2 ± 0.3 2.1 ±0.7 J 0.6 ± 0.4 0.7 ± 0.9 -0.7 ± 0.7 -0.6 ±0.7 f
Between Forearms
(ng/mL)
Net Local (Infused) 0.2±0.1 1.5 ± 1.2 1.4 ± 1.2 0.7 ±1.1 16.2 ± 4.7J 4.1 ±3.3 1.1 ±3.8 -3.3 ± 3.2 -3.3 ±1.9 *
Forearm Release
(ng/100 mL/min)
t-PA Activity Concentration Difference -0.5 ± 0.3 0.0±0.3 0.3 ± 0.4J 1.1±0.5{ 1.8±0.3J 0.8±0.2J -0.0±0.5 -0.4 ± 0.5 -0.8±0.7 f
Between Forearms
(IU/mL)
Net Local (Infused) -0.6 ±0.3 0.7 ±1.2 2.0 ±1.9 6.0 ± 2.5J 17.4 ± 3.9J 7.3±2.1J -0.6 ±4.8 -3.1 ±4.3 -2.7 ±2.6 *
Forearm Release
(IU/100 mL/min)
PAI-1 Antigen Non-infused Arm 37 ± 13 36 ± 13 39 ± 15 33 ± 12 33 ± 12 32 ± 12 30 ± 11 28 ± 8 24 ± 7§
(ng/mL)
Infused Arm 38 ± 13 41 ± 13 42 ± 12 40 ± 12 39 ± 12 37 ± 11 31 ±11 27 ±9 25 ± 7§
PAI-1 Activity Non-infused Arm
(AU/mL)
Infused Arm
12 ± 3 13 ± 3 12 ± 3 12 ± 3 11 ± 3
13 ± 4 10 ± 4 10 ± 4 10 ± 3 9 ± 3
11 ±3 10 ± 3
10 ± 3 10 ± 3
5 ± 2% 5 ± 2§
8±2| 4 ± 1J
One-way ANOVA: *p<0.001, fp<0.05
Paired /-test: Jp<0.05, §0.10>p>0.05 (vj baseline)
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during infusions of desmopressin at 70 and 100 ng/min. The estimated
net local release of t-PA was 13.5 ng/100 mL of tissue/min which
is similar to that previously reported by Wall and colleagues (11)
14.4 ng/100 mL of tissue/min.
Desmopressin induced vasodilatation and t PA release appear to bo
time-dependent, with a slow onset and offset of action, even when con¬
fined to locally active doses (11). These properties of desmopressin are
in marked contrast to those of other endothelium dependent stimulants
such as substance P and bradykinin. In the human forearm, local infu¬
sions uf substance P (12-14) and bradykinin (29) have a rapid onset and
offset of action (<5 min) and, in comparison to desmopressin, are able
to release 5-10-fold greater amounts of t-PA from the forearm (12, 29).
Indeed, in marked contrast to desmopressin, systemic doses of sub¬
stance P administered in the brachial artery of the forearm (12) cause a
substantial local release of t-PA with wide and significant differences
between the plasma t-PA concentrations of the infused and non-infused
forearms. Although some of these differences may reflect the pharma¬
cokinetics of the compounds, the infused forearm will have a local fore¬
arm concentration ~ 100-fold that of the systemic circulation and, in the
presence of a directly acting endothelial stimulant, such high local
concentrations should be reflected in substantial differences between
the plasma concentrations of the infused and non-infused forearms.
Substantial local release of l-PA did not occur with desmopressin infu¬
sion and the majority of the t-PA release occurred outwith the infused
forearm.
In the present study, desmopressin caused vasodilatation at all doses
used, t-PA release at doses >70 ng/min, and vWf and Factor VIILC re¬
lease at doses >300 ng/min. This apparent dose-dependence of respons¬
es to desmopressin may reflect a threshold effect on differing tissues
and receptors. In ex vivo studies (30, 31), desmopressin causes a rapid
onset and direct endothclium-dependent vasodilatation which is medi¬
ated through V3 receptors. However, desmopressin induced vWf re¬
lease appears to be dependent on the presence of monocytes (5) and
may he mediated by cytokines (22, 24). We, therefore, explored the re¬
lationship between 1L-6, a marker ofmoncyte activation, and the blood
flow, haemostatic and fibrinolytic responses to desmopressin infusion.
Wc have demonstrated that plasma 1L 6 concentrations rise in parallel
with vWf and Factor VIILC suggesting monocyte activation, possibly
through 1L-6, mediates the haemostatic response to desmopressin infu¬
sion.
Several studies have suggested that monocyte derived cytokines
may have a role in modifying fibrinolytic and coagulation responses
(32). Non-human primate studies indicate that 1L-6 can significantly
enhance the t-PA response to endotoxemia (33, 34). In human studies,
infusion of tumor necrosis factor in healthy volunteers (35) and patients
with cancer (36) is associated with marked increases in plasma t-PA
concentrations. Although we have only measured IL-6 concentrations,
it is equally possible that other, more rapidly mobilised, monocytic fac¬
tors may play a role ill mediating or augmenting the endothelial ltlcase
of t-PA, vWf or Factor VIILC. Moreover, although predominantly re¬
leased by monocytes, IL-6 is released by other cell types and the ob¬
served effects may not be directly attributable to monocytes alone. In¬
deed, in contrast to forearm skeletal muscle, adipocytes (37) and adi¬
pose tissue (38) can release significant amounts of IL-6.
Wc have previously demonstrated that substance P causes an isolat¬
ed increase in plasma t-PA concentrations without inducing vWf re¬
lease (12). In the present study, the differing time course of t-PA and
vWf release in response to desmopressin again indicates the presence of
separate and distinct endothelial storage pools and release mechanisms
for these factors. Impaired release of t-PA in response to venous occlu¬
sion and desmopressin has been previously reported in patients with
type 3 vWD (39-41). However, for the first time, we report the response
to high, locally active, concentrations of intra arterial desmopressin and
substance P in these patients. Despite different receptor mediated
mechanisms of endothelial cell activation (9, 30, 31), neither desmo
pressin nor substance P caused t-PA, vWf or Factor VIILC release in
these patients. Interestingly, desmopressin infusion was associated with
a similar increase in plasma IL -6 concentrations as with healthy volun
teers, suggesting normal desmopressin induced monocyte activation
but a generalised impairment in the release of endothelium derived
haemostatic and fibrinolytic factors.
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Editorial
Intracoronary infusions and the assessment of coronary blood
flow in clinical studies
Intracoronary drug administration may be desirable for a
number of reasons and is used in therapeutic, diagnostic,
interventional, and clinical research settings. One of the
main indications for intracoronary drug administration is
in the assessment of coronary blood flow either as a guide
to intervention or as a clinical research tool. There are
many methods of assessing coronary blood flow including
the use of the angiogram derived corrected TIMI (throm¬
bolysis in myocardial infarction) frame count' and the rate
of decorrelation of the radiofrequency signal from
intravascular ultrasound (IVUS) imaging catheters/ How¬
ever, the most direct and widely used method of assessing
coronary blood flow is the Doppler flow wire—a piezoelec¬
tric cell mounted on the lip of a 0.014 inch guide wire.1
The Doppler flow wire measures coronary blood flow
velocity and, in order to measure coronary blood flow,
knowledge of the cross sectional area of the vessel is
required. The latter is usually estimated using quantitative
coronary angiography (QCA), which assumes circular or
elliptical luminal geometry, although greater accuracy can
be obtained by using IVUS imaging catheters. Indices such
as coronary flow reserve—the ratio of maximal to basal
hyperaemic flow velocity—can be used to assess the func¬
tional severity of coronary stenoses and the dynamic integ¬
rity of the microcirculation without determining luminal
cross sectional area. However, fractional flow reserve,
which is measured using a pressure wire (guide wire with
ability to measure distal coronary artery pressure), is
increasingly being used to determine the functional sever¬
ity of coronary stenoses since it is more reproducible, lesion
specific, and less dependent on systemic haemodynamic
parameters.'1'
Clinical research studies assessing coronary vasomotor
responses to drug infusion have used endothelium
dependent and independent vasodilators as well as agonists
and antagonists of physiological mediators (table 1). The
magnitude and variability of coronary responsiveness is
highly dependent on the agent used and crucially on the
method of measurement and the mode of administration.
Assessment of coronary vasomotor responses: QCA
or IVUS
Although well established, QCA has many limitations in
the measurement of vasomotor and blood flow
responses.7 s It tends to underestimate the luminal area'
and functional severity of coronary stenoses.7 Contrast
agent injection not only necessitates the interruption of the
drug infusion and aspiration of the catheter,'" but may itself
be vasoactive and directly alter coronary blood flow and
confound measurements." Finally, many agents, especially
endothelium dependent vasodilators (for example, acetyl¬
choline, see fig l),have a near instantaneous onset and off¬
set of action, and performing QCA a minute after
injection'2 is likely to result in misleading measurements.
The use of IVUS can circumvent many of these
limitations and provide continuous ECG gated cross
sectional area and compliance measurements of the coron¬
ary artery. In addition, IVUS provides more detailed mor-
phometric information of the coronary artery including
plaque volume, composition, severity, and distribution.
Moreover, the combined use of IVUS and Doppler wire
does facilitate the functional assessment of both conduit
and resistance vessel function." Although cross talk can
occur between the IVUS and Dopplcr systems owing to
frequency overlap, meaningful image or signal loss is un¬
usual and rarely affects cross sectional area or velocity
measurements. However, the IVUS imaging catheter (cross
Table I hilracoronary administration of agents commonly used in the functional assessment of the coronary circulation
Agent Dose Receptor/mediator Comments
Endothelium independent vasodilators
Adenosine Bolus: 12-36 pg Purine receptors Causes transient heart block.
Infusion: 1-2 mg/min Causes maximal coronary vasodilatation and is
also used for the assessment of fractional flow-
reserve
Glyceryl trinitrate Bolus: 50-200 pg Nitric oxide donor Predominant action on cpicardial vessels
Papaverine Bolus: 4-12 mg Opiate derivative causing vascular Causes maximal coronary vasodilatation.
smooth muscle relaxation Potentially arrhythmogenic
Sodium nitroprusside Infusion: 5-40 pg/min Nitric oxide donor Predominant action on coronary resistance vessels
Endothelium dependent vasodilators
Acetylcholine Bolus: 1-100 nmol Muscarinic receptors Causes transient heart block. Target effective
Infusion: 1-1000 nmol/'min intracoronary concentration of 10"R to 10''' M.
May cause paradoxical vasoconstriction in
presence of atheroma
Bradykinin Bolus: 60-600 pmol Bradykinin type 2 receptor Tachyphylaxis and chest discomfort may occur
Infusion: 30-2500 pmol/min
Substance P Infusion: 5-40 pmol/min Neurokinin type 1 receptor
Endothelium dependent •vasoconstrictors
L-NMMA Infusion: 32-64 pmol/min Nitric oxide synthase inhibitor Slow onset and offset of action (10-20 minutes)
Boluses should be given in 2 nil followed by 3 ml saline flush. The bolus dose should be reduced by 30-50% for right coronary artery injection.
To avoid directly influencing coronary flow, infusion rates arc usually low at 1-2 ml/min.
Adenosine and papaverine may additionally cause endothelium dependent flow associated epicardial vessel vasodilatation.
Except L-NMMA, all agents have a rapid onset and offset of action with flow velocity usually returning to baseline within -2 minutes.
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Figure I Doppler flow velocity responses before, during, and following a
bolus injection of acetylcholine (2 ml of I (!'M) in the dominant
circumflex coronary artery.
sectional area —0.9 mm2) can cause significant obstruction
to flow, particularly in the presence of luminal stenoses of
5 70% and, therefore, heavily diseased arterial segments
or small calibre coronary arteries are not suited to this
approach and limit its more widespread application.
Moreover, unlike QCA, IVUS provides a single cross sec¬
tional image of the artery at a given time point, and
although three dimensional reconstructions of the artery
can be performed, it docs not permit an instantaneous
assessment of the entire arterial tree.
Method of drug administration
The method of administration of vasoactive agents under
investigation has been variable and inconsistent. For
example, acetylcholine has been administered as a
continuous infusion,'" 14 slow hand injection1,1 or rapid
bolus.12 Moreover, instillation of drug into the coronary
circulation has been achieved either via the instrumenting
catheter" " or a dedicated 2-3 French selective intracoro-
nary infusion catheter." '* Indeed, some workers have used
selective monorail infusion catheters which have remained
within the guide catheter." Finally, systemic intravenous
infusions of agents, such as adenosine (140 gg/kg/min),
have been administered but this approach can cause
pronounced systemic haenrodynamic and arrhythmogenic
effects which will confound the subsequent interpretation
of coronary responses.2"
BOLUS INJECTIONS
Consideration should be given to the catheter dead space
which can be significant, particularly when drugs are given
via the guide catheter. The administration of even a small
volume bolus will necessitate a 3 ml saline flush to eject the
drug from the catheter into the proximal coronary artery.
This will cause an instantaneous increase in blood flow
velocity which is attributable to the mechanical ejection of
fluid down the artery. Thereafter, a second rise or a subse¬
quent fall in blood flow velocity will occur which is attrib¬
utable to drug action (fig 1). Prolonged injection or large
volume boluses have the potential to obscure the second
phase response because of supcrimposition of mechanical
and pharmacological flow effects as well as inducing shear
stress and flow associated dilatation. Bolus injections
should, therefore, be kept to a minimal volume and must be
compared with control saline injections. Finally, bolus
injections of acetylcholine and adenosine into the right
coronary or dominant circumflex artery can result in atrio¬
ventricular block and transient ventricular standstill (fig 1).
If prolonged, this will confound the assessment of
vasodilatation and flow responses, and continuous infu¬
sions of acetylcholine or adenosine into these arteries
should be avoided.
CONTINUOUS OR GRADED INFUSIONS
The administration of drugs via the diagnostic or guide
catheter may be satisfactory for the application of drug
boluses by hand injection when maximal vasodilatory
responses are being assessed, such as with high dose (30 jig
bolus) adenosine. However, there is a concern that
continuous or graded infusions via the coronary guide
catheter do not reliably permit precise and selective intra-
coronary drug administration. The turbulence induced by
blood ejection from the heart and the potential incomplete
engagement of the catheter with the coronary ostium will
result in a variable degree of drug reflux into the aorta.
Furthermore, in the left coronary system, a variable
amount of the delivered drug will be administered to the
adjacent cpicardial vessel. Consequently, there is the theo¬
retical concern that guide catheter infusion will result in a
wide variability in the effective intracoronary drug concen¬
tration attained. When assessing the coronary vasomotor
response by QCA, these concerns are further compounded
by the necessity to aspirate the drug from the diagnostic or
guide catheter before contrast injection.10 " Finally, impac¬
tion of the guide catheter in the coronary ostium due to
superselection, or the use of large guide catheters, should
clearly be avoided as this will impair anterograde coronary
flow. Administration of drugs through guide catheters with
side holes is equally inappropriate, and it is likely that
smaller guide catheters will increasingly be used with the
wider use of 6 French compatible IVUS catheters.
We have recently been conducting a study to look at the
relation between endothelial function and atheromatous
plaque volume in the coronary circulation of patients with
normal or mildly diseased coronary arteries. The plaque
volume of the proximal left anterior descending coronary
artery was determined using three dimensional reconstruc¬
tion of an initial IVUS examination, and coronary blood
flow responses to incremental five minute infusions
(1 ml/min) of substance P were assessed by combined
Doppler wire and IVUS measurements. In 10 patients,
substance P was selectively infused via the flush port of the
IVUS catheter which caused significant and consistent
increases in coronary blood flow (fig 2). However, in a fur¬
ther 10 patients, where substance P was administered via
the guide catheter, the magnitude and consistency of the
coronary blood flow response was low and did not result in
significant increases in coronary blood flow despite a com¬
parable degree of proximal coronary atheroma (6.2 (1.0) v
5.8 (1.4) mm'/rnm of vessel, respectively). Therefore, we
believe that, to achieve reproducible vasomotor responses,
continuous or graded intracoronary drug administration
should be given using a selective intracoronary infusion
catheter which, to date, has not been universally employed.
www. hearljnl. com
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Figure 2 Coronary blood flow response to incremental substance P
infusion (1 tnl/min) administered via the guide catheter (open circles) or
IVUS catheter (closed circles), n - 10 per group. One way analysis of
variance (ANOVA) *p < 0.001; fp = not significant. Two way ANOVA
*p < 0.001.
Conclusions
The measurement of coronary blood flow responses to
vasoactive agents and investigational agents is an important
and essential area of clinical research. However, it would
appear that the method of assessment and the route of
intracoronary drug administration will have a significant
influence on subsequent coronary vasomotor responses.
Consequently, the method and technique used will depend
on the specific question under investigation and should be
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Local tissue factor pathway inhibitor release in the human
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Summary
Nineteen healthy men received unilateral brachial artery infu¬
sions of either unfractioned heparin (0.3-100 lU/min), saline
or the endothelium-dependent vasodilators substance P
(2-8 pmol/min) and bradykinin (100-1000 pmol/min), and
the endothelium-independent vasodilator sodium nitroprusside
(2-8 Hg/min). Heparin caused a dose-dependent increase in
plasmaTFPI concentrations in both arms (ANOVA, p <0.0001).
Estimated net forearm TFPI release was 7 ± 16, 29 ± 20 and
138 ± 72 ng/100 mLtissue/min during 10,30 and 100 lU/min of
Keywords
Tissue factor pathway inhibitor, haemostasis, heparin, substance
P, bradykinin
Introduction
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease
inhibitor that regulates the extrinsic coagulation cascade (1). It
is synthesised and released by endothelial cells, where it is
expressed on the cell surface as well as stored within intracellular
secretory granules (2). In addition to inhibiting tissue factor-
factor Vila complex, TFPI directly neutralises the catalytic
activity of factor Xa. The plasma form of TFPI is predominantly
present as a truncated C-terminal fragment that is a less efficient
inhibitor of tissue factor and represents only a small fraction of
the available TFPI (3). As such, changes in TFPI activity are
likely to be dependent on endothelial function, and in particular
on the acute cellular release and expression of TFPI.
An imbalance between TFPI and tissue factor concentrations
may be important in the pathogenesis of many conditions
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heparin respectively (ANOVA, p <0.0001). Compared to the
systemic circulation, the forearm sensitivity to heparin induced
TFPI release was 3.6-fold lower (166 ± 67 ng/IU vs. 596 + 252
ng/IU: t-test, p = 0.004). Substance P, bradykinin and sodium
nitroprusside all caused substantial dose-dependent increases
in blood flow (ANOVA, p <0.001 for all) without affecting plas¬
ma TFPI concentrations. There are important regional differ¬
ences in endothelial TFPI release, with the forearm circulation
being relatively insensitive to heparin.
Thromb Haemost 2003; 89: 438-45
associated with elevated tissue factor expression, such as
atherosclerosis (4-6), restenosis after angioplasty (7), sepsis (8),
diabetes mellitus (9), adult respiratory distress syndrome (10)
and glomerulonephritis (11). Such an imbalance may arise
because of impaired endothelial function (12) and lead to a
procoagulant state (13, 14). Administration of exogenous
(recombinant) TFPI may be beneficial in many of these clinical
situations (8,13,15-17) although the potential role of increasing
endogenous TFPI availability has yet to be tested. Under¬
standing the control of endogenous TFPI release may thus
provide novel therapeutic opportunities in the treatment of
tissue factor-mediated pathological conditions.
To date, few stimuli have been reported to induce acute TFPI
release apart from shear stress, heparin and other negatively
charged ions (18-21). The in vivo assessment ofTFPI release in
response to alterations in haemodynamics and shear stress
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presents several challenges. First, the liver is responsible for
rapid clearance of TFPI from the circulation and changes in
hepatic blood flow can have considerable effects on plasma
TFPI concentrations (22). Second, systemic drug administration
can cause concomitant effects on other organ systems, such as
the brain, kidney and heart, as well as influence neurohumoral
reflexes. Therefore, alterations of systemic as well as hepatic
haemodynamic variables could confound any assessment of
acute TFPI release. In contrast, the use of bilateral forearm
blood flow measurements coupled with unilateral brachial
artery infusion of vasoactive drugs at subsystemic, locally active
doses, provides a powerful and reproducible method of directly
assessing vascular responses in vivo (23). Combined with
bilateral forearm venous sampling, this technique permits the
assessment of local release of tissue and endothelium-derived
factors (24). Flowever, to date, this model has not been applied
to the assessment of acute endothelial TFPI release in vivo in
man. We, therefore, chose to assess the acute local forearm
release of TFPI in response to intra-arterial heparin infusion
since heparin has been previously demonstrated to be one of the
most potent compounds to induce its release (25). Using this
model, we also wished to determine whether endothelium-
dependent or -independent vasodilators would cause local TFPI
release in the human forearm circulation.
Methods
Subjects
Nineteen healthy non-smoking male volunteers subjects (age
19-35 years) participated in the study which was undertaken
with the approval of the local research ethics committee, in
accordance with the Declaration of Helsinki, and with the
written informed consent of each subject. None of the subjects
received vasoactive drugs in the week before each phase of the
study. All abstained from caffeine-containing drinks and alcohol
for at least 12 h before each study. All studies were carried out
in a quiet, temperature controlled room maintained at 22-24° C.
Study design
The brachial artery of the non-dominant arm was cannulated
with a 27-standard wire gauge steel needle (Cooper's Needle
Works Ltd, Birmingham, UK) under local anaesthesia (1%
lignocaine; Astra Pharmaceutical Ltd, Kings Langley, UK). The
total rate of intra-arterial infusions was maintained constant at
1 mL/min and forearm blood flow was measured every 10 min
throughout all studies. Saline was infused for 30 min prior to the
heparin, saline, substance P, sodium nitroprusside and
bradykinin infusions.
Protocol I
Unfractionated heparin was obtained from Akzo Nobel (Oss,
The Netherlands) and prepared for administration by the
pharmacy of the Leiden University Medical Center (Leiden,
The Netherlands) following European Pharmacopoeia standards.
In 6 subjects, heparin was infused at escalating doses of 0.3,1.0,
3.0, 10, 30, and 100 IU/min for 10 min at each dose. For safety
purposes, the activated partial thromboplastin time
(Coagucheck Plus, Roche Diagnostics, Mannheim, Germany)
was measured in the non-infused arm during the 10, 30 and
100 IU/min heparin infusions. Six additional subjects also
underwent a control 2 h intra-arterial saline infusion.
Protocol 2
This was performed as a sub-study (placebo day) of a previously
reported clinical investigation (26) in seven subjects. Intra-
brachial infusions of substance P (Clinalfa AG, Laufelfingen,
Switzerland; endothelium-dependent vasodilator) at 2, 4 and
8 pmol/min (24), sodium nitroprusside (David Bull Laborato¬
ries, Warwick, UK; endothelium-independent vasodilator) at
2, 4 and 8 pg/min (24, 27) and bradykinin (Clinalfa AG; endo¬
thelium-dependent vasodilator) at 100, 300 and 1000 pmol/min
(27) were given for 10 min at each dose in that order. Saline was
infused for 30 min prior to the substance P, sodium nitroprus¬
side and bradykinin infusions.
Measurements
Forearm blood flow and haemodynamics
Blood flow was measured in both forearms by venous occlusion
plethysmography using mercury-in-silastic strain gauges
applied to the widest part of the forearm as previously described
(23). Analogue voltage output from an EC-4 Strain Gauge
Plethysmograph (D. E. Hokanson Inc, Washington, USA)
was processed by a MacLab® analogue-to-digital converter
and Chart™ v3.3.8 software (AD Instruments Ltd, Castle
Hill, Australia) and recorded onto a Macintosh Classic II
computer (Apple Computers Inc, Cupertino, USA). Calibra¬
tion was achieved using the internal standard of the plethysmo¬
graph.
Blood pressure and heart rate were monitored in the
non-infused arm at intervals throughout each study using a
semi-automated non-invasive oscillometric sphygmomanometer
(Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).
Blood sampling and assays
Venous cannulae (17G) were inserted into large subcutaneous
veins of the antecubital fossa in both arms. Ten to twenty mL of
blood was withdrawn simultaneously from each arm and
collected into citrate tubes (Monovette®, Sarstedt, Niimbrecht,
Germany), and kept on ice before being centrifuged at 2000 g
for 30 min at 4° C. Platelet poor plasma was decanted, snap-
frozen in methanol with dry-ice, and stored at -80° C until
analysis.
Plasma total and free TFPI concentrations were determined
using enzyme-linked immunosorbent assays (Asserachrom®,
Figure I: Percent change in forearm blood flow (compared to baseline) and ratio infused/control arm ± SD during intra-arterial
heparin infusion (10 minutes each dose) and post-infusion. ANOVA p = 0.066 for the infused arm percent change and p = 0.024 for
the ratio, * p < 0.05 compared to baseline (Dunnett's)
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Diagnostica Stago, Asnieres, France). The range, and the intra-
and inter-assay coefficients of variation of the plasma total and
free TFPI concentrations were 4-230 ng/mL, 4.2% and 6.8%,
and 2-70 ng/mL, 3.9% and 4.4% respectively. The anti-lla
activity assay (Spectrolyse® Heparin) was calibrated against the
first International Standard from the National Institute for
Biological Standards and Control (Hertsfordshire, United
Kingdom; code 85/600) with intra- and inter-assay coefficients
of variation of <10% and a sensitivity of 0.01 IU/ml. The
activated partial thromboplastin time (APTT) was determined
on a STA® coagulation analyser (Roche Diagnostics,
Mannheim, Germany) using STA APTT reagent (Roche
Diagnostics) with intra- and inter-assay coefficients of variation
of <5%. Plasma t-PA and PAI-1 antigen and activity concentra¬
tions were determined using enzyme-linked immunosorbent
assays and a photometric method as previously described
(24).
Data analysis and statistics
Plethysmographic data were extracted from the Chart™ data
files. Forearm blood flows were calculated for individual
venous occlusion cuff inflations by use of a template spread¬
sheet (Excel v5.0; Microsoft Corporation, Cambridge, USA) as
previously described (24,27). Estimated net release of total and
free TFPI was defined as the product of the infused forearm
Saline Heparin infusion (iU/min) time (min) post-infusion Saline Heparin infusion (lU/min) time (min) post-infusion
Figure 2: Anti-lla activity and APTT ± SD pre-dose (saline), during intra-arterial heparin infusion (10 min each dose) and post-
infusion. ANOVA p <0.0001 for both arms,* p <0.05 compared to baseline (Dunnett's)
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Figure 3: Total and free tissue factor pathway inhibitor (TFPI) plasma concentration ± SD during pre-dose (saline), intra-arterial
heparin infusion (10 min each dose) and post-infusion. ANOVA p <0.0001 for both arms,* p <0.05 compared to baseline (Dunnett's)
plasma flow (based on the mean haematocrit and the infused
forearm blood flow) and the concentration difference between
the infused and non-infused arms (24). The anti-IIa activity was
used as a measure of heparin concentration (28) to assess
concentration-effect relationships. Average concentration-effect
relationships were calculated from the individual regression
lines.
Statistical analysis was performed, where appropriate, by
repeated measures analysis of variance (ANOVA), two-tailed
Dunnett's test, paired Student's /-tests and regression analysis
using SAS for Windows V8.2 (SAS Institute Inc., Cary, NC,
USA). Statistical significance was taken as p <0.05.
Results
All studies were well tolerated without significant adverse
effects. Consistent with previous studies (27), transient patchy
flushing and mild skin oedema of the infused arm occurred with
bradykinin and substance P infusion.
Protocol I
Vasomotor effects
Saline infusion had no effect on forearm blood flow in either
arm (data not shown). There was a trend (ANOVA, p = 0.066)
for heparin infusion to cause an increase in blood flow of the
Table I: Release of tissue factor
pathway inhibitor (TFPI) with heparin
infusion.




-10 0 -0.6 + 3.9 -2.1 +7.0
0 0 -0.9 ± 3.2 -0.5 ± 9.0
10 0.3 -0.8 ± 2.4 -0.6 + 7.7
20 1 0.7 ± 4.0 1.3 ± 11.0
30 3 -1.3 + 3.5 -2.8 ± 11.2
40 10 2.5 + 5.0 7.0 ± 15.7
50 30 8.6 + 4.9 28.8 + 20.4
60 100 44.4 + 18.6* 138.1 +71.7'
70 0 18.3+ 17.6* 40.7 ±38.6
90 0 -5.3 ±5.8 -10.2 ± 16.8
120 0 3.1 + 11.3 16.0 ±37.5
$ p<0.0001 ANOVA with factor time
* p<0.05 compared to mean baseline, Dunnctt's correction for multiple comparison
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Figure 4: Relationship between anti-lla activity (measure for heparin concentration) and forearm blood flow (left panel) and total
tissue factor pathway inhibitor (TFPI) plasma concentration (right panel). Arrows indicate direction of dose response. Relationship
between anti-lla activity and total TFPI was 3-4 fold weaker (p = 0.0035) in the infused arm compared to the control arm.
infused arm (maximum average increase 41 ± 36%; 95%
confidence interval, 5-77%: Fig. 1) that appeared to be dose-
dependent. The ratio of the infused arm and non-infused arm
blood flow increased in a dose-dependent manner (ANOVA,
p = 0.024: Fig. 1).
Anticoagulant effects and TFPI release
Isolated saline infusion had no effect on plasma total TFPI
concentrations in either ami at 0, 60 and 120 min (data not
shown). Heparin induced a dose-dependent increase in anti-lla
activity and APTT at >10 lU/min in the infused arm (ANOVA,
p <0.0001 for both) and at 100 IU/min in the non-infused arm
(ANOVA, p <0.0001 for both; Fig. 2). Anti-lla activity and
APTT returned to baseline values 60 min after cessation of the
heparin infusion.
Plasma total and free TFPI concentrations increased dose-
dependently in both the infused and non-infused arms
(ANOVA, p <0.0001 for all; Fig. 3). At lower heparin doses,
plasma TFPI concentrations appeared to increase before the
anti-lla activity (Fig. 2 and 3). Plasma TFPI concentrations
were higher in the infused arm with a dose-dependent increase
in the forearm difference of the total TFPI concentration at 30
and 100 IU/min of heparin (ANOVA, p <0.0001: Table 1).
Plasma total and free TFPI concentrations were similar in both
arms after cessation of the heparin infusion. The estimated net
forearm release of total TFPI increased to 7 ± 16, 29 ± 20 and






Bradykinin 0 -2.7 ±4.1 -11.7 ± 15.5
(pmol/min) 100 -3.0± 5.1 -35.4 ± 69.2
300 -2.4 + 6.9 -51.1 + 118.7
1000 -5.7 ±7.4 -110.4 ± 148.1
Substance P 0 1.4 ±5.1 0.9 + 21.8
(pmol/min) 2 -0.4 ± 3.6 -6.4 ± 40.8
4 -1.5 ±4.8 1+ 9s
8 -7.3 ±4.3 -96.9 + 74.6
Sodium 0 -1.2 ±2.9 -6.2+ 11.9
Nitroprusside 2 1.3 ±4.9 8.2 + 42.0
(pg/min) 4 (NT+1rn -40.2 ±47.8
8 3.6 ±6.3 41.3 ±79.7
Table 2: Release of tissue factor
pathway inhibitor (TFPI) with
bradykinin, substance P and sodium
nitroprusside infusion.
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Figure 5: Forearm





(ANOVA, p <0.001 for
all).
138 ± 72 ng/100 mL of tissue/min with 10, 30 and 100 lU/min
of heparin respectively (ANOVA, p <0.0001: Table 1).
Concentration-effect relationship
Forearm blood flow increased with anti-lla activity but
appeared to reach a maximum effect at 10 IU/min of heparin
(Fig. 4).
With increasing anti-lla activity, the proportionate rises
in plasma total and free TFPI concentrations were smaller in
the infused arm (total TFPI 166 ± 67 ng/lU, free TFPI 137 ±
63 ng/lU) than in the non-infused arm (total TFPI 596 ±
252 ng/IU, free TFPI 532 ± 196 ng/IU; p = 0.0035: Fig. 4).
The estimated net TFPI release in the infused arm directly
correlated with the anti-lla activity (average relation y = -6 +
159x, 95% confidence interval -18 to 7 for the intercept and
82 to 236 for the slope; r = 0.94-0.98 for the individual
regression lines, p <0.01).
Protocol 2
Vasomotor effects
Substance P, bradykinin and sodium nitroprusside produced a
dose-dependent increase in blood flow (ANOVA, p <0.001 for
all; Fig. 5). There were no significant changes in heart rate,
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Figure 6: Plasma
concentrations of total
TFPI (circles) and free
TFPI (squares) in the
infusion arm (closed
markers) and control







Table 3: Plasma tissue plasminogen activator (t-PA) antigen and activity concentrations in the infused and non-infused forearms
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8.5 ± 2.0 t
2.4 ± 0.4 *
tpcO.OOl. *p<0.05 ANOVA (dose response)
Fibrinolytic effects andTFPI release
Substance P and bradykinin, but not sodium nitroprusside, caused
a dose-dependent increase in plasma t-PA concentrations (ANOVA,
p <0.001 for all; Table 2). There were no changes in plasma total
and free TFPI or PAI-1 concentrations during substance P,
bradykinin, or SNP infusion (Fig. 6 and Table 4). There were no
changes in the concentration differences between the forearms
or the estimated net release ofTFPI in the infused arm (Table 2).
Discussion
We have shown that intra-arterial heparin causes modest
dose-dependent increases in local TFPI release directly from the
forearm vascular bed. This effect is specific to heparin since
neither marked vasodilatation induced by sodium nitroprusside
nor endothelial cell stimulation with the kinins, bradykinin and
substance P, were able to release TFPI despite marked increases
in blood flow and tissue plasminogen activator respectively.
However, in comparison to the systemic vasculature, the
forearm appears to have a relatively low sensitivity for heparin
induced TFPI release.
Intra-arterial heparin caused a dose-dependent increase in
TFPI release in the foreann, but this was associated with near
simultaneous increases in systemic plasma TFPI concentrations.
This cannot be attributable to an "overspill" of TFPI into the
systemic circulation since insufficient TFPI was released from
the forearm and the plasma half-life for TFPI is too brief due
to its rapid clearance by the liver (-700 mL/min) (22). At
30 IU/min, heparin caused the forearm release of 0.3 |xg/min of
TFPI whereas, in the absence of any clearance, the forearm
would need to produce at least 13 pg/min of TFPI to raise
systemic plasma concentrations to 20 ng/mL.
The concentration-effect relationship of intra-arterial heparin
(anti-Ila activity) and systemic plasma TFPI concentrations
was similar to our previous observations with intravenous
heparin administration (28). However, this relationship was 3 /\
fold weaker in the forearm circulation: 0.1 IU anti-IIa activity
causing a 17 ng/mL increase in the forearm compared with a
60 ng/mL increase in the systemic circulation. The difference
between local and systemic TFPI release will be underestimated
by such comparisons since the increase in forearm concentration
will be in part the result of systemically released TFPI.
Moreover, the systemic concentration-effect relationship is
probably steeper since TFPI is rapidly cleared by the liver (22).
These inferred differences in release rates are most likely due to
regional vascular differences in endothelial TFPI release. In the
present study, we cannot determine which vascular bed is
responsible for the major source of heparin induced TFPI
release but the skeletal muscle vasculature does not appear to
have a major role. Whichever vascular bed is responsible, it is
Table 4: Plasma plas¬
minogen activator
inhibitor type I (PAI-I)
antigen concentrations






Substance 1' Sodium Nitroprusside Bradykinin
(pmol/min) (pg/min) (pmol/min)
0 8 0 8 0 1000
Plasma PAI-1 Antigen
(ng/mL)
Infused Arm 14 + 2 14 ± 1 14 + 3 14 + 2 16 ± 2 1 1 ± 1
Non-infused Arm 15 ±4 15 ± 1 12 + 2 14 + 2 10 ± 1 13+2
TFPI release in the human forearm
very sensitive to the effects of heparin since the rise in systemic
plasma TFPI concentrations preceded the increase in anti-IIa
activity. This also reflects the relative insensitivity of the anti-
IIa activity assay as a biomarker for active heparin plasma
concentrations.
The endothelium-dependent vasodilators substance P (24),
bradykinin (27) and the p-receptor agonist isoprotenerol (29)
increase blood flow and endothelial tissue plasminogen activator
(t-PA) release. Since both TFPI and t-PA are stored within
intracellular vesicles and their release is dependent on intracellular
calcium ions (30), we hypothesised that endothelial stimulants
or increases in blood flow would also lead to TFPI release. We
here report that, despite substantial increases in blood flow and
t-PA release, we were unable to detect increases in plasma TFPI
concentrations using either endothelium-dependent or -inde¬
pendent vasodilators. Given that heparin also does not release t-
PA (31), it would appear that the pathways of t-PA and TFPI
release are mediated through distinct cellular mechanisms. This
is not entirely unexpected given that previous work has shown
release of other endothelium-derived factors, such as von
Willebrand factor, are also not induced by substance P (24) or
bradykinin (27).
In conclusion, although neither vasodilatation nor direct
kinin-mediated endothelial cell stimulation have an effect,
unfractionated heparin causes a modest direct local release of
TFPI in the human forearm. There are important regional
differences in endothelial TFPI release with the forearm
circulation being relatively insensitive to heparin.
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In recent years, impairment of endothelial function has
been a major focus of clinical research into cardiovas¬
cular disease. Endothelial dysfunction is associated with
classical risk factors and there is accumulating evid¬
ence that it also independently predicts cardiovas¬
cular outcome [1], This research has almost exclusively
focused on endothclium-dcpcndcnt vasodilatation as a
measure of endothelial function. However, although this
is important, it may not be representative of other
important aspects of endothelial function, such as the
regulation of fibrinolysis.
Following the initiation of intravascular thrombus for¬
mation, the endothelium acutely releases tissue-type
plasminogen activator (t-PA) in response to a range of
factors predominantly related to the coagulation cascade,
especially factor Xa and thrombin [2]. Once released,
t-PA catalyses the conversion of plasminogen to plasmin
and thereby facilitates thrombus dissolution through the
proteolytic degradation of fibrin to soluble fibrin degra¬
dation products. This endogenous fibrinolytic system
protects the circulation from intravascular fibrin for¬
mation and thrombosis that wotdd otherwise result in
vessel occlusion and tissue ischacmia. It follows that
impairment of acute t-PA release from the endothe¬
lium might be a specific mechanism through which
endothelial dysfunction mediates or potentiates throm¬
botic events.
Jern and colleagues [3] have previously reported that
dcsmopressin-induccd endothelial t-PA release is signifi¬
cantly impaired in patients with hypertension and have
since explored the mechanism responsible for this obser¬
vation. Using an ex vivo perfusion model in which shear
stress was kept constant, increased intraluminal pressure
in human umbilical veins decreased t-PA release, as well
as gene and protein expression. This suggested that
raised intraluminal pressure per se may be important in
mediating impaired t-PA release in hypertension. The
authors have now extended these findings and have
specifically investigated the effects of cyclic tensile,
rather than compressive, strain on endothelial t-PA pro¬
duction and release. In this issue of the journal, Ulfham-
mer et al. [4] show that cyclically stretching cultured
human aortic endothelial cells (HAECs) decreases both
t-PA mRNA production and protein secretion but
increases the production and secretion of plasminogen
activator inhibitor 1, the major natural inhibitor of t-PA
in vivo. If, as is suggested by this work, raised intraluminal
pressure, by increasing circumferential wall strain,
impairs the capacity for acute endothelial t-PA release
in vivo, this would provide a direct mechanistic link
between raised blood pressure and atherothrombotic
events. It might further be hypothesized that the clinical
benefit of blood pressure reduction in reducing these
events would, at least in part, be mediated through
improvements in endogenous fibrinolysis. Indeed, there
is now good evidence that the clinical benefit of anti¬
hypertensive therapy is predominantly related to blood
pressure reduction per se rather than being the result of
other drug class-spccifie effects [5]. Therefore, improve¬
ment in endothelial t-PA release might be a common
mechanism through which different antihypertensives
reduce cardiovascular events.
Of the agonists known to stimulate endothelial t-PA
release, bradykinin is one of the most potent. Bradykinin
is largely metabolized by angiotensin-converting enz¬
yme (ACE) and ACE inhibitors potentiate bradykinin-
induced t-PA release. Indeed, infusion of enalaprilat
stimulates t-PA release and this effect is mediated
through endogenous bradykinin [6], Thus, the estab¬
lished clinical benefit of ACE inhibitors in a range of
cardiovascular conditions may be partly related to effects
on endothelial t-PA release through preservation of
endogenous bradykinin. In patients with hypertension,
ACE inhibitors are no more effective than other anti¬
hypertensive classes in reducing cardiovascular events
[7]. This may suggest that any benefit that arises through
improved endothelial t-PA release with ACE inhibition is
predominantly due to blood pressure reduction rather
than specific ACE inhibitor-mediated effects on endo¬
genous bradykinin. Despite this, it is intriguing to specu¬
late that patients with drug-resistant hypertension might
benefit specifically from an ACE inhibitor even in the
absence of blood pressure reduction.
There arc some limitations to the work performed both
ex vivo and in vitro on the effect of mechanical forces on
0263-6352 © 2005 Lippincott Williams & Wilkins
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endothelial t-PA production and release. The effect of
strain on HAECs was only investigated at 10% stretch.
This is thought to correspond to an intraluminal pressure
of 170 mmHg in medium-sized arteries. However, endo¬
thelial cells in arteries are exposed to cyclical circumfer¬
ential strain under normal circumstances and it is possible
that, even at this level, t-PA production and release is
inhibited. Thus, the difference between the effects of
normal physiological strain and the greater strain associ¬
ated with hypertension may be more relevant. Further¬
more, neither model can be expected to reflect accurately
the complex pressure-related stresses on the arterial wall
that occur in hypertension. Indeed, these stresses will
vary both with the vessel size and the subtype of hyper¬
tension, whether diastolic, systolic or mixed. In particular,
the increased stiffness of large arteries that characterizes
isolated systolic hypertension will limit the change in
vessel diameter and therefore stretch on the endothelial
cell layer. As a result, despite high systolic pressures,
endothelial t-PA release might be relatively preserved.
It is now 7 years since Jern et al. [3] first described the
important observation that endothelial t-PA release is
impaired in patients with hypertension. However, many
questions remain. For example, is the relationship
between blood pressure and t-PA release linear? What
are the effects of the continuous and pulsatile com¬
ponents of blood pressure? Is there a regional or systemic
impairment of t-PA release? Docs blood pressure
reduction improve t-PA release? Arc there differences
between antihypertensive classes with respect to improv¬
ing t-PA release? Answering these and other, related,
questions may significantly contribute to our under¬
standing of how raised blood pressure leads to athcro-
thrombotic events and why antihypertensive therapy
effectively reduces their incidence.
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Abstract
The dynamic regulation of intravascular thrombus formation is central to our understanding ofboth acute and chronic atherosclerotic events.
The initiation, modification and resolution of thrombus associated with eroded or unstable coronary plaques is critically dependent on the
efficacy of endogenous fibrinolysis, a process that is itself reliant upon the cellular activation and function of the surrounding endothelium
and vascular wall. Bradykinin is a vasodilator peptide that stimulates the endothelium to release the pro-lytic factor, tissue-type plasminogen
activator and is released at sites of intravascular thrombus formation including the luminal surface of ruptured or eroded atheromatous
plaques. Recent studies have provided important and novel insights into the contribution of bradykinin to the regulation of endogenous
fibrinolysis and intravascular thrombosis in the peripheral and coronary circulations in vivo in man. Moreover, the pro-fibrinolytic effects
of bradykinin are markedly augmented in the presence of angiotensin-converting enzyme inhibition and may explain, at least in part, the
established anti-ischaemic effects of angiotensin-converting enzyme inhibitors in patients with atherosclerosis. The development of novel
agents that potentiate bradykinin and endogenous fibrinolysis, such as inhibitors of thrombin activatable fibrinolysis inhibitor, may provide
future therapeutic strategies to treat and prevent cardiovascular disease.
© 2005 Elsevier Ireland Ltd. All rights reserved.
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Fig. 1. Schematic diagram of plasma and tissue kinin—kallikrein systems. HMW: high molecular weight; LMW: low molecular weight.
Cardiovascular disease is the commonest cause of pre¬
mature death in most of the Western world. Despite the
identification of a variety of risk factors, the underlying
pathophysiological mechanisms remain only partially char¬
acterised. The dynamic regulation of intravascular thrombus
formation is central to our understanding of both acute and
chronic atherosclerotic events.
The maintenance and regulation of tissue perfusion is criti¬
cally dependent upon the integrity ofendothelial function and
the release of potent endothelium-dcrived factors. Following
the seminal work of Furchgott and Zawadski [1], it has been
widely recognised that an array of mediators can influence
vascular tone through endothclium-dcpendent actions. A role
for bradykinin in vascular homeostasis was first recognised
in 1909 following the demonstration that intravenous injec¬
tion of fractions extracted from human urine resulted in a
transient reduction in blood pressure [2], Subsequently, a sub¬
stantial body of evidence has implicated the kallikrein-kinin
system in a wide range ofphysiological and pathological pro¬
cesses including inflammation [3], nocioception [4], smooth
muscle contraction [5], vascular homeostasis [6,7] and blood
coagulation [8], Only recently, however, has the potential
significance of the relationship between bradykinin, endoge¬
nous fibrinolysis and atherothrombosis become apparent
[6,9].
1. Bradykinin
Bradykinin is the major effector for the plasma kinin
system and is released from high molecular weight kinino¬
gen following a eomplex interaction between Factor XII,
Factor XI and prekallikrein on the surface of endothelial
cells (Fig. 1) [10,1 1]. An alternative pathway exists in tis¬
sues whereby cleavage of low molecular weight kininogen
by tissue kallikreins yields the decapeptide, Lys-bradykinin
[12,13]. Subsequent removal of the N-terminal lysine of
Lys-bradykinin by aminopeplidases generates bradykinin
(Figs. 1 and 2) [12,13],
Once released, bradykinin is rapidly metabolised by
a number of peptidases, ensuring a half-life in blood
of <15 s [14-16], Angiotensin-converting enzyme (ACE;
EC 3.4.15.1) is the principal enzyme responsible for the
metabolism of bradykinin in human blood (Fig. 2). Other
enzymes implicated in the breakdown of bradykinin include
neutral endopeptidase (NEP; neprilysin, EC 3.4.24.11),
carboxypeptidase N (EC 3.4.17.3) and carboxypeptidase
U (thrombin activatable fibrinolysis inhibitor (TAFI), car¬
boxypeptidase R or B) (Fig. 2).
The biological effects of kinins in man are mediated by
two G-protein coupled transmembrane receptors, Bi and B2,
TAFI (Carboxypeptidase U)
Neutral Endopeptidase, Carboxypeptidas N
Arg^Pro^Pro^Gly^Phesjser^-Pro^Phe^Arg9
Angiotensin Converting Enzyme
Fig. 2. Amino-acid structure and C-terminal sites of enzymatic degradation
of bradykinin and des-Arg9-bradykinin. TAFI: thrombin activatable fibri¬
nolysis inhibitor.
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each with high affinity and specificity for their respective lig-
ands, des-Arg9-bradykinin and bradykinin [17], The B] and
B2 kinin receptors share only 36% homology with each other
and are distinguishable on the basis of their pharmacologi¬
cal and molecular characteristics [17-19]. The B2 receptor
is the most prevalent receptor subtype expressed on the vas¬
cular endothelium and smooth muscle under physiological
conditions. In contrast, the vascular Bi receptor is normally
expressed very weakly but is rapidly upregulated, at least in
animal models and in vitro in human tissue, in the presence of
inflammation [20-23], ischaemic left ventricular dysfunction
[24], cardiovascular disease [22,25,26] and ACE inhibition
[27,28]. In addition, intense endothelial B| receptor expres¬
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2. Bradykinin is an endothelium-dependent
vasodilatator
In animal studies, the haemodynamic effects ofbradykinin
vary depending on the species and tissue being studied and the
dose ofbradykinin applied. In mammals, intravenous admin¬
istration ofbradykinin results in arteriolar vasodilatation and
a rapidly reversible fall in blood pressure [12]. The short¬
lived nature of this hypotensive effect has been attributed to
reflex chronotropic and inotropic responses [12]. In human
coronary arteries in vitro, bradykinin causes endothelium-
dependent vasorelaxation [29] and intravenous and intra¬
arterial injection of bradykinin at systemic doses in man
results in a fall in blood pressure with a marked reduction
in peripheral vascular resistance [16,30], The arterio-venous
difference in the dose of bradykinin producing a similar
reduction in blood pressure suggests a pulmonary clearance
rate for bradykinin of 95% [16].
At a local level, intra-arterial infusion of bradykinin
causes endothelium dependent vasodilatation in the fore¬
arm (Fig. 3) [6,7,31] and coronary circulations [32,33],
Moreover, although (he epicardial coronary response to
bradykinin does not appear to correlate with presence of
risk factors for atherosclerosis [30], bradykinin-mediatcd
vasodilatation within the human coronary circulation is
impaired at sites where atherosclerotic plaque is present
[34].
Bradykinin does not appear to contribute to basal vascu¬
lar tone in the human forearm or systemic circulations under
normal physiological conditions. In the human forearm cir¬
culation, intra-brachial administration of the bradykinin B2
receptor antagonist, HOE-140, also known as icatibant, has
no effect on resting blood flow [35-37], Likewise, systemic
administration of HOE-140 has no effect on blood pres¬
sure in healthy volunteers [38]. In contrast, however, there
is evidence that bradykinin contributes to the regulation of
basal vascular tone in the coronary circulation in man [39],
Intra-coronary administration of HOE-140 increases coro¬

























Fig. 3. Effect of intra-arterial bradykinin on blood flow and venous tissue-
type plasminogen activator and activity concentration in the forearm circu¬
lation of patients with heart failure treated with enalapril lOmg twice daily
for 5 weeks (closed circles) and following ACE inhibitor withdrawal (open
circles; p <0.001, open vs. closed circles for all, ANOVA) [50].
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under basal conditions and during flow-associated vasodi¬
latation [39].
3. Endogenous fibrinolysis
The endogenous fibrinolytic system describes a complex
process ultimately resulting in the hydrolytic cleavage of
fibrin by plasmin to cause clot dissolution and generate fib¬
rin degradation products. The major role of this enzymatic
system is to protect the circulation from intravascular fibrin
formation and thrombosis that would otherwise result in ves¬
sel occlusion and tissue ischaemia. The main physiological
plasminogen activator involved in the degradation of intravas
cular fibrin in man is tissue-type plasminogen activator (t-PA)
[40,41],
Tissue-type plasminogen activator is released from the
endothelium through the translocation of a dynamic intra¬
cellular storage pool [42] and the efficacy of plasmino¬
gen activation and fibrin degradation is determined by the
relative balance between the acute local release of t-PA
and its subsequent inhibition through formation of com¬
plexes with the scrpiii, plasminogen activator inhibitor type 1
(PA I -1).
4. Bradykinin stimulates endothelial release of t-PA
Bradykinin is a potent stimulus for t-PA release from
endothelial cells in vitro and in animal models in vivo
[42-44], Subsequent work by Brown et al. demonstrated
an increase in venous t-PA antigen concentrations following
intravenous administration of bradykinin in human subjects
treated with ACE inhibition [30], Systemic bradykinin infu¬
sion, however, was associated with a significant fall in blood
pressure and an associated increase in heart rate [30], As
a result, the authors could not exclude the possibility that
plasma t-PA concentrations rose as a result of concomi¬
tant neurohumoral and haemodynamic effects, in particular
adrenergic stimulation [30,45],
Combining venous occlusion plethysmography with bilat¬
eral venous sampling led to the development of a novel in
vivo model for assessment of endogenous t-PA release in
the human forearm circulation in response to specific phar¬
macological stimuli in the absence of confounding systemic
responses [46], Using this powerful pharmacological model,
we and others have demonstrated that bradykinin stimulates
endothelial t-PA release in the human forearm circulation in
a dosc-dependent fashion (Fig. 3) without affecting plasma
concentrations of PA I -1 or von Willebrand factor [6,47,48],
Given the absence of an increase in t-PA with the vasodila¬
tor, sodium nitroprusside, this effect could not be attributed
to local changes in blood flow [6,47], Similarly, in the
human coronary circulation, bradykinin stimulates endothe¬
lial release of t-PA without affecting plasma concentrations
of PA 1-1 [49],
5. Mechanism of bradykinin-mediated vasodilatation
and t-PA release
In the human forearm circulation, bradykinin-induced
vasodilatation and endothelial t-PA release are both medi¬
ated via the B2, but not the Bj, kinin receptor [9,50,51]
Downstream signalling mechanisms differ between vasodi¬
latation and t-PA release, as well as the vascular bed being
studied.
In the human forearm circulation, high K+ concentrations
[52] and inhibitors ofK+ transport across the vascular smooth
muscle cell membrane [52-55], but not inhibitors of nitric
oxide synthase or prostaglandin synthesis [55], attenuate
bradykinin-mcdiatcd endothelium dependent vasodilatation
suggesting a role for an endothelium-derived hyperpolarising
factor. In contrast, in the coronary circulation in vivo in man,
inhibition of nitric oxide synthase attenuates the bradykinin-
mediated increase in coronary artery diameter and blood flow
[32],
The mechanism by which bradykinin induces t-PA release
downstream of the B2 kinin receptor is less clear. As with
bradykinin-mediated vasodilatation, inhibition ofnitric oxide
synthase and prostaglandin synthesis does not attenuate the
bradykinin-induced increase in t-PA release in the human
forearm circulation in vivo [9]. The effects of inhibitors of
endothclium-derived hyperpolarising factor on bradykinin-
mcdiated t-PA release are not known.
6. Bradykinin and angiotensin-converting enzyme
inhibition
Angiotensin-converting enzyme (ACE) inhibitors have
become a cornerstone in the management of a number of car¬
diovascular diseases including atherosclerosis and congestive
cardiac failure due to left ventricular systolic dysfunction. In
man inhibitors of ACE cause peripheral vasodilatation [56],
reduce peripheral vascular tone and systemic arterial pressure
[56], reverse endothelium-dependent vasomotor dysfunction
[57,58] and increase plasma t-PA concentrations [59,60],
There is now convincing evidence that the haemodynamic
and fibrinolytic effects ofACE inhibitors are, at least in part,
due to bradykinin [38,60,61],
Although the short half-life of bradykinin in plasma
makes accurate measurement difficult, elevated plasma
bradykinin concentrations have been reported in the pres¬
ence of ACE inhibition [62], In man, ACE inhibition
enhances flow-mediated dilatation of the brachial artery by a
bradykinin B2 receptor-dependent mechanism [37] and aug¬
ments bradykinin-mediated vasodilatation and endothelial
t-PA release in the forearm [7,35,47,63,64] (Fig. 3) and coro¬
nary [32,49,65] circulations.
An insertion deletion (I/D) polymorphism in intron 16
of the ACE gene accounts for ~50% of the variability
in human serum ACE levels [66], Angiotensin-converting
enzyme genotype has been shown to modulate the rate of
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bradykinin metabolism both in vitro [67] and in vivo [68]:
the D allele being associated with increased ACE activ-
ity [69]. Whilst the relationship between ACE genotype
and the vasodilator response to bradykinin appears com¬
plex and may be related to ethnicity [70,71], the D/D ACE
genotype has been associated with impaired bradykinin-
induced t-PA release in the human coronary circulation
[72],
In healthy volunteers, ACE inhibition with quinapril
increases bradykinin induced t-PA release 2-fold in com¬
parison to treatment with placebo or the angiotensin recep¬
tor blocker, losartan [47]. This is in marked contrast to
the 10-fold increase in bradykinin-induced t-PA release
observed in patients with heart failure due to ischaemic
heail disease during ACE inhibitor treatment compared to
its withdrawal (Fig. 3) [64], This massive augmentation
of t-PA release leads to local plasma l-PA concentrations
that approach those seen during systemic fibrinolytic ther¬
apy for acute myocardial infarction [64], These data under¬
score the vast reserves of intracellular t-PA present within
the endothelium and highlight the significant pro-fibrinolytic
potential of pharmacological strategies targeting this
pathway.
Consistent with data from animal models [73], bradykinin
receptor antagonism attenuates the haemodynamic effects
of ACE inhibition in man. In salt deplete healthy volun
teers as well as hypertensive subjects, Gainer et al. demon¬
strated that a systemic infusion of HOE-140 attenuates the
hypotensive response to a single dose of captopril [38],
The reduction in blood pressure observed following co¬
administration of HOE-140 and captopril was similar to that
seen with the angiotensin receptor blocker, losartan [38].
In patients with heart failure, the kinin receptor antagonist,
B9340, caused dose-dependent vasoconstriction in the fore¬
arm circulation in the presence, but not absence of ACE
inhibition [36]. Moreover, B9340 had a significant pres¬
sor effect when administered systemically in patients with
heart failure treated with enalapril compared to losartan
[61].
In addition to the haemodynamic effects, there is evidence
that bradykinin contributes to the increase in constitutive
t-PA release associated with ACE inhibitor therapy by a B2
receptor-dependent mechanism. In the forearm circulation of
healthy smokers, intra-arterial enalaprilat increased net basal
t-PA release and this effect was blocked by pre-treatment
with HOE-140 [60], In this study the authors also note that
ACE inhibition appears to augment bradykinin-mediated
endothelial t-PA release to a greater extent than vasodi¬
latation [60]. The reason for this discrepancy is not clear
but a number of explanations have been proposed includ¬
ing alterations in bradykinin receptor sensitivity through
direct ACE-receptor interactions [74] and modulation of
post-receptor signalling. Moreover, these data emphasise
(he differences between downstream signalling mechanisms
that regulate vascular tone anil t-PA release discussed
earlier.
7. Bradykinin, angiotensin II and plasminogen
activator inhibitor type-1
Besides alterations in plasma t-PA concentrations, ACE
inhibitors favourably alter endogenous fibrinolytic balance
through a reduction in plasma PA1-1 and the overall PAI-1 :t-
PA ratio [75-77], Inhibitors of ACE block the production of
angiotensin II in addition to increasing plasma bradykinin
concentrations. Although bradykinin has no effect on PAI 1
concentrations, angiotensin II causes the release of PAI-1
in vitro [78] and in animal models in vivo [79]. In man,
intravenous [80], but not intra-arterial [6], administration of
angiotensin II increases plasma PAI-1 concentrations with¬
out affecting t-PA concentrations. It is likely, therefore, that
in addition to potentiation of bradykinin, suppression of
angiotensin II mediated PAI-1 release contributes to the pro-
fibrinolytic effects of ACE inhibitor therapy.
8. Bradykinin and angiotensin receptor blockade
There are data indicating that bradykinin may contribute
to the vascular effects of angiotensin receptor blockers by an
angiotensin II type 2 receptor-mediated mechanism. In trans¬
genic mice overexpressing the AT2 receptor, angiotensin II
causes vasodilatation that is attonuatcd by HOE 140 [81].
Elevated plasma bradykinin concentrations have recently
been reported in subjects with hypertension treated with
losartan [82] and infusion of the bradykinin antagonist, HOE-
140, inhibits the improvement in flow-mediated vasodilata¬
tion associated with candesartan in healthy volunteers [83].
In addition, in patients with heart failure treated with losar¬
tan, we observed a small increase in blood pressure following
infusion of the bradykinin receptor antagonist, B9340, com¬
pared to placebo [61] lending further support to the hypoth¬
esis that bradykinin may contribute to the vascular effects of
angiotensin receptor blockade.
9. Bradykinin, angiotensin-converting enzyme
inhibition and inflammation
Inflammation is thought to play a key role in the patho¬
genesis of atherosclerosis. There is increasing evidence that
alterations in the inflammatory response may contribute to
the clinical benefits observed with ACE inhibitor therapy.
It remains unclear to what extent bradykinin, or indeed
angiotensin II, contributes to this action. Both angiotensin II
[84] and bradykinin [85] stimulate the release of interleukin-
6. In contrast, in patients with heart failure high-dose
enalapril therapy is associated with a significant decrease
in interleukin-6 activity [86], whilst in patients undergoing
coronary artery bypass grafting requiring cardiopulmonary
bypass, ACE inhibitors but not angiotensin receptor blockers
attenuate the associated interleukin-6 response [87], These
findings suggest that blockade of angiotensin II production
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may be of greater importance than bradykinin accumulation
in the anti-inflammatory properties of ACE inhibitor ther
apy. Further work is required to examine the contribution of
bradykinin and angiotensin 11 to the anti-inflammatory effects
of ACE inhibition and the relevance of this mechanism to
atherothrombosis.
10. Clinical relevance
Detailed post-mortem studies have shown that plaque
growth is induced by episodic subclinical plaque disruption
and thrombus formation [88], The prolonged presence of
residual thrombus over a disrupted or eroded plaque will
provoke smooth muscle migration and the production of
new connective tissue, leading to plaque expansion [88],
Consistent with this, enhanced macrovascular fibrin depo¬
sition and atherogenesis are seen in genetic murine models
of tissue-type plasminogen activator [89] and plasminogen
[90] deficiency. However, in the presence of an imbalance
in the fibrinolytic system, subclinical microthrombi on the
surface of atherosclerotic plaques may propagate and ulti¬
mately lead to arterial occlusion and tissue infarction [91].
Indeed, reduced plasma fibrinolytic activity has been associ¬
ated with an increased risk of myocardial infarction in both
healthy individuals [92] and patients with cardiovascular dis¬
ease [93], Thus, the initiation, modification and resolution of
thrombus associated with eroded and unstable plaques may
be critically dependent on the efficacy of endogenous fibri¬
nolysis.
There is now a clear link between impaired endothe¬
lial release of t-PA and risk factors for the progression of
atherosclerosis. In man, the capacity of the coronary endothe¬
lium in vivo to release t-PA in response to acute stimulation
with the neurokinin, substance P, is negatively associated
with increasing coronary atheromatous plaque burden and
smoking habit [94], Moreover, both bradykinin and substance
P-mediated endothelial t-PA release are impaired in the fore¬
arm circulation of cigarette smokers [95,96] Given that the
vasomotor effects of bradykinin in the human coronary cir¬
culation are attenuated at sites of atheromatous plaque [34],
it is likely that bradykinin-mcdiated endothelial t-PA release
may also be impaired.
Bradykinin is released during the contact phase of coagu¬
lation (Fig. 1) [10]. In clinical studies ofpatients with unstable
angina, activation of the kallikrein system is enhanced and
bradykinin release is increased [97]. Given that bradykinin
is a potent stimulator of endogenous t-PA release, this
local liberation of bradykinin in acute coronary syndromes
may represent an important negative feedback loop by
which bradykinin-induced endothelial t-PA release inhibits
thrombus formation within the vascular lumen. Moreover,
this process is further amplified by the action of plas-
min itself that, in combination with kallikrein, augments
bradykinin release from high-molecular weight kininogen
[98],
The major clinical benefits of ACE inhibition have been
incontrovertibly established in patients with coronary artery
disease. Although first demonstrated in patients with heart
failure, it is now clear from the HOPE [99] and EUROPA
[100] trials that ACE inhibitor therapy benefits all patients
with cardiovascular disease. Indeed, when comparing these
studies with a meta-analyses ofheart failure trials [101 ] there
is a clear and remarkably consistent anti-ischaemic effect of
ACE inhibitors with a 20-22% relative risk reduction in the
rate of myocardial infarction. In support of this hypothesis,
ACE inhibitor therapy reduces myocardial troponin release
in patients with acute coronary syndromes [102]. In contrast,
the beneficial effects on mortality appear to depend upon the
overall cardiovascular risk of the patient: greatest in those
with severe left ventricular dysfunction and least in those at
low risk with preserved left ventricular dysfunction. Thus,
both the augmentation of bradykinin-induced vasodilatation
and the marked increase in t-PA release described with ACE
inhibition in patients with ischaemic heart disease may con¬
tribute to the primary mechanism ofthe anti-ischaemic effects
associated with chronic ACE inhibitor therapy.
11. Novel therapeutic strategies
11.1. Inhibition of neutral endopeptidase
Based on the success ofACE inhibitor therapy in the treat¬
ment of atherosclerotic vascular disease and heart failure,
attention has focused on inhibiting alternative pathways of
bradykinin breakdown in an effort to augment both the vaso¬
motor and fibrinolytic actions of bradykinin.
Neutral endopeptidase (NEP) is a glycosylated metal-
lopeptidase that colocalises with ACE on the cell membrane
[103], Found in a wide variety of tissues including the vas¬
cular endothelium, NEP has a broad substrate specificity
metabolising a number ofbiologically active peptides includ¬
ing endolhelin, atrial natriuretic peptide, substance P and
bradykinin [ 103]. In the presence ofACE inhibition, the con¬
tribution ofNEP to bradykinin metabolism is increased [ 104],
We have recently demonstrated in patients with heart failure
that combined ACE and NEP inhibition augments the vaso¬
motor and fibrinolytic effects ofbradykinin compared to ACE
inhibition alone [51], Although a recent large-scale trial failed
to demonstrate a significant treatment benefit with combined
ACE and NEP inhibition in heart failure [105], the role of
combined ACE and NEP inhibition in the management of
atherosclerotic vascular disease remains unclear.
11.2. Inhibition of thrombin activatable fibrinolysis
inhibitor
The rate of removal of the C-terminal arginine from
bradykinin is more rapid than can be attributed to car-
boxypeptidase N alone [106] and it is likely that other
carboxypeptidases, in particular carboxypcptidase U, are
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involved in this mctubolic pathway [10]. Carboxypeplidaso
U hydrolyses bradykinin in vitro as efficiently as it does plas-
min cleaved fibrin peptides [107]. Although the contribution
to bradykinin metabolism in vivo remains to be determined,
carboxypeptidase U has additional properties that allow it to
modulate the fibrinoytic effects of bradykinin and these will
be discussed below.
Carboxypeptidasc U is a recently described enzyme that
is present in human plasma, circulates as a zymogen and is
activated by thrombin and plasmin [108]. In addition to its
effects on bradykinin metabolism, it also has a role in the reg¬
ulation of endogenous fibrinolysis and gives rise to its other
more commonly used name, TAFI [108]. Thrombin activat-
able fibrinolysis inhibitor acts through cleavage of the lysine
residues on fibrin and thereby prevents the binding of plas¬
minogen to the fibrin clot [108], This greatly reduces the
ability of t-PA to cleave plasminogen to plasmin and attenu¬
ates fibrinolysis. Thus, TAFI inhibits clot lysis in the presence
of high thrombin concentrations.
Several TAFI inhibitors are currently under development
and may lead to potentially novel and important therapies
in the treatment and prevention of coronary artery disease
[109,110]. Potato carboxypeptidase inhibitor (PCI) is a 39
amino acid peptide derived from potato tubers [109] and is
a specific inhibitor of activated TAFI [111,112]. In a canine
model of acute myocardial infarction, TAFI inhibition with
PCI produced a more rapid reperfusion of the infarct-related
artery during thrombolytic therapy [112]. Using thromboe-
lastography, we have recently demonstrated that PCI potenti¬
ates t-PA induced fibrinolysis in vitro in whole human blood
[113]. Inhibitors of TAFI, therefore, may not only render
intravascular thrombus more susceptible to the actions of
l-PA but also up regulate bradykinin-induced pathways of
endothelial t-PA release. To date, however, the effects ofTAFI
inhibition both on bradykinin metabolism and t-PA mediated
fibrinolysis in vivo in man are unknown.
On a more cautious note, it should be noted that potentiat¬
ing the vascular actions of bradykinin may have detrimental
effects. Bradykinin has been implicated in the pathogenesis
of ACE inhibitor-mediated angioedema [1 14]. Compared to
ACE inhibition an even greater incidence of angioedema has
been reported following treatment with combined ACE and
NEP inhibition [I 15]. Further work is required to establish
the role of bradykinin in the pathophysiology of this poten¬
tially life threatening condition.
12. Summary
The dynamic regulation of intravascular thrombus forma¬
tion is central to our understanding of both acute and chronic
atherosclerotic events. It has become clear that endogenous
fibrinolysis and t-PA play a key role in the initiation, modifi¬
cation and resolution of thrombus associated with eroded or
unstable coronary plaques. Bradykinin is a vasodilator pep¬
tide produced at sites of intravascular thrombus formation
that stimulates the endothelium to release t PA. Recent stud
ies have highlighted the potential importance of bradykinin
in the regulation of endogenous fibrinolysis and intravascu
lar thrombosis in vivo in man. Inhibitors of ACE markedly
augment both the vasomotor and pro-fibrinolytic effects
of bradykinin and this may explain, at least in part, the
potent anti-ischaemic effects of ACE inhibitors in patients
with atherosclerosis. The development of novel agents that
potentiate bradykinin and endogenous fibrinolysis, such as
inhibitors ofTAFI, may provide future therapeutic strategies
to treat and prevent cardiovascular disease.
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Stimulated Tissue Plasminogen Activator Release as a
Marker of Endothelial Function in Humans
James J. Oliver, David J. Webb, David E. Newby
Abstract—The initiation, modulation, and resolution of thrombus associated with eroded or unstable coronary plaques tire
critically dependent on the efficacy of endogenous fibrinolysis. This is dependent on the cellular function of the surrounding
endothelium and vascular wall. In particular, the acute release of tissue plasminogen activator from the endothelium makes
an important contribution to the defense against intravascular thrombosis. Here, we describe the rationale and methodology
for, and clinical relevance of, assessing acute endothelial tissue plasminogen activator release in humans. The investigation
of endothelial fibrinolytic function has the potential to provide major new insights into the pathophysiology of cardiovascular
disease, and to shape future therapeutic interventions. (Arterioscler Thromb Vase Biol. 2005;25:2470-2479.)
Key Words: arterial thrombosis ■ endothelial function ■ endothelium ■ fibrinolysis ■ thrombosis
The endothelium plays a vital role in the control of bloodflow, coagulation, fibrinolysis, and inflammation. To
date, clinical studies have focused on the assessment of
endothelium-dependent vasomotion as a surrogate measure of
endothelial function, and there is now extensive evidence of
abnormal endothelium-dcpendcnt vasodilatation in patients
with atherosclerosis and its associated risk factors.1 Abnormal
vasomotor responses independently predict cardiovascular
events.2 However, endothelium-dependent vasomotion may
not be representative of other important aspects of endothelial
function, such as the regulation of fibrinolysis.
In health, the endothelium prevents thrombus formation
through a number of mechanisms. Thrombomodulin, protein S,
heparan sulfate proteoglycans, and tissue factor pathway inhib¬
itor are all endothelium-derived inhibitors of coagulation,
whereas prostacyclin, nitric oxide (NO), and surface-bound
CD39 inhibit platelet aggregation. However, when endothelial
function is perturbed, for example with injury or inflammation,
it can rapidly become procoagulanl by downregulating its
anticoagulant functions, inducing tissue factor expression and
increasing secretion of factors such as fibronectin. von Wille-
brand factor (vWF), and platelet activating factor.3
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Figure 1. The endothelial fibrinolytic response to luminal thrombus. Agonists generated from the coagulation cascade act on endotheli¬
al cell surface G protein-coupled receptors (GPCRs) (1) to stimulate release of tissue plasminogen activator (t-PA) from storage gran¬
ules, a step that requires an increase in intracellular calcium (Ca4') concentration (2). Free t-PA acts on thrombus-bound plasminogen
(3) to produce plasmin (4) that, in turn, degrades cross-linked fibrin into fibrin degradation products (FDPs) (5), thus dissolving the
thrombus. The fibrinolytic process is inhibited by inactivation of t-PA by PAI-1 and plasmin by «2-antiplasmin.
Endogenous Fibrinolysis
The endogenous fibrinolytic system protects the circulation
from intravascular fibrin formation and thrombosis. After
initiation of thrombus formation, the endothelium acutely
releases tissue plasminogen activator (t-PA) in response to a
range of factors predominantly related to the coagulation
cascade, especially factor Xa and thrombin.4 Once released,
l-PA catalyzes the conversion of plasminogen to plasmin,
facilitating thrombus dissolution through the proteolytic deg¬
radation of fibrin to soluble fibrin degradation products
(Figure I). The conversion of plasminogen to plasmin by
t-PA is accelerated in the presence of fibrin and at the
endothelial cell surface,5-6 ensuring efficient localized activa¬
tion. Because plasminogen is present at vast molar excess
over t-PA in plasma, the onset and efficacy of fibrinolysis are
principally determined by the rapidity and magnitude of t-PA
release.
The concentration of t-PA in human plasma is =3 to 10
ng/mL. but a relatively small proportion is functionally active
because of the presence of serine protease inhibitors (scr-
pins); principally, plasminogen activator inhibitor (PA1) type
1 (PAI-1), but also PA1-2, PA1-3, a2-macroglobulin, and CI
esterase inhibitor (Figure 2).7 The proportion of active t-PA
varies inversely with plasma PAI-1 concentration, from 2% to
33%.8 The plasma half-life of t-PA is =»5 minutes, and the
liver is the major site of clearance.9 The interaction between
t-PA and PAI-1 has a rapid second order rale constant of
= I07 M"1 s~',IH and there is a several-fold molar excess of
PAI-1 over t-PA in plasma.8 Therefore, for active unbound
t-PA to reach a thrombus, rapid local release is vital,
particularly because fibrinolysis is much more effective if
t-PA is incorporated during, rather than after, thrombus
formation."
Synthesis, Storage, and Release of t-PA
Encoded by a gene on chromosome 8, l-PA is a 68 kDa serine
protease of 530 amino acids and the endothelium is its
principal site of generation. Endothelial cells in culture
synthesize and constitutivcly secrete l-PA.12 The rale of
synthesis is increased by a number of substances, including
thrombin and histamine,11 and is reduced by plasmin.14
However, although protein kinase C appears to play a role,15
the mechanisms regulating t-PA synthesis have not been
characterized in detail.
t-PA is released facultatively from storage granules and the
pathways of constitutive and facultative release differ.12
Some workers have suggested that l-PA is stored with vWF in
Weibel-Palade bodies,16 but there is now convincing evidence
that t-PA is stored in vesicles distinct from Weibel-Palade
bodies,1718 and this is consistent with the in vivo observation
►
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Plasminogen Activator Inhibitor (PA!-1)
Protease
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PAl-l Activity t-PA/PAI-l Complex t-PA Activity
Ik^
Tissue Plasminogen Activator (t-PA)
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:
Figure 2. Relationship between tissue plasminogen activator
(t-PA) and its major inhibitor, plasminogen activator inhibitor
type 1 (PAI-1), in plasma. Only the unbound fractions are active.
Other protease inhibitors, including PAI-2, PAI-3,
a2-macroglobulin, and C1 esterase inhibitor, also bind to t-PA in
plasma.
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Substances That Stimulate Acute Tissue Plasminogen Activator (t-PA) Release in Humans
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that agents stimulating t-PA release do not also release
vWF.IM'20 The precise signaling pathways regulating faculta¬
tive secretion have not been elucidated, but G-proleins and
increased intracellular calcium concentrations appear to be
important.18'21
Endothelial synthesis of t-PA varies with vessel size and
anatomic location. In humans, immunorcactivc I PA is pres¬
ent in normal endothelium of the internal mammary and
coronary arteries, saphenous vein, and aorta.22 24 Release of
l-PA also varies with region; the upper limbs, for example,
releasing more than the lower limbs.25 The capacity of the
endothelium to 3tore and release t PA is substantial: contin
uous t-PA release can be induced for many hours without
undergoing significant tachyphylaxis26'27 and the forearm can
release up to 4.5 jug/min,28 enough for local plasma concen¬
trations to approach those achieved during systemic therapeu¬
tic thrombolysis.
Acute Endothelial t-PA Release
In Vitro and Ex Vivo Assessment
The development of relatively simple models of acute t-PA
release has enabled much of the research on facultative t-PA
release to be performed in vivo in humans. However, inves¬
tigation of the relevant cellular and molecular pathways
requires alternative approaches including cell culture and ex
vivo animal models. Endothelial cell culture techniques have
limitations and may not truly represent the in vivo function of
these cells. Release of t-PA in cultured cells is slow and
modest, and prolonged incubation periods and sensitive t-PA
assays are required. Consequently, assessment of acute t-PA
release is difficult to achieve in vitro. Moreover, the pheno-
typc of cultured endothelial cells, including their ability to
release t-PA, also changes with increasing passages. Ex vivo
animal models, which provide a more favorable volume to
surface area ratio, have been used to investigate various
stimulants of acute t-PA release, for example, hydrogen
peroxide in isolated rat heart.2'1 The demonstration that
agonist-stimulated t-PA release in rat hind limb did not
require de novo protein synthesis30 led to the concept that
acute release results from translocation of a dynamic intra¬
cellular storage pool12 in response to blood coagulation and
humoral factors.4
In Vivo Assessment
In humans, acute release of t-PA can be assessed systemi-
cally, for example after intravenous infusion of desmopres
sin31 or bradykinin.32 However, this approach is limited by
potential confounding effects, such as changes in systemic
hemodynamics, clearance of t-PA and PA1-I, activation of
the sympathetic nervous system, and concomitant release of
other mediators. Direct assessment of local capacity for acute
t-PA release within individual vascular beds avoids these
problems and is likely to better represent the defense against
arterial thrombosis. Local availability of active t-PA depends
on the extent of loeal t-PA release rather than on the amount
of t-PA or PAI-I entering the tissue in arterial blood.33
Venous Occlusion Test
Regional t-PA release can be assessed in vivo by measuring
the increase in t PA concentration in pooled venous plasma.
Typically, an upper arm or leg cuff is inflated to between
systolic and diastolic blood pressure to cause venous pooling.
Blood is sampled before and 10 or 20 minutes after cuff
inflation.34 Using this methodology, reduced t-PA release has
been reported in various groups of subjects, including those
who smoke,35 although there are conflicting data on patients
with coronary artery disease.36-37 Whereas the increase in
t-PA in pooled venous blood may simply be because of
continued secretion at the basal rate,25 it has been suggested
that venous occlusion itself stimulates t-PA release.38 Al¬
though quite simple and widely applicable, the venous
occlusion technique is a rather blunt tool with relatively poor
reproducibility.39
Regional Tissue Release
Acute t-PA release has been assessed in both the forearm and
coronary circulations of humans using a number of endothe
lial stimulants including brudykinin, substance P, denmopres
sin, and methacholine (Table).
Downloaded from atvb.ahajournals.org at UNIV OF EDINBURGH on October 5, 2007









t-PA in arterial blood El Basal t-PA release IS t-PA released by agonist
Forearm Release
Two similar methodologies are used to assess forearm t-PA
release in response to intrabrachial infusions: one based on
the differences in plasma concentrations of t-PA between
inflowing arterial and outflowing venous plasma of a single
arm,4"-42 and the other based on the differences in venous
plasma concentrations between the 2 arms.411 For the arterio¬
venous technique, drugs are infused via an 18-gauge catheter
and the arteriovenous concentration gradient is calculated
from blood samples taken simultaneously from this and an
ipsilateral venous catheter. Forearm plasma flow is calculated
using forearm blood How (FBF). measured by strain gauge
plethysmography, and arterial hematocrit corrected for I %
trapped plasma. Net release is calculated as the product of the
arteriovenous concentration gradient and forearm plasma
flow:
Nel release=(Cv—Ca)XFBFX[(101 —hematocrit)/!00]
where Cv and C„ arc the venous and arierial concentrations,
respectively. The antigen concentrations of l-PA are mea¬
sured using enzyme-linked immunosorbent assays,44 and net
release is expressed as ng per 100 mL of forearm tissue per
minute. The activity of t-PA is determined photometrically45
and expressed as 1U per 100 mL of forearm tissue per min.
Typical resting arteriovenous differences in t-PA concen¬
trations in the forearm are only =10% of total venous
concentration and basal constitutive release is =0.4 to 1.3
ng/100 mL of tissue/min.19-26-40-42-46 48 There is no demon¬
strable release of PA1-1 across the forearm; therefore, t-PA
activity increases in parallel with t-PA antigen concentra¬
tion.19-4648 There is no consensus on whether it is better to
measure t-PA antigen or activity. Whereas it is only unbound
t-PA that is functionally active (Figure 2), ultimately the
efficacy of endogenous fibrinolysis is determined by the
magnitude of local t-PA release and the resultant l-PA
activity at the site of thrombus. Whether venous plasma t-PA
antigen or activity concentrations best reflect this dynamic
process remains unclear and will in part depend on local
tissue perfusion rates and plasma serpin concentrations.
Consequently, both t-PA antigen and activity are often
presented.
Figure 3. Schematic comparison of mea¬
suring forearm t-PA release using the arte¬
riovenous and venovenous techniques. A,
Basal release of t-PA across the forearm
can only be quantified with the arterio¬
venous technique. B, Through a dilutional
effect, isolated vasodilatation will reduce
the concentration of t-PA in venous
plasma in the infused arm. C, Agonists
that induce t-PA release also commonly
cause vasodilatation, for example, bradyki-
nin, substance P, and desmopressin.
Under these circumstances the arterio¬
venous and venovenous techniques pro¬
vide a similar measure of agonist-
stimulated t-PA release. When the
arteriovenous technique is used, basal
release (determined before infusion of the
agonist) should be subtracted from total
release to derive agonist-induced release.
Using the venovenous technique, drugs are infused into the
brachial artery via a 27-gauge needle. This is narrower than
the catheter used in arteriovenous studies because it is not
used for blood sampling. Net release is calculated in a similar
manner, except that the concentration gradient is that between
the venous plasma of the infused and noninfused arms. The
reproducibility of agonist-induced t-PA release using the
venovenous technique has been shown to be good.49
The arteriovenous and the venovenous approaches both
have benefits and limitations. Net release is calculated di¬
rectly in the arteriovenous technique but indirectly in the
venovenous technique, potentially resulting in different esti¬
mates of stimulated t-PA release under certain conditions
(Figure 3). Basal release cannot be calculated using the
venovenous technique. However, because basal release con¬
stitutes only a small proportion of the overall venous plasma
concentration, the venovenous technique does provide an
accurate assessment of stimulated t-PA release. The arterio¬
venous method is technically more challenging and the
larger-bore arterial catheter makes it less suitable for repeated
studies within individuals. Moreover, the arterial catheter
presents a larger thrombogenic surface that may itself stim¬
ulate the fibrinolytic system. Both techniques assume that
there is no clearance of t-PA across the forearm. This is a
reasonable assumption because the liver is the major site of
clearance, although there arc endothelial receptors capable of
clearing t-PA from the circulation.50
Cardiac Release
In the coronary circulation, dynamic t-PA release is assessed
by infusion of agents into the left main51-52 or left anterior
descending coronary artery,511 and samples arc obtained si¬
multaneously from the coronary sinus and either the aorta or
femoral artery.51--54 Sampling blood from the coronary sinus
is appropriate only during the evaluation of the left ventricle
and, particularly, during left anterior descending artery infu¬
sions. Care must be taken to ensure that catheters do not
impede flow in the coronary sinus, because this may divert
blood into the anterior cardiac or Thebesian veins. Net t-PA
release is calculated in a similar manner to the forearm
technique, but with blood flow measured using coronary
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Doppler combined with either quantitative coronary angiog¬
raphy or intravascular ultrasound (IVUS).
Stimulation of t-PA Release
Although a number of humoral and coagulant factors cause
t-PA release, other factors, including angiotensin II,-0 acetyl¬
choline,■)0-52-55 and atrial natriuretic peptide,56 do not release
t-PA, despite causing marked vasomotor effects.
Bradykinin is an inflammatory vasodilator peptide and a
powerful stimulant of endothelial t-PA release. It acts via the
B2 receptor in an NO-independent and prostaglandin (PG)-
independent fashion.57 An endotheliuni-derived hyperpolar-
izing factor probably contributes to bradykinin-induced va¬
sodilatation,5" although whether endothelium-derived
hyperpolarizing factor contributes to t-PA release is not
known.
The tachykinin vasodilator, substance P, acts mainly
through the neurokinin type 1 (NK|) receptor. It is a central
and peripheral neurotransmitter and mediates neurogenic
inflammation.59 Substance P induces t-PA release in both the
forearm and coronary circulations, and is the most potent
known stimulant of l-PA in humans.
The vasopressin analogue, desmopressin, is a V2 receptor
agonist that releases t-PA in the forearm circulation.26-48-60
When administered systemically, it also induces vWF
release.61
The muscarinic receptor agonist methacholine induces
t-PA release in the forearm, but to a lesser degree than
bradykinin62 or desmopressin.26-33 In contrast, acetylcholine,
also a muscarinic agonist, does not stimulate t-PA re-
lease40-52-55 The reason for this difference is not clear, al¬
though varying potencies and stabilities of the respective
compounds may be responsible. These agents also appear to
provoke vasodilatation via differing mechanisms with acetyl¬
choline, but not methacholine, being largely mediated
through NO production.63
The adrenergic agonists, norepinephrine41 and isoprcna-
line,47 both induce t-PA release in the forearm, as does mental
stress, which is associated with adrenergic activation.19-41
These data suggest a role for the sympathetic nervous system
in controlling vascular t-PA secretion. In support of this,
chemical sympathectomy in rats reduces basal plasma t-PA
concentrations and agonist-induced t-PA release in isolated
vessels.64 In a porcine model, stimulation of cardiac sympa¬
thetic nerves causes coronary t-PA release.65 Although nor¬
epinephrine from sympathetic nerve endings may act on the
endothelium to release t-PA, there is also intriguing evidence
that sympathetic neurons can themselves synthesize and
release t-PA.66
Both adenosine and uridine triphosphates (ATP and UTP)
stimulate t-PA release in the forearm, apparently indepen¬
dently of NO and PG pathways.67 This is of particular interest
because these nucleotides are released by activated platelets,
endothelial cells and cardiomyocytes during ischemia. The
doses of ATP and UTP administered67 resulted in similar
plasma concentrations of the nucleotides to those commonly
observed in the context of ischemia. Moreover, coronary
ischemia in the pig68 was associated with increased (-PA
release.
Regulation of l-PA Release
The role of NO in the mechanism of endothelial t-PA release
is unclear. Sodium nitroprusside, a spontaneous NO donor,
does not stimulate either synthesis or release in cultured
endothelial cells or stimulate release in vivo.40-46 48-53-60-69
However, substance P-induced t-PA release was inhibited by
the NO synthase inhibitor, N° monomethyl-L-arginine (L-
NMMA).27 In contrast, bradykinin-induced t-PA release was
unaffected by L-NMMA in one study57 and increased by
L-NMMA in another.70 Thus, NO alone does not induce t-PA
release, although it may play a permissive or synergistic role
in stimulated t-PA release.
Shear stress is a well-characterized stimulus for t-PA
secretion from cultured endothelial cells.71 In ex vivo human
conduit vessels, shear stress stimulates t-PA expression and
increases its intracellular storage pool without stimulating its
release.72 Consistent with this, marked increases in blood
flow during infusions of vasodilators such as sodium nitro¬
prusside and papaverine do not cause in vivo t-PA re¬
lease.51-52 A permissive role of increased shear stress is also
unlikely given that intrabrachial tumor necrosis factor-a
induces t-PA release without changing blood flow,73 and the
vasoconstrictor, norepinephrine, releases t-PA while reducing
How.41 Thus, blood flow and shear stress appear to regulate
endothelial t-PA synthesis and storage but do not affect its
acute release.
Genetic Influences on t-PA Release
A number of small studies have investigated genetic influ¬
ences on dynamic endothelial t-PA release. An Alu-repeat
polymorphism and 3 single nucleotide polymorphisms in
linkage disequilibrium with this74 associate with t-PA release
rates.74-75 Although not apparent in the forearm circulation,55
angiotensin-converting enzyme (ACE) I/D genotype may
influence bradykinin-induced t-PA release in the coronary
circulation.54 In addition, there was no difference between
healthy black and white Americans in bradykinin-induced
t-PA release.55 Further studies, with larger sample sizes, are
desirable to confirm genetic linkage.
Clinical Relevance of Endothelial t-PA Release
Acute rupture or erosion of a coronary atheromatous plaque,
and subsequent thrombosis, cause the majority of sudden
cardiac deaths and myocardial infarctions.76 Small areas of
denudation and thrombus are commonly found on atheroma¬
tous plaques and are usually subclinical.77 However, with
imbalance in the fibrinolytic system, such microthrombi may
propagate, leading to arterial occlusion.3 The importance of
acute endogenous t-PA release is further exemplified by the
high rate of spontaneous reperfusion in the infarct-related
artery after acute myocardial infarction.78
A reduction in t-PA activity or release is associated with an
increased incidence of major adverse cardiac events in
patients with stable79 or unstable angina.36 Rosenberg and
Aird3 have postulated that vascular bed-specific defects in
hemostasis exist, and that coronary thrombosis critically
depends on local fibrinolytic balance.
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Figure 4. After myocardial infarction,
smokers have a lower in-hospital mortal¬
ity than nonsmokers (A) (data from Bar-
bash et al'00), possibly because
thrombolytic therapy is more effective in
smokers (B) (data from de Chillou et
al87). Differences in the capacity for acute
t-PA release in the coronary circulation
(C) (data from Newby et al53) may explain
this observation. Thrombus that devel¬
ops despite normal endothelial cell t-PA
release might be expected to be less
susceptible to thrombolytic therapy than
thrombus that develops in an artery with
impaired capacity for endothelial t-PA
release. 'P&0.03.
Basal Plasma t-PA Concentrations
Several studies have investigated the relationship between
basal venous t-PA antigen concentrations and subsequent
coronary heart disease. In a meta-analysis of prospective
studies, the risk of coronary heart disease was «=50% greater
in those with plasma t-PA antigen concentrations in the
highest tertile compared with those in the lowest terlile.80
This may seem counterintuitive but in part reflects the
concomitant increase of plasma PAI-1 concentrations and
associated reduction in t-PA activity. However, whereas this
epidemiology is of interest, basal plasma t-PA does not reflect
the local capacity for acute endothelial t-PA release in
response to developing thrombus.33 This underscores the
importance of assessing acute endothelial t-PA release that is
likely to be of greater pathophysiological relevance.
Acute Coronary t-PA Release
The acute fibrinolytic activity of the heart is inversely
correlated with the extent of proximal coronary artery ath¬
erosclerosis.53 The mechanisms underlying this relationship
arc likely to involve chronic endothelial cell injury and
impaired vascular function. Alternatively, this association
may reflect chronic stimulation and upregulation of basal
t-PA release secondary to atheroma and arterial denudation.
The subsequent depletion of endothelial t-PA stores, and the
desensitizalion and reduction of the acute fibrinolytic re¬
sponse, would potentially he detrimental.
Questions of cause and effect cannot be resolved by such
observations and it remains possible that reduced fibrinolytic
activity enhances atherogenesis. The prolonged presence of
residual thrombus over a disrupted plaque will provoke
smooth muscle migration and new connective tissue produc¬
tion, leading to plaque expansion.81 This is consistent with the
enhanced macrovascular fibrin deposition and atherogenesis
seen in genetic murine models of l-PA deficiency.82
Smoking
Basal plasma t-PA concentrations arc either increased53-83 or
unaltered8-4 in chronic smokers, but dynamic endothelial l-PA
release is dramatically reduced. This has been consistently
demonstrated in the forearm62 83 and coronary circulations53
(Figure 4), as well as with the venous occlusion test35 and
systemic desmopressin infusion.31 The increased risk of
spontaneous thrombosis in smokers85 may, therefore, relate to
propagation of thrombus, which would otherwise undergo
lysis and remain subclinical.
Although smokers have a higher overall mortality from
myocardial infarction than nonsmokers,86 their in-hospital
mortality is lower (Figure 4).87 This may, in part, be ex¬
plained by the finding that in current smokers the infarct
related artery is more likely to become patent after
thrombolytic therapy.87 These observations arc consistent
with these findings on endothelial l-PA release because it
might be anticipated that patients with impaired endothelial
cell t-PA release would benefit most from thrombolytic
therapy, whereas those with a normal endogenous fibrinolytic
capacity are more likely to have coronary thrombus resistant
to fibrinolysis.
Hypercholesterolemia
Patients with hypercholesterolemia have impaired endotheli-
um-dependent vasodilatation. However, in contrast to smok¬
ers, hypercholesterolemia and lipid-lowcring therapy do not
influence acute t-PA release.40 This is consistent with the
finding that serum cholesterol concentrations, unlike smoking
status, do not influence the patency rate of the infarct related
artery after thrombolytic therapy.87 Moreover, hypercholes¬
terolemia is particularly associated with vulnerable plaque
rupture, whereas acute thrombosis develops in smokers even
without plaque rupture.76 It would therefore appear that, in
contrast to smoking, hypercholeslerolemia-associated plaque
rupture is such a dramatic event that thrombosis occurs
despite preserved local t-PA release.
Hypertension
Marked impairment of desmopressin-induced t-PA release
but not vasodilatation has been demonstrated in hyperten¬
sives,60 perhaps suggesting that impaired t-PA release may be
a more sensitive marker of endothelial damage in hyperten¬
sion. However, in contrast to the impaired desmopressin
response, methacholine-induced t-PA release is unaffected/40
Similar agonist-specific defects have been reported in smok¬
ers, in whom bradykinin62 and substance P,53-83 but not
methacholine,62 induced t-PA release is impaired. Although
the explanation for this discrepancy is unclear, it may simply
be more difficult to detect differences in release with a
relatively weak stimulus, such as methacholine. Alterna¬
tively, hypertension and smoking may have different effects
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on llie specific pathways of secretion for each agent. How¬
ever, the possibility that methacholine may be generally less
able than other agents at discriminating meaningful differ¬
ences in acute t-PA release between patient groups should be
considered for future studies.
Bradykinin and ACE Inhibition
Bradykinin is a potent endothelium-dependenl vasodilator
that has a brief duration of action caused by its rapid
degradation by ACE.8,1 In addition to being an inflammatory
mediator, it is closely involved in the fibrinolytic and coag¬
ulation cascades. During the contact phase of blood coagula¬
tion, it is released after the cleavage of high-molecular-weight
kininogen by kallikrein89 and is a potent stimulant for
endothelial t-PA release.20-12'40 Thus, when plaque rupture or
erosion activates the intrinsic coagulation pathway, liberation
of bradykinin may provide important negative feedback to
limit thrombus development. In keeping with this, bradykinin
generation is transiently increased after an episode of unsta¬
ble angina.90
Potentiation of endothelial t-PA release through the pres¬
ervation of endogenous bradykinin might account for some of
the cardiovascular benefits of ACE inhibitors. In support of
this, in the forearm of healthy men91 and patients with heart
failure,2892 ACE inhibition augments bradykinin, but not
substance P. induced l-PA release. Similarly, augmentation of
bradykinin-induced t-PA release by ACE inhibition has been
demonstrated in the coronary circulation.51'52 The effect of
ACE inhibition on t-PA release is mediated specifically
through bradykinin, because angiotensin II receptor blockade
has no effect on bradykinin-induccd t-PA release.51,91
Bradykinin antagonism reduces local t-PA release during
intra-brachial enalaprilat infusion,91 providing direct evi¬
dence that ACE inhibition augments endothelial t-PA release
through increased endogenous bradykinin. ACE inhibition
might also enhance endothelial t-PA release by increasing
bradykinin receptor expression.94
Endothelial t-PA Release as a Novel Measure
of Endothelial Function
The endothelium has a number of important functions,
including regulation of vascular tone, coagulation, fibrinoly¬
sis, and inflammation. However, to date, most clinical studies
on endothelial function have focused on endolhelium-
dependent vasomotion. Although this is a useful surrogate
marker for the role of the endothelium in atherothrombosis,2
measuring other aspects of endothelial function, including the
capacity for l-PA release, may provide additional and novel
insights.
Reports of preserved endothelium-dependent vasodilata¬
tion in smokers62 and in patients with hypertension60-95
despite reduced acute t-PA release suggest that, in some
circumstances, reduced t-PA release may be a more sensitive
marker of endothelial dysfunction. Moreover, some condi¬
tions associated with impaired endothelium-dependent vaso¬
dilatation, such as hypercholesterolemia, are not accompa¬
nied by reduced t-PA release.49 These data highlight the
complexity of vascular biology, and that it is perhaps naive to
expect endothelial dysfunction to be expressed by a uniform
phenotype irrespective of the insult. Vascular inflammation is
associated with augmentation of t-PA release despite impair¬
ing endothelium-dependent vasodilatation.71 This calls into
question the use of the term endothelial dysfunction. Is the
cell truly dysfunctional or in an altered state of activation? In
particular, the dominant use of this term to refer to endothe¬
lium-dependent and NO-dependent vasodilatation seems un¬
necessarily restrictive and inaccurate. The many and varied
actions of the endothelium may be potentiated and inhibited
simultaneously within the same cell. Whether this is ulti¬
mately beneficial or detrimental depends on the local and
systemic setting of the individual vessel, tissue, and patient.
Limitations of Clinical In Vivo Models
To date, most studies of dynamic endothelial t-PA release
have been relatively small because of the invasive nature of
the techniques. Measurement of coronary t-PA release is
likely to be of greatest relevance to coronary pathophysiology
but can only be performed in selected subjects undergoing
coronary angiography. Whereas forearm assessment can be
performed more widely, this vascular bed is less susceptible
to atherosclerosis and subsequent thrombosis, raising ques¬
tions on its validity as a surrogate for the coronary circulation.
Nevertheless, consistent findings between the peripher¬
als,83,91 antj coronary circulations52-53 support the notion that
the forearm model is a reasonable surrogate.
Although quantitative assessment of endothelial t-PA re¬
lease can be made using local infusions, the clinical models
used are relatively simplistic when compared with the com¬
plex in vivo response to developing thrombus. For example,
measuring t-PA release in response to components of the
coagulation cascade, such as activated factor X or thrombin,
might more closely mirror in vivo pathophysiology but would
risk inducing arterial thrombosis. The in vivo clinical models
also measure t-PA release across an entire vascular bed and it
does not necessarily follow that such measures reflect the
local capacity for t-PA release at the site of an eroded or
ruptured plaque.
Future Work
It can be reasonably hypothesized that reduced dynamic
endothelial t-PA release predisposes to events such as myo¬
cardial infarction and unstable angina. However, longitudinal
studies of t-PA release as a predictor of coronary events have
not been performed. Whereas assessment of t-PA release is
unlikely to become part of cardiovascular risk assessment,
demonstrating that impaired release predicts cardiovascular
events would support the hypothesis that reduced t-PA
release is of pathophysiological significance.
Although the capacity for endothelial t-PA release is
clearly reduced in some circumstances, the mechanisms are
unknown. Serum from smokers, but not from nonsmokers,
reduced substance P-induced t-PA release from cultured
endothelial cells,96 suggesting that a blood-borne mediator
may affect endothelial t-PA responses. Using ex vivo human
umbilical veins, increased intraluminal pressure decreased
t-PA release as well as gene and protein expression,97
suggesting that raised intraluminal pressure might itself
impair t-PA release. Detailed characterization of the path-
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ways of t-PA secretion and how these are affected by
different stimuli will provide a platform for the investigation
of the mechanisms of impaired secretion.
Improving t-PA release may represent a new therapeutic
target in cardiovascular prevention. There is mounting evi¬
dence that some of the benefits of ACE inhibitors may be the
result of enhanced t-PA release, whereas statins exert their
beneficial effects through alternative pathways. Once the
mechanisms of impaired t-PA release have been defined
further, there is the potential to develop agents that will
specifically augment endothelial t-PA release.
Conclusions
The dynamic regulation of intravascular thrombus formation
is central to our understanding of acute and chronic athero¬
sclerotic events. The initiation, modulation, and resolution of
thrombus associated with eroded or unstable coronary
plaques are critically dependent on the efficacy of endoge¬
nous fibrinolysis. It is perhaps remarkable that this funda¬
mentally important aspect of endothelial function has been
relatively underinvestigated in clinical studies to date. Here,
we have described the various methods of assessing acute
endothelial t-PA release in humans and have explored the
effects of various cardiovascular conditions and risk factors
on the endogenous fibrinolytic capacity. Impaired endothelial
t-PA release appears to be a particular feature of cigarette
smoking and atherosclerosis but not hypercholesterolemia.
Thus, endothelial dysfunction can be manifest in separate
distinct pathways depending on the nature of the insult,
underscoring the importance of critically investigating the
specific consequences of vascular injury. The investigation of
endothelial fibrinolytic function has the potential to provide
major new insights into the pathophysiology of cardiovascu¬
lar disease and to shape future therapeutic interventions.
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Emerging Thrombotic Effects of Drug Eluting Stents
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Drug eluting stents (DES) have been enthusiasticallyintroduced into contemporary interventional cardiol¬ogy practice. By delivering locally active doses of
antiproliferative drugs, they have demonstrated an impressive
capacity to inhibit restenosis caused by neointimal hyperpla¬
sia; a complication that has plagued uncoated "bare-metal"
stents (BMS). DES coated with either paclitaxel or rapamycin
(sirolimus) are now deployed in over 90% of coronary
interventions in the United States.1 However, clinical
follow-up has revealed significant concerns relating to the
incidence of late (> 30 days) stent thrombosis, especially in
long stents and after discontinuation of dual antiplatelet
therapy.2
See page 400
Stent thrombosis with DES has been attributed to various
potential mechanisms (Figure), but delayed or incomplete
stent endothelialization has been proposed as a major mech¬
anism. In a recent autopsy study.3 DES showed reduced
endothelialization (27±26% versus 66±25%), especially in
those with evidence of stent thrombosis. However, patients
with DES had stents that were almost twice as long and
included those receiving DES for indications not approved by
the Food and Drug Administration, including acute myocar¬
dial infarction. This selected autopsy group represents the
extreme end of the spectrum and may not reflect the situation
in the majority of patients who receive DES and survive.
The hypothesis that late stent thrombosis is attributable
solely to delayed endothelialization contrasts with porcine
models of coronary stent implantation. Although endotheli¬
alization may be more rapid than in humans, endothelial
coverage of DES and BMS in a porcine model is almost
complete after 28 days with no significant difference between
stents.4 Furthermore, the bulk of evidence now suggests that
reendolhelializ.ation is achieved by blood-borne endothelial
progenitor cells originating from the bone marrow.5 It is,
therefore, hard to reconcile the hypothesis that locally active
doses of antiproliferative agents impair reendolhelializ.ation
by inhibiting the proliferation of adjacent endothelial cells.
With these observations in mind, Muldowney and col¬
leagues in this issue of Arteriosclerosis, Thrombosis, and
Vascular Biology, present a fascinating alternative and sug¬
gest a potential pathophysiological mechanism to explain the
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occurrence of late stent thrombosis in DES.6 Using microar-
rays of more than 11 500 genes, they report that, after
incubation with either paclitaxel or rapamycin, the most
consistent change in human endothelial gene expression was
upregulation of the transcript for plasminogen activator in¬
hibitor type I (PAI-1). They confirmed that these transcrip¬
tional effects were associated with increased PAI-1 antigen
production. The upregulation of this antifibrinolytic factor
presents an important potential mechanism underlying the
prothrombotic effect of DES.
The fibrinolytic pathway describes a complex process
involving the hydrolytic cleavage of fibrin, by plasmin, to
cause clot dissolution. This process is regulated by a balance
between the acute endothelial release of tissue plasminogen
activator (t-PA) and its serpin inhibitor, PAI-1. Indeed, some
have suggested that coronary thrombosis is particularly sen¬
sitive to imbalances in this fibrinolytic pathway.7 Animal
models of PAI-1 overexpression exhibit spontaneous macro-
vascular coronary thrombosis and myocardial infarction.8
Plasma PAI-1 concentrations are independently predictive of
adverse cardiovascular events in healthy populations9 and
patients with coronary heart disease.10 Indeed, increased
plasma PAI-I concentrations are independently associated
with major adverse cardiac events following BMS insertion,11
and autopsy observations have further indicated that persis¬
tent fibrin deposition is a risk factor for late stent thrombosis
with DES.3
Of further interest, Muldowney reports contrasting effects
of paclitaxel and rapamycin on the expression and secretion
of t-PA. Although rapamycin caused downregulation of t-PA
mRNA expression and secretion, this effect was not seen in
cells incubated with paclitaxel. Indeed, paclitaxel caused an
increase in both expression and secretion in human umbilical
vein endothelial cells. In the presence of impaired t-PA
secretion, the prothrombotic effect of enhanced PAI-1 syn¬
thesis would be further amplified. Although other factors are
likely to play a role, it is tempting to speculate that the
combination of elevated PAI-1 and impaired t-PA secretion is
a plausible explanation for the higher incidence of late stent
thrombosis reported in one meta-analysis of patients treated
with rapamycin-coaled (Cypher, Cordis Corp) stents com¬
pared with paclitaxel-coated (Taxus, Boston Scientific Corp)
stents.12
Muldowney and colleagues extended their preliminary in
vitro findings by examining the effects of rapamycin and
paclitaxel delivered to transgenic mice expressing enhanced
green fluorescent protein (eGFP) linked to the human PAI-1
promoter. After 2 weeks of intraperitoneal infusion, the
expression of eGFP-linked PAT I promoter was increased in
coronary arteries, aorta, and kidney from animals treated with
these antiproliferative agents. Thus they were able to confirm
the consistency of their in vitro findings using an in vivo
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model. Given that local PAI-1 expression is induced by
percutaneous coronary inlervention, the effects of rapantycin
and paclitaxel would be anticipated lo be enhanced even
further at the site of stent implantation.
The dramatic reduction of in-stent restenosis associated
with DES is an important therapeutic advance that has had a
major impact on interventional cardiology. The small but
significant absolute increase in late stent thrombosis is an
important observation that remains a concern. Emerging
mechanisms of DES thrombosis, including the induction of
anlifibrinolytic endothelial phenotypes, are helping us to
understand this phenomenon. Such work will help inform the
further refinement of this major therapeutic advance to allow
physicians to have an effective and safe therapy for patients
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